<SUBMISSION>
<ACCESSION-NUMBER>0001104659-19-061704
<TYPE>S-1/A
<PUBLIC-DOCUMENT-COUNT>15
<FILING-DATE>20191108
<DATE-OF-FILING-DATE-CHANGE>20191108
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>Adynxx, Inc.
<CIK>0001054274
<ASSIGNED-SIC>3841
<IRS-NUMBER>582349413
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>S-1/A
<ACT>33
<FILE-NUMBER>333-232169
<FILM-NUMBER>191204327
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>100 PINE ST., STE. 500
<CITY>SAN FRANCISCO
<STATE>CA
<ZIP>94111
<PHONE>(415) 512-7740
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>100 PINE ST., STE. 500
<CITY>SAN FRANCISCO
<STATE>CA
<ZIP>94111
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>Alliqua BioMedical, Inc.
<DATE-CHANGED>20140610
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>Alliqua, Inc.
<DATE-CHANGED>20101222
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>HEPALIFE TECHNOLOGIES INC
<DATE-CHANGED>20030529
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>tv531005-s1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
  <head>
    <title>tv531005-s1a - block - 19.9353358s</title>
  </head>
  <body style="width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:19pt;margin-bottom:21.71pt;margin-left:27pt;width:541pt;">

          <div style="text-align:center; width:541pt; line-height:11pt;font-weight:bold;font-size:10pt;">As filed with the U.S. Securities and Exchange Commission on November&#160;8, 2019 </div>

        <div style="margin-top:-3pt; text-align:right; width:541pt; line-height:10pt;font-weight:bold;">Registration No. 333-232169&#8203;</div>
        <div style="margin-top:0.5pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541pt; line-height:11pt;font-weight:bold;font-size:10pt;">UNITED STATES <br >SECURITIES AND EXCHANGE COMMISSION <br >Washington, D.C. 20549 </div>
        <div style="margin-top:4.5pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style="margin-top:4pt; text-align:center; width:541pt; line-height:9pt;font-weight:bold;">AMENDMENT NO. 4 TO<br >FORM S-1 <br >REGISTRATION STATEMENT <br >UNDER <br >THE SECURITIES ACT OF 1933 </div>

        <div style="margin-top:4.5pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5pt; text-align:center; width:541pt; line-height:19pt;font-weight:bold;font-size:18pt;">ADYNXX, INC. </div>
        <div style="margin-top:-2pt; text-align:center; width:541pt; line-height:10pt;">(Exact name of registrant as specified in our charter) </div>
        <div style="margin-top:1.5pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:541pt;height:25.4pt;margin-top:1.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174.34pt;">
              <div style="text-align:center;">Delaware </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:168.33pt;">
              <div style="text-align:center;">2834 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174.33pt;">
              <div style="text-align:center;">58-2349413 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.4pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0.733pt 0pt 0.5pt 0pt; width:174.34pt;">
              <div style="text-align:center;">(State or Other Jurisdiction of <br >Incorporation or Organization)</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.733pt 0pt 0.5pt 0pt; width:168.33pt;">
              <div style="text-align:center;">(Primary Standard Industrial <br >Classification Code Number) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.733pt 0pt 0.5pt 0pt; width:174.33pt;">
              <div style="text-align:center;">(I.R.S. Employer <br >Identification No.)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-align:center; width:541pt; line-height:8pt;font-weight:bold;">Adynxx, Inc. <br >100 Pine Street, Suite 500 <br >San Francisco, CA 94111 <br >(415) 512-7740 <br ><font style="font-weight:normal;">(Address, including zip code, and telephone number, including</font> <br ><font style="font-weight:normal;">area code, of registrant&#8217;s principal executive offices) </font></div>
        <div style="margin-top:2.89pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541pt; line-height:8pt;font-weight:bold;">Rick Orr <br >President and Chief Executive Officer <br >Adynxx, Inc. <br >100 Pine Street, Suite 500 <br >San Francisco, CA 94111 <br >(415) 512-7740 <br ><font style="font-weight:normal;">(Name, address, including zip code, and telephone number, including</font> <br ><font style="font-weight:normal;">area code, of agent for service) </font></div>
        <div style="margin-top:2.8pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541pt; line-height:9pt;font-weight:bold;">Copies to:</div>
        <table style="width:501pt;margin-left:20pt;margin-top:-3pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8.3pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:244.5pt;">
              <div style="text-align:center;">Laura A. Berezin <br >John T. McKenna <br >Cooley LLP <br >3175 Hanover Street <br >Palo Alto, CA 94304 <br >(650) 843-5000</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:244.5pt;">
              <div style="text-align:center;">Rick A. Werner <br >Haynes and Boone, LLP <br >30 Rockefeller Plaza, 26th Floor <br >New York, NY 10112 <br >(212) 659-7300</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:1.5pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:1pt; text-align:center; width:541pt; line-height:8.5pt;font-weight:bold;font-size:8.5pt;">Approximate date of commencement of proposed sale to the public: <br >As soon as practicable after the effective date of this registration statement. </div>
        <div style="margin-top:1.733pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:1pt; width:541pt; line-height:8.5pt;font-size:8.3pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933 check the following box: &#9746;</div>
        <div style="text-indent:20pt; margin-top:0.5pt; width:541pt; line-height:8.5pt;font-size:8.3pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>
        <div style="text-indent:20pt; margin-top:0.5pt; width:541pt; line-height:8.5pt;font-size:8.3pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>
        <div style="text-indent:20pt; margin-top:0.5pt; width:541pt; line-height:8.5pt;font-size:8.3pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>
        <div style="text-indent:20pt; margin-top:0.5pt; width:541pt; line-height:8.5pt;font-size:8.3pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of&#8201; &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </div>
        <table style="width:501pt;height:24pt;margin-left:20pt;margin-top:1.29999999999995pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.5pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:120pt;white-space:nowrap;">Large accelerated filer<br ></div>
              <div style=" line-height:8pt; text-align:left; margin-left:120pt;">&#9744;</div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.5pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:120pt;white-space:nowrap;">Accelerated filer<br ></div>
              <div style=" line-height:8pt; text-align:left; margin-left:120pt;">&#9744;</div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; width:244.5pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:120pt;white-space:nowrap;">Non-accelerated filer<br ></div>
              <div style=" line-height:8pt; text-align:left; margin-left:120pt;">&#9746;</div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; width:244.5pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:120pt;white-space:nowrap;">Smaller reporting company<br ></div>
              <div style=" line-height:8pt; text-align:left; margin-left:120pt;">&#9746;</div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; width:244.5pt;">
              <div style=" float:left; line-height:8pt; text-align:left; width:120pt;white-space:nowrap;">Emerging growth company<br ></div>
              <div style=" line-height:8pt; text-align:left; margin-left:120pt;">&#9744;</div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:244.5pt;white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="width:541pt;">
          <div style="text-indent:20pt; margin-top:0.5pt; line-height:8.5pt;font-size:8.3pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9744;</div>
        </div>
        <div style="text-align:center; width:541pt; line-height:9pt;font-weight:bold;">Calculation of Registration Fee </div>
        <table style="width:541pt;height:71.79pt;margin-top:-7.00000000000006pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
          <tr style="line-height:7pt;white-space:nowrap;text-align:left;vertical-align:bottom;">
            <td style="border-bottom:3px double #000000;padding:0pt 0pt 1pt 0pt; width:0pt;" colspan="13">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
            <td style="border-bottom:1px solid #000000;padding:0.067pt 0pt 0.833pt 0pt; width:380.41pt;text-align:left;">
              <div style="white-space:nowrap;">Title of Each Class of Securities to be Registered </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.067pt 0pt 0.833pt 0pt;" colspan="4">
              <div style="text-align:center;">Proposed Maximum Aggregate <br >Offering Price<font style=" position:relative; bottom:2.75pt;font-size:5.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.067pt 0pt 0.833pt 0pt;" colspan="4">
              <div style="text-align:center;">Amount of <br >Registration Fee<font style=" position:relative; bottom:2.75pt;font-size:5.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0.9pt 0pt 0.5pt 0pt; width:380.41pt;text-align:left;">
              <div style="white-space:nowrap;">Common stock, par value $0.001 per share</div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0.9pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:0.9pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,125,000</td>
            <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:1.15pt 0pt 0.5pt 0pt; width:380.41pt;text-align:left;">
              <div style="white-space:nowrap;">Common warrants to purchase shares of common stock and common stock issuable upon exercise thereof</div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
            <td style="padding:1.15pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.15pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,125,000</td>
            <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:1.15pt 0pt 0.5pt 0pt; width:380.41pt;text-align:left;">
              <div style="white-space:nowrap;">Pre-funded warrants to purchase shares of common stock and common stock issuable upon exercise thereof </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
            <td style="padding:1.15pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.15pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,125,000<font style="position:absolute;"><font style=" position:relative; bottom:2.75pt;font-size:6pt;">(2)</font></font></td>
            <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:1.14pt 0pt 0.5pt 0pt; width:380.41pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Placement agent warrants to purchase shares of common stock and common stock issuable upon exercise thereof </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
            <td style="padding:1.14pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.14pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">759,375<font style="position:absolute;"><font style=" position:relative; bottom:2.75pt;font-size:6pt;">(3)</font></font></td>
            <td style="padding:0pt;padding-left:25.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:3px double #000000;padding:1.14pt 0pt 1pt 0pt; width:380.41pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:25.295pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:1.14pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.14pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">31,134,375<font style="position:absolute;"><font style=" position:relative; bottom:2.75pt;font-size:6pt;">(4)</font></font></td>
            <td style="padding:0pt;padding-left:25.295pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.745pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:1.14pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.14pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">4,042</td>
            <td style="padding:0pt;padding-left:15.745pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
          </tr>
        </table>

          <div style=" float:left; line-height:7.8pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">(1)<br ></div>
          <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:7.8pt; text-align:left; margin-left:20pt;font-size:7.5pt;">Estimated solely for purposes of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. The registrant previously paid $4,042 in connection with a prior filing of this Registration Statement. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; line-height:7.8pt; margin-top:2.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">(2)<br ></div>
        <div style=" margin-top:2.19pt; margin-bottom:0pt; line-height:7.8pt; text-align:left; margin-left:20pt;font-size:7.5pt;">The proposed maximum aggregate offering price of the common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the aggregate offering price of the pre-funded warrants offered and sold in the offering (plus the aggregate exercise price of the common stock issuable upon exercise of the pre-funded warrants), and as such the proposed aggregate maximum offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $10,125,000. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:7.7pt; margin-top:2.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">(3)<br ></div>
        <div style=" margin-top:2.29pt; margin-bottom:0pt; line-height:7.7pt; text-align:left; margin-left:20pt;font-size:7.5pt;">Represents warrants issuable to the placement agent or its designees to purchase a number of shares of common stock equal to 7.5% of the number of shares of common stock and pre-funded warrants being offered at an exercise price equal to 125% of the public offering price. See &quot;Plan of Distribution.&quot; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:7.7pt; margin-top:2.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">(4)<br ></div>
        <div style=" margin-top:2.18pt; margin-bottom:0pt; line-height:7.7pt; text-align:left; margin-left:20pt;font-size:7.5pt;">Pursuant to Rule 416 under the Securities Act of 1933, as amended, the securities being registered hereunder include such indeterminate number of additional securities as may be issuable to prevent dilution resulting from stock splits, dividends or similar transactions. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:541pt; line-height:8pt;font-weight:bold;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission acting pursuant to said Section&#160;8(a), may determine.</div>
        <div style="margin-top:0.8pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:19pt;margin-bottom:21.71pt;margin-left:63pt;width:505pt;">
        <div style="text-align:justify; width:505pt; line-height:9.5pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;font-size:7.4pt;">
          <font style="letter-spacing:-0.3pt;font-size:8pt;">The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities, and we are not soliciting offers to buy these securities, in any jurisdiction where the offer or sale is not permitted.</font>
        </div>

          <div style="margin-top:12pt; text-align:center; width:505pt; line-height:11pt;font-weight:bold;color:#FC0014;font-size:10pt;">Subject to Completion, Dated November&#160;8, 2019</div>

        <div style="margin-top:4pt; width:505pt; line-height:8.5pt;font-weight:bold;">PRELIMINARY PROSPECTUS </div>
        <div style="position:relative;z-index:-1;margin-top:7pt; text-align:center; width:505pt;">
          <img src="lg_adynxx.jpg" alt="[MISSING IMAGE: lg_adynxx.jpg]" height="60" width="241" >
        </div>
        <div style="margin-top:9pt; text-align:center; width:505pt; line-height:11pt;font-weight:bold;font-size:10pt;">7,500,000 Shares of Common Stock </div>
        <div style="margin-top:4pt; text-align:center; width:505pt; line-height:11pt;font-weight:bold;font-size:10pt;">Pre-Funded Warrants to Purchase Shares of Common Stock </div>
        <div style="margin-top:4pt; text-align:center; width:505pt; line-height:11pt;font-weight:bold;font-size:10pt;">Common Warrants to Purchase 7,500,000 Shares of Common Stock </div>
        <div style="text-indent:20pt; margin-top:4pt; width:505pt; line-height:8.5pt;">Adynxx, Inc. is offering 7,500,000 shares of common stock and accompanying common warrants to purchase an aggregate of 7,500,000 shares of our common stock. The accompanying common warrants will be exercisable immediately and will expire five years from the date of issuance. Each common warrant has an exercise price of&#8201; $&#8199;&#8199;&#8199;&#8199; per share of common stock. </div>
        <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">We are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded warrants, in lieu of shares of common stock that would otherwise result in such purchaser&#8217;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant is exercisable for one share of our common stock and will be accompanied by a common warrant to purchase one share of common stock. The purchase price of each pre-funded warrant is equal to the price at which a share of common stock is sold to the public in this offering, minus $0.01, and the exercise price of each pre-funded warrant will be $0.01 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. </div>
        <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">This offering also relates to the shares of common stock issuable upon exercise of the accompanying common warrants and any pre-funded warrants sold in this offering. For each pre-funded warrant that we sell, the number of shares of common stock we are offering will be reduced on a one-for-one basis. Therefore, the number of common warrants sold in this offering will not change as a result of a change in the mix of the shares of our common stock and pre-funded warrants sold. The shares of common stock and pre-funded warrants, and the accompanying common warrants, can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. </div>

          <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">Our common stock is presently quoted on The OTCQB Market tier of the OTC Markets Group, Inc., or OTCQB, under the symbol &#8220;ADYX.&#8221; On November&#160;6, 2019, the last reported sale price of our common stock was $1.00 per share. The prices quoted on the OTCQB may not be indicative of the market price of our common stock on a national securities exchange. There is no established public trading market for the pre-funded warrants and the accompanying common warrants, and we do not expect a market to develop. In addition, we do not intend to apply for a listing of our common stock, the pre-funded warrants or the accompanying common warrants on any national securities exchange or other nationally recognized trading system. </div>

        <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">The actual combined public offering price per share of common stock and accompanying common warrant or pre-funded warrant and accompanying common warrant, as the case may be, will be determined through negotiation between us and the investors in the offering and may be at a discount to the current market price. Therefore, the recent market price used throughout this prospectus may not be indicative of the offering price. We have retained H.C. Wainwright &amp; Co., LLC to act as our exclusive placement agent in connection with the securities offered by this prospectus. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The placement agent is not purchasing or selling any of the securities we are offering and the placement agent is not required to arrange the purchase or sale of any specific or minimum number of securities or dollar amount. We have agreed to pay to the placement agent the placement agent fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus. See &#8220;Plan of Distribution&#8221; for more information regarding these arrangements. </div>
        <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">Because there is no minimum offering amount required as a condition to the closing of this offering, the actual public offering amount, placement agent fees and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth below. We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue the business goals outlined in this prospectus. In addition, because there is no escrow account and no minimum offering amount in this offering, investors could be in a position where they have invested in us, but we are unable to fulfill our objectives due to a lack of interest in this offering. </div>
        <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8pt;font-weight:bold;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; beginning on page <a href="#tRF">9</a> of this prospectus.</div>
        <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8pt;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</div>
        <table style="width:465pt;height:50pt;margin-left:20pt;margin-top:0.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7.5pt;">
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.46pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">PER SHARE </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="text-align:center;">PER<br >PRE-FUNDED<br >WARRANT </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="text-align:center;">PER<br >COMMON<br >WARRANT</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">TOTAL<font style=" position:relative; bottom:3pt;font-size:5.5pt;">(2)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7.5pt;">
            <td style="padding:1.25pt 0pt 0.5pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Public offering price </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.5pt;width:0pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:12.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.895pt;width:0pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:15.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.085pt;width:0pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:10.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.25pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7.5pt;">
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Placement agent&#8217;s fees<font style=" position:relative; bottom:3pt;font-size:5.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.5pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.895pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.085pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7.5pt;">
            <td style="padding:1.5pt 0pt 1pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Proceeds, before expenses, to us </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.5pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 1pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.5pt 0pt 1pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.895pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 1pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.5pt 0pt 1pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.085pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 1pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.5pt 0pt 1pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 1pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.5pt 0pt 1pt 0pt; min-width:12pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.4pt; width:505pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.29pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8.29pt; margin-bottom:0pt; line-height:7.5pt; text-align:left; margin-left:20pt;">We have agreed to reimburse the placement agent for certain expenses in connection with this offering. See &#8220;Plan of Distribution.&#8221; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9.5pt; margin-top:-1.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:-1.2pt; margin-bottom:0pt; line-height:9.5pt; text-align:left; margin-left:20pt;">The public offering price is $&#8199;&#8199;&#8199;&#8199; per share of common stock, $&#8199;&#8199;&#8199;&#8199; per pre-funded warrant, and $&#8199;&#8199;&#8199;&#8199; per accompanying common warrant. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">Provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG, convertible notes in the aggregate principal amount of&#8201; $6.35 million held by entities affiliated with Domain Associates, and any unpaid accrued interest, will automatically convert into 4,874,744 shares of common stock, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying common warrant, the last reported sale price of our common stock by OTCQB on October 9, 2019. The issuance of these shares will not be registered under the Securities Act of 1933, as amended. </div>
        <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">Entities affiliated with Domain Associates, or Domain, and TPG Biotechnology Partners IV, L.P, or TPG, have indicated an interest in purchasing up to an aggregate of&#8201; $4.25 million of securities in this offering at the public offering price per share of common stock and accompanying common warrant or pre-funded warrant and accompanying common warrant, as the case may be. However, because indications of interest are not binding agreements or commitments to purchase, either of Domain or TPG may elect to purchase more, fewer or no securities in this offering or the placement agent may elect to sell more, fewer or no securities in this offering to either of Domain or TPG. The placement agent will receive the same fee from the sale of any of our securities to Domain or TPG as it will from any other of our securities sold to the public in this offering. Any securities purchased by Domain or TPG in this offering will not be subject to the lock-up agreements with the placement agent that are described below. </div>
        <div style="text-indent:20pt; margin-top:3pt; width:505pt; line-height:8.5pt;">Delivery of the shares of common stock, pre-funded warrants, and accompanying common warrants is expected to be made on or about &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2019. </div>
        <div style="margin-top:2pt; text-align:center; width:505pt; line-height:12pt;font-weight:bold;font-size:10pt;">H.C.Wainwright&#160;&amp; Co. </div>
        <div style="margin-top:4pt; text-align:center; width:505pt; line-height:12pt;font-size:10pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2019 </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">TABLE OF CONTENTS </div>
        <table style="width:456pt;height:424.5pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:414pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Page </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.75pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCD">Certain Defined Terms </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.75pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.75pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tCD">ii</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPS">Prospectus Summary </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tPS">1</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRF">Risk Factors </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tRF">9</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNR">Special Note Regarding Forward-Looking Statements </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tSNR">41</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIMD">Industry and Market Data </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tIMD">43</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP">Use of Proceeds </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tUOP">44</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDP">Dividend Policy </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tDP">46</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <a href="#tCAP">Capitalization</a>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tCAP">47</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <a href="#tDIL">Dilution</a>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tDIL">49</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMOCS">Market for Our Common Stock</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tMOCS">51</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMDA">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tMDA">52</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tOB">Our Business </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tOB">65</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMAN">Management </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tMAN">97</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tECOA">Executive Compensation of Adynxx</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tECOA">102</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tECA">Executive Compensation of Alliqua</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tECA">106</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCR">Certain Relationships and Related Person Transactions </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tCR">110</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPSS">Principal Stockholders </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tPSS">113</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDCS">Description of Capital Stock </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tDCS">116</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDSO">Description of Securities We Are Offering</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tDSO">120</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMAT">Material U.S. Federal Income Tax Consequences </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tMAT">123</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD">Plan of Distribution </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tPOD">130</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLM">Legal Matters </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tLM">135</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP">Experts </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tEXP">135</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF">Where You Can Find More Information </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tWYCF">135</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPF">Adynxx Inc. Unaudited Pro Forma Financial Information</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tPF">136</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIF">Index to Financial Statements</a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <a href="#tIF">F-1</a>
            </td>
            <td style="padding:0pt;padding-left:7.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.98pt; width:456pt; line-height:12pt;">Neither we nor the placement agent have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by us or on our behalf. Neither we nor the placement agent take responsibility for, and can provide no assurance as to the reliability of, any information that others may give you. We and the placement agent are not offering to sell, or seeking offers to buy, the securities offered hereby in any jurisdiction where such offer or sale is not permitted. The information contained in this prospectus or in any applicable free writing prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any sale of the securities offered hereby. Our business, financial condition, results of operations and prospects may have changed since that date. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Persons in jurisdictions outside the United States who come into possession of this prospectus and any applicable free writing prospectus must inform themselves about, and observe any restrictions relating to, this offering and the distribution of this prospectus and any applicable free writing prospectus applicable to such jurisdictions. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">i</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCD">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CERTAIN DEFINED TERMS </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">As used in this prospectus, unless the context otherwise requires, references to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">&#8220;Adynxx&#8221; or &#8220;Private Adynxx&#8221; refer to Adynxx, Inc. prior to the consummation of the Merger; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">&#8220;Alliqua&#8221; refers to Alliqua BioMedical, Inc. and, unless otherwise stated or the context otherwise requires, its consolidated subsidiaries prior to the consummation of the Merger; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">&#8220;Merger&#8221; refers to the business combination between Adynxx, Inc. and Alliqua BioMedical, Inc., consummated on May&#160;3, 2019, pursuant to which (i)&#160;Embark Merger Sub, Inc., a then wholly-owned subsidiary of Alliqua BioMedical, Inc., merged with and into Adynxx, Inc., with Adynxx, Inc. surviving as a wholly-owned subsidiary of Alliqua BioMedical, Inc., (ii) Alliqua BioMedical, Inc. issued shares of its common stock to stockholders of Adynxx, Inc. at an exchange rate of 0.0359 shares of common stock in exchange for each share of Adynxx, Inc. common stock outstanding immediately prior to the Merger (which exchange rate reflects a 1-for-6 reverse stock split of the issued and outstanding share capital of Alliqua BioMedical, Inc. effected on May&#160;3, 2019, or the &#8220;Merger Stock Split&#8221;). Immediately after the Merger, the former Private Adynxx stockholders, warrantholders and optionholders owned approximately 86% of the fully-diluted common stock of the combined company, and the Alliqua stockholders and optionholders, whose shares of Alliqua common stock remained outstanding after the Merger, owned approximately 14% of the fully-diluted common stock of the combined company, and (iii)&#160;Alliqua BioMedical, Inc. was renamed &#8220;Adynxx, Inc.&#8221;; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and similar references refer: (i)&#160;prior to the consummation of the Merger, to Adynxx, Inc., and (ii) following the consummation of the Merger, to Adynxx, Inc. (formerly Alliqua BioMedical, Inc.) and, unless otherwise stated or the context otherwise requires, all of its subsidiaries. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">ii</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPS">&#8203;</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PROSPECTUS SUMMARY </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">The following summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our securities, you should carefully read this entire prospectus carefully, including our consolidated financial statements and the related notes included in this prospectus and the information set forth herein under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are a clinical stage biopharmaceutical company focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Transcription factor decoys are short strands of DNA that specifically bind to and block the activity of their target transcription factors. Transcription factors are proteins that specifically bind to the regulatory regions of one or more target genes and regulate the expression of those genes. Since the founding of Adynxx in 2007, we have leveraged our AYX platform of proprietary transcription factor decoys to identify and develop novel product candidates designed to modify the course of pain. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe that our transcription factor decoy technology can transform the treatment of pain, and going forward has the potential to be applied to additional disease states. We plan to continue advancing our AYX platform programs while simultaneously developing new transcription factor decoy candidates, collaborating with twoXAR, our artificial intelligence-driven drug discovery partner, and evaluating in-licensing opportunities in order to expand our pipeline and leverage our business development, clinical development and regulatory expertise. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">The AYX Platform of Transcription Factor Decoys </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The AYX platform consists of a wide range of transcription factor decoys, each of which has multiple binding sites capable of targeting one or more transcription factors, and we believe that we have the technological expertise to generate additional decoys based on desired therapeutic characteristics. The AYX platform&#8217;s current drug candidates are intended to treat postoperative pain, or post-surgical, and chronic pain. We plan to leverage our expertise in transcription factor decoy drug discovery and development to identify additional product candidates to treat inflammation-related diseases, including, but not limited to, organ scarring, heart disease and cancer. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Product Pipeline </div>
          <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following table outlines the status of our development programs: </div>
          <div style="position:relative;z-index:-1;margin-top:10.98pt; text-align:center; width:456pt;">
            <img src="tv523241_chrt-org.jpg" alt="[MISSING IMAGE: tv523241_chrt-org.jpg]" height="143" width="553" >
          </div>
          <div style="margin-top:19.39pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Brivoligide for postoperative pain </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Based on data from the Agency for Healthcare Research and Quality&#8217;s 2014 Healthcare Cost and Utilization Project, there are more than 37&#160;million surgical procedures performed in the United States annually. Postoperative pain remains a significant clinical problem, compromising rehabilitation and </div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">health-related quality of life. Severe postoperative pain can result in increased opioid use, prolonged hospital stays, poorer prognosis, and poorer health overall compared to people with less intense pain. In addition, sustained postoperative pain that continues beyond the recovery period is relatively common and not well addressed by current therapies. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide is a transcription factor decoy specifically designed to inhibit the function of transcription factor Early Growth Response 1, or EGR1, in the dorsal root ganglia, or DRG, and spinal cord when administered at the time of surgery. EGR1 is a transcription factor expressed in the spinal cord and DRG in response to trauma such as surgery for a period of approximately 12 hours. In normal animals, EGR1 initiates a wide range of gene regulation that results in increased or exacerbated pain following trauma or injury. In contrast, in animals that are unable to express EGR1, third party studies have shown that there is a reduction of pain intensity in response to trauma or injury, which may suggest that EGR1 has a role in elevated post-surgical pain. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">By inhibiting the function of EGR1 in people undergoing surgery, we believe brivoligide can prevent the regulation of genes that lead to an increased sensitivity to pain in some patients following surgery. These patients, who are at greater risk of experiencing increased and prolonged pain after surgery, are readily identifiable prior to surgery as patients scoring high on the Pain Catastrophizing Scale, or PCS, and represent approximately one-third of the surgical population. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pain catastrophizing is an amplified, negative orientation toward pain, which may reflect a specific underlying physiology of pain associated with an enhanced response to painful stimuli as well as relative insensitivity to analgesic, or pain-relieving, therapies such as opioids. Catastrophizing is readily assessed by the PCS, a screening assessment tool for patient selection purposes. Once the PCS is completed by the patient, summation of the responses allows results to be easily available well in advance of surgery in order to determine which patients would potentially benefit from receiving brivoligide. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Patients who have high scores on the PCS may have a specific underlying physiology associated with an enhanced response to painful stimuli. Based on the clinical data we have generated to date from our clinical studies, we believe these patients have an altered pain response that results in the full manifestation of EGR1 activity in response to trauma such as surgery. In this population of patients undergoing surgery, post-hoc anlyses of data generated in the three Phase 2 studies of brivoligide conducted to date indicate that patients receiving a single administration of brivoligide at the time of surgery, in addition to standard of care, experienced reduced pain for weeks and shortened time to achieve mild pain, both as measured using the numerical rating scale, or NRS, when compared to patients receiving placebo and standard of care. These differences were either not statistically significant or could not be considered significant due to the post-hoc nature of the analyses. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We estimate that of the 37 million surgical procedures performed in the United States annually, approximately 16 million of those result in a sufficient duration and severity of postoperative pain to be characterized as high unmet analgesic need procedures. Of those 16 million high unmet analgesic need procedures, we expect that approximately one third will be conducted on patients scoring high (&ge;16) on the PCS, representing approximately 5.3 million patients who we believe could be candidates for brivoligide treatment. See &#8220;Business&#8201;&#8212;&#8201;Our Product Candidates&#8201;&#8212;&#8201;Postoperative Pain and Pain Catastrophizing.&#8221; </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have filed with the U.S. Food and Drug Administration, or the FDA, an Investigational New Drug application, or IND, for brivoligide for the reduction of postoperative pain in patients scoring &ge;16 on the PCS. This IND allows us to conduct the activities required for us to submit a New Drug Application, or NDA, to the FDA for marketing approval and eventual commercialization of brivoligide. In particular, an IND must become effective before human clinical studies for the applicable product candidate may begin and must be updated annually or when significant changes are made. Successful completion of human clinical studies is a prerequisite to submitting an NDA to the FDA, which must be approved before we may commercialize brivoligide in the United States. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We plan to conduct a Phase 2 randomized double-blind, placebo-controlled study to evaluate the safety and efficacy of a single intrathecal preoperative administration of brivoligide injection in patients with a PCS score &ge;16 undergoing mastectomy, with prospective enrichment of the study population (in which patients are chosen who are more likely to respond to drug treatment). We plan to commence this Phase 2 </div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">clinical trial as early as the first quarter of 2020, with top-line results expected as early as the first half of 2021, subject to receipt of additional capital to fund the trial through top-line results including receipt of additional funds from our grant award from the National Institute of Drug Abuse, or NIDA, described under &#8220;&#8212; NIH Grant.&#8221; In addition, we plan to conduct a Phase 2 randomized double-blind, placebo-controlled study to evaluate the safety and efficacy of a single intrathecal preoperative administration of brivoligide injection in patients with a PCS score &ge;16 undergoing total knee arthroplasty, or TKA to further explore the results obtained in prior Phase 2 studies in TKA in the proposed target population. We are evaluating whether to commence this Phase 2 clinical trial as early as the first quarter of 2020, with top-line results expected as early as the fourth quarter of 2020, subject to receipt of additional capital to fund the trial through top-line results. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">&#8220;Top-line&#8221; data from our clinical studies refer to the results from the initial planned analyses of primary and certain key secondary endpoints from our clinical trials after enrollment has been completed and the data from the study database is locked. Top-line data remain subject to audit and verification procedures that may result in the final data being materially different from previously published top-line data. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">AYX2 for chronic pain </div>
          <div style="text-indent:20pt; margin-top:5.21pt; width:456pt; line-height:12pt;">Chronic pain affects as many as 25 million patients annually in the United States and includes such types of pain as low back pain, pain associated with pinched or compressed nerves known as radiculopathy, and pain associated with inflammation of the spinal nerve root known as radiculitis. Chronic pain can be caused and maintained by changes in various components of the pain pathway, including the ongoing regulation of gene activity in the spinal cord and DRG. The transcription factors driving this regulation include a family of transcription factors known as Kruppel-like Factors, or KLF, and constitute a promising class of targets that can potentially alter the course of pain with a single or short-term treatment. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">AYX2, the second product candidate in our pipeline originating from the AYX platform, is a transcription factor decoy targeting the activity of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15. It is being developed for the treatment of chronic pain from multiple causes or origins, including pain resulting from inflammation known as inflammatory pain and pain resulting from nerve damage known as neuropathic pain. Our preclinical work showed that KLF6, KLF9 and KLF15 transcription factors are important to maintaining chronic inflammatory or neuropathic pain. AYX2 is designed to bind to KLF 6, KLF 9 and KLF 15 and block their activity in the spinal cord and DRG. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have tested AYX2 in multiple models of pre-clinical pain, including the spared-nerve injury, or SNI, and chronic constriction injury, or CCI, both of which are well recognized models to test the response to painful stimuli in rats. In these studies, AYX2 produced up to a 60% to 70% reduction in response to painful stimuli compared to control animals, or animals treated with an inactive solution, and the effect was sustained for several weeks. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">NIH Grants </div>
          <div style="text-indent:20pt; margin-top:5.21pt; width:456pt; line-height:12pt;">In December&#160;2018, we received a grant award from NIDA, part of the National Institutes of Health, or NIH, for up to $5.7&#160;million to be reimbursed over 2019 and 2020 to support the conduct of the Phase&#160;2 mastectomy study. If successful, we plan to follow the Phase&#160;2 studies of brivoligide with Phase&#160;3 pivotal studies in both TKA and mastectomy. The design and size of the Phase&#160;3 studies will be determined after completion of the respective Phase&#160;2 studies. Based on the funding opportunity announcement under which we received the award, and on the milestones and budget outlined in our application, following completion of milestones related to the Phase&#160;2 mastectomy study, including receipt of positive data for the Phase 2 mastectomy study and clear guidance from the FDA at an end of phase 2 meeting, we may be eligible to receive an additional award of up to $9.0&#160;million over three&#160;years to fund a Phase&#160;3 mastectomy study. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In September 2019, we received a Notice of Award from the National Institute on Neurological Disease and Stroke, or NINDS, part of the NIH, for up to approximately $0.6&#160;million to be paid over 12&#160;months to support our planned preclinical studies of AYX2. The funds will become available after approval from the Office of Laboratory Animal Welfare, or OLAW, of the planned preclinical studies for AYX2. </div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Collaboration with twoXAR to identify product candidates for the treatment of endometriosis </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Endometriosis is an often painful disorder in which tissue similar to the lining of the uterus grows in other places outside of the uterus. Approximately 4.4&#160;million women suffer from endometriosis in the United States, with up to 175,000 new diagnoses projected annually by 2022. Symptoms of endometriosis include chronic pelvic pain, painful menstruation and sexual intercourse, infertility, and painful hypersensitivity. In endometriosis patients, severity of symptoms increases with age, yet symptom severity is not always correlated with extent of disease. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2018, we entered into a collaboration with twoXAR, an artificial intelligence-driven drug discovery company, in order to identify product candidates for the treatment of endometriosis. Through this collaboration, we seek to identify product candidates with disease-modifying potential to treat or prevent the recurrence of endometriosis and associated symptoms. New disease-modifying treatments addressing the underlying pathology of endometriosis are sought to address the unmet need associated with the current standard of care. In June 2019, we received an initial set of product candidate predictions from twoXAR. We have initiated a review of the potential product candidates to determine if any are viable candidates for further research and development. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Highly experienced management team with significant operational and commercialization experience </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have a highly experienced management team whose members have, in the course of their prior employment, participated in bringing more than 10 product candidates through clinical development, regulatory approval and/or into commercialization, including such approved products as Zerbaxa, Teflaro, Doribax, Vibativ, Symproic, Embeda, Revlimid, Mulpleta, Osphena, Comtan, FocalinXR, Trileptal, Kapvay and Cuvposa. We plan to leverage our management team&#8217;s breadth and depth of experience in clinical and regulatory drug development as well as market development and commercialization to advance our existing product candidates, and to discover and develop additional product candidates in-house using the AYX platform and build our pipeline through collaboration and in-licensing activities.</div>

            <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Recent Developments</div>


            <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of September&#160;30, 2019, we had approximately $331,000 in cash and cash equivalents, as compared to $24,000 as of June&#160;30, 2019. This financial data as of September&#160;30, 2019 is preliminary and may change, and is based on information available to management as of the date of this prospectus and is subject to completion by management of our financial statements as of and for the quarter ended September&#160;30, 2019. There can be no assurance that our cash position as of September&#160;30, 2019 will not differ from this estimate. Our independent registered public accountants have not audited, reviewed or performed any procedures with respect to such preliminary financial data and accordingly do not express an opinion or any other form of assurance with respect thereto.</div>

          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Corporate Information </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Private Adynxx was a Delaware corporation that was originally formed in 2007 under the name Adynxx, Inc. On May&#160;3, 2019, Private Adynxx completed the Merger with Alliqua BioMedical, Inc., or Alliqua, and we survived as a wholly-owned subsidiary of Alliqua. Following the consummation of the Merger, Adynxx changed its name to Adynxx Sub, Inc., and Alliqua BioMedical, Inc. changed its name to Adynxx, Inc. Our common stock subsequently began trading on The Nasdaq Capital Market, or Nasdaq, under the symbol &#8220;ADYX.&#8221; In June 2019, Nasdaq delisted our common stock due to our noncompliance with Nasdaq&#8217;s minimum stockholders&#8217; equity requirement and minimum round lot shareholder requirement. Our common stock is presently quoted on The OTCQB Market tier of the OTC Markets Group, Inc., or OTCQB, under the symbol &#8220;ADYX.&#8221; We do not intend to list our common stock or any other securities offered hereby on a national securities exchange in connection with this offering. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Alliqua was a Delaware corporation that was originally formed in 1997 under the name Zeta Corporation in Florida. On April&#160;17, 2003, Zeta Corporation changed its name to Hepalife Technologies, Inc., and on December&#160;20, 2010, Zeta Corporation changed its name to Alliqua, Inc. On June&#160;6, 2014, pursuant to an Agreement and Plan of Merger, Alliqua merged with and into its wholly-owned Delaware subsidiary, Alliqua BioMedical, Inc. </div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our principal executive offices are located at 100 Pine Street, Suite 500, San Francisco, California 94111, and our telephone number is (415) 512-7740. Our corporate website address is www.adynxx.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">&#8220;Adynxx,&#8221; the Adynxx logo, &#8220;Alliqua&#8221; and other trademarks or service marks of Adynxx appearing in this prospectus are our property. This prospectus contains additional trade names, trademarks, and service marks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.<br ></div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">THE OFFERING </div>
          <div style="width:156pt;">
            <div style="margin-top:6pt; line-height:12pt;">Common stock offered by us </div>
          </div>
          <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">7,500,000 shares. </div>
          <div style="width:156pt;">
            <div style="margin-top:6pt; line-height:12pt;">Pre-funded warrants offered by us </div>
          </div>
          <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">We are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the closing of this offering, the opportunity to purchase, if such purchasers so choose, pre-funded warrants to purchase shares of common stock, in lieu of shares of common stock that would otherwise result in any such purchaser&#8217;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant is exercisable for one share of our common stock. The purchase price of each pre-funded warrant and accompanying common warrant is equal to the price at which a share of common stock and accompanying common warrant is being sold to the public in this offering, minus $0.01, and the exercise price of each pre-funded warrant is $0.01 per share. The pre-funded warrants are exercisable immediately and may be exercised at any time until all of the pre-funded warrants are exercised in full. </div>
          <div style="margin-left:180pt; margin-top:6pt; width:276pt; line-height:12pt;">This offering also relates to the shares of common stock issuable upon exercise of any pre-funded warrants sold in this offering. For each pre-funded warrant that we sell, the number of shares of common stock that we are offering will be reduced on a one-for-one basis. Because we will issue a common warrant for each share of our common stock and for each pre-funded warrant to purchase one share of our common stock sold in this offering, the number of common warrants sold in this offering will not change as a result of a change in the mix of the shares of our common stock and pre-funded warrants sold.</div>
          <div style="width:156pt;">
            <div style="margin-top:6pt; line-height:12pt;">Common warrants offered by us </div>
          </div>
          <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">Common warrants to purchase an aggregate of 7,500,000 shares of our common stock. Each share of our common stock and each pre-funded warrant is being sold together with a common warrant to purchase one share of our common stock. Each common warrant will have an exercise price of&#8201; $&#8199;&#8199;&#8199;&#8199; per share, will be immediately exercisable and will expire on the fifth anniversary of the original issuance date. This prospectus also relates to the offering of the shares of common stock issuable upon exercise of the common warrants. </div>
          <div style="width:156pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">Common stock to be outstanding after this offering </div>
          </div>
          <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">18,182,621 shares, assuming no sale of any pre-funded warrants and assuming no exercise of any common warrants issued in this offering. </div>
          <div style="width:156pt;">
            <div style="margin-top:6pt; line-height:12pt;">Use of proceeds </div>
          </div>
          <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">We estimate that the net proceeds from this offering will be approximately $8.2 million, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying common warrant, the last reported sale price of our common stock by OTCQB on October&#160;9, 2019, after </div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">6</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style="margin-left:180pt; width:276pt; line-height:12pt;">deducting placement agent fees and estimated offering expenses payable by us, and assuming the sale of the maximum offering amounts set forth in this prospectus. </div>
          <div style="margin-left:180pt; margin-top:6pt; width:276pt; line-height:12pt;">We intend to use the net proceeds from this offering to conduct clinical trials of brivoligide for postoperative pain and to further develop AYX2 for chronic pain, to fund continued research and development, to service our outstanding indebtedness and for working capital and other general corporate purposes. See &#8220;Use of Proceeds&#8221; for additional information. </div>
          <div style="width:156pt;">
            <div style="margin-top:6pt; line-height:12pt;">Risk factors </div>
          </div>
          <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">Investing in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our securities. </div>
          <div style="width:156pt;">
            <div style="margin-top:6pt; line-height:12pt;">OTCQB symbol </div>
          </div>
          <div style="margin-left:180pt; margin-top:-12pt; width:276pt; line-height:12pt;">&#8220;ADYX&#8221; </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June 2019, Nasdaq delisted our common stock due to our noncompliance with Nasdaq&#8217;s minimum stockholders&#8217; equity requirement and minimum round lot shareholder requirement. We do not intend to list the common stock, pre-funded warrants or common warrants on any securities exchange or nationally recognized trading system in connection with this offering. Without a trading market, the liquidity of the common stock, pre-funded warrants and common warrants will be extremely limited. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG, convertible notes in an aggregate principal amount of&#8201; $6.35&#160;million held by entities affiliated with Domain Associates, and any unpaid accrued interest, will automatically convert into 4,874,744&#160;shares of common stock, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying common warrant, the last reported sale price of our common stock by OTCQB on October&#160;9, 2019. The issuance of these shares will not be registered under the Securities Act of 1933, as amended, or the Securities Act. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Domain and TPG have indicated an interest in purchasing up to an aggregate of&#8201; $4.25 million of securities in this offering at the public offering price per share of common stock and accompanying common warrant or pre-funded warrant and accompanying common warrant, as the case may be. However, because indications of interest are not binding agreements or commitments to purchase, either of Domain or TPG may elect to purchase more, fewer or no securities in this offering or the placement agent may elect to sell more, fewer or no securities in this offering to either of Domain or TPG. The placement agent will receive the same fee from the sale of any of our securities to Domain or TPG as it will from any other of our securities sold to the public in this offering. Any securities purchased by Domain or TPG in this offering will not be subject to the lock-up agreements with the placement agent that are described below. </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The number of shares of common stock that will be outstanding after this offering is based on 5,807,877 shares of common stock outstanding as of June&#160;30, 2019, and excludes:</div>

            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">747,879 shares of common stock issuable upon the exercise of outstanding stock options as of June 30, 2019, with a weighted-average exercise price of&#8201; $24.95 per share, under our equity incentive plans or not granted pursuant to a written equity incentive plan;</div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">3,332 shares of common stock issuable from time to time after this offering upon the settlement of restricted stock awards, or RSAs, outstanding as of June&#160;30, 2019 under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">57,897 shares of common stock issuable upon the exercise of outstanding warrants as of June&#160;30, 2019, with a weighted-average exercise price of&#8201; $97.66 per share; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">9,188 shares of common stock reserved for future issuance under the Alliqua, Inc. 2011 Long-Term Incentive Plan; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">7</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-bottom:18.7099999999999pt; margin-left:14pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">72,436 shares of common stock reserved for future issuance under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, unless we specifically state otherwise, all information in this prospectus reflects or assumes: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the issuance of 4,874,744 shares of common stock at the closing of the offering upon the conversion of outstanding convertible notes in the aggregate principal amount of&#8201; $6.35&#160;million plus accrued interest based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying common warrant, the last reported sale price of our common stock by OTCQB on October&#160;9, 2019, provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">no exercise of the outstanding options or warrants described above; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">no exercise of the common warrants or placement agent warrants; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">no sale of any pre-funded warrants in this offering. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">8</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">RISK FACTORS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">Investing in the securities offered hereby involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this prospectus, including our consolidated financial statements and related notes included in this prospectus, before deciding whether to invest in the securities offered hereby. If any of these risks actually occur, it could harm our business, financial condition, results of operations and cash flows and our prospects. In that event, the trading price of our common stock and the value of the pre-funded warrants could decline and you could lose part or all of your investment.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Our Financial Condition and Capital Requirements </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have incurred losses since our inception, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are a clinical development-stage biopharmaceutical company with a limited operating history. On May&#160;3, 2019, we completed the Merger with Alliqua BioMedical, Inc., and we survived as a wholly-owned subsidiary of Alliqua. Following the consummation of the Merger, Adynxx changed its name to Adynxx Sub, Inc., and Alliqua BioMedical, Inc. changed its name to Adynxx, Inc. Adynxx was deemed to be the accounting acquirer in the Merger and the historical financial statements of Private Adynxx are deemed to be the historical financial statements of the combined company. We have incurred net losses for the past several&#160;years, including net losses of&#8201; $7.1&#160;million, $6.0&#160;million and $11.6&#160;million for the six&#160;months ended June&#160;30, 2019 and the&#160;years ended December&#160;31, 2018 and 2017, respectively. As of June&#160;30, 2019, we had an accumulated deficit of&#8201; $44.4&#160;million. </div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, we had $12.0&#160;million in current and long-term liabilities. In addition, since June&#160;30, 2019, we issued an additional $0.85&#160;million in convertible promissory notes, or Notes. Our management concluded that there is substantial doubt about our ability to continue as a going concern. The audit report to our financial statements for the year ended December&#160;31, 2018, which is included elsewhere in this prospectus, also includes an explanatory paragraph related to our ability to continue as a going concern. The doubts concerning our ability to continue as a going concern may impact our ability to obtain financing on reasonable terms or at all. As of June&#160;30, 2019, we had cash and cash equivalents of&#8201; $24,000. </div>

        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have devoted substantially all of our financial resources to identifying and developing our product candidates, including conducting clinical trials and providing general and administrative support for our operations. To date, we have financed our operations primarily through the sale of equity securities, payments associated with strategic collaborations, secured loan agreements and convertible notes. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We expect losses to increase as we continue Phase&#160;2 development of our lead program brivoligide in two models of postoperative pain and potentially advance additional product candidates through investigational new drug, or IND, enabling activities and into clinical development. While we have not yet commenced pivotal clinical trials for any product candidate and it may be several&#160;years, if ever, before we complete pivotal clinical trials and have a product candidate approved for commercialization, we expect to invest significant funds into these clinical candidates to determine the potential to advance these compounds to regulatory approval. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market acceptance, hospital formulary access, pricing, reimbursement from third-party payors, and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates, because the potential markets in which our product candidates may ultimately receive regulatory approval could be very small, we may never become profitable despite obtaining such market share and acceptance of our products.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">9</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">continue the clinical development of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">advance our programs into larger, more expensive clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">initiate additional nonclinical, clinical, or other studies for our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">identify and develop potential commercial opportunities, such as reduction in postoperative pain for patients scoring &ge;16 on the Pain Catastrophizing Scale, or PCS, for the brivoligide product candidate; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">seek regulatory and marketing approvals and reimbursement for our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">continue manufacturing our product candidates and plan for scale-up of outsourced manufacturing capabilities as we commence additional clinical trials for our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">seek to identify, assess, acquire, and/or develop other product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">make milestone, royalty or other payments under third party license agreements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">seek to maintain, protect, and expand our intellectual property portfolio; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">seek to attract and retain skilled personnel; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">experience any delays or encounter issues with the development and potential for regulatory approval of our clinical candidates such as safety issues, clinical trial accrual delays, longer follow-up for planned studies, additional major studies, or supportive studies necessary to support marketing approval. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have never generated any revenue from product sales and may never be profitable. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have no products approved for commercialization and have never generated any revenue from product sales. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of our product candidates. We do not anticipate generating revenue from product sales for the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">completing research and development of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">obtaining regulatory and marketing approvals for our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that meet regulatory requirements and our supply needs in sufficient quantities to meet market demand for our product candidates, if approved; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">marketing, launching and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">gaining market acceptance of our product candidates as treatment options; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">addressing any competing products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">10</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">protecting and enforcing our intellectual property rights, including patents, trade secrets, and know-how; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.62pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:3.62pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">obtaining reimbursement or pricing for our product candidates that supports profitability; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:3.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">attracting, hiring, and retaining qualified personnel. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. We will have to develop or acquire commercial-scale manufacturing capabilities in order to continue development and potential commercialization of our product candidates. Additionally, if we are not able to generate revenue from the sale of any approved products, we may never become profitable. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Servicing our indebtedness requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial indebtedness. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, our total current and long-term liabilities balance was $12.0&#160;million, of which $2.4&#160;million was secured indebtedness, collateral for which includes, but is not limited to, our intellectual property rights. Our ability to make scheduled payments of the principal, to pay interest on, to refinance the secured loan agreement with Oxford Finance, or the Loan Agreement, or Notes or to make cash payments in connection with any conversion of the Notes depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control and ability to raise additional capital. We may not be able to raise sufficient capital or generate cash flow from operations in the future sufficient to service our indebtedness and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives if they are available to us based on the terms of the instruments and agreements governing the indebtedness, such as restructuring indebtedness or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. If we default under the Loan Agreement, Oxford Finance will have the ability to exercise its rights as collateral agent to take possession and dispose of the collateral securing the indebtedness under the Loan Agreement, which collateral includes all of our property, including our intellectual property. Our business, financial condition and results of operations could be substantially harmed as a result of any such foreclosure. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Despite our current indebtedness levels, we may still incur substantially more indebtedness or take other actions which would intensify the risks discussed above. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Despite our current indebtedness levels, and the restrictions we are under based on the terms of the Loan Agreement from incurring additional senior indebtedness, we may be able to incur substantial additional indebtedness in the future, subject to any restrictions contained in our then-existing debt instruments, some of which may be secured indebtedness, however the terms of such indebtedness may not be commercially attractive, if available. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We face risks related to government funded awards. If NIDA/NIH or NINDS/NIH were to eliminate, reduce or delay funding from these awards, this would have a significant negative impact on the brivoligide program. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are substantially dependent upon awards from NIDA/NIH and NINDS/NIH for the costs related to the planned brivoligide Phase&#160;2 and Phase&#160;3 mastectomy model studies and the development of AYX2, respectively. If NIDA/NIH or NINDS/NIH were to eliminate, reduce or delay the funding for either or both of these awards or disallow some of our incurred costs, we would have to obtain additional funding for continued development or regulatory registration for brivoligide and AYX2 or significantly delay, reduce or stop the development effort. In contracting with NIDA/NIH and NINDS/NIH, we are subject to various U.S. government contract requirements which may limit reimbursement or if we are found to be in violation could result in contract termination. If the U.S. government terminates our award for its convenience, or if we default by failing to perform in accordance with the award schedule and terms, significant negative impact on our cash flows and operations could result. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">11</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">To the extent that we raise additional capital through the sale of equity, debt or other securities convertible into equity, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, would likely involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or more of our development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on potential business opportunities, which could materially affect our business, financial condition, and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to the Development of Our Product Candidates </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are heavily dependent on the success of our lead product candidate, brivoligide, which is in the early stages of clinical development, and our other product candidates, which are in pre-clinical development. We cannot give any assurance that we will generate data sufficient to receive regulatory approval, which will be required before any of our product candidates can be commercialized. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">To date, we have invested substantially all of our efforts and financial resources to identify and develop our portfolio of product candidates. Our future success is dependent on our ability to successfully further develop, obtain regulatory approval for, and commercialize one or more product candidates. We currently generate no revenue from sales of any drugs, and we may never be able to develop or commercialize a product candidate. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our product candidate brivoligide, which is currently in Phase&#160;2 of clinical development, is being developed for the reduction of postoperative pain in patients scoring &ge;16 on the PCS. We have not prospectively demonstrated a statistically significant clinical benefit in this patient population for the primary endpoint in any clinical trial and may not be able to do so. Furthermore, the U.S. Food and Drug Administration, or the FDA, has not previously granted an indication for the reduction of postoperative pain in patients scoring &ge;16 on the PCS. Additionally, in order to obtain an indication for the reduction of postoperative pain without restriction by type of surgical procedure, we intend to study brivoligide in pivotal trials in one orthopedic and one soft-tissue model of postoperative pain. We have studied brivoligide to date in TKA, an orthopedic model of postoperative pain, and intend to study brivoligide in mastectomy with immediate tissue expander or implant placement, or mastectomy, as a soft-tissue model of postoperative pain. Failure to demonstrate efficacy in both an orthopedic and soft-tissue model of postoperative pain may limit the likelihood of FDA approval for brivoligide for postoperative pain, may limit approval to a subset of surgical procedures, and may limit the addressable patient population and related commercial opportunity. Further, we may not be able to replicate or develop additional data to satisfy regulatory requirements for approval. Our other product candidate, AYX2, has not yet been evaluated in clinical trials and may fail to show the desired safety and efficacy during clinical development. There can be no assurance that the data that we develop for our product candidates in their planned indications will be sufficient to obtain regulatory approval. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our current product candidates are for the treatment of pain. The evaluation of pain therapeutics often relies upon patient-reported outcomes of pain, such as the Numerical Rating Scale, or NRS, as clinical trial endpoints. While these endpoints are well-validated and accepted by the FDA and comparable foreign authorities for evaluation of efficacy of product candidates for the treatment of pain, there may be increased variability associated with these patient-reported outcomes as compared to objective measures used in evaluation of efficacy for product candidates treating other disease states. If these patient-reported endpoints are associated with increased variability in future studies, the data generated may not be sufficient to obtain regulatory approval. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">12</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">In addition, none of our product candidates have advanced into a pivotal study for their proposed indications and it may be&#160;years before such studies are initiated and completed, if at all. We are not permitted to market or promote any of our product candidates before they receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our research and development is focused on discovering and developing novel drugs based on transcription factor decoys, and the approach we are taking to discover and develop drugs is not proven and may never lead to marketable products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The discovery and development of drugs based on transcription factor decoys is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing differentiated product candidates based on these discoveries is both preliminary and limited, and has not led to products which have obtained regulatory approval by the FDA or comparable foreign authorities. Therefore, we do not know if our approach will be successful. Failure by any transcription factor decoy, including those currently being developed by us, would adversely impact this platform technology. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, our product candidates are all based on a single platform technology. If we were required to discontinue development of brivoligide because the related trials are unsuccessful or do not demonstrate sufficiently positive results to continue development of brivoligide, development of our other product candidates may be harmed. Moreover, if we decide to leverage any success with brivoligide to develop our other product candidates reliant on our platform technology, we may not be successful in such efforts. In any such event, our business will be adversely impacted.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our research and development is focused on discovering and developing non-opioid therapies to treat pain. We are not developing our product candidates to address opioid dependence, and any potential impact these therapies may have on opioid usage is speculative and may never be supported by clinical data. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our product candidates are being developed for the treatment of pain. There can be no assurance that any of these product candidates will have any impact on potential opioid usage in patients who use our product candidates, if approved. There remains significant uncertainty regarding the assessment of opioid-sparing outcomes in clinical trials of product candidates addressing pain as well as the clinical relevance of any such results. Further, there is no clear guidance from regulators on the design or endpoints of clinical trials intended to evaluate pain and related opioid usage and what clinical data, if any, would be necessary to support potential claims of reduced opioid usage or opioid-sparing effects. As a result of this uncertainty, we cannot assess, and can provide no assurance of, the potential impact, if any, that our product candidates may have on opioid usage for pain or as analgesic therapy. In addition, we have not evaluated, and do not intend to evaluate, the potential effect of our product candidates on opioid dependence. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have yet to present the current clinical data to the relevant regulatory authorities to give an opinion on the clinical development pathway for brivoligide. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We plan to present the clinical and non-clinical data sets for brivoligide to the FDA and relevant foreign regulatory authorities after completion of the planned Phase&#160;2 studies at an End of Phase&#160;2 meeting or receipt of scientific advice from the EMA, as applicable. Until the results of these meetings are known and documented, there can no assurance as to what requirements may be imposed for filing a New Drug Application, or NDA, or Marketing Approval in the EMA for brivoligide. We are currently relying on opinions from experts and regulatory precedents to design our development program. It is possible that the official position of the applicable regulatory authorities will be substantially different from the advice we have received. Any such difference could increase both the time and cost required to obtain the necessary regulatory approvals for brivoligide, which may in turn limit or prohibit its further development, resulting in a material harm to our business, financial condition, results of operations and prospects. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">13</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Even if we successfully complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the regulatory approval may be for a more narrow indication than we seek. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many&#160;years following the commencement of clinical trials, and depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. We have not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the FDA or comparable foreign regulatory authorities may disagree with the design, size or implementation of our clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the FDA or comparable foreign regulatory authorities may disagree with the use of and definition of one orthopedic and one soft-tissue surgical model of postoperative pain as appropriate for approval for general postoperative pain; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the FDA does not currently have published guidance on the requirements for a general postoperative pain indication and may publish guidance that is not in alignment with our current clinical development plans, which may cause us to alter development plans, thereby increasing the costs and time required to complete clinical development of brivoligide; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the FDA or comparable foreign regulatory authorities may disagree with the use of the PCS as a tool for patient selection for treatment with brivoligide; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the population studied in our clinical trials may not be sufficiently broad or representative to assure safety in the full population for which we seek approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from our preclinical studies or clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United&#160;States or foreign jurisdictions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the FDA or comparable foreign regulatory authorities may find failures in our manufacturing processes, validation procedures and specifications, or facilities of the third-party manufacturers with which we contract for clinical and commercial supplies that may delay or limit our ability to obtain regulatory approval for our product candidates; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our NDA or other applicable regulatory submissions insufficient for approval. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The lengthy and uncertain regulatory approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. Even if our product candidates meet their safety and efficacy endpoints in clinical trials, the relevant regulatory authorities may not complete their review processes in a timely manner, may issue a complete response letter, or ultimately, may not approve our product candidates. In addition, we may experience delays or rejections if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">14</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of data obtained from preclinical and clinical testing could delay, limit or prevent the receipt of marketing approval for a product candidate. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Drug development involves a lengthy and expensive process with an uncertain outcome, and results of preclinical studies and earlier clinical trials may not be predictive of future results. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Clinical testing is expensive and generally takes many&#160;years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of larger, later-stage clinical trials. Product candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical trials. Our clinical trials to date have been conducted on a small number of patients in limited numbers of clinical sites. We will have to conduct larger studies in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. We have spent several years conducting clinical studies for our lead product candidate and anticipate that we will continue conducting clinical studies for a few more years. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether any Phase&#160;2, Phase&#160;3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to obtain regulatory approval to receive regulatory approval or market our product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Interim, &#8220;top-line,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as additional analyses are conducted, and as the data are subject to audit and verification procedures that could result in material changes in the final data.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">From time to time, we may publish interim, &#8220;top-line,&#8221; or preliminary data from our clinical studies. Interim data are data analyzed before completion of enrollment of a clinical trial, and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. &#8220;Top-line&#8221; or preliminary data from our clinical studies refer to the initial planned analyses of primary and certain key secondary endpoints from clinical trials after enrollment has been completed and the data from the study database is locked. These data remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, &#8220;top-line&#8221; and preliminary data should be viewed with caution until the final data are available. Significant changes between preliminary, &#8220;top-line,&#8221; or interim data and final data could harm our business.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may find it difficult to enroll patients in our clinical trials given the limited number of patients scoring &ge;16&#160;on the PCS who are undergoing the procedures we intend to use as our models of postoperative pain for testing of brivoligide. We may also find it difficult to enroll patients in surgical models that are performed under general anesthesia due to the intrathecal route of administration of brivoligide. Difficulty in enrolling patients could delay or prevent the completion of clinical trials of our product candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Identifying and qualifying patients to participate in clinical trials of our product candidates is essential to their success. The timing of our clinical trials depends in part on the rate at which we can recruit patients to participate in clinical trials of our product candidates, and we may experience delays in completion of our clinical trials if we encounter difficulties in enrollment. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In future clinical trials of brivoligide, we will be evaluating brivoligide using surgical models including but not limited to TKA and mastectomy. While we have successfully completed enrollment in three Phase&#160;2 studies of postoperative pain following TKA to date within projected timelines, we may not be able to do so successfully in the future. We have never conducted a study using the mastectomy model of postoperative pain, and may not meet projected enrollment timelines. Some competitors have ongoing clinical trials for product candidates that use the same surgical models as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in competitors&#8217; clinical trials. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The eligibility criteria of our planned clinical trials may further limit the availability of suitable clinical trial participants as we expect to require that patients have specific measurable characteristics or meet </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">15</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">certain criteria to assure that they are appropriate for inclusion in our clinical trials. In future clinical trials of brivoligide, we will be evaluating brivoligide in patients scoring &ge;16 on the PCS. Approximately one-third of individuals score &ge;16 on the PCS, however if this rate is not reflected in patient populations at the clinical trial sites, we may have fewer patients eligible for enrollment than expected. In addition, we may not be able to identify, recruit, and enroll a sufficient number of patients to complete our clinical trials in a timely fashion because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical trials, the willingness of patients to receive an intrathecal injection if undergoing a surgical procedure typically performed under general anesthesia, and the willingness of physicians to participate in our planned clinical trials. If patients are unwilling to participate in our clinical trials for any reason, the timeline for conducting studies and obtaining regulatory approval of our product candidates may be delayed. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In addition, any delays in completing our clinical trials would likely increase overall costs, impair product candidate development and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences may harm our business, financial condition, and prospects significantly. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Clinical trials are costly, time consuming and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Clinical development is expensive, time consuming and involves significant risk. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of development. Events that may prevent successful or timely completion of clinical development include but are not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">inability to generate satisfactory preclinical, toxicology, or other <font style="font-style:italic;">in vivo</font> or <font style="font-style:italic;">in vitro</font> data to support the initiation or continuation of clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">delays in reaching agreement on acceptable terms with contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">delays in obtaining required Institutional Review Board, or IRB, approval at each clinical trial site; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">refusal to permit the conduct of a clinical trial by regulatory authorities, after review of an IND, or equivalent foreign application or amendment; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">delays in recruiting qualified patients in our clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">failure by clinical sites or our CROs or other third parties to adhere to clinical trial requirements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">failure to perform in accordance with the FDA&#8217;s Good Clinical Practice requirements, or GCP, or applicable foreign regulatory guidelines; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">high patient drop-out rate in our clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">occurrence of adverse events, or AEs, associated with our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the cost of clinical trials of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">negative or inconclusive results from our clinical trials which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development programs in other ongoing or planned indications for a product candidate; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">delays in reaching agreement on acceptable terms with third party manufacturers and the time for manufacture of sufficient quantities of our product candidates for use in clinical trials. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">16</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Any inability to successfully complete clinical development and obtain regulatory approval could result in additional costs to us or impair our ability to generate revenue. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow competitors to develop and bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or terminate clinical trials, delay regulatory approval by the FDA or comparable foreign regulatory authorities or, even if approved, result in restrictive labelling of our products. We will continue to evaluate our product candidates in additional clinical trials, and there is no guarantee that severe side effects will not be identified. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide targets Early Growth Response 1, or EGR1, a transcription factor that has a role in memory consolidation within the hippocampus. There is a potential risk of transient alteration in memory function with brivoligide if sufficient material is distributed to the brain. This risk has been evaluated in preclinical studies and in the clinical trials conducted to date, but has not been observed; however, studies using the mastectomy model will involve movement of the brivoligide injection to the upper regions of the spinal canal which may involve increased risk of brain exposure and possible transient cognitive or memory dysfunction. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide is intended to prevent or reduce exacerbated pain following surgery and not to mask, numb or otherwise alter a patient&#8217;s normal response to pain. However, we have not conducted studies on or otherwise evaluated any masking effect of brivoligide on a patient&#8217;s pain response function. If patients, physicians or other healthcare providers consider brivoligide to alter patients&#8217; normal pain response in a manner that would be considered detrimental to recovery, that would be considered an undesirable side effect and would harm our ability to develop brivoligide and future market acceptance of brivoligide. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additionally, even if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, potentially significant negative consequences could result, including but not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">withdrawal of regulatory approvals of such products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">requirements by regulatory authorities to place additional warnings on the label of such products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">requirement by regulatory authorities to create a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">potential lawsuits, which may result in us being held liable for harm caused to patients; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reputational harm. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, even if approved, and could significantly harm our business, results of operations, and prospects. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may not be successful in any efforts to identify, license, discover, develop, or commercialize additional product candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although a substantial amount of our effort will focus on the continued clinical testing, potential approval, and commercialization of our existing product candidates, the success of our business is also expected to depend in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development and commercialization for a number of reasons, including but not limited to the following: </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">17</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our collaboration with twoXAR, which relies upon artificial intelligence technology to generate potential product opportunities, may not generate viable product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our product candidates may not succeed in preclinical or clinical testing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">competitors may develop alternatives that render our product candidates obsolete or less attractive; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the market for a product candidate may change during our development program so that such a product may become unreasonable to continue to develop; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, license, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may not be successful in meeting our diligence obligations under our existing collaboration with twoXAR or under future license agreements necessary to maintain and continue to use product candidate licenses in effect. In addition, if required in order to commercialize our product candidates, we may be unsuccessful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may seek to obtain rights to intellectual property, through licenses from third parties and under patents that we do not own, to develop and commercialize additional product candidates, such as our collaboration with twoXAR. Because our programs may require the collaboration with or use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to maintain in effect these collaborations and proprietary rights. For example, we have certain specified diligence obligations under our collaboration with twoXAR. We may not be able to achieve the required diligence milestones in a timely manner, which may result in a right of termination by twoXAR, and we may be unable to successfully negotiate an extension or waiver of those termination rights. Any termination of the collaboration with twoXAR or future license agreements with third parties with respect to our product candidates would be expected to negatively impact our business prospects. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if we are able to license or acquire third-party intellectual property rights that are necessary for our product candidates, there can be no assurance that they will be available on favorable terms. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">18</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We collaborate with U.S. and foreign academic institutions to identify product candidates, accelerate our research and conduct development. Typically, these institutions have provided us with an option to negotiate an exclusive license to any of the institution&#8217;s rights in the patents or other intellectual property resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue a program of interest to us. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we are unable to successfully obtain and maintain rights to required third-party intellectual property, we may have to abandon development of that product candidate or pay additional amounts to the third party, and our business and financial condition could suffer. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory requirements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If our product candidates are approved, they will be subject to ongoing regulatory requirements with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy and other post-approval information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Manufacturers and manufacturers&#8217; facilities are required to continuously comply with FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices, or cGMP, regulations and corresponding foreign regulatory manufacturing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA or marketing authorization application, or MAA. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product candidate may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase&#160;4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. We will be required to report certain adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. If our original marketing approval for a product candidate was obtained through an accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial in order to confirm the clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If a regulatory agency discovers previously unknown problems with a product, such as AEs of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, the regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">issue warning letters; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">impose civil or criminal penalties; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">suspend or withdraw regulatory approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">suspend any of our ongoing clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">refuse to approve pending applications or supplements to approved applications submitted by us; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">require a product recall. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">19</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Any government investigation of alleged violations of law would be expected to require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to develop and commercialize our products and our value and operating results would be adversely affected. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We rely on third parties to conduct our clinical trials, and perform other clinical development-related services, such as drug shipping, blinding and randomization, data collection, and biostatistical analysis. If these third parties do not successfully perform and comply with regulatory requirements, we may not be able to successfully complete clinical development, obtain regulatory approval or commercialize our product candidates and our business could be substantially harmed. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have relied upon and plan to continue to rely upon third-party CROs to conduct, monitor and manage our ongoing clinical program. We rely on these parties for execution of clinical trials and we manage and control only certain aspects of their activities. We remain responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with all applicable laws, regulations and guidelines, including those required by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. If we or any of our CROs or vendors fail to comply with applicable laws, regulations and guidelines, the results generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot guarantee that our CROs and other vendors will meet these requirements, or that upon inspection by any regulatory authority, such regulatory authority will determine that activities conducted by our third-party vendors in support of any of our clinical trials comply with applicable requirements. Failure to comply with these laws, regulations and guidelines may require us to repeat clinical trials, which would be costly and delay the regulatory approval process. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs in a timely manner or do so on commercially reasonable terms. In addition, our CROs may not prioritize our clinical trials relative to those of other customers and any turnover in personnel or delays in the allocation of CRO employees by the CRO may negatively affect our clinical trials. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, our clinical trials may be delayed or terminated and we may not be able to meet our current plans with respect to our product candidates. CRO contracts may also involve higher costs than anticipated, which could negatively affect our financial condition and operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, and if approved, we intend to rely on third parties to produce and process our product candidates. Our commercialization of any of our product candidates could be stopped, delayed or made less profitable if those third parties fail to obtain approval of government regulators, fail to provide us with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We do not currently have nor do we plan to acquire the infrastructure or capability internally to manufacture our clinical supplies for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on outside vendors to manufacture clinical supplies of our product candidates and plan to continue relying on third parties to manufacture our product candidates on a commercial scale, if approved. We plan to rely on third-party manufacturers and their responsibilities will include purchasing from third-party suppliers the materials necessary to produce our product candidates for our clinical trials and regulatory approval. There are expected to be a limited number of suppliers for the materials that we expect to use to manufacture our product candidates, and we may not be able to identify alternative suppliers to prevent a possible disruption of the manufacture our product candidates for our clinical trials, and, if approved, ultimately for commercial sale. Although we generally do not expect to begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the study, any significant delay or discontinuity in the supply of a product candidate, or the active ingredient or other material components in the manufacture of the product candidate could delay completion of our clinical trials and result in potential delay in regulatory approval of our product candidates, which would harm our business and results of operations. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">20</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We do not have long-term supply agreements or commitments from those parties to supply our materials. Moreover, even if we had a longer-term supply arrangement, we may be precluded from entering into a back-up or alternative supplier arrangement which may increase the risk for further development, regulatory approval, or commercialization of our product candidates. We may also receive supply of drug substance or drug product that is deficient in quality or otherwise does not meet the specifications required to be used in clinical trials. In the past, we have experienced such deficiencies and have been required to seek alternative sources to meet our needs. We have not established clinical trial material supply agreements for AYX2 and may not be able to do so. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Certain components used in the manufacture of brivoligide are sourced from a single vendor. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide is an oligonucleotide, and there are currently a limited number of oligonucleotide manufacturers with commercial sale capabilities globally. We currently use Nitto-Denko Avecia, Inc., or Avecia, as a single supplier for the brivoligide drug substance and do not have a long-term supply agreement or commitment from Avecia to supply our drug substance. If Avecia is unable or unwilling to meet our current or future needs for our drug substance on acceptable terms, or at all, we may be unable to locate alternative suppliers or manufacturers. While we intend to develop secondary sources for manufacturing of our drug candidates in the future, we may not be able to do so on commercially reasonable terms or at all. Any interruption in the supply of a key material could significantly delay our research and development process or increase our expenses for development and commercialization of our product candidates. Any interruption in supply of our product candidates from Avecia could result in delay of our clinical trials or interrupt our commercial supply, which would harm our business and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We face intense competition from other companies developing products for the reduction of postoperative pain. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide faces significant competition. If we are able to successfully develop brivoligide for the reduction of postoperative pain, it would compete with EXPAREL (bupivacaine liposome injectable suspension, marketed by Pacira Pharmaceuticals, Inc.), HTX-011 (bupivacaine and meloxicam, in development by Heron Therapeutics, NDA submitted to the FDA in 2019), Ofirmev (intravenous acetaminophen, marketed by Mallinckrodt Pharmaceuticals), branded and generic oral opioid pain therapeutics, branded and generic oral nonsteroidal anti-inflammatory drugs, or NSAIDs, and potentially other products in development for the reduction of postoperative pain that reach the market. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do, and have significantly greater experience in the discovery and development of product candidates, as well as in obtaining regulatory approvals of those product candidates in the United&#160;States and in foreign countries. Many of our current and potential future competitors also have significantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a smaller number of our competitors. Competition may reduce the number and types of patients available to us to participate in clinical trials, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Small or early-stage companies and research institutions may also prove to be significant competitors, particularly through collaborative arrangements with large and established pharmaceutical companies. We will also face competition from these parties in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, and acquiring or in-licensing technologies and products complementary to our programs or potentially advantageous to our business. If any of our competitors succeed in obtaining approval from the FDA or other regulatory authorities for their products sooner than we do or for products that are more effective or less costly than our products, our commercial opportunity could be significantly reduced. Major technological changes can happen quickly in the biotechnology and pharmaceutical industries, and the development of new mechanisms of action, technologically improved or different products or drug delivery technologies may make our product candidates or platform technologies obsolete or noncompetitive. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">21</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We currently have no marketing and sales experience or capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have no experience selling and marketing our product candidates and we currently have no marketing or sales organization. To successfully commercialize any products that may result from our development programs, we will need to invest in and develop these capabilities, either on our own or with others, which would be expensive, difficult and time consuming. Any failure or delay in the timely development of our internal commercialization capabilities could adversely impact the potential for success of our products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Further, given our lack of prior experience in marketing and selling pharmaceutical products, we may rely on future collaborators to commercialize our products. If collaborators do not commit sufficient resources to commercialize our future products and we are unable to develop the necessary marketing and sales capabilities on our own, we will be unable to generate sufficient product revenue to sustain or grow our business. We may be competing with companies that currently have extensive and well-funded marketing and sales operations, in particular in the markets our product candidates are intended to address. Without appropriate capabilities, whether directly or through third-party collaborators, we may be unable to compete successfully against these more established companies. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The commercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to extensive internal efforts, the successful commercialization of brivoligide will require many third parties, over whom we have no control, to choose to utilize brivoligide. These third parties include physicians and hospital pharmacy and therapeutics committees, or P&amp;T committees. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, there is significant uncertainty related to the insurance coverage and reimbursement for newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for products such as our and what reimbursement codes our products may receive. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to limit or reduce healthcare costs may result in restrictions on coverage and the level of reimbursement for new products and, as a result, they may not cover or provide adequate payment for our products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Physicians must prescribe brivoligide for our commercialization to be successful. Because administration of brivoligide will be intended for patients scoring &ge;16 on the PCS, and will require administration of the one-page PCS evaluation tool prior to surgery, physicians may not accept brivoligide as a viable addition to their patient treatment pathway. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">If brivoligide does not achieve broad market acceptance, the revenues that are generated from our sales will be limited. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to our Business Operations </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our future success depends in part on our ability to retain our President and Chief Executive Officer, Chief Medical Officer, and Chief Scientific Officer, and to attract, retain, and motivate other qualified personnel. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are highly dependent upon the efforts of our senior management, including Rick Orr, our President and Chief Executive Officer, Donald C. Manning, our Chief Medical Officer, and Julien Mamet, our founder and Chief Scientific Officer. The loss of the services provided by these individuals may adversely impact the achievement of our objectives. These individuals could leave our employment at any time, as they are &#8220;at will&#8221; employees. The loss of the services of these individuals and other members of our senior management could delay or prevent the achievement of research, development, marketing, or product commercialization objectives. We do not maintain any &#8220;key-man&#8221; insurance policies on any of the key </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">22</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">employees nor do we intend to obtain such insurance coverage. Recruiting and retaining other qualified employees, consultants, and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of highly qualified personnel in our industry, which is likely to continue. As a result, competition for personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, failure to succeed in development and commercialization of our product candidates may make it more challenging to recruit and retain qualified personnel. The inability to recruit and retain qualified personnel, or the loss of the services of key members of senior management could impede the progress of our research, development, and commercialization objectives. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations. </div>
        <div style="text-indent:20pt; margin-top:4.81pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, we had six full-time employees. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial, legal, and other resources. Our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.</div>
        <div style="text-indent:20pt; margin-top:4.62pt; width:456pt; line-height:12pt;">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, research data, our proprietary business information and that of our suppliers, technical information about our products, clinical trial plans and employee records. Similarly, our third-party providers possess certain of our sensitive data and confidential information. The secure maintenance of this information is critical to our operations and business strategy. Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, ransomware, cyber fraud, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, encrypted, lost or stolen. Any such access, inappropriate disclosure of confidential or proprietary information or other loss of information, including our data being breached at third-party providers, could result in legal claims or proceedings, liability or financial loss under laws that protect the privacy of personal information, disruption of our operations or our product development programs and damage to our reputation, which could adversely affect our business. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions. </div>
        <div style="text-indent:20pt; margin-top:4.61pt; width:456pt; line-height:12pt;">We may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">23</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing, and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot provide any assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on our business and prospects. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict and may have a significant adverse effect on our business and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate postapproval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Among policy makers and payors in the United States there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access and the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the Affordable Care Act, substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S.&#160;pharmaceutical industry. The Affordable Care Act, among other things: (1)&#160;introduced a new average manufacturer price definition for drugs and biologics that are inhaled, infused, instilled, implanted or injected and not generally dispensed through retail community pharmacies; (2)&#160;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and expanded rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well; (3)&#160;established a branded prescription drug fee that pharmaceutical manufacturers of branded prescription drugs must pay to the federal government; (4)&#160;expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program; (5)&#160;established a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts (which through subsequent legislative amendments, was increased to 70% from 50% starting in 2019) off negotiated prices of applicable branded drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D; (6)&#160;extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; (7)&#160;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals, including individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability; (8)&#160;created a licensure framework for follow-on biologic products; and (9)&#160;established a Center for Medicare and Medicaid Innovation at the Centers for Medicare and Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the Affordable Care Act. For example, the Tax Cuts and Jobs Act of 2017, or TCJA, was enacted, which includes a provision repealing, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the Affordable Care Act are invalid as well. While the Trump administration and CMS have both stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, if any, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">24</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">pursuant to the Budget Control Act of 2011 and subsequent laws, which began in 2013 and will remain in effect through 2027, unless additional Congressional action is taken. In January&#160;2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. New laws may result in additional reductions in Medicare and other healthcare funding, which may materially adversely affect customer demand and affordability for our products and, accordingly, the results of our financial operations. Also, there has been heightened governmental scrutiny recently over the manner in which pharmaceutical companies set prices for their marketed products, which have resulted in several Congressional inquiries and proposed federal legislation, as well as state efforts, designed to, among other things, bring more transparency to product pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part&#160;D plans to negotiate the price of certain drugs under Medicare Part&#160;B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the Trump administration released a &#8220;Blueprint,&#8221; or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. While some proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Most recently, the Trump administration released a &#8220;Blueprint,&#8221; or plan, to reduce the cost of drugs. The Trump administration&#8217;s Blueprint contains certain measures that the U.S. Department of Health and Human Services is already working to implement. At the state level, individual states in the United States are increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we obtain FDA approval for any of our product candidates and begins commercializing those products in the United States, our operations may be subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations. These laws may impact, among other things, our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">25</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, which imposes certain requirements relating to the privacy, security, and transmission of individually identifiable health information; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the federal physician sunshine requirements under the Health Care Reform Laws requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S.&#160;Department of Health and Human Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. For example, the Health Care Reform Law, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the Health Care Reform Law provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities may involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of hazardous materials. In some cases, hazardous materials and various wastes resulting from their use may be stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of hazardous materials generally comply with the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">26</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. </div>
        <div style="margin-top:9.43pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </div>
        <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;">Our corporate headquarters is located in the San Francisco Bay Area which has in the past experienced severe earthquakes and other natural disasters. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations or those of our collaborators, and have a material adverse effect on our business, results of operations, financial condition, and prospects. If a natural disaster, terrorist attack, power outage, or other event occurred that prevented us from using or damaged critical elements of our business and operations (such as the manufacturing facilities of our third-party contract manufacturers) our business may be disrupted for a substantial period of time. We have limited or no disaster recovery and business continuity plans in place currently and our business would be impaired in the event of a serious disaster or similar event. We may incur substantial expenses to develop and implement any disaster recovery and business continuity plans, which could have a material adverse effect on our business. </div>
        <div style="margin-top:9.43pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The terms of our Loan Agreement with Oxford place restrictions on our operating and financial flexibility. </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">The Loan Agreement subjects us and our subsidiaries to various affirmative and restrictive covenants, including a covenant against the occurrence of a &#8220;change in control,&#8221; financial reporting obligations, and certain limitations on the incurrence of indebtedness, liens (including a negative pledge on intellectual property and other assets), investments, distributions (including dividends), collateral, transactions with affiliates or mergers or acquisitions. Compliance with these covenants may limit our flexibility in operating our business and our ability to take actions that might be advantageous to us and our shareholders. </div>
        <div style="text-indent:20pt; margin-top:5.01pt; width:456pt; line-height:12pt;">Additionally, we may be required to repay the entire amount of outstanding indebtedness under the Loan Agreement in cash if we fail to stay in compliance with our covenants or suffer some other event of default under the Loan Agreement. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In that case, we may be required to delay, limit, reduce or terminate our clinical development efforts or grant to others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Oxford could also exercise its rights as collateral agent to take possession and dispose of the collateral securing the loan for its benefit, which collateral includes all of our property, including our intellectual property. Our business, financial condition and results of operations could be substantially harmed as a result of any of these events. </div>
        <div style="margin-top:9.43pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Substantially all of our assets are subject to a first-priority lien in favor of Oxford under the Loan Agreement. The foreclosure on such assets or exercise of other remedies available to Oxford under the Loan Agreement could substantially harm our business operations and financial condition. </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">Substantially all of our assets are subject to a first-priority lien in favor of Oxford under the Loan Agreement. There can be no assurance that we will remain in compliance with our obligations under the Loan Agreement, including making required payments and complying with affirmative and negative covenants. In the event of foreclosure or exercise of other remedies by Oxford under such agreement on the assets pledged to Oxford, our business operations and financial condition will be substantially harmed. </div>
        <div style="margin-top:9.42pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to our Intellectual Property </div>
        <div style="margin-top:8.23pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We intend to rely on exclusivity from patent rights for our product candidates and any future product candidates. If we are unable to obtain or maintain exclusivity, we may not be able to compete effectively in our markets. </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business. This process can be </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">27</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain in flux. We own the rights to issued patents and to patent applications that cover our product candidates and their application. The patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. Further, third parties may challenge the validity of our issued patents, their enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing intellectual property around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have filed several patent applications covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may not have sufficient patent term protections for our products to effectively protect our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20&#160;years after it is filed. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, our products may be open to competition from generic medications. In addition, upon issuance in the United States any patent term can be adjusted based on certain delays caused by the applicant(s) or the United States Patent and Trademark Office, or USPTO. For example, a patent term can be reduced based on certain delays caused by the patent applicant during patent prosecution. Further, it is possible for a third party to challenge the validity of our issued patents via litigation and/or post-grant administrative proceedings at the USPTO, which if successful, could invalidate the issued patents and lead to earlier market entry and competition by others. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Patent term extensions under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent or data, regulatory exclusivity terms associated with the products. With respect to our product candidates brivoligide and AYX2, a portion of the potential commercial opportunity will likely rely on patent term extensions, and we cannot provide any assurances that any such patent term extensions will be obtained and, if so, for how long. As a result, we may not be able to maintain exclusivity for our products for an extended period, which would negatively impact our business and results of operations. If we do not have sufficient patent terms or regulatory exclusivity to protect our products, our business and results of operations will be adversely affected. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Patent laws and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of their protection. The laws of foreign countries may not protect our patent rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. We therefore cannot be certain that we were the first to make the invention claimed in our owned and licensed patents or pending applications, or that we were the first to file for patent protection of </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">28</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">such inventions. Assuming the other requirements for patentability are met, in the United States prior to March&#160;15, 2013, the first to make the claimed invention is entitled to the patent, while outside the United&#160;States, the first to file a patent application is entitled to the patent. After March&#160;15, 2013, under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted on September&#160;16, 2011, the United&#160;States has moved to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and may also affect patent litigation. The applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. In general, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although we require all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements can be duly enforced or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. We have conducted freedom to operate analyses with respect to only certain of our product candidates, and have not requested independent formal written opinions, and therefore we do not know whether there are any third-party patents that would impair our ability to commercialize these product candidates. We also </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">29</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">cannot guarantee that any of our analyses are exhaustive, nor can we be sure that we have identified each and every patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our product candidates. Because patent applications can take many&#160;years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, third parties may obtain patents in the future and claim that the use of our technologies infringes upon their patents. If any third-party patents were held by a court of competent jurisdiction to cover aspects of our product candidate&#8217;s formulations, manufacturing process, methods of use, or of any molecules formed during their manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Such a license may not be available on commercially reasonable terms, or at all. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Intellectual property may be discovered in the future through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have received grant awards from NIDA/NIH and NINDS/NIH for the development of brivoligide in the mastectomy&#160;model of postoperative pain and the development of AYX2, respectively. Intellectual property may be generated through the use of this U.S. government funding and would therefore be subject to certain federal regulations. As a result, the U.S.&#160;government may in the future have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or the Bayh-Dole Act. These U.S.&#160;government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we fail to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our product candidates may be subject to generic competition. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application, or ANDA, seeking approval of a generic copy of an approved innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA under section 505(b)(2) that references the FDA&#8217;s finding of safety and effectiveness of a previously approved drug. A 505(b)(2) NDA product may be </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">30</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">for a new or improved version of the original innovator product. Innovative small molecule drugs may be eligible for certain periods of regulatory exclusivity (e.g., five&#160;years for new chemical entities, three&#160;years for changes to an approved drug requiring a new clinical trial, seven&#160;years for orphan drugs), which preclude FDA approval (or in some circumstances, FDA filing and review of) an ANDA or 505(b)(2) NDA relying on the FDA&#8217;s finding of safety and effectiveness for the innovative drug. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the final drug product, which would be listed with the product in the FDA publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; known as the &#8220;Orange Book.&#8221; If there are patents listed in the Orange Book, a generic applicant that seeks to market its product before expiration of the patents must include in the ANDA or 505(b)(2) what is known as a &#8220;Paragraph IV certification,&#8221; challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the innovator, too, and if within 45&#160;days of receiving notice the innovator sues to protect its patents, approval of the ANDA is stayed for 30&#160;months, or as lengthened or shortened by the court. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If there are patents listed for our product candidates in the Orange Book, ANDAs and 505(b)(2) NDAs with respect to those product candidates would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict whether any patents issuing from our pending patent applications will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or licenses. Moreover, if any patents that are granted and listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could more immediately face generic competition and our sales would likely decline materially. Should sales decline, we may have to write off a portion or all of the intangible assets associated with the affected product and our results of operations and cash flows could be materially and adversely affected. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">All of our assets are subject to a first-priority lien in favor of Oxford under a security agreement entered into in connection with the Loan Agreement with Oxford. The foreclosure on such assets or exercise of other remedies available to Oxford under the Loan Agreement could materially adversely affect our business operations and future prospects. </div>
        <div style="text-indent:20pt; margin-top:5.6pt; width:456pt; line-height:12pt;">All of the assets (including intellectual property) owned by us are subject to a first-priority lien in favor of Oxford under a security agreement entered into in connection with the Loan Agreement with Oxford. There can be no assurance that we will remain in compliance with our obligations under the Loan Agreement. In the event of foreclosure or exercise of other remedies by Oxford under such agreement on the assets (including such intellectual property) pledged to Oxford, our ability to use and develop our product candidates as well as our business operations and future prospects will be materially adversely affected. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Although we are not currently involved in any significant litigation, we may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming, and unsuccessful. </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">Competitors may infringe our patents or the patents of our potential licensors. Although we are not currently involved in any litigation, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are a commonplace. Grounds for a validity challenge of a patent could be an alleged failure to meet any of several statutory requirements for patentability, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome of such interference proceeding could require us to cease using </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">31</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we have written agreements and make every effort to ensure that our employees, consultants, and independent contractors do not use the proprietary information or intellectual property rights of others in their work for us, and we are not currently subject to any claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties, we may in the future be subject to such claims. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United&#160;States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop our own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">32</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Risks Related to our Corporate Governance </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of a fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws; any action asserting a claim against us that is governed by the internal affairs doctrine; or, to the maximum extent permitted by law, any other claim or dispute. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of, and consented to, the provisions of our bylaws described in the preceding sentence. If a court were to find the choice of forum provisions contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a significant impact on our business, financial condition and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, jurisdiction over which is exclusively vested by statute in the U.S. federal courts. As a result, this may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and such persons. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Some provisions of our charter document and Delaware law may have antitakeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by the our stockholders to replace or remove our management. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Provisions in our certificate of incorporation and bylaws as well as provisions of the DGCL, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit stockholders, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">allowing the authorized number of our directors to be changed only by resolution of the board of directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">authorizing the issuance of&#8201;&#8201; &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">eliminating the ability of stockholders to call a special meeting of stockholders; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove management by making it more difficult for stockholders to replace members of our board of directors, which will be responsible for appointing the members of our management. In addition, we will be subject to Section&#160;203 of the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three&#160;years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by the board of directors. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are not subject to compliance with rules requiring the adoption of certain corporate governance measures and as a result our stockholders may have limited protections. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Each of the New York Stock Exchange and the Nasdaq Stock Market LLC require the implementation of various measures relating to corporate governance for listed companies. These measures </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">33</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">are designed to enhance the integrity of corporate management and the securities markets and apply to securities which are listed on those stock exchanges. While we have adopted these measures, we will not be required to comply with many of the corporate governance provisions in the future for so long as our common stock is not listed on a national securities exchange. As a result, if we elect to cease compliance with any such measures, our stockholders may lose protections afforded to listed companies. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to this Offering and Ownership of the Securities Offered Hereby </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Private Adynxx has a material weakness in its internal control over financial reporting. If this material weakness persists or if we fail to establish and maintain effective internal control over financial reporting, our ability to accurately report its financial results could be adversely affected. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to the closing of the Merger, Adynxx was a private company and had limited accounting and financial reporting personnel and other resources with which to address its internal control over financial reporting. In connection with the audit of Private Adynxx&#8217;s financial statements for the year ended December&#160;31, 2018 and preparation of interim financial statements for the first quarter of 2019, Private Adynxx and its independent registered public accounting firm identified a material weakness in Private Adynxx&#8217;s internal controls over financial reporting. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity&#8217;s financial statements will not be prevented or detected and corrected on a timely basis. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The material weakness related to Private Adynxx&#8217;s inability to prepare accurate financial statements, resulting from a lack of adequate accounting personnel to timely and appropriately account for and disclose the impact of complex, non-routine transactions in accordance with GAAP, including the recording of convertible note and related disclosures. In response to the material weakness, Adynxx is currently working to remediate the material weakness by retaining third-party consultants to help enhance its internal controls over financial reporting. There can be no assurance that these efforts will remediate the material weakness or avoid future weaknesses or deficiencies. Any failure to remediate the material weakness and any future weaknesses or deficiencies or any failure to implement required new or improved controls or difficulties encountered in their implementation could cause Adynxx to fail to meet its reporting obligations or result in material misstatements in its financial statements. Following the closing of this offering, Adynxx&#8217;s management will be required to assess the effectiveness of its disclosure controls and procedures and internal control over financial reporting. If Adynxx is unable to remediate its material weakness, Adynxx&#8217;s management may not be able to conclude that its disclosure controls and procedures or internal control over financial reporting are effective, which could result in investors losing confidence in its reported financial information and may lead to a decline in the stock price. Failure to comply with Section&#160;404 of Sarbanes-Oxley could potentially subject Adynxx to sanctions or investigations by the SEC, the Financial Industry Regulatory Authority or other regulatory authorities, as well as increasing the risk of liability arising from litigation based on securities law. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our stock price may be volatile and may decline regardless of our operating performance. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our stock price has been and is likely to continue to be volatile. The trading prices of the securities of companies in our industry have been highly volatile. As a result of this volatility, investors may not be able to sell their common stock at or above their purchase price. The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">adverse regulatory decisions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the commencement, enrollment or results of any future clinical trials we may conduct, or changes in the development status of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">adverse results from, delays in or termination of clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">34</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">unanticipated serious safety concerns related to the use of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">lower than expected market acceptance of our product candidates following approval for commercialization; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">changes in financial estimates by us or by any securities analysts who might cover our stock; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">conditions or trends in our industry; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">changes in the market valuations of similar companies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the pharmaceutical industry; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">investors&#8217; general perception of our company and our business; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">recruitment or departure of key personnel; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">overall performance of the equity markets; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">limited trading volume of our common stock; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">significant lawsuits, including patent or stockholder litigation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">proposed changes to healthcare laws in the United States or foreign jurisdictions, or speculation regarding such changes; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">failure to comply with covenants and obligations under our debt instruments and agreements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">general political and economic conditions; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">other events or factors, many of which are beyond our control. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies in our industry. Stock prices of such companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management, and harm our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Based upon our common stock outstanding as of June&#160;30, 2019, our executive officers, directors and current beneficial owners of 5% or more of our common stock, in the aggregate, beneficially own approximately 89.3% of our outstanding common stock. These stockholders, acting together, are able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and any merger or other significant corporate transactions. The interests of this group of stockholders may not coincide with the interests of other stockholders. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">35</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We will incur costs and demands upon our management as a result of complying with the laws and regulations affecting reporting companies in the United States, which may harm our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As a public company in the United States quoted on the OTCQB and subject to the reporting requirements of the Exchange Act, we will incur significant additional legal, accounting and other expenses. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from regular business activities to compliance activities. If, notwithstanding our efforts, we fail to comply with new laws, regulations and standards, regulatory authorities may initiate legal proceedings against us and our business may be harmed. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Failure to comply with these rules might also make it more difficult for us to obtain certain types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The sale or availability for sale of a substantial number of shares of our common stock could negatively impact the market price of our shares. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Sales of a significant number of shares of our common stock, or the expectation that such sales may occur, including by our directors, officers and significant stockholders following the expiration of lock-up arrangements entered into in connection with the Merger, could significantly reduce the market price of our common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additionally, sales of our common stock by our officers or directors, even when done during an open trading window under our policies with respect to insider sales may adversely impact the trading price of our common stock. Although we do not expect that the relatively small volume of such sales will itself significantly impact the trading price of our common stock, the market could react negatively to the announcement of such sales, which could in turn affect the trading price of our common stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Shares of our common stock are thinly traded and may continue to be thinly traded in the future. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although a trading market for our common stock exists, the trading volume has not been significant, due in part to a substantial number of our outstanding shares being subject to contractual lock-up and other legal restrictions. There can be no assurance that an active trading market for our common stock will develop or, if developed, be sustained in the future, even following the lapse or expiration of such lock-up or other legal restrictions. As a result of the thin trading market or &#8220;float&#8221; for our stock, the market price for our common stock may fluctuate significantly more than the stock market as a whole. Without a large float, our common stock is less liquid than the stock of companies with broader public ownership and, as a result, the trading prices of our common stock may be more volatile. In the absence of an active public trading market, an investor may be unable to liquidate his or her investment in our common stock. Trading of a relatively small volume of our common stock may have a greater impact on the trading price for our stock than would be the case if our public float were larger. We cannot predict the prices at which our common stock will trade in the future. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, the price of our securities can vary due to general economic conditions and forecasts, our general business condition and the release of our financial reports. Additionally, because our securities are currently quoted on the OTC Markets, the liquidity and price of our securities may be substantially more limited than if we were quoted or listed on another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained. In the absence of an active trading market for our common stock, stockholders may not be able to sell their common stock at or above the price at which they acquired the shares or at the time that they would like to sell. We cannot predict the prices at </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">36</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">which our common stock will trade. We do not intend to apply to list the common stock on any securities exchange or nationally recognized trading system in connection with the offering. In addition, we cannot assure you that we will be able to meet the initial listing standards of any national securities exchange, or, if we do meet such initial qualitative listing standards, that we will be able to maintain any such listing. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports about our business, or if they downgrade our common stock, the price of our common stock could decline. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We are not currently covered by any securities or industry analysts. If no analysts elect to cover us in the future, or if one or more of the analysts who may cover us in the future downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. Further, we do not have any control over these analysts. In addition, if our operating results fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Management will have broad discretion as to the use of the net proceeds from this offering, and we may not use these proceeds effectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. Accordingly, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development of our products and cause the price of our common stock to decline. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If you purchase shares of our common stock in this offering, you will suffer immediate dilution of your investment. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The assumed combined public offering price per share of our common stock and accompanying warrant is substantially higher than the pro forma as adjusted net tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock and accompanying common warrants in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted net tangible book value per share after this offering. Based on an assumed combined public offering price of $1.35 per share of common stock and accompanying common warrant, the closing price of our common stock as reported by OTCQB on October&#160;9, 2019, you will experience immediate dilution of&#8201; $1.09 per share, representing the difference between our pro forma as adjusted net tangible book value per share after this offering and the assumed combined public offering price. In addition, to the extent outstanding stock options are exercised, there will be further dilution to investors in this offering. See &#8220;Dilution&#8221; for a more detailed description of the dilution to investors in the offering. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our certificate of incorporation authorizes us to issue up to 95,000,000 shares of common stock and up to 1,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. For example, we have issued from time to time Notes to certain of our significant shareholders that will convert into shares of our common stock upon, among other things, the closing of this offering. We have also previously issued and currently have outstanding warrants to purchase shares of our common stock. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">37</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">There is no public market for the pre-funded warrants or common warrants being offered in this offering.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There is no established public trading market for the pre-funded warrants or common warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the pre-funded warrants or common warrants on any securities exchange or nationally recognized trading system. Without an active market, the liquidity of the pre-funded warrants and common warrants will be limited.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Holders of our pre-funded warrants and common warrants will have no rights as a common stockholder until they acquire our common stock.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Until you acquire shares of our common stock upon exercise of your pre-funded warrants or common warrants, you will have no rights with respect to shares of our common stock issuable upon exercise of your pre-funded warrants or common warrants. Upon exercise of your pre-funded warrants or common warrants, you will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The pre-funded warrants and common warrants are speculative in nature. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Except in limited circumstances, neither the pre-funded warrants nor the common warrants offered hereby confer any rights of common stock ownership on their holders, such as voting rights, but rather merely represent the right to acquire shares of common stock at a fixed price. Specifically, commencing on the date of issuance, holders of the pre-funded warrants may acquire the common stock issuable upon exercise of such warrants at an exercise price of&#8201; $0.01 per share of common stock and holders of the common warrants may acquire the common stock issuable upon exercise of such warrants at an exercise price of&#8201; $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. Moreover, following this offering, the market value of the pre-funded warrants and common warrants is uncertain and there can be no assurance that the market value of the pre-funded warrants or common warrants will equal or exceed their public offering price. There can be no assurance that the market price of the common stock will ever equal or exceed the exercise price of the pre-funded warrants or common warrants, and consequently, whether it will ever be profitable for holders of the pre-funded warrants to exercise the pre-funded warrants or the holders of the common warrants to exercise the common warrants. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our common stock is subject to the &#8220;penny stock&#8221; rules of the SEC and the trading market in the securities is limited, which makes transactions in the stock cumbersome and may reduce the value of an investment in the stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Rule 15g-9 under the Exchange Act establishes the definition of a &#8220;penny stock,&#8221; for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person&#8217;s account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In order to approve a person&#8217;s account for transactions in penny stocks, the broker or dealer must: (a)&#160;obtain financial information and investment experience objectives of the person and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) confirms that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers may be less willing to execute transactions in securities subject to the &#8220;penny stock&#8221; rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our common stock. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">38</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker or dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.</div>
        <div style="margin-top:9.82pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we fail to remain current in our reporting requirements, we could lose certain privileges on the OTCQB which would impact the ability of broker-dealers to sell our securities and the ability of stockholders to sell their securities in the secondary market. </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">As a company traded on the OTCQB, we must be current with our filings pursuant to Sections 13 and 15(d) of the Exchange Act in order to maintain price quotation privileges on the OTCQB. If we fail to remain current in our reporting requirements, the market liquidity of our securities could be harmed by impacting the ability of broker-dealers to trade our securities and the ability of stockholders to sell their securities in the secondary market. </div>
        <div style="margin-top:9.82pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our common stock is not listed on a national securities exchange. As a result, holders of the common warrants or pre-funded warrants may not be able to exercise their warrants without compliance with applicable state securities laws, and the value of such warrants may be significantly reduced. </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">Our common stock is not listed on a national securities exchange, and we do not intend to list our common stock on any national securities exchange in connection with this offering. As a result, the exercise of the common warrants or the pre-funded warrants by holders may not be exempt from state securities laws. Depending on the state of residence of a holder of the common warrants or the pre-funded warrants, a holder may not be able to exercise its common warrants or pre-funded warrants unless we comply with any state securities law requirements necessary to permit such exercise or an exemption applies. Although we plan to use our reasonable efforts to assure that holders will be able to exercise their common warrants or pre-funded warrants under applicable state securities laws if no exemption exists, there is no assurance that we will be able to do so. As a result, your ability to exercise your warrants or pre-funded warrants may be limited until such time that our common stock is listed on a national securities exchange, if at all. The value of the common warrants or pre-funded warrants may be significantly reduced if holders are not able to exercise their warrants or pre-funded warrants under applicable state securities laws. </div>
        <div style="margin-top:9.83pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Because our offering will be conducted on a best efforts basis, there can be no assurance that we can raise the maximum proceeds set forth in this prospectus.</div>
        <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;">The placement agent is offering the securities on a &#8220;best efforts&#8221; basis with no minimum, and the placement agent is under no obligation to purchase any securities for their own account. The placement agent is not required to sell any specific number or dollar amount of securities in this offering but will use its best efforts to sell the securities offered in this prospectus. As a &#8220;best efforts&#8221; offering, there can be no assurance that the offering contemplated hereby will ultimately be consummated. If the offering is not consummated or we receive less than the maximum proceeds, our business could be harmed.</div>
        <div style="margin-top:9.83pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Because there is no minimum required for the offering to close, investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue the business goals outlined in this prospectus.</div>
        <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;">We have not specified a minimum offering amount nor have or will we establish an escrow account in connection with this offering. Because there is no escrow account and no minimum offering amount, investors could be in a position where they have invested in our company, but we are unable to fulfill our objectives due to a lack of interest in this offering. Further, because there is no escrow account in operation and no minimum investment amount, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. Investor funds will not be returned under any circumstances whether during or after the offering. </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Since our securities will be listed on the OTCQB, our securities holders may face significant restrictions on the resale of our securities due to state &#8220;blue sky&#8221; laws. </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">Each state has its own securities laws, often called &#8220;blue sky&#8221; laws, which (i) limit sales of securities to a state&#8217;s residents unless the securities are registered in that state or qualify for an exemption from </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">39</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">registration, and (ii) govern the reporting requirements for broker-dealers doing business directly or indirectly in the state. Before a security is sold in a state, there must be a registration in place to cover the transaction, or the transaction must be exempt from registration. The applicable broker must be registered in that state. We do not know whether securities will be registered or exempt from registration under the laws of any state. Since our securities will be listed on the OTCQB, a determination regarding registration will be made by those broker-dealers, if any, who agree to serve as the market-makers for our common stock. There may be significant state blue sky law restrictions on the ability of investors to sell, and on purchasers to buy, our securities. You should therefore consider the resale market for our securities to be limited, as you may be unable to resell our securities without the significant expense of state registration or qualification. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our ability to use net operating losses to offset future taxable income may be subject to limitation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our net operating loss, or NOL, carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Our NOLs generated in tax&#160;years ending on or prior to December&#160;31, 2017 are only permitted to be carried forward for 20&#160;years under applicable U.S. tax law. Under the tax act informally known as the 2017 Tax Cuts and Jobs Act, our federal NOLs generated in tax&#160;years ending after December&#160;31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited. It is uncertain if and to what extent various states will conform to the 2017 Tax Cuts and Jobs Act. As of December&#160;31, 2018, we had federal net operating loss carry forwards of approximately $33.5&#160;million. The net operating loss of $28.7&#160;million, carried forward from tax&#160;years ended before January&#160;1, 2018, will begin to expire in 2033. Net operating losses incurred after December&#160;31, 2017, which currently amounts to $4.8&#160;million, may be carried forward indefinitely and will not expire. As of January&#160;1, 2019, we had federal and California research and development tax credit carry forwards of approximately $1.8&#160;million and $0.7&#160;million, respectively. The federal research and development tax credit carry forwards will begin to expire in 2031 and the California research and development tax credit carry forwards are available indefinitely until utilized. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or, the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating losses and net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. It is possible that we have in the past undergone, and in the future may undergo, an ownership change, which could result in additional limitations on our use of net operating loss carryforwards and certain other tax attributes. This could have a material adverse effect on cash flow and results of operations. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">40</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNR">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This prospectus contains forward-looking statements about us and our industry within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;contemplate&#8221; or the negative of these terms or other similar expressions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, factors and assumptions described under the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus regarding, among other things: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to continue as a going concern; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the progress, timing, costs and results of our clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the timing of meetings with and feedback from regulatory authorities as well as any submission of filings for regulatory approval of brivoligide or any of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the potential advantages and differentiated profile of our product candidates compared to existing therapies or other product candidates in development; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to successfully commercialize any of our product candidates, if approved; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the rate and degree of market acceptance of any of our product candidates, if approved; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our expectations regarding the size of the patient populations for and opportunity for and clinical utility of brivoligide or any other product candidates, if approved for commercial use; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to identify, acquire or in-license and develop new product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to maintain intellectual property protection for our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the uncertainty regarding the adequacy of our liquidity to pursue or complete business objectives; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to comply with Current Good Manufacturing Practices, or cGMPs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">loss or retirement of key executives; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our plans to make significant additional outlays of working capital before we expect to generate significant revenues and the uncertainty regarding when we will begin to generate significant revenues, if we are able to do so; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">adverse economic conditions and/or intense competition; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">loss of a key supplier; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">entry of new competitors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">adverse federal, state and local government regulation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">technical problems with our research and products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">risks of mergers and acquisitions including the time and cost of implementing transactions and the potential failure to achieve expected gains, revenue growth or expense savings; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">price increases for supplies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">41</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">inability to carry out our business plans; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our planned uses of the proceeds of this offering; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to service our indebtedness and interest thereon when it becomes due; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our dependence on funding from government sources;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">our ability to maintain collaborations and enter into new collaborations; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the other factors discussed under the heading &#8220;Risk Factors&#8221; in this prospectus. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These forward-looking statements are based on information available as of the date of this prospectus, and current expectations, forecasts and assumptions, and involve a number of risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, statements that we &#8220;believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to such party as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and these statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">You should not place undue reliance on these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">You should read this prospectus with the understanding that our actual future results, levels of activity, performance and achievements may be different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.<br ></div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">42</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIMD">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">INDUSTRY AND MARKET DATA </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This prospectus contains estimates, projections and other information concerning our industry and our business, including estimated market size, projected growth rates and the incidence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market, medical and other information from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this information is derived. In that regard, when we refer to one or more sources of this type of information in any paragraph, you should assume that other information of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This industry, business, market, medical and other information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information included in this prospectus. Although we are responsible for all of the disclosure contained in this prospectus and we believe the market position, market opportunity, market size and medical information included in this prospectus is reliable, such information is inherently imprecise. In addition, projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">43</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">USE OF PROCEEDS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We estimate that the net proceeds to us from the sale of 7,500,000 shares of common stock and accompanying warrants will be approximately $8.2 million, based on an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying common warrant (the closing price of our common stock as reported by OTCQB on October&#160;9, 2019), after deducting placement agent fees and estimated offering expenses payable by us. However, this is a best efforts offering with no minimum, and we may not sell all or any of the securities; as a result, we may receive significantly less in net proceeds, and the net proceeds received may not be sufficient to continue to operate our business. If a holder of common warrants elects to exercise the common warrants issued in this offering, we may also receive proceeds from the exercise of the common warrants. We cannot predict when or if the common warrants will be exercised. It is possible that the common warrants may expire and may never be exercised. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Each $1.00 increase or decrease in the assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying common warrant would increase or decrease, respectively, our net proceeds by $6.9 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting placement agent fees and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase or decrease of 1,000,000 in the number of shares we are offering would increase or decrease, respectively, the net proceeds from this offering, after deducting placement agent fees, by $1.2&#160;million, assuming the assumed combined public offering price stays the same. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We intend to use the net proceeds from this offering, together with our existing cash and additional funds from our grant awards from NIDA/NIH and NINDS/NIH, as follows: </div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">fund drug product manufacturing for brivoligide and our planned Phase&#160;2a clinical trial of brivoligide for the treatment of postoperative pain in patients undergoing mastectomy to support initiation of patient enrollment;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">conduct activities to support a pre-IND meeting with the FDA for AYX2 for the treatment of chronic pain; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the remaining proceeds for research and drug discovery activities related to additional product candidates and general corporate purposes, funding our working capital needs, servicing of our indebtedness, including scheduled principal and interest payments to Oxford Finance under the Loan Agreement, and any necessary capital expenditures.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table sets forth the expected uses of proceeds assuming the sale of 25%, 50%, 75% and 100% of the common stock and accompanying warrants offered hereby.</div>


          <table style="width:456pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:221.34pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">25%</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">50%</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">75%</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">100%</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.917pt 0pt 0.5pt 0pt; width:221.34pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Fund drug product manufacturing for brivoligide and fund our planned Phase 2 clinical trial of brivoligide for the treatment of postoperative pain in patients undergoing mastectomy to support initiation of patient enrollment<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.917pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">206,250</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.917pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,275,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.917pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,127,500</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:2.917pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,065,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.167pt 0pt 0.5pt 0pt; width:221.34pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Conduct activities to support a pre-IND meeting with the FDA for AYX2 for the treatment of chronic pain<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">250,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">500,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.167pt 0pt 0.5pt 0pt; width:221.34pt;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Research and drug discovery activities related to <br >additional product candidates and general <br >corporate purposes, funding our working capital <br >needs, servicing our indebtedness, including <br >scheduled principal and interest payments to <br >Oxford Finance under the Loan Agreement, and <br >any necessary capital expenditures </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,000,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,200,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,385,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,485,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.167pt 0pt 0.5pt 0pt; width:221.34pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Placement agent fees and estimated offering expenses </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,293,750</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,525,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,737,500</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,950,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:221.34pt;text-align:left;">
                <div style="white-space:nowrap;">Gross proceeds </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,500,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,000,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">7,500,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10,000,000</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">44</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
          <div style=" margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">If we sell less than 100% of the common stock and accompanying warrants offered hereby, we expect to require additional funds to initiate patient enrollment for our Phase 2 clinical trial of brivoligide for the treatment of postoperative pain in patients undergoing mastectomy. We will require additional capital to complete this clinical trial after initiating patient enrollment.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
          <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">If we sell less than 100% of the common stock and accompanying warrants offered hereby, we expect to require additional funds to conduct a pre-IND meeting with the FDA, if scheduled.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:10.99pt; width:456pt; line-height:12pt;">We anticipate the net proceeds from this offering, together with our existing cash and additional funds from our grant awards from NIDA/NIH and NINDS/NIH, will be sufficient to fund our planned operations through at least the second quarter of 2020. However, due to the uncertainties inherent in the product development process, the amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development, the status of our results from clinical trials, as well as any collaborations that we may enter with third parties or any other product candidates we may seek to develop, and any unforeseen cash needs. As a result, management will have broad discretion over the use of the net proceeds from this offering. The amounts and timing of our expenditures will depend upon numerous factors including the results of our research and development efforts, the timing and success of preclinical studies and any ongoing clinical trials or clinical trials we may commence in the future, the timing of regulatory submissions and the amount of cash obtained through future collaborations, if any. Following this offering, we will require additional funding in order to complete clinical development and commercialize our product candidates. </div>
        <div style="text-indent:20pt; margin-top:10.98pt; width:456pt; line-height:12pt;">Pending the use of the proceeds from this offering as described above, we intend to invest the net proceeds in interest-bearing investment-grade securities or government securities.<br ></div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">45</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDP">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DIVIDEND POLICY </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Special Cash Dividend </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In April&#160;2019, Alliqua announced a one-time special cash distribution to the pre-Merger holders of shares of Alliqua as of April&#160;22, 2019 in the amount of&#8201; $1.05 per share, for an aggregate of&#8201; $5,245,000. On May&#160;29, 2019, we paid $6.30 per share to the pre-Merger holders of record of Alliqua BioMedical, Inc. as of April&#160;22, 2019. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, we are restricted from making dividend payments except under limited circumstances under our Loan Agreement. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Divestiture of AquaMed </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2019, we completed the distribution of all outstanding shares of AquaMed Technologies, Inc., previously our wholly-owned subsidiary, on a pro&#160;rata basis to the record holders of Alliqua common stock as of April&#160;22, 2019, which distribution was previously approved by the board of directors of Alliqua in November&#160;2018.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">46</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCAP">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CAPITALIZATION </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table sets forth our cash and cash equivalents and our capitalization as of June&#160;30, 2019, on: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">an actual basis; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">a pro forma basis to reflect&#160;the issuance of 4,874,744 shares of common stock at the closing of the offering upon the conversion of outstanding convertible promissory notes in the aggregate principal amount of&#8201; $6.35 million (which includes $0.85 million additional principal amount of convertible promissory notes issued subsequent to June 30, 2019), plus accrued but unpaid interest, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the closing price of our common stock as reported by OTCQB on October&#160;9, 2019, provided that this offering results in total proceeds to us of at least $5.0&#160;million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">a pro forma as adjusted basis to reflect the sale of 7,500,000 shares of common stock and accompanying warrants in this offering at an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the closing price of our common stock as reported by OTCQB on October&#160;9, 2019, after deducting placement agent fees and estimated offering expenses payable by us. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">You should read this information together with the sections of this prospectus titled &#8220;Description of Capital Stock,&#8221; and &#8220;Description of Securities We are Offering&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; as well as our consolidated financial statements and related notes included elsewhere in this prospectus. </div>
        <table style="width:416pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">June&#160;30, 2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Actual </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Pro <br >Forma</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Pro Forma <br >As <br >Adjusted<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="text-align:center;">(unaudited)<br >(in thousands, except share data) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">8,188</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible promissory notes<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">5,497</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Term loan, net of discount </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,390</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,390</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,390</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">Stockholders&#8217; equity:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Common stock, $0.001 par value per share, 95,000,000 shares <br >authorized, actual, pro forma and pro forma as adjusted; <br >5,807,877 shares outstanding, actual; 10,682,621 shares <br >outstanding, pro forma; and 18,182,621 shares outstanding, <br >pro forma as adjusted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Additional paid-in capital </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">35,160</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">41,736</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">49,893</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Accumulated deficit </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,417<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,417<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,417<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Total stockholders&#8217; equity (deficit) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(9,251<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,670<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">5,494</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Total capitalization </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,364<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.0199999999999996pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">7,884</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Each $1.00 increase or decrease in the assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the closing price of our common stock as reported by OTCQB on October&#160;9, 2019, would increase or decrease, respectively, the amount of cash and cash equivalents, additional paid-in-capital, total stockholders&#8217; equity (deficit) and total capitalization by $6.9 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same after deducting placement agent fees and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase or decrease of 1,000,000 in the number of shares we are offering would increase or decrease, respectively, the amount of cash and cash equivalents, additional paid-in-capital, total stockholders&#8217; equity (deficit) </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">47</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">and total capitalization by $1.2 million, assuming the assumed combined public offering price per share, as set forth on the cover page of this prospectus, remains the same and after deducting placement agent fees and estimated offering expenses payable by us. The pro forma as adjusted information is illustrative only, and will be adjusted based on the actual offering price and other terms of this offering determined at pricing. </div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Figure is shown net of unamortized debt issuance costs. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:10.98pt; width:456pt; line-height:12pt;">The number of shares of common stock that will be outstanding after this offering is based on 5,807,877 shares of common stock outstanding as of June&#160;30, 2019, and excludes: </div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">747,879 shares of common stock issuable upon the exercise of outstanding stock options as of June 30, 2019, with a weighted-average exercise price of&#8201; $24.95 per share, under our equity incentive plans or not granted pursuant to a written equity incentive plan; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">3,332 shares of common stock issuable from time to time after this offering upon the settlement of restricted stock awards, or RSAs, outstanding as of June&#160;30, 2019 under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">57,897 shares of common stock issuable upon the exercise of outstanding warrants as of June&#160;30, 2019, with a weighted-average exercise price of&#8201; $97.66 per share; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">9,188 shares of common stock reserved for future issuance under the Alliqua, Inc. 2011 Long-Term Incentive Plan; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">72,436 shares of common stock reserved for future issuance under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">48</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DILUTION </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering price per share of our common stock and accompanying warrants and the pro forma as adjusted net tangible book value (deficit) per share of our common stock immediately after the closing of this offering. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The pro forma net tangible book deficit of our common stock as of June&#160;30, 2019 was $(10.1)&#160;million, or $(1.74) per share, based on the total number of shares of our common stock outstanding as of June&#160;30, 2019, after giving effect to the issuance and sale of&#8201; $0.85 million additional principal amount of convertible promissory notes subsequent to June 30, 2019. Pro forma net tangible book value per share represents our total tangible assets less our total liabilities, divided by the number of outstanding shares of common stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">After giving effect to (i)&#160;the receipt of the net proceeds from our sale of 7,500,000 shares of common stock and accompanying common warrants in this offering at an assumed combined public offering price of $1.35 per share of common stock and accompanying warrant, the closing price of our common stock as reported by OTCQB on October&#160;9, 2019, after deducting placement agent fees and estimated offering expenses payable by us, and (ii)&#160;the issuance of 4,874,744 shares of common stock at the closing of the offering upon the conversion of outstanding convertible promissory notes in the aggregate principal amount of&#8201; $6.35 million, plus accrued but unpaid interest, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the closing price of our common stock as reported by OTCQB on October&#160;9, 2019, provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG, our pro forma as adjusted net tangible book value as of June&#160;30, 2019 would have been $4.6 million, or $0.26 per share. This represents an immediate increase in pro forma net tangible book value of&#8201; $2.00 per share to our existing stockholders and immediate dilution of $1.09 per share to investors purchasing common stock in this offering. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following table illustrates this dilution on a per share basis to new investors: </div>
        <table style="width:416pt;height:131pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:290pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Assumed combined public offering price per share and accompanying common warrant </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.35</td>
            <td style="padding:0pt;padding-left:21.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Pro forma net tangible book deficit per share as of June&#160;30, 2019 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(1.74<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:290pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Increase in pro forma as adjusted net tangible book value per share attributable to new investors purchasing shares in this offering </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">2.00</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.645pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.645pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:290pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Pro forma as adjusted net tangible book value per share after this offering </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.26</td>
            <td style="padding:0pt;padding-left:21.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:290pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Dilution in pro forma net tangible book value per share to new investors in this offering </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:15.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.645pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">1.09</td>
            <td style="padding:0pt;padding-left:21.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:10.01pt; width:456pt; line-height:12pt;">Each $1.00 increase or decrease in the assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying comon warrant would increase or decrease, respectively, our pro forma as adjusted net tangible book value per share after this offering by $0.46 and $0.32 per share, respectively, and the dilution to new investors by $0.54 and $0.68 per share, respectively, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting placement agent fees and estimated offering expenses payable by us. An increase of 1,000,000 shares in the number of shares of common stock offered by us would increase the pro forma as adjusted net tangible book value by $0.05 per share and the dilution to new investors would decrease by $0.05 per share, assuming the assumed combined public offering price remains the same and after deducting placement agent fees. A decrease of 1,000,000 shares in the number of shares of common stock offered by us would decrease the pro forma as adjusted net tangible book value by $0.06 per share and the dilution to new investors would increase by $0.06 per share, assuming the assumed combined public offering price remains the same and after deducting placement agent fees. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The information discussed above is illustrative only and will be adjusted based on the actual combined public offering price of the common stock and accompanying common warrant or pre-funded warrant and accompanying common warrant, as the case may be, the actual number of shares that we offer in this </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">49</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">offering, and other terms of this offering determined at pricing. The discussion and table above assume (i) no sale of pre-funded warrants, which, if sold, would reduce the number of shares of common stock that we are offering on a one-for-one basis and (ii) no exercise of common warrants accompanying the shares of common stock, if any, sold in this offering.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If investors in this offering exercise in full the common warrants for 7,500,000 shares of common stock offered hereby for cash at an assumed exercise price of&#8201; $1.35 per share (the closing price of our common stock as reported by OTCQB on October&#160;9, 2019), our pro forma as adjusted net tangible book value after this offering would be $0.29 per share, representing an increase in pro forma as adjusted net tangible book value of&#8201; $2.03 per share and immediate dilution in pro forma net tangible book value of&#8201; $1.06 per share to new investors in this offering.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The number of shares of common stock that will be outstanding after this offering is based on 5,807,877 shares of common stock outstanding as of June&#160;30, 2019, and excludes: </div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">747,879 shares of common stock issuable upon the exercise of outstanding stock options as of June 30, 2019, with a weighted-average exercise price of&#8201; $24.95 per share, under our equity incentive plans or not granted pursuant to a written equity incentive plan; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">3,332 shares of common stock issuable from time to time after this offering upon the settlement of restricted stock awards, or RSAs, outstanding as of June&#160;30, 2019 under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">57,897 shares of common stock issuable upon the exercise of outstanding warrants as of June&#160;30, 2019, with a weighted-average exercise price of&#8201; $97.66 per share; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">9,188 shares of common stock reserved for future issuance under the Alliqua, Inc. 2011 Long-Term Incentive Plan; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">72,436 shares of common stock reserved for future issuance under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, to the extent any outstanding options or warrants are exercised, new investors would experience further dilution. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">50</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMOCS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">MARKET FOR OUR COMMON STOCK </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Since July&#160;22, 2019, our common stock has been listed on the OTCQB under the symbol &#8220;ADYX,&#8221; and from June&#160;13, 2019 until July&#160;18, 2019, our common stock was listed on the OTC Pink tier of the OTC Markets under the symbol &#8220;ADYX.&#8221; Prior to June 13, 2019, our common stock was listed on the Nasdaq Capital Market under the symbol &#8220;ADYX.&#8221; Any over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions. The prices of our common stock quoted on the OTCQB may not be indicative of the market price of our common stock on a national securities exchange. As of September&#160;30, 2019, there were 258 holders of record of our common stock. We do not intend to list our common stock or any of the other securities offered hereby on a national securities exchange in connection with this offering.<br ></div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">51</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMDA">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION <br >AND RESULTS OF OPERATIONS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included in this prospectus. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere particularly in the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">On May&#160;3, 2019, Private Adynxx completed the Merger with Alliqua BioMedical, Inc., or Alliqua, and we survived as a wholly-owned subsidiary of Alliqua. Following the consummation of the Merger, Adynxx changed its name to Adynxx Sub, Inc., and Alliqua BioMedical, Inc. changed its name to Adynxx, Inc. For financial reporting purposes, Alliqua was deemed to be the acquired entity in the Merger. The following management&#8217;s discussion and analysis relates to the results of operations of Adynxx, Inc. for periods subsequent to the Merger and Adynxx, the private company, for periods prior to the Merger. Accordingly, references in this section to &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221; refer to pre-Merger Adynxx.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are a clinical stage biopharmaceutical company focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market novel, disease-modifying products for the treatment of pain and inflammation. Transcription factor decoys are short strands of DNA that specifically bind to and block the activity of their target transcription factors. Transcription factors are proteins that specifically bind to the regulatory regions of one or more target genes and regulate the expression of those genes. Since our founding in 2007, we have leveraged our AYX platform of proprietary transcription factor decoys to identify and develop novel product candidates designed to modify the course of pain. We believe that our transcription factor decoy technology can transform the treatment of pain, and going forward has the potential to be applied to additional disease states. We plan to continue advancing our AYX platform programs while simultaneously developing new transcription factor decoy candidates, collaborating with twoXAR, our artificial intelligence-driven drug discovery partner, and evaluating in-licensing opportunities in order to expand our pipeline and leverage our business development, clinical development and regulatory expertise. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have no products approved for commercial sale and have not generated any revenue from product sales. From inception to June&#160;30, 2019, we have raised net cash proceeds of approximately $62.2&#160;million, primarily through the sale of equity securities, receipts associated with a strategic collaboration, issuance of Notes, and gross proceeds from the Oxford term loans. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2018, we received a grant from the National Institute on Drug Abuse, or NIDA, part of the National Institutes of Health, or NIH, the NIH grant, to support the clinical development of our lead product candidate, brivoligide. NIH grants provide funds for certain types of expenditures in connection with research and development activities over a contractually defined period. The maximum funding to be available under this grant for qualified expenditures over the next two&#160;years is expected&#8201;to be approximately $5.7&#160;million. We started drawing from this NIH grant in February&#160;2019 and recognized $1.2 million and $0 as grant reimbursement contra-expense in our operating expenses for the six&#160;months ended June&#160;30, 2019 and 2018, respectively. In September 2019, we received a Notice of Award from the National Institute on Neurological Disease and Stroke, or NINDS, part of the NIH, for up to approximately $0.6&#160;million to be paid over 12&#160;months to support our planned preclinical studies of AYX2. The funds will become available after approval from the Office of Laboratory Animal Welfare, or OLAW, of the planned preclinical studies for AYX2, and we have not yet drawn from this NIH grant. We intend to continue to evaluate pursuing additional government grant opportunities on a case-by-case basis. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have incurred operating losses in each year since inception, with the exception of 2014, when we received a $20.0&#160;million option payment as part of a strategic collaboration, which was subsequently terminated in 2014. Our net losses were $7.1 million and $2.9 million, for the six months ended June 30, 2019 and 2018, respectively. As of June 30, 2019, we had an accumulated deficit of&#8201;&#8201;$44.4 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">52</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We expect to incur significant expenses and increasing operating losses for at least the next several&#160;years as we initiate and continue the clinical development of, and seek regulatory approval for, our product candidates and add personnel necessary to operate as a public company with an advanced clinical pipeline of products. In addition, operating as a publicly traded company involves the hiring of additional financial and other personnel, upgrading our financial information systems and incurring costs associated with operating as a public company. We expect that our operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of clinical development programs and efforts to achieve regulatory approval of any of our product candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our current capital resources are insufficient to fund our planned operations for a 12-month period, and therefore, raise substantial doubt about our ability to continue as a going concern. We will continue to require substantial additional capital to continue our clinical development and potential commercialization activities. Accordingly, we will need to raise substantial additional capital to continue to fund our operations. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Basis of Presentation </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Research and Development Expenses </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Research and development expenses represent costs incurred to conduct research and development, such as the development of our product candidates. We recognize all research and development costs as they are incurred. Research and development expenses consist primarily of the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">expenses incurred under agreements with consultants and clinical trial sites that conduct research and development activities on our behalf; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">laboratory and vendor expenses related to the execution of clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">contract manufacturing expenses, primarily for the production of clinical supplies; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">internal costs that are associated with activities performed by our research and development organization. These costs are not separately allocated by product candidate as we typically use our employee resources across various research and development activities. Unallocated internal research and development costs consist primarily of: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#9702;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">personnel costs, which include salaries, benefits and stock-based compensation expense; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#9702;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">regulatory expense related to development activities. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The largest component of our operating expenses has historically been the investment in research and development activities. However, we do not allocate internal research and development costs, such as salaries, benefits, stock-based compensation expense and indirect costs to product candidates on a program-specific basis. The following table shows our research and development expenses by program (in&#160;thousands): </div>
        <table style="width:456pt;height:140pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Years Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six Months Ended June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(unaudited) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">Direct research and development expenses by program:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-005 TKA </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">185</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">892</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-004 TKA </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,201</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">95</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">87</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">AYX Platform </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">607</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">125</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">918</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-006 Mastectomy </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">26</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">455</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-003 TKA </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">twoXAR Platform </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">75</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">53</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <table style="width:456pt;height:74.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Years Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Six Months Ended <br >June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:251.19pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(unaudited) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">Internal research and development costs </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,913</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,706</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,125</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">884</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:251.19pt;text-align:left;">
              <div style="white-space:nowrap;">Total research and development expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">8,722</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,137</td>
            <td style="padding:0pt;padding-left:5.42pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,269</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,226</td>
            <td style="padding:0pt;padding-left:6.07pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.19pt; width:456pt; line-height:12pt;">We expect research and development expenses will increase in the future as we advance our product candidates into and through clinical trials and pursue regulatory approvals, which will require a significant investment in regulatory support and contract manufacturing. In addition, we continue to evaluate opportunities to acquire or in-license other product candidates and technologies, which may result in higher research and development expenses due to license fees and/or milestone payments. While we are engaged in discussions to in-license other product candidates and technologies, we will need to raise additional capital before consummating any such transaction. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2018, we received a NIH grant to support the clinical development of our lead product candidate, brivoligide. The grant is expected to provide approximately $2.8&#160;million in funding in 2019 that will support research and development activities for the ADYX-006 Mastectomy study. We record qualified expenses reimbursable under the NIH grant as grant reimbursements, a contra operating expense. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in timely developing and achieving regulatory approval for our product candidates. The probability of success of our product candidates may be affected by numerous factors, including clinical data, competition, intellectual property rights, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">General and Administrative Expenses </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our general and administrative expenses consisted of personnel-related costs, professional fees for legal, consulting, audit and tax services, overhead expenses, such as rent, equipment depreciation, insurance and utilities, and other general operating expenses not otherwise included in research and development expenses. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We expect to incur additional expenses associated with operating as a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, and standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to increase the size of our administrative headcount to support the growth of our business and operate as a public company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Grant Reimbursements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We accounted for reimbursements of qualified grant related research and development expenses in accordance with the guidance provided by the Financial Accounting Standards Board, or FASB, in the Accounting Standards Update (ASU) 2018-08, &#8220;<font style="font-style:italic;">Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made</font>,&#8221; or ASU 2018-08, which it adopted in January&#160;2019. Based on this guidance, we determined that reimbursements of qualified expenses per the terms of the grant, met the definition of a &#8216;conditional contribution&#8217; (versus an exchange contract) because (i)&#160;we have limited discretion in the way the funds may be spent, which creates a barrier to entitlement, and (ii) the grant contains provisions that release the awarding agency from the obligation to transfer funds that are not expended at the time the award is terminated. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We recognized the grant reimbursements as a contra operating expense in the period in which the related costs are incurred and the related services are rendered, provided that the applicable performance obligations under the government grants have been met. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">54</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Interest Income (Expense), Net </div>
        <div style="text-indent:20pt; margin-top:5.01pt; width:456pt; line-height:12pt;">Interest income (expense), net, consists primarily of cash interest expense on the Oxford term loans, or Term Loans, and non-cash interest expense and amortization of debt issuance and debt discount costs related to the Term Loans and the debt discounts on the issuance of Notes, as well as the recognition of $2.1 million of a contingent beneficial conversion feature that was recognized upon the date of the Merger. Debt discount is accreted to interest expense over the debt borrowing term. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Other Income </div>
        <div style="text-indent:20pt; margin-top:5.01pt; width:456pt; line-height:12pt;">Other income consists primarily of gains and losses resulting from the revaluation of our preferred stock warrant liabilities and convertible debt derivative liabilities, both of which are revalued at the end of each reporting period and any change in fair value recorded as a component of other income or expense. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We had preferred stock warrants related to Term Loans as well as convertible debt derivatives relating to the issuance of Notes. Both the warrants and Notes derivatives were recorded as a liability, with an offsetting amount recorded as debt discount. The preferred stock warrants were converted into warrants to purchase shares of common stock upon the closing of the Merger. We recorded adjustments to the fair value of the convertible debt derivative liability, as applicable, for the duration that they were outstanding. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Income Taxes </div>
        <div style="text-indent:20pt; margin-top:4.82pt; width:456pt; line-height:12pt;">We recognize deferred income taxes for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. We periodically evaluate the positive and negative evidence bearing upon realizability of our deferred tax assets. Based upon the weight of available evidence, which includes our historical operating performance, reported cumulative net losses since inception and difficulty in accurately forecasting our future results, we maintained a full valuation allowance on the net deferred tax assets at June&#160;30, 2019 and December&#160;31, 2018. We intend to maintain a full valuation allowance on the federal and state deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Results of Operations </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Comparison of the Six Months Ended June&#160;30, 2018 and 2019 (in thousands) </div>
        <table style="width:416pt;height:182.5pt;margin-left:20pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.46pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.75pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six Months Ended June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.46pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 1.75pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 1.75pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 1.75pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Dollar Change </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:251.46pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(unaudited) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.75pt 0pt; width:251.46pt;text-align:left;">Operating expenses:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="margin-left:10pt;">Research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,269</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3,226</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,957</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="margin-left:10pt;">General and administrative </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,292</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,317</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,025</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="margin-left:10pt;">Grant reimbursements </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,198<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,198<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="margin-left:20pt;">Total operating expenses, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,561</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">4,345</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,784</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,561<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,345<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,784<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Interest expense, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(445<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,641<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,196<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Other income (expense), net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">60</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(94<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(154<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from continuing operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,946<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(7,080<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,134<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from discontinued operations </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(58<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(58<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 2.5pt 0pt; width:251.46pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,946<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(7,138<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.405pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,192<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-style:italic;">Research and Development </div>
        <div style="text-indent:20pt; margin-top:4.81pt; width:456pt; line-height:12pt;">Research and development expenses increased by $1.9 million to $3.2 million for the six months ended June&#160;30, 2019, from $1.3 million for the six months ended June&#160;30, 2018. The increase was primarily due to&#8201;$1.3 million in connection with start-up activities related to the planned Phase 2 ADYX-005 TKA and Phase 2 ADYX-006 Mastectomy clinical trials and $0.8 million related to the initiation of drug supply manufacturing with Avecia, partially offset by a $0.2 million reduction in salaries and benefits associated with the resignation of one employee. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">55</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;">General and Administrative </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">General and administrative expenses increased by $1.0 million to $2.3 million for the six months ended June&#160;30, 2019, from $1.3 million for the six months ended June&#160;30, 2018. This increase was primarily due to an increase of&#8201;$0.9 million in legal and professional service costs incurred in connection with the Merger and preparation to be a public company, and an increase of&#8201; $0.1 million in other general and administrative costs, including insurance, associated with us being a public company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Grant Reimbursements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Beginning in February 2019, we started to receive payments from a NIH grant to support the clinical development of our lead product candidate, brivoligide. In the six months ended June&#160;30, 2019, we recorded $1.2 million of grant reimbursements relating to qualified expenses incurred under the terms of the NIH grant. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Interest Expense, Net </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Interest expense, net, increased by $2.2 million to $2.6 million during the six months ended June&#160;30, 2019, from $0.4 million during the six months ended June&#160;30, 2018. The increase was primarily attributable to the recognition of&#8201; $2.1 million associated with the beneficial conversion feature recognized upon the modification and conversion of two Notes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Loss from Discontinued Operations </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Loss on discontinued operations relates to the AquaMed business that was incurred from the date of the Merger to its spin-off that occurred on June&#160;21, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Comparison of the Year Ended December&#160;31, 2017 and 2018 (in thousands) </div>
        <table style="width:416pt;height:143.5pt;margin-left:20pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:254.06pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Years Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:254.06pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Dollar Change </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:254.06pt;text-align:left;">Operating expenses:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:254.06pt;text-align:left;">
              <div style="margin-left:10pt;">Research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">8,722</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,137</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,585<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:254.06pt;text-align:left;">
              <div style="margin-left:10pt;">General and administrative </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,341</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,982</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">641</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:254.06pt;text-align:left;">
              <div style="margin-left:20pt;">Total operating expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">11,063</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">5,119</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,944<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:254.06pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,063<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,119<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">5,944</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:254.06pt;text-align:left;">
              <div style="white-space:nowrap;">Interest expense, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(515<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(992<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(477<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:254.06pt;text-align:left;">
              <div style="white-space:nowrap;">Other income </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">126</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">109</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:254.06pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,561<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,985<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">5,576</td>
            <td style="padding:0pt;padding-left:8.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-style:italic;">Research and Development </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Research and development expenses decreased by $6.6&#160;million to $2.1&#160;million in 2018, from $8.7&#160;million in 2017. This decrease was primarily due to a decrease of&#8201;$6.4&#160;million related to the completion of the ADYX-004 clinical trial initiated in 2017. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">General and Administrative </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">General and administrative expenses increased by $0.7&#160;million to $3.0&#160;million in 2018, from $2.3&#160;million in 2017. This increase was primarily due to an increase of&#8201;$0.7&#160;million for legal and professional fees incurred in connection with the Merger and preparation to be a public company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Interest Expense, Net </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Interest expense, net, increased by $0.5&#160;million to $1.0&#160;million in 2018, from $0.5&#160;million in 2017. The increase was primarily attributable to an increase in interest paid on the Term Loans, accretion of a final charge due at maturity for the Term Loans, accrued interest on outstanding Notes, and the amortization of debt discount related to the embedded derivatives for the Notes. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">56</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;">Other Income (Expense), Net </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">Other income (expense), net increased by $0.1&#160;million to $0.1&#160;million in 2018 due primarily to the change in valuation of the warrant liability and embedded derivatives related to the Notes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Liquidity and Capital Resources </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Since inception through June&#160;30, 2019, our operations have been financed primarily by the sale of equity securities, payments from strategic collaborators, borrowings under term loans and the issuance of convertible notes. As of June&#160;30, 2019, we had $24,000 in cash and cash equivalents and an accumulated deficit of&#8201; $44.4&#160;million. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We expect that our research and development and general and administrative expenses will increase, and, as a result, we anticipate that we will continue to incur increasing losses in the foreseeable future. As stated above, we also expect that our current capital resources will be insufficient to fund our planned operations for a 12-month period. Therefore, we will need to raise additional capital to fund our operations, which may be through the issuance of additional equity, and potentially through the incurrence of additional debt. In addition, we may be required to raise additional capital in the future to service our indebtedness, including outstanding indebtedness that will become due and payable during fiscal year 2019, and make necessary capital expenditures. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts and our ability to refinance outstanding indebtedness before the applicable maturity date. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. In addition, if we default under the loan and security agreement, or the Loan Agreement, with Oxford Finance, Oxford Finance will have the ability to exercise its rights as collateral agent to take possession and dispose of the collateral securing the indebtedness under the Loan Agreement, which collateral includes all of our property, including our intellectual property. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Beginning in February&#160;2019, we started to receive payments from a NIH grant to support the clinical development of our lead product candidate, brivoligide. While these payments will offset certain qualifying expenses incurred on this research and development program, it will not be adequate to cover other expenses expected to be incurred for research, development, general and administrative expenses. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have not generated any revenue from product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize any of our product candidates. At the same time, we expect our expenses to increase in connection with our ongoing development and manufacturing activities, particularly as we continue the research, development, manufacture and clinical trials of, and seek regulatory approval for, our product candidates. Subject to obtaining regulatory approvals of any of our product candidates, we anticipate that we will need substantial additional funding in connection with our continuing operations. Further, we expect to continue to incur additional costs associated with operating as a public company following the Merger. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Until we can generate a sufficient amount of product revenue to finance our cash requirements, we expect to finance our future cash needs primarily through the issuance of additional equity and potentially through borrowings, and strategic alliances with partner companies. To the extent that we raise additional capital through the issuance of additional equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates to third parties that we would otherwise prefer to develop and market ourselves.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">57</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash Flows </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">The following table shows a summary of our cash flows for each of the periods shown below (in thousands): </div>
        <table style="width:456pt;height:104.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:265.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Years Ended <br >December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Six Months Ended <br >June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:265.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:265.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">(unaudited) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">(unaudited) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:265.61pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash used in operating activities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,183<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,019<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,527<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,223<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:265.61pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash used in investing activities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:265.61pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash (used) provided by financing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(59<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">3,610</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">884</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,559</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:265.61pt;text-align:left;">
              <div style="white-space:nowrap;">Net decrease in cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,245<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,414<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,643<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,664<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.82pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash Flows from Operating Activities </div>
        <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;">Cash used in operating activities for the six months ended June&#160;30, 2019 was $4.2 million, consisting of a net loss of&#8201;&#8201;$7.1 million, which was offset by non-cash charges of&#8201;&#8201;$2.9 million primarily for non-cash interest expense on Notes, stock-based compensation expense, accretion of the charge due upon maturity of debt, and amortization of right of use assets, and a net increase in cash resulting from changes in operating assets and liabilities of&#8201;$0.1 million. The change in our net operating assets and liabilities included cash generated from an increase in accounts payable of&#8201;$1.3 million and an increase of&#8201;&#8201;$0.5 million for accrued liabilities, both of which were due primarily to an increase in legal, accounting and other professional fees and expenses incurred in connection with the Merger and preparation to be a public company, which was offset by cash used due to an increase in prepaid expense of&#8201; $1.6 million primarily related to clinical trial activity and $0.1 million of lease liability payments. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">Cash used in operating activities for the six months ended June&#160;30, 2018 was $3.5 million, consisting of a net loss of&#8201;&#8201;$2.9 million, which was offset by noncash charges of&#8201;&#8201;$0.4 million primarily for stock-based compensation expense, accretion of the charge due upon maturity of debt and amortization of debt discount and debt financing costs. In addition, $0.9 million of cash was consumed resulting from changes in operating assets and liabilities. The change in our net operating assets and liabilities was due primarily to a decrease in accounts payable of&#8201;&#8201;&#8201;$0.6 million related to the completion of the ADYX-004 clinical trial initiated in 2017 and a decrease of&#8201;&#8201;&#8201;$0.3 million due to the reduction of accrued liabilities relating to the ADYX-004 clinical trial. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">Cash used in operating activities for 2018 was $6.0&#160;million, consisting of a net loss of&#8201;&#8201;$6.0&#160;million, which was offset by non-cash charges of&#8201;$0.8&#160;million primarily for stock-based compensation expense, non-cash interest expense, and accretion of final charge due upon maturity of debt, and net cash used due to changes in operating assets and liabilities of&#8201;$0.8&#160;million. The cash used in our net operating assets and liabilities was primarily due to the decrease of&#8201; $0.6&#160;million for the reduction of accrued liabilities relating to the completion of the ADYX-004 clinical trial initiated in 2017 and $0.2&#160;million for the reduction of accounts payable related to clinical trial activity and professional fees related to merger activities. </div>
        <div style="text-indent:20pt; margin-top:5.01pt; width:456pt; line-height:12pt;">Cash used in operating activities for 2017 was $10.2&#160;million, consisting of a net loss of&#8201;&#8201;$11.6&#160;million, which was offset by non-cash charges of&#8201;$0.5&#160;million primarily for stock-based compensation expense, accretion of final charge due upon maturity of debt and amortization of debt discount and debt financing costs, and a net increase in cash resulting from a changes in operating assets and liabilities of&#8201;$0.9&#160;million. The change in our net operating assets and liabilities was due primarily to an increase in accounts payable of&#8201;$0.6&#160;million related to increased clinical trial activity and a decrease of&#8201;$0.3&#160;million in prepaid expenses primarily related to research and development activities. </div>
        <div style="margin-top:10.82pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash Flows from Investing Activities </div>
        <div style="margin-left:20pt; margin-top:4.02pt; width:436pt; line-height:12pt;">Cash used in investing activities for all periods presented was nominal. </div>
        <div style="margin-top:10.82pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash Flows from Financing Activities </div>
        <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;">During the six months ended June&#160;30, 2019, net cash provided by financing activities was $2.6 million, consisting of&#8201; $4.0 million proceeds from the issuance of Notes, offset by $1.4 million used to repay principal of the Term Loans. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">58</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">During the six months ended June&#160;30, 2018, net cash used in financing activities was $0.9 million consisting of&#8201; $1.5 million proceeds from the issuance of Notes, offset by $0.6 million used to repay principal under the Term Loans. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2018, net cash provided by financing activities was $3.6&#160;million consisting primarily of proceeds from the issuance of Notes of&#8201;&#8201;$4.5&#160;million, offset by $0.9&#160;million used to repay principal of the Term Loans. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2017, net cash used in financing activities was $59,000 resulting primarily from $139,000 used to repay principal for the Term Loans, offset partially by $80,000 cash generated from the exercise of warrants to purchase our Series&#160;A preferred stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Contractual Obligations and Commitments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table summarizes our contractual obligations as of December&#160;31, 2018 (in thousands): </div>
        <table style="width:456pt;height:90.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:240pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">Payments Due by Period </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:240pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Less <br >Than <br >1 Year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">1&#8201;&#8211;&#8201;3 <br >Years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">3&#8201;&#8211;&#8201;5 <br >Years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">More <br >Than <br >5&#160;years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Term loan and interest<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,683</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,683</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible promissory notes and interest<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,712</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,712</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Operating lease commitments<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,634</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,395</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:7.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Reflects principal, interest payments and final balloon payment due to Oxford Finance under a loan and security agreement. Interest rate is floating and future interest payments are estimated based upon the December&#160;2018 interest rate. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">See &#8220;&#8212;&#8201;Convertible Notes&#8221; below.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">We lease our office space under a non-cancellable long-term operating lease. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following table summarizes our contractual obligations as of June&#160;30, 2019 (in thousands): </div>
        <table style="width:456pt;height:90.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:240pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">Payments Due by Period </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:240pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Less <br >Than <br >1 Year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">1 &#8211; 3 <br >Years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">3 &#8211; 5 <br >Years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.583pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">More <br >Than <br >5&#160;years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Term loan and interest<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,135</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,135</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible promissory notes and interest<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,941</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,941</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Operating lease commitments<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-2.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,006</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">346</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">463</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">197</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:240pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,082</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,422</td>
            <td style="padding:0pt;padding-left:1.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">463</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">197</td>
            <td style="padding:0pt;padding-left:2.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:7.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Reflects principal, interest payments and final balloon payment due to Oxford Finance under a loan security agreement. Interest rate is floating and future interest payments are estimated based upon the June&#160;2019 interest rate. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">See &#8220;&#8212;&#8201;Convertible Notes&#8221; below.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">We lease our office space under a non-cancellable long-term operating lease. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Notes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, $5.5 million aggregate principal amount remained outstanding under outstanding Notes. In July 2019, we issued additional Notes to affiliates of a significant stockholder that totaled $0.6 million principal amount for general corporate purposes and working capital. Provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from securities sold to Domain Associates or TPG, these convertible promissory notes, plus accrued but unpaid interest, will convert into 4,874,744 shares of common stock, based upon an assumed combined </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">59</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the last reported sale price of our common stock by OTCQB on October 9, 2019, provided that this offering results in total proceeds to us of at least $5.0&#160;million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG. The issuance of these shares will not be registered under the Securities Act. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In November&#160;2015, we entered into the Loan Agreement with Oxford Finance pursuant to which Oxford Finance agreed to lend us up to $10.0&#160;million principal amount issuable in three tranches, or the Term Loans, of which $5.0&#160;million had been drawn as of June&#160;30, 2019. The Term Loans will mature on November&#160;1, 2019. The Loan Agreement has been amended several times. We have the option to prepay all, but not less than all, of the borrowed amounts, provided that we will be obligated to pay a prepayment fee. The Term Loans bear interest at a floating per annum rate equal to (i)&#160;7.06% plus (ii) the greater of&#8201; (a)&#160;the 30-day U.S. Dollar LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (b)&#160;0.19%. We will be required to make a final payment of 4.25% of the funded amount, payable on the earlier of&#8201;&#8201;(i) the maturity date or (ii)&#160;the prepayment of the Term Loans. Our obligations under the Loan Agreement are secured by a perfected first-priority lien on all of our assets, including our intellectual property. In connection with the Merger, Alliqua was named as an additional borrower under the Loan Agreement. As of June&#160;30, 2019, we were in compliance with all covenants under the Loan Agreement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January&#160;2019, we and Oxford Finance amended the Loan Agreement to provide for two&#160;months of interest-only payments followed by eight&#160;months of repayments. We also placed $200,000 in a segregated bank account that is subject to a blocked control agreement in favor of Oxford Finance. The funds in the segregated account will be released upon the closing of this offering. The amendment fee was $50,000. The amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In May&#160;2019, we and Oxford agreed to an additional amendment to provide consent to the Merger. This consent amended certain provisions of the term loan to protect Oxford&#8217;s rights under the original Term Loan agreement. The consent allowed Alliqua to be named as an additional borrower. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June 2019, we and Oxford agreed to amend the Loan Agreement. Oxford agreed to two months of interest-only payments and the maturity date of the Term Loans was extended two months to January&#160;1, 2020. The amendment fee amounted to $20,000. The amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with the Loan Agreement, we issued warrants to purchase our preferred stock to Oxford Finance. Upon the closing of the Merger, these warrants were converted into warrants to purchase 11,829 shares of our common stock at an exercise price of&#8201; $6.34 per share. The warrants are immediately exercisable and expire ten&#160;years from the issuance date. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Other Contracts </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We enter into contracts in the normal course of business with various third parties for preclinical research studies, clinical trials, testing and other general and administrative services. These contracts generally provide for termination upon notice, and therefore we believe that our non-cancelable obligations under these agreements are not material. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Off-Balance Sheet Arrangements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December 31, 2017 and 2018 and June&#160;30, 2018 and 2019, we did not have any off-balance sheet arrangements and did not have any holdings in variable interest entities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Summary of Significant Accounting Policies and Estimates </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Use of Estimates </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with Generally Accepted Accounting Principles, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">60</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Merger Transaction</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Merger was treated by Alliqua as a reverse merger and recapitalization effected by a share exchange for financial accounting and reporting purposes. The pro forma condensed combined financial information under the section titled &#8220;Adynxx, Inc. Unaudited Pro Forma Financial Information&#8221; also gives effect to the spin-off of Alliqua&#8217;s wholly owned subsidiary, AquaMed, which is engaged in the custom hydrogel manufacturing business, in the form of a pro rata distribution of the common equity of the subsidiary to Alliqua&#8217;s stockholders. Since Alliqua was deemed to have no operations upon consummation of the spin-off, Alliqua was not considered to be a business for accounting purposes. Accordingly, no goodwill or intangible assets was recorded as a result of the merger. Because Private Adynxx was treated as the acquiring company, Private Adynxx&#8217;s assets and liabilities were recorded at their pre-combination carrying amounts.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Accrued Research and Development Expenses </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We record accrued expenses for estimated costs of our research and development activities conducted by external service providers. We recognize external development costs based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations that conduct and manage clinical trials on our behalf. This process involves reviewing contracts with service providers, identifying services that have been performed on our behalf, confirming the level of service performed are aligned with the contract, expected remaining period of performance and the associated cost incurred for the service when we have not been invoiced or otherwise notified of actual cost. We estimate our accrued research and development expenses as of the date of each of our balance sheets. Expenses that are paid in advance of performance are deferred as a prepaid expense and expensed as the services are provided. Our management made significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Through June&#160;30, 2019, we have had no significant adjustments to accrued clinical trial expense. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Stock-based Compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We recognize compensation costs related to stock-based awards granted to employees, directors and non-employees based on the estimated fair value of the awards on the date of grant. We estimate the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options, the fair value of our common stock on the date of grant for restricted stock&#160;units, or RSUs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We generally recognized the grant date fair value of the stock-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. For non-employee awards, the grant date fair value is recognized on a straight-line basis over the associated service period of the award. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We use the Black-Scholes valuation model to assist us in determining the fair value of our stock options. The Black-Scholes valuation model requires the use of following assumptions: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;">Expected volatility.&nbsp;&nbsp;&nbsp;</font>Expected volatility is estimated using comparable public companies&#8217; volatility for similar terms. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;">Expected term.&nbsp;&nbsp;&nbsp;</font>The expected term represents the period that our stock-based awards are expected to be outstanding and is determined using the simplified method. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">61</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;">Risk-free interest rate.&nbsp;&nbsp;&nbsp;</font>The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:3.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;">Expected dividend.&nbsp;&nbsp;&nbsp;</font>The Black-Scholes model calls for a single expected dividend yield as an input. We have never paid dividends and have no plans to pay cash dividends. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the guidance of ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, we accounted for forfeitures as they occurred. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We did not grant any stock options to employees during the six months ended June&#160;30, 2019 or the years ended December&#160;31, 2018 and 2017. Stock-based compensation expense recorded in research and development and general and administrative expenses was $136,000 and $150,000 for the six months ended June&#160;30, 2019 and 2018, respectively, and $293,000 and $301,000 for the years ended December&#160;31, 2018 and 2017, respectively. As of June&#160;30, 2019, unrecognized stock-based compensation expense related to employees totaled approximately $395,000, which is expected to be recognized over approximately 1.5 years. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Stock-based compensation expense recorded in exchange for services related to non-employee options was $32,000 and $0 for the six months ended June&#160;30, 2019 and 2018, respectively. As of June&#160;30, 2019, unrecognized stock-based compensation expense related to unvested non-employees stock options was approximately $16,000, which is expected to be recognized over a weighted-average period of three months. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Income Taxes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We account for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We provide a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In evaluating the ability to recover our deferred income tax assets, we consider all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event we determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We recognize the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company&#8217;s tax return. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Freestanding warrants are classified as liabilities on our balance sheets. Warrants are subject to re-measurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. We will continue to adjust the carrying values of freestanding warrants classified as liabilities for changes in fair value until the earlier of the exercise or expiration of the warrants. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Derivative Instruments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We evaluate our convertible debt to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Accounting Standards Codification, or ASC 815-15, &#8220;<font style="font-style:italic;">Derivatives and Hedging: Embedded Derivatives</font>.&#8221; The result of this accounting treatment is that the fair value of the bifurcated derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the Statement of Operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">62</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12&#160;months of the balance sheet date. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Debt Modifications and Extinguishments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">When we modify debt, we do so in accordance with ASC 470-50, &#8220;<font style="font-style:italic;">Debt: Modifications and Extinguishments,</font>&#8221; which requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#8220;substantial modifications.&#8221; Based on the guidance relied upon and the analysis performed, if the debt modifications were considered to be substantial modifications, then they were treated as an extinguishment of the debt. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In accordance with ASC 470-50 we determined that the October&#160;2018 modification of the March&#160;2018 and September&#160;2018 Notes to add an additional conversion option in the event of a reverse merger, was considered to be a &#8220;substantial modification.&#8221; As a result, we treated this modification as an &#8220;extinguishment&#8221; of those debts and recognized $11,000 of net gain from this debt extinguishment in other income. All other changes to debt provisions were not considered substantial and were treated as debt modifications. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Recently Adopted Accounting Pronouncements </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Lease Accounting </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In February 2016, the FASB issued ASU No. 2016-02, <font style="font-style:italic;">Leases (Topic 842)</font>, or ASU 2016-02. ASU 2016-02 is intended to improve financial reporting of leasing transactions by requiring organizations that lease assets to recognize assets and liabilities for the rights and obligations created by leases that extend more than 12 months on the balance sheet. This accounting update also requires additional disclosures surrounding the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for financial statements issued for annual and interim periods beginning after December 15, 2018 for public business entities. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1) its effective date or (2) the beginning of the earliest comparative period presented in the financial statements as its date of initial application. We adopted the new standard on January 1, 2019 and used the effective date as its date of initial application. Consequently, we have not adjusted prior period amounts. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have elected the package of practical expedients permitted in ASC Topic 842. Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a) whether the contracts contain a lease under ASC Topic 842, (b) whether classification of the operating leases would be different in accordance with ASC Topic 842, or (c) whether the unamortized initial direct costs would have met the definition of initial direct costs in ASC Topic 842 at lease commencement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The most significant impact from the adoption of this standard was the recognition of right-of-use, or ROU, assets and lease obligations on the balance sheet for operating leases. This standard did not have a material impact on our cash flows from operations and operating results. As a result of the adoption of the new lease accounting guidance, we recognized on January 1, 2019 (a) a lease liability of approximately $227,000, which represents the present value of the remaining lease payments of approximately $239,000, discounted using the Company&#8217;s incremental borrowing rate of 9.41%, and (b) a ROU asset of approximately $227,000 which represents the lease liability of&#8201; $227,000. The ROU asset is being amortized over the remaining term of the lease of 12 months from January 1, 2019.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">63</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Recent Accounting Pronouncements Not Yet Effective </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In August 2018, the FASB issued No. ASU 2018-13, <font style="font-style:italic;">Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820)</font>. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year, with early adoption permitted. We are currently assessing whether these amendments will have a material effect on our financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In August 2018, the FASB issued ASU 2018-15, <font style="font-style:italic;">Intangibles&#8201;&#8212;&#8201;Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</font>, or ASU 2018-15. The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January 1, 2020 and early adoption is permitted. We are currently assessing whether these amendments will have a material effect on our financial statements. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">64</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tOB">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">OUR BUSINESS </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are a clinical stage biopharmaceutical company focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Transcription factor decoys are short strands of DNA that specifically bind to and block the activity of their target transcription factors. Transcription factors are proteins that specifically bind to the regulatory regions of one or more target genes and regulate the expression of those genes. Since the founding of Adynxx in 2007, we have leveraged our AYX platform of proprietary transcription factor decoys to identify and develop novel product candidates designed to modify the course of pain. Our resulting pipeline includes brivoligide, a Phase&#160;2 drug candidate intended to address postoperative, or post-surgical pain in a readily-identified group of patients with a greater risk of experiencing increased pain and elevated opioid use following surgery, and AYX2, a pre-clinical candidate intended to treat chronic pain. Both programs were discovered by us and are part of our AYX platform of transcription factor decoys. We plan to continue advancing our AYX platform programs while simultaneously developing new transcription factor decoy candidates, collaborating with twoXAR, our artificial intelligence-driven drug discovery partner, and evaluating in-licensing opportunities to expand our pipeline and leverage our business development, clinical development and regulatory expertise. We are currently collaborating with twoXAR to use their artificial intelligence-driven drug discovery platform to identify endometriosis treatments. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following table outlines the status of our development programs: </div>
        <div style="position:relative;z-index:-1;margin-top:10.98pt; text-align:center; width:456pt;">
          <img src="tv523241_chrt-org.jpg" alt="[MISSING IMAGE: tv523241_chrt-org.jpg]" height="143" width="553" >
        </div>
        <div style="text-indent:20pt; margin-top:13.98pt; width:456pt; line-height:12pt;">We believe that our transcription factor decoy technology can transform the treatment of pain, and going forward has the potential to be applied to additional disease states. The AYX platform drug candidates are currently focused on postoperative pain and pre-existing chronic pain. We plan to leverage our expertise in transcription factor decoy drug discovery and development to identify additional product candidates in inflammation related disease states including but not limited to organ scarring, heart disease and cancer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have a highly experienced management team whose members have, in the course of their prior employment, participated in bringing more than 10 product candidates through clinical development, regulatory approval and/or into commercialization, including such approved products as Zerbaxa, Teflaro, Doribax, Vibativ, Symproic, Embeda, Revlimid, Mulpleta, Osphena, Comtan, FocalinXR, Trileptal, Kapvay and Cuvposa. We plan to leverage our management team&#8217;s breadth and depth of experience in clinical and regulatory drug development as well as market development and commercialization to continue to develop existing product candidates, and to discover and develop additional product candidates in-house using the AYX platform and build our pipeline through collaboration and in-licensing activities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Strategy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our goal is to be a leader in the development and commercialization of novel therapeutics for pain and inflammation. Our focus to achieve this goal will be to utilize our experience and capabilities to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Advance our existing product candidates through late-stage clinical trials, generating meaningful clinical results; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">65</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">Work with U.S. and international regulatory authorities for expeditious, efficient development pathways toward registration of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:4.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Prepare for commercialization of each program; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:4.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Use our expertise in transcription factor decoy drug development to discover and develop&#160;additional transcription factor decoy product candidates targeting a range of inflammation-related diseases; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:4.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Collaborate with twoXAR to use AI-driven drug discovery technology to identify novel drug candidates for the treatment of endometriosis; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:4.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Use our industry and academic relationships and experience to source, evaluate and in-license well-characterized product candidates to continue pipeline development; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:4.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Identify potential commercial or distribution partners for our product candidates in relevant territories. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Transcription Factor Decoy Technology </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Transcription factor decoys are short strands of DNA that specifically bind to and block the activity of their target transcription factors by preventing their interaction with DNA (Figure 1). Transcription factors are proteins that specifically bind to the regulatory regions of one or more target genes and regulate the expression of those genes. Using a screening assay, we discover and develop transcription factor decoys that are designed with binding and size parameters suitable for clinical application. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Figure 1<br >&#8199;<br >Transcription Factor Decoy Mechanism of Action </div>
        <div style="position:relative;z-index:-1;margin-top:7pt; text-align:center; width:456pt;">
          <img src="tv523241_img.jpg" alt="[MISSING IMAGE: tv523241_img.jpg]" height="133" width="368" >
        </div>
        <div style="margin-top:11pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">Transcription Factor Decoy Mechanism of Action.</font> (A) A transcription factor, or TF, binds to the regulatory region of the target gene on the DNA to regulate gene expression. (B) A TF decoy mimics the regulatory region of the target gene normally bound by its TF target. The mechanism of action is direct; by binding its TF target, the decoy prevents it from binding to its intended target, and thus blocks gene expression. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The AYX Platform of Transcription Factor Decoys </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The AYX platform consists of a wide range of transcription factor decoys, each of which has multiple binding sites capable of targeting one or more transcription factors, and we believe that we have the technological expertise to generate additional decoys based on desired therapeutic characteristics. The current AYX drug candidates are intended to treat postoperative pain and chronic pain. We plan to leverage our expertise in transcription factor decoy drug discovery and development to identify additional product candidates to treat inflammation-related diseases, including but not limited to organ scarring, heart disease and cancer. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Product Candidates </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Brivoligide for Postoperative Pain </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide is a transcription factor decoy specifically designed to inhibit the function of the transcription factor Early Growth Response 1, or EGR1, when administered at the time of surgery. EGR1 is expressed in the spinal cord and dorsal root ganglia, or DRG, in response to trauma such as surgery for a period of </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">66</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">approximately 12 hours. In normal animals, EGR1 initiates a wide range of gene regulation that results in increased or exacerbated pain following trauma or injury. In contrast, in animals that are unable to express EGR1, third party studies have shown that there is a reduction of pain intensity in response to trauma or injury, which may suggest that EGR1 has a role in elevated post-surgical pain. By inhibiting the function of EGR1 in people undergoing surgery, we believe brivoligide can prevent the regulation of genes that lead to an increased sensitivity to pain in some patients following surgery. We have evaluated brivoligide in four clinical trials: a Phase&#160;1 dose-escalating safety study in healthy volunteers and three Phase&#160;2 studies in subjects undergoing unilateral total knee arthroplasty, or TKA. A total of 264 subjects have received a single injection of brivoligide into the spinal canal, or an intrathecal injection, in doses ranging from 1.25 mg/3 mL (1.25 milligrams of brivoligide in 3 milliliters of solution) to 1,100 mg/10 mL. Brivoligide has been observed to be well-tolerated in the trials we have completed to date. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Post-hoc analyses of data generated in the three completed Phase 2 studies indicate that patients receiving a single administration of brivoligide at the time of surgery, in addition to standard of care, experienced reduced pain for weeks and shortened time to achieve mild pain, both as measured using the numerical rating scale, or NRS, when compared to patients receiving placebo and standard of care, in each case in a population of patients at greater risk of experiencing increased and prolonged pain following surgery. These differences were either not statistically significant or could not be considered significant due to the post-hoc nature of the analyses. These patients are readily indentifiable prior to surgery as patients who score high on the Pain Catastrophizing Scale, or PCS, and represent approximately one-third of the surgical population. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Postoperative Pain and Pain Catastrophizing </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to varying across the type of surgery, the severity and duration of postoperative pain varies across individuals. A growing body of literature indicates that the psychological construct known as pain catastrophizing is also an important factor in predicting the onset, severity, and duration of postoperative pain. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pain catastrophizing is as an amplified, negative orientation toward pain. It&#160;is comprised of elements of rumination (continuous or repetitive thoughts, anxious preoccupation with pain, and the inability to inhibit pain-related thoughts and fears); magnification (magnification of the unpleasantness of pain situations and expectations for negative outcomes from pain); and a sense of helplessness (perceived inability to control painful situations and experiences). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pain catastrophizing likely reflects a specific underlying physiology of pain associated with an enhanced response to painful stimuli, both in intensity and duration, as well as a relative insensitivity to pain relieving or analgesic therapies such as opioids. This physiology is associated with an enhanced and prolonged response to painful stimuli that suggests limited ability to appropriately inhibit pain signals being conveyed to the brain. Further, there is evidence that this underlying physiology can be inherited.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We estimate that of the 37 million surgical procedures performed in the United States annually, approximately 16 million of those result in a sufficient duration and severity of postoperative pain to be characterized as high unmet analgesic, or pain relieving, need procedures. Of those 16 million high-unmet analgesic need procedures, based on publications focused on the PCS, we expect that approximately one third will be conducted on patients scoring high (&ge;16) on the PCS, representing approximately 5.3 million patients who we believe could be candidates for brivoligide treatment. See &#8220;&#8212; The Role of the PCS in Identifying Patients Who May Benefit from Brivoligide.&#8221;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">To estimate the number of surgical procedures and the number of high-unmet analgesic need procedures, we use datasets sourced from samples and databases maintained by the Healthcare Cost and Utilization Project, or HCUP. The HCUP is a family of health care databases and related software tools and products developed through a federal-state industry partnership with and sponsored by the Agency for Healthcare Research and Quality, or the AHRQ. The HCUP is based on statewide data collected by individual data organizations across the United States and provided to AHRQ through the HCUP partnership. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For inpatient procedure estimates, we used the HCUP Nationwide Inpatient Sample, or the NIS, a large publicly available all-payer inpatient care database in the United States containing data on more than </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">67</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">seven million hospital stays. We believe that the large sample size from the NIS is ideal for developing national and regional estimates and enables analyses of rare conditions, uncommon treatments, and special populations. For outpatient procedure estimates we used the HCUP State Ambulatory Surgery and Services Database, or the SASD, which includes 29 states and captures two-thirds of the United States population. The SASD also includes data for ambulatory surgery and other outpatient services from hospital-owned facilities and, for some states, from non-hospital-owned facilities. There is no dataset available after 2015 for SASD, and as a result, the 2014 data are the most recent for both NIS and SASD. However, we believe that the 2014 data remain relevant for purposes of estimating the quantity of surgical procedures due to the relative year-over-year stability of prior estimates in this dataset and the fact that 2014 is the most recently available complete year of this large dataset.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Based on consultations with pain management experts, we classified individual surgical procedures to identify those that we believe result in a sufficient duration and severity of postoperative pain to be characterized as high-unmet analgesic need procedures. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Table 1: Estimated Annual Procedures with High-Unmet Analgesic Need</div>
        <table style="width:456pt;height:269pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Procedure classes </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Inpatient <br >Procedures <br >HCUP NIS 2014</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">ASC/Outpatient <br >Procedures <br >HCUP SASD <br >2014</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Total <br >Procedures</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">TKA (incl. revisions) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">755,226</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">83,255</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">838,481</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Lower extremity orthopedic surgeries </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">742,295</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">44,339</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">786,634</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:234pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Hip arthroplasty (incl. revisions and partial arthroplasties) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">521,080</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">21,678</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">542,758</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Spine/Back </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">844,161</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">322,679</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,166,840</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Other orthopedic procedures </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,390,091</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">927,404</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,317,495</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Chest/lung/thoracotomy </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">381,145</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">50,901</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">432,046</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Breast procedures </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">69,790</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">817,511</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">887,301</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Abdominal </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">527,410</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">660,044</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,187,454</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Cardiac </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">432,310</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">43,527</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">475,837</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Genital/urinary </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">471,050</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">524,039</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">995,089</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Hernia </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">166,885</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">856,442</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,023,327</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Lower gastrointestinal </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">612,310</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">122,088</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">734,398</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">OB/Gyn </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">821,665</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">828,702</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,650,367</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Upper gastrointestinal </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">430,035</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">92,784</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">522,819</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Vascular </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,333,795</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">338,927</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,672,723</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Other </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">829,343</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">829,343</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:234pt;text-align:left;">Total</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">9,499,248</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">6,563,663</td>
            <td style="padding:0pt;padding-left:9.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">16,062,912</td>
            <td style="padding:0pt;padding-left:10.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The Role of the PCS in Identifying Patients Who May Benefit from Brivoligide </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Catastrophizing is readily assessed by the PCS, a screening assessment tool that contains 13 questions covering the three components of pain catastrophizing: rumination, helplessness and magnification of pain. Each question is self-rated on a five point scale (from zero to four) and the total score ranges from zero to 52. The PCS has been extensively validated, having been established in over 100 studies. For patient selection purposes, the PCS can be segmented, with high scores predictive of more pain and lower analgesic response after surgery. Results from the literature and from the brivoligide study data suggest that a PCS of&#8201;&ge;16 may represent a clinically relevant threshold among TKA patients to predict positive response to brivoligide. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The importance of determining how a specific patient will respond to a specific treatment or procedure, or patient phenotyping, to predict the response to novel therapies has been recognized by the FDA. Once the PCS is completed by the patient, summation of the responses allows results to be easily available well in advance of surgery in order to determine which patients would potentially benefit from receiving brivoligide due to their underlying physiology. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">68</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Publications focused on the PCS suggest that approximately one-third of people presenting for surgery have PCS scores &ge; 16 and that these same patients experience postoperative pain that is higher in intensity and longer in duration than expected and display a relative resistance to standard analgesic therapies. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Current Therapy for Postoperative Pain </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Postoperative pain management is currently largely opioid-based and supported by adjunctive therapies and techniques such as local anesthetic nerve blocks and direct administration of local anesthetic into the surgical site, all of which only provide short-term relief. The proliferation of adjunctive and alternative therapies suggests that there are a considerable number of patients receiving inadequate pain relief, especially from movement-evoked pain, which is particularly insensitive to opioids. Persistent opioid use after surgery, even among those who are new to opioids, puts patients at increased risk of developing opioid use disorder. A non-opioid approach to postoperative pain relief specifically targeting the high PCS scoring population, a population that is relatively insensitive to standard postoperative analgesic therapies, is urgently needed. We believe there is no approved therapeutic agent that can provide weeks to&#160;months of reduction in postoperative pain and opioid utilization in patients who score high on the PCS with a single administration at the time of surgery. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Solution: Brivoligide for Postoperative Pain in Patients Scoring &ge;16 on the PCS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are pursuing an innovative approach to postoperative pain in people scoring &ge;16 on the PCS. Our lead compound, brivoligide, is designed to be a non-opioid, non-addictive agent given a single time prior to surgery and directed at core mechanisms of increased sensitivity to pain in the high PCS scoring population. In this population, brivoligide may reduce the intensity and duration of acute pain in the postoperative period. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pharmacology of Brivoligide </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">EGR1 is a transcription factor expressed in the spinal cord and dorsal root ganglia, or DRG, in response to trauma such as surgery for a period of approximately 12 hours. In normal animals, EGR1 initiates a wide range of gene regulation that results in increased or exacerbated pain following trauma or injury. In contrast, in animals that are unable to express EGR1, studies have shown that there is a reduction of pain intensity in response to trauma or injury. The structure of brivoligide has not been modified to protect it from breakdown through metabolic processes. In the space near the spinal cord and DRG for intrathecal injections, based on results from our animal studies, we have observed that brivoligide is present for a certain period of time and at a concentration sufficient in such studies to inhibit the function of EGR1 when administered into the intrathecal space at the time of injury. However, outside of the intrathecal space, there are higher rates of metabolic activity, which break down brivoligide in a matter of minutes, preventing concentrations from reaching levels with meaningful pharmacologic activity. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As described above, patients who have high scores on the PCS have an amplified, negative orientation toward pain which likely reflects a specific underlying physiology associated with an enhanced response to painful stimuli. Based on the data we have generated to date from clinical studies, we believe these patients have an altered pain response that results in the full manifestation of EGR1 activity in response to trauma such as surgery. By binding to EGR1 and inhibiting its activity in the spinal cord and DRG during surgery, we believe brivoligide can reduce the severity and duration of postoperative pain in patients that score high on the PCS and would otherwise experience increased or exacerbated pain following surgery. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Brivoligide Clinical Data </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide has been evaluated in four clinical trials, all of which were sponsored and conducted by us under an Investigational New Drug application, or IND, owned by us: a Phase&#160;1 dose-escalating safety study in healthy volunteers and three Phase&#160;2 studies in subjects undergoing unilateral TKA. A total of 264&#160;subjects have received a single intrathecal administration of brivoligide injection in doses ranging from 1.25 mg/3 mL to 1,100 mg/10 mL (Table 2). Brivoligide was shown to be well tolerated by patients in clinical&#160;trials conducted to date. In the Phase&#160;1 study in healthy volunteers, the study drug (highest dose of&#160;330mg/3mL) was well tolerated by all 25 people that received it. All of the AEs that were reported are among those expected when an injection in the spinal canal is given (for example, headache, backache, and </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">69</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">nausea). In&#160;three subsequently completed Phase&#160;2 clinical trials in TKA evaluating doses of brivoligide up to 1,100mg/10mL, there was no meaningful difference between the study drug and placebo groups in the rate of the complications that are typically seen in patients undergoing knee replacement surgery with spinal anesthetic and receiving analgesic medication. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Table 2: Brivoligide Doses Administered </div>
        <table style="width:416pt;height:137.5pt;margin-left:20pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">Study Number(s) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:68.64pt;">
              <div style="white-space:nowrap; text-align:center;">Dose </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:99.53pt;">
              <div style="text-align:center;">Number of Subjects Receiving <br >Dose </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-001 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">1.25 mg/3 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">5 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-001 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">5 mg/3 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">5 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-001 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">20 mg/3 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">5 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-001 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">80 mg/3 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">5 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-002 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">110 mg/3 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">13 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-001 and ADYX-002 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">330 mg/3 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">46 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-003 and ADYX-004 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="text-align:center;">660 mg/6 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">147 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:223.83pt;text-align:left;">
              <div style="white-space:nowrap;">ADYX-003 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:68.64pt;">
              <div style="white-space:nowrap; text-align:center;">1,100 mg/10 mL </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:99.53pt;">
              <div style="text-align:center;">38</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.59pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">ADYX-001:</font>&nbsp;&nbsp;&nbsp;The first-in-human study, ADYX-001, was a Phase&#160;1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ascending dose levels of a&#160;single intrathecal injection of brivoligide versus placebo in healthy adult subjects. Single doses&#160;of intrathecal brivoligide versus placebo were evaluated in five sequential ascending dose cohorts: 1.25 mg/3 mL, 5 mg/3 mL, 20 mg/3 mL, 80 mg/3 mL, and 330 mg/3 mL; six subjects were randomized 5:1&#160;to receive brivoligide injection or placebo in each cohort (total n=30). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All 30 subjects received study drug (25 subjects received brivoligide injection and five subjects received placebo) and completed the in-house and 30-day follow-up visits. Safety assessments consisted of the collection of adverse events, or AEs, and serious adverse events, or SAEs, clinical laboratory assessments, vital signs, and physical/neurological examination. AEs that occurred or worsened after administration of the study drug were classified as treatment emergent adverse events, or TEAEs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A total of 41 TEAEs were reported in 20 of the 30 study subjects. Most of the TEAEs were consistent with an intrathecal route of administration (backache, headache and associated nausea). All AEs were transient and resolved completely. There were no SAEs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to the safety evaluations, including physical/neurological exam, vital signs, ECG, clinical labs, and collection of other medications taken after surgery, or concomitant medications, a battery of cognitive assessments was performed to evaluate any potential effects of brivoligide on memory. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The cognitive assessments were performed at screening, baseline and after dosing at two hours, eight&#160;hours, 24 hours and on Day 3. No clinically significant changes in cognitive function from baseline were observed at any dose level. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">ADYX-002:</font>&nbsp;&nbsp;&nbsp;ADYX-002 was a Phase&#160;2 randomized, double-blind, placebo-controlled, adaptive study to evaluate the safety and efficacy of a single intrathecal preoperative administration of brivoligide injection at two dose levels compared to placebo in patients undergoing unilateral TKA. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ADYX-002 assessed the effect of brivoligide on acute and persistent (subacute) pain at rest and with movement as well as effects on opioid requirements in subjects undergoing unilateral TKA. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The study population consisted of healthy male and female subjects between 40 and 80&#160;years of age, inclusive, who were scheduled to undergo primary unilateral TKA for painful osteoarthritis with an American Society of Anesthesiologists Physical Status Classification System of&#8201;&#8201;&le;3, which system assesses fitness of patients before surgery on a scale of zero to six. Subjects randomized to the brivoligide treatment group received a single 3 mL intrathecal brivoligide injection (110 mg/3 mL or 330 mg/3 mL) just before administration of anesthesia using the same needle. Subjects participated in the study for 42&#160;days (&#177; 5&#160;days). </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">70</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The primary and key secondary endpoints were assessed using a standard numerical rating scale, or NRS, whereby subjects are asked to select a number between 0 and 10 that best represents their pain intensity. An NRS score of 0 represents no pain and a score of 10 represents the worst pain possible. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following assessments were used to evaluate efficacy: NRS pain assessment at rest; NRS pain assessment before removal of intravenous patient controlled analgesic therapy, and before administration of opioid medication in hospital; a defined distance walk (5 meters inpatient, 15 meters outpatient) with NRS pain assessment before and after; range of motion, or ROM, with NRS pain assessments; Brief Pain Inventory, or BPI, questionnaire daily through Day 28 and at Day 42; and the collection of analgesic medication data through Day 42. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Safety profile assessments consisted of the collection of AEs and SAEs, clinical laboratory assessments, vital signs, and physical/neurological examination. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Out of 100 subjects randomized, six withdrew and 94 completed the study post dosing. After initial dosing of 30 patients randomized 1:1:1 between 3 mL placebo, 110 mg/3 mL brivoligide and 330 mg/3 mL brivoligide, the Data Monitoring Committee reviewed the data to select the appropriate dose going forward based on prespecified criteria. Following review by the Data Monitoring Committee, all remaining subjects were enrolled in the 3 mL placebo or 330 mg/3mL brivoligide groups. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Safety </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Overall, 44 subjects treated with placebo, 13 subjects treated with brivoligide 110 mg/3 mL and 40&#160;subjects treated with brivoligide 330 mg/3 mL groups reported at least one TEAE. The overall AE profile was 96% mild or moderate with no AE clearly related to brivoligide. Four SAEs in three subjects were reported in the brivoligide group and two SAEs in two subjects were reported in the placebo group. No SAEs were considered related to brivoligide. In summary, brivoligide was shown to be well tolerated in patients. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Efficacy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For pain with walking, at rest, and with joint range of motion, as well as total use of opioid medications, either during the hospital stay or following discharge, no significant difference was observed between brivoligide 330 mg/3 mL and placebo 3 mL treated groups. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Post-hoc analysis of the study data suggested higher doses in larger volumes could provide broader distribution and clinically meaningful benefit, regardless of injection site. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">ADYX-003:</font>&nbsp;&nbsp;&nbsp;The second Phase&#160;2 study, ADYX-003, was a randomized, double-blind, placebo-controlled, two-stage study to evaluate the safety and efficacy of two dose levels of brivoligide injection administered at one of two potential spinal injection sites before surgery in patients undergoing TKA. The two potential spinal injection sites are the space between lumbar vertebrae 3 and 4, or L 3/4, and the space between lumbar vertebrae 4 and 5, or L 4/5. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The total subject population was 120 subjects distributed over two dose, and two injection sites within each dose, with a brivoligide to placebo control ratio of 2:1 in each group: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Brivoligide (660 mg in 6 mL) injected at L4/5; n= 20 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Placebo (vehicle control 6 mL) injected at L4/5; n= 10 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Brivoligide (660 mg in 6 mL) injected at L3/4; n=20 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Placebo (vehicle control 6 mL) injected at L3/4; n=10 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Brivoligide (1,100 mg in 10 mL) injected at L4/5; n=20 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Placebo (vehicle control 10 mL) injected at L4/5; n=10 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Brivoligide (1,100 mg in 10 mL) injected at L3/4; n=20 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Placebo (vehicle control 10mL) injected at L3/4; n=10 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">71</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The following assessments were used to evaluate efficacy: NRS pain assessment at rest; a defined distance walk (5 meters inpatient, 15 meters outpatient), with NRS for pain upon standing for the walk and pain during the walk; range of motion with NRS pain assessments; and collection of analgesic medication data through Day 42. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Safety assessments consisted of the collection of AEs and SAEs, clinical laboratory assessments, vital signs and physical/neurological examination. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Safety </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Overall, all subjects in the brivoligide 660 mg/6 mL and brivoligide 1,100 mg/10 mL groups, and 95% of subjects in the placebo 6 mL and placebo 10 mL groups, reported at least one TEAE. The overall AE profile was 90% mild to moderate with no AE clearly related to brivoligide. No subject withdrew in association with an AE. Ten SAEs in nine subjects were reported in the brivoligide group and three SAEs in two subjects were reported in the placebo group. No SAEs were considered related to study drug. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Efficacy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide 660 mg/6 mL significantly reduced pain with walking (15 meters) during the Day 7&#8201;to Day&#8201;28 period (LS Mean 2.0 &#177; 0.2 vs. 2.9 &#177; 0.3, p=0.026) as illustrated in Figure 2. Neither dose of brivoligide gave statistically significant reduction of pain with walking (5 meters) during the zero to 48 hour period. This early period (0-48 hours) is consistent with the time required for the effect of EGR1-driven gene regulations to show effects on pain. NRS pain scores with brivoligide 1,100 mg/10 mL did not show statistical significance compared with placebo 10 mL for pain scores with walking. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide 660 mg/6 mL also significantly reduced pain scores at rest during the outpatient period&#160;(Day 7&#8201;to Day&#8201;28) when compared to placebo 6 mL across injection groups (LS Mean 1.5 &#177; 0.2 vs. 2.4 &#177; 0.3, p=0.033) as illustrated in Figure 3. Brivoligide 660 mg/6 mL had no statistically significant effect on pain scores at rest during the 0-48 hour period. NRS pain scores with brivoligide 1,100 mg/10 mL, did not show statistical significance compared with placebo 10 mL for pain scores at rest. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A p-value is a statistical measure of the probability that the difference in two values could have occurred by chance. The smaller the p-value, the greater the statistical significance and confidence in the result. Typically, results are considered statistically significant if they have a p-value less than 0.05, meaning that there is less than a one-in-20 likelihood that the observed results occurred by chance.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">72</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
          <tr style="line-height:12pt;min-height:59pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">
              <div style="text-align:center;">Figure 2<br >&#8199;<br >ADYX-003 Least Squares Means Estimate <br >for NRS Pain During the 5 and 15-Meter Walk Tests <br >(Imputation Method 1, mITT Population) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">
              <div style="text-align:center;">Figure 3<br >&#8199;<br >ADYX-003 Least Squares Means Estimate <br >for NRS Pain at Rest (mITT Population) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="min-height:196pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 5pt 0pt; width:222pt;">
              <div style="position:relative;margin-left:10pt; text-align:center;">
                <img src="tv523241_chrt-line1.jpg" alt="[MISSING IMAGE: tv523241_chrt-line1.jpg]" height="251" width="261" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 5pt 0pt; width:222pt;">
              <div style="position:relative;text-align:center;">
                <img src="tv523241_chrt-line2.jpg" alt="[MISSING IMAGE: tv523241_chrt-line2.jpg]" height="247" width="265" >
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:55pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:222pt;">
              <div style="margin-left:20pt; line-height:10pt;">Imputation Method 1: If the walk test was not <br >completed due to pain or the entire distance was not <br >completed due to pain, the worst possible pain score <br >(10) was used.<br >mITT: Modified intent to treat population</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:222pt;text-align:center;">
              <div style="text-align:center;">mITT: Modified intent to treat population</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.98pt; width:456pt; line-height:12pt;">Brivoligide 660 mg/6 mL demonstrated similar differences in pain reduction between injection sites (L3/4 vs. L4/5) when compared to the combined 6 mL placebo, suggesting brivoligide 660 mg/6 mL can be administered without limitation as to injection site. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Opioid utilization was similar between brivoligide 660 mg/6 mL and 1,100 mg/10 mL and placebo groups during the zero to&#8201;48 hour inpatient and Day 7&#8201;to Day 28 outpatient periods. The use of opioids for postoperative pain management was collected to evaluate the potential impact, if any, differential opioid use may have on pain scores. The study was not designed to evaluate the potential for brivoligide to reduce opioid usage, and surgeons were allowed to prescribe opioids on a fixed scheduled basis without restriction. No clinically significant difference was noted for range of motion assessments in either time period. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pain ratings in the 1,100 mg/10 mL dose group showed a reduction relative to placebo only at the earliest time points. The 1,100 mg/10 mL dose did not display any dose related safety concerns and was not superior to 660 mg/6 mL for efficacy, so 660&#160;mg/6 mL was the dose selected for use in subsequent studies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">ADYX-004:</font>&nbsp;&nbsp;&nbsp;ADYX-004 was a multicenter, Phase&#160;2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of brivoligide injection 660 mg/6 mL compared to placebo 6 mL administered intrathecally before surgery in patients undergoing TKA. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Protocol changes relative to ADYX-003 included: allowance of NSAIDs from the perioperative period and beyond; allowance of local anesthetic mixtures injected between joints; lengthened follow-up to 90&#160;days post-surgery; use of an eDiary to collect daily pain ratings for least, average and worst pain as well as daily collection of opioid use out to 90&#160;days; and postoperative and outpatient opioid dosing was to be on an &#8220;as needed&#8221; basis and not on a fixed schedule. In addition, ADYX-004 was designed to assure a balance in the high PCS scoring subjects by using PCS scores &ge;20/&lt;20 for randomization.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following assessments were used to evaluate efficacy: NRS pain assessment at rest; a defined distance walk (5 meters inpatient, 15 meters outpatient), with NRS for pain during the walk; NRS pain assessment with rising from a seated position and worst, least and average pain over the last 24 hours (collected by subjects daily via eDiary); and collection of analgesic medication data through Day 90. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">73</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Safety assessments consisted of physical examination, vital signs, clinical laboratory assessments, and collection of AEs and SAEs. AEs were monitored from the time of randomization through Day 28 and SAEs were monitored from the time of consent through Day 28. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The primary efficacy endpoint was the mean NRS pain rating with walking during the 15-meter distance walk Day 7 to Day 28. The secondary efficacy endpoints included: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Mean NRS pain rating at rest, Day 7 to Day 28; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Total use of postoperative opioid medications 48 hours to Day 90 (analyzed for mITT and for PCS &ge;20/&lt;20);</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Total use of postoperative opioid medications 0 to 48 hours (analyzed for mITT and for PCS &ge;20/&lt;20); and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Time to achieve an NRS pain score of&#8201; &le;3 for worst pain (analyzed for mITT and for PCS&#160;&ge;20/&lt;20).</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A total of 210 subjects were dosed with either brivoligide 660 mg/6 mL (108 subjects) or placebo (102&#160;subjects) and 17 subjects prematurely discontinued from the study (five subjects prior to dosing and 12&#160;subjects after dosing): nine subjects in the brivoligide treatment group (two prior to dosing) and eight&#160;subjects in the placebo group (three prior to dosing). One subject was randomized to placebo but incorrectly received brivoligide and was incorporated into the brivoligide group only for the safety analyses. A total of 198 subjects completed the study. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Safety </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">No subject withdrew because of an AE and no tolerability signals were identified following dosing of brivoligide 660 mg/6 mL. The overall AE profile was primarily mild to moderate with no AE clearly related to brivoligide. No subjects were discontinued from the study due to TEAEs. Five SAEs in five subjects were reported in the brivoligide group and eight SAEs in six subjects were reported in the placebo group. No SAEs were considered related to study drug except for one SAE in the placebo group that was considered possibly related. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Efficacy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For the primary endpoint, no significant difference was observed between the brivoligide 660 mg/6 mL and placebo 6 mL treated groups. The results of the analyses of the secondary and additional endpoints in the total mITT population also did not show a clinically relevant effect of brivoligide 660 mg/6 mL vs. placebo 6 mL. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although results of the analyses were not clinically relevant, several prespecified secondary and additional endpoints suggested efficacy of brivoligide when compared with placebo in subjects with PCS score &ge;20. These endpoints included time to achieve an NRS pain score &le;3 for worst pain over the previous 24 hours and opioid use over the period of 48 hours to Day 90. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A Kaplan-Meier analysis of time to achieve an NRS pain score of&#8201;&#8201;&le;3 for worst pain is presented in Table 3. A Kaplan-Meier analysis is a statistical method used to measure the fraction of patients that have a particular trait or attribute over a given period of time.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">74</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Table 3 </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">ADYX-004 Time to NRS Pain Score &le;3 for Worst Pain&#8201;&#8212;&#8201;Kaplan Meier Analysis (mITT and Sub Populations) </div>
        <table style="width:456pt;height:157pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:170.4pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">PCS Score &ge;20 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">PCS Score &lt;20 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Overall </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">Endpoint Statistic </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL <br >(N=25) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Placebo <br >6 mL <br >(N=27) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL <br >(N=82) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Placebo <br >6 mL <br >(N=76) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL <br >(N=107) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Placebo <br >6 mL <br >(N=103) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">N </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">76</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">103</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">N of Censored </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">22</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:170.4pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">Days to NRS pain score &le;3 for derived <br >worst pain</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">25<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> Percentile </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.0</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">24.0</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">14.0</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">13.0</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">13.0</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">14.0</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">Median </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">15.0</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">41.0</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">31.0</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">29.0</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">27.0</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">31.0</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">75<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> Percentile </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">47.0</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">70.0</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">62.0</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">48.0</td>
            <td style="padding:0pt;padding-left:4.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">59.0</td>
            <td style="padding:0pt;padding-left:13.105pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">62.0</td>
            <td style="padding:0pt;padding-left:5.56pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.4pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.184</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.432</td>
            <td style="padding:0pt;padding-left:1.9pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.542</td>
            <td style="padding:0pt;padding-left:10.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:8.99pt; width:436pt; line-height:12pt;">Abbreviations: NRS = Numeric Rating Scale, PCS = Pain Catastrophizing Scale, NE = Not Estimable. <br >Note: An event is defined as 3 consecutive pain scores &le;3 over a 4-day period (allows for one missing eDiary entry). Time to event (days) is defined as the date of the first pain score &le;3 that starts the event&#8201;&#8212;&#8201;the end date of surgery. Subjects who reach Day 90 or withdraw from the study before an event are censored on the date of the last NRS score assessed or Day 90 if the last score is collected after Day 90. Subjects who do not have any eDiary pain scores for an assessment are censored on the day of surgery. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Derived worst pain is the higher score (of the reported worst/least scores) reported in the eDiary. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Total postoperative opioid utilization 48 hours to Day 90 is presented in Table 4. If an eDiary day was missing, the dosage for the opioid medications were imputed with the mean morphine equivalent from the previous two days with recordings. Indications of no opioid use for a day were counted as zero. The results of these analyses without imputation were similar.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">75</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:18pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Table 4 </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">ADYX-004 Total Postoperative Opioid Medication Use: 48 Hours to Day 90&#8201;&#8212;&#8201;IV Morphine Equivalents (mg) (mITT Postoperative Opioid Use Population) </div>
      </div>
      <div style="margin-top:18pt;margin-bottom:18pt;margin-left:27.5pt;width:541pt;">
        <table style="width:541pt;height:220pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
          <tr style="line-height:7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:114.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">PCS Score &ge;20 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">PCS Score &lt;20 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Overall </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">Postoperative Duration Statistic </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL <br >(N=25) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="text-align:center;">Placebo <br >6 mL <br >(N=27) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL <br >(N=82) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="text-align:center;">Placebo <br >6 mL <br >(N=75) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL <br >(N=107) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="text-align:center;">Placebo <br >6 mL <br >(N=102) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.25pt 0pt 2pt 0pt; width:114.18pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">48 Hours to Day 90 (with imputation)<font style=" position:relative; bottom:3.5pt;font-size:6.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">N </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">75</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">102</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">Mean (SD) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">225.16 (235.911) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">371.39 (340.927) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">376.08 (463.543) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">317.20 (291.180) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">340.82 (425.338) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">331.54 (304.333) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">Median </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">172.50</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">228.75</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">189.58</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">212.92</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">176.25</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">220.21</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">(Min, Max) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(5.2, 1148.2) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(22.5, 1202.5) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(0.0, 2431.7) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(1.7, 1138.8) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(0.0, 2431.7) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(1.7, 1202.5) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">P-value</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.105</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.915</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.366</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">48 Hours to Day 90 (no imputation)</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">N </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">75</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">102</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">Mean (SD) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">213.66 (229.409) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">352.17 (329.340) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">355.79 (440.461) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">305.66 (281.431) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">322.58 (404.743) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">317.97 (293.900) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">Median </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">150.00</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">228.75</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">181.25</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">182.50</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">170.83</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">213.13</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">(Min, Max) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(5.2,1118.2) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(22.5, 1202.5) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(0.0,2375.4) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(1.7,1135.1) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(0.0,2375.4) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;" colspan="4">
              <div style="text-align:center;">(1.7,1202.5) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8.5pt;">
            <td style="padding:3.5pt 0pt 2pt 0pt; width:114.18pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.115</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.936</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">0.391</td>
            <td style="padding:0pt;padding-left:17.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:18pt;height:357pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:20pt; margin-top:11.48pt; width:436pt; line-height:12pt;font-size:10pt;">Abbreviation: PCS = Pain Catastrophizing Scale. </div>
        <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">(1)<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">For 48 Hours to Day 90, morphine equivalents for missing eDiary dates are imputed with the mean of the previous two days. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;font-size:10pt;">Post-hoc Analysis </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-size:10pt;">In the endpoints analyzed by PCS score &ge;20, including opioid utilization out to 90 days and time to achieve NRS pain score &le;3 for worst pain, there were numerical but not statistically significant differences between the brivoligide 660 mg/6 mL treatment group and the placebo 6 mL group that suggested a clinically meaningful effect. Further investigation was then undertaken by post-hoc analysis, including mixed effects analysis of pain with walking, pain at rest, analysis of worst pain, time to NRS pain score &le;3 for worst pain, total opioid utilization, and time to little or no opioid utilization. Post-hoc analyses also included investigation of these analyses using a PCS cut-off value of&#8201;&#8201;&ge;16. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-size:10pt;">A mixed effects analysis of NRS pain score with walking during the 15-meter distance walk from Days&#160;7 to 28 by baseline PCS score is presented in Table 5. Similar post-hoc analyses of NRS pain score at rest from Days 7 to 28 by baseline PCS score, worst pain over the last 24 hours from the patient diary by baseline PCS for the additional time period of Day 3 to 28 and Day 7 to 28, time to NRS pain score &le;3 for worst pain by baseline PCS score, and total postoperative opioid utilization by baseline PCS score consistently suggest that a PCS score &ge;16 represents an appropriate cut-off value.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">76</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Table 5 </div>
        <div style="margin-top:15.98pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">ADYX-004 Mixed Effects Analysis of NRS Pain Score with Walking During the 15-Meter Walk Test Days 7&#160;to 28 by Baseline PCS Score (mITT&#8201;&#8212;&#8201;15-Meter Walk Population) </div>
        <table style="width:456pt;height:323.5pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Visit Mixed Effects Results<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60pt;">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60pt;">
              <div style="text-align:center;">Difference <br >Brivoligide&#8201;&#8211;&#8201;Placebo </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:66pt;">
              <div style="text-align:center;">Placebo <br >6 mL </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">PCS &lt; 20 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">79 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:66pt;">
              <div style="text-align:center;">72 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">LS mean (95% CI) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
              <div style="text-align:center;">2.73 <br >(1.29, 3.16) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
              <div style="text-align:center;">2.56 <br >(2.10, 3.01) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Difference in LS means </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.17 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">95% CI for Difference </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-0.46, 0.80 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.595 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">PCS &ge; 20 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">24 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;">
              <div style="text-align:center;">26 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">LS mean (95% CI) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
              <div style="text-align:center;">2.61 <br >(1.82, 3.40) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
              <div style="text-align:center;">3.52 <br >(2.76, 4.29) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Difference in LS means </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-0.91 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">95% CI for Difference </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-2.01, 0.19 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.106 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">PCS &ge; 16 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">30 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;">
              <div style="text-align:center;">33 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">LS mean (95% CI) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
              <div style="text-align:center;">2.53 <br >(1.83, 3.23) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
              <div style="text-align:center;">3.61 <br >(2.94, 4.28) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Difference in LS means </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-1.08 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">95% CI for Difference </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-2.05, -0.11 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.029</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:20pt; margin-top:11.98pt; width:436pt; line-height:12pt;">Abbreviations: NRS = Numeric Rating Scale, LS = Least Square, CI = Confidence Interval, PCS = Pain Catastrophizing Scale. </div>
        <div style="margin-left:20pt; margin-top:11.98pt; width:436pt; line-height:12pt;">Note: The worst rating (score of 10) is imputed if missing due to pain. </div>
        <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Results are obtained from a mixed effects model with terms for treatment, actual Screening PCS and treatment by Screening PCS interaction as fixed effects. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:10.99pt; width:456pt; line-height:12pt;">A Kaplan Meier analysis of time to less than 5mg of opioid per day analyzed by PCS &ge;16 is presented in Figure 4. This analysis suggests that brivoligide has the potential to shorten the time required for patients to achieve little to no postoperative opioid utilization.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">77</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always;margin-left:-8pt;margin-top:-8pt;position:relative;width:595.31pt;height:775.71pt;overflow:hidden;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;position:absolute;z-index:1;top:8pt;left:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:54pt;left:70pt;height:660pt;width:464pt;z-index:0;">
        <div style="text-align:center; width:456pt; line-height:12pt;">Figure 4<br >&#8199;<br >ADYX-004 Kaplan-Meier Analysis of Time to<br >&lt;5mg Opioid Use for Subjects with a Baseline PCS &ge;16 </div>
        <div style="position:relative;z-index:-1;margin-top:10.78pt; text-align:center; width:456pt;">
          <img src="tv523241_chrt-line3.jpg" alt="[MISSING IMAGE: tv523241_chrt-line3.jpg]" height="283" width="378" >
        </div>
        <div style="margin-top:17pt; width:456pt; line-height:11pt;font-style:italic;">ADYX-003 and ADYX-004 Data Combination and Meta-analysis by PCS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-weight:normal;">Due to the similar study design and brivoligide dose used in studies ADYX-003 and ADYX-004, these studies were combined and analyzed for consistency of PCS score effect on brivoligide efficacy. Data for the combined studies analyzed by PCS &ge;16 suggested a consistent therapeutic effect of brivoligide in patients scoring &ge;16 on the PCS and are presented in Figure 5 and Figure 6. </div>
        <table style="width:456pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
          <tr style="line-height:12pt;min-height:59pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">
              <div style="text-align:center;">Figure 5 <br >&#8199;<br >Combined ADYX-003 and ADYX-004 <br >NRS during the 5 and 15-Meter Walk Test for Subjects with PCS&ge;16 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;white-space:nowrap;">
              <div style="text-align:center;">Figure 6 <br >&#8199;<br >Combined ADYX-003 and ADYX-004 <br >NRS at Rest for Subjects with PCS&ge;16 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="min-height:233.7pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 0.5pt 0pt; width:222pt;">
              <div style="position:relative;margin-left:10pt;">
                <img src="tv523241_chrt-line4.jpg" alt="[MISSING IMAGE: tv523241_chrt-line4.jpg]" height="281" width="289" >
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 0.5pt 0pt; width:222pt;white-space:normal;">
              <div style="position:relative;">
                <img src="tv523241_chrt-line5.jpg" alt="[MISSING IMAGE: tv523241_chrt-line5.jpg]" height="280" width="288" >
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="width:456pt; line-height:12pt;font-weight:normal;"></div>
      </div>
      <div style="position:absolute;top:730pt;left:70pt;height:12pt;width:464pt;z-index:0;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-weight:normal;">78</div>
      </div>
      <hr style="margin-top:773.71pt;" >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Post-hoc mixed effect analyses of NRS pain score with walking during the 15-meter distance walk and at rest from Days 7 to 28 by baseline PCS score are presented in Table 6 and Table 7, respectively. These analyses suggest patients scoring &ge;16 on the PCS who received brivoligide at the time of surgery reported lower levels of pain than patients scoring &ge;16 on the PCS who did not receive brivoligide, and reported similar levels of pain to patients scoring &lt;16 on the PCS. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Table 6</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Combined ADYX-003 and ADYX-004 Meta-Analysis: Mixed Effects Analysis of NRS Pain Score <br >with Walking During the 15-Meter Walk Test Days 7 to 28 by Baseline PCS Score <br >(mITT&#8201;&#8211;&#8201;15-Meter Walk Population) </div>
        <table style="width:456pt;height:323.5pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Visit Mixed Effects Results<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60pt;">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60pt;">
              <div style="text-align:center;">Difference <br >Brivoligide&#8201;&#8211;&#8201;Placebo </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:66pt;">
              <div style="text-align:center;">Placebo <br >6 mL </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Overall </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">142 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:66pt;">
              <div style="text-align:center;">118 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">LS mean (95% CI) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
              <div style="text-align:center;">2.51 <br >(2.20, 2.82) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
              <div style="text-align:center;">2.80 <br >(2.46, 3.14) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Difference in LS means </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-0.29 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">95% CI for Difference </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-0.75, 0.17 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.213 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">PCS &ge; 16 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">38 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;">
              <div style="text-align:center;">42 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">LS mean (95% CI) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
              <div style="text-align:center;">2.32 <br >(1.72, 2.91) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
              <div style="text-align:center;">3.55 <br >(2.98, 4.11) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Difference in LS means </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-1.23 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">95% CI for Difference </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-2.05, -0.41 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.003 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">PCS &lt; 16 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">104 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;">
              <div style="text-align:center;">76 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">LS mean (95% CI) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
              <div style="text-align:center;">2.58 <br >(2.22, 2.94) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
              <div style="text-align:center;">2.39 <br >(1.98, 2.81) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Difference in LS means </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.19 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">95% CI for Difference </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-0.36, 0.73 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.506</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.48pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:20pt; margin-top:11.98pt; width:436pt; line-height:12pt;">Abbreviations: NRS = Numeric Rating Scale, LS = Least Square, CI = Confidence Interval, PCS = Pain Catastrophizing Scale. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Note: The worst rating (score of 10) is imputed if missing due to pain. </div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Results are obtained from a mixed effects model with terms for treatment, actual Screening PCS and treatment by Screening PCS interaction as fixed effects.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">79</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Table 7</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Combined ADYX-003 and ADYX-004 Meta-Analysis: Mixed Effects Analysis of NRS Pain Score <br >with Rest Days 7 to 28 by Baseline PCS Score (mITT) </div>
        <table style="width:456pt;height:323.5pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Visit Mixed Effects Results<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60pt;">
              <div style="text-align:center;">Brivoligide <br >660 mg/6 mL </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60pt;">
              <div style="text-align:center;">Difference <br >Brivoligide&#8201;&#8211;&#8201;Placebo </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:66pt;">
              <div style="text-align:center;">Placebo <br >6 mL </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Overall </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">142 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:66pt;">
              <div style="text-align:center;">118 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">LS mean (95% CI) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
              <div style="text-align:center;">1.94 <br >(1.64, 2.23) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
              <div style="text-align:center;">2.39 <br >(2.06, 2.72) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Difference in LS means </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-0.46 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">95% CI for Difference </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-0.90, -0.01 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.044 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">PCS &ge; 16 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">38 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;">
              <div style="text-align:center;">42 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">LS mean (95% CI) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
              <div style="text-align:center;">1.77 <br >(1.21, 2.34) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
              <div style="text-align:center;">3.13 <br >(2.59, 3.67) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Difference in LS means </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-1.35 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">95% CI for Difference </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-2.14, -0.57 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.0008 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">PCS &lt; 16 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">104 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66pt;">
              <div style="text-align:center;">76 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Day 7 to Day 28 (Overall Treatment Effect)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">LS mean (95% CI) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:60pt;">
              <div style="text-align:center;">2.00 <br >(1.65, 2.34) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:66pt;">
              <div style="text-align:center;">1.99 <br >(1.59, 2.39) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">Difference in LS means </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.007 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">95% CI for Difference </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">-0.52, 0.53 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;text-align:left;">
              <div style="white-space:nowrap;">P-value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:60pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:60pt;">
              <div style="text-align:center;">0.980</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">Abbreviations: NRS = Numeric Rating Scale, LS = Least Square, CI = Confidence Interval, PCS = Pain Catastrophizing Scale. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Note: The worst rating (score of 10) is imputed if missing due to pain. </div>
        <div style=" float:left; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Results are obtained from a mixed effects model with terms for treatment, actual Screening PCS and treatment by PCS interaction as fixed effects. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In summary, we believe high scores on the preoperative PCS can be used to identify people that may benefit from brivoligide administration before surgery. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Brivoligide Development Plan and Registration Strategy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have filed with the FDA an IND for brivoligide for the reduction of postoperative pain in patients scoring &ge;16 on the PCS. This IND allows us to conduct the activities required for us to submit an NDA to the FDA for marketing approval and eventual commercialization of brivoligide. In particular, an IND must become effective before human clinical studies for the applicable product candidate may begin and must be updated annually or when significant changes are made. Successful completion of human clinical studies is a prerequisite to submitting an NDA to the FDA, which must be approved before we may commercialize brivoligide in the United States. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We plan to conduct a Phase 2 study in subjects undergoing mastectomy with predictive enrichment of the study population with patients scoring &ge;16 on the PCS. If successful, we intend to file for Breakthrough Therapy Designation, as positive data on a clinically significant endpoint from that study could support that brivoligide may offer substantial treatment advantages over existing options for patients scoring &ge;16 on </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">80</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">the PCS and suffering from postoperative pain, a condition that we believe qualifies as serious. We have received a grant award from NIDA/NIH for up to $5.7 million to support the conduct of the Phase 2 mastectomy study. We also plan to conduct a study in subjects undergoing TKA who score high on the PCS to further explore the results obtained in the prior Phase 2 studies in TKA in the proposed target population. If successful, we plan to follow the Phase&#160;2 studies of brivoligide with Phase&#160;3 pivotal studies in both TKA and mastectomy. The design and size of the Phase&#160;3 studies will be determined after completion of the respective Phase&#160;2 studies. Based on the funding opportunity announcement under which we received the award, and on the milestones and budget outlined in our application, following completion of milestones related to the Phase&#160;2 mastectomy study, including receipt of positive data for the Phase&#160;2 mastectomy study and clear guidance from the FDA at an end of phase&#160;2 meeting, we may be eligible to receive an additional award of up to $9.0&#160;million over three years to fund a Phase&#160;3 mastectomy study. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">&#8220;Top-line&#8221; data from our clinical studies refer to the results from the initial planned analyses of primary and certain key secondary endpoints from our clinical trials after enrollment has been completed and the data from the study database is locked. Top line data remain subject to audit and verification procedures that may result in the final data being materially different from previously published top line data. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We propose to use a predictive enrichment strategy in which patients are chosen who are more likely to respond to the drug treatment than other patients with the condition being treated and only enroll subjects with PCS scores &ge;16 in the Phase&#160;3 studies of brivoligide. The rationale for this approach is as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Post-hoc analyses of Phase&#160;2 studies ADYX-003 and ADYX-004 suggest that patients with PCS scores of&#8201;&#8201;&ge;16 are more likely to respond to brivoligide treatment, while analyses of those with PCS &lt;16 do not show meaningful evidence of efficacy; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">The PCS is an easy to administer assessment and can be incorporated into clinical practice to identify patients who are more likely to respond to brivoligide treatment; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Adequate data has been generated from the 180 subjects with PCS &lt;16 (104 brivoligide vs. 76 placebo) in studies ADYX-003 and ADYX-004 to suggest that this patient population is unlikely to derive a benefit from brivoligide treatment, and continuing to enroll subjects in this patient population would be medically inappropriate; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">We believe predictive enrichment of the Phase&#160;3 studies will support an indication of reduction of postoperative pain in patients who score &ge;16 on the PCS. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">ADYX-005 Study </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ADYX-005 is a Phase&#160;2 randomized double-blind, placebo-controlled study to evaluate the safety and efficacy of a single intrathecal preoperative administration of brivoligide injection in patients with a PCS score &ge;16 undergoing TKA. We are evaluating whether to commence this Phase&#160;2 clinical trial as early as the first quarter of 2020, with top-line results expected as early as the fourth quarter of 2020, subject to receipt of additional capital to fund the trial through top-line results. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The study protocol calls for approximately 122 subjects to be enrolled in the study and randomized 1:1&#160;into two treatment groups (brivoligide injection 660 mg/6 mL and placebo 6 mL) with randomization by study center. Subjects will receive study drug just prior to administration of spinal anesthesia via the same needle. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Safety and laboratory assessments will be performed in the standard manner up to Day 28. Concomitant medications will be collected through Day 28; analgesic medications will be collected through Day 42. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pain at rest and with walking will be recorded by study staff postoperatively at follow-up visits. Daily ratings of worst pain over the previous 24 hours will be collected via electronic diary, or eDiary, by subjects every evening from Day 1 until the Day 42 visit. Analgesic medication use will be collected via eDiary by subjects daily after discharge until the Day 42 visit. Follow-up visits will occur on Days 7, 14, 21, 28 and 42 </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">81</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">The primary endpoint will be reduction in pain with walking from Day 7 to Day 28 as measured using the NRS. Secondary endpoints include pain at rest and pain with passive knee flexion to 90 degrees from Day 7 to day 28 as measured by the NRS, and total use of postoperative opioid medications (morphine equivalents) postoperatively to Day 42. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">ADYX-006 Study </div>
        <div style="text-indent:20pt; margin-top:4.41pt; width:456pt; line-height:12pt;">ADYX-006 is a Phase&#160;2 randomized double-blind, placebo-controlled study to evaluate the safety and efficacy of a single intrathecal preoperative administration of brivoligide injection in patients with a PCS score &ge;16 undergoing mastectomy. We plan to commence this Phase&#160;2 clinical trial as early as the first quarter of 2020, with top-line results expected as early as the first half of 2021, subject to receipt of additional capital to fund the trial through top-line results, including receipt of additional funds from our grant award from the National Institute of Drug Abuse, or NIDA, described under &#8220;&#8212;&#8201;Our Solution: Brivoligide for Postoperative Pain in Patients Scoring &ge;16 on the PCS&#8201;&#8212;&#8201;Brivoligide Development Plan and Registration Strategy.&#8221; </div>
        <div style="text-indent:20pt; margin-top:5.42pt; width:456pt; line-height:12pt;">The study protocol calls for approximately 126 subjects to be enrolled in the study and randomized 1:1 into two treatment groups (brivoligide injection 660 mg/6 mL and placebo 6 mL). Safety and laboratory assessments will be performed up to Day 21. Concomitant medications will be collected through Day 21; analgesic medications will be collected through Day 21. </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">Data for pain at rest with general movement involving the chest and upper body, and worst pain over the last 24 hours, with deep full breath and forceful cough, will be collected by subjects via eDiary every evening from Day 1 until the Day 21 visit. NRS pain assessment upon certain movements of the arm will be collected by subjects via eDiary from Day 14 to 21 as allowed by the subject&#8217;s surgeon. Analgesic medication use will be recorded after discharge until the Day 21 visit by subjects daily via eDiary. A physical well-being questionnaire will be collected at screening and at the Day 21 follow-up visit. Follow-up visits will occur on Days 7 and 21. The primary endpoint will be mean pain rating with general movement involving the chest and upper body from Day 3 to Day 14. Secondary endpoints include pain at rest and pain with deep full breath and forceful cough from Day 3 to Day 14, and total use of postoperative opioid medications (morphine equivalents) from Day 3 to Day 14. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">AYX2 for Chronic Pain </div>
        <div style="text-indent:20pt; margin-top:4.42pt; width:456pt; line-height:12pt;">Chronic pain, which includes types of pain such as low back pain, pain associated with pinched or compressed nerves known as radiculopathy, and pain associated with inflammation of the spinal nerve root known as radiculitis, affects as many as 25&#160;million patients annually in the United States. Chronic pain can be caused by changes in various components of the pain pathway, including the ongoing regulation of gene activity in the spinal cord and DRG. The transcription factors driving this regulation include a family of transcription factors known as Kruppel-like Factors, or KLF, and constitute a promising class of targets that can potentially alter the course of pain with a single or short-term treatment. AYX2 is a differential inhibitor of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pharmacology of AYX2 </div>
        <div style="text-indent:20pt; margin-top:4.22pt; width:456pt; line-height:12pt;">Chronic pain is a dynamic state that is maintained by a number of factors, including the ongoing regulation of gene activity in the spinal cord and DRG. We identified a group of transcription factors with the potential to control these gene regulations based on their known functions. We then screened decoys designed against those factors and identified two decoys that bind to KLF6, KLF9 and KLF15 that significantly reduced chronic pain following a single administration in multiple models testing the response to painful stimuli in rats, including the spared-nerve injury, or SNI, and chronic constriction injury, or CCI, models. </div>
        <div style="text-indent:20pt; margin-top:5.21pt; width:456pt; line-height:12pt;">Results demonstrated that a single administration of decoys binding to KLF6, KLF9, and KLF15 produced a significant and weeks-long reduction in pain sensitivity compared to controls. In the SNI model, the clinical reduction in pain sensitivity from a given decoy was correlated to its capacity to bind KLF15 and KLF9 at a specific ratio. In the CCI model, the clinical reduction in pain sensitivity from a given decoy was correlated to the combined binding capacity to KLF6 and KLF9. AYX2 was optimized to achieve both binding patterns. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">82</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We conducted a non-Good Laboratory Practice toxicology study to determine potential toxicity and tolerability of single and repeated AYX2 intrathecal injections in a study that included a total of 30 rats. Standard toxicology study data were collected, including clinical observations, clinical pathology, spinal and brain histopathology. Single and repeated AYX2 injections were well tolerated. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">AYX2 Development Path </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Based on the non-clinical data generated to date, we believe AYX2 has the potential to be developed as a one-time or short-course treatment for chronic pain. We plan to conduct an IND-enabling toxicology program. Phase&#160;1 is planned to be a single ascending dose study design, using healthy subjects. An initial Phase&#160;2 proof-of-concept is planned in radiculopathy and radiculitis. The study is planned to be a randomized, placebo-controlled, safety and efficacy study of single administration AYX2 or placebo. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In September 2019, we received a Notice of Award from the National Institute on Neurological Disease and Stroke, or NINDS, part of the NIH, for up to approximately $0.6&#160;million to be paid over 12&#160;months to support our planned preclinical studies of AYX2. The funds will become available after approval from the Office of Laboratory Animal Welfare, or OLAW, of the planned preclinical studies for AYX2. </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Discovery and Development of Additional Product Candidates Using the AYX Platform</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The AYX platform drug candidates are currently focused on postoperative pain and pre-existing chronic pain. We plan to leverage our expertise in transcription factor decoy drug discovery and development to identify additional product candidates in inflammation related disease states including but not limited to organ scarring, heart disease and cancer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The discovery and preclinical development of an AYX decoy may include the following steps, as appropriate and relevant depending on the target disease: (1)&#160;identifying potentially relevant transcription factor targets based on pre-established scientific knowledge in the target disease or in biological systems with similar features and/or on the direct analysis of transcription factor DNA binding motives in the promoter of relevant genes, (2)&#160;designing preliminary decoys against those potential transcription factor targets using their known, consensus DNA binding sequence and directly screening the therapeutic profile of those decoys for efficacy in non-clinical models, (3)&#160;designing AYX decoy by optimizing the sequences of the initial decoys into sequences optimal for clinical use and confirming their therapeutic profile, mechanism of action and pharmacology in non-clinical models, (4)&#160;performing IND-enabling studies to allow submitting an IND and testing the decoy in clinical trials. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">twoXAR Collaboration </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe that artificial intelligence-, or AI-based platforms, such as twoXAR&#8217;s, are helping create portfolios of drug programs more efficiently through faster, more predictive models than traditional approaches. Such technology can accelerate the entire drug development process, decrease risk and substantially reduce overall costs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Endometriosis is an often painful disorder in which tissue similar to the lining of the uterus grows in other places outside of the uterus. We are seeking to identify product candidates with the potential to address the underlying biological drivers of endometriosis instead of masking symptoms, in order to significantly differentiate from standard of care, using twoXAR&#8217;s proprietary AI-driven platform, which has demonstrated <font style="font-style:italic;">in vivo</font> success rates significantly greater than those of traditional approaches across therapeutic areas including diseases such as liver cancer, rheumatoid arthritis, and type 2 diabetes. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2018 we entered into a collaboration agreement with twoXAR. Under our agreement, twoXAR will use its proprietary AI technology to identify a set of medical treatments with the potential to treat or prevent the recurrence of endometriosis and associated symptoms. We will select product candidate(s) from this set to test for efficacy in <font style="font-style:italic;">in vivo</font> models of endometriosis based on predetermined criteria. Following identification of one or more candidate compounds based on those evaluated <font style="font-style:italic;">in vivo</font>, we intend to select one or more compounds on which to conduct preclinical characterization work, IND-enabling work and clinical development. If currently approved compounds are identified, we could potentially employ the 505(b)(2) regulatory pathway to efficiently develop this indication. Under the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">83</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">agreement, we will use commercially reasonable efforts to develop and commercialize selected compounds, and we are subject to a number of obligations including, but not limited to, the outside dates for initiation of pre-clinical and clinical development activities and regulatory filing. Both we and twoXAR will not develop drug candidates with the same product profile as the selected compounds for the term of the agreement. In June 2019, we received an initial set of product candidate predictions from twoXAR. We have initiated a review of the potential product candidates to determine if any are viable candidates for further research and development. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Approximately 4.4&#160;million women suffer from endometriosis in the United States, with up to 175,000 new diagnoses projected annually by 2022. Symptoms of endometriosis include chronic pelvic pain, painful menstruation and sexual intercourse, infertility, and/or painful hypersensitivity. Over time, endometriosis may be associated with pain-related adhesions and scarring from chronic inflammation and in some cases cancer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Initial diagnosis of endometriosis is based on clinical presentation, with definitive diagnosis requiring laparoscopy with histologic confirmation. There is no accepted screening or preoperative diagnostic test, and because symptoms may be vague, and because diagnosis is invasive and carries a small risk of complications, diagnosis can be delayed for more than six&#160;years. We believe that existing therapies are insufficient, and new disease-modifying treatments addressing the underlying disease drivers of endometriosis are sought to address the unmet need associated with the current standard of care. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">twoXAR retains all intellectual property rights to its computational methods and disease models and grants us a non-exclusive license to use intellectual property rights solely for the development of our selected product candidates for the treatment of endometriosis. We own all intellectual property developed following selection of the selected product candidates, twoXAR will assign all residual right, title and interests to such intellectual property to us. Under the agreement, we control prosecution, defense and enforcement of such intellectual property rights relating to selected product candidates, and twoXAR has backup rights to prosecution, defense and enforcement with respect to such intellectual property for which we elect not to exercise such rights. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The agreement with twoXAR will remain in effect until expiration of the applicable royalty term unless terminated by us upon 60&#160;days prior written notice to twoXAR or terminated by either party upon certain events of material breach. Upon termination, all licenses granted under the agreement will terminate. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Competition </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The biopharmaceutical industry is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Given the significant unmet medical need for novel therapies to treat pain, as well as the ongoing public health crisis associated with OUD in the United States, many public and private universities and research organizations are actively engaged in the discovery, research and development of product candidates. As a result, there are and will likely continue to be extensive resources invested in the discovery and development of new products to treat these unmet medical needs. We anticipate facing intense and increasing competition as new products enter the market and advanced technologies become available. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, there are numerous multinational pharmaceutical companies and large biotechnology companies currently marketing or pursuing the development of products or product candidates targeting the same indications as our product candidates. Many of our competitors, either alone or with strategic partners, have or will have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than us in developing or marketing products and technologies that are more effective, safer or less costly. Additionally, our competitors may obtain regulatory approval for their products more rapidly and may achieve more widespread market acceptance. Accelerated mergers and acquisitions activity in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">84</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">While brivoligide has a novel therapeutic profile, competing non-opioid products and product candidates for postoperative pain include, but are not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">EXPAREL (marketed by Pacira Pharmaceuticals, Inc.); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Ofirmev (marketed by Mallinckrodt Pharmaceuticals); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">HTX-011 (in development by Heron Therapeutics, NDA submitted to FDA in 2018, Complete Response Letter received from FDA on April&#160;30, 2019); and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">CA-008 (in development by Concentric Analgesics). </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additional competitive products that comprise current analgesic standard of care include opioids and oral and topical NSAIDs. Potential competitive products or product candidates for AYX2 include opioids, oral and topical NSAIDs, oral gabapentinoids, and steroid injections. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe that the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety and tolerability profile, duration of effect, product labeling, cost-effectiveness, price, the level of generic competition, hospital formulary access, and the availability of reimbursement from the government and other third-parties. Our commercial opportunity could be reduced or eliminated for any of our products if our competitors have products that are approved earlier than our product candidates or are superior compared to our product candidates or if our product candidates do not result in an improvement in condition compared to those other products. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Manufacturing </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We currently contract with third parties for the drug substance supply and manufacturing of our product candidates for preclinical studies and clinical trials and intend to do so in the future. We do not own or operate manufacturing facilities for the production of clinical trial quantities of our product candidates and do not plan to build our own clinical or commercial scale manufacturing capabilities. Although we rely on contract manufacturers, we have extensive experience overseeing CMOs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We contract drug substance for preclinical and clinical studies from several suppliers in the United States. For IND-enabling and for clinical trials, we contract with the largest manufacturer of GMP oligonucleotide worldwide. Alternate GMP manufacturers exist for oligonucleotide product candidates but they do not currently have the production scale of our current supplier. Drug product manufacturing is contracted by a separate CMO. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">With respect to our brivoligide product candidate, we rely on Nitto-Denko Avecia, Inc., or Avecia, for drug substance manufacturing, and Pyramid Laboratories, Inc., or Pyramid, for drug product supply. We do not have long-term supply agreements or commitments from those parties to supply our materials. We may also receive supply of drug substance or drug product that is deficient in quality or otherwise does not meet the specifications required to be used in clinical trials. In the past, we have experienced such deficiencies and have been required to seek alternative sources to meet our needs. We expect our current drug substance manufacturer to be capable of providing sufficient quantities of our product candidates to meet anticipated full-scale commercial demand. However, while preliminary feasibility assessments have been conducted with the manufacturer, we cannot be certain that full commercial scale production can be successful, cost effective, or completed on a timely basis without significant delay in the development or commercialization of our product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Brivoligide </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Brivoligide drug substance for all clinical trials was manufactured by Avecia and brivoligide drug product was manufactured by Pyramid or Corden Pharma GmbH. We currently have sufficient drug substance available to conduct the currently planned ADYX-005 and ADYX-006 studies, subject to standard testing by the manufacturer to confirm the material meets manufacturing specifications; however, we will have to manufacture new drug product for these studies. We do not have long-term supply agreements or commitments from any parties to supply drug substance or drug product. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">85</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">AYX2 </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">AYX2 drug substance for preclinical studies was manufactured by Avecia, TriLink BioTechnologies, Inc., and Invitrogen Corporation. We currently plan to use the same CMOs for drug substance and drug product for AYX2 GMP manufacturing as currently used for brivoligide. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Intellectual Property </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">We are dedicated to protecting our proprietary technologies that are core to our business. We seek and maintain, where available, patent protection for our product candidates including but not limited to composition of matter, method(s) of use and/or formulation. We plan to continue to expand our intellectual property portfolio by filing patent applications on new dosage or formulation forms, methods of treatment, and compositions of matter for our product candidates as appropriate. We file and prosecute patent applications in the United States and Europe, and when appropriate, additional countries, including Canada, Australia, Japan, Brazil, Russia, India or China. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our success will depend significantly upon our ability to: (i)&#160;obtain and maintain patents and other available exclusivity protections for commercially important technology, inventions and know-how related to our business; (ii) prosecute our patent applications to issue as patents and defend and enforce our patents; (iii) maintain any licenses to use intellectual property owned by others; (iv) preserve the confidentiality of our trade secrets, and (v)&#160;operate without infringing the valid and enforceable patents and other proprietary rights of others. In addition to maintaining our existing proprietary assets, we seek to strengthen our proprietary positions when economically reasonable to do so. Our ability to augment our proprietary position relies on our: (i)&#160;know-how; (ii) ability to access technological innovations, and (iii)&#160;ability to in-license technology when appropriate. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The patent positions of pharmaceutical/biotechnology companies like us are generally uncertain and involve complex legal, scientific, and factual issues. In addition, the scope claimed in a patent application can be significantly reduced before any patent issues. After issuance of a patent application, if the issued patent is challenged, then the courts can redefine the scope of the patent, including by invalidating it or rendering it unenforceable in its entirety. Consequently, we do not know with certainty whether patents will issue in each country where it or our licensor&#8217;s file patent applications, or if those patent applications, if ever issued, will issue with claims that cover our product candidates, or, even if they do whether the patent or our relevant claims will remain enforceable upon challenge. Accordingly, we cannot predict with certainty whether the patent applications we are currently pursuing will issue as patents in a particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from potential competitors to make any of our products commercially successful. Any of our patents, including already issued in-licensed patents or any patents that may issue to us or our licensors in the future could potentially be challenged, narrowed, circumvented, or invalidated by third parties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Because newly filed patent applications in the United States Patent and Trademark Office, or the USPTO, and certain other patent offices are maintained in secrecy for a minimum of 18&#160;months, and because publications of discoveries in the scientific or patent literature often lag far behind the actual discoveries themselves, we cannot be certain of the priority of our inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention, although patent applications filed after 2013 are given priority based on first to file in the U.S. The date of an invention is typically not publicly disclosed. Also, while we are not currently participating in any interferences or post-grant challenge proceedings, such as patent oppositions and patent litigation, that seek to invalidate the patentability of patents before or after they issue, respectively, we may have to participate in such proceedings in the future. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The term of individual patents depends upon the legal term of the patents in the countries where they are issued. In most countries, the standard patent term for inventions relating to human drugs and their formulation and use is 20&#160;years from the date of filing the first non-provisional patent or international application under the Patent Cooperation Treaty of 1970, or the PCT. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have received grant awards from NIDA/NIH and NINDS/NIH for the development of brivoligide in the mastectomy&#160;model of postoperative pain and the developmentof AYX2, respectively. Intellectual property may be generated through the use of this U.S.&#160;government funding and would therefore be subject </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">86</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">to certain federal regulations. As a result, the U.S.&#160;government may in the future have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S.&#160;government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we fail to disclose the invention to the government or fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Patent Protection of our Product Candidates </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We fully-own the patents and patent applications protecting our oligonucleotide product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Brivoligide </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The patent and patent applications protecting brivoligide encompass composition of matter, method of use, formulation, dosage and target patient populations. Composition of matter and method of use for brivoligide and closely related compounds patents have issued in the United States and additional geographies. Those patents will expire in 2028 and 2029 and could be subject to extension. The brivoligide formulation patent has also issued in the United States and is under prosecution in additional geographies. It will expire in 2033 and could be subject to extension. A dosing regimen patent application is under prosecution in the United States with an expiration date, if issued, of 2037 that could be subject to extension. An International PCT patent application pertaining to the brivoligide target patient population (&ge;16 on the PCS) was filed in February&#160;2019. We anticipate prosecuting this application at least in the United States, Europe, Canada, Japan, Australia, Brazil, Russia, India and China. If issued, this application would be valid until 2039 and could be subject to extension. The final list of countries to prosecute this application under will be decided at the time of National Stage Entry of the current PCT application, which occurs in August&#160;2020. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">AYX2 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A patent covering AYX2 composition of matter and method of use has been issued in the U.S. and will expire in 2035 and could be subject to extension. Further, patent applications covering AYX2 composition of matter and method of use are also under prosecution in the United States, Europe, Japan, Canada, Australia, Brazil, Russia, India and China. If issued, these patents will expire in 2035 and could be subject to extension. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Patent Term </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Depending upon the timing, duration and specifics of the FDA approval of our drug candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five&#160;years beyond the normal expiration of the patent, limited to the approved indication (or any additional indications approved during the period of extension), as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">87</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. Similar provisions may be available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug. In Europe, through the European Medicines Agency, there is a period of ten&#160;years of regulatory data exclusivity from the time of approval if the centralized procedure is used, however under the centralized procedure this term would run concurrently with the period of exclusivity provided by the patent. When possible, depending upon the length of clinical trials and other factors involved in the filing of NDAs for our products, we expect to apply for PTEs for patents covering our product candidates and their methods of use both in the United States and any foreign jurisdiction where available. There is no guarantee, however, that the applicable authorities will agree to grant extensions, and if granted, what the length of those extensions will be. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Other Proprietary Rights and Processes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We also rely on trade secret protection for some of our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets and disclose our technology. If these events happen, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business, scientific, development or financial affairs that are either developed or made known to the individual during the course of the individual&#8217;s relationship with us are to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or based on the employee&#8217;s use of our confidential information are our exclusive property or that we have an exclusive royalty free license to use such technology. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Government Regulations and Product Approvals </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">FDA Approval Process </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All of our current product candidates are subject to regulation in the United States by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDC Act, and its implementing regulations. The FDA subjects drugs to extensive pre and post market regulation. Failure to comply with the FDC Act and other federal and state statutes and regulations may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal penalties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">FDA approval is required before any new unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States. The process required by the FDA before a new drug may be marketed in the United States is long, expensive, and inherently uncertain. Drug development in the United States typically involves completion of preclinical laboratory and animal tests, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">88</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">submission to the FDA of an IND, which must become effective before clinical testing may commence, approval by an IRB, at each clinical site before each trial may be initiated, performance of adequate and well controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought, submission to the FDA of an NDA, satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced, and FDA review and approval of the NDA. Developing the data to satisfy FDA pre-market approval requirements typically takes many&#160;years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product, disease or indication. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Preclinical tests include laboratory evaluation of the product&#8217;s chemistry, formulation, and toxicity, as well as animal studies to characterize and assess the potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practice, or GLP, regulations. These preclinical results are submitted to the FDA as part of an IND along with other information, including information about the product&#8217;s chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term preclinical studies including reproductive toxicity and carcinogenicity may be initiated or continue after the IND is submitted. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">An IND must become effective before United States clinical trials may begin. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the IND automatically becomes effective and the clinical trial proposed in the IND may begin. If the FDA does raise any concerns or questions and places the clinical trial on a clinical hold, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, a submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations, including GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials; and (ii) with protocols that detail, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to and approved by an IRB at each study site before the study commences at that site and the IRB must monitor the clinical trial until it is completed. An IRB may also require the clinical trial at that site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or if the drug candidate has been associated with unexpected serious harm to patients, or the IRB may impose other conditions. The study sponsor or the FDA may also suspend or discontinue a clinical trial at any time on various grounds, including a determination that the subjects are being exposed to an unacceptable health risk. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Clinical trials to support an NDA for marketing approval are typically conducted in three sequential phases, although there is leeway to overlap or combine these phases.&nbsp;&nbsp;&nbsp; </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Phase&#160;1.&nbsp;&nbsp;&nbsp;</font>The drug candidate is initially introduced into healthy human subjects or patients with the target disease or condition, and is tested to assess safety, dosage tolerance, pharmacokinetics and pharmacological activity, and, when possible, to ascertain evidence of efficacy. The drug candidate may also be tested in patients with severe or life-threatening diseases to gain an early indication of its effectiveness. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Phase&#160;2.&nbsp;&nbsp;&nbsp;</font>The trials are conducted using a limited patient population for the purposes of preliminarily determining the effectiveness of the drug in that particular indication, ascertaining dosage tolerance, discerning the optimal dosage, and identifying possible adverse effects and safety&#160;risks. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">89</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;">Phase&#160;3.&nbsp;&nbsp;&nbsp;</font>If a compound demonstrates evidence of efficacy and has an acceptable safety profile in the Phase&#160;2 clinical trials, then Phase&#160;3 clinical trials are undertaken to obtain additional information from an expanded and diverse patient population, at multiple, geographically dispersed clinical trial sites, in randomized controlled studies often with a double-blind design to maximize the reproducibility of the study results. Typically, a minimum of two positive Phase&#160;3 clinical trials are submitted to support the product&#8217;s marketing application. These Phase&#160;3 clinical trials are intended to provide sufficient data demonstrating evidence of the efficacy and safety of the drug such that the FDA can evaluate the overall benefit-risk of the drug and provide adequate information for the labeling and package insert for the drug. Trials conducted outside of the United States under similar, GCP-compliant conditions in accordance with local applicable laws may also be acceptable to FDA in support of product approval. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Sponsors of clinical trials for investigational drugs must publicly disclose certain clinical trial information, including detailed trial design. These requirements are subject to specific timelines and apply to most Phase&#160;3 clinical trials of FDA-regulated products. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In some cases, FDA may condition approval of an NDA for a product candidate on the sponsor&#8217;s agreement to conduct additional clinical trials after NDA approval. In other cases, a sponsor may voluntarily conduct additional clinical trials post approval to gain more information about the drug. Such post approval trials are typically referred to as Phase&#160;4 clinical trials. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if SAEs occur. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the study. Phase&#160;1, Phase&#160;2, Phase&#160;3 and Phase&#160;4 clinical trials may not be completed successfully within any specified period, or at all. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Concurrent with clinical trials, companies usually finalize a process for manufacturing the drug in commercial quantities in accordance with current good manufacturing practice, or cGMP, requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA requesting approval to market the drug for one or more specified indications. FDA review and approval of the NDA is required before marketing of the product may begin in the United States. The NDA must include the results of all preclinical, clinical, and other testing, including negative or ambiguous results as well as positive findings, together with other detailed information including compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. The NDA must also contain extensive manufacturing information. The FDA reviews an NDA to determine, among other things, whether a drug is safe and effective for its intended use. The cost of preparing and submitting an NDA is substantial. Under federal law, the submission of most NDAs is subject to both a substantial application user fee and annual program user fees. The sum of these fees may total several million dollars and they are typically increased annually. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA has 60&#160;days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. Once the submission is accepted for filing, the FDA begins an in-depth review. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the Prescription Drug User Fee Act PDUFA, guidelines that are currently in effect, the FDA has agreed to certain performance goals in the review of NDAs. Standard NDAs are generally reviewed within ten&#160;months of filing, or twelve&#160;months from submission. Although FDA often meets its user fee performance goals, the FDA can extend these timelines if necessary, and FDA review may not occur on a </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">90</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">timely basis. The FDA usually refers applications for novel drugs, or drugs that present difficult questions of safety or efficacy, to an advisory committee&#8201;&#8212;&#8201;a panel of independent experts, typically including clinicians and other scientific experts&#8201;&#8212;&#8201;for review, evaluation, and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of the advisory committee, but it generally follows its recommendations. Before approving an NDA, the FDA will typically inspect one, or more, clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve an application unless it verifies that compliance with cGMP requirements is satisfactory and that the manufacturing processes and facilities are adequate to assure consistent production of the product within required specifications. The FDA will not approve a drug unless the application contains data showing substantial evidence that it is safe and effective in the indication studied. </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">After the FDA evaluates the NDA and conducts its inspections, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies contained in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application, including potentially significant, expensive and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. Even if such data are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data from clinical trials are not always conclusive, and the FDA may interpret data differently than we do. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the application, the FDA will typically issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six&#160;months depending on the type of additional information requested. FDA approval is never guaranteed. The FDA may refuse to approve an NDA if applicable regulatory criteria are not satisfied. </div>
        <div style="text-indent:20pt; margin-top:5.62pt; width:456pt; line-height:12pt;">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. The approval for a drug may be significantly more limited than requested in the application, including limitations on the specific diseases and dosages or the indications for use, which could restrict the commercial value of the product. The FDA may also require that certain contraindications, warnings, or precautions be included in the product&#8217;s package insert, or labeling. </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">In addition, as a condition of approval, the FDA may require a REMS, to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guidelines, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing-including dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS or use of a companion diagnostic with a drug can materially affect the potential market and profitability of the drug. Moreover, product approval may require, as a condition of approval, substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. The FDA may also condition approval on, among other things, changes to proposed labeling or development of adequate controls and specifications. </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">Once granted, product approvals may be withdrawn if compliance with regulatory standards are not maintained or problems are identified following initial marketing. In addition, after approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Breakthrough Therapy Designation</div>
        <div style="text-indent:20pt; margin-top:4.62pt; width:456pt; line-height:12pt;">Breakthrough Therapy Designation by the FDA provides more extensive development consultation opportunities with FDA senior staff, allows for the rolling review of the product&#8217;s application for approval and indicates that the product could be eligible for priority review if supported by clinical data at the time of application submission for products that are intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new product candidate may request that FDA designate the product candidate for a specific indication as a breakthrough therapy concurrent with, or after, the filing of the IND for the product candidate. The FDA must determine if the product candidate qualifies for Breakthrough Therapy Designation within 60 days of receipt of the sponsor&#8217;s request. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">91</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Advertising and Promotion </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing post-approval regulatory requirements. For instance, the FDA closely regulates the post-approval marketing, labeling, advertising and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Failure to comply with these requirements can result in adverse publicity as well as significant penalties, including the issuance of warning letters directing a company to correct any deviations from the FDA&#8217;s standards. The FDA may also impose a requirement that future advertising and promotional materials be pre-cleared by the FDA, and we may face federal and/or state civil and criminal investigations and prosecutions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">AE Reporting and cGMP Compliance </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Recordkeeping, AE reporting and the submission of periodic reports are required following the FDA&#8217;s approval of an NDA. The FDA also may require post-marketing testing or Phase&#160;4 clinical trials, REMS, or surveillance to monitor the effects of an approved drug. In addition, the FDA may place conditions on an approval that could restrict the distribution or use of the product. Furthermore, manufacture, packaging, labeling, storage and distribution procedures must continue to conform to cGMPs after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies to assess compliance with ongoing regulatory requirements, including cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMPs. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that it or our present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may halt our clinical trials, require us to recall a drug from distribution or withdraw approval of the NDA for that drug. Regulatory authorities may also withdraw product approvals, request product recalls, or impose marketing restrictions through labeling changes or product removals upon discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Other Healthcare Laws and Compliance Requirements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA. These other agencies include, without limitation, the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services,&#160;the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, as well as state and local governments. Such agencies enforce a variety of laws, including without limitation, anti-kickback and false claims laws, data privacy and security laws, and physician payment transparency&#160;laws. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or arranging for or </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">92</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to or approval by the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-reimbursable, uses. In addition, the civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. HIPAA, created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, ACA broadened the reach of certain criminal healthcare fraud statutes created under HIPAA by amending the intent requirement such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, including the final Omnibus Rule published on January&#160;25, 2013, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, defined as service providers of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties and gave state attorneys general new authority to file civil actions for </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">93</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health information in certain circumstances, many of which differ from HIPAA and each other in significant ways and may not have the same effect, thus complicating compliance efforts. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. ACA imposed, among other things, new annual reporting requirements for covered manufacturers for certain payments and &#8220;transfers of value&#8221; provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties of up to an aggregate of&#8201;&#8201;$150,000 per year and up to an aggregate of&#8201;&#8201;$1&#160;million per year for &#8220;knowing failures.&#8221; Covered manufacturers were required to begin collecting data on August&#160;1, 2013 and submit reports on aggregate payment data to the government for the first reporting period (August&#160;1, 2013&#8201;&#8212;&#8201;December&#160;31, 2013) by March&#160;31, 2014, and were required to report detailed payment data for the first reporting period and submit legal attestation to the completeness and accuracy of such data by June&#160;30, 2014. Thereafter, covered manufacturers must submit reports by the 90<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> day of each subsequent calendar year. In addition, certain states require implementation of commercial compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or tracking and reporting of gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to it, we may be subject to penalties, including potentially significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">International Regulation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, commercial sales, and distribution of drugs. Whether or not we obtain FDA approval for a drug, we or our collaborators must obtain approval of the drug by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing of the drug in those countries. The approval process varies from country to country and the time to approve may be longer or shorter than that required for FDA approval. Further, to the extent that any of our products are sold in a foreign country, we may be subject to additional foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pharmaceutical Coverage, Pricing and Reimbursement </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the United States and other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of any products for which we receive regulatory approval for commercial sale will therefore depend in part on the availability of reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Generally, if we obtain FDA approval of brivoligide, before we can attempt to sell brivoligide in a hospital, brivoligide must be approved for addition to that hospital&#8217;s list of approved drugs, or formulary list, by the hospital&#8217;s P&amp;T committee. A hospital&#8217;s P&amp;T committee typically governs all matters pertaining to the use of medications within the institution, including the review of medication formulary data and recommendations for the appropriate use of drugs within the institution to the medical staff. The frequency </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">94</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">of P&amp;T committee meetings at hospitals varies considerably, and P&amp;T committees often require additional information to aid in their decision-making process. We may experience substantial delays in obtaining formulary approvals, and hospital pharmacists may be concerned that the cost of acquiring brivoligide for use in their institutions will adversely impact their overall pharmacy budgets, which could cause pharmacists to resist efforts to add brivoligide to the formulary, or to implement restrictions on the usage of brivoligide in order to control costs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The process for determining whether a third-party payor will provide coverage for a drug product typically is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payor not to cover our product candidates could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of drug products and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. By way of example, in the United&#160;States, ACA contains provisions that may reduce the profitability of drug products. The ACA, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions for individuals enrolled in Medicaid managed care plans, imposed mandatory discounts for certain Medicare Part&#160;D beneficiaries and subjected manufacturers to new annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Other legislative changes have been proposed and adopted since ACA was enacted. On August&#160;2, 2011, the President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not recommend and Congress did not enact legislation to reduce the deficit by at least $1.2 trillion for the&#160;years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and will remain in effect through 2024 unless additional Congressional action is taken. On January&#160;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">95</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Legal Proceedings </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Facilities </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, we conducted all of our operations, other than our outsourced operations, at office space located at 100 Pine Street, Suite 500, San Francisco, CA 94111. This office space is subleased from REC Americas, LLC, and the term of the lease is for 62&#160;months and expires on December&#160;31, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employees </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, we had a total of six full-time employees in the United States, three of whom were primarily engaged in research and development activities and three of whom were engaged in general management and administration. Two of our employees have either an M.D. or a Ph.D. None of our employees are represented by a labor union or subject to a collective bargaining agreement. We have never experienced any work stoppage and consider our relations with our employees to be good. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">96</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAN">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">MANAGEMENT </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Executive Officers and Board of Directors </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following persons are our executive officers and directors as of September&#160;30, 2019. </div>
        <table style="width:456pt;height:164.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:162pt;">
              <div style="white-space:nowrap;">Name </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:36pt;">
              <div style="white-space:nowrap;">Age </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:234pt;">
              <div style="white-space:nowrap;">Position(s) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:162pt;">Executive Officers</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
              <div style="white-space:nowrap;">Rick Orr</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">58 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">President, Chief Executive Officer and Director </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
              <div style="white-space:nowrap;">Julien Mamet, Ph.D.</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">43 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Chief Scientific Officer and Director </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
              <div style="white-space:nowrap;">Donald Manning, M.D., Ph.D.</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">61 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Chief Medical Officer </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:162pt;">Non-Employee Directors</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
              <div style="white-space:nowrap;font-size:7.5pt;">
                <font style="font-size:10pt;">Dennis Podlesak</font><font style=" position:relative; bottom:4.25pt;">(1)(2)(3)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">61 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Chairperson </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
              <div style="white-space:nowrap;">Eckard Weber, M.D.<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">69 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Director </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
              <div style="white-space:nowrap;font-size:7.5pt;">
                <font style="font-size:10pt;">Stan Abel</font><font style=" position:relative; bottom:4.25pt;">(1)(3)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">53 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Director </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
              <div style="white-space:nowrap;">Gregory J. Flesher</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">49 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Director </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:162pt;">
              <div style="white-space:nowrap;">Matthew Ruth<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:36pt;">50 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Director</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:6.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:6.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Member of the Audit Committee. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Member of the Compensation Committee. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Member of the Nominating and Corporate Governance Committee. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Executive Officers </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Rick Orr</font> has served as a member of our board of directors and as President and Chief Executive Officer since May&#160;2019. From December&#160;2010 to May&#160;2019, Mr.&#160;Orr served as a member of the board of directors and as President and Chief Executive Officer of Adynxx. Prior to joining Adynxx, Mr.&#160;Orr was Chief Operating Officer at Corthera, Inc., a private, clinical-stage biopharmaceutical company focused on developing therapies for acute heart failure, from May&#160;2009 to July&#160;2010. Corthera was acquired by Novartis Pharmaceuticals Corporation in February&#160;2010. Prior to Corthera, Mr.&#160;Orr served as Sr. Vice President of Operations at Cerexa, Inc., a wholly owned subsidiary of Forest Laboratories, Inc. focused on developing novel anti-infective therapies, from October&#160;2007 to May&#160;2009. Mr.&#160;Orr was part of the management team that founded Cerexa in July&#160;2005 and served as General Counsel from the company&#8217;s inception until October&#160;2007. Forest Laboratories acquired Cerexa in January&#160;2007. Mr.&#160;Orr received a B.A. from The Ohio State University, an M.A. from the University of California, Santa Barbara, and a J.D. from the University of San Francisco School of Law. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr.&#160;Orr was selected to serve on the Adynxx board of directors because of his extensive experience in the biopharmaceutical industry and his executive leadership experience. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Julien Mamet, Ph.D.</font> has served as a member of our board of directors and our Chief Scientific Officer since May&#160;2019. Prior to joining us, Dr.&#160;Mamet founded Adynxx and served as a member of its board of directors since its inception in October&#160;2007 and as Chief Scientific Officer since December&#160;2010. Previously, Dr.&#160;Mamet served as President and Chief Executive Officer of Adynxx from its inception to December&#160;2010. Prior to founding Adynxx, Dr.&#160;Mamet completed his post-doctoral work at the Scripps Research Institute, a nonprofit biomedical research institute, from September&#160;2006 to December&#160;2006, and at the Genomics Institute of the Novartis Research Foundation, a research institute of Novartis International AG, a global pharmaceutical company, from February&#160;2004 to September&#160;2006. Dr.&#160;Mamet received a B.S. and M.S. from the University Claude Bernard in Lyon, France and a Ph.D. from the Institute of Molecular and Cellular Pharmacology in Nice-Sophia Antipolis, France. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Dr.&#160;Mamet was selected to serve on the Adynxx board of directors because of extensive experience as inventor of the AYX technology platform. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">97</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Donald C. Manning, M.D., Ph.D.</font> has served as our Chief Medical Officer since May&#160;2019. From January&#160;2012 to May&#160;2019, Dr.&#160;Manning served as Chief Medical Officer of Adynxx. Prior to joining Adynxx, Dr.&#160;Manning served as Chief Medical Officer at Shionogi Inc., the U.S. subsidiary of Shionogi &amp; Co., Ltd., a global pharmaceutical company, from July&#160;2009 to May&#160;2011 and as Executive Vice President of Clinical Development, Medical Affairs and Pharmacovigilance from March&#160;2010 to May&#160;2011. Prior to Shionogi, Dr.&#160;Manning served as Vice President of Medical Affairs at King Pharmaceuticals Inc., from January&#160;2009 to June&#160;2009, and as Vice President of Clinical Research and Development at Alpharma Inc., a global specialty pharmaceutical company, from August&#160;2008 to January&#160;2009. Alpharma was acquired by King Pharmaceuticals in January&#160;2009. Prior to Alpharma, Dr.&#160;Manning served as Vice President and Therapeutic Area Head for Neurosciences at Celgene Corporation, a biotechnology company that develops and commercializes medicines for cancer and inflammatory disorders, from October&#160;2006 to August&#160;2008 and as Executive Director from April&#160;2003 to October&#160;2006. Dr.&#160;Manning received a B.S. from McGill University and an M.D. and Ph.D. from Johns Hopkins School of Medicine. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Non-Employee Directors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Dennis Podlesak</font> has served as a member of our board of directors since May&#160;2019 and has served as a member of the board of directors of Adynxx since 2010. Since 2007, Mr.&#160;Podlesak has served as a Partner of Domain Associates LLC, a private venture capital management firm focused on life sciences. While at Domain, Mr.&#160;Podlesak has been the founder and the Chief Executive Officer of a number of companies, including Calixa Therapeutics, Inc., a privately held biopharmaceutical company which was acquired by Cubist Pharmaceuticals, Inc. in December&#160;2009. Mr.&#160;Podlesak was also the Executive Chairman of Corthera, Inc., a biopharmaceutical company, which was acquired by Novartis AG in January&#160;2010. Mr.&#160;Podlesak currently serves as the chairperson of the board of directors of Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company. Mr.&#160;Podlesak received a B.A. from Western Illinois University and an M.B.A. from Pepperdine University. He completed post-graduate studies at The Wharton School, University of Pennsylvania. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr.&#160;Podlesak was selected to serve on the Adynxx board of directors because of his experience as the Chief Executive Officer and Chairman of other successful companies in the biotechnology industry, his over 20&#160;years of strategic, operational and commercial experience in the pharmaceutical industry, and his service as a director of other publicly traded and privately held life science companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Eckard Weber, M.D.</font> has served as a member of our board of directors since May&#160;2019 and has served as a member of the board of directors of Adynxx since 2010. Dr.&#160;Weber has served as a partner with Domain Associates, LLC, a private venture capital management firm focused on life sciences, since 2001. Dr.&#160;Weber has been the founding Chief Executive Officer of multiple Domain Associates portfolio companies including Acea Pharmaceuticals, Ascenta Therapeutics, Calixa Therapeutics, Cytovia and NovaCardia, each a biopharmaceutical company. Dr.&#160;Weber received his German undergraduate degree from Kolping Kolleg in Germany and an M.D. from the University of Ulm Medical School in Germany. Dr.&#160;Weber received his postdoctoral training in neuroscience at Stanford University Medical School. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Dr.&#160;Weber was selected to serve on the Adynxx board of directors because of his extensive experience in the life sciences industry as an entrepreneur, chief executive officer and venture capitalist, as well as his training as a physician. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Stan Abel</font> has served as a member of our board of directors since May&#160;2019 and has served as a member of the board of directors of Adynxx since 2008. Since 2010, Mr.&#160;Abel has served as the President and Chief Executive Officer of SiteOne Therapeutics Inc., a pain company focused on developing a novel platform of highly selective sodium channel 1.7 inhibitors. From 2007 to 2010, Mr.&#160;Abel served as Chief Executive Officer of Corthera, Inc., a biopharmaceutical company, through the sale of the company to Novartis AG in February&#160;2010. Mr.&#160;Abel received a B.S. in Business from Indiana University and an M.B.A., with honors, from the University of Chicago. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr.&#160;Abel was selected to serve on the Adynxx board of directors because of his extensive experience in strategic biopharmaceutical transactions and leadership of clinical-stage companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Gregory&#160;J. Flesher</font> has served as a member of our board of directors since July 2019. Mr.&#160;Flesher has served as the Chief Executive Officer and a member of the board of directors of Novus Therapeutics, Inc., </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">98</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose and throat, since May&#160;2017. Prior to Novus, Mr.&#160;Flesher served as Chief Executive Officer and a member of the board of directors for Otic Pharma, Ltd. from 2015 to 2017. Mr.&#160;Flesher has more than 20&#160;years of pharmaceutical industry experience and has been closely involved with several successful drug development programs that have resulted in multiple product approvals and commercial launches in the U.S. and Europe. Prior to Otic Pharma, Mr.&#160;Flesher served as Senior Vice President of Corporate Development and Chief Business Officer, and other executive management roles at Avanir Pharmaceuticals, Inc. from 2006 to 2015. Mr.&#160;Flesher received his B.S. in Biology from Purdue University and studied Biochemistry and Molecular Biology at Indiana University School of Medicine. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr.&#160;Flesher was selected to serve on the Adynxx board of directors because of his extensive senior leadership experience at numerous biopharmaceutical companies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;">Matthew Ruth</font> has served as a member of our board of directors since May&#160;2019. Mr.&#160;Ruth is currently Senior Vice President, US Chief Commercial Officer for Adapt Pharma, a division of Emergent Bio Solutions commercializing Narcan Nasal Spray, a product that can reverse the effects of opioid and heroin overdoses. From 2012 to 2015, Mr.&#160;Ruth was Chief Operating Officer for RightCare Solutions. Mr.&#160;Ruth earned a Bachelor of Science degree from Missouri State University. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our board of directors believes that Mr.&#160;Ruth&#8217;s experience in leading commercial roles at a number of biopharmaceutical companies qualifies him to serve as a member of our board of directors. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Family Relationships </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">There are no family relationships among any of our directors or executive officers. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Board Composition </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our board of directors consists of seven members. Our certificate of incorporation and bylaws provide that directors are to be elected at each annual meeting of stockholders to hold office until the next annual meeting and until their respective successors are elected and qualified. Vacancies on the board of directors resulting from death, resignation, retirement, disqualification or removal may be filled by the affirmative vote of a majority of the remaining directors then in office, whether or not a quorum of the board of directors is present. Newly created directorships resulting from any increase in the number of directors may, unless the board of directors determines otherwise, be filled only by the affirmative vote of the directors then in office, whether or not a quorum of the board of directors is present. Any director elected as a result of a vacancy shall hold office for a term expiring at the next annual meeting of stockholders and until such director&#8217;s successor shall have been elected and qualified. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Committees of the Board of Directors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our board of directors has the authority to appoint committees to perform certain management and administration functions. Our board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee. The composition and responsibilities of each committee are described below. Members will serve on these committees until their resignation or until otherwise determined by the board of directors. The charters for each of these committees are available on our website at www.adynxx.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of such website address in this prospectus is an inactive textual reference only. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Audit Committee </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our audit committee consists of Mr.&#160;Abel, Mr.&#160;Podlesak and Mr.&#160;Ruth. The board of directors has determined that each committee member is independent under Rule&#160;10A-3(b)(1) of the Exchange Act. The chairperson of our audit committee is Mr.&#160;Abel. The board of directors has determined that Mr.&#160;Abel is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. In arriving at this determination, the board of directors has examined each audit committee member&#8217;s scope of experience and the nature of their employment in the life sciences industry. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">99</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The primary purpose of the audit committee is to discharge the responsibilities of the board of directors with respect to our accounting, financial, and other reporting and internal control practices and to oversee our independent registered accounting firm. Specific responsibilities of our audit committee include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">selecting a qualified firm to serve as the independent registered public accounting firm to audit our financial statements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">helping to ensure the independence and performance of the independent registered public accounting firm; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing policies on risk assessment and risk management; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing related party transactions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">obtaining and reviewing a report by the independent registered public accounting firm at least annually, that describes our internal quality-control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">approving (or, as permitted, pre-approving) all audit and all permissible non-audit service to be performed by the independent registered public accounting firm.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Compensation Committee </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The compensation committee consists of Mr.&#160;Podlesak and Dr.&#160;Weber. Our board of directors has determined each member is a &#8220;non-employee director&#8221; as defined in Rule&#160;16b-3 promulgated under the Exchange Act. The chairperson of the compensation committee is Mr. Podlesak. The primary purpose of the compensation committee is to discharge the responsibilities of the board of directors to oversee our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate. Specific responsibilities of the compensation committee will include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing and approving, or recommending that our board of directors approve, the compensation of our executive officers; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing and recommending to our board of directors the compensation of our directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing and approving, or recommending that our board of directors approve, the terms of compensatory arrangements with our executive officers; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">administering our stock and equity incentive plans; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">selecting independent compensation consultants and assessing whether there are any conflicts of interest with any of the committee&#8217;s compensation advisors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing and approving, or recommending that our board of directors approve, incentive compensation and equity plans, severance agreements, change-of-control protections and any other compensatory arrangements for our executive officers and other senior management, as appropriate; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing and establishing general policies relating to compensation and benefits of our employees; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing our overall compensation philosophy.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">100</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">Our nominating and corporate governance committee consists of Mr.&#160;Abel and Mr. Podlesak. The chairperson of our nominating and corporate governance committee is Mr.&#160;Podlesak. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Specific responsibilities of our nominating and corporate governance committee include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">identifying, evaluating and selecting, or recommending that our board of directors approve, nominees for election to our board of directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">evaluating the performance of our board of directors and of individual directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing developments in corporate governance practices; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">evaluating the adequacy of our corporate governance practices and reporting; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">reviewing management succession plans; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">developing and making recommendations to our board of directors regarding corporate governance guidelines and matters. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">101</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tECOA">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">EXECUTIVE COMPENSATION <font style="text-transform:uppercase;">of adynxx</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Adynxx&#8217;s named executive officers, consisting of Adynxx&#8217;s principal executive officer and the next two most highly compensated executive officers, for the year ended December&#160;31, 2018, were: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Rick Orr, Adynxx&#8217;s President and Chief Executive Officer; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Julien Mamet, Ph.D., Adynxx&#8217;s Chief Scientific Officer; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Donald Manning, M.D., Ph.D., Adynxx&#8217;s Chief Medical Officer. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Following the consummation of the Merger in May&#160;2019, each of Adynxx&#8217;s executive officers, including Adynxx&#8217;s named executive officers, were appointed as our executive officers. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Summary Compensation Table </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table presents all of the compensation paid or awarded to or earned by Adynxx&#8217;s named executive officers during 2018: </div>
        <table style="width:456pt;height:92.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:265.26pt;text-align:left;">
              <div style="white-space:nowrap;">Name and Principal Position </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Salary </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">All Other <br >Compensation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0.917pt 0pt 0.5pt 0pt; width:265.26pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Rick Orr<br ><font style="font-style:italic;">President and Chief Executive Officer</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">435,663</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">37,926<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font></font></td>
            <td style="padding:0pt;padding-left:4.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">473,589</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:265.26pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Julien Mamet, Ph.D.<br ><font style="font-style:italic;">Chief Scientific Officer</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">340,540</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.19pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">37,926<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font></font></td>
            <td style="padding:0pt;padding-left:4.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">378,466</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:265.26pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Donald Manning, M.D., Ph.D.<br ><font style="font-style:italic;">Chief Medical Officer</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">360,149</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.19pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">37,926<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font></font></td>
            <td style="padding:0pt;padding-left:4.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">398,075</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Comprised of non-elective 401(k) plan safe harbor contributions, health insurance premium payments and gym membership and related fee reimbursements. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Outstanding Equity Awards as of December&#160;31, 2018 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table provides information about outstanding equity awards held by each of our named executive officers at December&#160;31, 2018. </div>
        <table style="width:456pt;height:173.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:242.61pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">Option Awards </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:23pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:242.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Number of Securities <br >Underlying Unexercised <br >Options (#) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Option <br >Exercise <br >Price </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Option <br >Expiration <br >Date </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:242.61pt;text-align:left;">
              <div style="white-space:nowrap;">Name </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Exercisable<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Unexercisable </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:242.61pt;text-align:left;">
              <div style="white-space:nowrap;">Rick Orr </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">660<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(6)</font></font></td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.39</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/17/2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:242.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">95,416<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(2)(5)</font></font></td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.06</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/15/2026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.61pt;text-align:left;">
              <div style="white-space:nowrap;">Julien Mamet, Ph.D. </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">33<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(6)</font></font></td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.39</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/17/2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:242.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">158,148<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(3)(5)</font></font></td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.06</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/15/2026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:242.61pt;text-align:left;">
              <div style="white-space:nowrap;">Donald Manning, M.D., Ph.D. </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">23,857<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(6)</font></font></td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.11</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/7/2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:242.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">7,886<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(6)</font></font></td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.39</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7/16/2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:242.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">3,943<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(6)</font></font></td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.39</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/17/2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:242.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">56,406<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(4)(5)</font></font></td>
            <td style="padding:0pt;padding-left:6.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.175pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.06</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/15/2026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Each option held by the named executive officers is exercisable immediately following grant, also known as &#8220;early exercisable,&#8221; and unvested shares purchased upon an early exercise are subject to a repurchase right in our favor on termination of employment that lapses along the same vesting schedule as contained in the option grant. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">1/4<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> of the shares subject to the option vested one year after December&#160;16, 2016, the vesting commencement date, and 1/36<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> of the shares subject to the option vest monthly thereafter. As of December&#160;31, 2018, 47,708 shares underlying the option were vested. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">102</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">1/4<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> of the shares subject to the option vested one year after December&#160;16, 2016, the vesting commencement date, and 1/36<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> of the shares subject to the option vest monthly thereafter. As of December&#160;31, 2018, 79,074 shares underlying the option were vested. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" margin-top:3.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">1/4<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> of the shares subject to the option vested one year after December&#160;16, 2016, the vesting commencement date, and 1/36<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> of the shares subject to the option vest monthly thereafter. As of December&#160;31, 2018, 28,203 shares underlying the option were vested. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">During the 12&#160;months following a change in control and the three months preceding a change of control, if&#8201; (a)&#160;the named executive officer is involuntarily terminated without cause or (b)&#160;the named executive officer resigns for good reason, and in either case, other than as a result of death or disability (and provided such termination constitutes a separation from service, without regard to any alternative definition thereunder), then the vesting of the option shall be accelerated such that 100% of the total unvested shares under the option shall be vested.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
        <div style=" margin-top:3.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">All shares subject to this option have vested as of December&#160;31, 2018. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employment Arrangements </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">Upon the closing of the Merger, the executive officers of Private Adynxx were appointed as our executive officers, and each of Alliqua&#8217;s then-appointed executive officers resigned. Our executive officers following the consummation of the Merger consist of Mr.&#160;Orr, our and Adynxx&#8217;s President and Chief Executive Officer, Dr.&#160;Mamet, our and Adynxx&#8217;s Chief Scientific Officer, and Dr.&#160;Manning, our and Adynxx&#8217;s Chief Medical Officer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have offer letters with each of our executive officers. The offer letters generally provide for at-will employment and set forth the executive officer&#8217;s initial base salary, eligibility for employee benefits and confirmation of the terms of previously issued equity grants, including in some cases severance benefits on a qualifying termination of employment. The key terms of employment with our and Adynxx&#8217;s named executive officers set forth in the tables above are described below. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Rick Orr </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">In October&#160;2010, Adynxx entered into an offer letter with Mr.&#160;Orr, our President and Chief Executive Officer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2018, Mr.&#160;Orr received a base salary of&#8201; $435,663. For 2019, Mr.&#160;Orr will receive an annual base salary of&#8201; $443,913 with an annual target bonus of 40% of such base salary, payable based on the achievement of certain corporate and individual performance goals to be established by our Compensation Committee. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon an involuntary termination without cause or termination due to constructive termination, Mr.&#160;Orr will be entitled to receive a lump sum cash payment equal to 12&#160;months of his annual base salary and an amount equal to 100% of his most recently paid bonus. In addition, Mr.&#160;Orr will be eligible for 12&#160;months of continued company paid health insurance benefits (assuming he timely elects continued coverage under COBRA). All such severance benefits are subject to Mr.&#160;Orr signing a general release in our favor of all known and unknown claims in substantially the form provided in his offer letter. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Julien Mamet, Ph.D. </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">In September&#160;2011, Adynxx entered into an offer letter with Dr.&#160;Mamet, our Chief Scientific Officer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2018, Dr. Mamet received a base salary of&#8201; $340,540. For 2019, Dr.&#160;Mamet will receive an annual base salary of&#8201; $348,790 with an annual target bonus of 35% of such base salary, payable based on the achievement of certain corporate and individual performance goals to be established by our Compensation Committee. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon an involuntary termination without cause or termination due to constructive termination, Dr.&#160;Mamet will be entitled to receive a lump sum cash payment equal to 12&#160;months of his annual base salary. In addition, Dr.&#160;Mamet will be eligible for 12&#160;months of continued company paid health insurance benefits (assuming he timely elects continued coverage under COBRA). All such severance benefits are subject to Dr.&#160;Mamet signing a general release in our favor of all known and unknown claims in substantially the form provided in his offer letter. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">103</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Donald Manning, M.D., Ph.D. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January&#160;2012, Adynxx entered into an offer letter with Dr.&#160;Manning, our Chief Medical Officer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2018, Dr.&#160;Manning received a base salary of&#8201; $360,149. For 2019, Dr.&#160;Manning will receive an annual base salary of&#8201; $368,399 with an annual target bonus of 35% of such base salary, payable based on the achievement of certain corporate and individual performance goals to be established by our Compensation Committee. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon an involuntary termination without cause or termination due to constructive termination, not within one month prior to or 13&#160;months following a change in control, Dr.&#160;Manning will be entitled to receive a lump sum cash payment equal to 9&#160;months of his annual base salary. In addition, Dr.&#160;Manning will be eligible for nine months of company paid continued health insurance benefits (assuming he timely elects continued coverage under COBRA). Upon an involuntary termination without cause or termination due to constructive termination, within one month prior to or 13&#160;months following a change in control, Dr.&#160;Manning will be entitled to receive a lump sum cash payment equal to 12&#160;months of his annual base salary. In addition, Dr.&#160;Manning will be eligible for 12&#160;months of continued company paid health insurance benefits (assuming he timely elects continued coverage under COBRA) and all unvested stock options held by Dr.&#160;Manning will immediately vest in full. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All such severance benefits are subject to Dr.&#160;Manning signing a general release in our favor of all known and unknown claims in substantially the form provided in his offer letter. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employee Benefit Plans </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe that our ability to grant equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders. In addition, we believe that our ability to grant options and other equity-based awards helps us to attract, retain and motivate employees, consultants and directors and encourages them to devote their best efforts to our business and financial success. The principal features of our equity incentive plans, our health benefit plan and our 401(k) plan are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans, which, other than the health benefit plan and 401(k) plan, are filed or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">2010 Equity Incentive Plan </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the closing of the Merger, we assumed the Adynxx 2010 Equity Incentive Plan, or the Adynxx Plan, and all outstanding stock options thereunder. The Adynxx Plan was adopted by the board of directors of Adynxx and approved by Adynxx&#8217;s stockholders in December 2010. The Adynxx Plan provides for the granting of stock options to employees and consultants of Adynxx. Options granted under the Adynxx Plan may be either incentive stock options, or ISOs, or nonqualified stock options, or NSOs. ISOs may be granted only to Adynxx employees (including officers and directors who are also employees). NSOs may be granted to Adynxx employees and consultants. Options under the Adynxx Plan may be granted for periods of up to 10&#160;years and at prices no less than 100% of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the Adynxx board of directors; provided, however, that the exercise price of an ISO and NSO granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. The Adynxx Plan requires that options be exercised no later than 10&#160;years after the grant. A total of 690,071 shares of common stock are reserved for issuance under the Adynxx Plan as of December&#160;31, 2018. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">401(k) Plan </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We maintain a 401(k) plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees are able to defer compensation up to certain limits imposed by the Code. We have the ability to make matching and discretionary contributions to the 401(k) plan. Currently, we do not make matching contributions to the 401(k) plan. We make a nonelective 401(k) safe harbor contribution on behalf of each employee equal to 3% of their annual salary. The 401(k) plan is intended to be qualified under Section&#160;401(a) of the Code, with the related trust intended to be tax exempt </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">104</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">under Section&#160;501(a) of the Code. As a tax-qualified retirement plan, contributions to the 401(k) plan are deductible by us when made, and contributions and earnings on those amounts are generally not taxable to a participating employee until withdrawn or distributed from the 401(k) plan. </div>
        <div style="margin-top:16.98pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Health and Welfare Benefits </div>
        <div style="text-indent:20pt; margin-top:9.99pt; width:456pt; line-height:12pt;">We pay premiums for medical insurance, dental insurance and vision insurance for all full-time employees, including our named executive officers. These benefits are available to all full-time employees, subject to applicable laws. </div>
        <div style="margin-top:16.98pt; width:456pt; line-height:11pt;font-weight:bold;">Pension Benefits </div>
        <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">Adynxx&#8217;s named executive officers did not participate in, or otherwise receive any benefits under, any pension or defined benefit retirement plan sponsored by Adynxx during the year ended December&#160;31, 2018. </div>
        <div style="margin-top:16.98pt; width:456pt; line-height:11pt;font-weight:bold;">Nonqualified Deferred Compensation </div>
        <div style="text-indent:20pt; margin-top:9.99pt; width:456pt; line-height:12pt;">Adynxx&#8217;s named executive officers did not participate in, or earn any benefits under, a non-qualified deferred compensation plan sponsored by Adynxx during the year ended December&#160;31, 2018. </div>
        <div style="margin-top:16.98pt; width:456pt; line-height:11pt;font-weight:bold;">Director Compensation </div>
        <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">The following table sets forth information regarding compensation earned by or paid to Adynxx&#8217;s non-employee directors during 2018. Adynxx did not have any compensation arrangements or policies with respect to non-employee directors during 2018. </div>
        <table style="width:416pt;height:62.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:304.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Fees Earned or <br >Paid in Cash</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:304.61pt;text-align:left;">
              <div style="white-space:nowrap;">Dennis Podlesak<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">120,000</td>
            <td style="padding:0pt;padding-left:5.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">120,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.61pt;text-align:left;">
              <div style="white-space:nowrap;">Eckard Weber<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">120,000</td>
            <td style="padding:0pt;padding-left:5.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">120,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:304.61pt;text-align:left;">
              <div style="white-space:nowrap;">Stan Abel<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.985pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">72,000</td>
            <td style="padding:0pt;padding-left:5.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">72,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">As of December&#160;31, 2018, Mr.&#160;Podlesak held options to purchase an aggregate of 56,275 shares of common stock.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">As of December&#160;31, 2018, Mr.&#160;Weber held options to purchase an aggregate of 56,275 shares of common stock.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">As of December&#160;31, 2018, Mr&#160;Abel held options to purchase an aggregate of 28,137 shares of common stock.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:10.99pt; width:456pt; line-height:12pt;">We expect that our board of directors will adopt a director compensation policy for non-employee directors following the closing of this offering. Pursuant to this policy, we expect that any director who is also an employee of ours or our subsidiary will not receive any additional compensation for his or her service as a director. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">105</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tECA">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">EXECUTIVE COMPENSATION OF ALLIQUA </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Alliqua&#8217;s named executive officers, consisting of Alliqua&#8217;s principal executive officer and the next two most highly compensated executive officers, for the year ended December&#160;31, 2018, were: </div>
        <div style=" float:left; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">David Johnson, Alliqua&#8217;s former President and Chief Executive Officer; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Bradford Barton, Alliqua&#8217;s former Chief Operating Officer; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Pellegrino Pionati, Alliqua&#8217;s former Chief Strategy and Marketing Officer; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Joseph Warusz, Alliqua&#8217;s former Chief Financial Officer, Treasurer and Secretary. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Following the consummation of the Merger in May&#160;2019, each of Alliqua&#8217;s executive officers, including Alliqua&#8217;s named executive officers, resigned and Adynxx&#8217;s executive officers were appointed as our executive officers. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Summary Compensation Table </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table presents all of the compensation paid or awarded to or earned by Alliqua&#8217;s former named executive officers during 2017 and 2018: </div>
        <table style="width:456pt;height:161.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt; width:165.84pt;text-align:left;">
              <div style="white-space:nowrap;">Name and Principal Position </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Salary </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Bonus </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Stock <br >Awards<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">All Other <br >Compensation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7.25pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:165.84pt;white-space:normal;text-align:left;" rowspan="2">
              <div style="margin-left:10pt; text-indent:-10pt; line-height:12pt; padding-bottom:0.666666666666667pt;font-style:italic;">
                <font style="font-style:normal;">David Johnson</font><font style=" position:relative; bottom:4.25pt;font-style:normal;font-size:7.5pt;">(6)</font>
                <br >Former President and Chief Executive Officer</div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">350,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">279,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">11,400<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(3)</font></font></td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">640,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:24pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">350,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">276,500<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(2)</font></font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">274,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">11,400<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(3)</font></font></td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 10.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">911,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:13pt;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:165.84pt;text-align:left;" rowspan="2">
              <div style="margin-left:10pt; text-indent:-10pt; line-height:12pt; padding-bottom:0pt;">Bradford Barton<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(6)</font><br ><font style="font-style:italic;">Former Chief Operating Officer</font></div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">87,040</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">53,301</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">263,730<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(5)</font></font></td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">404,071</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:13pt;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">246,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">118,310<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(2)</font></font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">103,829</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">8,400<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(4)</font></font></td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">477,339</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:13pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:165.84pt;text-align:left;" rowspan="2">
              <div style="margin-left:10pt; text-indent:-10pt; line-height:12pt; padding-bottom:0pt;">Pellegrino Pionati<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(6)</font><br ><font style="font-style:italic;">Former Chief Operating Officer</font></div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">87,040</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">54,970</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">263,730<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(5)</font></font></td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">405,740</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:13pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">246,800</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">118,310<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(2)</font></font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">103,829</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">8,400<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(4)</font></font></td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">477,339</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:13pt;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:165.84pt;white-space:normal;text-align:left;" rowspan="2">
              <div style="margin-left:10pt; text-indent:-10pt; line-height:12pt; padding-bottom:0.666666666666667pt;font-style:italic;">
                <font style="font-style:normal;">Joseph Warusz</font><font style=" position:relative; bottom:4.25pt;font-style:normal;font-size:7.5pt;">(6)</font>
                <br >Former Chief Financial Officer, Treasurer and Secretary</div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">281,960</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 0.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">281,960</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:27pt;white-space:nowrap;text-align:right;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 11pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">The amounts reported represent the aggregate grant date fair value of the awards, calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic&#160;718&#8201;&#8212;&#8201;Compensation&#8201;&#8212;&#8201;Stock Compensation, or ASC 718, with the exception that the amount shown assumes no forfeitures. Alliqua used the Black-Scholes option-pricing model to estimate the fair value of its stock-based awards. Assumptions used in the calculation of these amounts include, for the year ended December 31, 2017, the risk free interest rate of 1.81% to 2.43%, expected term of 5.04 to 6.50 years, expected volatility of 81.94% to 87.00% and no expected dividends. The risk-free interest rate is based on rates of treasury securities with the same expected term as the options. Alliqua used the &#8220;simplified method&#8221; to calculate the expected term of employee and director stock-based options. The expected term used for consultants is the contractual life. Alliqua utilized an expected volatility figure based on a review of Alliqua&#8217;s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that Alliqua had not historically paid dividends, and did not expect to pay dividends in the near future. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents a discretionary year-end performance bonus earned in 2017 paid in 2018. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Comprised of&#8201; (i)&#160;automobile expense allowance payments of&#8201; $9,000 and (ii) life insurance premium payments of&#8201; $2,400. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Comprised of automobile expense allowance payments. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Comprised of&#8201; (i)&#160;automobile expense allowance payments of&#8201; $2,927, (ii) vacation payout payments of $11,203 and (iii) severance payments of&#8201; $249,600. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">106</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">In May&#160;2018, Mr.&#160;Barton resigned as Alliqua&#8217;s Chief Operating Officer and Mr.&#160;Pionati resigned as Alliqua&#8217;s Chief Strategy and Marketing Officer. Mr.&#160;Warusz resigned in March&#160;2019. Mr.&#160;Johnson resigned in May&#160;2019 in connection with the consummation of the Merger. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Outstanding Equity Awards as of December&#160;31, 2018 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table provides information about outstanding equity awards held by each of Alliqua&#8217;s named executive officers at December&#160;31, 2018. </div>
        <table style="width:456pt;height:284.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:231.95pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">Option Awards </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:14pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Number of Securities Underlying <br >Unexercised Options (#) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Option <br >Exercise <br >Price </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Option <br >Expiration <br >Date </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:231.95pt;text-align:left;">
              <div style="white-space:nowrap;">Name </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Exercisable </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Unexercisable </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:231.95pt;text-align:left;">
              <div style="white-space:nowrap;">David Johnson </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">986</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">262.30</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/29/2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">986</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">393.60</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/29/2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">986</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">525.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/29/2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4,653</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">196.80</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/4/2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,952</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">210.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/14/2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">12,176</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">409.20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/20/2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,917</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">373.80</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/6/2025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:231.95pt;text-align:left;">
              <div style="white-space:nowrap;">Bradford Barton </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">914</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">262.80</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/10/2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">914</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">328.20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/10/2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">914</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">393.60</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/10/2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">914</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">525.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/10/2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">914</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">656.40</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/10/2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,167</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">540.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/6/2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,917</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">373.80</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/6/2025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:231.95pt;text-align:left;">
              <div style="white-space:nowrap;">Pellegrino Pionati </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,667</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">315.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">6/15/2025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:231.95pt;text-align:left;">
              <div style="white-space:nowrap;">Joseph Warusz </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employment Arrangements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the closing of the Merger, the executive officers of Private Adynxx were appointed as our executive officers, and each of Alliqua&#8217;s then-appointed executive officers resigned. The key terms of employment with the former named executive officers of Alliqua set forth in the table above are described below. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">David Johnson </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with the appointment of David Johnson as Chief Executive Officer, in February 2013, Alliqua entered into an Executive Employment Agreement with Mr. Johnson, as subsequently amended. Mr. Johnson&#8217;s service as Chief Executive Officer was terminated without cause immediately prior to consummation of the Merger. Pursuant to the terms of his employment agreement, and subject to compliance with the confidentiality, non-solicitation and non-disparagement requirements of the employment agreement and the execution of a release of claims, Alliqua paid Mr. Johnson an aggregate amount of&#8201; $1,050,000 following the closing of the Merger.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Bradford Barton </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with the appointment of Mr. Barton as Chief Operating Officer, in May 2013, Alliqua entered into an Offer Letter with Mr. Barton. In May 2018, Alliqua and Mr.&#160;Barton entered into a general release and severance agreement, or the Barton Separation Agreement, which became effective in May&#160;2018. Pursuant to the Barton Separation Agreement, Mr.&#160;Barton released Alliqua from any and all claims. In consideration of the Barton Separation Agreement and his general release of claims, Mr.&#160;Barton was </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">107</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">entitled to&#160;his 2017 performance bonus of&#8201; $118,310, severance pay equal to his base salary for 12&#160;months and the stock options and restricted stock previously granted to Mr.&#160;Barton&#160;became fully and immediately vested. The stock options shall remain exercisable until the earlier of May 2020 or the end of the applicable stock option&#8217;s term. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pellegrino Pionati </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Alliqua and Mr.&#160;Pionati entered into a general release and severance agreement, or the Pionati Separation Agreement, which became effective in May&#160;2018. Pursuant to the Pionati Separation Agreement, Mr.&#160;Pionati released Alliqua from any and all claims. In consideration of the Pionati Separation Agreement and his general release of claims, Mr.&#160;Pionati was entitled to&#160;his 2017 performance bonus of&#8201;&#8201; $118,310.40, severance pay equal to his base salary for 12&#160;months and the stock options and restricted stock previously granted to Mr.&#160;Pionati&#160;became fully and immediately vested. The stock options shall remain exercisable until the earlier of May 2020 or the end of the applicable stock option&#8217;s term. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Joseph Warusz </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr.&#160;Warusz did not have an employment agreement with Alliqua and his employment was terminable by either party at any time upon written notice. Mr.&#160;Warusz was entitled to an hourly salary of&#8201; $250 per hour. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employee Benefit Plans </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Alliqua Stock Compensation Plans </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The principal features of Alliqua&#8217;s equity incentive plans are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans, which are filed or incorporated by reference as exhibits to the registration statement of which this prospectus is a part.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">2011 Long-Term Incentive Plan </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The 2011 Long-Term Incentive Plan, or the 2011 Plan, was adopted by Alliqua&#8217;s board of directors in November&#160;2011 and approved by Alliqua&#8217;s stockholders in December&#160;2011. The 2011 Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock&#160;units, performance awards, dividend equivalent rights, and other awards which may be granted singly, in combination, or in tandem, and which may be paid in cash or shares of common stock. The 2011 Plan is administered by our board of directors. A total of 30,476 shares of common stock are reserved for award under the 2011 Plan, of which 7,854 remained available for future awards as of December&#160;31, 2018. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">2014 Long-Term Incentive Plan </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The 2014 Long-Term Incentive Plan, or the 2014 Plan, was adopted by Alliqua&#8217;s board of directors in April&#160;2014 and approved by Alliqua&#8217;s stockholders in June&#160;2014. In February&#160;2015, Alliqua&#8217;s board of directors approved an amendment to the 2014 Plan to increase the total number of shares available for issuance pursuant to awards under the 2014 Plan, which was approved by Alliqua&#8217;s stockholders in May&#160;2015. The 2014 Plan provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock&#160;units, performance awards, dividend equivalent rights, and other awards which may be granted singly, in combination, or in tandem, and which may be paid in cash or shares of common stock. The 2014 Plan is administered by our board of directors. A total of 158,333 shares of common stock are reserved for award under the 2014 Plan, of which 70,519 remained available for future awards as of December&#160;31, 2018.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">108</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Director Compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">The following table sets forth information regarding compensation earned by or paid to Alliqua&#8217;s non-employee directors during 2018. </div>
        <table style="width:376pt;height:77.5pt;margin-left:40pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:269.61pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Fees Earned or <br >Paid in Cash </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:269.61pt;text-align:left;">
              <div style="white-space:nowrap;">Joseph Leone </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">33,750</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">33,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.61pt;text-align:left;">
              <div style="white-space:nowrap;">Gary Restani </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">32,626</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">32,626</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.61pt;text-align:left;">
              <div style="white-space:nowrap;">Jeffrey Sklar </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">34,500</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">34,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.61pt;text-align:left;">
              <div style="white-space:nowrap;">Mark Wagner </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">27,750</td>
            <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">27,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.99pt; width:456pt; line-height:12pt;">For the year ended December&#160;31, 2018, cash compensation for non-employee directors, including the chairperson of the board of directors, was $26,250. In addition, the audit committee chairperson was paid $10,500, the compensation committee chairperson was paid $8,750, other audit committee members were each paid $5,250, other compensation committee members were each paid $3,938, and nominating and corporate governance committee members, including the chairperson, were each paid $2,625. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">109</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCR">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">The following is a summary of transactions since January&#160;1, 2017 to which Alliqua and Private Adynxx have been a participant, in which: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the amount involved exceeded or will exceed the lesser of&#8201; $120,000 or 1% of our average total assets at year end for the last two completed fiscal&#160;years; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any of our directors, executive officers, or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest, other than compensation and other arrangements that are described in the sections titled &#8220;Executive Compensation of Adynxx&#8221; and &#8220;Executive Compensation of Alliqua&#8221;, or that were approved by our compensation committee. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe the terms obtained or consideration that Alliqua or Private Adynxx, as applicable, paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable in arm&#8217;s-length transactions. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Adynxx </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Notes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In March&#160;2018 and September&#160;2018, Private Adynxx issued $3.0&#160;million aggregate principal amount of Notes to entities affiliated with Domain Associates LLC and TPG Biotech, which beneficially owned more than 5% of Adynxx&#8217;s capital stock at the time of such issuance. The Notes accrued simple interest on the outstanding principal amount at a rate of 8.0% per annum. The Notes converted into 367,041 shares of our common stock upon the closing of the Merger. </div>
        <table style="width:456pt;height:38.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:348.67pt;">
              <div style="white-space:nowrap;">Purchaser </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Aggregate Principal Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:348.67pt;text-align:left;">
              <div style="white-space:nowrap;">Entities affiliated with Domain Associates LLC<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:24.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,350,000</td>
            <td style="padding:0pt;padding-left:24.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:348.67pt;text-align:left;">
              <div style="white-space:nowrap;">TPG Biotechnology Partners IV, L.P. </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:24.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">650,000</td>
            <td style="padding:0pt;padding-left:24.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Mr.&#160;Podlesak and Dr.&#160;Weber, each a member of our board of directors, are Partners with Domain Associates LLC. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">From December&#160;2018 to May&#160;2019, Private Adynxx issued $5.5&#160;million aggregate principal amount of Notes, and in July 2019 and August 2019, we issued $0.85&#160;million aggregate principal amount of Notes, in each case to entities affiliated with Domain Associates LLC, which beneficially owned more than 5% of Adynxx&#8217;s capital stock at the time of such issuance. The Notes accrue simple interest on the outstanding principal amount at a rate of 8.0% per annum and mature on the first anniversary of the applicable issuance date. The Notes have conversion and repayment options as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event that we issue and sell shares of our preferred stock or common stock to investors in a qualified financing with total proceeds to us of not less than $5.0&#160;million, excluding conversion of the Notes, then the outstanding principal amount of the Notes and any unpaid accrued interest will automatically convert in whole into equity securities sold in the qualified financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the qualified financing; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if we consummate a change of control while the Notes remain outstanding, we will repay the holders in cash in an amount equal to 200% of the outstanding principal amount of the Notes, plus any unpaid accrued interest on the original principal. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of September&#160;30, 2019, $6.35&#160;million aggregate principal amount remained outstanding under the Notes.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">110</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The following table summarizes the issuances of Notes outstanding immediately prior to the offering held by entities Domain Associates LLC: </div>
        <table style="width:456pt;height:23.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:348.67pt;">
              <div style="white-space:nowrap;">Purchaser </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Aggregate Principal Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:348.67pt;text-align:left;">
              <div style="white-space:nowrap;">Entities affiliated with Domain Associates LLC<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:24.96pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6,350,000</td>
            <td style="padding:0pt;padding-left:24.96pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Mr.&#160;Podlesak and Dr.&#160;Weber, each a member of our board of directors, are Partners with Domain Associates LLC.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Employment Arrangements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have entered into offer letters with our executive officers. For more information regarding these offer letters, see &#8220;Executive Compensation of Adynxx&#8201;&#8212;&#8201;Employment Arrangements.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Alliqua </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Separation Agreements </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;">Brian Posner </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with his resignation as Alliqua&#8217;s Chief Financial Officer, in March&#160;2018, Alliqua and Brian Posner entered into a general release and severance agreement, or the Separation Agreement. Pursuant to the Separation Agreement, Mr.&#160;Posner released Alliqua from any and all claims. In consideration of the Separation Agreement and his general release of claims, Mr.&#160;Posner was entitled to (i)&#160;his 2017 performance bonus in the amount of&#8201;$118,310 (less applicable taxes and other withholdings) and (ii) severance pay in an amount equal to his base salary for 12&#160;months, less applicable taxes and other withholdings. Stock options and restricted stock previously granted to Mr.&#160;Posner remain outstanding, and his stock options are fully vested and remain exercisable until the earlier of April 2020 or the end of the applicable stock option&#8217;s term. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;">David Johnson </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mr. Johnson&#8217;s service as Chief Executive Officer was terminated without cause immediately prior to the consummation of the Merger. For more information regarding his separation arrangements, see &#8220;Executive Compensation of Alliqua&#8201;&#8212;&#8201;Employment Arrangements&#8201;&#8212;&#8201;David Johnson.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Private Placement </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On February&#160;27, 2017, Alliqua closed a private placement of 923,333 shares of common stock at a purchase price of&#8201;$3.00 per share, for gross proceeds of&#8201;$2,770,000. Celgene Corporation, or Celgene, which beneficially owned more than 5% of Alliqua&#8217;s common stock at the time of the closing, purchased 4,000,000 shares of common stock for a purchase price of&#8201;&#8201;$2,000,000, and Dr.&#160;Zeldis, the former chairman of Alliqua&#8217;s board of directors, purchased 66,666 shares of common stock for a purchase price of&#8201;&#8201;$200,000 in the private placement. Additional shares of common stock were issuable to Celgene and Dr.&#160;Zeldis pursuant to the &#8220;most favored nation&#8221; provision in the securities purchase agreement entered into in the private placement, or the Securities Purchase Agreement, which issuance was subject to stockholder approval as may be required by the applicable rules and regulations of Nasdaq. Following approval at the 2017 annual meeting of stockholders, Alliqua issued 117,287 additional shares of common stock to Celgene and 16,666 additional shares of common stock to Dr.&#160;Zeldis, in each case, pursuant to the &#8220;most favored nation&#8221; provision in the Securities Purchase Agreement. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Perceptive Credit Agreement and Warrant </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In May&#160;2015, Alliqua and each of its subsidiaries entered into a credit agreement, or the Credit Agreement, with Perceptive Credit Opportunities Fund, L.P., or Perceptive, an affiliate of Perceptive Advisors, LLC, which beneficially owned more than 5% of our common stock. The Credit Agreement provided for a $15.5&#160;million senior secured term loan. The Credit Agreement had a four year term, accrued interest at an annual rate equal to the greater of&#8201;(a) one-month LIBOR or 1% plus (b)&#160;9.75%, provided for interest-only payments for the first 24&#160;months, followed by monthly amortization payments of&#8201; $225,000, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">111</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">with the remaining unpaid balance due on the maturity date, and was secured by a first priority lien on substantially all of our assets. In May&#160;2018, Alliqua fully repaid the amounts outstanding under the Credit Agreement and terminated the Credit Agreement in connection with the sale of substantially all of its assets to Celularity, Inc. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with the entry into the Credit Agreement, a five-year warrant, or the Warrant, to purchase 12,500 shares of Alliqua common stock at an exercise price of&#8201;&#8201;$330.828 per share, was issued to Perceptive. Alliqua granted Perceptive customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon exercise of the Warrant. In June&#160;2017, Alliqua amended the Warrant to be exercisable for 35,000 shares of common stock at an exercise price of&#8201;&#8201;$28.20 per share. Perceptive will not have the right to exercise the warrant to the extent that after giving effect to such exercise, Perceptive would beneficially own in excess of 9.99% of the common stock outstanding immediately after giving effect to such exercise. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Manufacturing Supply Agreement </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Mark Wagner, a former member of Alliqua&#8217;s board of directors, is a director of Minnetronix, Inc. In November&#160;2015, Alliqua entered into a manufacturing supply agreement with Minnetronix, pursuant to which Minnetronix agreed to perform manufacturing and other services in exchange for certain fees and expenses, with such amounts being variable and contingent on various factors. During 2017, Alliqua incurred costs of&#8201; $412,000 under the manufacturing supply agreement. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Related Party Transaction Policy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although Adynxx did not have a written policy for the review and approval of transactions with related persons, its board of directors historically reviewed and approved any transaction where a director or officer had a financial interest, including the transactions described above. Prior to approving such a transaction, the material facts as to a director or officer&#8217;s relationship or interest in the agreement or transaction were disclosed to the board of directors. Adynxx&#8217;s board of directors took this information into account when evaluating the transaction and in determining whether such transaction was fair to the company and in the best interest of all its stockholders. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Alliqua had adopted, and we have assumed, a formal written policy that its executive officers, directors, holders of more than 5% of any class of our voting securities, and any member of the immediate family of and any entity affiliated with any of the foregoing persons, will not be permitted to enter into a related party transaction with us without the prior consent of our audit committee, or other independent members of our board of directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict of interest. Any request for Alliqua to enter into a transaction with an executive officer, director, principal stockholder, or any of their immediate family members or affiliates, in which the amount involved exceeds the lesser of&#8201; $120,000 or 1% of its average total assets at year end for the last two completed fiscal&#160;years must first be presented to the audit committee for review, consideration and approval. In approving or rejecting any such proposal, the audit committee will consider the relevant facts and circumstances available and deemed relevant to the audit committee, including, but not limited to, whether the transaction will be on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related party&#8217;s interest in the transaction. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Indemnification Agreements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our amended certificate of incorporation contains provisions limiting the liability of directors, and our bylaws provide that we will indemnify the directors and executive officers to the fullest extent permitted under Delaware law. Our amended certificate of incorporation and bylaws will also provide the board of directors with discretion to indemnify the other officers, employees, and agents when determined appropriate by the board of directors. In addition, we have entered into an indemnification agreement with each of our directors and executive officers, which requires us to indemnify them. For more information regarding these agreements, see &#8220;Description of Capital Stock&#8201;&#8212;&#8201;Limitation on Liability and Indemnification of Directors and Officers.&#8221;</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">112</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPSS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PRINCIPAL STOCKHOLDERS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table sets forth information regarding the beneficial ownership of shares of our common stock as of September&#160;30, 2019: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">each of our current executive officers; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">each of our current directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">all of our current executive officers and directors as a group. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have determined beneficial ownership in accordance with the rules of the SEC and therefore it represents sole or shared voting or investment power with respect to our securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable. We have deemed shares of common stock subject to options that are currently exercisable or exercisable within 60&#160;days of September&#160;30, 2019, to be outstanding and to be beneficially owned by the person holding the option for the purpose of computing the&#160;percentage ownership of that person but have not treated them as outstanding for the purpose of computing the&#160;percentage ownership of any other person. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have based&#160;percentage ownership of common stock before this offering on 5,807,877 shares of common stock outstanding as of September&#160;30, 2019. Percentage ownership of common stock following this offering assumes (i)&#160;the sale of 7,500,000 shares of common stock in this offering, (ii) the issuance of 4,874,744&#160;shares of common stock at the closing of the offering upon the conversion of convertible promissory notes in the aggregate principal amount of&#8201; $6.35&#160;million, plus accrued but unpaid interest, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the last reported sale price of our common stock as reported by OTCQB on October 9, 2019, provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG, and (iii)&#160;no exercise of the common warrants or the placement agent warrants or sale of any pre-funded warrants. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Domain and TPG have indicated an interest in purchasing up to an aggregate of&#8201; $4.25&#160;million of securities in this offering at the public offering price per share of common stock and accompanying common warrant or pre-funded warrant and accompanying common warrant, as the case may be. However, because indications of interest are not binding agreements or commitments to purchase, either of Domain or TPG may elect to purchase more, fewer or no securities in this offering or the placement agent may elect to sell more, fewer or no securities in this offering to either of Domain or TPG. The placement agent will receive the same fee from the sale of any of our securities to Domain or TPG as it will from any other of our securities sold to the public in this offering. Any securities purchased by Domain or TPG in this offering will not be subject to the lock-up agreements with the placement agent that are described below. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o&#160;Adynxx, Inc., 100 Pine Street, Suite 500, San Francisco, California 94111. </div>
        <table style="width:456pt;height:123pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Shares Beneficially <br >Owned Prior to this<br >Offering </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Shares Beneficially<br >Owned Following this<br >Offering </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:213pt;text-align:left;">
              <div style="white-space:nowrap;">Name of Beneficial Owner </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">% </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">% </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">5% Shareholder</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">
              <div style="margin-left:10pt;">Entities Affiliated with Domain Associates<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,058,571</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">52.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">7,933,315</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">43.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">
              <div style="margin-left:10pt;">TPG Biotechnology Partners IV, L.P.<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font></div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,112,290</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">19.2</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,112,290</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.1</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">Executive Officers and Directors</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">
              <div style="margin-left:10pt;">Rick Orr<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3)</font></div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">238,166</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.0</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">238,166</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.3</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">
              <div style="margin-left:10pt;">Donald Manning, M.D., Ph.D.<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(4)</font></div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">92,092</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.6</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">92,092</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">113</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <table style="width:462pt;height:149pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:213pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Shares Beneficially<br >Owned Prior to this<br >Offering </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Shares Beneficially<br >Owned Following this<br >Offering </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 2pt 0pt; width:213pt;text-align:left;">
              <div style="white-space:nowrap;">Name of Beneficial Owner </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">% </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">% </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:213pt;text-align:left;">
              <div style="margin-left:10pt;">Julien Mamet, Ph.D.<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(5)</font></div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">398,635</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.7</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">398,635</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2.2</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:213pt;text-align:left;">
              <div style="margin-left:10pt;">Dennis Podlesak<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(6)</font></div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">141,529</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.4</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">141,529</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:213pt;text-align:left;">
              <div style="margin-left:10pt;">Eckard Weber<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(7)</font></div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">141,529</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.4</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">141,529</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:213pt;text-align:left;">
              <div style="margin-left:10pt;">Stan Abel<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(8)</font></div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">82,254</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.4</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">82,254</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:213pt;text-align:left;">
              <div style="margin-left:10pt;">Gregory Flesher</div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:213pt;text-align:left;">
              <div style="margin-left:10pt;">Matthew Ruth </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.667pt 0pt 1pt 0pt; width:213pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">All current executive officers and directors as a group (8&#160;persons)<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(9)</font></div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.667pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,094,205</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.667pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">17.4</td>
            <td style="padding:0pt;padding-left:18.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.667pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,094,205</td>
            <td style="padding:0pt;padding-left:6.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:1.667pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.667pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">5.9</td>
            <td style="padding:0pt;padding-left:19.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" margin-top:8.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents beneficial ownership of less than one&#160;percent. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Consists of&#8201;&#8201;(i) 3,036,044 shares held of record by Domain Partners VIII, L.P. (&#8220;DP VIII) and (ii)&#160;22,527 shares held of record by DP VIII Associates, L.P. (&#8220;DP VIII A&#8221;). The sole general partner of DP VIII and DP VIII A is One Palmer Square Associates VIII, LLC, a Delaware limited liability company (&#8220;OPSA VIII&#8221;). The principal business of OPSA VIII is that of acting as the general partner of DP VIII and DP VIII A. James C. Blair, Jesse I. Treu, Brian H. Dovey, Brian K. Halak, and Nicole Vitullo are the managing members of OPSA VIII. The principal business address of each of the entities in this footnote 1 is c/o&#160;Domain Associates, LLC, 202 Carnegie Center, Suite 104, Princeton, NJ 08540. The share amounts and percentage set forth under the column &#8220;Shares Beneficially Owned Following this Offering&#8221; include 4,874,744 shares of common stock to be issued at the closing of this offering upon the conversion of convertible promissory notes in the aggregate principal amount of $6.35&#160;million, plus accrued but unpaid interest, based upon an assumed combined public offering price of&#8201; $1.35 per share of common stock and accompanying warrant, the last reported sale price of our common stock as reported by OTCQB on October 9, 2019, provided that this offering results in total proceeds to us of at least $5.0 million, excluding the conversion of any debt and proceeds from offered securities sold to Domain Associates or TPG. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">TPG Group Holdings (SBS) Advisors, Inc. (&#8220;TPG Group Advisors&#8221;) is the is the sole member of TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG Group Holdings (SBS), L.P., a Delaware limited partnership, which is the sole member of TPG Holdings I-A, LLC, a Delaware limited liability company, which is the general partner of TPG Holdings I, L.P., a Delaware limited partnership, which is the sole member of TPG Biotechnology GenPar IV Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG Biotechnology GenPar IV, L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology Partners IV, L.P., a Delaware limited partnership (&#8220;TPG Biotech IV&#8221;). Because of the relationship of TPG Group Advisors to TPG Biotech IV, TPG Group Advisors may be deemed to beneficially own the shares of common stock held by TPG Biotech IV. David Bonderman and James G. Coulter are sole shareholders of TPG Group Advisors. Because of the relationship of Messrs. Bonderman and Coulter to TPG Group Advisors, each of Messrs. Bonderman and Coulter may be deemed to beneficially own the shares of common stock held by TPG Biotech IV. Messrs. Bonderman and Coulter disclaim beneficial ownership of the shares of common stock held by TPG Biotech IV except to the extent of their pecuniary interest therein. The principal business address of each of the entities in this footnote 2 is c/o&#160;TPG Global, LLC, 301 Commerce Street, Suite 3300, Fort Worth, Texas 76102. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents (i)&#160;142,090 shares of common stock and (ii) 96,076 shares of common stock issuable pursuant to immediately exercisable options, including 70,234 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Consists of 92,092 shares of common stock issuable pursuant to immediately exercisable options, including 76,816 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">114</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">Represents (i)&#160;240,454 shares of common stock and (ii) 158,181 shares of common stock issuable pursuant to immediately exercisable options, including 115,350 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents (i)&#160;85,254 shares of common stock and (ii) 56,275 shares of common stock issuable pursuant to immediately exercisable options, including 41,141 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(7)<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents of&#8201; (i)&#160;85,254 shares of common stock held of record by Eckard Weber Living Trust and (ii)&#160;56,275 shares of common stock issuable pursuant to immediately exercisable options, including 41,141 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. Mr.&#160;Weber is the sole trustee of the Eckard Weber Living Trust and holds sole voting and dispositive power over these shares. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(8)<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents (i)&#160;54,117 shares of common stock and (ii) 28,137 shares of common stock issuable pursuant to immediately exercisable options, including 20,570 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(9)<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Includes (i)&#160;607,169 shares of common stock and (ii) 487,036 shares of common stock issuable pursuant to immediately exercisable options, including 365,252 shares of common stock issuable following exercise of such options that are scheduled to vest within 60&#160;days of September&#160;30, 2019. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">115</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDCS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DESCRIPTION OF CAPITAL STOCK </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">The description below of our capital stock and provisions of our amended certificate of incorporation and bylaws are summaries and are qualified by reference to the amended certificate of incorporation and the bylaws filed as exhibits to the registration statement of which this prospectus is part, and by the applicable provisions of Delaware law. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Capital Stock </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have authorized 96,000,000 shares of capital stock, par value $0.001 per share, of which 95,000,000 are common stock and 1,000,000 are preferred stock. As of June 30, 2019, there were 5,807,877 shares of common stock issued and outstanding, held by 262 stockholders of record, and no shares of preferred stock issued and outstanding. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Common Stock </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The holders of our common stock are entitled to one vote per share. Our certificate of incorporation does not provide for cumulative voting. The holders of our common stock are entitled to take any action that may be taken at an annual or special meeting of stockholders through a consent in writing, setting forth the action taken and signed by the holders of outstanding stock of at least the minimum number of votes that would be necessary to authorize or take such action at a meeting of stockholders. The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by our board of directors out of legally available funds; however, the current policy of our board of directors is to retain earnings, if any, for operations and growth. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all assets that are legally available for distribution. The holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated solely by action of our board of directors and issued in the future. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our common stock is presently quoted on OTCQB under the symbol &#8220;ADYX.&#8221; In June 2019, Nasdaq delisted our common stock due to our noncompliance with Nasdaq&#8217;s minimum stockholders&#8217; equity requirement and minimum round lot shareholder requirement. We do not intend to list the common stock on a national securities exchange in connection with this offering. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Preferred Stock </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our board of directors is authorized, subject to any limitations prescribed by law, without further vote or action by our stockholders, to issue from time to time shares of preferred stock in one or more series and, as to each series, to establish the number of shares to be included in each such series, and to fix the designations, preferences, voting powers, qualifications, and special or relative rights or privileges of the shares in each such series, which may include, among others, dividend rights, voting rights, liquidation preferences, conversion rights and preemptive rights. Issuance of preferred stock by our board of directors could result in such shares having dividend or liquidation preferences senior to the rights of the holders of our common stock and could dilute the voting rights of the holders of our common stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to the issuance of shares of each series of preferred stock, our board of directors is required by the DGCL and our certificate of incorporation to adopt resolutions and file a certificate of designation with the Secretary of State of the State of Delaware. The certificate of designation fixes for each class or series the designations, powers, preferences, rights, qualifications, limitations and restrictions, including, but not limited to, some or all of the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the number of shares constituting that series and the distinctive designation of that series, which number may be increased or decreased (but not below the number of shares then outstanding) from time to time by action of the board of directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the dividend rate and the manner and frequency of payment of dividends on the shares of that series, whether dividends will be cumulative, and, if so, from which date; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">116</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">whether that series will have voting rights, in addition to any voting rights provided by law, and, if so, the terms of such voting rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the terms and conditions of any conversion privilege of the series, including provision for adjustment of the conversion rate in such events as the board of directors may determine; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">whether or not the shares of that series will be redeemable, and, if so, the terms and conditions of such redemption; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">whether that series will have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of such sinking fund; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">whether or not the shares of that series will have priority over, be on a parity with or be junior to the shares of any other series or class in any respect; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the rights of the shares of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of the corporation, and the relative rights or priority, if any, of payment of shares of that series; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any other relative rights, preferences and limitations of that series. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although our board of directors has no intention at the present time of doing so, it could authorize the issuance of a series of preferred stock that could, depending on the terms of such series, impede the completion of a merger, tender offer or other takeover attempt. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Delaware Anti-Takeover Law </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are subject to Section&#160;203 of the Delaware General Corporation Law. Section&#160;203 generally prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three&#160;years after the date of the transaction in which the person became an interested stockholder, unless: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (i)&#160;shares owned by persons who are directors and also officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66<font style=" position:relative; bottom:2.66pt;font-size:7pt;">2</font>&#8725;<font style="font-size:7pt;">3</font>% of the outstanding voting stock which is not owned by the interested stockholder. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Section&#160;203 defines a business combination to include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any merger or consolidation involving the corporation and the interested stockholder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with, or controlling, or controlled by, the entity or person. The term &#8220;owner&#8221; is broadly defined to include any </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">117</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">person that, individually, with or through that person&#8217;s affiliates or associates, among other things, beneficially owns the stock, or has the right to acquire the stock, whether or not the right is immediately exercisable, under any agreement or understanding or upon the exercise of warrants or options or otherwise or has the right to vote the stock under any agreement or understanding, or has an agreement or understanding with the beneficial owner of the stock for the purpose of acquiring, holding, voting or disposing of the stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The restrictions in Section&#160;203 do not apply to corporations that have elected, in the manner provided in Section&#160;203, not to be subject to Section&#160;203 of the Delaware General Corporation Law or, with certain exceptions, which do not have a class of voting stock that is listed on a national securities exchange or held of record by more than 2,000 stockholders. Our certificate of incorporation and bylaws do not opt out of Section&#160;203. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Section&#160;203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Certificate of Incorporation and Bylaws </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Provisions of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which shareholders might otherwise receive a premium for their shares, or transactions that our shareholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our certificate of incorporation and bylaws: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">permit our board of directors to issue up to 1,000,000 shares of preferred stock, without further action by the shareholders, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">provide that the authorized number of directors may be changed only by resolution of the board of directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">provide that special meetings of our shareholders may be called only by our board of directors; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">set forth an advance notice procedure with regard to the nomination, other than by or at the direction of our board of directors, of candidates for election as directors and with regard to business to be brought before a meeting of shareholders. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Choice of Forum </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for: (i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action asserting a breach of fiduciary duty owed by any director, officer or other employee to us or our stockholders; (iii)&#160;any action asserting a claim against us or any director or officer or other employee arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or bylaws; (iv)&#160;any action asserting a claim against us or any director or officer or other employee that is governed by the internal affairs doctrine or (v)&#160;to the maximum extent permitted by law, any other claim or dispute. This exclusive forum provision will not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">118</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">not have subject matter jurisdiction. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, jurisdiction over which is exclusively vested by statute in the U.S. federal courts. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Limitations on Liability and Indemnification of Officers and Directors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our certificate of incorporation contains a provision permitted under the DGCL relating to the liability of directors. This provision eliminates a director&#8217;s personal liability to the fullest extent permitted by the DGCL for monetary damages resulting from a breach of fiduciary duty; provided that such provision will not eliminate or limit a director&#8217;s liability for: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any breach of the director&#8217;s duty of loyalty; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of the law; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Section&#160;174 of the DGCL (unlawful dividends); or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">any transaction from which the director derives an improper personal benefit. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The principal effect of the limitation on liability provision is that a stockholder is unable to prosecute an action for monetary damages against a director unless the stockholder can demonstrate a basis for liability for which indemnification is not available under the DGCL. This provision, however, should not limit or eliminate our rights or any stockholder&#8217;s rights to seek non-monetary relief, such as an injunction or rescission, in the event of a breach of a director&#8217;s fiduciary duty. This provision does not alter a director&#8217;s liability under federal securities laws. The inclusion of this provision in our certificate of incorporation may discourage or deter stockholders or management from bringing a lawsuit against directors for a breach of their fiduciary duties, even though such an action, if successful, might otherwise have benefited us and our stockholders. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our certificate of incorporation and bylaws provide that we are required to indemnify our directors and officers, to the fullest extent permitted by law, subject to any permissible expansion or limitation of such indemnification, as may be set forth in any stockholders&#8217; or directors&#8217; resolution or by contract. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have entered into indemnification agreements and employment agreements with our directors and certain of our executive officers, respectively, pursuant to which we have agreed to indemnify such persons against any liability, damage, cost or expense incurred in connection with the defense of any action, suit or proceeding to which such persons are a party to the extent permitted by applicable law, subject to certain exceptions. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">119</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDSO">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">DESCRIPTION OF SECURITIES WE ARE OFFERING </div>
        <div style="text-indent:20pt; margin-top:4.61pt; width:456pt; line-height:12pt;">We are offering 7,500,000 shares of our common stock and/or pre-funded warrants and accompanying common warrants to purchase up to 7,500,000 shares of our common stock. The shares of common stock, pre-funded warrants, and accompanying common warrants will be issued separately. We are also registering the shares of common stock issuable from time to time upon exercise of the pre-funded warrants and common warrants offered hereby. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Common Stock </div>
        <div style="text-indent:20pt; margin-top:4.62pt; width:456pt; line-height:12pt;">The material terms and provisions of our common stock and each other class of our securities which qualifies or limits our common stock are described under the caption &#8220;Description of Capital Stock&#8221; in this prospectus. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Pre Funded Warrants </div>
        <div style="text-indent:20pt; margin-top:4.61pt; width:456pt; line-height:12pt;font-style:italic;">The following summary of certain terms and provisions of pre-funded warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the pre-funded warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of pre-funded warrant for a complete description of the terms and conditions of the pre-funded warrants.</div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Duration and Exercise Price.</font>&nbsp;&nbsp;&nbsp;Each pre-funded warrant offered hereby will have an initial exercise price per share equal to $0.01. The pre-funded warrants will be immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. </div>
        <div style="text-indent:20pt; margin-top:5.62pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Exercisability.</font>&nbsp;&nbsp;&nbsp;The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the pre-funded warrant to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61&#160;days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s pre-funded warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such&#160;percentage ownership is determined in accordance with the terms of the pre-funded warrants. Purchasers of pre-funded warrants in this offering may also elect prior to the issuance of the pre-funded warrants to have the initial exercise limitation set at 9.99% of our outstanding common stock. No fractional shares of common stock will be issued in connection with the exercise of a pre-funded warrant. In lieu of fractional shares, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share. </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Cashless Exercise.</font>&nbsp;&nbsp;&nbsp;If, at the time a holder exercises its pre-funded warrants, a registration statement registering the issuance of the shares of common stock underlying the pre-funded warrants under the Securities Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the pre-funded warrants. </div>
        <div style="text-indent:20pt; margin-top:5.62pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Transferability.</font>&nbsp;&nbsp;&nbsp;Subject to applicable laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrant to us together with the appropriate instruments of transfer. </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Exchange Listing.</font>&nbsp;&nbsp;&nbsp;There is no trading market available for the pre-funded warrants on any securities exchange or nationally recognized trading system. We do not intend to list the pre-funded warrants on any securities exchange or nationally recognized trading system. </div>
        <div style="text-indent:20pt; margin-top:5.42pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Right as a Stockholder.</font>&nbsp;&nbsp;&nbsp;Except as otherwise provided in the pre-funded warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holders of the pre-funded warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their pre-funded warrants. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">120</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Fundamental Transaction.</font>&nbsp;&nbsp;&nbsp;In the event of a fundamental transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction. </div>
        <div style="margin-top:11.02pt; width:456pt; line-height:11pt;font-weight:bold;">Common Warrants </div>
        <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;font-style:italic;">The following summary of certain terms and provisions of common warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the common warrants, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of common warrant for a complete description of the terms and conditions of the common warrants.</div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Duration and Exercise Price.</font>&nbsp;&nbsp;&nbsp;Each common warrant offered hereby will have an initial exercise price per share equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The common warrants will be immediately exercisable and will expire on the fifth anniversary of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. The common warrants will be issued separately from the common stock, and may be transferred separately immediately thereafter. A common warrant to purchase one share of our common stock will be issued for every one share of common stock or pre-funded warrant purchased in this offering. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Exercisability.</font>&nbsp;&nbsp;&nbsp;The common warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s common warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants. Purchasers in this offering may also elect prior to the issuance of the common warrants to have the initial exercise limitation set at 9.99% of our outstanding common stock. No fractional shares of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, we will either pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Cashless Exercise.</font>&nbsp;&nbsp;&nbsp;If, at the time a holder exercises its common warrants, a registration statement registering the issuance of the shares of common stock underlying the common warrants under the Securities Act is not then effective or available and an exemption from registration under the Securities Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the common warrants. </div>
        <div style="text-indent:20pt; margin-top:5.01pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Transferability.</font>&nbsp;&nbsp;&nbsp;Subject to applicable laws, a common warrant may be transferred at the option of the holder upon surrender of the common warrant to us together with the appropriate instruments of transfer. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Exchange Listing.</font>&nbsp;&nbsp;&nbsp;There is no trading market available for the common warrants on any securities exchange or nationally recognized trading system. We do not intend to list the common warrants on any securities exchange or nationally recognized trading system. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Right as a Stockholder.</font>&nbsp;&nbsp;&nbsp;Except as otherwise provided in the common warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holders of the common warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their common warrants. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">121</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Fundamental Transaction.</font>&nbsp;&nbsp;&nbsp;In the event of a fundamental transaction, as described in the common warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the common warrants will be entitled to receive upon exercise of the common warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the common warrants immediately prior to such fundamental transaction. Notwithstanding the foregoing, in the event of a fundamental transaction, the holders will have the option, which may be exercised within 30 days after the consummation of the fundamental transaction, to require us or our successor entity to purchase the common warrants from the holder by paying to the holder an amount of cash equal to the Black Scholes value of the remaining unexercised portion of the common warrant on the date of the consummation of the fundamental transaction. However, if the fundamental transaction is not within our control, including not approved by our board of directors, the holder will only be entitled to receive from us or our successor entity, as of the date of consummation of such fundamental transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes value of the unexercised portion of the common warrant, that is being offered and paid to the holders of common stock in connection with the fundamental transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of common stock are given the choice to receive from among alternative forms of consideration in connection with the fundamental transaction. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">122</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAT">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following is a general discussion of the material U.S. federal income tax considerations of the purchase, ownership and disposition of shares of our common stock issued pursuant to this offering, or Shares, the purchase, exercise, disposition and lapse of warrants to purchase shares of our common stock issued pursuant to this offering, or Common Warrants, and the purchase, ownership and disposition of shares of our common stock issuable upon exercise of the Common Warrants, or Warrant Shares, and the purchase, ownership and disposition of pre-funded warrants to purchase shares of our common stock issued pursuant to this offering, or Pre-Funded Warrants. The Shares, the Common Warrants, the Warrant Shares and the Pre-Funded Warrants are collectively referred to herein as our &#8220;securities.&#8221; The foregoing defined terms only apply to this section and not in other sections of this prospectus. All prospective holders of our securities should consult their tax advisors with respect to the U.S. federal, state, local and non-U.S. tax consequences of the purchase, ownership and disposition of our securities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating to the purchase, ownership and disposition of our securities. This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing U.S. Treasury Regulations promulgated thereunder, published administrative pronouncements and rulings of the U.S. Internal Revenue Service, or the IRS, and judicial decisions, all as in effect as of the date of this prospectus. These authorities are subject to change and to differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the tax consequences to holders described in this discussion. There can be no assurance that a court or the IRS will not challenge one or more of the tax consequences described herein, and we have not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax consequences to a holder of the purchase, ownership or disposition of our securities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We assume in this discussion that a holder holds our securities as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular holder in light of that holder&#8217;s individual circumstances, nor does it address any alternative minimum, Medicare contribution, estate or gift tax consequences, or any aspects of U.S. state, local or non-U.S. taxes or any other U.S. federal tax laws. This discussion also does not address consequences relevant to holders subject to special tax rules, such as holders that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below), corporations that accumulate earnings to avoid U.S. federal income tax, tax-exempt organizations, governmental organizations, banks, financial institutions, investment funds, insurance companies, brokers, dealers or traders in securities, commodities or currencies, tax-qualified retirement plans, holders who hold or receive our securities pursuant to the exercise of employee stock options or otherwise as compensation, holders holding our securities as part of a hedge, straddle or other risk reduction strategy, conversion transaction or other integrated investment, holders deemed to sell our securities under the constructive sale provisions of the Code, holders subject to special tax accounting rules under Section&#160;451(b) of the Code, controlled foreign corporations, passive foreign investment companies and certain former U.S. citizens or long-term residents. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, this discussion does not address the tax treatment of partnerships (or entities or arrangements that are treated as partnerships or disregarded entities for U.S. federal income tax purposes) or persons that hold our securities through such partnerships. If a partnership, including any entity or arrangement treated as a partnership for U.S. federal income tax purposes, holds our securities, the U.S. federal income tax treatment of a partner in such partnership will generally depend upon the status of the partner and the activities of the partnership. Such partners and partnerships should consult their tax advisors regarding the tax consequences of the purchase, ownership and disposition of our securities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Treatment of Pre-Funded Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although it is not entirely free from doubt, we believe a Pre-Funded Warrant should be treated as a Share for U.S. federal income tax purposes and a holder of Pre-Funded Warrants should generally be taxed in the same manner as a holder of Shares, as described below. Accordingly, no gain or loss should be recognized upon the exercise of a Pre-Funded Warrant and, upon exercise, the holding period of a Pre-Funded Warrant should carry over to the Share received. Similarly, the tax basis of the Pre-Funded Warrant should carry over to the Share received upon exercise, increased by the exercise price of&#8201; $0.01 per </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">123</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">share. However, our characterization is not binding on the IRS, and the IRS may treat our Pre-Funded Warrants as warrants to acquire our common stock. If so, the amount and character of your gain with respect to an investment in our Pre-Funded Warrants could change. Accordingly, each holder should consult his, her or its own tax advisor regarding the risks associated with the acquisition of Pre-Funded Warrant pursuant to this offering (including potential alternative characterizations). The balance of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax purposes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Allocation of Purchase Price </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For U.S. federal income tax purposes, the purchase of Shares and the associated Common Warrants or Pre-Funded Warrants and the associated Common Warrant in this offering by holders should be treated for U.S. federal income tax purposes as an &#8220;investment unit&#8221; consisting of one Share and the associated Common Warrant or one Pre-Funded Warrant and the associated Common Warrant. Each holder must allocate its purchase price of such unit between each Share or Pre-Funded Warrant, as applicable, and the Common Warrant based on their respective relative fair market values of each at the time of issuance. This allocation of the purchase price will establish the holder&#8217;s initial tax basis for U.S. federal income tax purposes for each Share, Pre-Funded Warrant and Common Warrant. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A holder&#8217;s allocation of the purchase price among the Shares, Pre-Funded Warrants and Common Warrants is not binding on the IRS or the courts, and no assurance can be given that the IRS or the courts will agree with a holder&#8217;s allocation. Each holder should consult its own tax advisor regarding the allocation of the purchase price among the Shares, Pre-Funded Warrants and Common Warrants. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Tax Considerations Applicable to U.S. Holders </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Definition of U.S. Holder </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In general, a &#8220;U.S. holder&#8221; means a beneficial owner of our securities (other than a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes) that is, for U.S. federal income tax purposes: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">an individual who is a citizen or resident of the United States; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">a corporation, or an entity treated as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States or of any state thereof or the District of Columbia; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">a trust if&#8201; (a)&#160;a U.S. court can exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons have the authority to control all of the trust&#8217;s substantial decisions or (b)&#160;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Distributions on the Shares, the Warrant Shares or the Common Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As described in the section entitled &#8220;Dividend Policy,&#8221; we do not anticipate paying any future distributions on our common stock. However, if we do make distributions (including constructive distributions as described below) on the Shares, the Warrant Shares or the Common Warrants, such distributions will constitute dividends to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles, and will be includible in your income as ordinary income when received. However, with respect to dividends received by individuals, such dividends are generally taxed at the lower applicable long-term capital gains rates, provided certain holding period requirements are satisfied. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the U.S. holder&#8217;s investment, up to such U.S. holder&#8217;s adjusted tax basis in the Shares, the Warrant Shares or the Common Warrants, as applicable. Any remaining excess will be treated as capital gain from the sale or exchange of such Shares, Warrant Shares or Common Warrants, subject to the tax treatment described below in &#8220;&#8212;&#8201;Sale or Other Taxable Disposition of the Shares and Warrant Shares.&#8221; </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">124</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Sale or Other Taxable Disposition of the Shares and Warrant Shares </div>
        <div style="text-indent:20pt; margin-top:4.81pt; width:456pt; line-height:12pt;">Upon the sale, exchange or other taxable disposition of the Shares or Warrant Shares, a U.S. holder will generally recognize capital gain or loss equal to the difference between the amount of cash and the fair market value of any property received upon the sale, exchange or other taxable disposition and such U.S. holder&#8217;s adjusted tax basis in the Shares or Warrant Shares. This capital gain or loss will be long-term capital gain or loss if the U.S. holder&#8217;s holding period in such Shares or Warrant Shares is more than one year at the time of the sale, exchange or other taxable disposition. Long-term capital gains recognized by certain non-corporate U.S. holders, including individuals, generally will be subject to reduced rates of U.S. federal income tax. The deductibility of capital losses is subject to certain limitations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Sale or Other Disposition or Exercise of Common Warrants </div>
        <div style="text-indent:20pt; margin-top:4.82pt; width:456pt; line-height:12pt;">Upon the sale or other disposition of a Common Warrant (other than by exercise), a U.S. holder will generally recognize capital gain or loss equal to the difference between the amount realized on the sale or other disposition and the U.S. holder&#8217;s tax basis in the Common Warrant. This capital gain or loss will be long-term capital gain or loss if the U.S. holder&#8217;s holding period in such Common Warrant is more than one year at the time of the sale or other disposition. The deductibility of capital losses is subject to certain limitations. </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">A U.S. holder generally will not recognize gain or loss on the exercise of a Common Warrant and the related receipt of Warrant Shares (unless cash is received in lieu of the issuance of a fractional Warrant Share). A U.S. holder&#8217;s initial tax basis in a Warrant Share will be equal to the sum of&#8201; (a)&#160;such U.S. holder&#8217;s tax basis in the Common Warrant plus (2)&#160;the exercise price paid by such U.S. holder on the exercise of such Common Warrant. A U.S. holder&#8217;s holding period in a Warrant Share received on the exercise of a Common Warrant should begin on the day after the date that such Common Warrant is exercised by such U.S. holder. Although there is no direct legal authority as to the U.S. federal income tax treatment of an exercise of a warrant on a cashless basis, we intend to take the position that such exercise will not be taxable, either because the exercise is not a gain realization event or because it qualifies as a tax-free recapitalization. In the former case, the holding period of the Warrant Share should commence on the day after the Common Warrant is exercised. In the latter case, the holding period of the Warrant Share would include the holding period of the exercised Common Warrant. However, our position is not binding on the IRS, and the IRS may treat a cashless exercise of a Common Warrant as a taxable exchange. U.S. holders are urged to consult their tax advisors as to the consequences of an exercise of a Common Warrant on a cashless basis, including with respect to their holding period and tax basis in the Warrant Share. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Lapse of Common Warrants </div>
        <div style="text-indent:20pt; margin-top:4.61pt; width:456pt; line-height:12pt;">If a U.S. holder allows a Common Warrant to expire unexercised, such U.S. holder will recognize a capital loss in an amount equal to such holder&#8217;s tax basis in the Common Warrant. Because the term of the Common Warrants purchased in this offering is more than one year, the U.S. holder&#8217;s capital loss will be treated as a long-term capital loss. The deductibility of capital losses is subject to certain limitations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Constructive Dividends on Common Warrants </div>
        <div style="text-indent:20pt; margin-top:4.62pt; width:456pt; line-height:12pt;">Under Section&#160;305 of the Code, an adjustment to the number of Warrant Shares that will be issued on the exercise of the Common Warrants, or an adjustment to the exercise price of the Common Warrants, may be treated as a constructive distribution to a U.S. holder of the Common Warrants if, and to the extent that, such adjustment has the effect of increasing such U.S. holder&#8217;s proportionate interest in our earnings and profits as determined under U.S. federal income tax principles or our assets, depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or other property to our shareholders). </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Backup Withholding and Information Reporting </div>
        <div style="text-indent:20pt; margin-top:4.61pt; width:456pt; line-height:12pt;">A U.S. holder may be subject to information reporting and backup withholding when such holder receives payments on our securities (including constructive dividends) or receives proceeds from the sale or other taxable disposition of our securities. Certain U.S. holders are exempt from backup withholding, including C corporations and certain tax-exempt organizations. A U.S. holder will be subject to backup withholding if such holder is not otherwise exempt and such holder: </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">125</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">fails to furnish the holder&#8217;s taxpayer identification number, which for an individual is ordinarily his or her social security number; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">furnishes an incorrect taxpayer identification number; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">is notified by the IRS that the holder previously failed to properly report payments of interest or dividends; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">fails to certify under penalties of perjury that the holder has furnished a correct taxpayer identification number and that the IRS has not notified the holder that the holder is subject to backup withholding. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a U.S. holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. U.S. holders should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Tax Considerations Applicable to Non-U.S. Holders </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Definition of non-U.S. Holder </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For purposes of this discussion, a &#8220;non-U.S. holder&#8221; is a beneficial owner of our securities that is neither a U.S. holder nor a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Exercise of Common Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A non-U.S. holder generally will not recognize gain or loss on the exercise of a Common Warrant and the related receipt of Warrant Shares (unless cash is received in lieu of the issuance of a fractional Warrant Share and certain other conditions are present, as discussed below under &#8220;&#8212;&#8201;Gain on Sale, Exchange or Other Taxable Disposition of Our Securities&#8221;). See &#8220;&#8212;&#8201;Tax Considerations Applicable to U.S. Holders&#8201;&#8212; Sale or Other Disposition or Exercise of Common Warrants.&#8221; However, if a cashless exercise of Common Warrants results in a taxable exchange, as described in &#8220;&#8212;&#8201;Tax Considerations Applicable to U.S. Holders&#8201;&#8212;&#8201;Sale or Other Disposition or Exercise of Common Warrants,&#8221; the rules described below under &#8220;Gain on Sale, Exchange or Other Taxable Disposition of Our Securities&#8221; would apply. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Lapse of Common Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If a non-U.S. holder allows a Common Warrant to expire unexercised, such non-U.S. holder will recognize a capital loss in an amount equal to such holder&#8217;s tax basis in the Common Warrant. See &#8220;&#8212;&#8201;Tax Considerations Applicable to U.S. Holders&#8201;&#8212;&#8201;Lapse of Common Warrants&#8221; above. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Constructive Dividends on the Common Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">See the discussion of the rules applicable to constructive distributions on a Common Warrant under the heading &#8220;&#8212;Tax Considerations Applicable to U.S. Holders&#8212;Constructive Dividends on Common Warrants&#8221; above. If an adjustment to the number of Warrant Shares that will be issued on the exercise of the Common Warrants, or an adjustment to the exercise price of the Common Warrants, results in a constructive distribution, as described in &#8220;&#8212;&#8201;Tax Considerations Applicable to U.S. Holders&#8201;&#8212; Constructive Dividends on Common Warrants,&#8221; the rules described below under &#8220;&#8201;Distributions on the Shares, the Warrant Shares or the Common Warrants&#8221; would apply. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Distributions on the Shares, the Warrant Shares or the Common Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we make distributions (including constructive distributions as described above) on the Shares, the Warrant Shares or the Common Warrants, such distributions will constitute dividends to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder&#8217;s investment, up to such non-U.S. holder&#8217;s adjusted tax </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">126</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">basis in the Shares, the Warrant Shares or the Common Warrants, as applicable. Any remaining excess will be treated as capital gain from the sale or exchange of such Shares, Warrant Shares or Common Warrants, subject to the tax treatment described below in &#8220;&#8212;&#8201;Gain on Sale, Exchange or Other Taxable Disposition of Our Securities.&#8221; </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Dividends paid to a non-U.S. holder will generally be subject to withholding of U.S. federal income tax at a 30% rate of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty between the United States and such non-U.S. holder&#8217;s country of residence for purposes of such treaty. In the case of any constructive dividend, it is possible that the U.S. federal tax on the constructive dividend would be withheld from Warrant Shares, sales proceed subsequently paid or credited, or other amounts payable or distributable to a non-U.S. holder. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Dividends that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States, are generally exempt from the 30% withholding tax if the non-U.S. holder satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code). Any U.S. effectively connected income received by a non-U.S. holder that is a corporation may also, under certain circumstances, be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such non-U.S. holder&#8217;s country of residence for purposes of such treaty. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">To claim a reduction or exemption from withholding, a non-U.S. holder generally will be required to provide (a) a properly executed IRS Form W-8BEN or IRS Form W-8BEN-E (or successor form) and satisfy applicable certification and other requirements to claim the benefit of an applicable income tax treaty between the United States and such non-U.S. holder&#8217;s country of residence, or (b)&#160;a properly executed IRS Form W-8ECI stating that dividends are not subject to withholding because they are effectively connected with such non-U.S. holder&#8217;s conduct of a trade or business within the United States. Non-U.S. holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Distributions will also be subject to the discussion below under the headings &#8220;&#8212;&#8201;Backup Withholding and Information Reporting&#8221; and &#8220;&#8212;&#8201;Foreign Accounts.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Gain on Sale, Exchange or Other Taxable Disposition of Our Securities </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Subject to the discussion below under the headings &#8220;&#8212;&#8201;Backup Withholding and Information Reporting&#8221; and &#8220;&#8212;&#8201;Foreign Accounts,&#8221; in general, a non-U.S. holder will not be subject to any U.S. federal income tax on any gain realized upon such non-U.S. holder&#8217;s sale, exchange or other taxable disposition of our securities unless: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:3.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the gain is effectively connected with a U.S. trade or business of the non-U.S. holder and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed base maintained in the United States by such non-U.S. holder, in which case the non-U.S. holder generally will be taxed at the graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code) and, if the non-U.S. holder is a foreign corporation, the branch profits tax described above in &#8220;&#8212;&#8201;Distributions on the Shares, the Warrant Shares or the Common Warrants&#8221; also may apply; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:3.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the non-U.S. holder is a nonresident alien individual who is present in the United States for 183&#160;days or more in the taxable year of the disposition and certain other conditions are met, in which case the non-U.S. holder will be subject to a 30% U.S. federal income tax (or such lower rate as may be specified by an applicable income tax treaty) on the net gain derived from the disposition, which may be offset by U.S. source capital losses of the non-U.S. holder, if any (even though the individual is not considered a resident of the United States); or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">127</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">we are, or have been, at any time during the five-year period preceding such disposition (or the non-U.S. holder&#8217;s holding period, if shorter) a &#8220;U.S. real property holding corporation&#8221; in which case such non-U.S. holder generally will be taxed on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code) and may be subject to withholding at a rate of 15%. Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. Even if we are or become a U.S. real property holding corporation, provided that our common stock is regularly traded, as defined by applicable U.S. Treasury Regulations, on an established securities market, the Shares and the Warrant Shares will be treated as a U.S. real property interest only with respect to a non-U.S. holder that holds more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the 5-year period ending on the date of the disposition or the period that the non-U.S. holder held the Shares or Warrant Shares, as applicable. There can be no assurance that our common stock will continue to qualify as regularly traded on an established securities market. Disposition by a non-U.S. holder of our Common Warrants (that are not expected to be regularly traded on an established securities market) may also be eligible for an exemption from withholding even if we are treated as a U.S. real property holding corporation, if on the date such Common Warrants were acquired by such non-U.S. holder such holdings had a fair market value no greater than the fair market value on that date of 5% of our regularly-traded common stock, provided that, if a non-U.S. holder holding our not-regularly-traded Common Warrants subsequently acquires additional Common Warrants, then such interests would be aggregated and valued as of the date of the subsequent acquisition to apply this 5% limitation. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Backup Withholding and Information Reporting </div>
        <div style="text-indent:20pt; margin-top:5.61pt; width:456pt; line-height:12pt;">We must report annually to the IRS and to each non-U.S. holder the gross amount of the dividends on our securities paid to such non-U.S. holder and the tax withheld, if any, with respect to such dividends. Non-U.S. holders will have to comply with specific certification procedures to establish that the holder is not a U.S. person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to any dividends on our securities. A non-U.S. holder generally will not be subject to U.S. backup withholding with respect to payments of dividends on our securities if it certifies its non-U.S. status by providing a valid IRS Form W-8BEN or IRS Form W-8BEN-E (or successor form) or IRS Form W-8ECI, or otherwise establishes an exemption; provided we do not have actual knowledge or reason to know such non-U.S. holder is a U.S. person, as defined in the Code. Dividends paid to non-U.S. holders subject to the U.S. withholding tax, as described above in &#8220;&#8212;&#8201;Distributions on the Shares, the Warrant Shares or the Common Warrants,&#8221; generally will be exempt from U.S. backup withholding. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Information reporting and backup withholding will generally apply to the proceeds of a disposition of our securities by a non-U.S. holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Copies of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is established under the provisions of a specific treaty or agreement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder may be allowed as a credit against the non-U.S. holder&#8217;s U.S. federal income tax liability, if any, and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">128</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Foreign Accounts </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Code generally imposes a U.S. federal withholding tax of 30% on dividends and, subject to the discussion below regarding proposed regulations recently issued by the U.S. Treasury Department, the gross proceeds of a disposition of our securities paid to a &#8220;foreign financial institution&#8221; (as defined in the Code), unless such institution enters into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding accounts held by certain &#8220;specific United States persons&#8221; or &#8220;United States-owned foreign entities&#8221; (each as defined in the Code), or otherwise qualifies for an exemption from these rules. A U.S. federal withholding tax of 30% also applies to dividends and, subject to the discussion below regarding proposed regulations recently issued by the U.S. Treasury Department, will apply to the gross proceeds of a disposition of our securities paid to a &#8220;non-financial foreign entity&#8221; (as defined in the Code), unless such entity provides the withholding agent with either a certification that it does not have any substantial United States owners&#8221; (as defined in the Code), provides information regarding each substantial United States owners of the entity, or otherwise qualifies for an exemption from these rules. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of such taxes. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The withholding provisions described above currently apply to dividends paid on our securities. The U.S. Treasury Department recently released proposed regulations which, if finalized in their present form, would eliminate the U.S. federal withholding tax of 30% applicable to the gross proceeds of a sale or other disposition of our securities. In its preamble to such proposed regulations, the U.S. Treasury Department stated that taxpayers may generally rely on the proposed regulations until final regulations are issued. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE AND LOCAL AND NON-U.S. TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR SECURITIES, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">129</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PLAN OF DISTRIBUTION </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We engaged H.C. Wainwright &amp; Co., LLC, which we refer to as H.C. Wainwright or the placement agent, to act as our exclusive placement agent to solicit offers to purchase the securities offered by this prospectus. H.C. Wainwright is not purchasing or selling any securities, nor are they required to arrange for the purchase and sale of any specific number or dollar amount of securities, other than to use their &#8220;reasonable best efforts&#8221; to arrange for the sale of the securities by us. Therefore, we may not sell the entire amount of the securities being offered. There is no minimum amount of proceeds that is a condition to closing of this offering. We will enter into a securities purchase agreement directly with the institutional investors, at the investor&#8217;s option, which purchase our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering. H.C. Wainwright may engage one or more sub-placement agents or selected dealers to assist with the offering. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Domain and TPG have indicated an interest in purchasing up to an aggregate of&#8201; $4.25&#160;million of securities in this offering at the public offering price per share of common stock and accompanying common warrant or pre-funded warrant and accompanying common warrant, as the case may be. However, because indications of interest are not binding agreements or commitments to purchase, either of Domain or TPG may elect to purchase more, fewer or no securities in this offering or the placement agent may elect to sell more, fewer or no securities in this offering to either of Domain or TPG. As discussed in more detail below, the placement agent&#8217;s fees are partially dependent on the total amount of our securities that the placement agent sells in this offering to investors other than Domain or TPG. Any securities purchased by Domain or TPG in this offering will not be subject to the lock-up agreements with the placement agent that are described below. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Fees and Expenses </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table shows the placement agent fees we will pay in connection with the sale of the securities in this offering, assuming the purchase of all of the securities we are offering. </div>
        <table style="width:416pt;height:52pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:379pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Per share of common stock and accompanying common warrant placement agent cash <br >fees </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:379pt;text-align:left;">
              <div style="margin-left:10pt;">Per pre-funded warrant and accompanying common warrant placement agent cash fees </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:379pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have agreed to pay the placement agent a total cash fee equal to a percentage of the aggregate gross proceeds raised in this offering as follows:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are less than $2.5 million, a cash fee equal to 7% of the aggregate gross proceeds raised in this offering (inclusive of any gross proceeds raised from Domain and TPG); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are $2.5 million or more, a cash fee equal to 7.25% of the aggregate gross proceeds raised in this offering (inclusive of any gross proceeds raised from Domain and TPG); or</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are $5.0 million or more, a cash fee equal to 7.5% of the aggregate gross proceeds raised in this offering (inclusive of any gross proceeds raised from Domain and TPG).</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have also agreed to pay the placement agent a management fee equal to a percentage of the aggregate gross proceeds raised in this offering as follows:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are less than $2.5 million, no management fee; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are $2.5 million or more, a management fee equal to 0.5% of the aggregate gross proceeds raised in this offering (inclusive of any gross proceeds raised from Domain and TPG); or</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">130</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are $5.0 million or more, a management fee equal to 1.0% of the aggregate gross proceeds raised in this offering (inclusive of any gross proceeds raised from Domain and TPG).</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, we have agreed to reimburse the placement agent for up to $150,000 of certain of its counsel fees and expenses and other out-of-pocket and non-accountable expenses and up to $10,000 for clearing expenses. In addition, upon consummation of the Merger, the placement agent received additional compensation of 21,704&#160;shares of our common stock. Pursuant to FINRA Rule&#160;5110(g)(1), the placement agent has agreed not to sell, transfer, assign, pledge, or hypothecate, or not to have such shares be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of such shares by any person for a period of 180&#160;days immediately following the date of effectiveness or commencement of sales of this offering, except as provided in FINRA Rule&#160;5110(g)(2). We estimate the total offering expenses of this offering that will be payable by us, excluding the placement agent fees and expenses, will be approximately $1,100,000. After deducting the placement agent fees and our estimated offering expenses, we expect the net proceeds from this offering to be approximately $8.2&#160;million, which assumes that we will sell the maximum amount of securities offered hereby. However, because there is no minimum offering amount required as a condition to closing in this offering, the actual offering amount, placement agent fees and proceeds to us, if any, in this offering may be substantially less than the maximum offering amounts set forth in this prospectus. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Placement Agent Warrants</div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have agreed to issue placement agent warrants to H.C. Wainwright or its designees to purchase a number of shares of our common stock equal to a percentage of the aggregate number of shares of common stock and pre-funded warrants issued in this offering (but excluding the warrants issued in this offering) as follows:</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are less than $2.5 million, no placement agent warrants; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are $2.5 million or more, a number of placement agent warrants equal to 3.75% of the aggregate number of shares of common stock and pre-funded warrants issued in this offering (inclusive of any shares of common stock and pre-funded warrants issued to Domain and TPG); or</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate gross proceeds raised in this offering (other than any gross proceeds raised from Domain and TPG) are $5.0 million or more, a number of placement agent warrants equal to 7.5% of the aggregate number of shares of common stock pre-funded warrants issued in this offering (inclusive of any shares of common stock and pre-funded warrants issued to Domain and TPG).</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The placement agent warrants will have an exercise price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (125% of the public offering price of the securities offered hereby) and will terminate on the five year anniversary of the effective date of the offering, pursuant to FINRA Rule&#160;5110(f)(2)(G)(i). The placement agent warrants are registered on the registration statement of which this prospectus is a part. Pursuant to FINRA Rule 5110(g), the placement agent warrants and any shares issued upon exercise of the placement agent warrants shall not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the date of effectiveness or commencement of sales of this offering, except the transfer of any security:</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">by operation of law or by reason of our reorganization;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction set forth above for the remainder of the time period;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the aggregate amount of our securities held by the placement agent or related persons do not exceed 1% of the securities being offered;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">131</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">that is beneficially owned on a pro rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund and the participating members in the aggregate do not own more than 10% of the equity in the fund; or</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:3.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the exercise or conversion of any security, if all securities remain subject to the lock-up restriction set forth above for the remainder of the time period. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Right of First Refusal </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">We have also granted the placement agent a 12-month right of first refusal to act as sole book-running manager, sole underwriter or sole placement agent for each and every future public or private equity or debt offering or debt refinancing by us or any of our successors or subsidiaries, as well as the right to serve as exclusive financial advisor in the event of any disposition, acquisition or other business combination, in each case subject to certain limitations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Tail Financing Payments </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">We have also agreed to pay the placement agent a tail fee equal to the cash and warrant compensation in this offering, if any investor, who was contacted or introduced to us by the placement agent during the term of the placement agent&#8217;s engagement, provides us with capital in any public or private offering or other financing or capital raising transaction during the 12-month period following expiration or termination of our engagement of the placement agent.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Other Relationships </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">The placement agent in the past has provided investment banking and other financial services to Alliqua and its affiliates for which the placement agent and its affiliates have received compensation. </div>
        <div style="text-indent:20pt; margin-top:5.01pt; width:456pt; line-height:12pt;">In February&#160;2017, the placement agent acted as a financial advisor to Alliqua in connection with a private placement of common stock for which the placement agent received a financial advisory fee of approximately $160,000. In April&#160;2017, the placement agent acted as the sole book-running manager of a public offering by Alliqua of common stock for which the placement agent received fees of approximately $210,000. In March&#160;2018, the placement agent was engaged by Alliqua in connection with a proposed offering that was never consummated and received reimbursement of&#8201; $50,000 of legal fees. </div>

          <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">In addition, the placement agent acted as financial advisor to Alliqua in connection with the Merger. The placement agent was paid a fee of&#8201; $50,000 at the time of its engagement for its services in connection with the Merger and a fee of&#8201; $250,000 for rendering its fairness opinion delivered in connection with the Merger. In addition, upon consummation of the Merger, the placement agent received additional compensation of&#8201; $350,000 of cash and, as specified above, 21,704 shares of our common stock. Alliqua also reimbursed the placement agent for $50,000 of expenses incurred in connection with the Merger. In accordance with Financial Industry Regulatory Authority, Inc. Rule&#160;5110, the placement agent&#8217;s reimbursed expenses and the compensation received by the placement agent in connection with the Merger may be deemed underwriting compensation for this offering. </div>

        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Determination of Offering Price </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">The public offering price of the securities we are offering and the exercise price and other terms of the pre-funded warrants and common warrants were negotiated between us and the investors, in consultation with the placement agent based on the trading of our common stock prior to the offering, among other things, and may be at a discount to the current market price. Other factors considered in determining the public offering price of the securities we are offering and the exercise price and other terms of the pre-funded warrants and common warrants include our history and prospects, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management, general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Lock-up Agreements </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">We, our officers and our directors and certain significant stockholders have agreed, subject to certain specified exceptions, not to directly or indirectly, for a period of 90&#160;days after the date of the prospectus, without the prior written consent of H.C. Wainwright: </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">132</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#8220;put equivalent position&#8221; within the meaning of Rule&#160;16a-1(h) under the Exchange Act, or otherwise dispose of, any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">enter into any swap, hedge or other agreement or transaction that transfers, in whole or in part, the economic consequence of ownership of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">publicly announce an intention to do any of the foregoing. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The restrictions in the immediately preceding paragraph do not apply in certain circumstances, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the issuance of shares of our common stock in this offering and shares of our common stock underlying the pre-funded warrants and common warrants; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">transfers by gift, will or operation of law; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">transfers to certain related entities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">certain exercises of options; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">the establishment of 10b5-1 trading plans, provided no sales can occur during the 90-day lock-up period; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">transfers of shares of common stock and accompanying warrants acquired in this offering or on the open market following this offering; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">transfers to us pursuant to contractual arrangements that provide for the repurchase of shares by us in connection with the termination of employment with us. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, we and each such person agree that, without the prior written consent of H.C. Wainwright, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">H.C. Wainwright may, in its sole discretion and at any time or from time to time before the termination of the 90-day period, release all or any portion of the securities subject to lock-up agreements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Transfer Agent and Registrar </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The transfer agent and registrar for our common stock is Action Stock Transfer Corporation. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Listing </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our common stock is presently quoted on OTCQB under the trading symbol &#8220;ADYX.&#8221; We do not intend to apply to list any of our securities on any securities exchange or nationally recognized trading system in connection with this offering. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">State Blue Sky Information</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have not applied to register the securities to be issued in this offering for offers and sales to retail customers under the securities laws, or &#8220;blue sky&#8221; laws, of any state. In connection with this offering, we will rely on exemptions from registration for sales of securities in this offering solely to institutional investors pursuant to an exemption provided for sales to these investors under state blue sky laws. The definition of an &#8220;institutional investor&#8221; varies from state to state but generally includes financial institutions, broker-dealers, banks, insurance companies and other qualified entities.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The National Securities Markets Improvement Act of 1996, or NSMIA, which is a federal statute, pre-empts states from regulating transactions in certain securities, which are referred to as &#8220;covered securities.&#8221; The resale of the securities issued in this offering by persons other than underwriters or dealers </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">133</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">is exempt from state registration requirements under NSMIA because we are required to file periodic and annual reports under the Exchange Act. However, states are permitted to require notice filings and collect fees with regard to these transactions and a state may suspend the offer and sale of securities within such state if any such required filing is not made or fee is not paid. Whether a notice filing or fee payment is required is a state-by-state analysis. Additionally, if any state that has not yet adopted a statute relating to NSMIA adopts such a statute in the future requiring a filing or fee or if any state amends its existing statutes with respect to its requirements, we would need to comply with those new requirements in order for our securities to continue to be eligible for resale in those jurisdictions.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Aside from the exemption from registration provided by NSMIA, the securities issued in this offering may be eligible for sale on a secondary market basis in various states based on the availability of other applicable exemptions from state registration requirements, in certain instances subject to waiting periods, notice filings or fee payments. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Indemnification </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have agreed to indemnify the placement agent against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the placement agent may be required to make with respect to any of these liabilities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Regulation&#160;M </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The placement agent may be deemed to be an underwriter within the meaning of Section&#160;2(a)(11) of the Securities Act and any fees received by it and any profit realized on the sale of the securities by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. The placement agent will be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule&#160;10b-5 and Regulation&#160;M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities by the placement agent. Under these rules and regulations, the placement agent may not (i)&#160;engage in any stabilization activity in connection with our securities; and (ii) bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until they have completed their participation in the distribution.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">134</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLM">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">LEGAL MATTERS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The validity of the securities offered hereby will be passed upon for us by Cooley LLP, Palo Alto, California. Haynes and Boone, LLP, New York, New York is acting as counsel to the placement agent in connection with this offering. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">EXPERTS </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The financial statements of Adynxx, Inc. as of December&#160;31, 2018 and 2017, and for the&#160;years then ended, included in this prospectus have been so included in reliance on the report of BDO USA, LLP, independent registered public accounting firm (the report on the financial statements contains an explanatory paragraph regarding our ability to continue as a going concern), appearing elsewhere herein, given on the authority of said firm as experts in auditing and accounting. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the securities being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further information with respect to our company and the securities offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">You can read our SEC filings, including the registration statement, over the internet at the SEC&#8217;s website at www.sec.gov. We are subject to the information reporting requirements of the Exchange Act, and file annual, quarterly and special reports, proxy statements and other information with the SEC. These reports, proxy statements and other information are available for inspection on the website of the SEC referred to above. We also maintain a website at www.adynxx.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated into, this prospectus.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">135</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">
          <font style="text-transform:uppercase;">ADYNXX INC. Unaudited Pro Forma Financial Information</font></div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">The following unaudited pro&#160;forma condensed combined financial statements were prepared using the acquisition method of accounting under U.S. GAAP and gives effect to the merger transaction (the &#8220;Merger&#8221;) between Alliqua BioMedical, Inc. (&#8220;Alliqua&#8221;) and privately-held Adynxx (&#8220;Private Adynxx&#8221;). The merger will be treated by Alliqua as a reverse merger and recapitalization effected by a share exchange for financial accounting and reporting purposes. The notes below titled &#8220;<font style="font-style:italic;">Adynxx Transactions</font>&#8221; and &#8220;<font style="font-style:italic;">Distribution of Cash</font>&#8221; provide additional information regarding this transaction. The pro&#160;forma condensed combined financial statements give effect to the spin-off of Alliqua&#8217;s wholly owned subsidiary, AquaMed Technologies, Inc. (&#8220;AquaMed&#8221;), engaged in the custom hydrogel manufacturing business, in the form of a pro&#160;rata distribution of the common equity of the subsidiary to Alliqua&#8217;s stockholders, (the &#8220;Spin-off Transaction&#8221;). See note below titled &#8220;<font style="font-style:italic;">Aquamed Spin-Off.</font>&#8221; Since Alliqua will be deemed to have no operations upon consummation of the Spin-off, Alliqua is not considered to be a business for accounting purposes. Accordingly, no goodwill or intangible assets will be recorded as a result of the merger. Because Private Adynxx will be treated as the acquiring company, Private Adynxx&#8217;s assets and liabilities will be recorded at their pre-combination carrying amounts and the historical operations that are reflected in the unaudited pro&#160;forma condensed combined financial information will be those of Private Adynxx. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Private Adynxx was determined to be the accounting acquirer based upon the terms of the Merger Agreement and other factors including: (i)&#160;Private Adynxx equity holders owned approximately 86% of the voting interests of the combined company immediately following the closing of the transaction and Alliqua equity holders owned approximately 14%; (ii) directors appointed by Private Adynxx hold a majority of board seats in the combined company; and (iii) Private Adynxx management held all key positions in the management of the combined company. </div>
        <div style="margin-top:6pt; width:456pt; line-height:11pt;font-style:italic;">Adynxx Transactions </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, Adynxx, Inc., formerly known as &#8220;Alliqua BioMedical, Inc.,&#8221; completed a business combination with Private Adynxx in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of October&#160;11, 2018, as amended and supplemented from time to time (the &#8220;Merger Agreement&#8221;) by and among us, Embark Merger Sub, Inc. (&#8220;Merger Sub&#8221;), and Private Adynxx, pursuant to which Merger Sub merged with and into Private Adynxx, with Private Adynxx surviving as a wholly-owned subsidiary of the re-named Adynxx, Inc. which is referred to herein as the Merger. Also, on May&#160;3, 2019, in connection with, and immediately prior to the completion of the Merger, we effected a reverse stock split at a ratio of one new share for every six shares of our common stock outstanding (the &#8220;Merger Stock Split&#8221;) and immediately following the Merger, we changed our name to &#8220;Adynxx, Inc.&#8221; Following the completion of the Merger, the business conducted by Private Adynxx became primarily the business conducted by us, which is the development of novel, disease-modifying pharmaceutical product candidates for the treatment of pain and inflammation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the terms of the Merger Agreement, we issued shares of our common stock to Private Adynxx&#8217;s stockholders at an exchange rate of 0.0359 shares of common stock in exchange for each share of Private Adynxx common stock outstanding immediately prior to the Merger (which exchange rate reflects the Merger Stock Split). The exchange rate was determined pursuant to the terms of the Merger Agreement. We also assumed all of the stock options outstanding under Private Adynxx&#8217;s 2010 Equity Incentive Plan (the &#8220;Private Adynxx Plan&#8221;) with such stock options representing the right to purchase a number of shares of our common stock equal to 0.0359 multiplied by the number of shares of Private Adynxx common stock previously represented by such options under the Private Adynxx Plan. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Immediately after the Merger, the former Private Adynxx stockholders, warrant holders and option holders owned approximately 86% of the fully-diluted common stock of the combined company, with our stockholders and option holders immediately prior to the Merger, whose shares of our common stock remain outstanding after the Merger, owning approximately 14% of the fully-diluted common stock of the combined company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Distribution of Cash </div>
        <div style="text-indent:20pt; margin-top:5.21pt; width:456pt; line-height:12pt;">On April&#160;11, 2019, Alliqua announced that its board of directors has (i)&#160;declared a conditional special cash dividend (the &#8220;Special Dividend&#8221;) of&#8201; $1.05 for each share of common stock outstanding as of the close of business on April&#160;22, 2019 (the &#8220;Record Date&#8221;), for an aggregate of&#8201; $5,245,000, and (ii) set the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">136</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">Record Date as the record date for determining stockholders entitled to receive shares of AquaMed in connection with Alliqua&#8217;s spin-off of AquaMed. </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">The payment of the Special Dividend was subject to the consummation of the Merger. In May&#160;2019, we made a one-time special cash distribution to the pre-Merger holders of shares of Alliqua BioMedical, Inc. in the amount of&#8201; $6.30 per share, post-split. </div>
        <div style="margin-top:6pt; width:456pt; line-height:11pt;font-style:italic;">AquaMed Spin-Off </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">AquaMed is engaged in the custom hydrogel manufacturing business. In June 2019, we effectuated the spin-off of AquaMed into a separate, stand-alone company upon consummation of the following steps:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Pursuant to an Asset Contribution and Separation Agreement entered into by and between us and AquaMed, or the Separation Agreement, we transfered certain assets and liabilities utilized primarily in connection with Alliqua&#8217;s custom hydrogels contract manufacturing business to AquaMed;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">AquaMed issued shares of its common stock to us in consideration of the contribution of assets pursuant to the Separation Agreement; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">We distributed to the pre-Merger holders of shares of Alliqua as of April&#160;22, 2019 all of the issued and outstanding shares of common stock, par value $0.001 per share, of AquaMed by way of a pro rata dividend.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The unaudited pro&#160;forma condensed combined statements of operations for the six&#160;months ended June&#160;30, 2019 and for the year ended December&#160;31, 2018, assumes that the transactions took place as of January&#160;1, 2018, and combines the historical results of Alliqua for the period from January&#160;1, 2019 to May&#160;2, 2019 and the year ended December&#160;31, 2018 and Private Adynxx for the six months ended June&#160;30, 2019 and year ended December&#160;31, 2018, respectively. The historical financial statements of Alliqua and Private Adynxx have been adjusted to give pro&#160;forma effect to events that are (i)&#160;directly attributable to the transaction, (ii) factually supportable, and (iii) with respect to the statements of operations, expected to have a continuing impact on the combined company&#8217;s results. </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">The following information also gives effect to the Merger Stock Split as if such split occurred on the same date as the transactions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The unaudited pro&#160;forma condensed combined financial statements are based on the assumptions and adjustments that are described in the accompanying notes. The pro&#160;forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro&#160;forma condensed combined financial statements. Differences between these preliminary estimates and the final amounts, expected to be completed after the closing of the transaction, will occur and these differences could have a material impact on the accompanying unaudited pro&#160;forma condensed combined financial statements and the combined company&#8217;s future results of operations and financial position. </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">The unaudited pro&#160;forma condensed combined financial statements do not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro&#160;forma condensed combined financial statements are preliminary and have been prepared for illustrative purposes only and are not necessarily indicative of the financial position or results of operations in future periods or the results that actually would have been realized had Alliqua and Private Adynxx been a combined company during the specified periods. The actual results reported in periods following the transaction may differ significantly from those reflected in the unaudited pro&#160;forma condensed combined financial statements presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this pro&#160;forma financial statement. </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:12pt;">The unaudited pro&#160;forma condensed combined financial statements, including the notes thereto, should be read in conjunction with the Private Adynxx historical financial statements. Private Adynxx&#8217;s historical unaudited financial statements for the six&#160;months ended June&#160;30, 2019, and audited financial statements for the years ended December&#160;31, 2018 and December&#160;31, 2017 are included elsewhere in this prospectus.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">137</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:18pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Adynxx, Inc.</div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Unaudited Pro Forma Condensed Combined Statement of Operations <br >For the Six Months Ended June&#160;30, 2019 <br >(In thousands, except per share data) </div>
      </div>
      <div style="margin-top:18pt;margin-bottom:18pt;margin-left:27.5pt;width:541pt;">
        <table style="width:541pt;height:354.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Adynxx, Inc. <br >(Accounting <br >Acquirer) <br >Historical </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Alliqua <br >BioMedical, <br >Inc. <br >(Accounting <br >Acquiree)<br >From <br >January&#160;1, 2019 <br >to May&#160;2, 2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">AquaMed <br >Spin-off </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Adynxx <br >Transactions </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Total Pro <br >Forma <br >Adjustments </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:19.94pt;">
              <div style="white-space:nowrap; text-align:center;">Notes </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Pro Forma <br >Combined </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
              <div style="white-space:nowrap;">Revenue, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">152</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(152<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(152<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">
              <div style="text-align:center;">(n) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:182.85pt;text-align:left;">
              <div style="white-space:nowrap;">Cost of revenues </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">300</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(300<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:19.94pt;text-align:center;">
              <div style="text-align:center;">(n) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
              <div style="white-space:nowrap;">Gross loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(148<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">148</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">148</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:9pt 0pt 0.5pt 0pt; width:182.85pt;">Operating expenses:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
              <div style="margin-left:10pt;">Selling, general and administrative </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">2,317</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">1,070</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(762<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(762<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">
              <div style="text-align:center;">(n) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">2,625</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
              <div style="margin-left:10pt;">Research and product development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">3,226</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">3,226</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
              <div style="margin-left:10pt;">Grant reimbursement </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(1,198<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(1,198<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:182.85pt;text-align:left;">
              <div style="margin-left:10pt;">Acquisition related expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">2,401</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,401<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(2,401<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:19.94pt;text-align:center;">
              <div style="text-align:center;">(p) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:182.85pt;text-align:left;">
              <div style="white-space:nowrap;">Total operating expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">4,345</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">3,471</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(762<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,401<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(3,163<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">4,653</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(4,345<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(3,619<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">910</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,401</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,311</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(4,653<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:9pt 0pt 0.5pt 0pt; width:182.85pt;">Interest and other income (expense):</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
              <div style="margin-left:10pt;">Interest income (expense) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(2,641<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">81</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">81</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">
              <div style="text-align:center;">(q) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,101</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,101</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">
              <div style="text-align:center;">(r) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(443<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:182.85pt;text-align:left;">
              <div style="margin-left:10pt;">Change in fair value of warrant liability </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">(94<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">94</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">94</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3pt 0pt 2pt 0pt; width:19.94pt;text-align:center;">
              <div style="text-align:center;">(o)</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:182.85pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from continuing operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">(7,080<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(3,603<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">910</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">4,677</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,587</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">(5,096<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:8.25pt 0pt 0.5pt 0pt; width:182.85pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">Net loss per share basic and diluted common share</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:182.85pt;text-align:left;">
              <div style="margin-left:10pt;">Loss from continuing operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(1.43<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.94pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(0.88<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 2.75pt 0pt; width:182.85pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Pro&#160;forma weighted average shares outstanding <br >used in computing basic and diluted net loss <br >per common share </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">4,966,491</td>
            <td style="padding:0pt;padding-left:1.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.695pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">841,386</td>
            <td style="padding:0pt;padding-left:3.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.75pt 0pt; width:19.94pt;text-align:center;">
              <div style="text-align:center;">(t)(u)</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">5,807,877</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="41">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:18pt;margin-bottom:172.5pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-size:10pt;">&nbsp;&nbsp;&nbsp;</div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:10pt;">See accompanying notes to the unaudited pro forma condensed combined financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">138</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:18pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Adynxx, Inc.</div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Unaudited Pro Forma Condensed Combined Statement of Operations <br >For the Year Ended December&#160;31, 2018 <br >(In Thousands, Except Per Share Data) </div>
      </div>
      <div style="margin-top:18pt;margin-bottom:18pt;margin-left:27.5pt;width:541pt;">
        <table style="width:541pt;height:511.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Adynxx, Inc. <br >(Accounting <br >Acquirer) <br >Historical </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Alliqua <br >BioMedical, <br >Inc. <br >(Accounting <br >Acquiree) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">AquaMed <br >Spin-Off </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Adynxx <br >Transactions </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Total Pro <br >Forma <br >Adjustments </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:19.41pt;">
              <div style="white-space:nowrap; text-align:center;">Notes </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Pro Forma <br >Combined </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
              <div style="white-space:nowrap;">Revenue, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">2,216</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,216<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(2,216<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">
              <div style="text-align:center;">(n) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
              <div style="white-space:nowrap;">Cost of revenues </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,720</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(1,720<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">(1,720<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:19.41pt;text-align:center;">
              <div style="text-align:center;">(n) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
              <div style="white-space:nowrap;">Gross profit </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">496</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(496<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(496<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:9pt 0pt 0.5pt 0pt; width:186.76pt;">Operating expenses:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
              <div style="margin-left:10pt;">Selling, general and administrative </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,982</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,778</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,502<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(2,502<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">
              <div style="text-align:center;">(n) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">5,258</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
              <div style="margin-left:10pt;">Acquisition related expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,014</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(1,014<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(1,014<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">
              <div style="text-align:center;">(p) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:186.76pt;text-align:left;">
              <div style="margin-left:10pt;">Research and development </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">2,137</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">2,137</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:186.76pt;text-align:left;">
              <div style="white-space:nowrap;">Total operating expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">5,119</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,792</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,502<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(1,014<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">(3,516<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">7,395</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(5,119<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(5,296<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,006</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">1,014</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">3,020</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(7,395<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:9pt 0pt 0.5pt 0pt; width:186.76pt;">Interest and other income (expenses):</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
              <div style="margin-left:10pt;">Interest income (expense) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(980<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">334</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">334</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">
              <div style="text-align:center;">(q) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(622<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
              <div style="margin-left:10pt;">Change in fair value of warrant liability </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(97<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(26<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">97</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">97</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">
              <div style="text-align:center;">(o) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(26<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
              <div style="margin-left:10pt;">Change in fair value of derivative liability </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">211</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(211<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">(211<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">
              <div style="text-align:center;">(q) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:186.76pt;text-align:left;">
              <div style="margin-left:10pt;">Loss on early extinguishment of debt, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">(1,706<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(1,706<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:186.76pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss from continuing operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(5,985<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">(7,004<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">2,006</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">1,234</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">3,240</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(9,749<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:8.25pt 0pt 0.5pt 0pt; width:186.76pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">Net loss per share basic and diluted common share</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;text-align:left;">
              <div style="margin-left:10pt;">Loss from continuing operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(8.54<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(1.68<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 2.75pt 0pt; width:186.76pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Pro&#160;forma weighted average shares outstanding used in computing basic and diluted net loss per common share </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">820,565</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">4,987,870</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.75pt 0pt; width:19.41pt;text-align:center;">
              <div style="text-align:center;">(t)</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">5,808,435</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:9.5pt 0pt 0.5pt 0pt; width:186.76pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">Reconciliation of pro&#160;forma weighted average shares outstanding:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:186.76pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Weighted average number of shares held by Adynxx shareholders pre-merger </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">136,866,375</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:186.76pt;text-align:left;">
              <div style="margin-left:10pt;">Conversion ratio </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:19.41pt;text-align:center;">
              <div style="text-align:center;">(s)</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">0.0364</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:186.76pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Weighted average number of shares held by Adynxx shareholders post-merger </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">4,987,870</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:186.76pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Weighted average number of shares held by Alliqua shareholders </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:19.41pt;text-align:center;">
              <div style="text-align:center;">(s)</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">820,565</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:186.76pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Total pro&#160;forma weighted average shares outstanding </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.62pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.0949999999999989pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:19.41pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">5,808,435</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="41">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:18pt;margin-bottom:15.5pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-size:10pt;">&nbsp;&nbsp;&nbsp;</div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:10pt;">See accompanying notes to the unaudited pro forma condensed combined financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">139</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to the Unaudited Pro Forma Condensed Combined Financial Information </div>
        <div style=" float:left; line-height:11pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">1.<br ></div>
        <div style=" margin-top:12pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:20pt;font-weight:bold;">Description of Transaction and Basis of Presentation </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The unaudited pro&#160;forma condensed combined financial information was prepared pursuant to the rules and regulations of SEC Regulation&#160;S-X and presents the pro&#160;forma financial position and results of operations of the combined companies based upon the historical data of Alliqua and Private Adynxx. The Merger will be treated by Alliqua as a reverse merger and recapitalization effected by a share exchange for financial accounting and reporting purposes. The pro&#160;forma condensed combined financial information also gives effect to the spin-off of Alliqua&#8217;s wholly owned subsidiary, AquaMed, engaged in the custom hydrogel manufacturing business, in the form of a pro&#160;rata distribution of the common equity of the subsidiary to Alliqua&#8217;s stockholders. See note below titled &#8220;AquaMed Spin-Off.&#8221; Since Alliqua will be deemed to have no operations upon consummation of the Spin-off Transaction, Alliqua is not considered to be a business for accounting purposes. Accordingly, no goodwill or intangible assets will be recorded as a result of the merger. Because Private Adynxx will be treated as the acquiring company, Private Adynxx&#8217;s assets and liabilities will be recorded at their pre-combination carrying amounts and the historical operations that are reflected in the unaudited pro&#160;forma condensed combined financial information will be those of Private Adynxx. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Description of Transaction </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, Adynxx, Inc., formerly known as &#8220;Alliqua BioMedical, Inc.,&#8221; completed a business combination with privately-held &#8220;Adynxx, Inc.&#8221; in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of October&#160;11, 2018, as amended and supplemented from time to time, by and among us, Merger Sub, and Private Adynxx, pursuant to which Merger Sub merged with and into Private Adynxx, with Private Adynxx surviving as a wholly-owned subsidiary of the re-named Adynxx, Inc. which is referred to herein as the Merger. Also, on May&#160;3, 2019, in connection with, and immediately prior to the completion of the Merger, we effected the Merger Stock Split, and immediately following the Merger, we changed our name to &#8220;Adynxx, Inc.&#8221; Following the completion of the Merger, the business conducted by Private Adynxx became primarily the business conducted by us, which is the development of novel, disease-modifying pharmaceutical product candidates for the treatment of pain and inflammation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under the terms of the Merger Agreement, we issued shares of our common stock to Private Adynxx&#8217;s stockholders at an exchange rate of 0.0359 shares of common stock in exchange for each share of Private Adynxx common stock outstanding immediately prior to the Merger (which exchange rate reflects the Merger Stock Split). The exchange rate was determined pursuant to the terms of the Merger Agreement. We also assumed all of the stock options outstanding under the Private Adynxx Plan, with such stock options representing the right to purchase a number of shares of our common stock equal to 0.0359 multiplied by the number of shares of Private Adynxx common stock previously represented by such options under the Private Adynxx Plan. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Immediately after the Merger, the former Private Adynxx stockholders, warrant holders and option holders owned approximately 86% of the fully-diluted common stock of the combined company, with our stockholders and option holders immediately prior to the Merger, whose shares of our common stock remain outstanding after the Merger, owning approximately 14% of the fully-diluted common stock of the combined company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Distribution of Cash </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On April&#160;11, 2019, Alliqua announced that its board of directors has (i)&#160;declared the Special Dividend of&#8201; $1.05 for each share of common stock outstanding as of the Record Date, for an aggregate of $5,245,000, and (ii) set the Record Date as the record date for determining stockholders entitled to receive shares of AquaMed in connection with the Spin-off Transaction. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The payment of the Special Dividend was subject to the consummation of the Merger. In May&#160;2019, we made a one-time special cash distribution to the pre-Merger holders of shares of Alliqua BioMedical, Inc. in the amount of&#8201; $6.30 per share, post-split. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">140</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to the Unaudited Pro Forma Condensed Combined Financial Information<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;">AquaMed Spin-Off </div>
        <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">AquaMed is engaged in the custom hydrogel manufacturing business. In June 2019, we effectuated the spin-off of AquaMed into a separate, stand-alone company upon consummation of the following steps:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Pursuant to an Asset Contribution and Separation Agreement entered into by and between us and AquaMed, or the Separation Agreement, we transfered certain assets and liabilities utilized primarily in connection with Alliqua&#8217;s custom hydrogels contract manufacturing business to AquaMed;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">AquaMed issued shares of its common stock to us in consideration of the contribution of assets pursuant to the Separation Agreement; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">We distributed to the pre-Merger holders of shares of Alliqua as of April&#160;22, 2019 all of the issued and outstanding shares of common stock, par value $0.001 per share, of AquaMed by way of a pro rata dividend.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:10.98pt; width:456pt; line-height:12pt;">The pro&#160;forma adjustments described in Note 2 were based on available information and certain assumptions made by management and may be revised as additional information becomes available. The historical financial information has been adjusted in the unaudited pro&#160;forma condensed combined financial information to give effect to events that are (1)&#160;directly attributable to the merger transaction, (2)&#160;factually supportable, and (3)&#160;with respect to the statement of operations, expected to have a continuing impact on the combined results. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">2.<br ></div>
        <div style=" margin-top:15.99pt; margin-bottom:0pt; line-height:11pt; text-align:left; margin-left:20pt;font-weight:bold;">Pro Forma Adjustments </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">The accompanying unaudited pro&#160;forma condensed combined statement of operations has been prepared as if the acquisition was completed on January&#160;1, 2018 in each of the periods presented. </div>
        <div style="text-indent:20pt; margin-top:10.98pt; width:456pt; line-height:12pt;">The calculation of the net loss per share in the unaudited pro&#160;forma condensed combined statement of operations assume the issuance of common shares to Alliqua stockholders in the Merger had occurred on January&#160;1, 2018.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">141</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to the Unaudited Pro Forma Condensed Combined Financial Information<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The unaudited pro&#160;forma condensed combined statements of operations reflect the following pro&#160;forma adjustments: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(n)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To reflect the impact of the Spin-off Transaction whereby Alliqua is expected to spin-off its existing contract manufacturing operations prior to the Merger. After this Spin-off Transaction, Alliqua will no longer have any operating assets and liabilities and no operating activities. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(o)<br ></div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To eliminate the changes in fair value of warrant liability. In connection with the Merger, the outstanding warrants held by Adynxx shareholders were exchanged for warrants that are exercisable into shares of common stock and qualify for equity classification. As such, mark-to-market adjustments are no longer applicable. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(p)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To eliminate the impact of acquisition costs incurred by Alliqua prior and up-to the consummation of the Merger. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(q)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To eliminate interest expense and changes in the fair value of the derivative liability as a result of the conversion of the associated 2018 Notes as described more fully in item (g)&#160;above. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(r)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To eliminate the impact of the beneficial conversion feature of&#8201; $2.1&#160;million that was recognized as interest expense by Private Adynxx. In accordance with ASC 470-20-25-6, the contingent beneficial conversion feature is not recognized in earnings until the contingency is resolved. Upon the date of the Merger (occurrence of the contingency), the full amount of the beneficial conversion feature of&#8201; $2.1&#160;million was recognized as interest expense in the condensed consolidated statement of operations for the six months ended June&#160;30, 2019. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(s)<br ></div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To compute the impacts of the Merger on the weighted average shares outstanding, computed as the sum of&#8201; (1)&#160;the weighted average shares held by Adynxx shareholders prior to the Merger, adjusted for an estimated exchange ratio on January&#160;1, 2018 of 0.0364 and (2)&#160;the weighted average shares outstanding held by Alliqua shareholders derived from the Alliqua Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2018, adjusted for the 1-for-6 Merger Stock Split effected at the time of the Merger. The estimated exchange ratio will vary from the actual exchange ratio established on the closing date of the Merger due to difference in shares outstanding at January&#160;1, 2018 and May&#160;3, 2019. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(t)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">Because the pro&#160;forma combined statement of operations yields a net loss, pro&#160;forma weighted average shares outstanding, adjusted for the Merger Stock Split, excludes the impacts of 101,000 warrants outstanding, 3,266,269 options outstanding and 3,333 non-vested restricted stock at December&#160;31, 2018 and 50,774 warrants outstanding and 747,880 options outstanding at June&#160;30, 2019, as the effects of such dilutive securities are anti-dilutive.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(u)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To adjust the weighted average shares outstanding as if the Merger occurred on January&#160;1, 2018. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">142</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a><a name="tIF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Years Ended December&#160;31, 2017 and 2018 <br >and Six Months Ended June&#160;30, 2018 and 2019 (Unaudited) </div>
        <table style="width:456pt;height:293.5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:414pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 3.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Page </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.25pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">Audited Consolidated Financial Statements for the Years Ended December 31, 2017 and 2018</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tfRIRPAF">Report of Independent Registered Public Accounting Firm </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfRIRPAF">F-2</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">Financial Statements:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfBS">Balance Sheets </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfBS">F-3</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfSO">Statements of Operations </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfSO">F-4</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfSRCPSSD">Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfSRCPSSD">F-5</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfSCF">Statements of Cash Flows </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfSCF">F-6</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfNFS">Notes to Financial Statements </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfNFS">F-7</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.167pt 0pt 1.833pt 0pt; width:414pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Unaudited Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2018 and 2019</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">Condensed Consolidated Financial Statements:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfuBS">Condensed Consolidated Balance Sheets </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfuBS">F-27</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfuSO">Condensed Consolidated Statements of Operations </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfuSO">F-28</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.167pt 0pt 1.833pt 0pt; width:414pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <a href="#tfuSRC">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.167pt 0pt 1.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.167pt 0pt 1.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfuSRC">F-29</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfuSCF">Condensed Consolidated Statements of Cash Flows </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfuSCF">F-30</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:4.5pt 0pt 2.5pt 0pt; width:414pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tfuNFS">Notes to Condensed Consolidated Financial Statements </a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4.5pt 0pt 2.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <a href="#tfuNFS">F-31</a>
            </td>
            <td style="padding:0pt;padding-left:5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="width:456pt; line-height:12pt;"></div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfRIRPAF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">Stockholders and Board of Directors <br >Adynxx, Inc. <br >San Francisco, California </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Opinion on the Financial Statements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have audited the accompanying balance sheets of Adynxx, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2017 and 2018, the related statements of operations, redeemable convertible preferred stock and stockholders&#8217; deficit, and cash flows for the&#160;years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2017 and 2018, and the results of its operations and its cash flows for the&#160;years then ended, in conformity with accounting principles generally accepted in the United States of America. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Going Concern Uncertainty </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company does not have a commercial product that can generate cash and accordingly will need to raise additional capital to fund its operations. These factors, among others, raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Basis for Opinion </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">/s/ BDO USA, LLP </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">We have served as the Company&#8217;s auditor since 2012. </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">San Jose, California <br >June&#160;7, 2019 </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfBS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:72pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Balance Sheets <br >(In thousands, except share and per share data) </div>
        <table style="width:456pt;height:489.5pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:363.53pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:13.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Assets:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Current assets</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:10pt;">Cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,301</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,887</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:10pt;">Restricted cash </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 1.75pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:10pt;">Prepaid expenses and other current assets </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">34</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:20pt;">Total current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,335</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,952</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="white-space:nowrap;">Property and equipment, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="white-space:nowrap;">Restricted cash </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 1.75pt 0pt; width:363.53pt;text-align:left;">
              <div style="white-space:nowrap;">Other assets </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:20pt;">Total assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">4,421</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,980</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:8.25pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Current liabilities</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:10pt;">Accounts payable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">491</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:10pt;">Accrued liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,158</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">857</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:10pt;">Operating lease liability </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:10pt;">Convertible promissory notes&#8201;&#8211;&#8201;related party </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 1.75pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:10pt;">Current portion of term loan, net of discount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,711</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">3,812</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:20pt;">Total current Liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,572</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,660</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="white-space:nowrap;">Term loan, net of current portion and discount </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,951</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="white-space:nowrap;">Warrant liability </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Commitments and contingencies (Note 6)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Redeemable convertible preferred stock:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:363.53pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Series&#160;A redeemable convertible preferred stock, $0.001 par value; 57,002,183 shares authorized; 56,672,658 shares issued and outstanding as of December&#160;31, 2017 and 2018 (liquidation value of&#8201; $12,898,697 as of December&#160;31, 2017 and 2018) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12,814</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12,814</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:363.53pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Series&#160;B redeemable convertible preferred stock, $0.001 par value; 51,069,262 shares authorized; 51,069,262 shares issued and outstanding as of December&#160;31, 2017 and 2018 (liquidation value of&#8201; $16,000,000 as of December&#160;31, 2017 and 2018) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">15,897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">15,897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">Stockholders&#8217; deficit:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:363.53pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Common stock, $0.001 par value; 148,000,000 shares authorized; 19,548,969 shares issued and outstanding as of December&#160;31, 2017 and 2018 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:10pt;">Additional paid-in capital </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">419</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">728</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 1.75pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:10pt;">Accumulated deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(31,294<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(37,279<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:20pt;">Total stockholders&#8217; deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(30,855<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(36,531<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:363.53pt;text-align:left;">
              <div style="margin-left:30pt;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; deficit </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">4,421</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,980</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:10pt;">The accompanying notes are an integral part of these financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">F-3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfSO">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:387.5pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Statements of Operations <br >(In thousands) </div>
        <table style="width:456pt;height:167.5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:344pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">Years Ended <br >December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:15.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">Operating expenses</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">8,722</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,137</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">General and administrative </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,341</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,982</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Total operating expenses, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">11,063</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">5,119</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,063<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,119<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Interest expense, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(515<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(992<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Other income (expense), net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">126</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,561<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,985<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;">The accompanying notes are an integral part of these financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfSRCPSSD">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:18pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit <br >(In thousands, except share data) </div>
      </div>
      <div style="margin-top:18pt;margin-bottom:18pt;margin-left:27.5pt;width:541pt;">
        <table style="width:541pt;height:142pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
          <tr style="line-height:8pt;height:25.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:158.28pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:8pt; padding-bottom:0pt;">For the periods ended: </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Series&#160;A Redeemable <br >Convertible <br >Preferred Stock </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Series&#160;B Redeemable <br >Convertible <br >Preferred Stock </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Common Stock </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">Additional <br >Paid-in <br >Capital </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">Accumulated <br >Deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">Total <br >Stockholders&#8217; <br >Deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:7pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:158.28pt;text-align:left;">
              <div style="white-space:nowrap;">Balance, December&#160;31, 2016 </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">56,321,165</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">12,734</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">51,069,262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">15,897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">19,548,969</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">118</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(19,733<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(19,595<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:158.28pt;text-align:left;">
              <div style="white-space:nowrap;">Exercise of warrants </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">351,493</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">80</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:158.28pt;text-align:left;">
              <div style="white-space:nowrap;">Stock-based compensation expense </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">301</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">301</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:158.28pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(11,561<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(11,561<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:158.28pt;text-align:left;">
              <div style="white-space:nowrap;">Balance, December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">56,672,658</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">12,814</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">51,069,262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">15,897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">19,548,969</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">419</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(31,294<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(30,855<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:158.28pt;text-align:left;">
              <div style="white-space:nowrap;">Stock-based compensation expense </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">309</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">309</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:158.28pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(5,985<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(5,985<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:158.28pt;text-align:left;">
              <div style="white-space:nowrap;">Balance, December&#160;31, 2018 </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">56,672,658</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">12,814</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">51,069,262</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">15,897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">19,548,969</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:6pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9pt; text-align:right; white-space:nowrap;">728</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(37,279<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(36,531<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:18pt;margin-bottom:392pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-size:10pt;">&nbsp;&nbsp;&nbsp;</div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:10pt;">The accompanying notes are an integral part of these financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">F-5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfSCF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:137.5pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Statements of Cash Flows <br >(In thousands) </div>
        <table style="width:456pt;height:424pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:344pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">Years Ended <br >December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:13.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">Cash flows from operating activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,561<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,985<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;">
              <div style="margin-left:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Depreciation expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Stock-based compensation expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">301</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">309</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Changes in fair value of warrant liability </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">98</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Accretion of final charge upon maturity of Oxford Term Loan A and B </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">106</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">224</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:344pt;white-space:normal;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">Amortization of issuance cost and discounts for term loans and convertible notes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">54</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">40</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Non-cash interest expense on convertible promissory notes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">126</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Changes in operating assets and liabilities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Prepaid expenses and other current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">329</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">23</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Other assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Accounts payable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">601</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(212<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Accrued liabilities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(650<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:30pt;">Net Cash Used in Operating Activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,183<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,019<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">Cash flows from investing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Purchases of property and equipment </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Net cash used in investing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">Cash flows from financing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Payments on term loan </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(139<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(890<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Proceeds from exercise of warrants </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">80</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Proceeds from issuance of convertible promissory notes&#8201;&#8211;&#8201;related party </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">4,500</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:20pt;">Net cash provided (used) by financing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(59<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">3,610</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Net decrease in cash and cash equivalents and restricted cash </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,245<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,414<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 1.75pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Cash and cash equivalents and restricted cash at beginning of year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">14,601</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">4,356</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Cash and cash equivalents and restricted cash at end of year </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">4,356</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,942</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">Other supplemental disclosure:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:3pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Cash paid for interest </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">355</td>
            <td style="padding:0pt;padding-left:3.38pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.75pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">376</td>
            <td style="padding:0pt;padding-left:8.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:10pt;">The accompanying notes are an integral part of these financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">F-6</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfNFS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 1.&nbsp;&nbsp;&nbsp;Organization and Basis of Presentation </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The Company </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Adynxx, Inc. (the &#8220;Company&#8221;) was incorporated on October&#160;24, 2007, in the state of Delaware. The Company is a clinical-stage pharmaceutical entity that is developing a technology platform to address pain at its molecular roots. The Company is primarily engaged in developing initial product technology, recruiting personnel, and raising capital. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Basis of Presentation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying financial statements have been prepared using accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Liquidity </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As of December&#160;31, 2018, the Company had $1.9 million in cash and cash equivalents, had Oxford term loans, or Term Loans, including accrued interest outstanding of&#8201;$4.2 million, and convertible promissory notes, or Notes, including accrued interest, outstanding to investors of&#8201;$4.6 million. From inception through December&#160;31, 2018 the Company had an accumulated deficit of approximately $37.2 million. The Company expects to incur substantial losses in future periods. The Company is subject to risks common to companies in the clinical stage, including, but not limited to, development of new products, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product development plans. The Company has a limited operating history and has yet to generate any revenues from customers. There is no guarantee that profitable operations, if ever achieved, could be sustained on a continuing basis. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company plans to finance its operations and capital funding needs through equity and/or debt financing. However, there can be no assurance that additional funding will be available to the Company on acceptable terms on a timely basis, if at all, or that the Company will generate sufficient cash from operations to adequately fund operating needs or ultimately achieve profitability. The conditions above, among others, raise substantial doubt about the ability of the Company to continue as a going concern within one year after the date of the issuance of the financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying financial statements do not include any adjustments that might result from the outcome of these uncertainties. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 2.&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Use of Estimates </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Actual results could differ from those estimates and such differences could be material to the Company&#8217;s financial position and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Significant estimates and assumptions include the valuation of equity instruments and equity-linked instruments, including the valuation of the Company&#8217;s common stock and the valuation of the Company&#8217;s common stock options for purposes of accounting for stock-based compensation, and accruals for clinical trials and the valuation allowances on deferred tax assets.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-7</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk and Other Risks and Uncertainties </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation insured limits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company&#8217;s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company&#8217;s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support its growth. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s postoperative pain reduction product candidate, brivoligide, is an oligonucleotide. The Company currently uses Avecia as a single supplier for the brivoligide drug substance. There are currently a limited number of oligonucleotide manufacturers with commercial scale capabilities globally. While the Company intends to develop secondary sources for manufacturing of its drug candidates in the future, there can be no assurance that it will be able to do so on commercially reasonable terms, or at all. Any interruption in the supply of this key material could significantly delay the research and development process or increase the expenses for development and commercialization of the Company&#8217;s product candidates. The quality of materials can be critical to the performance of a drug delivery technology. Therefore, the lack of a reliable source that provides a consistent supply of high quality materials would harm the Company. At December&#160;31, 2018, this vendor&#8217;s activity was not material to total accounts payable. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At December&#160;31, 2017, two vendors represented 56% and 31%, of total accounts payable. The vendor that represented 56% of the Company&#8217;s accounts payable, supported manufacturing activities and the other vendor was associated with clinical study activities. At December&#160;31, 2018, three vendors represented 52%, 26% and 15% of total accounts payable. Two of these vendors supported general and administrative activities, primarily associated with the Merger and next round of equity financing, which accounted for 67% of the total accounts payable. The remaining vendor supported clinical study activities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Clinical Trial Accruals </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s clinical trial accruals are based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical trials on the Company&#8217;s behalf. The Company accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, the Company modifies the estimates of accrued expenses accordingly. To date, the Company has had no significant adjustments to accrued clinical trial expenses. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In March&#160;2018, the Company closed its contracts with Premier Research International LLC and CRF Health, Inc. (&#8220;Contract Research Organizations or CROs&#8221;) upon completion of a Phase&#160;2 clinical trial in March&#160;2018. For the&#160;years ended December&#160;31, 2017 and 2018, the Company incurred $6.2 million and $95,000, respectively, of expenses in connection with this clinical study. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In November&#160;2018, the Company entered into agreements with PRA Health, Inc. and CRF Health, Inc. (&#8220;Contract Research Organizations or CROs&#8221;) pursuant to which the CROs agreed to assist the Company with the conduct of a Phase&#160;2 clinical trial. To support additional clinical trial activities the Company also entered into agreements with Premier Research International LLC for biostatistical services, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-8</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">ICON Central Laboratories for laboratory services and Almac Clinical Services for storage and distribution services. In connection with this clinical study, the Company incurred expenses of&#8201; $0 and $185,000 for the&#160;years ended December&#160;31, 2017 and 2018, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company considers all highly liquid investments purchased with a maturity of three&#160;months or less on the date of acquisition to be cash and cash equivalents. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Property and Equipment, Net </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line method over the estimated useful lives of the assets, generally three to five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. As of December&#160;31, 2017 and 2018, the Company had not experienced any impairment losses on its long-lived assets. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Restricted Cash </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December 31, 2017 and 2018, the Company had $55,000 restricted and held by a bank as collateral for a letter of credit provided to the Company&#8217;s facility landlord.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Stock-Based Compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company uses the Black-Scholes option-pricing model (the &#8220;Black-Scholes model&#8221;) as the method for determining the estimated fair value of stock options. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected Term&#8201;&#8212; </font>The expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected Volatility&#8201;&#8212; </font>Expected volatility is estimated using comparable public companies&#8217; volatility for similar terms. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected Dividend&#8201;&#8212; </font>The Black-Scholes model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Risk-Free Interest Rate&#8201;&#8212; </font>The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-9</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Research and Development </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, preclinical studies, clinical studies performed by Contract Research Organizations (or &#8220;CROs&#8221;), materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development costs, including clinical study costs, to expense when incurred. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Collaboration Agreement </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2018, the Company entered into a collaboration agreement with twoXAR, an artificial intelligence-driven drug discovery company, in order to identify potential product candidates for the treatment of endometriosis. Through December&#160;31, 2018, the Company was not obligated to make any payments under the terms of the collaboration agreement. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Grant Reimbursements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2018, the Company received a Notice of Award from the National Institute on Drug Abuse (&#8220;NIDA&#8221;), part of the National Institutes of Health (&#8220;NIH&#8221;), to support the clinical development of its lead product candidate, brivoligide. NIH grants provide funds for certain types of expenditures in connection with research and development activities over a contractually defined period. The maximum funding expected to be available under this grant for qualified expenditures over the two year period through December&#160;2020 is&#8201;approximately $5.7&#160;million. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">As of December&#160;31, 2018, the Company had not incurred qualified expenses. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Income Taxes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company&#8217;s tax return. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Preferred Stock Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Freestanding warrants to acquire shares of convertible preferred stock are classified as liabilities on the accompanying balance sheets. These warrants are subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. The Company will continue to adjust the carrying values of freestanding warrants classified as liabilities for changes in fair value until the earlier of the exercise or expiration of the warrants or the completion of a liquidation event, including the completion of an initial public offering. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-10</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Debt Modifications and Extinguishments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">When the Company modifies debt, it does so in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 470-50, <font style="font-style:italic;">Debt: Modifications and Extinguishments</font>, which requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#8220;substantial modifications&#8221;. A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, the Company determined that the October&#160;2018 modification of the March&#160;2018 and September&#160;2018 Notes, to add an additional conversion option in the event of a reverse merger, was considered to be a &#8220;substantial modification&#8221;. As a result, it treated this modification as an &#8216;extinguishment&#8217; of those debts and recognized $11,000 of net gain from this debt extinguishment in other income. All other changes to debt provisions were not considered substantial and were treated as debt modifications. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Derivative Instruments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASC 815-15, <font style="font-style:italic;">Derivatives and Hedging: Embedded Derivatives</font>, generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a)&#160;the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b)&#160;the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)&#160;a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirement of ASC 815. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company issued certain Notes in March&#160;2018, September&#160;2018, and December&#160;2018, which contained various embedded derivative features. In particular, these Notes contained the following features: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">A share settled redemption in a qualified preferred stock financing; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">The right to an accelerated cash repayment in the event of a change in control. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These embedded features were not considered clearly and closely related to the debt host, therefore, they were bifurcated and accounted for separately from the debt host as a derivative liability. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in the statement of operations at each period end while such instruments are outstanding. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In October&#160;2018, the Company modified the March&#160;2018 and September&#160;2018 Notes to add an additional conversion feature. The Company determined this was a <font style="font-style:italic;">&#8220;substantial modification&#8221; </font>as defined in ASC 470-50 <font style="font-style:italic;">&#8216;Debt: Modifications and Extinguishments&#8217;</font>. As a result, these Notes were accounted for as an &#8216;extinguishment&#8217; of the debt and related derivative liability. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2018, the Company determined that there was no fair value associated with the embedded derivatives that remained with the modified March&#160;2018, the modified September&#160;2018 and December&#160;2018 Notes. See <font style="font-style:italic;">&#8216;Note 5&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217; </font>for further discussion of the Notes and the bifurcated derivative liability. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASC 820-10, <font style="font-style:italic;">Fair Value Measurement</font>, provides a framework for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. The standard defines fair value as an exit price, representing the amount that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. The standard also establishes a fair value hierarchy, which prioritizes the inputs used in measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Level&#160;1&#8201;&#8212; </font>Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-11</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Level&#160;2</font>&#8201;&#8212; Inputs other than quoted prices included within Level&#160;1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Level&#160;3</font>&#8201;&#8212; Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following tables present the Company&#8217;s fair value hierarchy for all of its financial instruments measured at fair value on a recurring basis as of December&#160;31, 2017 and December&#160;31, 2018 (in thousands): </div>
        <table style="width:456pt;height:63.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:48pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;1 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:48pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;2 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:48pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;3 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:54pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:210pt;">Financial liabilities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:210pt;text-align:left;">
              <div style="margin-left:10pt;">Warrant liability </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:210pt;text-align:left;">
              <div style="margin-left:20pt;">Total financial liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:63.5pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, 2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:48pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;1 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:48pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;2 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:48pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;3 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:54pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:210pt;">Financial liabilities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:210pt;text-align:left;">
              <div style="margin-left:10pt;">Warrant liability </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:210pt;text-align:left;">
              <div style="margin-left:20pt;">Total financial liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.39pt; width:456pt; line-height:12pt;">The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the Company&#8217;s term loan is based on the borrowing rate currently available to the Company for borrowings with similar terms and maturity and approximates its carrying value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Derivative liability instruments are considered Level&#160;3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level&#160;3 liability instruments consist of the preferred stock warrant liability and derivative liability, for both of which there is no observable market data for the determination of fair value and requires significant management judgment and estimation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The fair value of the warrant liability was determined using the Black-Scholes model (see <font style="font-style:italic;">&#8216;Note 8&#8201;&#8212; Warrants&#8217; </font>for a further discussion of the preferred stock warrants). The change in fair value of the preferred stock warrant liability is summarized below (in thousands): </div>
        <table style="width:456pt;height:98.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">Years Ended <br >December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:338.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:338.5pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value, beginning of period </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">54</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:338.5pt;text-align:left;">
              <div style="white-space:nowrap;">Preferred stock warrants &#8211; exercised </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:338.5pt;text-align:left;">
              <div style="white-space:nowrap;">Change in fair value of preferred stock warrants </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">98</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:338.5pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value at end of period </div>
            </td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:17.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:16.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.39pt; width:456pt; line-height:12pt;">The fair value of the embedded derivative liability related to the Company&#8217;s Notes was determined using a bond plus option model. As of December&#160;31, 2018, the Company determined that there was no fair value remaining for the embedded derivatives associated with the modified March&#160;2018, modified September&#160;2018 and December&#160;2018 Notes. See <font style="font-style:italic;">&#8216;Note 5&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217;</font> for further discussion on the derivative liability activity. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-12</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The change in fair value of the derivative liability relating to the Notes is summarized below (in thousands): </div>
        <table style="width:456pt;height:124.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">Years Ended <br >December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:337.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value, beginning of period </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Embedded derivative liability from the issuance of Notes </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">864</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Change in value of embedded derivatives </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(211<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.667pt 0pt 1.333pt 0pt; width:337.5pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Termination of the embedded derivative liability due to the extinguishment of the related Notes </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.667pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.667pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.667pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.667pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(653<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value at end of period </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-weight:bold;">Recently Adopted Accounting Pronouncements </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Restricted Cash </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In November&#160;2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows: Restricted Cash. This ASU requires changes in restricted cash during the period to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. If cash, cash equivalents and restricted cash are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the total in the statement of cash flows to the related captions in the balance sheet. This guidance is effective for fiscal periods beginning after December&#160;15, 2017 and interim periods within that fiscal year, with early adoption permitted. The amendments in this ASU should be applied retrospectively to all periods presented. The Company adopted the guidance on a retrospective basis on January&#160;1, 2018 and the beginning and ending of cash and cash equivalents for all periods presented in our statements of cash flows include restricted cash. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Non-employee Share-Based Payment Accounting </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2018, FASB issued ASU No. 2018-07, &#8220;Compensation&#8201;&#8212;&#8201;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&#8221; (&#8220;ASU 2018-07&#8221;). This new guidance changes the accounting for non-employee share-based payments to align with the accounting for employee stock compensation. The Company early adopted the guidance as of January&#160;1, 2018 and the impact to its financial statements was not material. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Recent Accounting Pronouncements Not Yet Effective </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Lease Accounting</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02. This standard introduces the new leases standard that applies a right-of-use (&#8220;ROU&#8221;) model and requires a lessee to record, for all leases with a lease term of more than 12 months, an asset representing its right to use the underlying asset and a liability to make lease payments. For leases with a term of 12 months or less, a practical expedient is available whereby a lessee may elect, by class of underlying asset, not to recognize an ROU asset or lease liability. At inception, lessees must classify all leases as either finance or operating based on five criteria. Balance sheet recognition of finance and operating leases is similar, but the pattern of expense recognition in the income statement, as well as the effect on the statement of cash flows, differs depending on the lease classification. This ASU is effective for public entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. The Company is currently assessing whether these amendments will have a material effect on its financial statements. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-13</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">In August&#160;2018, the FASB issued No. ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2019, including interim periods within that fiscal year, with early adoption permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 3.&nbsp;&nbsp;&nbsp;Property and Equipment, Net </div>
        <div style="margin-left:20pt; margin-top:5.41pt; width:436pt; line-height:12pt;">Property and equipment, net, consist of the following (in thousands): </div>
        <table style="width:456pt;height:132pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Furniture and fixtures </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Office equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Computer equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Laboratory equipment </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="margin-left:10pt;">Total property and equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">51</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Less accumulated depreciation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(44<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(41<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:330pt;text-align:left;">
              <div style="margin-left:10pt;">Property and equipment, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:9.41pt; width:456pt; line-height:12pt;">Depreciation expense for the&#160;years ended December&#160;31, 2017 and 2018 was $10,000 and $8,000, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 4.&nbsp;&nbsp;&nbsp;Accrued Liabilities </div>
        <div style="margin-left:20pt; margin-top:5.41pt; width:436pt; line-height:12pt;">Accrued liabilities consist of the following (in thousands): </div>
        <table style="width:456pt;height:103.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Payroll and related expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">273</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">241</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Accrued term loan final payment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">197</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">421</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Accrued clinical trial expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">654</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Professional fees and other costs </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">34</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">195</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:330pt;text-align:left;">
              <div style="margin-left:10pt;">Total accrued liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,158</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">857</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-weight:bold;">Note 5.&nbsp;&nbsp;&nbsp;Term Loans and Convertible Promissory Notes </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Term Loans </div>
        <div style="text-indent:20pt; margin-top:5.41pt; width:456pt; line-height:12pt;">On November&#160;24, 2015, the Company entered into a loan and security agreement (&#8220;Loan Agreement&#8221;) with Oxford Finance, LLC (&#8220;Oxford&#8221;), pursuant to which Oxford agreed to lend the Company up to $10.0&#160;million, issuable in three tranches of&#8201; $3.0&#160;million (the &#8220;Term Loan A&#8221;), $2.0&#160;million (the &#8220;Term Loan&#160;B&#8221;) and $5.0&#160;million (the &#8220;Term Loan C&#8221;). Term Loan A, Term Loan B and Term Loan C will collectively be referred to as Term Loans. On November&#160;24, 2015, the Company received $3.0&#160;million in proceeds from Term Loan A and on January&#160;29, 2016, the Company received $2.0&#160;million in proceeds from Term Loan B. Warrants were issued in connection with Term Loan A and Term Loan B (See <font style="font-style:italic;">Note 8&#8201;&#8212; Warrants</font>). Under the terms of the Loan Agreement, the Company may, at its sole discretion, borrow $5.0&#160;million under the Term Loan C following the achievement of a defined milestone event until the earlier of 30&#160;days thereafter or March&#160;31, 2016. The Company did not draw on Term Loan C at March&#160;31, 2016 and the availability of the $5.0&#160;million under Term Loan C expired. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-14</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">All outstanding Term Loans will mature on November&#160;1, 2019 (the &#8220;Maturity Date&#8221;) and the Company will have interest only payments through November&#160;1, 2016, followed by 36&#160;months of principal and interest payments. The term loans will bear interest at a floating per annum rate equal to (a)&#160;7.06% plus (ii) the greater of&#8201; (a)&#160;the 30 day U.S. Dollar LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (b)&#160;0.19%. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has the option to prepay all, but not less than all, of the borrowed amounts, provided that the Company will be obligated to pay a prepayment fee equal to (i)&#160;3% of the outstanding principal balance of the applicable Term Loan if prepayment is made prior to the first anniversary of the applicable funding date of the Term Loan, provided, however, the prepayment fee will be reduced to 1% if the Company is acquired within six&#160;months from the Term Loan closing date, or (ii) 2% of the outstanding principal balance of the applicable Term Loan if prepayment is made prior to the second anniversary of the applicable funding date of the Term Loan, or (iii) 1% of the applicable Term Loan prepaid thereafter and prior to the Maturity Date. The Company will be required to make a final payment of 4.25% of the funded amount, payable on the earlier of&#8201; (i)&#160;the Maturity Date or (ii) the prepayment of the Term Loan. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company may use the proceeds from the Term Loans solely for working capital and to fund its general business requirements. The Company&#8217;s obligations under the Loan Agreement are secured by a perfected first priority lien in all of its assets with a negative pledge on owned intellectual property. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January&#160;2017, the Company and Oxford Finance agreed to amend the Loan Agreement. After the Company made principal payments on December&#160;1, 2016 and January&#160;1, 2017, Oxford agreed to an additional 12&#160;months of interest-only payments followed by 23&#160;months of amortization. The amendment fee amounted to $100,000. The amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In March&#160;2018, the Company and Oxford Finance agreed to amend the Loan Agreement. After the Company made principal payments on January&#160;1, 2018, February&#160;1, 2018 and March&#160;1, 2018 Oxford agreed to another 5&#160;months of interest-only payments followed by 15&#160;months of amortization. The amendment fee amounted to $200,000. This amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">In September&#160;2018, the Company and Oxford Finance agreed to amend the debt agreement. Oxford agreed to 1 month of interest-only payments upon closing a $1.5&#160;million convertible promissory note with current investors followed by 2&#160;months of interest-only payments upon entering into a merger followed by 11&#160;months of repayments. The maturity date of the Term Loans remains unchanged. The amendment fee amounted to $25,000. The amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">In December&#160;2018, the Company and Oxford Finance agreed to amend the debt agreement. Oxford agreed to 1 month of interest-only payments upon closing a $1.5&#160;million convertible promissory note with current investors by December&#160;31, 2018, followed by 10&#160;months of repayments. The maturity date of the loans remains unchanged. The amendment fee amounted to $35,000. The amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">The amendment fees are due and payable upon the earlier of: (i)&#160;the Maturity Date, (ii) the acceleration of any Term Loan, or (iii) the prepayment of a Term Loan, and are being accrued over the expected term of the Term Loan as interest expense. </div>
        <div style="text-indent:20pt; margin-top:5.82pt; width:456pt; line-height:12pt;">Upon the respective dates of the debt modifications, no gain or loss was recorded, and a new effective interest rate was established based on the carrying value of the debt and the revised cash flows. </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">The Term Loan A was recorded at its initial carrying value of&#8201; $3.0&#160;million less debt issuance costs of approximately $141,000, Term Loan B was recorded at its initial carrying value of&#8201; $2.0&#160;million, less debt issuance costs of approximately $3,000. The debt issuance costs are being amortized to interest expense over the life of the Term Loan using the effective interest method. The final payment is accrued over the life of the Term Loan through interest expense using the effective interest method. At December&#160;31, 2017, $2.8&#160;million was outstanding under Term Loan A and $1.9&#160;million was outstanding under Term Loan B. As of December&#160;31, 2018, $2.3&#160;million was outstanding under Term Loan A and $1.5&#160;million was outstanding under Term Loan B.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-15</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">Interest expense recorded for the years ended December&#160;31, 2017 and 2018 was $515,000 and $644,000, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2018, the Company was in compliance with all covenants under the Loan Agreement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Future principal payments for the Term Loans due under the Loan Agreement as of December&#160;31, 2018, were as follows (in thousands): </div>
        <table style="width:416pt;height:40.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">Year Ending, <br >December&#160;31, <br >2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.667pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Total principal payments </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.667pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.667pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,833</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.39pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Promissory Notes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The table below reflects the principal amount of the Notes issued by the Company to current investors (in thousands): </div>
        <table style="width:456pt;height:89.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on March&#160;29, 2019, interest at 8.0% p.a. </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on September&#160;27, 2019, interest at 8.0% p.a. </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on December&#160;21, 2019, interest at 8.0% p.a. </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:330pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:19.59pt; width:456pt; line-height:11pt;font-style:italic;">Conversion rights </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The December&#160;2018 Notes were issued with conversion and repayment rights, which are as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event that the Company issues and sells shares of its preferred stock to the investors with proceeds to the Company of at least $5&#160;million, on or before the maturity date, and prior to the closing of a reverse merger, then the outstanding principal amount of these Notes and any unpaid accrued interest will automatically convert in whole into equity securities sold in the preferred stock financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the such preferred stock financing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(b)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event that the Company issues and sells shares of its common stock to the investors with proceeds to the Company of at least $5&#160;million, on or before the maturity date, and after the closing of a reverse merger, then the outstanding principal amount of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities sold in the common stock financing at a conversion price equal to the cash price paid per share for equity securities by the investors in the common stock financing, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(c)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event of a preferred stock financing after the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) has determined that the Company should not pursue the proposed reverse merger with Alliqua BioMedical, Inc. or that such reverse merger is not viable, then in connection with the preferred stock financing the conversion price shall equal eighty&#160;percent (80%) of the cash price paid per share for the preferred securities by the investors in the preferred stock financing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(d)<br ></div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the Company consummates a change of control while the Notes remain outstanding, the Company shall repay the holders in cash in an amount equal to 200% of the outstanding principal amount of the Notes; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-16</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:-1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(e)<br ></div>
        <div style=" margin-top:-1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event the Company consummates an IPO on or before the maturity date, then the outstanding principal amount of the Notes and any unpaid accrued interest will automatically convert into common stock at a conversion price equal to the per share offering price to the public for common stock in the IPO. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Modified March&#160;2018 and Modified September&#160;2018 Notes were outstanding as of December&#160;31, 2018, and had conversion and repayment rights as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event that the Company issues and sells shares of its preferred stock to the investors on or before the maturity date, in a preferred stock financing, then the outstanding principal amount of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities sold in the qualified financing at a conversion price equal to 80% of the cash price paid per share for equity securities by the investors in the qualified financing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(b)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the Company consummates a change of control while the Notes remain outstanding, the Company shall repay the holders in cash in an amount equal to 200% of the outstanding principal amount of the Notes; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(c)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event the Company consummates an IPO on or before the maturity date, then the outstanding principal amount of the Notes and any unpaid accrued interest will automatically convert into common stock at a conversion price equal to the per share offering price to the public for common stock in the IPO. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(d)<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In October&#160;2018, the Company modified the terms of the March&#160;2018 and September&#160;2018 Notes to add an additional conversion option. The additional conversion option stipulated that if the Company consummates a reverse merger on or before the Maturity Date and prior to a Qualified Financing (as such terms are defined in the Notes Agreement), then the outstanding principal amount of the Notes and any unpaid accrued interest, shall automatically convert in whole without any further action by the Holder into shares of the Company&#8217;s Series&#160;B convertible preferred stock at a conversion price equal to $0.3133 per share immediately prior to the closing of the reverse merger. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In October&#160;2018, the Company determined that the modification of the March&#160;2018 and September&#160;2018 Notes adding the additional conversion right upon a reverse merger was a &#8220;substantial modification&#8221; as outlined in ASC 470-50 <font style="font-style:italic;">&#8216;Debt: Modifications and Extinguishments&#8217; </font>and treated this modification as an extinguishment of the original Notes and recognized an $11,000 gain from debt extinguishment in its statement of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Derivative Liability </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company evaluated its Notes and determined that embedded components relating to conversion and redemption features of those contracts qualified as derivatives, which need to be separately accounted for in accordance with ASC 815. The Notes contained embedded features that are required to be bifurcated as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">On or before the maturity date of the March&#160;2018 and September&#160;2018 notes, the principal and accrued interest of the notes will automatically convert into equity securities issued and sold in the initial closing of the Company&#8217;s next qualified equity financing with gross proceeds of at least $5.0&#160;million, exclusive of the conversion of the notes. The number of shares to be issued to the note holders will be equal to dividing the outstanding principal and any unpaid accrued interest by 80% of the price paid per share of the next equity security sold to investors. The discount in share price to note holders is not considered clearly and closely related to the debt host and results in an embedded derivative that must be bifurcated and accounted for separately from the debt host. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">For all Notes, in the event of a change in control prior to repayment, the outstanding principal and unpaid accrued interest will be repaid in cash, plus a repayment premium equal to 100% of </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-17</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-left:40pt; margin-top:1pt; width:416pt; line-height:12pt;">the outstanding principal at the time of the change in control. Change in control means (i)&#160;a merger, consolidation, or other capital reorganization or business combination transaction of the Company, with or into, another corporation after which the shares of the capital stock represent a minority after the close of the transaction, or (ii) any transaction or series of related transactions to which the Company is a party in which in excess of 50% of the Company&#8217;s voting power is transferred, or (iii) the sale of all or substantially all of the Company&#8217;s assets or the exclusive license of all or substantially all of the Company&#8217;s material intellectual property. The premium to note holders is not considered clearly and closely related to the debt host and results in an embedded derivative that must be bifurcated and accounted for separately from the debt host. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">For the December&#160;2018 Notes, in the event the Company&#8217;s Board of Directors has determined the proposed reverse merger should not be pursued or is not viable, then in connection with the closing of a preferred stock financing with gross proceeds of at least $5.0&#160;million exclusive of the conversion of the notes, the conversion price shall equal 80% of the cash price paid per share for the securities in the preferred stock financing. However, if any of the holder&#8217;s shares of preferred stock of the Company are converted into common stock or any other equity security that is junior to the shares issued in the preferred stock financing, the notes shall not convert into equity securities sold in the preferred stock financing without the holder&#8217;s prior written consent and instead shall remain outstanding. The discount in share price to note holders is not considered clearly and closely related to the debt host and results in an embedded derivative that must be bifurcated and accounted for separately from the debt host. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Accordingly, upon the issuance of the March&#160;2018 Notes, the estimated fair value of the embedded derivative was determined using a bond plus option valuation model and assuming a probability of 30% that a qualified financing would occur and a probability of 15% that a change in control would occur. The Company recorded the estimated fair value of these embedded derivatives as a liability of&#8201; $496,000 with an offsetting amount recorded as debt discount, which offsets the carrying amount of the debt. The debt discount is amortized over the debt&#8217;s expected term of one year. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the issuance of the September&#160;2018 Notes, the estimated fair value of the embedded derivatives was determined using a bond plus option valuation model and assuming a probability of 40% that a qualified financing would occur and a zero probability that a change in control would occur. The Company recorded the estimated fair value of these embedded derivatives as a liability of&#8201; $368,000 with an offsetting amount recorded as debt discount, which offsets the carrying amount of the debt. The debt discount is amortized over the debt expected term of one year. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In October&#160;2018, the Company modified the March&#160;2018 and September&#160;2018 Notes by adding an additional conversion right upon a reverse merger. The Company deemed this modification to be a <font style="font-style:italic;">&#8220;substantial modification&#8221;</font> as defined in ASC 470-50 <font style="font-style:italic;">&#8216;Debt: Modifications and Extinguishments&#8217;</font> and treated it as an extinguishment of the original Notes and the termination of the related derivative liability. The extinguishment of the March&#160;2018 and September&#160;2018 Notes, resulted in a net gain of&#8201; $11,000 being recorded in other income due to the expensing of the unamortized debt discount of&#8201; $641,000 and the release of the then fair value of the derivative liabilities of&#8201; $653,000. As of December&#160;31, 2018, the Company evaluated the fair value of the derivative liability associated with the modified March&#160;2018, modified September&#160;2018 and December&#160;2018 Notes. It determined that the bifurcated derivative liability had no value because the Company assumed a zero probability that a qualified financing would occur if the then planned reverse merger was not consummated and a zero probability that a change in control would occur. As a result, the Company estimated the fair value of the derivative liability to be $0 at December&#160;31, 2018. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For the&#160;years ended December&#160;31, 2017, and 2018, the Company had recorded interest expense for debt discount on these Notes of&#8201; $0 and $223,000, respectively. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-18</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">Note 6.&nbsp;&nbsp;&nbsp;Commitments and Contingencies </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Operating Leases </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company leases office facilities under a non-cancelable operating lease agreement expiring on December&#160;31, 2019. The total undiscounted future non-cancellable lease payments under the Company&#8217;s operating lease as of December&#160;31, 2018 are as follows (in thousands): </div>
        <table style="width:416pt;height:46pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:338pt;">
              <div style="white-space:nowrap;">Year ending December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">Future <br >Commitments </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:338pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.98pt; width:456pt; line-height:12pt;">Rent expense related to the Company&#8217;s operating leases was $225,000 and $232,000 for the&#160;years ended December&#160;31, 2017 and 2018, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Indemnifications </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has agreed to indemnify its directors and officers for certain events or occurrences arising as a result of the officers or directors serving in such capacity. The Company has a directors&#8217; and officers&#8217; liability insurance policy that limits its exposure and enables the Company to recover a portion of any future amounts paid resulting from the indemnification of its officers and directors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. The Company&#8217;s management believes the estimated fair value of these indemnification agreements is minimal and has not recorded a liability for these agreements as of December&#160;31, 2018. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 7.&nbsp;&nbsp;&nbsp;Stockholders&#8217; Deficit </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Redeemable Convertible Preferred Stock </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017 and 2018, the Company had 56,672,658 shares of Series&#160;A convertible preferred stock issued and outstanding, including 3,531,889 shares issued as a result of a conversion of notes to investors and accrued interest to Series&#160;A convertible preferred stock in 2010. As of December&#160;31, 2017 and 2018, the Company had 51,069,262 shares of Series&#160;B convertible preferred stock issued and outstanding, including 6,469,356 shares issued as a result of a conversion of notes to investors and accrued interest to Series&#160;B convertible preferred stock in 2016. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The holders of preferred stock have various rights and preferences including the following: </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Voting Rights&#8201;&#8212; </font>A holder of each share of Series&#160;A and Series&#160;B convertible preferred stock shall have the right to one vote for each share of common stock into which such preferred stock could be converted. Series&#160;A convertible preferred stock holders voting as a separate class are entitled to elect two directors to the Company&#8217;s Board of Directors as long as shares of Series&#160;A convertible preferred stock remain outstanding. Series&#160;B convertible preferred stock holders voting as a separate class are entitled to elect one director to the Company&#8217;s Board of Directors as long as at least 10,000,000 shares of Series&#160;B convertible preferred stock remain outstanding. Common stockholders voting as a separate class are entitled to elect two directors. The holders of preferred and common stock voting together as a single class on an as-if-converted basis are entitled to elect all remaining directors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Dividends&#8201;&#8212; </font>Holders of Series&#160;B convertible preferred stock, in preference to the holders of Series&#160;A preferred and common stock, are entitled to receive noncumulative dividends at the annual rate of&#8201; $0.0251 per share, when, as, and if declared by the Board of Directors. Holders of Series&#160;A convertible preferred </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-19</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">stock are entitled to receive noncumulative dividends at the annual rate of&#8201; $0.0182 per share, when, as, and if declared by the Board of Directors. No dividends on preferred stock have been declared by the Board of Directors during the&#160;years ended December&#160;31, 2017 and 2018. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Liquidation Preference&#8201;&#8212; </font>In the event of any liquidation, dissolution, or winding up of the Company, including a merger, acquisition, or sale of assets, as defined, the holders of Series&#160;B convertible preferred stock are entitled to receive an amount of&#8201; $0.3133 per share (as adjusted for recapitalizations, stock combinations, stock dividends, stock splits, and the like), plus any declared but unpaid dividends prior to and in preference to any distribution to the holders of Series&#160;A preferred or common stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">After distributions have been made to all holders of Series&#160;B convertible preferred stock as described above, the remaining assets of the Company available for distribution to stockholders shall be distributed to all holders of Series&#160;A convertible preferred stock. The holders of Series&#160;A convertible preferred stock are entitled to receive an amount of&#8201; $0.2276 per share (as adjusted for recapitalizations, stock combinations, stock dividends, stock splits, and the like), plus any declared but unpaid dividends prior to and in preference to any distribution to the holders of common stock. The remaining assets of the Company available for distribution to stockholders shall be distributed ratably among the holders of the common stock and preferred stock on an as-if-converted basis. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Conversion Rights&#8201;&#8212; </font>Each share of Series&#160;A and Series&#160;B convertible preferred stock is convertible, at the option of the holder, into shares of common stock on a one for one basis (subject to adjustment for certain events). The preferred stock will also be converted automatically into shares of common stock (1)&#160; immediately prior to an initial public offering with aggregate proceeds of at least $40&#160;million and an offering price of not less than $1.00 per common share or (2)&#160;upon the date specified by written consent of holders of a majority of the outstanding preferred shares on an as-converted basis. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Series&#160;A and Series&#160;B Preferred Stock were classified as temporary equity in the accompanying balance sheets as of the December&#160;31, 2017 and 2018, as shares are subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control. As of December&#160;31, 2017 and 2018, the Series&#160;A and Series&#160;B Preferred Stock were not redeemable. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Common Stock </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s articles of incorporation, as amended, authorize the Company to issue 148,000,000 shares of&#8201; $0.001 par value common stock. As of December&#160;31, 2017 and 2018, the Company had 19,548,969 shares outstanding. Common stockholders are entitled to dividends when and if declared by the Board of Directors and after any Series&#160;B and Series&#160;A convertible preferred shares dividends are fully paid. The holder of each share of common stock is entitled to one vote. At December&#160;31, 2018, no dividends had been declared. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Shares Reserved for Future Issuance </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The Company reserved shares of common stock for future issuances as follows (in thousands): </div>
        <table style="width:456pt;height:103.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Series&#160;A convertible preferred stock </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">56,673</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">56,673</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Series&#160;B convertible preferred stock </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">51,069</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">51,069</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Warrants for Series&#160;A convertible preferred stock </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">330</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">330</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:330pt;text-align:left;">
              <div style="white-space:nowrap;">Common stock options issued and outstanding </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">19,222</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">19,222</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:330pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">127,294</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">127,294</td>
            <td style="padding:0pt;padding-left:10.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-20</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">Note 8.&nbsp;&nbsp;&nbsp;Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with convertible notes agreements with investors issued between January&#160;1, 2009 and July&#160;1, 2010, the Company issued warrants to purchase such number of shares of Series&#160;A convertible preferred stock issued in the next round of equity financing equal to 20% of notes payable principal amounts divided by the price per share of such preferred stock. The warrants are exercisable after closing of each preferred stock financing for five&#160;years and expire seven&#160;years from the issuance date. At the issuance dates, the Company estimated the fair value of issued warrants as minimal due to the uncertainty of the Series&#160;A convertible preferred stock financing. The Company estimated the fair value of outstanding warrants at the date of closing of the Series&#160;A convertible preferred stock financing and used the Black-Scholes model with the following assumptions: expected lives equal to the remaining contractual life in a range of 3.92 to 7&#160;years, risk-free interest rates in a range of 1.46% to 2.66%, expected dividend yield of zero, volatility in the range of 73.6% to 81.5%, and a fair value of Series&#160;A convertible preferred stock of $0.2276 per share. As of December&#160;31, 2017, the outstanding warrants had been exercised. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with the Oxford Loan Agreement signed in November&#160;2015, the Company issued a warrant to purchase 197,715 shares of the Company&#8217;s preferred stock at an exercise price equal to the Series&#160;A preferred stock price of&#8201; $0.2276. The warrant is exercisable after closing and expires ten&#160;years from the issuance date. The Company estimated the fair value of the warrant at closing and used the Black-Scholes model with the following assumptions: expected life equal to the remaining contractual life of 10&#160;years, risk-free interest rate of 2.07%, expected dividend yield of zero, volatility of 68.7%, and a fair value of Series&#160;A convertible preferred stock of&#8201; $0.20 per share. The Company recorded the fair value of the warrant of&#8201; $33,000 as a debt discount to be amortized to interest expense over the life of the Term Loan&#160;A. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January&#160;2016, in connection with the Oxford Loan Agreement signed in November&#160;2015, the Company issued a warrant to purchase 131,810 shares of the Company&#8217;s preferred stock at an exercise price equal to the Series&#160;A preferred stock price of&#8201; $0.2276. The warrant is exercisable after closing and expires ten&#160;years from the issuance date. The Company estimated the fair value of the warrant at closing and used the Black-Scholes model with the following assumptions: expected life equal to the remaining contractual life of 10&#160;years, risk-free interest rate of 2.09%, expected dividend yield of zero, volatility of 68.6%, and a fair value of Series&#160;A convertible preferred stock of&#8201; $0.23 per share. The Company recorded the fair value of the warrant of&#8201; $22,000 as a debt discount to be amortized to interest expense over the life of the Term Loan B. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The change in fair value of the warrants issued in connection with Term Loan A and B at December&#160;31, 2017 and 2018 of&#8201; ($12,000) and $98,000 respectively, were recorded to other expense (income). As of December&#160;31, 2018, the warrants remained outstanding and exercisable. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The above Black-Scholes model assumptions were determined as follows: </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;font-style:italic;">Term<font style="font-style:normal;">&#8201;&#8212; The term represents the remaining contractual term of the warrants. </font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Risk-free interest rate&#8201;&#8212; </font>The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal the remaining term of the warrants. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected</font> <font style="font-style:italic;">volatility</font>&#8201;&#8212; The expected volatility is derived from historical volatilities of several unrelated publicly listed peer companies over a period approximately equal to the remaining term of the warrants because the Company has limited information on the volatility of the preferred stock since there is currently no trading history. When making the selections of the Company&#8217;s industry peer companies to be used in the volatility calculation, the Company considered the size and operational and economic similarities to the Company&#8217;s principal business operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected dividend yield</font>&#8201;&#8212; The expected dividend yield is based on the Company&#8217;s history of not paying dividends. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-21</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The warrants are classified as a liability as they are exercisable into shares that are potentially redeemable. The fair value of the warrant liability is re-measured at each balance sheet date with the change as other income recorded in the statements of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The fair value of the Series&#160;A convertible preferred stock warrants outstanding at December&#160;31, 2017 and 2018 was $42,000 and $140,000 respectively, and the details of the warrants were as follows: </div>
        <table style="width:456pt;height:69pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:237.1pt;text-align:left;">
              <div style="white-space:nowrap;">Issuance Date </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:68.9pt;">
              <div style="white-space:nowrap; text-align:center;">Expiration Date </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Exercise Price </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >Shares <br >(in thousands) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:237.1pt;text-align:left;">
              <div style="white-space:nowrap;">November, 2015 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0.5pt 1pt 0pt; width:68.9pt;">
              <div style="white-space:nowrap; text-align:right;">November, 2025&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.2276</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">198</td>
            <td style="padding:0pt;padding-left:22.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:237.1pt;text-align:left;">
              <div style="white-space:nowrap;">January, 2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0.5pt 2pt 0pt; width:68.9pt;">
              <div style="text-align:right;">January, 2026&#8203;</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">0.2276</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">132</td>
            <td style="padding:0pt;padding-left:22.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:237.1pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.75pt 0pt; width:68.9pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">330</td>
            <td style="padding:0pt;padding-left:22.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.99pt; width:456pt; line-height:12pt;">The fair value of the Series&#160;A convertible preferred stock warrants was determined using the following assumptions: </div>
        <table style="width:456pt;height:89pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:323.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:323.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:45.83pt;">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:62.28pt;">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:323.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:45.83pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:62.28pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:323.89pt;text-align:left;">
              <div style="white-space:nowrap;">Risk-free interest rate </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:45.83pt;">
              <div style="text-align:center;">2.28% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:62.28pt;">
              <div style="text-align:center;">2.56%&#8201;&#8211;&#8201;2.59% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:323.89pt;text-align:left;">
              <div style="white-space:nowrap;">Remaining contractual life (in&#160;years) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:45.83pt;">
              <div style="text-align:center;">7.92&#8201;&#8211;&#8201;8.08 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:62.28pt;">
              <div style="text-align:center;">6.92&#8201;&#8211;&#8201;7.08 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:323.89pt;text-align:left;">
              <div style="white-space:nowrap;">Dividend yield </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:45.83pt;">
              <div style="text-align:center;">&#8212;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:62.28pt;">
              <div style="text-align:center;">&#8212;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:323.89pt;text-align:left;">
              <div style="white-space:nowrap;">Expected volatility </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:45.83pt;">
              <div style="text-align:center;">71.00% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:62.28pt;">
              <div style="text-align:center;">76.84%</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.98pt; width:456pt; line-height:11pt;font-weight:bold;">Note 9.&nbsp;&nbsp;&nbsp;Stock Option Plans </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2010, the Company adopted the 2010 Equity Incentive Plan (the &#8220;Plan&#8221;). The Plan provides for the granting of stock options to employees and consultants of the Company. Options granted under the Plan may be either incentive stock options (&#8220;ISOs&#8221;) or non-qualified stock options (&#8220;NSOs&#8221;). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants. The Company has 19,222,032 shares of common stock reserved for issuance under the Plan as of December&#160;31, 2018. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Options under the Plan may be granted for periods of up to 10&#160;years and at prices no less than 100% of the estimated fair value of the underlying shares of common stock on the date of grant as determined by the Board of Directors provided, however, that the exercise price of an ISO and NSO granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant. The Plan requires that options be exercised no later than 10&#160;years after the grant. Options granted to employees generally vest ratably on a monthly basis over four&#160;years. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-22</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The following table summarizes stock option activity under the Company&#8217;s stock plan and related information (in thousands, except exercise prices and&#160;years): </div>
        <table style="width:456pt;height:156pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:183.48pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.21pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.21pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">Outstanding Options</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:183.48pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Shares <br >Available <br >For Grant </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Options <br >Outstanding </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted- <br >Average <br >Exercise <br >Price <br >Per Share </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted- <br >Average <br >Remaining <br >Contractual <br >Life <br >(in years) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Aggregate <br >Intrinsic <br >Value<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(a)</font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:183.48pt;text-align:left;">
              <div style="white-space:nowrap;">Balance at December&#160;31, 2016 </div>
            </td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;5</td>
            <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,222</td>
            <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.10</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">9.4</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 2.75pt 0pt; width:183.48pt;text-align:left;">
              <div style="white-space:nowrap;">Balance at December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;5</td>
            <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,222</td>
            <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.10</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">8.4</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,639</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 2.75pt 0pt; width:183.48pt;text-align:left;">
              <div style="white-space:nowrap;">Balance at December&#160;31, 2018 </div>
            </td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;5</td>
            <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,222</td>
            <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.10</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.4</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,956</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 2.083pt 0pt; width:183.48pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Vested and expected to vest as of December&#160;31, 2018 </div>
            </td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,222</td>
            <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.10</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.4</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,956</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 2.083pt 0pt; width:183.48pt;text-align:left;">
              <div style="white-space:nowrap;">Exercisable at December&#160;31, 2018 </div>
            </td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">11,146</td>
            <td style="padding:0pt;padding-left:6.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.09</td>
            <td style="padding:0pt;padding-left:5.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.4</td>
            <td style="padding:0pt;padding-left:13.475pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt; width:9pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.333pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,119</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:9.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the Company&#8217;s common stock of&#8201; $0.46 and $0.44 per share as of December&#160;31, 2018 and 2017.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:10.98pt; width:456pt; line-height:12pt;">The Company did not grant any common stock options to employees during the&#160;years ended December&#160;31, 2017 and 2018. Stock-based compensation expense recorded in research and development and general and administrative expenses was $301,000 and $293,000 for the&#160;years ended December&#160;31, 2017 and 2018, respectively. As of December&#160;31, 2018, unrecognized stock-based compensation expense related to employees totaled approximately $531,000, which is expected to be recognized over approximately 2.0&#160;years. </div>
        <div style="margin-top:16.98pt; width:456pt; line-height:11pt;font-style:italic;">Stock Options Granted to Non-Employees </div>
        <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">Stock-based compensation expense recorded in exchange for services related to non-employee options was $0 and $16,000 for the&#160;years ended December&#160;31, 2017 and 2018, respectively. </div>
        <div style="text-indent:20pt; margin-top:10.99pt; width:456pt; line-height:12pt;">As of December&#160;31, 2018, unrecognized stock-based compensation expense related to unvested non-employees stock options was approximately $48,000, which is expected to be recognized over a weighted-average period of nine&#160;months. </div>
        <div style="margin-top:16.98pt; width:456pt; line-height:11pt;font-weight:bold;">Note 10.&nbsp;&nbsp;&nbsp;Income Taxes </div>
        <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">The Company recorded no income tax benefit or expense for the years ended December&#160;31, 2017 and 2018. No tax benefit was recorded through December&#160;31, 2018 because, given the history of operating losses, the Company believes it is more likely than not that the deferred tax asset will not be realized, and a full valuation allowance has been provided. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-23</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table presents significant components of the Company&#8217;s deferred tax assets (in thousands): </div>
        <table style="width:416pt;height:120pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Net operating loss carry forward </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">6,158</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">7,051</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Research and development credits </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,284</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,601</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Accruals and reserves </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">99</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">142</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Fixed assets </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:266pt;text-align:left;">
              <div style="margin-left:10pt;">Total deferred tax asset </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">7,541</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">8,795</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:266pt;text-align:left;">
              <div style="white-space:nowrap;">Valuation allowance </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(7,541<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(8,795<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:266pt;text-align:left;">
              <div style="margin-left:10pt;">Net deferred tax asset </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:17.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:9.41pt; width:456pt; line-height:12pt;">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#8217;s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2017 and 2018. The valuation allowance decreased approximately $964,000 and increased $1.2 million during the&#160;years ended December&#160;31, 2017 and 2018, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On December&#160;22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;). The Tax Act makes broad and complex changes to the U.S. tax code that affect fiscal 2017, including, but not limited to requiring a one-time transition tax on certain un-repatriated earnings of foreign subsidiaries (the &#8220;Transition Tax&#8221;). The Tax Act also establishes new tax laws that will affect 2018 and later&#160;years, including, but not limited to, a reduction of the U.S. federal corporate tax rate from 35% to 21% and a transition of U.S. international taxation from a worldwide tax system to a territorial system. During the year ended December&#160;31, 2017, the Company did not recognize an amount for the one-time transition tax, nor did the Company make any accounting policy elections on the treatment of the other international provisions of tax reform due to the fact the Company does not currently have any foreign subsidiaries. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2017, the Company corrected the balance of Net Operating Losses and Research and Development Credits and the associated Valuation Allowances in connection with the Company&#8217;s determination of nexus in an additional state which was previously not identified correctly. The correction of such error did not have any impact on the Company&#8217;s financial position and results of operations for any period presented or any prior period results. The Company has corrected the gross amount of deferred tax assets and the valuation allowance for 2016 to correct the error. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2018, the Company had federal net operating loss, or NOL, carry forwards of $33.5&#160;million available to reduce future taxable income, if any. The NOL carry forwards prior to January&#160;1, 2018 of&#8201; $28.7&#160;million will begin to expire in 2033. The NOL carry forwards incurred post December&#160;31, 2017 of&#8201; $4.8&#160;million will carry forward indefinitely. As of December&#160;31, 2018, the Company had federal and state research and development credits of&#8201; $1.8&#160;million and $0.7&#160;million, respectively. The federal research and development credits will begin to expire in 2031. The state research and development credit will carry forward indefinitely. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Internal Revenue Code (&#8220;IRC&#8221;) Section&#160;382 and similar California rules place a limitation on the amount of taxable income that can be offset by NOL and credit carry forwards after a change in control. Generally, after a control change, a corporation cannot deduct NOL or credit carry forwards in excess of the Section&#160;382 limitations. Although the Company has not completed an analysis under Section&#160;382 of the Code since the year ended December&#160;31, 2012, it believes that it is unlikely that the utilization of the NOLs and tax credit carry forwards will be substantially limited. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-24</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The tax return&#160;years 2014 through 2018 remain open to examination by the major domestic taxing jurisdictions to which the Company is subject. Net operations losses generated on a tax return basis by the Company for calendar&#160;years 2013 and 2015 to 2018 remain open to examination by the IRS. Net operating losses generated on state returns by the Company for calendar&#160;years 2007 to 2013 and 2015 to 2018 remain open to examination by state authorities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASC 740-10 requires companies to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities. The following table summarizes the activity related to the Company&#8217;s gross unrecognized tax benefits (in thousands): </div>
        <table style="width:416pt;height:83pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">Years Ended <br >December&#160;31, <br >2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Balance at December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">331</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Changes related to prior year positions </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">330</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Increases related to current year positions </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Balance at December&#160;31, 2018 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">703</td>
            <td style="padding:0pt;padding-left:23pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:11.2pt; width:456pt; line-height:12pt;">The Company&#8217;s policy is to record interest related to uncertain tax positions as interest and any penalties as other expense in its statement of operations. As of the date of adoption and through December&#160;31, 2018, the Company did not have any interest and penalties associated with unrecognized tax benefits. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 11.&nbsp;&nbsp;&nbsp;Related-Party Transactions </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In March&#160;2018, September&#160;2018, and December&#160;2018, the Company issued Notes to the Company&#8217;s majority investors totaling $4.5&#160;million as of December&#160;31, 2018. These Notes accrue simple interest on the outstanding principal amount at the rate of 8% per annum. As of December&#160;31, 2018, accrued interest on the Notes was $126,000&#8201;&#8212; for further details see the section above titled <font style="font-style:italic;">&#8216;Note 5&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217;.</font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 12.&nbsp;&nbsp;&nbsp;Employee Benefit Plan </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has established a 401(k) Plan (the &#8220;401(k) Plan&#8221;) that permits participants to make contributions by salary deduction pursuant to Section&#160;401(k) of the IRC. The Company may, at its discretion, make matching contributions to the 401(k) Plan. The Company has made no contributions to the 401(k) Plan since its inception. The Company makes a nonelective 401(k) safe harbor contribution on behalf of each employee equal to 3% of their annual salary. The Company&#8217;s non-elective safe harbor contributions totaled $54,000 and $49,000 for the&#160;years ended December&#160;31, 2017 and 2018, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 13.&nbsp;&nbsp;&nbsp;Subsequent Events </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In January 2019, the Company and Oxford Finance agreed to amend the debt agreement. Oxford agreed to 2 months of interest-only payments followed by 8 months of repayments upon delivery by February 1, 2019 of an executed term sheet between the Company and Domain, the Company&#8217;s majority investor and an affiliate thereof, that would result in aggregate proceeds to the Company of&#8201;$20.0 million. The Company was also required to place $200,000 in a segregated bank account that is subject to a blocked control agreement in favor of Oxford. The funds in the segregated account were to be released upon the earlier of, the consummation of a merger by March 31, 2019 or the consummation of the equity financing. The Company recorded the $200,000 as restricted cash in its balance sheet at March 31, 2019. The maturity date of the loans remained unchanged. The amendment fee amounted to $50,000. The amendment was accounted for as a debt modification. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Beginning in January 2019, the Company amended the 401(k) Plan to discontinue the nonelective safe harbor contribution on behalf of each employee equal to 3% of their annual salary. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-25</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc.</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">In April&#160;2019 and May&#160;2019, the Company&#8217;s primary investor agreed to provide the Company with $2.0&#160;million and $0.5&#160;million in the form of Notes to fund the Company&#8217;s operations. These notes accrue simple interest on the outstanding principal amount at the rate of 8% per annum and mature on April&#160;26, 2020 and May&#160;29, 2020. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In May&#160;2019, the Company and Oxford Finance agreed to a seventh amendment to provide consent to the Merger. This consent amended certain provisions of the term loan to protect Oxford&#8217;s rights under the original term loan agreement. The consent allowed Alliqua to be named as an additional borrower. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;3, 2019 the Company completed its Merger into Alliqua Biomedical Inc. (&#8220;Alliqua&#8221;). Immediately following the Merger, the combined company&#8217;s name was changed from &#8220;Alliqua BioMedical, Inc.&#8221; to &#8220;Adynxx, Inc.&#8221; The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. Under the Exchange Ratio formula in the Merger Agreement, as of immediately following the Merger, but excluding the effect of certain financings (as further described in the Merger Agreement), Adynxx equity holders now own approximately 86% of the aggregate number of shares of the combined company and Alliqua equity holders own approximately 14% of the combined company. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Subject to the terms and conditions of the Merger Agreement (a)&#160;each outstanding share of capital stock of Adynxx, was converted into the right to receive the number of shares of Alliqua&#8217;s common stock equal to the Exchange Ratio formula in the Merger Agreement and (b)&#160;each outstanding Adynxx stock option, whether vested or unvested, and warrant that has not previously been exercised, was assumed by the post merged company and converted into a stock option or warrant, as the case may be, to purchase shares of the post merged Adynxx Company&#8217;s common stock at the Exchange Ratio formula in the Merger Agreement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, prior to the closing of the Merger, the $3.0&#160;million of Notes and $203,000 of cumulative accrued interest, was converted into 10,223,996 shares of Series&#160;B convertible preferred stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has evaluated subsequent events through June&#160;7, 2019, the date the financial statements were issued, for appropriate accounting and financial statement disclosures.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-26</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfuBS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:11pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Condensed Consolidated Balance Sheets <br >(In thousands, except share and per share data) <br >(unaudited) </div>
        <table style="width:456pt;height:539pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">December&#160;31, <br >2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">June&#160;30, <br >2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:350.37pt;">Assets:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;">Current assets</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:10pt;">Cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,887</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">24</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:10pt;">Restricted cash </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">254</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:10pt;">Prepaid expenses and other current assets </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,622</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:20pt;">Total current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,952</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,900</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="white-space:nowrap;">Property and equipment, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="white-space:nowrap;">Right of use asset, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">779</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="white-space:nowrap;">Other assets </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:20pt;">Total assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,980</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,703</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:7.75pt 0pt 0.5pt 0pt; width:350.37pt;">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;">Current liabilities</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:10pt;">Accounts payable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">491</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,748</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:10pt;">Accrued liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">857</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,480</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:10pt;">Current portion of operating lease liability </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">346</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:10pt;">Convertible promissory notes - related party </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,500</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">5,497</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:10pt;">Current portion of term loan, net of discount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">3,812</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:20pt;">Total current liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,660</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">11,461</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="white-space:nowrap;">Operating lease liability, net of current portion </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">493</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="white-space:nowrap;">Warranty liability </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;">
              <div style="white-space:nowrap;">Commitments and contingencies (Note 7) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;">Redeemable convertible preferred stock</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:350.37pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Series&#160;A redeemable convertible preferred stock, $0.001 par value; 2,046,378 shares authorized, 2,034,548 shares issued and outstanding at December&#160;31, 2018, 0 shares authorized, issued and outstanding at June&#160;30, 2019 (unaudited) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12,814</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:350.37pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Series&#160;B redeemable convertible preferred stock, $0.001 par value; 1,833,387 shares authorized, issued and outstanding at December&#160;31, 2018, 0 shares authorized, issued and outstanding at June&#160;30, 2019 (unaudited); </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">15,897</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;">Stockholders&#8217; deficit</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:350.37pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Preferred stock, $0.001 par value; 1,000,000 shares authorized no shares issued or outstanding </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:350.37pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Common stock, $0.001 par value; 5,313,200 shares authorized, 701,808 shares issued and outstanding at December&#160;31, 2018, 95,000,000 shares authorized, 5,807,877 shares issued and outstanding at June&#160;30, 2019 (unaudited) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:10pt;">Additional paid-in capital </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">747</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">35,160</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:10pt;">Accumulated deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(37,279<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,417<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.5pt 0pt; width:350.37pt;text-align:left;">
              <div style="margin-left:20pt;">Total stockholders&#8217; deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(36,531<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(9,251<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0.917pt 0pt 1.583pt 0pt; width:350.37pt;white-space:normal;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; deficit </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,980</td>
            <td style="padding:0pt;padding-left:4.775pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.917pt 0pt 0.333pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,703</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-27</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfuSO">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:281.5pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Condensed Consolidated Statements of Operations <br >(In thousands, except share and per share data) <br >(Unaudited) </div>
        <table style="width:456pt;height:268.5pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six Months Ended June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;">Operating expenses</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">Research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,269</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,226</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">General and administrative </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,317</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">Grant reimbursements </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1,198<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:20pt;">Total operating expenses, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,561</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">4,345</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(2,561<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(4,345<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">Interest expense, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(445<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(2,641<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">Other income (expense), net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">60</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(94<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from continuing operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(2,946<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(7,080<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from discontinued operations </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(58<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(2,946<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(7,138<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:341.17pt;">Net loss per basic and diluted share:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">Loss from continuing operations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(0.64<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(1.43<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">Loss from discontinued operations </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(0.01<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss per basic and diluted share </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(0.64<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1.44<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">Weighted-average number of common shares outstanding&#8201;&#8211;&#8201;basic and diluted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">4,569,742</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">4,966,491</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-28</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfuSRC">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-bottom:18pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit<br >(In thousands, except share amounts) (Unaudited)</div>
      </div>
      <div style="margin-top:18pt;margin-bottom:309pt;margin-left:27.5pt;width:541pt;">
        <table style="width:541pt;height:260pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
          <tr style="line-height:8pt;height:25.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Series&#160;A Redeemable <br >Convertible <br >Preferred Stock </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Series&#160;B Redeemable <br >Convertible <br >Preferred Stock </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Common Stock </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">Additional <br >Paid-In <br >Capital </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">Accumulated <br >Deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">Total <br >Stockholders&#8217; <br >Deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:7pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 3pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:5pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">
              <div style="white-space:nowrap;">Balance, December&#160;31, 2018 </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">2,034,548</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">12,814</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">1,833,387</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">15,897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">701,808</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">747</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(37,279<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(36,531<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">
              <div style="white-space:nowrap;">Stock-based compensation expense </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">84</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">84</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:159.64pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,462<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(2,462<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:159.64pt;text-align:left;">
              <div style="white-space:nowrap;">Balance, March&#160;31, 2019 </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">2,034,548</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">12,814</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">1,833,387</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">15,897</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">701.808</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:6pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">831</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(39,741<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(38,909<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:159.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Conversion of convertible notes into convertible preferred stock </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">367,041</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">3,203</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:159.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Recognition of beneficial conversion feature upon conversion of convertible notes </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,101</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:159.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Conversion of of convertible preferred stock into common stock </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,034,548<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(12,814<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(2,200,428<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(21,201<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,234,976</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">34,011</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">34,015</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">
              <div style="white-space:nowrap;">Issuance of common stock for merger </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">854,017</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">
              <div style="white-space:nowrap;">Equity issuance costs paid in stock </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">17,076</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:159.64pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Impact of change of warrants subject to fair value measure to equity warrants </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">234</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">234</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">
              <div style="white-space:nowrap;">Spin-off of AquaMed </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.64pt;text-align:left;">
              <div style="white-space:nowrap;">Stock-based compensation expense </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">84</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">84</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:159.64pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(4,676<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(4,676<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:159.64pt;text-align:left;">
              <div style="white-space:nowrap;">Balance, June&#160;30, 2019 </div>
            </td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:4.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">5,807,877</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:6pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:5.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">35,160</td>
            <td style="padding:0pt;padding-left:2.19pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(44,417<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.51pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt; width:5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(9,251<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.45pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="">&#8203;</td>
            <td style="" colspan="4">&#8203;</td>
            <td style="">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:338pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">F-29</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfuSCF">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Condensed Consolidated Statements of Cash Flows <br >(In thousands) (Unaudited) </div>
        <table style="width:456pt;height:540pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:352.3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six&#160;Months Ended June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:352.3pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:352.3pt;">Cash flows from operating activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,946<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(7,138<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;">
              <div style="margin-left:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Depreciation expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Stock-based compensation expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">150</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">168</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Changes in fair value of warrant liability </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">95</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Changes in fair value of derivative liability </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(60<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Accretion of final charge upon maturity of Oxford Term Loan A and B </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">94</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">148</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:352.3pt;white-space:normal;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">Amortization of issuance cost and discounts for term loans and convertible notes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">130</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Non-cash interest expense on convertible promissory notes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">31</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,304</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Non-cash operating lease cost </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;">
              <div style="margin-left:10pt;">Changes in operating assets and liabilities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Prepaid expenses and other current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1,611<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Other assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Accounts payable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(607<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,255</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Accrued liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(312<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">475</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:20pt;">Lease liability </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(136<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:30pt;">Net cash used in operating activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,527<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(4,223<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:352.3pt;">Cash flows from investing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:30pt;">Net cash used in investing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:352.3pt;">Cash flows from financing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Payments on term loan </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(616<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1,437<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Proceeds from issuance of convertible promissory notes - related party </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">3,996</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:30pt;">Net cash provided by financing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">884</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,559</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="white-space:nowrap;">Net decrease in cash, cash equivalents and restricted cash </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,643<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(1,664<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:352.3pt;text-align:left;">
              <div style="white-space:nowrap;">Cash, cash equivalents and restricted cash at beginning of period </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">4,356</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">1,942</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:352.3pt;text-align:left;">
              <div style="white-space:nowrap;">Cash, cash equivalents and restricted cash at end of period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,713</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">278</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:352.3pt;">Other supplemental disclosure:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Cash paid for interest </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">190</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">173</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:352.3pt;">Non-cash investing and financing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Right-of-use assets obtained in exchange for operating lease obligations<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">227</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Reclassification of warrant liability to paid in capital </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">234</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:352.3pt;text-align:left;">
              <div style="margin-left:10pt;">Conversion of convertible preferred stock into common stock </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">34,015</td>
            <td style="padding:0pt;padding-left:3.99pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:9.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Amounts for the six&#160;months ended June&#160;30, 2019 pertains to the transition adjustment for the adoption of ASC 842.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-30</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tfuNFS">&#8203;</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 1.&nbsp;&nbsp;&nbsp;Organization and Basis of Presentation </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The Company </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, Adynxx, Inc. (&#8220;Adynxx&#8221; or the &#8220;Company&#8221;), formerly known as &#8220;Alliqua BioMedical, Inc.,&#8221; or Alliqua completed its reverse merger with what was then known as Adynxx, Inc., or Private Adynxx, which we refer to as the Merger. This transaction was accounted for as a reverse merger. See <font style="font-style:italic;">&#8216;Note 3&#8201;&#8212;&#8201;Reverse Merger&#8217;</font>. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company is a clinical stage biopharmaceutical company focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company is primarily engaged in developing initial product technology, recruiting personnel, and raising capital. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Basis of Presentation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These unaudited financial statements represent the condensed consolidated financial statements of Adynxx and, for periods prior to the Merger, the condensed consolidated financial statements of Private Adynxx. The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and pursuant to the instructions of the SEC on Form 10-Q and Article&#160;10 of Regulation&#160;S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the Company&#8217;s financial position on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the periods ended June&#160;30, 2018 and 2019 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the periods ended June&#160;30, 2018 and 2019 is unaudited. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements and the notes thereto as set forth in the Company&#8217;s Form 8-K/A filed with the SEC on June&#160;10, 2019. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All share and per share data, for all periods presented, of the issued and outstanding common stock of Adynxx, Inc., have been retroactively restated to reflect the exchange ratio used in the Merger of 0.0359 shares of capital stock in exchange for each share of Private Adynxx, Inc. capital stock outstanding immediately prior to the Merger (which exchange ratio reflects a 1-for-6 reverse stock split of the issued and outstanding capital stock of Alliqua BioMedical, Inc. effected on May 3, 2019 immediately prior to the reverse merger). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amount of assets, liabilities, revenue, costs, expenses and other (expenses) income that are reported in the condensed consolidated financial statements and accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events, historical experience, actions that the Company may undertake in the future and on various other assumptions that are believed to be reasonable under the circumstances. As a result, actual results may be different from these estimates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Liquidity </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As of June&#160;30, 2019, the Company had $24,000 in cash and cash equivalents, had term loans (&#8220;Term Loans&#8221;), including accrued interest outstanding, of&#8201; $3.0&#160;million from Oxford Finance, LLC (&#8220;Oxford&#8221;), and $5.6&#160;million aggregate principal amount of convertible promissory notes (&#8220;Notes&#8221;), including accrued interest, outstanding. From inception through June&#160;30, 2019, the Company had an accumulated deficit of approximately $44.4&#160;million. The Company expects to incur substantial losses in </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-31</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">future periods. The Company is subject to risks common to companies in the clinical stage, including, but not limited to, development of new products, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product development plans. The Company has a limited operating history and has yet to generate any revenues from customers. There is no guarantee that profitable operations, if ever achieved, could be sustained on a continuing basis. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In April&#160;2019 and May&#160;2019, the Company issued Notes to current investors and received an additional $2.0&#160;million and $0.5&#160;million, respectively. The Notes accrue interest at 8% per annum and mature on the first anniversary of the applicable issuance date. For further details, see the section below titled <font style="font-style:italic;">&#8216;Note 6&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217;.</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company plans to finance its operations and capital funding needs through equity and/or debt financing. However, there can be no assurance that additional funding will be available to the Company on acceptable terms on a timely basis, if at all, or that the Company will generate sufficient cash from operations to adequately fund operating needs or ultimately achieve profitability. The conditions above, among others, raise substantial doubt about the ability of the Company to continue as a going concern within one year after the date of the issuance of the financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying financial statements do not include any adjustments that might result from the outcome of these uncertainties. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 2.&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Use of Estimates </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Actual results could differ from those estimates and such differences could be material to the Company&#8217;s financial position and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Significant estimates and assumptions include the valuation of equity instruments and equity-linked instruments, including the valuation of the Company&#8217;s common stock and the valuation of the Company&#8217;s common stock options for purposes of accounting for stock-based compensation, and accruals for clinical trials and the valuation allowances on deferred tax assets. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk and Other Risks and Uncertainties </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation insured limits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company&#8217;s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company&#8217;s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support its growth. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s postoperative pain reduction product candidate, brivoligide, is an oligonucleotide. The Company currently uses Nitto-Denko Avecia, Inc. (&#8220;Avecia&#8221;) as a single supplier for the brivoligide drug substance. There are currently a limited number of oligonucleotide manufacturers with commercial scale </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-32</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">capabilities globally. While the Company intends to develop secondary sources for manufacturing of its drug candidates in the future, there can be no assurance that it will be able to do so on commercially reasonable terms, or at all. Any interruption in the supply of this key material could significantly delay the research and development process or increase the expenses for development and commercialization of the Company&#8217;s product candidates. The quality of materials can be critical to the performance of a drug delivery technology. Therefore, the lack of a reliable source that provides a consistent supply of high quality materials would harm the Company. At June&#160;30, 2019, this vendor&#8217;s activity was not material to total accounts payable. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At December&#160;31, 2018, three vendors represented 52%, 26% and 15% of total accounts payable. Two of these vendors supported general and administrative activities, primarily associated with the Merger and next round of equity financing, which accounted for 67% of the total accounts payable. The remaining vendor supported clinical study activities. At June&#160;30, 2019, three vendors represented 26%, 22% and 17% of total accounts payable, respectively. Two of these vendors supported general and administrative activities associated with the Merger and the next round of equity financing, which accounted for 44% of the total accounts payable. The remaining supported clinical study activities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Clinical Trial Accruals </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s clinical trial accruals are based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical trials on the Company&#8217;s behalf. The Company accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, the Company modifies the estimates of accrued expenses accordingly. To date, the Company has had no significant adjustments to accrued clinical trial expenses. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company considers all highly liquid investments purchased with a maturity of three&#160;months or less on the date of acquisition to be cash and cash equivalents. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Property and Equipment, Net </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line method over the estimated useful lives of the assets, generally three to five&#160;years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. As of December&#160;31, 2018 and June&#160;30, 2019, the Company had not experienced any impairment losses on its long-lived assets. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-33</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Restricted Cash </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At December 31, 2018 and June 30, 2019, the Company had $55,000 restricted and held by a bank as collateral for a letter of credit provided to the Company&#8217;s facility landlord. In addition, as of June 30, 2019, the Company had $200,000 restricted from withdrawal and held by a bank in the form of a secured money market account as collateral for Oxford in conjunction with a debt amendment that occurred in January 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Stock-Based Compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company uses the Black-Scholes option-pricing model (the &#8220;Black-Scholes model&#8221;) as the method for determining the estimated fair value of stock options. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected Term</font>&#8201;&#8212; The expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected Volatility&#8201;&#8212; </font>Expected volatility is estimated using comparable public companies&#8217; volatility for similar terms. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Expected Dividend&#8201;&#8212; </font>The Black-Scholes model calls for a single expected dividend yield as an input. Other than the dividend paid in connection with the Merger, the Company has never paid dividends and has no plans to pay dividends. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Risk-Free Interest Rate&#8201;&#8212; </font>The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of the option. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Research and Development </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, preclinical studies, clinical studies performed by contract research organizations (&#8220;CROs&#8221;), materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development costs, including clinical study costs, to expense when incurred. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Collaboration Agreement </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2018, the Company entered into a collaboration agreement with twoXAR, an artificial intelligence-driven drug discovery company, in order to identify potential product candidates for the treatment of endometriosis. In May&#160;2019, the Company made a collaboration initiation payment of $75,000, which was charged to research and development expenses for the six&#160;months ended June&#160;30, 2019. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2019, Adynxx received an initial set of candidate predictions from twoXAR. The Company has initiated a review of the potential products to determine if any are viable candidates for further research and development. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Grant Reimbursements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2018, the Company received a Notice of Award from the National Institute on Drug Abuse (&#8220;NIDA&#8221;), part of the National Institutes of Health (&#8220;NIH&#8221;), to support the clinical development of its lead product candidate, brivoligide. NIH grants provide funds for certain types of expenditures in </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-34</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">connection with research and development activities over a contractually defined period. The maximum funding expected to be available under this grant for qualified expenditures over the two-year period through December&#160;2020 is&#8201;approximately $5.7&#160;million. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On January&#160;1, 2019, the Company adopted Accounting Standards Update (ASU) 2018-08, &#8220;Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made.&#8221; Based on this guidance, the Company determined that grant payments received met the definition of a &#8216;conditional contribution&#8217; (versus an exchange contract) because (i)&#160;the Company has limited discretion in the way the funds may be spent, which creates a barrier to entitlement, and (ii) the grant contains provisions that release the awarding agency from the obligation to transfer funds that are not expended at the time the award is terminated. The Company recognizes grant reimbursements as a contra operating expense and reflects this as a component of its loss from operations in the period during which the qualifying expenses are incurred and the related services rendered, provided that the applicable performance obligations have been met. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For the six&#160;months ended June&#160;30, 2019, the Company incurred qualified expenses and recognized $1,198,000 of grant reimbursements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Income Taxes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company&#8217;s tax return. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Preferred Stock Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At December&#160;31, 2018, freestanding warrants to acquire shares of convertible preferred stock were classified as liabilities on the accompanying balance sheet. These warrants were subject to remeasurement at fair value at each balance sheet date, and any change in fair value is recognized as a component of other income or expense. In connection with the Merger, the warrants were exchanged into warrants that no longer met the definition of a derivative and thus, $234,000 of warrant liabilities was reclassified into equity during the six&#160;months ended June&#160;30, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Debt Modifications and Extinguishments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">When the Company modifies debt, it does so in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 470-50, <font style="font-style:italic;">Debt: Modifications and Extinguishments</font>, which requires modification to debt instruments to be evaluated to assess whether the modifications are considered &#8220;substantial modifications&#8221;. A substantial modification of terms shall be accounted for like an extinguishment. Based on the guidance relied upon and the analysis performed, the Company determined that the October&#160;2018 modification of the March&#160;2018 and September&#160;2018 Notes, to add an additional conversion option in the event of a reverse </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-35</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">merger, was considered to be a &#8220;substantial modification&#8221;. As a result, it treated this modification as an &#8216;extinguishment&#8217; of those debts and recognized $11,000 of net gain from this debt extinguishment in other income in October&#160;2018. All other changes to debt provisions were not considered substantial and were treated as debt modifications. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Derivative Instruments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASC 815-15, <font style="font-style:italic;">Derivatives and Hedging: Embedded Derivatives</font>, generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a)&#160;the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b)&#160;the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c)&#160;a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirement of ASC 815. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At December 31, 2018 and June&#160;30, 2019, the Company maintained outstanding Notes which contained various embedded derivative features. In particular, these Notes contained the following features: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">A share settled redemption in a qualified preferred stock financing; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">The right to an accelerated cash repayment in the event of a change in control. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These embedded features were not considered clearly and closely related to the debt host, therefore, they were bifurcated and accounted for separately from the debt host as a derivative liability. Derivative financial liabilities are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in the statement of operations at each period end while such instruments are outstanding. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December 31, 2018 and June&#160;30, 2019, the Company determined that there was no fair value associated with the embedded derivatives that remained with the outstanding convertible notes. See <font style="font-style:italic;">&#8216;Note&#160;6&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217; </font>for further discussion of the Notes and the bifurcated derivative liability. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASC 820-10, <font style="font-style:italic;">Fair Value Measurement</font>, provides a framework for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. The standard defines fair value as an exit price, representing the amount that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. The standard also establishes a fair value hierarchy, which prioritizes the inputs used in measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Level&#160;1</font>&#8201;&#8212; Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Level&#160;2</font>&#8201;&#8212; Inputs other than quoted prices included within Level&#160;1 that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;">Level&#160;3</font>&#8201;&#8212; Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-36</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The following table presents the Company&#8217;s fair value hierarchy for its warrant liability measured at fair value on a recurring basis at December&#160;31, 2018 (in thousands): </div>
        <table style="width:456pt;height:63.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:211.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31, 2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:211.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;1 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;2 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;3 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:211.5pt;">Financial liabilities</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:211.5pt;text-align:left;">
              <div style="margin-left:10pt;">Warrant liability </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:15.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:211.5pt;text-align:left;">
              <div style="margin-left:20pt;">Total financial liabilities </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:15.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:11pt; width:456pt; line-height:12pt;">The Level&#160;3 derivative at December&#160;31, 2018 consisted of a warrant liability of Private Adynxx that, at December&#160;31, 2018, was exercisable into preferred shares that were potentially redeemable. In connection with the Merger, the warrants were exchanged into warrants that no longer met the definition of a derivative and thus, the balance was reclassified into equity during the six&#160;months ended June&#160;30, 2019. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The change in fair value of the warrant liability for the six&#160;months ended June&#160;30, 2018 and 2019 are as follows (in thousands): </div>
        <table style="width:416pt;height:77.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six&#160;Months Ended June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value, beginning of period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">140</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Change in fair value of preferred stock warrants </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">94</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Exchange of warrants upon Merger </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(234<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value at end of period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:15.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:11pt; width:456pt; line-height:12pt;">The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the Company&#8217;s term loan is based on the borrowing rate currently available to the Company for borrowings with similar terms and maturity and approximates its carrying value. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Derivative liability instruments are considered Level&#160;3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Level&#160;3 liability instruments consist of the preferred stock warrant liability and derivative liability, for both of which there is no observable market data for the determination of fair value and requires significant management judgment and estimation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">While the Company&#8217;s Notes contain embedded derivative liabilities, the Company determined that the fair value of these liabilities were zero at December&#160;31, 2018 and June&#160;30, 2019. See &#8216;<font style="font-style:italic;">Note 6&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217;</font> for further discussion on the derivative liability activity. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The change in fair value of the derivative liability relating to the Notes for the six&#160;months ended June&#160;30, 2018 and 2019 is summarized below (in thousands): </div>
        <table style="width:416pt;height:77.5pt;margin-left:20pt;margin-top:8.00000000000006pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six&#160;Months Ended June&#160;30, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value, beginning of period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Embedded derivative liability from the issuance of Notes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">496</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Change in value of embedded derivatives </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(60<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Fair value at end of period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">436</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Discontinued Operations </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Discontinued operations represent the activities of the AquaMed business between the date of the Merger and the date of the spin-off. See &#8216;<font style="font-style:italic;">Note 3&#8201;&#8212; Reverse Merger&#8217;</font>. There are no ongoing activities or obligations associated with discontinued operations at June&#160;30, 2019. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-37</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Lease Accounting </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In February&#160;2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;). ASU 2016-02 is intended to improve financial reporting of leasing transactions by requiring organizations that lease assets to recognize assets and liabilities for the rights and obligations created by leases that extend more than twelve&#160;months on the balance sheet. This accounting update also requires additional disclosures surrounding the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for financial statements issued for annual and interim periods beginning after December&#160;15, 2018 for public business entities. A modified retrospective transition approach is required, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either (1)&#160;its effective date or (2)&#160;the beginning of the earliest comparative period presented in the financial statements as its date of initial application. The Company adopted the new standard on January&#160;1, 2019 and used the effective date as its date of initial application. Consequently, the Company has not adjusted prior period amounts. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has elected the package of practical expedients permitted in ASC Topic 842. Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a)&#160;whether the contracts contain a lease under ASC Topic 842, (b)&#160;whether classification of the operating leases would be different in accordance with ASC Topic 842, or (c)&#160;whether the unamortized initial direct costs would have met the definition of initial direct costs in ASC Topic 842 at lease commencement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The most significant impact from the adoption of this standard was the recognition of right-of-use, or ROU, assets and lease obligations on the balance sheet for operating leases. This standard did not have a material impact on the Company&#8217;s cash flows from operations and operating results. As a result of the adoption of the new lease accounting guidance, the Company recognized on January&#160;1, 2019 (a)&#160;a lease liability of approximately $227,000, which represents the present value of the remaining lease payments of approximately $239,000, discounted using the Company&#8217;s incremental borrowing rate of 9.41%, and (b)&#160;a right-of-use asset of approximately $227,000 which represents the lease liability of&#8201; $227,000. The ROU asset is being amortized over the remaining term of the lease of twelve&#160;months from January&#160;1, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Effective </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In August&#160;2018, the FASB issued No. ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. This ASU is effective for fiscal&#160;years beginning after December&#160;15, 2019, including interim periods within that fiscal year, with early adoption permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In August&#160;2018, the FASB issued ASU 2018-15, Intangibles&#8201;&#8212;&#8201;Goodwill and Other&#8201;&#8212;&#8201;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, (&#8220;ASU 2018-15&#8221;). The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. The new standard will be effective beginning January&#160;1, 2020 and early adoption is permitted. The Company is currently assessing whether these amendments will have a material effect on its financial statements. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-38</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">Note 3.&nbsp;&nbsp;&nbsp;Reverse Merger </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Merger </div>
        <div style="text-indent:20pt; margin-top:4.41pt; width:456pt; line-height:12pt;">On May&#160;3, 2019 the Company completed its reverse merger with Alliqua BioMedical Inc. (&#8220;Alliqua&#8221;). Immediately following the Merger, the combined company&#8217;s name was changed from &#8220;Alliqua BioMedical, Inc.&#8221; to &#8220;Adynxx, Inc.&#8221; Private Adynxx changed its name to &#8220;Adynxx Sub, Inc.&#8221; and is currently a wholly owned subsidiary of the Company. The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. </div>
        <div style="text-indent:20pt; margin-top:5.42pt; width:456pt; line-height:12pt;">Subject to the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of October&#160;11, 2018, as amended and supplemented from time to time (the &#8220;Merger Agreement&#8221;), (a)&#160;each outstanding share of capital stock of Private Adynxx, was converted into the right to receive the number of shares of Alliqua&#8217;s common stock equal to the exchange ratio formula in the Merger Agreement (&#8220;Exchange Ratio&#8221;) of 0.0359 shares of common stock (which exchange rate reflects a 1-for-6 reverse stock split of the issued and outstanding capital stock of Alliqua BioMedical, Inc. effected on May&#160;3, 2019 immediately prior to the Merger) and (b)&#160;each outstanding Private Adynxx stock option, whether vested or unvested, and warrant that has not previously been exercised, was assumed by the post-Merger company and converted into a stock option or warrant, as the case may be, to purchase shares of the post-Merger Adynxx Company&#8217;s common stock at the Exchange Ratio formula in the Merger Agreement. </div>
        <div style="text-indent:20pt; margin-top:5.22pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, prior to the closing of the Merger, $3.0&#160;million aggregate principal amount of Notes and $203,000 of cumulative accrued interest on such Notes were converted into 367,041 shares of common stock. </div>
        <div style="text-indent:20pt; margin-top:5.21pt; width:456pt; line-height:12pt;">Upon the completion of the Merger, Private Adynxx equity holders held 4,936,784 shares of common stock. Equity issuance costs in connection with the Merger were recorded as an offset to additional paid in capital. </div>
        <div style="text-indent:20pt; margin-top:5.22pt; width:456pt; line-height:12pt;">As described in &#8220;Spin-off&#8221; below, at the time of the Merger, Alliqua had in place a plan to spin-off all existing operations. Since Alliqua was deemed to have no operations upon consummation of the Spin-off, Alliqua was not considered to be a business for accounting purposes. Accordingly, no goodwill or intangible assets were recorded as a result of the Merger. Because Private Adynxx is treated as the acquiring company, Private Adynxx&#8217;s assets and liabilities are recorded at their pre-combination carrying amounts and the historical operations that are reflected in periods prior to the closing date of the Merger will be those of Private Adynxx. All share and per share amounts have been retroactively restated to give effect to the Exchange Ratio. </div>
        <div style="text-indent:20pt; margin-top:5.21pt; width:456pt; line-height:12pt;">Private Adynxx was determined to be the accounting acquirer based upon the terms of the Merger Agreement and other factors including: (i)&#160;Private Adynxx equity holders owned approximately 86% of the voting interests of the combined company immediately following the closing of the transaction and Alliqua equity holders owned approximately 14%; (ii) directors appointed by Private Adynxx hold a majority of board seats in the combined company; and (iii) Private Adynxx management hold all key positions in the management of the combined company. </div>
        <div style="text-indent:20pt; margin-top:5.22pt; width:456pt; line-height:12pt;">In connection with a previous modification of its Notes, the Company had computed a contingent beneficial conversion feature (&#8220;BCF&#8221;) that was contingent upon the occurrence of a reverse merger. In accordance with ASC 470-20-25-6, the contingent BCF is not recognized in earnings until the contingency is resolved. Upon the date of the Merger, the full amount of beneficial conversion feature of&#8201; $2.1&#160;million was recognized as interest expense in the condensed consolidated statement of operations for the six&#160;months ended June&#160;30, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Dividend </div>
        <div style="text-indent:20pt; margin-top:4.22pt; width:456pt; line-height:12pt;">In contemplation of the Merger, Alliqua declared a special cash dividend to the pre-Merger shareholders of Alliqua as of April&#160;22, 2019. The aggregate dividend of&#8201; $5,245,000, or $1.05 per share, was paid on May&#160;29, 2019. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-39</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Spin-off </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On November&#160;27, 2018, Alliqua had entered into an agreement whereby its existing operations would be distributed to existing shareholders as of a record date. With the exception of a corporate lease, substantially all of Alliqua&#8217;s assets and liabilities were contributed to a subsidiary, AquaMed Technologies Inc. (&#8220;AquaMed&#8221;), whose shares were then distributed to the pre-Merger shareholders of Alliqua by way of a pro&#160;rata stock dividend on June&#160;21, 2019. The book value of the dividend was less than $0.01 per share. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Because the historical periods presented prior to the merger are those of Private Adynxx, the results of AquaMed are only reflected in these financial statements from the merger date to the date of the pro&#160;rata dividend of AquaMed and are presented as discontinued operations in the condensed consolidated statement of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pro Forma Financial Information </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As the only significant operations of Alliqua have been discontinued with the spin-off transaction, pro&#160;forma financial information for periods prior to the merger is not presented herein as such results are not meaningful. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 4.&nbsp;&nbsp;&nbsp;Property and Equipment, Net </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Property and equipment, net, consist of the following (in thousands): </div>
        <table style="width:416pt;height:116.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">December&#160;31, <br >2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">June&#160;30, <br >2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Furniture and fixtures </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Office equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Computer equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Laboratory equipment </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Total property and equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">51</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">51</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Less accumulated depreciation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(41<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(45<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Property and equipment, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:14.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:17.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.98pt; width:456pt; line-height:12pt;">Depreciation expense at December 31, 2018 and for the six&#160;months ended June&#160;30, 2018 and 2019 was $8,000, $4,000 and $4,000, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 5.&nbsp;&nbsp;&nbsp;Other Balance Sheet Information </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Prepaid and other current assets consist of the following (in thousands): </div>
        <table style="width:416pt;height:88pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">December&#160;31, <br >2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">June&#160;30, <br >2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Prepaid clinical trial expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">435</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Equity issuance costs </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">343</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Prepaid insurance </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">670</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Other prepaid expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">174</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Total prepaid and other current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:16.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,622</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-40</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-left:20pt; margin-top:1pt; width:436pt; line-height:12pt;">Accrued liabilities consist of the following (in thousands): </div>
        <table style="width:416pt;height:88pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">December&#160;31, <br >2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">June&#160;30, <br >2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Payroll and related expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">241</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">508</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Accrued term loan final payment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">421</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">569</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Accrued clinical trial expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Professional fees and other costs </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">195</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">395</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Total accrued liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">857</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,480</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-weight:bold;">Note 6.&nbsp;&nbsp;&nbsp;Term Loans and Convertible Promissory Notes </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Term Loans </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On November&#160;24, 2015, the Company entered into a loan and security agreement (&#8220;Loan Agreement&#8221;) with Oxford, pursuant to which the Company received $3.0&#160;million in proceeds from a Term Loan A and $2.0&#160;million in proceeds from a Term Loan B under the Loan Agreement (collectively the &#8220;Term Loans&#8221;). Warrants to purchase 11,829 shares of common stock were issued to Oxford in connection with the Term Loans (&#8216;<font style="font-style:italic;">Note 9&#8201;&#8212; Warrants&#8217;</font>). The Term Loans bear interest at a floating per annum rate equal to (a)&#160;7.06% plus (ii) the greater of&#8201; (a)&#160;the 30 day U.S. Dollar LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (b)&#160;0.19%. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Term Loan A was recorded at its initial carrying value of&#8201; $3.0&#160;million less debt issuance costs of approximately $141,000, and the Term Loan B was recorded at its initial carrying value of&#8201; $2.0&#160;million, less debt issuance costs of approximately $3,000. The debt issuance costs are being amortized to interest expense over the life of the Term Loans using the effective interest method. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2018, $2.3&#160;million was outstanding under Term Loan A and $1.5&#160;million was outstanding under Term Loan B. At June&#160;30, 2019, $1.4&#160;million was outstanding under Term Loan A and $1.0&#160;million was outstanding under Term Loan B. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following modifications have been made during the six&#160;months ended June&#160;30, 2019: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In January&#160;2019, the Company and Oxford agreed to amend the Loan Agreement. Oxford agreed to two&#160;months of interest-only payments followed by eight&#160;months of repayments upon delivery by February&#160;1, 2019 of an executed term sheet for equity financing that would result in aggregate proceeds to the Company of&#8201; $20.0&#160;million. The Company was also required to place $200,000 in a segregated bank account that is subject to a blocked control agreement in favor of Oxford. The funds in the segregated account were to be released upon the earlier of the consummation of a merger by March&#160;31, 2019 or the consummation of an equity financing by March&#160;31, 2019. The Company recorded the $200,000 as restricted cash in its balance sheet at June&#160;30, 2019. The maturity date of the Term Loans remained unchanged. The amendment fee amounted to $50,000. The amendment was accounted for as a debt modification. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In May&#160;2019, the Company and Oxford agreed to an amendment to provide consent to the Merger. This consent amended certain provisions of the Term Loans to protect Oxford&#8217;s rights under the original Loan Agreement. The consent allowed Alliqua (now Adynxx, Inc.) to be named as an additional borrower. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In June&#160;2019, the Company and Oxford agreed to amend the Loan Agreement. Oxford agreed to two&#160;months of interest-only payments and the maturity date of the Term Loans was extended two&#160;months to January&#160;1, 2020. The amendment fee amounted to $20,000. The amendment was accounted for as a debt modification. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-41</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">Upon the respective dates of the debt modifications, no gain or loss was recorded, and a new effective interest rate was established based on the carrying value of the debt and the revised cash flows. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Interest expense associated with the Term Loans was $309,000 and $336,000 for the six&#160;months ended June&#160;30, 2018 and 2019, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, the Company was in compliance with all covenants under the Loan Agreement. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Principal payments for the Term Loans due under the Loan Agreement as of June&#160;30, 2019 are due monthly beginning September&#160;1, 2019 and the Term Loans mature on January&#160;1, 2020. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Promissory Notes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The table below reflects the principal amount of the Notes issued by the Company (in thousands): </div>
        <table style="width:416pt;height:116pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">December&#160;31, <br >2018 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">June&#160;30, <br >2019 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on March&#160;29, 2019 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on September&#160;27, 2019 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on December&#160;21, 2019 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on March&#160;29, 2020 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on April&#160;26, 2020 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible note payable, due on May&#160;29, 2020 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,500</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,500</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18pt; width:456pt; line-height:11pt;font-style:italic;">Outstanding Notes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Notes outstanding at June&#160;30, 2019 were issued with conversion and repayment rights as described below: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" margin-top:8.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the event that the Company issues and sells equity securities with proceeds to the Company of at least $5&#160;million, on or before the maturity date, then the outstanding principal amount of this convertible promissory note and any unpaid accrued interest will automatically convert in whole into equity securities of the same class sold in the equity financing at a conversion price equal to the cash price paid per share for equity securities in the financing, and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(b)<br ></div>
        <div style=" margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the Company consummates a change of control while the Notes remain outstanding, the Company shall repay the holders in cash in an amount equal to 200% of the outstanding principal amount of the Notes. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In April&#160;2019 and May&#160;2019, affiliates of Domain Partners, LLC, a significant shareholder of the Company, purchased from the Company $2.0&#160;million and $0.5&#160;million aggregate principal amount of Notes. The proceeds from the issuances were used for general corporate purposes and working capital. These Notes accrue simple interest on the outstanding principal amount at a rate of 8% per annum and mature on April&#160;26, 2020 and May&#160;29, 2020, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Converted Notes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In May&#160;2019, under the terms of the then-outstanding Notes, the principal and accrued unpaid interest of two Notes totaling $3.2&#160;million were automatically converted into the Company&#8217;s Series&#160;B convertible preferred stock. Upon consummation of the Merger, and subject to the terms and conditions of the Merger Agreement, each outstanding share of capital stock of Adynxx was converted into the right to receive the number of shares of the combined Company&#8217;s common stock equal to the Exchange Ratio. An aggregate of 367,041 post-Merger common shares were issued associated with the conversion of these Notes. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-42</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">In connection with a previous modification, the Company had computed a contingent BCF that was contingent upon the occurrence of a reverse merger. In accordance with ASC 470-20-25-6, the contingent BCF is not recognized in earnings until the contingency is resolved. Upon the date of the Merger, the full amount of beneficial conversion feature of&#8201; $2.1&#160;million was recognized as interest expense in the condensed consolidated statement of operations for the six&#160;months ended June&#160;30, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Derivative Liability </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company evaluated its outstanding Notes and determined that certain embedded components relating to conversion and redemption features of those contracts qualified as derivatives, which need to be separately accounted for in accordance with ASC 815. With the consummation of the Merger, several of these clauses no longer apply. However, the redemption provision upon change of control described above is an embedded feature that is required to be bifurcated. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December 31, 2018, the Company evaluated the fair value of the derivative liability and determined that the bifurcated derivative liability had no value because the Company estimated a zero probability of the embedded feature being triggered. As a result, the Company estimated the fair value of the derivative liability to be zero at December 31, 2018. Similarly, the embedded derivatives that were in place at June&#160;30, 2019 also had a fair value of zero. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 7.&nbsp;&nbsp;&nbsp;Leases </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company leases office facilities under a non-cancelable operating lease agreement expiring on December&#160;31, 2019. The Company also leases a corporate office facility previously utilized by Alliqua through an operating lease agreement, located in Yardley, Pennsylvania that expires in 2023. Effective February&#160;1, 2019, this property has been subleased to The Pinnacle Health Group, Inc. through April&#160;20, 2023 and the Company receives monthly lease payments. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Future minimum payments under non-cancellable leases as of June&#160;30, 2019 are as follows (in thousands): </div>
        <table style="width:416pt;height:130.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:350pt;">
              <div style="white-space:nowrap;">Period ending December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">Future <br >Commitments </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">2019 (remaining 6&#160;months) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">232</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">2020 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">227</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">2021 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">232</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">2022 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">236</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">2023 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">80</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">Total future minimum lease payments </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,007</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">Less: imputed interest </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">(167<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:350pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">840</td>
            <td style="padding:0pt;padding-left:13.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.78pt; width:456pt; line-height:12pt;">Total operating lease expenses for the six&#160;months ended June&#160;30, 2018 and 2019 was $115,000 and $165,000, respectively, and are reflected in general and administrative expenses in the condensed consolidated statements of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of June&#160;30, 2019, the Company had no leases that were classified as a financing lease. As of June&#160;30, 2019, the Company did not have additional operating and financing leases that have not yet commenced.&nbsp;&nbsp;&nbsp; </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During the six&#160;months ended June&#160;30, 2019, the Company recognized $42,000 of sublease income on its condensed consolidated statement of operations, which is recorded as an offset against general and administrative expenses. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-43</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">Note 8.&nbsp;&nbsp;&nbsp;Redeemable Convertible Preferred Stock </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At December&#160;31, 2018, Private Adynxx had 2,034,548 shares of Series&#160;A convertible preferred stock issued and outstanding, and 1,833,387 shares of Series&#160;B convertible preferred stock issued and outstanding. During 2019, prior to the Merger, an additional 367,041 shares were issued upon conversion of convertible notes described in <font style="font-style:italic;">&#8216;Note 6&#8201;&#8212; Term Loans and Convertible Promissory Notes&#8217;.</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Upon the consummation of the Merger, all outstanding shares of Series&#160;A and Series&#160;B convertible preferred stock were cancelled and exchanged for shares of the Company&#8217;s common stock. Following the Merger, Private Adynxx survived as a wholly-owned subsidiary of new Adynxx, Inc. and adopted a new certificate of incorporation with no shares of preferred stock authorized or outstanding. The Company has 1,000,000 shares of preferred stock authorized under its certificate of incorporation, as amended. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 9.&nbsp;&nbsp;&nbsp;Warrants </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Private Adynxx had issued warrants that were previously classified as a liability as they were exercisable for preferred shares that were potentially redeemable. The fair value of the warrant liability was re-measured at each balance sheet date up through the date of the Merger with the change as other income recorded in the statements of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, in connection with the closing of the Merger, each outstanding Adynxx warrant that had not previously been exercised was converted into a stock warrant to purchase shares of the Company&#8217;s common stock at the Exchange Ratio and, as a result, outstanding warrants were converted into warrants to purchase an aggregate of 11,829 shares of the Company&#8217;s common stock at an exercise price of&#8201; $6.34 per share. As such warrants qualify for equity classification, the Company reclassified the balance of&#8201; $234,000 from warrant liability to additional paid in capital. These warrants are exercisable at any time and expire in 2025 and 2026. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additionally, upon the closing of the Merger on May&#160;3, 2019, the Company assumed outstanding Alliqua warrants to purchase an aggregate of 38,945 shares of common stock at exercise prices ranging from $26.40 to $28.20 per share. These warrants are exercisable at any time and expire in 2022. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 10.&nbsp;&nbsp;&nbsp;Stock Options </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;3, 2019, in connection with the closing of the Merger, each outstanding Private Adynxx stock option, whether vested or unvested, was converted into a stock option to purchase shares of the Company&#8217;s common stock at the Exchange Ratio and, as a result, the Company issued options to purchase an aggregate of 690,058 shares of the Company&#8217;s common stock at exercise prices ranging from $1.11 to $3.06 per share. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additionally, at the date of the Merger, Alliqua had outstanding employee options to purchase an aggregate of 57,822 shares of the post-Merger Company&#8217;s common stock at exercise prices ranging from $21.00 to $656.40 per share to former Alliqua option holders that were assumed as part of the merger. All Alliqua employees were terminated in connection with the Merger; however, such options have provisions that extend the expiration date beyond the employees&#8217; termination date. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-44</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">A summary of the Company&#8217;s stock option activity during the six&#160;months ended June&#160;30, 2019 is as follows (in thousands, except exercise prices): </div>
        <table style="width:456pt;height:122pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:211.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >Options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >Average <br >Exercise Price </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >Average <br >Remaining <br >Life In Years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Intrinsic Value </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:211.5pt;text-align:left;">
              <div style="white-space:nowrap;">Outstanding, December&#160;31, 2018 </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">690</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2.76</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:211.5pt;text-align:left;">
              <div style="margin-left:10pt;">Alliqua options assumed in Merger </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">58</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">289.76</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:211.5pt;text-align:left;">
              <div style="margin-left:10pt;">Exercised </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:211.5pt;text-align:left;">
              <div style="margin-left:10pt;">Cancelled </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:211.5pt;text-align:left;">
              <div style="white-space:nowrap;">Outstanding, June&#160;30, 2019 </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">748</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">24.95</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">6.2</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">188</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.75pt 0pt; width:211.5pt;text-align:left;">
              <div style="white-space:nowrap;">Exercisable, June&#160;30, 2019 </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">530</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">33.93</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">5.7</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">188</td>
            <td style="padding:0pt;padding-left:17.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.98pt; width:456pt; line-height:12pt;">A summary of the Company&#8217;s stock options as of June&#160;30, 2019 is as follows (in thousands, except exercise prices): </div>
        <table style="width:456pt;height:118.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;height:8.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:151.5pt;" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Range of Exercise Price </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Options Outstanding </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">Options Exercisable </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:39.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:center;">Weighted <br >Average <br >Exercise <br >Price </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Outstanding <br >Number of <br >Options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >Average <br >Exercise Price </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >Average <br >Remaining <br >Life In Years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">Exercisable <br >Number of <br >Options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; width:151.5pt;text-align:center;">
              <div style="text-align:center;">$1.11 &#8211; $1.38 </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1.11</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">73</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1.11</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2.5</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">73</td>
            <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:151.5pt;text-align:center;">
              <div style="text-align:center;">1.39 &#8211; 3.05</div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1.39</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">37</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1.39</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">3.2</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">37</td>
            <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; width:151.5pt;text-align:center;">
              <div style="text-align:center;">3.06 &#8211; 20.99</div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3.06</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">580</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3.06</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">7.5</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">362</td>
            <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:151.5pt;text-align:center;">
              <div style="text-align:center;">21.00 &#8211; 656.40 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">289.81</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">58</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">289.81</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">0.7</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.25pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">58</td>
            <td style="padding:0pt;padding-left:20.25pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:151.5pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">24.95</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">748</td>
            <td style="padding:0pt;padding-left:18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">24.95</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">5.7</td>
            <td style="padding:0pt;padding-left:19.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">530</td>
            <td style="padding:0pt;padding-left:20.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.99pt; width:456pt; line-height:12pt;">The Company did not grant any stock options to employees during the six months ended June 30, 2019. Stock-based compensation expense recorded in research and development and general and administrative expenses was $150,000 and $136,000 for the six months ended June 30, 2018 and 2019, respectively. As of June 30, 2019, unrecognized stock-based compensation expense related to employees totaled approximately $395,000, which is expected to be recognized over approximately 1.5 years. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Stock-based compensation expense recorded in exchange for services related to non-employee options was $0 and $32,000 for the six months ended June 30, 2018 and 2019, respectively. As of June 30, 2019, unrecognized stock-based compensation expense related to unvested non-employees stock options was approximately $16,000, which is expected to be recognized over a weighted-average period of three months.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Note 11.&nbsp;&nbsp;&nbsp;Related-Party Transactions </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="font-style:normal;">At June&#160;30, 2019, the Company had $5.5&#160;million aggregate principal amount of outstanding convertible notes issued to a significant shareholder. &#8216;</font>Note 6&#8201;&#8212;&#8201;Term Loans and Convertible Promissory Notes&#8217;<font style="font-style:normal;">. </font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In connection with the Merger, Alliqua&#8217;s existing CEO resigned from the company and received severance pay of&#8201; $1,091,000. As such amounts were accrued by Alliqua prior to the Merger, this severance payment had no impact to our condensed consolidated statement of operations for six&#160;months ended June&#160;30, 2019.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-45</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Adynxx, Inc. (formerly Alliqua Biomedical, Inc.)</div>
        <div style="margin-top:9pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Notes to Unaudited Condensed Consolidated Financial Statements<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">Note 12.&nbsp;&nbsp;&nbsp;Subsequent Events </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In July&#160;2019, affiliates of Domain Partners, LLC, a significant shareholder of the Company, purchased from the Company $600,000 aggregate principal amount of Notes. The proceeds from the issuance of the Notes will be used for general corporate purposes and working capital. These Notes accrue simple interest on the outstanding principal amount at a rate of 8% per annum and mature one year from the date of issuance.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On August 1, 2019 and August 2, 2019, the Company&#8217;s board of directors and a majority of the Company&#8217;s stockholders, respectively, approved a reverse stock split at a range of between 1-for-2 and 1-for-10, with the final exchange ratio to be determined by the board of directors, which as of the date of filing has not yet occurred. The share and per share information contained in the financial statements and footnotes do not reflect the impact of any such reverse stock split. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In August 2019, the Company and Oxford agreed to amend the Loan Agreement pursuant to a ninth amendment to the Loan Agreement. The ninth amendment provides for two additional months of interest-only payments by the Company, contingent upon the completion of certain financing events by specified dates. The ninth amendment also clarifies that the secured funds will be released by Oxford upon the receipt by the Company of net proceeds of at least $10 million from the issuance and sale of its equity securities.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-46</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:28pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:3.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;z-index:-1;margin-top:110.5pt; text-align:center; width:456pt;">
          <img src="lg_adynxx.jpg" alt="[MISSING IMAGE: lg_adynxx.jpg]" height="60" width="241" >
        </div>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:17pt;font-weight:bold;font-size:14pt;">7,500,000 Shares of Common Stock <br >Pre-Funded Warrants to Purchase Shares of Common Stock <br >Common Warrants to Purchase 7,500,000 Shares of Common Stock<br >&#8199;<br >&#8199;<br >&#8199;<br >&#8199;</div>
        <div style="margin-top:48.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 27.302%; margin-right: 27.302%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">PRELIMINARY PROSPECTUS </div>
        <div style="margin-top:16.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 27.302%; margin-right: 27.302%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:10pt; width:456pt; line-height:12pt;">&#8199;<br >&#8199;<br >&#8199;<br >&#8199;<br >&#8199; <br >&#8199;<br >&#8199;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:19pt;font-weight:bold;font-size:18pt;">H.C. Wainwright &amp; Co. </div>
        <div style="margin-top:120pt; text-align:center; width:456pt; line-height:11pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2019 </div>
        <div style="margin-top:49.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PART II<br >&#8199; <br >INFORMATION NOT REQUIRED IN PROSPECTUS </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;13. Other Expenses of Issuance and Distribution. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table sets forth all costs and expenses, other than placement agent fees, payable by us in connection with the sale of the common stock, common warrants and pre-funded warrants being registered. All amounts shown are estimates except for the SEC registration fee and the Financial Industry Regulatory Authority, or FINRA, filing fee. </div>
        <table style="width:456pt;height:144pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:390pt;">
              <div style="white-space:nowrap;">Item </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
              <div style="white-space:nowrap;">SEC registration fee </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,894</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
              <div style="white-space:nowrap;">FINRA filing fee </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
              <div style="white-space:nowrap;">Printing and engraving expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">145,000</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
              <div style="white-space:nowrap;">Legal fees and expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">700,000</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
              <div style="white-space:nowrap;">Accounting fees and expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">200,000</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
              <div style="white-space:nowrap;">Blue Sky fees and expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">10,000</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:390pt;text-align:left;">
              <div style="white-space:nowrap;">Transfer agent and registrar fees and expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">10,000</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:390pt;text-align:left;">
              <div style="white-space:nowrap;">Miscellaneous </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">26,106</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:390pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,100,000</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:20.98pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;14. Indemnification of Directors and Officers. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Section&#160;145 of the Delaware General Corporation Law authorizes a court to award, or a corporation&#8217;s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act of 1933, as amended, or the Securities Act. Our certificate of incorporation, as amended, allows for our indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the Delaware General Corporation Law, and our bylaws provide for indemnification of our directors and executive officers to the maximum extent permitted by the Delaware General Corporation Law. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have entered into indemnification agreements with our directors and officers, whereby we have agreed to indemnify our directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee, or agent of Adynxx, Inc., provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of Adynxx, Inc. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At present, there is no pending litigation or proceeding involving a director or officer regarding which indemnification is sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the Securities Exchange Act of 1934, as amended, that might be incurred by any director or officer in his or her capacity as such.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Item&#160;15. Recent Sales of Unregistered Securities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">The following sets forth information regarding all unregistered securities sold within the last three years: </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Issuances of Capital Stock </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In February 2017, Alliqua issued an aggregate of 92,333 shares of common stock to certain accredited investors at a purchase price per share of&#8201; $30.00.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">From April to June 2017, Alliqua issued an aggregate of 23,083 shares of common stock to certain accredited investors for no consideration pursuant to anti-dilution adjustments set forth in a securities purchase agreement entered in February 2017. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In May&#160;2019, we issued an aggregate of 4,975,548 shares of common stock to 21 stockholders in connection with the Merger. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Convertible Promissory Notes </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" margin-top:7.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">From May&#160;through August 2019, we issued and sold convertible promissory notes in the aggregate principal amount of&#8201; $1.85&#160;million to two accredited investors. The outstanding principal amount under such notes, along with any unpaid accrued interest, will automatically convert into shares of common stock at the public offering price upon the consummation of the offering to which this Registration Statement relates. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Issuances of Common Stock Warrants</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">From January to June 2017, Alliqua amended outstanding warrants to purchase common stock to provide for the purchase of an additional aggregate of 22,500 shares of common stock to one investor at an exercise price per share of&#8201; $28.20.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">In April 2017, Alliqua issued warrants to purchase up to an aggregate of 3,949 shares of common stock to a total of six investors at an exercise price per share of&#8201; $26.40.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Issuances of Restricted Stock Awards and Options to Purchase Common Stock</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(7)<br ></div>
        <div style=" margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">From March 31, 2016 through the date of this registration statement, Alliqua issued to certain employees, consultants and directors restricted stock awards for an aggregate of 45,307 shares of common stock under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(8)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">From March 31, 2016 through the date of this registration statement, Alliqua issued to certain employees, consultants and directors options to purchase an aggregate of 48,812 shares of common stock under the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan, at exercise prices ranging from $12.54 to $74.40 per share. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise specified above, we believe these transactions were exempt from registration under the Securities Act in reliance on Section&#160;4(a)(2) of the Securities Act (and Regulation&#160;D promulgated thereunder), or Rule&#160;701 promulgated under Section&#160;3(b) of the Securities Act as transactions by an issuer not involving any public offering or under benefit plans and contracts relating to compensation as provided under Rule&#160;701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Item&#160;16. Exhibits and Financial Statement Schedules. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;font-size:10pt;">(a) Exhibits. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">Exhibit&#160;Index </div>

          <table style="width:456pt;margin-top:7pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:45.51pt;" rowspan="2">
                <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Exhibit<br >Number </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:187.01pt;" rowspan="2">
                <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Description </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">Incorporation By Reference </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:30.48pt;">
                <div style="white-space:nowrap; text-align:center;">Form </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:45.92pt;">
                <div style="text-align:center;">SEC File <br >No. </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:36.29pt;">
                <div style="white-space:nowrap; text-align:center;">Exhibit </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:77pt;">
                <div style="white-space:nowrap; text-align:center;">Filing Date</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex1-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="tv531005_ex1-1.htm">1.1</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex1-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex1-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="tv531005_ex1-1.htm">Engagement Letter, dated as of June&#160;10, 2019, between Adynxx, Inc. and H.C. Wainwright &amp; Co., LLC, as amended on November&#160;7, 2019</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex1-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex1-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex1-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex1-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex1-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">2.1&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">Agreement and Plan of Merger and Reorganization, dated as of October&#160;11, 2018, as amended and supplemented from time to time, by and among Alliqua BioMedical, Inc., Embark Merger Sub, Inc., and Adynxx, Inc. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">DEFM <br >14A </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">Annex A </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">January&#160;24, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419002660/tv507918-defm14a.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">2.2&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">Amendment No. 1, dated January&#160;8, 2019, to Agreement and Plan of Merger </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">10-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">2.8 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="white-space:nowrap; text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">February&#160;22, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419009551/tv512818_ex2-8.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">2.3&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">Amendment No. 2, dated April 29, 2019, to Agreement and Plan of Merger </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">8-K</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">001-36278</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">2.3</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">April 12, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419019544/tv518790_ex2-3.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">3.1&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">Certificate of Incorporation of Alliqua BioMedical, Inc. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">3.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">June&#160;11, 2014 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">3.2&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">Certificate of Amendment to the Certificate of Incorporation dated June&#160;5, 2014 </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">3.3 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">June&#160;11, 2014 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-3.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">3.3&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">Certificate of Amendment to the Certificate of Incorporation dated May&#160;6, 2016 </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">3.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">May&#160;6, 2016 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420416099527/v439171_ex3-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">3.4&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">Certificate of Amendment to the Certificate of Incorporation dated October&#160;5, 2017 </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">3.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">October&#160;5, 2017 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417051525/v476548_ex3-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">3.5&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">Certificate of Amendment to the Certificate of Incorporation dated May&#160;3, 2019 </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">3.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143695.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">3.6&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">Certificate of Amendment to the Certificate of Incorporation dated May&#160;3, 2019 </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">3.2 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143890.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">3.7&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">Bylaws </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">3.2 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">June&#160;11, 2014 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">4.1&#8224; </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <div style="white-space:nowrap;">Reference is made to Exhibits&#160;<a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-1.htm">3.1</a> through <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex3-2.htm">3.7</a></div>
              </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">4.2&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">Form of Common Stock Certificate </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">4.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143748.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">4.3&#8201;&#8201; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">Form of Common Warrant</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">S-1</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">333-232169</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">4.3</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">October&#160;11, 2019</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-3.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">4.4&#8201;&#8201; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">Form of Pre-Funded Warrant</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">S-1</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">333-232169</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">4.4</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">October&#160;11, 2019</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex4-4.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex4-5.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="tv531005_ex4-5.htm">4.5</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex4-5.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex4-5.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="tv531005_ex4-5.htm">Form of Placement Agent Warrant </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex4-5.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex4-5.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex4-5.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex4-5.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex4-5.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">5.1&#8201;&#8201; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">Form of Opinion of Cooley LLP</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">S-1</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">333-232169</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">5.1</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">October&#160;11, 2019</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="tv531005_ex10-1.htm">10.1&#8224;&#8199;&#8201; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-1.htm">Loan and Security Agreement, dated as of November&#160;24, 2015 and as amended from time to time, including by the tenth amendment, by and among Adynxx, Inc. and Oxford Finance LLC</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">10.2+&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">Offer Letter, dated as of October&#160;15, 2010, by and between Rick Orr and Adynxx, Inc. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">10.4 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143697.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">10.3+&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">Offer Letter, dated as of January&#160;4, 2012, by and between Donald Manning, M.D., Ph.D., and Adynxx, Inc. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">10.5 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143699.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">10.4+&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">Offer Letter, dated as of September&#160;1, 2011, by and between Julien Mamet, Ph.D., and Adynxx, Inc. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">10.6 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143698.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">10.5+&#8224; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">Adynxx, Inc. 2010 Equity Incentive Plan </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">10.7 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">May&#160;9, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143700.htm">&#8203;</a>
              </td>
            </tr>
          </table>

      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">II-3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <table style="width:456pt;height:643.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:45.51pt;" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Exhibit<br >Number </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:187.01pt;" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Description </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Incorporation By Reference </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:30.48pt;">
              <div style="white-space:nowrap; text-align:center;">Form </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:45.92pt;">
              <div style="text-align:center;">SEC File<br >No. </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:36.29pt;">
              <div style="white-space:nowrap; text-align:center;">Exhibit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:77pt;">
              <div style="white-space:nowrap; text-align:center;">Filing Date</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">10.6+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">Form of Stock Option Grant Notice and Notice of Exercise under the Adynxx, Inc. 2010 Equity Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">10.8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
            <td style="padding:2.583pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">May&#160;9, 2019 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143893.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">10.7+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">2011 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">000-29819 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">10.1 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="white-space:nowrap; text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">December&#160;20, 2011 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448811005086/hplf_ex101.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">10.8+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">First Amendment to the 2011 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">000-29819 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">10.1 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="white-space:nowrap; text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">December&#160;20, 2012 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448812006529/alqa_ex101.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">10.9+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">Form of Nonstatutory Stock Option Agreement under the 2011 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">10-K/A </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">000-29819 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">10.32 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">May&#160;16, 2013 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1032.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8201;10.10+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">Form of Incentive Stock Option Agreement under the 2011 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">10-K/A </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">000-29819 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">10.33 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">May&#160;16, 2013 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000135448813002935/alqa_ex1033.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8201;10.11+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">Nonqualified Stock Option Agreement dated December&#160;20, 2013, by and between Alliqua, Inc. and David Johnson </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">000-29819 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">10.2 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="white-space:nowrap; text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">December&#160;27, 2013 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420413069217/v364047_ex10-2.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8201;10.12+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">Form of Restricted Stock Award Agreement under the 2011 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">10-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">10.62 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">March 24, 2014 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-62.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8201;10.13+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">Form of Restricted Stock Award Agreement for 2013 Executive Bonuses under the 2011 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">10-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">10.63 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">March 24, 2014 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414017298/v370705_ex10-63.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8201;10.14+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">Form of Nonqualified Stock Option Agreement (outside of any incentive plan) </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">S-8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">333-193513 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">99.8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">January&#160;23, 2014 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414003677/v365495_ex99-8.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">10.15+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:187.01pt;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">2014 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">10.1 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">June&#160;11, 2014 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414036947/v381085_ex10-1.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">10.16+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">First Amendment to the 2014 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">10.1 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">May&#160;6, 2015 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415027905/v409750_ex10-1.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">10.17+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">Form of Incentive Stock Option Agreement under the 2014 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">S-8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">333-206133 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">99.3 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">August&#160;6, 2015 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-3.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8201;10.18+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">Form of Nonqualified Stock Option Agreement under the 2014 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">S-8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">333-206133 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">99.4 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">August&#160;6, 2015 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-4.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8201;10.19+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">Form of Restricted Stock Award Agreement under the 2014 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">S-8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">333-206133 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">99.5 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">August&#160;6, 2015 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-5.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">10.20+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">Form of Restricted Stock Unit Agreement under the 2014 Long-Term Incentive Plan </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">S-8 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">333-206133 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">99.6 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">August&#160;6, 2015 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415046785/v417253_ex99-6.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">10.21+&#8224; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">Second Amendment to the Alliqua BioMedical, Inc. 2014 Long-Term Incentive Plan, effective as of June&#160;23, 2017 </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">10.1 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">June&#160;23, 2017 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417033794/v469546_ex10-1.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">10.22&#8224;&#8201; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">Form of promissory note issued to Oxford Finance LLC </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">10.2 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">May&#160;9, 2019 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143749.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">10.23&#8224;&#8201; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">Form of warrant issued to Oxford Finance LLC </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">10.3 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">May&#160;9, 2019 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919009338/ex_143696.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">10.24&#8224;&#8201; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">Form of convertible promissory note issued to Domain Partners </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">10-Q </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">10.24 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">August&#160;14, 2019 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153627.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">10.25&#8224;&#8201; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">Warrant, dated May&#160;29, 2015, by and between Alliqua BioMedical, Inc. and Perceptive Credit Opportunities Fund, LP </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">10.3 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">June&#160;1, 2015 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420415034855/v412088_ex10-3.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">10.26&#8224;&#8201; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">Amended Warrant, dated January&#160;26, 2017, by and between Alliqua BioMedical, Inc. and Perceptive Credit Holdings, LP. </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">10.2 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">January&#160;30, 2017 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417004778/v457912_ex10-2.htm">&#8203;</a>
            </td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.51pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">10.27&#8224;&#8201; </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">Amended Warrant, dated March&#160;7, 2017, by and between Alliqua BioMedical, Inc. and Perceptive Credit Holdings, LP. </a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:30.48pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">8-K </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:45.92pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">001-36278 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:36.29pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">10.2 </a>
              </div>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:0pt; width:3.38pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
            <td style="padding:2.833pt 0pt 0.5pt 0pt; width:77pt;">
              <div style="text-align:center;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">March&#160;13, 2017 </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">
              <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417014255/v461704_ex10-2.htm">&#8203;</a>
            </td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">II-4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">

          <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:45.51pt;" rowspan="2">
                <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Exhibit<br >Number </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:187.01pt;" rowspan="2">
                <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">Description </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">Incorporation By Reference </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:30.48pt;">
                <div style="white-space:nowrap; text-align:center;">Form </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:45.92pt;">
                <div style="text-align:center;">SEC File<br >No. </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:36.29pt;">
                <div style="white-space:nowrap; text-align:center;">Exhibit </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.38pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:77pt;">
                <div style="white-space:nowrap; text-align:center;">Filing Date</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">10.28&#8224;&#8201; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">Amended Warrant, dated April&#160;6, 2017, by and between Alliqua BioMedical, Inc. and Perceptive Credit Holdings, LP. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">10.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.583pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">April&#160;12, 2017 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417020139/v464094_ex10-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">10.29&#8224;&#8201; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">Form of Warrant, dated April&#160;14, 2014, by and between Alliqua, Inc. and certain accredited investors </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">10.2 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">April&#160;15, 2014 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420414022694/v374829_ex10-2.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">10.30&#8224;&#8199;&#8201; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">Form of Warrant, dated April&#160;3, 2017, by and between Alliqua BioMedical, Inc. and H.C. Wainwright &amp; Co. LLC and its designees </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">4.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">April&#160;4, 2017 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420417018819/v463525_ex4-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">10.31&#8224;&#8199; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">Sublease, dated as of February&#160;8, 2016, by and between the Registrant and REC Americas LLC, to the Office Lease, dated as of October&#160;27, 2014, by and between REC Americas LLC and 100 Pine Street Investment Group LLC </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">10-Q </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">10.31 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">August&#160;14, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_153746.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">10.32&#8224;&#8199; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">Form of Indemnification Agreement, by and between the Registrant and each of its directors and executive officers </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">10-Q </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">10.32 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">August&#160;14, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919016653/ex_154195.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">10.33&#8224;&#8199;</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">Asset Contribution and Separation Agreement between Alliqua BioMedical, Inc. and AquaMed Technologies, Inc.<font style=" position:relative; bottom:4pt;font-size:7pt;">#</font></a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">S-1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">333-232169 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">10.33 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">July&#160;25, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523729_ex10-33.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">10.34&#8199; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">Form of Securities Purchase Agreement </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:30.48pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:45.92pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:36.29pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:77pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex10-34.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">16.1&#8224;&#8199;&#8199; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">Letter from Marcum LLP to the Securities and Exchange Commission, dated May&#160;29, 2019. </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">8-K </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">001-36278 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">16.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">May&#160;31, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000143774919011171/ex_146256.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:9.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">21.1&#8224;&#8199;&#8199; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:187.01pt;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">Subsidiaries of the Registrant </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">S-1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">333-232169 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">21.1 </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.5pt 0pt 1pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">July&#160;25, 2019 </a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419035849/tv523241_ex21-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex23-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="tv531005_ex23-1.htm">23.1&#8199;&#8199;&#8199; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex23-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex23-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="tv531005_ex23-1.htm">Consent of Independent Registered Public Accounting Firm </a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="tv531005_ex23-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex23-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex23-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex23-1.htm">&#8203;</a>
              </td>
              <td colspan="3">
                <a style="-sec-extract:exhibit" href="tv531005_ex23-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">23.2&#8199;&#8199;&#8199; </a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">Consent of Cooley LLP (included in Exhibit&#160;5.1)</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:30.48pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">S-1</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.92pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">333-232169</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:36.29pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">23.2</a>
                </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:3.38pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:77pt;">
                <div style="text-align:center;">
                  <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">October&#160;11, 2019</a>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419048109/tv528145_ex5-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">24.1&#8224;&#8199;&#8199;&#8199; </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:187.01pt;white-space:normal;text-align:left;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419031211/tv523241-s1.htm#tPOA">Power of Attorney (see signature page to the </a><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419031211/tv523241-s1.htm">registration statement on Form S-1 filed June&#160;17, 2019</a> and <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1054274/000114420419041009/tv525885-s1a.htm">August&#160;22, 2019</a>) </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
            <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9.5pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:45.51pt;">
                <div style="text-align:center;">101&#8224;&#8199;&#8199;&#8201; </div>
              </td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:0pt; width:3.38pt;">&#8203;</td>
              <td style="padding:2.833pt 0pt 0.667pt 0pt; width:0pt;white-space:normal;text-align:left;" colspan="13">The following financial information of Adynxx, Inc. formatted in Extensible Business Reporting Language (XBRL) is filed herewith: (i) Balance sheets as of June&#160;30, 2019 (unaudited), December 31, 2018 and December 31, 2017; (ii) Statements of operations for the six months ended June&#160;30, 2019 (unaudited) and June&#160;30, 2018 (unaudited), and years ended December 31, 2018 and 2017; (iii)&#160;Statements of redeemable convertible preferred stock and stockholders&#39; deficit for the six months ended June&#160;30, 2019 (unaudited) and June&#160;30, 2018 (unaudited), and the years ended December 31, 2018 and 2017; (iv) Statements of cash flows for the six months ended June&#160;30, 2019 (unaudited) and June&#160;30, 2018 (unaudited), and the years ended December 31, 2018 and 2017; and (v) Notes to financial statements</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:11.8pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style=" float:left; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">+<br ></div>
          <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">Indicates management contract or compensatory plan or arrangement. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">&#8224;<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">Indicates documents that have been previously filed.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">#<br ></div>
        <div style=" margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;font-size:10pt;">(b) Financial Statement Schedules. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-size:10pt;">All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or the notes thereto. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">II-5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Item&#160;17. Undertakings. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The undersigned registrant hereby undertakes:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(i)<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(ii)<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &quot;Calculation of Registration Fee&quot; table in the effective registration statement;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(iii)<br ></div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(i)<br ></div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424 (&#167;230.424 of this chapter);</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(ii)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(iii)<br ></div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-6</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:40pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">(iv)<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:60pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
        <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-7</div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSIG">&#8203;</a>
      </div>
      <div style="margin-top:46pt;min-height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SIGNATURES </div>

          <div style="text-indent:20pt; margin-top:9.98pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Francisco, California on November&#160;8, 2019. </div>

        <div style="margin-left:240pt; margin-top:4.99pt; width:216pt; line-height:12pt;font-weight:bold;">ADYNXX, INC.</div>
        <div style=" float:left; margin-left:240pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">By:<br ></div>
        <div style=" margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:260pt;">/s/ <font style="text-transform:uppercase;">R<font style="font-size:7pt;">ick</font> O<font style="font-size:7pt;">rr</font></font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:260pt; margin-top:2.5pt; width:196pt;">
          <div style="margin-left: 0pt; width: 196pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:260pt; margin-top:2pt; width:196pt; line-height:12pt;">Name: Rick Orr <br >Title:&nbsp;&nbsp;&nbsp;President and Chief Executive Officer </div>
        <div style="text-indent:20pt; margin-top:10.98pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </div>

          <table style="width:456pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.25pt 0pt; width:114pt;">
                <div style="white-space:nowrap; text-align:center;">Signature </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.25pt 0pt; width:235pt;">
                <div style="white-space:nowrap; text-align:center;">Title </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.25pt 0pt; width:83pt;">
                <div style="white-space:nowrap; text-align:center;">Date </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:6.667pt 0pt 1.833pt 0pt; width:114pt;">
                <div style="text-align:center;">/s/ <font style="text-transform:uppercase;">R<font style="font-size:7pt;">ick</font> O<font style="font-size:7pt;">rr</font></font></div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Rick Orr </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:6.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;font-style:italic;">
                  <font style="font-style:normal;">President and Chief Executive Officer and Director</font> <br >(Principal Executive Officer and Principal Financial&#160;Officer)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:6.667pt 0pt 1.833pt 0pt; width:83pt;white-space:nowrap;">
                <div style="white-space:nowrap; text-align:center;">November&#160;8, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">/s/<font style="text-transform:uppercase;"> D<font style="font-size:7pt;">ina</font> G<font style="font-size:7pt;">onzalez</font></font></div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Dina Gonzalez </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Controller <br ><font style="font-style:italic;">(Principal Accounting Officer)</font></div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="white-space:nowrap; text-align:center;">November&#160;8, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Dennis Podlesak </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Chairman of the Board of Directors </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="white-space:nowrap; text-align:center;">November&#160;8, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Stan Abel </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="white-space:nowrap; text-align:center;">November&#160;8, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Gregory J. Flesher </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="white-space:nowrap; text-align:center;">November&#160;8, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Julien Mamet, Ph.D. </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="white-space:nowrap; text-align:center;">November&#160;8, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Matthew Ruth </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="white-space:nowrap; text-align:center;">November&#160;8, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:114pt;white-space:normal;">
                <div style="text-align:center;">*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 114pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Eckard Weber, M.D. </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:235pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 1.833pt 0pt; width:83pt;">
                <div style="white-space:nowrap; text-align:center;">November&#160;8, 2019 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:9.667pt 0pt 1.833pt 0pt; width:114pt;">
                <div style=" float:left; line-height:10pt; text-align:left; width:25pt;white-space:nowrap;">*By:<br ></div>
                <div style=" line-height:10pt; text-align:left; margin-left:25pt;">/s/ <font style="text-transform:uppercase;">R<font style="font-size:7pt;">ick</font> O<font style="font-size:7pt;">rr</font></font></div>
                <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
                <div style="margin-left:25.03pt; margin-top:2.5pt;">
                  <div style="margin-left: 0pt; width: 88.97pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-left:25.03pt; margin-top:2pt;">Rick Orr<br ><font style="font-style:italic;">Attorney-in-fact</font></div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="3">&#8203;</td>
              <td colspan="3">&#8203;</td>
            </tr>
          </table>

      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tv531005_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="tv531005_ex1-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Execution Version</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">October 11, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>STRICTLY CONFIDENTIAL</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adynxx, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 Pine Street, Suite 500<BR>
San Francisco, CA 94111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Rick Orr, President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Mr. Orr:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter agreement
(this &ldquo;<U>Agreement</U>&rdquo;) constitutes the agreement between Adynxx, Inc. (the &ldquo;<U>Company</U>&rdquo;) and H.C.
Wainwright &amp; Co., LLC (&ldquo;<U>Wainwright</U>&rdquo;), that Wainwright shall serve as the sole book-running underwriter in
a firmly underwritten public offering or the exclusive placement agent in a best efforts public offering (each the &ldquo;<U>Public
Offering</U>&rdquo;) of securities of the Company (the &ldquo;<U>Securities</U>&rdquo;) during the Term (as hereinafter defined)
of this Agreement pursuant to a registration statement to be filed on Form S-1 (the &ldquo;<U>Registration Statement</U>&rdquo;)
and amends and restates that certain letter agreement, dated as of June 10, 2019, entered into between the parties. The terms of
the Public Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright
and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that
the Company shall have an obligation to issue any Securities. It is understood that Wainwright&rsquo;s assistance in the Public
Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright
deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connection with the transaction.
The Company expressly acknowledges and agrees that Wainwright&rsquo;s involvement in the Public Offering is strictly on a reasonable
best efforts basis, until such time as an Underwriting Agreement (as defined below), if any, is executed between parties, and that
the consummation of the Public Offering will be subject to, among other things, market conditions. The execution of this Agreement
does not constitute a commitment by Wainwright to purchase the Securities and does not ensure a successful Public Offering of the
Securities or the success of Wainwright with respect to securing any other financing on behalf of the Company. Only the execution
of an underwriting agreement, if any, will constitute a firm commitment by Wainwright to purchase the Securities, subject to customary
closing conditions. Wainwright may retain other brokers, dealers, agents or underwriters on its behalf in connection with the Public
Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation;
Reimbursement</U>. At the closing of the Public Offering (the &ldquo;<U>Closing</U>&rdquo;), the Company shall compensate Wainwright
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt">1.</TD><TD STYLE="text-align: justify"><I>Cash Fee</I>. The Company shall pay to Wainwright a cash fee, or as to an underwriting Public
Offering, an underwriting discount, equal to a percentage of the aggregate gross proceeds raised in the Public Offering, as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #474746"><FONT STYLE="font-size: 8pt">430
Park Avenue&nbsp; | &nbsp;New York, New York 10022&nbsp; | &nbsp;212.356.0500&nbsp; | &nbsp;www.hcwco.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #474746"><FONT STYLE="font-size: 8pt">Member:
FINRA/SIPC</FONT></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.5pt"></TD><TD STYLE="width: 18pt">a.</TD><TD STYLE="text-align: justify">If the aggregate gross proceeds raised in the Public Offering (other than any gross proceeds raised
from Domain Associates and TPG Biotechnology Partners IV, L.P or their respective affiliates or any other directors or executive
officers of the Company (collectively, the &ldquo;<U>Insiders</U>&rdquo;)) is less than $2.5 million, 7.0% of the aggregate gross
proceeds raised in the Public Offering (inclusive of any gross proceeds raised from the Insiders);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.5pt"></TD><TD STYLE="width: 18pt">b.</TD><TD STYLE="text-align: justify">If the aggregate gross proceeds raised in the Public Offering (other than any gross proceeds raised
from the Insiders) is $2.5 million or more, 7.25% of the aggregate gross proceeds raised in the Public Offering (inclusive of any
gross proceeds raised from the Insiders); or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.5pt"></TD><TD STYLE="width: 18pt">c.</TD><TD STYLE="text-align: justify">If the aggregate gross proceeds raised in the Public Offering (other than any gross proceeds raised
from Insiders is $5.0 million or more, 7.5% of the aggregate gross proceeds raised in the Public Offering (inclusive of any gross
proceeds raised from the Insiders).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt">2.</TD><TD STYLE="text-align: justify"><I>Warrant Coverage</I>. The Company shall issue to Wainwright or its designees at each Closing,
warrants (the &ldquo;<U>Wainwright Warrants</U>&rdquo;) to purchase that number of shares of common stock of the Company equal
to a percentage of the aggregate number of shares of common stock (or common stock equivalent, if applicable) placed in the Public
Offering (inclusive of the shares of common stock placed with the Insiders) (and if the Public Offering includes a &ldquo;greenshoe&rdquo;
or &ldquo;additional investment&rdquo; component, such number of shares of common stock underlying such &ldquo;greenshoe&rdquo;
or &ldquo;additional investment&rdquo; component, with the Wainwright Warrants issuable upon the exercise of such component), as
follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.5pt"></TD><TD STYLE="width: 18pt">a.</TD><TD STYLE="text-align: justify">If the aggregate gross proceeds raised in the Public Offering (other than any gross proceeds raised
from the Insiders) is less than $2.5 million, 0%;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.5pt"></TD><TD STYLE="width: 18pt">b.</TD><TD STYLE="text-align: justify">If the aggregate gross proceeds raised in the Public Offering (other than any gross proceeds raised
from the Investors is $2.5 million or more, 3.75%; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.5pt"></TD><TD STYLE="width: 18pt">c.</TD><TD STYLE="text-align: justify">If the aggregate gross proceeds raised in the Public Offering (other than any gross proceeds raised
from the Insiders is $5.0 million or more, 7.5%.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">If the Securities included in
the Public Offering are convertible, the Wainwright Warrants shall be determined by dividing the gross proceeds raised in such
Public Offering by the Offering Price (as defined hereunder). The Wainwright Warrants shall be in a customary form reasonably acceptable
to Wainwright, have a term of five (5) years and an exercise price equal to 125% of the offering price per share (or unit, if applicable)
in the applicable Public Offering and if such offering price is not available, the market price of the common stock on the date
the Public Offering is commenced (such price, the &ldquo;<U>Offering Price</U>&rdquo;). If warrants are issued to investors in
the Public Offering, the Wainwright Warrants shall have the same terms as the warrants issued to investors in the applicable Public
Offering, except that such Wainwright Warrants shall have an exercise price equal to 125% of the Offering Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt">3.</TD><TD STYLE="text-align: justify"><I>Expense Allowance</I>. Out of the proceeds of the initial Closing of the Public Offering, the
Company also agrees to pay Wainwright a management fee equal to a percentage of the aggregate gross proceeds raised in the Public
Offering, as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.5pt"></TD><TD STYLE="width: 18pt">a.</TD><TD STYLE="text-align: justify">If the aggregate gross proceeds raised in the Public Offering (other than any gross proceeds raised
from the Insiders) is less than $2.5 million, no management fee;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.5pt"></TD><TD STYLE="width: 18pt">b.</TD><TD STYLE="text-align: justify">If the aggregate gross proceeds raised in the Public Offering (other than any gross proceeds raised
from the Insiders) is $2.5 million or more, 0.5% of the aggregate gross proceeds raised in the Public Offering (inclusive of any
gross proceeds raised from the Insiders); or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 76.5pt"></TD><TD STYLE="width: 18pt">c.</TD><TD STYLE="text-align: justify">If the aggregate gross proceeds raised in the Public Offering (other than any gross proceeds raised
from Insiders is $5.0 million or more, 1.0% of the aggregate gross proceeds raised in the Public Offering (inclusive of any gross
proceeds raised from the Insiders).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">In addition, the Company also
agrees to pay Wainwright up to $150,000 for fees and expenses of legal counsel and other out-of-pocket or non-accountable expenses;
plus, if applicable, the costs associated with the use of a third-party electronic road show service (such as NetRoadshow); provided,
however, that such amount in no way limits or impairs the indemnification and contribution provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt">4.</TD><TD STYLE="text-align: justify"><I>Tail</I>. Wainwright shall be entitled to compensation under clauses (1) and (2) hereunder,
calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising
transaction of any kind (&ldquo;Tail Financing&rdquo;) to the extent that such financing or capital is provided to the Company
by investors whom Wainwright had contacted during the Term or introduced to the Company during the Term, if such Tail Financing
is consummated at any time within the 12-month period following the expiration or termination of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt">5.</TD><TD STYLE="text-align: justify"><I>Right of First Refusal</I>. If, from the date hereof until the 12-month anniversary following
the consummation of the Public Offering, the Company or any of its subsidiaries (a) decides to dispose of or acquire business units
or acquire any of its outstanding securities or make any exchange or tender offer or enter into a merger, consolidation or other
business combination or any recapitalization, reorganization, restructuring or other similar transaction, including, without limitation,
an extraordinary dividend or distributions or a spin-off or split-off, and the Company decides to retain a financial advisor for
such transaction, Wainwright (or any affiliate designated by Wainwright) shall have the right to act as the Company&rsquo;s exclusive
financial advisor for any such transaction; or (b) decides to finance or refinance any indebtedness using a manager or agent, Wainwright
(or any affiliate designated by Wainwright) shall have the right to act as sole book-runner, sole manager, sole placement agent
or sole agent with respect to such financing or refinancing; or (c) decides to raise funds by means of a public offering (other
than an at-the-market facility) or a private placement or any other capital-raising financing of equity, equity-linked or debt
securities using an underwriter or placement agent, Wainwright (or any affiliate designated by Wainwright) shall have the right
to act as sole book-running manager, sole underwriter or sole placement agent for such financing. If Wainwright or one of its affiliates
decides to accept any such engagement, the agreement governing such engagement will contain, among other things, provisions for
customary fees for transactions of similar size and nature and the provisions of this Agreement, including indemnification, which
are appropriate to such a transaction.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Term
and Termination of Engagement; Exclusivity</U>. The term of Wainwright&rsquo;s exclusive engagement will begin on the date hereof
and end on the earlier of (i) the closing of the Public Offering and (ii) six (6) months following the date hereof (the &ldquo;<U>Term</U>&rdquo;).
The Company agrees that the provisions relating to reimbursement of expenses (Paragraph A.2), tail (Paragraph A.3), right of first
refusal (Paragraph A.4) indemnification and contribution (Paragraphs F. and H.), confidentiality (Paragraph E.), conflicts (Paragraph
K.), independent contractor (Paragraph G.) and waiver of the right to trial by jury (Paragraph I.) will survive any termination
or expiration of this Agreement; provided however, that upon the execution the Underwriting Agreement (as defined below), if any,
the Engagement Letter shall terminate and no provisions of the Engagement Letter shall survive and the respective obligations of
the parties shall be governed exclusively by the terms of such Underwriting Agreement. Notwithstanding anything to the contrary
contained herein, the Company has the right to terminate the Agreement for cause in compliance with FINRA Rule 5110(f)(2)(D)(ii).
The exercise of such right of termination for cause eliminates the Company&rsquo;s obligations with respect to the provisions relating
to the tail fees and right of first refusal. Notwithstanding anything to the contrary contained in this Agreement, in the event
that the Public Offering pursuant to this Agreement shall not be carried out for any reason whatsoever during the Term, the Company
shall be obligated to pay to Wainwright its actual and accountable out-of-pocket expenses related to the Public Offering (including
the fees and disbursements of Wainwright&rsquo;s legal counsel) up to a maximum of $150,000. During Wainwright&rsquo;s engagement
hereunder: (i) the Company will not, and will not permit its representatives to, other than in coordination with Wainwright, contact
or solicit institutions, corporations or other entities or individuals as potential purchasers of the Securities and (ii) the Company
will not pursue any financing transaction which would be in lieu of the Public Offering. Furthermore, the Company agrees that during
Wainwright&rsquo;s engagement hereunder, all inquiries from prospective investors will be referred to Wainwright and will be deemed
to have been contacted by Wainwright in connection with the Public Offering. Additionally, except as set forth hereunder, the Company
represents, warrants and covenants that no brokerage or finder&rsquo;s fees or commissions are or will be payable by the Company
or any subsidiary of the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank
or other third-party with respect to the Public Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Information;
Reliance</U>. The Company shall furnish, or cause to be furnished, to Wainwright all information requested by Wainwright for the
purpose of rendering services hereunder and conducting due diligence (all such information being the &ldquo;<U>Information</U>&rdquo;).
In addition, the Company agrees to make available to Wainwright upon request from time to time the officers, directors, accountants,
counsel and other advisors of the Company. The Company recognizes and confirms that Wainwright (a) will use and rely on the Information,
including any documents provided to investors in the Public Offering (the &ldquo;<U>Offering Documents</U>&rdquo;), which shall
include any Purchase Agreement (as defined hereunder) and on information available from generally recognized public sources in
performing the services contemplated by this Agreement without having independently verified the same; (b) does not assume responsibility
for the accuracy or completeness of the Offering Documents or the Information and such other information; and (c) will not make
an appraisal of any of the assets or liabilities of the Company. Upon reasonable request, the Company will meet with Wainwright
or its representatives to discuss all information relevant for disclosure in the Registration Statement and will cooperate in any
investigation undertaken by Wainwright thereof, including any document included or incorporated by reference therein. At the Closing
of the Public Offering (and upon the closing of any &ldquo;greenshoe&rdquo; exercise), at the request of Wainwright, the Company
shall deliver such legal letters (including, without limitation, negative assurance letters), opinions, comfort letters, officers&rsquo;
and secretary certificates and good standing certificates, all in form and substance satisfactory to Wainwright and its counsel
as is customary for the Public Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Related
Agreements</U>. The Company shall enter into the following additional agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 18pt">1.</TD><TD STYLE="text-align: justify"><I>Underwritten Offering</I>. If the Public Offering is on a firm commitment underwriting basis,
the Company and Wainwright shall enter into a customary underwriting agreement in form and substance reasonably satisfactory to
Wainwright and its counsel and the Company (the &ldquo;<U>Underwriting Agreement</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 18pt">2.</TD><TD STYLE="text-align: justify"><I>Best Efforts Offering</I>. If the Public Offering is on a best efforts basis, the sale of Securities
to the investors in the Public Offering will be evidenced by a purchase agreement (&ldquo;Purchase Agreement&rdquo;) between the
Company and such investors in a form reasonably satisfactory to the Company and Wainwright. Wainwright shall be a third party beneficiary
of any representations, warranties, covenants and closing conditions made by the Company in any Offering Documents, including representations,
warranties, covenants and closing conditions made to any investor in the Public Offering. Prior to the signing of any Purchase
Agreement, officers of the Company with responsibility for financial affairs will be available to answer inquiries from prospective
investors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 18pt">3.</TD><TD STYLE="text-align: justify"><I>Escrow, Settlement and Closing</I>. If each Public Offering is not settled via delivery versus
payment (&ldquo;<U>DVP</U>&rdquo;), the Company and Wainwright may mutually agree to enter into an escrow agreement with a third
party escrow agent pursuant to which Wainwright&rsquo;s compensation and expenses shall be paid from the gross proceeds of the
Securities sold. If the Public Offering is settled in whole or in part via DVP, Wainwright shall arrange for its clearing agent
to provide the funds to facilitate such settlement. The Company shall pay Wainwright closing costs, which shall also include the
reimbursement of the out-of-pocket cost of the escrow agent or clearing agent, as applicable, which closing costs shall not exceed
$10,000.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 18pt">4.</TD><TD STYLE="text-align: justify"><I>FINRA Amendments</I>. Notwithstanding anything herein to the contrary, in the event that Wainwright
determines that any of the terms provided for hereunder shall not comply with a FINRA rule, including but not limited to FINRA
Rule 5110, then the Company shall agree to amend this Agreement (or include such revisions in the final underwriting agreement)
in writing upon the request of Wainwright to comply with any such rules; provided that any such amendments shall not provide for
terms that are less favorable to the Company than are reflected in this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>.
In the event of the consummation or public announcement of the Public Offering, Wainwright shall have the right to disclose its
participation in such Public Offering, including, without limitation, the Public Offering at its cost of &ldquo;tombstone&rdquo;
advertisements in financial and other newspapers and journals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 18pt">1.</TD><TD STYLE="text-align: justify">In connection with the Company&rsquo;s engagement of Wainwright hereunder, the Company hereby agrees
to indemnify and hold harmless Wainwright and its affiliates, and the respective controlling persons, directors, officers, members,
shareholders, agents and employees of any of the foregoing (collectively the &ldquo;<U>Indemnified Persons</U>&rdquo;), from and
against any and all claims, actions, suits, proceedings (including those of shareholders), damages, liabilities and expenses incurred
by any of them (including the reasonable fees and expenses of counsel), as incurred, whether or not the Company is a party thereto
(collectively a &ldquo;<U>Claim</U>&rdquo;), that are (A) related to or arise out of (i) any actions taken or omitted to be taken
(including any untrue statements made or any statements omitted to be made) by the Company, or (ii) any actions taken or omitted
to be taken by any Indemnified Person in connection with the Company&rsquo;s engagement of Wainwright, or (B) otherwise relate
to or arise out of Wainwright&rsquo;s activities on the Company&rsquo;s behalf under Wainwright&rsquo;s engagement, and the Company
shall reimburse any Indemnified Person for all expenses (including the reasonable fees and expenses of counsel) as incurred by
such Indemnified Person in connection with investigating, preparing or defending any such claim, action, suit or proceeding, whether
or not in connection with pending or threatened litigation in which any Indemnified Person is a party. The Company will not, however,
be responsible for any Claim that is finally judicially determined to have resulted from the gross negligence or willful misconduct
of any person seeking indemnification for such Claim. The Company further agrees that no Indemnified Person shall have any liability
to the Company for or in connection with the Company&rsquo;s engagement of Wainwright except for any Claim incurred by the Company
as a result of such Indemnified Person&rsquo;s gross negligence or willful misconduct.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 18pt">2.</TD><TD STYLE="text-align: justify">The Company further agrees that it will not, without the prior written consent of Wainwright, settle,
compromise or consent to the entry of any judgment in any pending or threatened Claim in respect of which indemnification may be
sought hereunder (whether or not any Indemnified Person is an actual or potential party to such Claim), unless such settlement,
compromise or consent includes an unconditional, irrevocable release of each Indemnified Person from any and all liability arising
out of such Claim.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 18pt">3.</TD><TD STYLE="text-align: justify">Promptly upon receipt by an Indemnified Person of notice of any complaint or the assertion or institution
of any Claim with respect to which indemnification is being sought hereunder, such Indemnified Person shall notify the Company
in writing of such complaint or of such assertion or institution but failure to so notify the Company shall not relieve the Company
from any obligation it may have hereunder, except and only to the extent such failure results in the forfeiture by the Company
of substantial rights and defenses. If the Company is requested by such Indemnified Person, the Company will assume the defense
of such Claim, including the employment of counsel for such Indemnified Person and the payment of the fees and expenses of such
counsel, provided, however, that such counsel shall be satisfactory to the Indemnified Person and provided further that if the
legal counsel to such Indemnified Person reasonably determines that the use of counsel chosen by the Company to represent the Indemnified
Person would present such counsel with a conflict of interest or if the defendant in, or target of, any such Claim, includes an
Indemnified Person and the Company, and legal counsel to such Indemnified Person reasonably concludes that there may be legal defenses
available to it or other Indemnified Persons different from or in addition to those available to the Company, such Indemnified
Person will employ its own separate counsel (including local counsel, if necessary) to represent or defend him, her or it in any
such Claim and the Company shall pay the reasonable fees and expenses of such counsel. If such Indemnified Person does not request
that the Company assume the defense of such Claim, such Indemnified Person will employ its own separate counsel (including local
counsel, if necessary) to represent or defend him, her or it in any such Claim and the Company shall pay the reasonable fees and
expenses of such counsel. Notwithstanding anything herein to the contrary, if the Company fails timely or diligently to defend,
contest, or otherwise protect against any Claim, the relevant Indemnified Person shall have the right, but not the obligation,
to defend, contest, compromise, settle, assert crossclaims, or counterclaims or otherwise protect against the same, and shall be
fully indemnified by the Company therefor, including without limitation, for the reasonable fees and expenses of its counsel and
all amounts paid as a result of such Claim or the compromise or settlement thereof. In addition, with respect to any Claim in which
the Company assumes the defense, the Indemnified Person shall have the right to participate in such Claim and to retain his, her
or its own counsel therefor at his, her or its own expense.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 18pt">4.</TD><TD STYLE="text-align: justify">The Company agrees that if any indemnity sought by an Indemnified Person hereunder is held by a
court to be unavailable for any reason then (whether or not Wainwright is the Indemnified Person), the Company and Wainwright shall
contribute to the Claim for which such indemnity is held unavailable in such proportion as is appropriate to reflect the relative
benefits to the Company, on the one hand, and Wainwright on the other, in connection with Wainwright&rsquo;s engagement referred
to above, subject to the limitation that in no event shall the amount of Wainwright&rsquo;s contribution to such Claim exceed the
amount of fees actually received by Wainwright from the Company pursuant to Wainwright&rsquo;s engagement. The Company hereby agrees
that the relative benefits to the Company, on the one hand, and Wainwright on the other, with respect to Wainwright&rsquo;s engagement
shall be deemed to be in the same proportion as (a) the total value paid or proposed to be paid or received by the Company pursuant
to the applicable Public Offering (whether or not consummated) for which Wainwright is engaged to render services bears to (b)
the fee paid or proposed to be paid to Wainwright in connection with such engagement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 94.5pt"></TD><TD STYLE="width: 18pt">5.</TD><TD STYLE="text-align: justify">The Company&rsquo;s indemnity, reimbursement and contribution obligations under this Agreement
(a) shall be in addition to, and shall in no way limit or otherwise adversely affect any rights that any Indemnified Person may
have at law or at equity and (b) shall be effective whether or not the Company is at fault in any way.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">G.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
of Engagement to the Company</U>. The Company acknowledges that Wainwright has been retained only by the Company, that Wainwright
is providing services hereunder as an independent contractor (and not in any fiduciary or agency capacity) and that the Company&rsquo;s
engagement of Wainwright is not deemed to be on behalf of, and is not intended to confer rights upon, any shareholder, owner or
partner of the Company or any other person not a party hereto as against Wainwright or any of its affiliates, or any of its or
their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act or Section 20
of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;)), employees or agents. Unless otherwise
expressly agreed in writing by Wainwright, no one other than the Company is authorized to rely upon this Agreement or any other
statements or conduct of Wainwright, and no one other than the Company is intended to be a beneficiary of this Agreement. The
Company acknowledges that any recommendation or advice, written or oral, given by Wainwright to the Company in connection with
Wainwright&rsquo;s engagement is intended solely for the benefit and use of the Company&rsquo;s management and directors in considering
a possible Public Offering, and any such recommendation or advice is not on behalf of, and shall not confer any rights or remedies
upon, any other person or be used or relied upon for any other purpose. Wainwright shall not have the authority to make any commitment
binding on the Company. The Company, in its sole discretion, shall have the right to reject any investor introduced to it by Wainwright.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">H.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
of Wainwright&rsquo;s Liability to the Company</U>. Wainwright and the Company further agree that neither Wainwright nor any of
its affiliates or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of
the Securities Act or Section 20 of the Exchange Act), employees or agents shall have any liability to the Company, its security
holders or creditors, or any person asserting claims on behalf of or in the right of the Company (whether direct or indirect, in
contract, tort, for an act of negligence or otherwise) for any losses, fees, damages, liabilities, costs, expenses or equitable
relief arising out of or relating to this Agreement or the services rendered hereunder, except for losses, fees, damages, liabilities,
costs or expenses that arise out of or are based on any action of or failure to act by Wainwright and that are finally judicially
determined to have resulted solely from the gross negligence or willful misconduct of Wainwright.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements
made and to be fully performed therein. Any disputes that arise under this Agreement, even after the termination of this Agreement,
will be heard only in the state or federal courts located in the City of New York, State of New York. The parties hereto expressly
agree to submit themselves to the jurisdiction of the foregoing courts in the City of New York, State of New York. The parties
hereto expressly waive any rights they may have to contest the jurisdiction, venue or authority of any court sitting in the City
and State of New York. In the event Wainwright or any Indemnified Person is successful in any action, or suit against the Company,
arising out of or relating to this Agreement, the final judgment or award entered shall be entitled to have and recover from the
Company the costs and expenses incurred in connection therewith, including its reasonable attorneys&rsquo; fees. Any rights to
trial by jury with respect to any such action, proceeding or suit are hereby waived by Wainwright and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">J.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices hereunder will be in writing and sent by certified mail, hand delivery, overnight delivery, fax or e-mail, if sent
to Wainwright, at the address set forth on the first page hereof, e-mail: notices@hcwco.com, Attention: Head of Investment Banking,
and if sent to the Company, to the address set forth on the first page hereof, e-mail: Rick Orr, Attention: President and Chief
Executive Officer. Notices sent by certified mail shall be deemed received five days thereafter, notices sent by hand delivery
or overnight delivery shall be deemed received on the date of the relevant written record of receipt, notices delivered by fax
shall be deemed received as of the date and time printed thereon by the fax machine and notices sent by e-mail shall be deemed
received as of the date and time they were sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">K.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conflicts</U>.
The Company acknowledges that Wainwright and its affiliates may have and may continue to have investment banking and other relationships
with parties other than the Company pursuant to which Wainwright may acquire information of interest to the Company. Wainwright
shall have no obligation to disclose such information to the Company or to use such information in connection with any contemplated
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">L.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Anti-Money
Laundering</U>. To help the United States government fight the funding of terrorism and money laundering, the federal laws of the
United States require all financial institutions to obtain, verify and record information that identifies each person with whom
they do business. This means Wainwright must ask the Company for certain identifying information, including a government-issued
identification number (e.g., a U.S. taxpayer identification number) and such other information or documents that Wainwright considers
appropriate to verify the Company&rsquo;s identity, such as certified articles of incorporation, a government-issued business license,
a partnership agreement or a trust instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">M.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.
The Company represents and warrants that it has all requisite power and authority to enter into and carry out the terms and provisions
of this Agreement and the execution, delivery and performance of this Agreement does not breach or conflict with any agreement,
document or instrument to which it is a party or bound. This Agreement shall not be modified or amended except in writing signed
by Wainwright and the Company. This Agreement shall be binding upon and inure to the benefit of both Wainwright and the Company
and their respective assigns, successors, and legal representatives. This Agreement constitutes the entire agreement of Wainwright
and the Company with respect to the subject matter hereof and supersedes any prior agreements with respect to the subject matter
hereof. If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will
not affect such provision in any other respect, and the remainder of the Agreement shall remain in full force and effect. This
Agreement may be executed in counterparts (including facsimile or electronic counterparts), each of which shall be deemed an original
but all of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In acknowledgment that the foregoing correctly
sets forth the understanding reached by Wainwright and the Company, please sign in the space provided below, whereupon this letter
shall constitute a binding Agreement as of the date indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>H.C. WAINWRIGHT &amp; CO., LLC</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:&nbsp;&nbsp;<U>/s/ Edward D. Silvera&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Edward D. Silvera</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: Chief Operating Officer </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: 10/11/2019</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 238.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted and Agreed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Adynxx, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:&nbsp;&nbsp; <U>/s/ Rick Orr&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Name: Rick Orr</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Title: President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="tv531005_ex1-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">November 7, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>STRICTLY CONFIDENTIAL</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Adynxx, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 Pine Street, Suite 500<BR>
San Francisco, CA 94111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Rick Orr, President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Mr. Orr:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reference is hereby
made to that certain engagement agreement (the &ldquo;<U>Agreement</U>&rdquo;), dated as of October 11, 2019, by and between Adynxx,
Inc. (the &ldquo;<U>Company</U>&rdquo;) and H.C. Wainwright &amp; Co., LLC (&ldquo;<U>Wainwright</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and Wainwright
hereby agree to amend the Engagement Agreement (the &ldquo;<U>Amendment</U>&rdquo;), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following sentence
shall be added at the end of Section A.2, Warrant Coverage:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;For the avoidance
of doubt, Wainwright shall not be entitled to Wainwright Warrants with respect to any shares of common stock underlying warrants
to be issued in an Offering to investors, other than with respect to shares of common stock underlying pre-funded warrants.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as expressly
set forth above, all of the terms and conditions of the Agreement shall continue in full force and effect after the execution of
this Amendment. Defined terms used herein but not defined herein shall have the meanings given to such terms in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amendment may
be executed in two or more counterparts and by facsimile or &ldquo;.pdf&rdquo; signature or otherwise, and each of such counterparts
shall be deemed an original and all of such counterparts together shall constitute one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature page follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #474746"><FONT STYLE="font-size: 8pt">430
Park Avenue&nbsp; | &nbsp;New York, New York 10022&nbsp; | &nbsp;212.356.0500&nbsp; | &nbsp;www.hcwco.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #474746"><FONT STYLE="font-size: 8pt">Member:
FINRA/SIPC</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In acknowledgment that
the foregoing correctly sets forth the understanding reached by Wainwright and the Company, please sign in the space provided below,
whereupon this Amendment shall constitute a binding agreement as of the date indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>H.C. WAINWRIGHT &amp; CO., LLC</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:&nbsp;&nbsp;<U>/s/ Edward D. Silvera&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Edward D. Silvera</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: Chief Operating Officer </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 238.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted and Agreed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Adynxx, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:&nbsp;&nbsp; <U>/s/ Rick Orr&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Name: Rick Orr</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Title: President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Options: NewSection Last; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>3
<FILENAME>tv531005_ex4-5.htm
<DESCRIPTION>EXHIBIT 4.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.5</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLACEMENT AGENT COMMON STOCK PURCHASE
WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADYNXX,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Warrant Shares: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: right"><FONT STYLE="font-size: 10pt">Initial Exercise Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Issue Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">THIS PLACEMENT AGENT&rsquo;S WARRANT TO PURCHASE
COMMON STOCK (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after [ISSUE DATE] (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on
or prior to 5:00 p.m.&nbsp;(New York City time) on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2024<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT>
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Adynxx,&nbsp;Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>2</SUP></FONT>
(as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share
of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b). This Warrant is issued
pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright &amp; Co., LLC, dated as of October
11, 2019, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section&nbsp;1</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section&nbsp;1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then
listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as
applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group,&nbsp;Inc. (or a similar organization or
agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or
(d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which
banking institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Common Stock Equivalents</U>&rdquo;
means any securities of the Company or any subsidiaries of the Company which would entitle the holder thereof to acquire at any
time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT>The date that is the five (5) year anniversary of the effective date of the registration statement for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP></FONT>The total number of Warrant Shares to be issued shall be calculated based on the shares of common stock sold in the
offering and the shares of common stock underlying pre-funded warrants sold in the offering and shall exclude any shares of common
stock underlying investors&rsquo; warrants sold in the offering.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo; means
an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Registration Statement</U>&rdquo;
means the Company&rsquo;s registration statement on Form&nbsp;S-1 (File No.&nbsp;333-232169).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question:
the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange
(or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means Action Stock Transfer Corporation, the current transfer agent of the Company, with a mailing address of 2469 E. Fort Union
Blvd, Suite 214, Salt Lake City, Utah 84121, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo; means,
for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as
applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported in the &ldquo;Pink Sheets&rdquo; published by OTC Markets Group,&nbsp;Inc. (or a similar organization or
agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or
(d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section&nbsp;2</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Exercise of Warrants</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other
office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder
appearing on the books of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the
form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and
(ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein)
following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price to the Company for the Warrant
Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in the applicable Notice of Exercise. No&nbsp;ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice
of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been
exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder
and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice. <B>The Holder
and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Without limiting the rights of a Holder to
receive Warrant Shares on a &ldquo;cashless exercise&rdquo; and without limiting the liquidated damages provision in Section&nbsp;2(d)(i)&nbsp;and
the buy-in provision in Section&nbsp;2(d)(iv), in no event will the Company be required to net cash settle a Warrant exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise Price</U>. The exercise price per Warrant Share under this Warrant shall be $[&bull;], subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised,
in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.7pt">(A)&nbsp;=&nbsp;&nbsp; as applicable: (i)&nbsp;the
VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both
executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both executed and
delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule&nbsp;600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at
the option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of
Exercise or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the
time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours
after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the
VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of
Exercise is both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof after the close of &ldquo;regular trading hours&rdquo;
on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.7pt">(B)&nbsp;=&nbsp;&nbsp; the Exercise Price, as adjusted
hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt">(X)&nbsp;=&nbsp;&nbsp; the number of Warrant Shares
that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means
of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">If Warrant Shares are issued in
such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company agrees
not to take any position contrary to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 82pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with
The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is
then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the
Warrant Shares to or resale of the Warrant Shares by the Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise
and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder
or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified
by the Holder in the Notice of Exercise by the date that is the earlier of (i)&nbsp;the earlier of (A)&nbsp;two (2)&nbsp;Trading
Days after the delivery to the Company of the Notice of Exercise and (B)&nbsp;one (1)&nbsp;Trading Day after delivery of the aggregate
Exercise Price to the Company and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the
Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that
payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i)&nbsp;two
(2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following delivery of
the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of
Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth (5th) Trading Day after such liquidated
damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or
Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long
as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the
standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to
the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section&nbsp;2(d)(i)&nbsp;by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with
the provisions of Section&nbsp;2(d)(i)&nbsp;above pursuant to an exercise on or before the Warrant Share Delivery Date, and if
after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares
which the Holder anticipated receiving upon such exercise but did not receive (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company
shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying
(1)&nbsp;the number of Warrant Shares that the Company was required to deliver, but failed to deliver, to the Holder in connection
with the exercise at issue times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed,
and (B)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for
which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number
of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations
hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect
to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000,
under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder
shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request
of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies
available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive
relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No&nbsp;Fractional Shares or Scrip</U>. No&nbsp;fractional shares or scrip representing fractional shares shall be issued upon
the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal
to such fraction multiplied by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">vi.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by
the Holder; <U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name
of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice
of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions)
required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">vii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates,
and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution
Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise
or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence,
for purposes of this Section&nbsp;2(e), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;and regulations promulgated thereunder, it being acknowledged by the Holder that the Company
is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d)&nbsp;of the Exchange Act and
the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership
Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination
as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act
and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the number of
outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public
announcement by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number
of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one (1)&nbsp;Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the
number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such
number of outstanding shares of Common Stock was reported. The &ldquo; <U>Beneficial Ownership Limitation</U>&rdquo; shall be
[9.99/4.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial
Ownership Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock upon exercise of this Warrant held by the Holder and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply.
Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to
the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section&nbsp;2(e)&nbsp;to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to
properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section&nbsp;3</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend
or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues
by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall
become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the
Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property
pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder
could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant
(without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately
before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken,
the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in
the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other
than cash) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock other than
as set forth in Section&nbsp;3(a), by way of return of capital or otherwise (including, without limitation, any distribution of
stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme
of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would
have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this
Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such
extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the
portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more
related transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company, directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or
more of the outstanding Common Stock, (iv)&nbsp;the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly
or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or
group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including
any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the
other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental
Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each
Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
at the option of the Holder (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the
number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and/or any additional consideration (the &ldquo;<U>Alternate Consideration</U> &ldquo;) receivable as a result of such Fundamental
Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such
Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to
the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the
Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental
Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant
from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised portion
of this Warrant on the date of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, if the Fundamental
Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, Holder
shall only be entitled to receive from the Company or any Successor Entity, as of the date of consummation of such Fundamental
Transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes Value (as defined below)
of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether
the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the
Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black and Scholes
Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement
of the applicable Fundamental Transaction and the Termination Date, (B)&nbsp;an expected volatility equal to the greater of 100%
and the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public
announcement of the applicable Fundamental Transaction, (C)&nbsp;the underlying price per share used in such calculation shall
be the greater of (i)&nbsp;the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration,
if any, being offered in such Fundamental Transaction and (ii)&nbsp;the greater of (x)&nbsp;the last VWAP immediately prior to
the public announcement of such Fundamental Transaction and (y)&nbsp;the last VWAP immediately prior to the consummation of such
Fundamental Transaction and (D)&nbsp;a remaining option time equal to the time between the date of the public announcement of
the applicable Fundamental Transaction and the Termination Date.&nbsp; The payment of the Black Scholes Value will be made by
wire transfer of immediately available funds within five Business Days of the Holder&rsquo;s election (or, if later, on the effective
date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under
this Warrant in accordance with the provisions of this Section&nbsp;3(d)&nbsp;pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction
and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such
Fundamental Transaction, and with an Exercise price which applies the Exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value
of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity
shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this
Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such
Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may
be. For purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3,
the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notice to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C)&nbsp;the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for
or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company
shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company
is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or
involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to
be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant
Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice
stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or
warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such
dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification,
consolidation, liquidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as
of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, liquidation, merger, sale, transfer
or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not
affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in
this Warrant constitutes, or contains, material, non-public information regarding the Company or any subsidiaries of the Company,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder
shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of
the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section&nbsp;4</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Transferability</U>. Pursuant to FINRA Rule 5110(g)(1), neither this Warrant nor any Warrant Shares issued upon exercise of
this Warrant shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative,
put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of
180 days immediately following the date of effectiveness or commencement of sales of the offering pursuant to which this Warrant
is being issued, except the transfer of any security:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">i.</TD><TD>by operation of law or by reason of reorganization of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">ii.</TD><TD>to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred
remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time period;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">iii.</TD><TD>if the aggregate amount of securities of the Company held by the underwriter or related persons do not exceed 1% of the securities
being offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">iv.</TD><TD>that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member
manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the
equity in the fund; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">v.</TD><TD>the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section
4(a) for the remainder of the time period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Subject to the foregoing restriction,
this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant
in full, in which case, the Holder shall surrender this Warrant to the Company within two (2)&nbsp;Trading Days of the date on
which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in
accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section&nbsp;5</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No&nbsp;Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or
other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Saturdays, Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any
right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on
the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">The Company covenants that during
the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares
to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing
the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized,
validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the
issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Except and to the extent as waived
or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will
at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality
of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor
upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal
courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall
commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or
proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred
with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Nonwaiver and Expenses</U>. No&nbsp;course of dealing or any delay or failure to exercise any right hereunder on the part of
Holder shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting
any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to
cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by email, or sent by a nationally recognized
overnight courier service, addressed to the Company, at Adynxx,&nbsp;Inc., 100 Pine Street, Suite 500, San Francisco, California
94111, Attention: Principal Financial Officer, email address: rorr@adynxx.com, or such other facsimile number, email address or
address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries
to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally
recognized overnight courier service addressed to each Holder at the facsimile number,&nbsp; e-mail address or address of such
Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and
effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via facsimile at the
facsimile number or via e-mail at the e-mail address set forth in this Section&nbsp;prior to 5:30 p.m.&nbsp;(New York City time)
on any date, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or via e-mail at the email address set forth in this Section&nbsp;on a day that is not a Trading Day or
later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (iii)&nbsp;the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the party to whom such notice
is required to be given.&nbsp; To the extent that any notice provided hereunder constitutes, or contains, material, non-public
information regarding the Company or any subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant
to a Current Report on Form&nbsp;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Limitation of Liability</U>. No&nbsp;provision hereof, in the absence of any affirmative action by the Holder to exercise this
Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any
liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is
asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be
adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to
waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or
the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">IN WITNESS WHEREOF, the Company has caused
this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADYNXX,&nbsp;INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B>ADYNXX,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(1)&nbsp;&nbsp; The undersigned hereby elects
to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warrant Shares of the Company pursuant to the terms of the attached
Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(2)&nbsp;&nbsp; Payment shall take the form
of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-family: Wingdings">o</FONT> in lawful
money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-family: Wingdings">o</FONT> if permitted
the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(3)&nbsp;&nbsp; Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrant Shares shall be delivered to the following DWAC
Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Name of Investing Entity:</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name of Authorized Signatory:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title of Authorized Signatory:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.75pt"><I>(To assign the foregoing Warrant, execute
this form and supply required information.&nbsp; Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing Warrant
and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Phone Number:</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Email Address:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dated:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Holder&rsquo;s Address:</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>tv531005_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LOAN AND SECURITY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS LOAN AND SECURITY
AGREEMENT </B>(as the same may from time to time be amended, modified, supplemented or restated, this &ldquo;<B>Agreement</B>&rdquo;)
dated as of November 24, 2015 (the &ldquo;<B>Effective Date</B>&rdquo;) among OXFORD FINANCE LLC, a Delaware limited liability
company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (&ldquo;<B>Oxford</B>&rdquo;), as collateral
agent (in such capacity, &ldquo;<B>Collateral Agent</B>&rdquo;), the Lenders listed on <U>Schedule 1.1</U> hereof or otherwise
a party hereto from time to time including Oxford in its capacity as a Lender (each a &ldquo;<B>Lender</B>&rdquo; and collectively,
the &ldquo;<B>Lenders</B>&rdquo;), and ADYNXX, INC., a Delaware corporation with an office at 731 Market Street, Suite 420, San
Francisco, California 94103 (&ldquo;<B>Borrower</B>&rdquo;), provides the terms on which the Lenders shall lend to Borrower and
Borrower shall repay the Lenders. The parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B><U>ACCOUNTING AND OTHER TERMS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><B>1.1 </B>&nbsp;Accounting
terms not defined in this Agreement shall be construed in accordance with GAAP. Calculations and determinations must be made in
accordance with GAAP. Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section 13.
All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent
such terms are defined therein. All references to &ldquo;<B>Dollars</B>&rdquo; or &ldquo;<B>$</B>&rdquo; are United States Dollars,
unless otherwise noted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B><U>LOANS AND TERMS OF PAYMENT</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.1&nbsp;&nbsp;Promise to Pay. </B>Borrower hereby unconditionally promises to pay each Lender, the outstanding principal amount of all Term Loans
advanced to Borrower by such Lender and accrued and unpaid interest thereon and any other amounts due hereunder as and when due
in accordance with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.2&nbsp;&nbsp;Term
Loans.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;<U>Availability.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1in">(i) Subject to the terms
and conditions of this Agreement, the Lenders agree, severally and not jointly, to make term loans to Borrower on the Effective
Date in an aggregate amount of Three Million Dollars ($3,000,000.00) according to each Lender&rsquo;s Term A Loan Commitment as
set forth on <U>Schedule 1.1</U> hereto (such term loans are hereinafter referred to singly as a &ldquo;<B>Term A Loan</B>&rdquo;,
and collectively as the &ldquo;<B>Term A Loans</B>&rdquo;). After repayment, no Term A Loan may be re-borrowed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1in">(ii) Subject to the
terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Second Draw Period, to make term
loans to Borrower in an aggregate amount up to Two Million Dollars ($2,000,000.00) according to each Lender&rsquo;s Term B Loan
Commitment as set forth on <U>Schedule 1.1</U> hereto (such term loans are hereinafter referred to singly as a &ldquo;<B>Term B
Loan</B>&rdquo;, and collectively as the &ldquo;<B>Term B Loans</B>&rdquo;). After repayment, no Term B Loan may be re-borrowed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1in">(iii) Subject to the
terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Third Draw Period, to make term
loans to Borrower in an aggregate amount up to Five Million Dollars ($5,000,000.00) according to each Lender&rsquo;s Term C Loan
Commitment as set forth on <U>Schedule 1.1</U> hereto (such term loans are hereinafter referred to singly as a &ldquo;<B>Term C
Loan</B>&rdquo;, and collectively as the &ldquo;<B>Term C Loans</B>&rdquo;; each Term A Loan, Term B Loan or Term C Loan is hereinafter
referred to singly as a &ldquo;<B>Term Loan</B>&rdquo; and the Term A Loans, Term B Loans and the Term C Loans are hereinafter
referred to collectively as the &ldquo;<B>Term Loans</B>&rdquo;). After repayment, no Term C Loan may be re-borrowed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.75in">(b) <U>Repayment</U>.
Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of
each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately
preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest
payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. Commencing
on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive monthly
payments of equal amounts of principal, and the applicable interest, in arrears, to each Lender, as calculated by Collateral Agent
(which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender&rsquo;s Term Loan,
(2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to (i) thirty-six (36)
months if the Equity Event does not occur, or (ii) thirty (30) months if the Equity Event does occur. All unpaid principal and
accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may
only be prepaid in accordance with Sections 2.2(c) and 2.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c) <U>Mandatory Prepayments.</U>
If the Term Loans are accelerated following the occurrence of an Event of Default, Borrower shall immediately pay to Lenders, payable
to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of: (i) all outstanding principal of
the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (ii) the Final Payment, (iii) the Prepayment
Fee, plus (iv) all other Obligations that are due and payable, including Lenders&rsquo; Expenses and interest at the Default Rate
with respect to any past due amounts. Notwithstanding (but without duplication with) the foregoing, on the Maturity Date, if the
Final Payment had not previously been paid in full in connection with the prepayment of the Term Loans in full, Borrower shall
pay to Collateral Agent, for payment to each Lender in accordance with its respective Pro Rata Share, the Final Payment in respect
of the Term Loan(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(d) <U>Permitted Prepayment
of Term Loans.</U> Borrower shall have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders
under this Agreement, provided Borrower (i) provides written notice to Collateral Agent of its election to prepay the Term Loans
at least ten (10) days prior to such prepayment (and if such notice of prepayment indicates that such prepayment is to be funded
with the proceeds of a refinancing or in connection with the consummation of a specified transaction, such notice of prepayment
may be revoked if the financing or specified transaction is not consummated), and (ii) pays to the Lenders on the date of such
prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A) all outstanding
principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (B) the Final Payment, (C) the
Prepayment Fee, plus (D) all other Obligations that are due and payable, including Lenders&rsquo; Expenses and interest at the
Default Rate with respect to any past due amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.3&nbsp;&nbsp;Payment
of Interest on the Credit Extensions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) <U>Interest Rate.</U>
Subject to Section 2.3(b), the principal amount outstanding under the Term Loans shall accrue interest at a floating per annum
rate equal to the Basic Rate, which interest shall be payable monthly in arrears in accordance with Sections 2.2(b) and 2.3(e).
Interest shall accrue on each Term Loan commencing on, and including, the Funding Date of such Term Loan, and shall accrue on the
principal amount outstanding under such Term Loan through and including the day on which such Term Loan is paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) <U>Default Rate</U>.
Immediately upon the occurrence and during the continuance of an Event of Default, Obligations shall accrue interest at a per annum
floating rate equal to the rate that is otherwise applicable thereto plus five percentage points (5.00%) (the &ldquo;<B>Default
Rate</B>&rdquo;). Payment or acceptance of the increased interest rate provided in this Section 2.3(b) is not a permitted alternative
to timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies
of Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c) <U>360-Day Year.</U>
Interest shall be computed on the basis of a three hundred sixty (360) day year, and the actual number of days elapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(d) <U>Debit of Accounts</U>.
Collateral Agent and each Lender may debit (or ACH), first the Designated Deposit Account, and second, any other deposit accounts
maintained by Borrower or any of its Subsidiaries, for principal and interest payments or any other amounts Borrower owes the Lenders
under the Loan Documents when due. Any such debits (or ACH activity) shall not constitute a set-off. Without limiting the foregoing,
Collateral Agent and each Lender shall use commercially reasonably efforts to provide prior notification to the Borrower for the
reasons, and amounts thereof, of debiting of any amounts (other than principal and interest payments) debited from Borrower&rsquo;s
deposit accounts in respect of this Agreement; provided, however, failure to provide such notice shall not be considered a breach
of any provision hereof by Collateral Agent or any Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(e) <U>Payments.</U>
Except as otherwise expressly provided herein, all payments by Borrower under the Loan Documents shall be made to the respective
Lender to which such payments are owed, at such Lender&rsquo;s office in immediately available funds on the date specified herein.
Unless otherwise provided, interest is payable monthly on the Payment Date of each month. Payments of principal and/or interest
received after 2:00 p.m. Eastern time are considered received at the opening of business on the next Business Day (unless such
payments are received after 2:00 p.m. Eastern time as a result of any Lender debiting Borrower&rsquo;s account after 2:00 p.m.
Eastern time, in which case such payments are considered received the date such payment was due). When a payment is due on a day
that is not a Business Day, the payment is due the next Business Day and additional fees or interest, as applicable, shall continue
to accrue until paid. All payments to be made by Borrower hereunder or under any other Loan Document, including payments of principal
and interest, and all fees, expenses, indemnities and reimbursements, shall be made without set-off, recoupment or counterclaim,
in lawful money of the United States and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.4 Secured
Promissory Notes. </B>The Term Loans shall be evidenced by one or more Secured Promissory Notes substantially in the form
attached as <U>Exhibit D</U> hereto (each a &ldquo;<B>Secured Promissory Note</B>&rdquo;), and shall be repayable as set
forth in this Agreement. Borrower irrevocably authorizes each Lender to make or cause to be made, on or about the Funding
Date of any Term Loan or at the time of receipt of any payment of principal on such Lender&rsquo;s Secured Promissory Note,
an appropriate notation on such Lender&rsquo;s Secured Promissory Note Record reflecting the making of such Term Loan or (as
the case may be) the receipt of such payment. The outstanding amount of each Term Loan set forth on such Lender&rsquo;s
Secured Promissory Note Record shall be prima facie evidence of the principal amount thereof owing and unpaid to such Lender,
but the failure to record, or any error in so recording, any such amount on such Lender&rsquo;s Secured Promissory Note
Record shall not limit or otherwise affect the obligations of Borrower under any Secured Promissory Note or any other Loan
Document to make payments of principal of or interest on any Secured Promissory Note when due. Upon receipt of an affidavit
in form and content reasonably acceptable to Borrower of an officer of a Lender as to the loss, theft, destruction, or
mutilation of its Secured Promissory Note<B>, </B>Borrower shall issue, in lieu thereof, a replacement Secured Promissory
Note in the same principal amount thereof and of like tenor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.5&nbsp; Fees. </B>Borrower
shall pay to Collateral Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) <U>Facility Fee.</U>&nbsp;&nbsp;&nbsp;A
fully earned, non-refundable facility fee of Fifty Thousand Dollars ($50,000.00) to be shared between the Lenders pursuant to their
respective Commitment Percentages payable on the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) <U>Good Faith
Deposit</U>. An amount of Thirty Thousand Dollars ($30,000.00) as good faith deposit from Borrower (which Collateral Agent acknowledges
was received on or about October 5, 2015) and shall be applied towards the facility fee payable under Section 2.5(a) on the Effective
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c) <U>Final Payment.</U>
The Final Payment, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(d) <U>Prepayment
Fee.</U> The Prepayment Fee, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata
Shares; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(e) <U>Lenders&rsquo;
Expenses.</U> All Lenders&rsquo; Expenses (including reasonable attorneys&rsquo; fees and expenses for documentation and negotiation
of this Agreement) incurred through and after the Effective Date, when due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.6 Withholding.
</B>Payments received by the Lenders from Borrower hereunder will be made free and clear of and without deduction for any and all
present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or other charges imposed by any governmental
authority (including any interest, additions to tax or penalties applicable thereto). Specifically, however, if at any time any
Governmental Authority, applicable law, regulation or international agreement requires Borrower to make any withholding or deduction
from any such payment or other sum payable hereunder to the Lenders, Borrower hereby covenants and agrees that the amount due from
Borrower with respect to such payment or other sum payable hereunder will be increased to the extent necessary to ensure that,
after the making of such required withholding or deduction, each Lender receives a net sum equal to the sum which it would have
received had no withholding or deduction been required and Borrower shall pay the full amount withheld or deducted to the relevant
Governmental Authority; provided, that a Lender that shall have become a Lender pursuant to a Lender Transfer shall be entitled
to receive only such additional amounts as such Lender&rsquo;s assignor would have been entitled to receive pursuant to this Section
2.6. Borrower will, upon request, furnish the Lenders with proof reasonably satisfactory to the Lenders indicating that Borrower
has made such withholding payment; provided, however, that Borrower need not make any withholding payment if the amount or validity
of such withholding payment is contested in good faith by appropriate and timely proceedings and as to which payment in full is
bonded or reserved against by Borrower. The agreements and obligations of Borrower contained in this Section 2.6 shall survive
the termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.</B></TD><TD STYLE="text-align: justify"><B><U>CONDITIONS OF LOANS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.1 Conditions Precedent
to Initial Credit Extension. </B>Each Lender&rsquo;s obligation to make a Term A Loan is subject to the condition precedent that
Collateral Agent and each Lender shall consent to or shall have received, in form and substance satisfactory to Collateral Agent
and each Lender, such documents, and completion of such other matters, as Collateral Agent and each Lender may reasonably deem
necessary or appropriate, including, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) original Loan
Documents, each duly executed by Borrower and each Subsidiary, as&nbsp;applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) duly executed
original Control Agreements with respect to any Collateral Accounts maintained by Borrower or any of its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c) duly executed
original Secured Promissory Notes in favor of each Lender according to its Term A Loan Commitment Percentage;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(d) the Operating
Documents and good standing certificates of Borrower and its Subsidiaries certified by the Secretary of State (or equivalent agency)
of Borrower&rsquo;s and such Subsidiaries&rsquo; jurisdiction of organization or formation and each jurisdiction in which Borrower
and each Subsidiary is qualified to conduct business, each as of a date no earlier than thirty (30) days prior to the Effective
Date<B>;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(e) a completed Perfection
Certificate for Borrower and each of its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(f) the Annual Projections,
for the current calendar year;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(g) duly executed
original officer&rsquo;s certificate for Borrower and each Subsidiary that is a party to the Loan Documents, in a form reasonably
acceptable to Collateral Agent and the Lenders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(h) certified copies,
dated as of date no earlier than thirty (30) days prior to the Effective Date, of financing statement searches, as Collateral Agent
shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such
financing statements either constitute Permitted Liens or have been or, in connection with the initial Credit Extension, will be
terminated or released;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(i) a landlord&rsquo;s
consent executed in favor of Collateral Agent in respect of all of Borrower&rsquo;s and each Subsidiaries&rsquo; leased locations
where Borrower or any Subsidiary maintains Collateral having a book value in excess of One Hundred Thousand Dollars ($100,000.00)
or its books or records;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(j) a bailee waiver
executed in favor of Collateral Agent in respect of each third party bailee where Borrower or any Subsidiary maintains Collateral
having a book value in excess of One Hundred Thousand Dollars ($100,000.00);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(k) a duly executed
legal opinion of counsel to Borrower dated as of the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(l) evidence satisfactory
to Collateral Agent and the Lenders that the insurance policies required by Section 6.5 hereof are in full force and effect, together
with appropriate evidence showing loss payable and/or additional insured clauses or endorsements in favor of Collateral Agent,
for the ratable benefit of the Lenders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(m) a copy of any
applicable Registration Rights Agreement or Investors&rsquo; Rights Agreement and any amendments thereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(n) payment of the
fees and Lenders&rsquo; Expenses then due, as specified in Section 2.5 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.2&nbsp;&nbsp;Conditions
Precedent to all Credit Extensions. </B>The obligation of each Lender to make each Credit Extension, including the initial Credit
Extension, is subject to the following conditions precedent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) receipt by Collateral
Agent of an executed Disbursement Letter in the form of <U>Exhibit B</U>&nbsp;attached hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) the representations
and warranties in Section 5 hereof shall be true, accurate and complete in all material respects on the date of the Disbursement
Letter and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall not be applicable
to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided,
further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in
all material respects as of such date, and no Event of Default shall have occurred and be continuing or result from the Credit
Extension. Each Credit Extension is Borrower&rsquo;s representation and warranty on that date that the representations and warranties
in Section 5 hereof are true, accurate and complete in all material respects; provided, however, that such materiality qualifier
shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text
thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true,
accurate and complete in all material respects as of such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c) in such Lender&rsquo;s
sole but reasonable discretion, there has not been any Material Adverse Change or any material adverse deviation by Borrower from
the Annual Projections of Borrower presented to and accepted by Collateral Agent and each Lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(d) to the extent
not delivered at the Effective Date, duly executed original Secured Promissory Notes and Warrants, in number, form and content
acceptable to each Lender, and in favor of each Lender according to its Commitment Percentage, with respect to each Credit Extension
made by such Lender after the Effective Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(e) payment of the
fees and Lenders&rsquo; Expenses then due as specified in Section 2.5 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.3 Covenant to Deliver.
</B>Borrower agrees to deliver to Collateral Agent and the Lenders each item required to be delivered to Collateral Agent under
this Agreement as a condition precedent to any Credit Extension. Borrower expressly agrees that a Credit Extension made prior to
the receipt by Collateral Agent or any Lender of any such item shall not constitute a waiver by Collateral Agent or any Lender
of Borrower&rsquo;s obligation to deliver such item, and any such Credit Extension in the absence of a required item shall be made
in each Lender&rsquo;s sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.4 Procedures for
Borrowing. </B>Subject to the prior satisfaction of all other applicable conditions to the making of a Term Loan set forth in this
Agreement, to obtain a Term Loan, Borrower shall notify the Lenders (which notice shall be irrevocable) by electronic mail, facsimile,
or telephone by 12:00 noon Eastern time three (3) Business Days prior to the date the Term Loan is to be made. Together with any
such electronic, facsimile or telephonic notification, Borrower shall deliver to the Lenders by electronic mail or facsimile a
completed Disbursement Letter executed by a Responsible Officer or his or her designee. The Lenders may rely on any telephone notice
given by a person whom a Lender reasonably believes is a Responsible Officer or designee. On the Funding Date, each Lender shall
credit and/or transfer (as applicable) to the Designated Deposit Account, an amount equal to its Term Loan Commitment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>4.</B></TD><TD STYLE="text-align: justify"><B><U>CREATION OF SECURITY INTEREST</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.1 Grant of Security
Interest. </B>Borrower hereby grants Collateral Agent, for the ratable benefit of the Lenders, to secure the payment and performance
in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent, for the ratable benefit
of the Lenders, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products
thereof. Borrower represents, warrants, and covenants that the security interest granted herein is and shall at all times continue
to be a first priority perfected security interest in the Collateral, subject only to Permitted Liens that are permitted by the
terms of this Agreement to have priority to Collateral Agent&rsquo;s Lien. If Borrower shall acquire a commercial tort claim (as
defined in the Code) with an anticipated value in excess of $25,000, Borrower, shall promptly notify Collateral Agent in a writing
signed by Borrower, as the case may be, of the general details thereof (and further details as may be required by Collateral Agent)
and grant to Collateral Agent, for the ratable benefit of the Lenders, in such writing a security interest therein and in the proceeds
thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Collateral
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Agreement is
terminated, Collateral Agent&rsquo;s Lien in the Collateral shall continue until the Obligations (other than inchoate indemnity
obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) are repaid in full
in cash. Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations and any other obligations which,
by their terms, are to survive the termination of this Agreement) and at such time as the Lenders&rsquo; obligation to make Credit
Extensions has terminated, Collateral Agent shall, at the sole cost and expense of Borrower, (i) release its Liens in the Collateral
and all rights therein shall revert to Borrower, (ii) execute and deliver to Borrower all documents that Borrower reasonably requests
to evidence the release of the security interest in the Collateral and (iii) deliver to Borrower any stock certificates and other
Collateral in Collateral Agent&rsquo;s possession.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.2 Authorization
to File Financing Statements. </B>Borrower hereby authorizes Collateral Agent to file financing statements or take any other action
required to perfect Collateral Agent&rsquo;s security interests in the Collateral, without notice to Borrower, with all appropriate
jurisdictions to perfect or protect Collateral Agent&rsquo;s interest or rights under the Loan Documents, including a notice that
any disposition of the Collateral, except to the extent permitted by the terms of this Agreement, by Borrower, or any other Person,
shall be deemed to violate the rights of Collateral Agent under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.</B></TD><TD STYLE="text-align: justify"><B><U>REPRESENTATIONS AND WARRANTIES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower represents
and warrants to Collateral Agent and the Lenders as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.1 Due Organization,
Authorization: Power and Authority. </B>Borrower and each of its Subsidiaries is duly existing and in good standing as a Registered
Organization in its jurisdictions of organization or formation and Borrower and each of its Subsidiaries is qualified and licensed
to do business and is in good standing in any jurisdiction in which the conduct of its businesses or its ownership of property
requires that it be qualified except where the failure to do so could not reasonably be expected to have a Material Adverse Change.
In connection with this Agreement, Borrower and each of its Subsidiaries has delivered to Collateral Agent a completed perfection
certificate signed by an officer of Borrower or such Subsidiary (each a &ldquo;<B>Perfection Certificate</B>&rdquo; and collectively,
the &ldquo;<B>Perfection Certificates</B>&rdquo;). Borrower represents and warrants that (a) Borrower and each of its Subsidiaries&rsquo;
exact legal name is that which is indicated on its respective Perfection Certificate and on the signature page of each Loan Document
to which it is a party; (b) Borrower and each of its Subsidiaries is an organization of the type and is organized in the jurisdiction
set forth on its respective Perfection Certificate; (c) each Perfection Certificate accurately sets forth each of Borrower&rsquo;s
and its Subsidiaries&rsquo; organizational identification number or accurately states that Borrower or such Subsidiary has none;
(d) each Perfection Certificate accurately sets forth Borrower&rsquo;s and each of its Subsidiaries&rsquo; place of business, or,
if more than one, its chief executive office as well as Borrower&rsquo;s and each of its Subsidiaries&rsquo; mailing address (if
different than its chief executive office); (e) Borrower and each of its Subsidiaries (and each of its respective predecessors)
have not, in the past five (5) years, changed its jurisdiction of organization, organizational structure or type, or any organizational
number assigned by its jurisdiction; and (f) all other information (other than amounts on deposit in deposit, investment, payroll
or securities accounts) set forth on the Perfection Certificates pertaining to Borrower and each of its Subsidiaries, is accurate
and complete in all material respects (it being understood and agreed that Borrower and each of its Subsidiaries may from time
to time update certain information in the Perfection Certificates (including the information set forth in clause (d) above) after
the Effective Date pursuant to Section 6.2(b) and such Perfection Certificates shall be deemed updated as of the first day of such
month corresponding to the Compliance Certificate delivered); such updated Perfection Certificates subject to the review and approval
of Collateral Agent. If Borrower or any of its Subsidiaries is not now a Registered Organization but later becomes one, Borrower
shall notify Collateral Agent of such occurrence and provide Collateral Agent with such Person&rsquo;s organizational identification
number within five (5) Business Days of receiving such organizational identification number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The execution, delivery
and performance by Borrower and each of its Subsidiaries of the Loan Documents to which it is a party have been duly authorized,
and do not (i) conflict with any of Borrower&rsquo;s or such Subsidiaries&rsquo; organizational documents, including its respective
Operating Documents, (ii) contravene, conflict with, constitute a default under or violate any material Requirement of Law applicable
thereto, (iii) contravene, conflict or violate any material applicable order, writ, judgment, injunction, decree, determination
or award of any Governmental Authority by which Borrower or such Subsidiary, or any of their property or assets may be bound or
affected, (iv) require any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental
Authority (except such Governmental Approvals which have already been obtained and are in full force and effect) or are being obtained
pursuant to Section 6.1(b), or (v) constitute an event of default under any material agreement by which Borrower or any of such
Subsidiaries, or their respective properties, is bound. Neither Borrower nor any of its Subsidiaries is in default under any agreement
to which it is a party or by which it or any of its assets is bound in which such default could reasonably be expected to have
a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.2 Collateral.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) Borrower and each
its Subsidiaries have good title to, have rights in, and the power to transfer each item of the Collateral upon which it purports
to grant a Lien under the Loan Documents, free and clear of any and all Liens except Permitted Liens, and neither Borrower nor
any of its Subsidiaries have any Deposit Accounts, Securities Accounts, Commodity Accounts or other investment accounts other than
the Collateral Accounts or the other investment accounts, if any, described in the Perfection Certificates delivered to Collateral
Agent in connection herewith with respect of which Borrower or such Subsidiary has given Collateral Agent notice and taken such
actions as are necessary to give Collateral Agent a perfected security interest therein other than with respect to Excluded Accounts.
The Accounts are bona fide, existing obligations of the Account Debtors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) On the Effective
Date, and except as disclosed on the Perfection Certificate (i) the Collateral is not in the possession of any third party bailee
(such as a warehouse), and (ii) no such third party bailee possesses components of the Collateral in excess of One Hundred Thousand
Dollars ($100,000.00). None of the components of the Collateral (other than locations where Collateral is held solely for, or in
transition to or from, a clinical study for research and development purposes) are maintained at locations other than as disclosed
in the Perfection Certificates on the Effective Date or as permitted pursuant to Section 6.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c) All Inventory
is in all material respects of good and marketable quality, free from&nbsp;material defects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(d) Borrower and each
of its Subsidiaries is the sole owner of the Intellectual Property each respectively purports to own, free and clear of all Liens
other than Permitted Liens. Except as noted on the Perfection Certificates, neither Borrower nor any of its Subsidiaries is a party
to, nor is bound by, any material license or other material agreement with respect to which Borrower or such Subsidiary is the
licensee that (i) prohibits or otherwise restricts Borrower or its Subsidiaries from granting a security interest in Borrower&rsquo;s
or such Subsidiaries&rsquo; interest in such material license or material agreement or any other property, or (ii) for which a
default under or termination of could interfere with Collateral Agent&rsquo;s or any Lender&rsquo;s right to sell any Collateral.
Borrower shall provide written notice to Collateral Agent and each Lender within ten (10) days of Borrower or any of its Subsidiaries
entering into or becoming bound by any license or agreement with respect to which Borrower or any Subsidiary is the licensee (other
than over-the-counter software that is commercially available to the public).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.3 Litigation. </B>Except
as disclosed (i) on the Perfection Certificates, or (ii) in accordance with Section 6.9 hereof, there are no actions, suits, investigations,
or proceedings pending or, to the knowledge of the Responsible Officers, threatened in writing by or against Borrower or any of
its Subsidiaries involving more than One Hundred Fifty Thousand Dollars ($150,000.00).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.4 No Material Deterioration
in Financial Condition; Financial Statements. </B>All consolidated financial statements for Borrower and its Subsidiaries, delivered
to Collateral Agent fairly present, in conformity with GAAP, in all material respects the consolidated financial condition of Borrower
and its Subsidiaries, and the consolidated results of operations of Borrower and its Subsidiaries, subject, in the case of interim
financial statements, to normal year audit adjustments and absence of footnotes. There has not been any material deterioration
(excluding, for the avoidance of doubt, operating losses in the ordinary course of business that are consistent with the then applicable
Annual Projections) in the consolidated financial condition of Borrower and its Subsidiaries since the date of the most recent
financial statements submitted to any Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.5 Solvency. </B>Borrower
is Solvent and Borrower and its Subsidiaries, taken as a whole, are Solvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.6 Regulatory Compliance.
</B>Neither Borrower nor any of its Subsidiaries is an &ldquo;investment company&rdquo; or a company &ldquo;controlled&rdquo; by
an &ldquo;investment company&rdquo; under the Investment Company Act of 1940, as amended. Neither Borrower nor any of its Subsidiaries
is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal
Reserve Board of Governors). Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair
Labor Standards Act. Neither Borrower nor any of its Subsidiaries is a &ldquo;holding company&rdquo; or an &ldquo;affiliate&rdquo;
of a &ldquo;holding company&rdquo; or a &ldquo;subsidiary company&rdquo; of a &ldquo;holding company&rdquo; as each term is defined
and used in the Public Utility Holding Company Act of 2005. Neither Borrower nor any of its Subsidiaries has violated any laws,
ordinances or rules, the violation of which could reasonably be expected to have a Material Adverse Change. Neither Borrower&rsquo;s
nor any of its Subsidiaries&rsquo; properties or assets has been used by Borrower or such Subsidiary or, to Borrower&rsquo;s knowledge,
by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material
compliance with applicable laws. Borrower and each of its Subsidiaries has obtained all consents, approvals and authorizations
of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue
their respective businesses as currently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of Borrower, any
of its Subsidiaries, or any of Borrower&rsquo;s or its Subsidiaries&rsquo; Affiliates or any of their respective agents acting
or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism
Law, (ii) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding
or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person. None of Borrower,
any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity
in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving
any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages
in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No.13224, any similar
executive order or other Anti-Terrorism Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.7 Investments.
</B>Neither Borrower nor any of its Subsidiaries owns any stock, shares, partnership interests or other equity securities except
for Permitted Investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.8 Tax Returns and
Payments; Pension Contributions. </B>Borrower and each of its Subsidiaries has timely filed all required tax returns and reports,
and Borrower and each of its Subsidiaries, has timely paid all foreign and federal taxes, assessments, deposits and contributions
(and all material state and local taxes, assessments, deposits and contributions owed by Borrower and such Subsidiaries, in all
jurisdictions in which Borrower or any such Subsidiary is subject to state and local taxes, assessments, deposits and contributions
in an aggregate amount of $50,000 or more for Borrower and all Subsidiaries together), unless such taxes are being contested in
accordance with the following sentence. Borrower and each of its Subsidiaries, may defer payment of any contested taxes, provided
that Borrower or such Subsidiary, (a) in good faith contests its obligation to pay the taxes by appropriate proceedings promptly
and diligently instituted and conducted, (b) if such contested amount is in excess of $50,000, notifies Collateral Agent in writing
of the commencement of, and any material development in, the proceedings, and (c) posts bonds or takes any other steps required
to prevent the Governmental Authority levying such contested taxes from obtaining a Lien upon any of the Collateral that is other
than a &ldquo;<B>Permitted Lien</B>.&rdquo; Neither Borrower nor any of its Subsidiaries is aware of any claims or adjustments
proposed for any of Borrower&rsquo;s or such Subsidiaries&rsquo;, prior tax years which could result in material additional taxes
becoming due and payable by Borrower or its Subsidiaries. Borrower and each of its Subsidiaries have paid all amounts necessary
to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms, and neither Borrower
nor any of its Subsidiaries have, withdrawn from participation in, and have not permitted partial or complete termination of, or
permitted the occurrence of any other event with respect to, any such plan, in each case, which could reasonably be expected to
result in any material liability of Borrower or its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation
or its successors or any other Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.9 Use of Proceeds.
</B>Borrower shall use the proceeds of the Credit Extensions solely as working capital and to fund its general business requirements
in accordance with the provisions of this Agreement (including, without limitation, for Permitted Investments), and not for personal,
family, household or agricultural purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.10 Full Disclosure.
</B>No written representation, warranty or other statement of Borrower in any certificate or written statement given to Collateral
Agent or any Lender, as of the date such representation, warranty, or other statement was made, taken together with all such written
certificates and written statements given to Collateral Agent or any Lender, contains any untrue statement of a material fact or
omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading (it
being recognized that the projections and forecasts provided by Borrower were prepared in good faith and based upon reasonable
assumptions at the time provided and are not to be viewed as facts and that actual results during the period or periods covered
by such projections and forecasts may differ from the projected or forecasted results).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.11 Definition of
</B>&ldquo;<B>Knowledge.</B>&rdquo; For purposes of the Loan Documents, whenever a representation or warranty is made to Borrower&rsquo;s
knowledge or awareness, to the &ldquo;best of&rdquo; Borrower&rsquo;s knowledge, or with a similar qualification, knowledge or
awareness means the actual knowledge, after reasonable investigation, of the Responsible Officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B><U>AFFIRMATIVE COVENANTS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower shall, and
shall cause each of its Subsidiaries to, do all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.1 Government Compliance.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) Maintain its and
all its Subsidiaries&rsquo; legal existence and good standing in their respective jurisdictions of organization and maintain qualification
in each jurisdiction in which the failure to so qualify could reasonably be expected to have a Material Adverse Change. Comply
with all laws, ordinances and regulations to which Borrower or any of its Subsidiaries is subject, the noncompliance with which
could reasonably be expected to have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) Obtain and keep
in full force and effect, all of the material Governmental Approvals necessary for the performance by Borrower and its Subsidiaries
of their respective businesses and obligations under the Loan Documents and the grant of a security interest to Collateral Agent
for the ratable benefit of the Lenders, in all of the Collateral. Borrower shall promptly (but in any event on or prior to the
next Monthly Reporting Date) provide notice to Collateral Agent of any material Governmental Approvals obtained by Borrower or
any of its Subsidiaries and if requested by Collateral Agent, also provide copies of such Governmental Approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.2&nbsp; Financial
Statements, Reports, Certificates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a)&nbsp;&nbsp;&nbsp;Deliver
to each Lender:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) as soon as available,
but no later than thirty (30) days after the last day of each month, a company prepared consolidated and consolidating balance
sheet, income statement and cash flow statement covering the consolidated operations of Borrower and its Subsidiaries for such
month certified by a Responsible Officer and in a form reasonably acceptable to Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) as soon as available,
but no later than (x) September 30th of the calendar year occurring after the last day of Borrower&rsquo;s fiscal year or (y) if
Borrower becomes subject to the reporting requirements under the Securities Exchange Act of 1934, as amended, one hundred twenty
(120) days after the last day of Borrower&rsquo;s fiscal year or within five (5) days of filing with the SEC, audited consolidated
financial statements prepared under GAAP, consistently applied, together with an unqualified opinion (other than any &ldquo;going
concern&rdquo; or like qualification or exception solely in connection with the need to raise equity) on the financial statements
from BDO USA, LLP or another independent certified public accounting firm acceptable to Collateral Agent in its reasonable discretion
(provided, however, Borrower must also deliver to each Lender such financial statements for its fiscal year ended December 31,
2014, on or before November 30, 2015);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii) as soon as available
after approval thereof by Borrower&rsquo;s Board of Directors, but no later than sixty (60) days after the last day of each of
Borrower&rsquo;s fiscal years, Borrower&rsquo;s annual financial projections for the entire current fiscal year as approved by
Borrower&rsquo;s Board of Directors, which such annual financial projections shall be set forth in a month-by-month format (such
annual financial projections as originally delivered to Collateral Agent and the Lenders are referred to herein as the &ldquo;<B>Annual
Projections</B>&rdquo;; provided that, any revisions of the Annual Projections approved by Borrower&rsquo;s Board of Directors
shall be delivered to Collateral Agent and the Lenders no later than seven (7) days after such approval);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv) within five (5)
days of delivery, copies of all statements, reports and notices regarding substantive matters made available to Borrower&rsquo;s
security holders or holders of Subordinated Debt in their capacity as security holders or holders of Subordinated Debt, respectively;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v) in the event that
Borrower becomes subject to the reporting requirements under the Securities Exchange Act of 1934, as amended, within five (5) days
of filing, all reports on Form 10-K, 10-Q and 8-K filed with the Securities and Exchange Commission,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi) prompt notice of
any material amendments to the capitalization table of Borrower and of any amendments or changes to the Operating Documents of
Borrower or any of its Subsidiaries, together with any copies reflecting such amendments or changes with respect thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vii) prompt notice
of any event that could reasonably be expected to materially and adversely affect the value of the Intellectual Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(viii) as soon as available,
but no later than thirty (30) days after the last day of each month, copies of the month-end account statements for each Collateral
Account maintained by Borrower or its Subsidiaries, which statements may be provided to Collateral Agent and each Lender by Borrower
or directly from the applicable institution(s), and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ix) other information
as reasonably requested by Collateral Agent or any Lender, in&nbsp;good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, documents
required to be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed
with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which
Borrower posts such documents, or provides a link thereto, on Borrower&rsquo;s website on the internet at Borrower&rsquo;s website
address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) Concurrently with
the delivery of the financial statements specified in Section 6.2(a)(i) above but no later than thirty (30) days after the last
day of each month, deliver to each Lender, a duly completed Compliance Certificate signed by a Responsible Officer, which such
Compliance Certificate shall include any updates necessary to cause the information in the existing Perfection Certificates to
be true and correct in all material respects (and such existing Perfection Certificates shall be deemed amended by delivery of
such Compliance Certificate upon review and approval by Collateral Agent of such updates to such information for the purpose of
incorporation in the Perfection Certificates). Notwithstanding anything herein to the contrary, upon the reasonable request of
Collateral Agent, Borrower shall promptly provide a revised and updated Perfection Certificate the information wherein shall be
then current and which shall be subject to review and approval of Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c) Keep proper books
of record and account in accordance with GAAP in all material respects, in which full, true and correct entries shall be made of
all dealings and transactions in relation to its business and activities. Borrower shall allow, subject to following sentence,
Collateral Agent or any Lender, during regular business hours upon reasonable prior notice (provided that no notice shall be required
when an Event of Default has occurred and is continuing), to visit and inspect any of its properties, to examine and make abstracts
or copies from any of its books and records, and to conduct a collateral audit and analysis of its operations and the Collateral.
Such inspections and audits shall be at the Borrower&rsquo;s expense and conducted no more often than once every year unless (and
more frequently if) an Event of Default has occurred and is continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.3 Inventory; Returns.
</B>Keep all Inventory in good and marketable condition, free from material defects. Borrower must promptly notify (but in any
event on or prior to the next Monthly Reporting Date) Collateral Agent and the Lenders of all returns, recoveries, disputes and
claims that involve more than One Hundred Thousand Dollars ($100,000.00) individually or in the aggregate to any one or related
Account Debtors in any calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.4 Taxes; Pensions.
</B>Timely file and require each of its Subsidiaries to timely file, all required tax returns and reports and timely pay, and require
each of its Subsidiaries to timely file, all foreign, federal, state, and local taxes, assessments, deposits and contributions
owed by Borrower or its Subsidiaries, except for deferred payment of any taxes contested pursuant to the terms of Section 5.8 hereof,
and shall deliver to Lenders, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to
fund all present pension, profit sharing and deferred compensation plans in accordance with the terms of such plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.5 Insurance. </B>Keep
Borrower&rsquo;s and its Subsidiaries&rsquo; business and the Collateral insured for risks and in amounts standard for companies
in Borrower&rsquo;s and its Subsidiaries&rsquo; industry and location and as Collateral Agent may reasonably request. Insurance
policies shall be in a form, with companies, and in amounts that are reasonably satisfactory to Collateral Agent and Lenders (it
being agreed that all insurance policies of the Borrower that are in effect as of the Effective Date are satisfactory to Collateral
Agent and Lenders as of the Effective Date). All property policies shall have a lender&rsquo;s loss payable endorsement showing
Collateral Agent as lender loss payee and waive subrogation against Collateral Agent, and all liability policies shall show, or
have endorsements showing, Collateral Agent, as additional insured. The Collateral Agent shall be named as lender loss payee and/or
additional insured with respect to any such insurance providing coverage in respect of any Collateral, and each provider of any
such insurance shall agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to
the Collateral Agent, that it will give the Collateral Agent thirty (30) days prior written notice before any such policy or policies
shall be materially altered or canceled (except for ten (10) days prior written notice in the case of cancellation due to non-payment
of premiums). At Collateral Agent&rsquo;s request, Borrower shall deliver certified copies of policies and evidence of all premium
payments. Proceeds payable under any policy shall, at Collateral Agent&rsquo;s option, be payable to Collateral Agent, for the
ratable benefit of the Lenders, on account of the Obligations. Notwithstanding the foregoing, (a) so long as no Event of Default
has occurred and is continuing, Borrower shall have the option of applying the proceeds of any casualty policy up to Two Hundred
Fifty Thousand Dollars ($250,000.00) with respect to any loss, but not exceeding Two Hundred Fifty Thousand Dollars ($250,000.00),
in the aggregate for all losses under all casualty policies in any one year, toward the replacement or repair of destroyed or damaged
property; provided that any such replaced or repaired property (i) shall be of equal or like value as the replaced or repaired
Collateral and (ii) shall be deemed Collateral in which Collateral Agent has been granted a first priority security interest, and
(b) after the occurrence and during the continuance of an Event of Default, all proceeds payable under such casualty policy shall,
at the option of Collateral Agent, be payable to Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations.
If Borrower or any of its Subsidiaries fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish
any required proof of payment to third persons, Collateral Agent and/or any Lender may make, at Borrower&rsquo;s expense, all or
part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies Collateral
Agent or such Lender deems prudent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.6&nbsp; Operating
Accounts.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) Maintain all of
Borrower&rsquo;s and its Subsidiaries&rsquo; Collateral Accounts in accounts which are subject to a Control Agreement in favor
of Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) Borrower shall
provide Collateral Agent five (5) days&rsquo; prior written notice before Borrower or any of its Subsidiaries establishes any Collateral
Account. In addition, for each Collateral Account that Borrower or any of its Subsidiaries, at any time maintains, Borrower or
such Subsidiary shall cause the applicable bank or financial institution at or with which such Collateral Account is maintained
to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Collateral
Agent&rsquo;s Lien in such Collateral Account in accordance with the terms hereunder prior to the establishment of such Collateral
Account, which Control Agreement may not be terminated without prior written consent of Collateral Agent. The provisions of the
previous sentence shall not apply to Excluded Accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c) Neither Borrower
nor any of its Subsidiaries shall maintain any Collateral Accounts except Collateral Accounts maintained in accordance with Sections
6.6(a) and (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.7 Protection of
Intellectual Property Rights. </B>Borrower shall: (a) use commercially reasonable efforts to protect, defend and maintain the validity
and enforceability of its Intellectual Property that is material to Borrower&rsquo;s business; (b) promptly advise Collateral Agent
in writing of material infringement by a third party of its Intellectual Property, which is material to the Borrower&rsquo;s business;
and (c) not allow any Intellectual Property material to Borrower&rsquo;s business, to be abandoned, forfeited or dedicated to the
public without Collateral Agent&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.8 Litigation Cooperation.
</B>Commencing on the Effective Date and continuing through the termination of this Agreement, make available to Collateral Agent
and the Lenders, without expense to Collateral Agent or the Lenders, Borrower and each of Borrower&rsquo;s officers, employees
and agents and Borrower&rsquo;s Books, upon reasonable prior notice and at reasonable places and times to the extent that Collateral
Agent or any Lender may reasonably deem them necessary to prosecute or defend any third-party suit or proceeding instituted by
or against Collateral Agent or any Lender with respect to any Collateral or relating to Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.9 Notices of Litigation
and Default. </B>Borrower will give prompt written notice to Collateral Agent and the Lenders, upon obtaining knowledge, of any
litigation or governmental proceedings pending or threatened (in writing) against Borrower or any of its Subsidiaries, which could
reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries of One Hundred Fifty Thousand Dollars
($150,000.00) or more or which could reasonably be expected to have a Material Adverse Change. Without limiting or contradicting
any other more specific provision of this Agreement, promptly (and in any event within three (3) Business Days) upon Borrower becoming
aware of the existence of any Event of Default or event which, with the giving of notice or passage of time, or both, would constitute
an Event of Default, Borrower shall give written notice to Collateral Agent and the Lenders of such occurrence, which such notice
shall include a reasonably detailed description of such Event of Default or event which, with the giving of notice or passage of
time, or both, would constitute an Event of Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.10 Intentionally
Omitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.11 Landlord Waivers;
Bailee Waivers. </B>In the event that Borrower or any of its Subsidiaries, after the Effective Date, intends to add any new offices
or business locations, including warehouses, or otherwise store any portion of the Collateral with, or deliver any portion of the
Collateral to, a bailee, in each case pursuant to Section 7.2, then Borrower or such Subsidiary will first notify Collateral Agent
and, in the event that the Collateral at any new location is valued in excess of One Hundred Thousand ($100,000.00) in the aggregate
or includes any books or records of Borrower or any of its Subsidiaries, such bailee or landlord, as applicable, must execute and
deliver a bailee waiver or landlord waiver, as applicable, in form and substance reasonably satisfactory to Collateral Agent on
or prior to the addition of any new offices or business locations, or any such storage with or delivery to any such bailee, as
the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.12 Creation/Acquisition
of Subsidiaries. </B>In the event Borrower, or any of its Subsidiaries creates or acquires any Subsidiary, Borrower shall provide
prior written notice to Collateral Agent and each Lender of the creation or acquisition of such new Subsidiary and take all such
action as may be reasonably required by Collateral Agent or any Lender to cause each such Subsidiary to become a co-Borrower hereunder
or to guarantee the Obligations of Borrower under the Loan Documents and, in each case, grant a continuing pledge and security
interest in and to the assets of such Subsidiary (substantially as described on <U>Exhibit A</U> hereto); and Borrower (or its
Subsidiary, as applicable) shall grant and pledge to Collateral Agent, for the ratable benefit of the Lenders, a perfected security
interest in the stock, units or other evidence of ownership of each such newly created Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.13 Further Assurances</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) Execute any further
instruments and take further action as Collateral Agent or any Lender reasonably requests to perfect or continue Collateral Agent&rsquo;s
Lien in the Collateral or to effect the purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) Deliver to Collateral
Agent and Lenders, within five (5) days after the same are sent or received, copies of all material correspondence, reports, documents
and other filings with any Governmental Authority that could reasonably be expected to have a material adverse effect on any of
the Governmental Approvals material to Borrower&rsquo;s business or otherwise could reasonably be expected to have a Material Adverse
Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.</B></TD><TD STYLE="text-align: justify"><B><U>NEGATIVE COVENANTS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower shall not,
and shall not permit any of its Subsidiaries to, do any of the following without the prior written consent of the Required Lenders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.1 Dispositions.
</B>Convey, sell, lease, transfer, assign, or otherwise dispose of (collectively, &ldquo;<B>Transfer</B>&rdquo;), or permit any
of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (a) of Inventory in the ordinary
course of business; (b) of worn out, damaged, surplus or obsolete Equipment; (c) in connection with Permitted Liens, Permitted
Investments, Permitted Licenses, transactions permitted by Section 7.3 and transactions permitted by Section 7.7(a); (d) of Accounts
in connection with the compromise, settlement or collection thereof in the ordinary course of business (and not as part of a bulk
sale or receivables financing), provided, however, the aggregate value of such Accounts during any given fiscal year shall not
exceed $100,000; (e) resulting from any casualty or other damage to, or any taking under power of eminent domain or by condemnation
or similar proceedings, the aggregate value of which shall not exceed $100,000; and (f) not otherwise permitted in this Section
7.1, the aggregate value of which shall not exceed $100,000 in the aggregate in any fiscal year, provided, however such disposition
shall not be of Intellectual Property or any licenses to Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.2 Changes in Business,
Management, Ownership, or Business Locations. </B>(a) Engage in or permit any of its Subsidiaries to engage in any business other
than the businesses engaged in by Borrower as of the Effective Date or reasonably related thereto; (b) liquidate or dissolve; or
(c) (i) any Key Person shall cease to be actively engaged in the management of Borrower unless written notice thereof is provided
to Collateral Agent within 5 days of such change, or (ii) consummate any transaction or series of related transactions in which
the stockholders of Borrower who were not stockholders immediately prior to the first such transaction own more than forty nine
percent (49%) of the voting stock of Borrower immediately after giving effect to such transaction or related series of such transactions
(other than by the sale of Borrower&rsquo;s equity securities in a public offering, a private placement of public equity or to
venture capital investors so long as Borrower identifies to Collateral Agent the venture capital investors prior to the closing
of the transaction). Borrower shall not, without at least fifteen (15) days&rsquo; prior written notice to Collateral Agent (which
such notice shall be deemed to amend the Perfection Certificates as applicable upon review and approval of Collateral Agent): (A)
add any new offices or business locations, including warehouses (unless such new offices or business locations contain less than
One Hundred Thousand Dollars ($100,000.00) in assets or property of Borrower or any of its Subsidiaries); (B) change its jurisdiction
of organization, (C) change its organizational structure or type, (D) change its legal name, or (E) change any organizational number
(if any) assigned by its jurisdiction of organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.3 Mergers or Acquisitions.
</B>Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or acquire, or permit
any of its Subsidiaries to acquire, all or substantially all of the capital stock, shares or property of another Person. A Subsidiary
may merge or consolidate into another Subsidiary (provided such surviving Subsidiary is a &ldquo;co-Borrower&rdquo; hereunder or
has provided a secured Guaranty of Borrower&rsquo;s Obligations hereunder) or with (or into) Borrower provided Borrower is the
surviving legal entity, and as long as no Event of Default is occurring prior thereto or arises as a result therefrom. Without
limiting the foregoing, Borrower shall not, without Collateral Agent&rsquo;s prior written consent, enter into any binding contractual
arrangement with any Person to attempt to facilitate a merger or acquisition of Borrower, unless (i) no Event of Default exists
when such agreement is entered into by Borrower, (ii) such agreement does not give such Person the right to claim any fees, payments
or damages from Borrower in excess of Two Hundred Fifty Thousand Dollars ($250,000) and (iii) Borrower notifies Collateral Agent
within five (5) days of entering into such an agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.4 Indebtedness.
</B>Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.5 Encumbrance.
</B>Create, incur, allow, or suffer any Lien on any of its property, or assign or convey any right to receive income, including
the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, or permit any Collateral not
to be subject to the first priority security interest granted herein (except for Permitted Liens that are permitted by the terms
of this Agreement to have priority over Collateral Agent&rsquo;s Lien), or enter into any agreement, document, instrument or other
arrangement (except with or in favor of Collateral Agent, for the ratable benefit of the Lenders) with any Person which directly
or indirectly prohibits or has the effect of prohibiting Borrower, or any of its Subsidiaries, from assigning, mortgaging, pledging,
granting a security interest in or upon, or encumbering any of Borrower&rsquo;s or such Subsidiary&rsquo;s Intellectual Property,
except as is otherwise permitted in Section 7.1 hereof and the definition of &ldquo;<B>Permitted Liens</B>&rdquo; herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.6 Maintenance of
Collateral Accounts. </B>Maintain any Collateral Account except pursuant to the terms of Section 6.6 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.7 Distributions;
Investments. </B>a) Pay any dividends or make any distribution or payment in respect of or redeem, retire or purchase any capital
stock (other than dividends, distributions or payments (i) payable solely in capital stock, or (ii) repurchases pursuant to the
terms of employee stock purchase plans, employee restricted stock agreements, stockholder rights plans, director or consultant
stock option plans, or similar plans, provided such repurchases do not exceed Two Hundred Fifty Thousand Dollars ($250,000.00)
in the aggregate per fiscal year) or (b) directly or indirectly make any Investment other than Permitted Investments, or permit
any of its Subsidiaries to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.8 Transactions
with Affiliates. </B>Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower
or any of its Subsidiaries, except for (a) transactions that are in the ordinary course of Borrower&rsquo;s or such Subsidiary&rsquo;s
business, upon fair and reasonable terms that are no less favorable to Borrower or such Subsidiary than would be obtained in an
arm&rsquo;s length transaction with a non-affiliated Person, (b) Subordinated Debt or equity investments by Borrower&rsquo;s investors
in Borrower or its Subsidiaries and (c) transactions that are explicitly allowed hereunder to be entered into with Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.9 Subordinated
Debt. </B>(a) Make or permit any payment on any Subordinated Debt, except under the terms of the subordination, intercreditor,
or other similar agreement to which such Subordinated Debt is subject, or (b) amend any provision in any document relating to the
Subordinated Debt which would increase the amount thereof or adversely affect the subordination thereof to Obligations owed to
the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.10 Compliance.
</B>Become an &ldquo;investment company&rdquo; or a company controlled by an &ldquo;investment company&rdquo;, under the Investment
Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock
(as defined in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension
for that purpose; fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction,
as defined in ERISA, to occur that results in a liability or penalties in excess of $10,000 in the aggregate or otherwise could
reasonably be expected to have a Material Adverse Change; fail to comply in all material respects with the Federal Fair Labor Standards
Act or violate any other law or regulation, if the violation could reasonably be expected to have a Material Adverse Change, or
permit any of its Subsidiaries to do so; withdraw or permit any Subsidiary to withdraw from participation in, permit partial or
complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred
compensation plan which could reasonably be expected to result in any liability of Borrower or any of its Subsidiaries, including
any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.11 Compliance with
Anti-Terrorism Laws. </B>Collateral Agent hereby notifies Borrower and each of its Subsidiaries that pursuant to the requirements
of Anti-Terrorism Laws, and Collateral Agent&rsquo;s policies and practices, Collateral Agent is required to obtain, verify and
record certain information and documentation that identifies Borrower and each of its Subsidiaries and their principals, which
information includes the name and address of Borrower and each of its Subsidiaries and their principals and such other information
that will allow Collateral Agent to identify such party in accordance with Anti-Terrorism Laws. Neither Borrower nor any of its
Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit any Affiliate to, directly or indirectly, knowingly enter
into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists. Borrower and each of its Subsidiaries
shall immediately notify Collateral Agent if Borrower or such Subsidiary has knowledge that Borrower, or any Subsidiary or Affiliate
of Borrower, is listed on the OFAC Lists or (a) is convicted on, (b) pleads <I>nolo contendere </I>to, (c) is indicted on, or (d)
is arraigned and held over on charges involving money laundering or predicate crimes to money laundering. Neither Borrower nor
any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate to, directly or indirectly,
(i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making
or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise
engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any
similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or
avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order
No. 13224 or other Anti-Terrorism Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.</B></TD><TD STYLE="text-align: justify"><B><U>EVENTS OF DEFAULT</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any one of the following
shall constitute an event of default (an &ldquo;<B>Event of Default</B>&rdquo;) under this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.1 Payment Default.
</B>Borrower fails to (a) make any payment of principal or interest on any Credit Extension on its due date; provided that no default
shall have been deemed to occur as a result of any Lender neglecting to debit or deliberately not debiting Borrower&rsquo;s account
as provided in Section 2.3(d), or (b) pay any other Obligations within three (3) Business Days after such Obligations are due and
payable (which three (3) Business Day grace period shall not apply to payments due on the Maturity Date or the date of acceleration
pursuant to Section 9.1 (a) hereof). During the cure period, the failure to cure the payment default is not an Event of Default
(but no Credit Extension will be made during the cure period);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.2&nbsp;&nbsp;Covenant
Default.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a)&nbsp;&nbsp;Borrower
or any of its Subsidiaries fails or neglects to perform any obligation in Sections 6.2 (Financial Statements, Reports, Certificates),
6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (Protection of Intellectual Property Rights), 6.9 (Notice of Litigation
and Default), 6.12 (Creation/Acquisition of Subsidiaries) or 6.13 (Further Assurances) or Borrower violates any covenant in Section
7; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) Borrower, or any
of its Subsidiaries, fails or neglects to perform, keep, or observe any other term, provision, condition, covenant or agreement
contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section 8) under such
other term, provision, condition, covenant or agreement that can be cured, has failed to cure the default within ten (10) days
after the occurrence of such default; provided, however, that if the default cannot by its nature be cured within the ten (10)
day period or cannot after diligent attempts by Borrower be cured within such ten (10) day period, and such default is likely to
be cured within a reasonable time, then Borrower shall have an additional period (which shall not in any case exceed thirty (30)
days) to attempt to cure such default, and within such reasonable time period the failure to cure the default shall not be deemed
an Event of Default (but no Credit Extensions shall be made during such cure period). Grace periods provided under this Section
shall not apply, among other things, to financial covenants or any other covenants set forth in subsection (a) above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.3&nbsp;&nbsp;Material
Adverse Change. </B>A Material Adverse Change occurs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.4&nbsp;&nbsp;Attachment;
Levy; Restraint on Business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) (i) The service
of process seeking to attach, by trustee or similar process, any funds of Borrower or any of its Subsidiaries or of any entity
under control of Borrower or its Subsidiaries on deposit with any Lender or any Lender&rsquo;s Affiliate or any bank or other institution
at which Borrower or any of its Subsidiaries maintains a Collateral Account, or (ii) a notice of lien, levy, or assessment is filed
against Borrower or any of its Subsidiaries or their respective assets by any government agency, and the same under subclauses
(i) and (ii) hereof are not, within ten (10) days after the occurrence thereof, discharged or stayed (whether through the posting
of a bond or otherwise); provided, however, no Credit Extensions shall be made during any ten (10) day cure period; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) (i) any material
portion of Borrower&rsquo;s or any of its Subsidiaries&rsquo; assets is attached, seized, levied on, or comes into possession of
a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents Borrower or any of its Subsidiaries from conducting
any part of its business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.5 Insolvency. </B>(a)
Borrower or any of its Subsidiaries is or becomes Insolvent; (b) Borrower or any of its Subsidiaries begins an Insolvency Proceeding;
or (c) an Insolvency Proceeding is begun against Borrower or any of its Subsidiaries and not dismissed or stayed within forty-five
(45) days (but no Credit Extensions shall be made while Borrower or any Subsidiary is Insolvent and/or until any Insolvency Proceeding
is dismissed);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.6 Other Agreements.
</B>There is a default in any agreement to which Borrower or any of its Subsidiaries is a party with a third party or parties resulting
in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness owed by Borrower
or such Subsidiary in an amount in excess of One Hundred Fifty Thousand Dollars ($150,000.00) or that could reasonably be expected
to have a Material Adverse Change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.7 Judgments. </B>One
or more judgments, orders, or decrees for the payment of money in an amount, individually or in the aggregate, of at least One
Hundred Fifty Thousand Dollars ($150,000.00) (not covered by independent third-party insurance as to which liability has been accepted
by such insurance carrier) shall be rendered against Borrower or any of its Subsidiaries and shall remain unsatisfied, unvacated,
or unstayed for a period of ten (10) days after the entry thereof (provided that no Credit Extensions will be made prior to the
satisfaction, vacation, or stay of such judgment, order or decree);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.8 Misrepresentations.
</B>Borrower or any of its Subsidiaries or any Person acting for Borrower or any of its Subsidiaries makes any representation,
warranty, or other statement now or later in this Agreement, any Loan Document or in any writing delivered to Collateral Agent
and/or Lenders or to induce Collateral Agent and/or the Lenders to enter this Agreement or any Loan Document, and such representation,
warranty, or other statement is incorrect in any material respect when made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.9 Subordinated
Debt. </B>A default or breach occurs under any agreement between Borrower or any of its Subsidiaries and any creditor of Borrower
or any of its Subsidiaries that signed a subordination, intercreditor, or other similar agreement with Collateral Agent or the
Lenders resulting in a right, or will result in a right with the passage of time, by such creditor, whether or not exercised, to
accelerate the maturity of any Indebtedness owed by Borrower or such Subsidiary to such creditor (provided, however, that if such
default or breach will not result in such a right, Borrower must promptly notify Collateral Agent of such default or breach and
promptly remedy it), or any such creditor that has signed such an subordination, intercreditor, or other similar agreement with
Collateral Agent or the Lenders breaches any terms of such agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.10&nbsp;Reserved</B>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.11 Governmental
Approvals. </B>Any Governmental Approval shall have been revoked, rescinded, suspended, modified in an adverse manner, or not renewed
in the ordinary course for a full term <I>and </I>such revocation, rescission, suspension, modification or non-renewal has resulted
in or could reasonably be expected to result in a Material Adverse Change; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.12 Lien Priority</B>.
Any Lien created hereunder or by any other Loan Document shall at any time fail to constitute a valid and perfected Lien on any
of the Collateral purported to be secured thereby, subject to no prior or equal Lien, other than Permitted Liens which are permitted
to have priority in accordance with the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>9.</B></TD><TD STYLE="text-align: justify"><B><U>RIGHTS AND REMEDIES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.1&nbsp;&nbsp;&nbsp;Rights
and Remedies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) Upon the occurrence
and during the continuance of an Event of Default, Collateral Agent may, and at the written direction of Required Lenders shall,
without notice or demand, do any or all of the following: (i) deliver notice of the Event of Default to Borrower, (ii) by notice
to Borrower declare all Obligations immediately due and payable (but if an Event of Default described in Section 8.5 occurs all
Obligations shall be immediately due and payable without any action by Collateral Agent or the Lenders) or (iii) by notice to Borrower
suspend or terminate the obligations, if any, of the Lenders to advance money or extend credit for Borrower&rsquo;s benefit under
this Agreement (but if an Event of Default described in Section 8.5 occurs all obligations, if any, of the Lenders to advance money
or extend credit for Borrower&rsquo;s benefit under this Agreement shall be immediately terminated without any action by Collateral
Agent or the Lenders).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) Without limiting
the rights of Collateral Agent and the Lenders set forth in Section 9.1(a) above, upon the occurrence and during the continuance
of an Event of Default, Collateral Agent shall have the right at the written direction of the Required Lenders<B>, </B>without
notice or demand, to do any or all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;foreclose
upon and/or sell or otherwise liquidate, the Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) apply to the Obligations
any (a) balances and deposits of Borrower that Collateral Agent or any Lender holds or controls, or (b) any amount held or controlled
by Collateral Agent or any Lender owing to or for the credit or the account of Borrower; and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii) commence and prosecute
an Insolvency Proceeding or consent to Borrower commencing any Insolvency Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c)&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting the rights of Collateral Agent and the Lenders set forth in Sections 9.1(a) and (b) above, upon the occurrence and during
the continuance of an Event of Default, Collateral Agent shall have the right, without notice or demand, to do any or all of the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) settle or adjust
disputes and claims directly with Account Debtors for amounts on terms and in any order that Collateral Agent considers advisable,
notify any Person owing Borrower money of Collateral Agent&rsquo;s security interest in such funds, and verify the amount of such
account;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) make any payments
and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the Collateral.
Borrower shall assemble the Collateral if Collateral Agent requests and make it available in a location as Collateral Agent reasonably
designates. Collateral Agent may enter premises where the Collateral is located, take and maintain possession of any part of the
Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and
pay all expenses incurred. Borrower grants Collateral Agent a license to enter and occupy any of its premises, without charge,
to exercise any of Collateral Agent&rsquo;s rights or remedies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii) ship, reclaim,
recover, store, finish, maintain, repair, prepare for sale, and/or advertise for sale, the Collateral. Collateral Agent is hereby
granted a non-exclusive, royalty-free license or other right to use, without charge, Borrower&rsquo;s and each of its Subsidiaries&rsquo;
labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names, trademarks, service marks, and
advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale,
and selling any Collateral and, in connection with Collateral Agent&rsquo;s exercise of its rights under this Section 9.1, Borrower&rsquo;s
and each of its Subsidiaries&rsquo; rights under all licenses and all franchise agreements inure to Collateral Agent, for the benefit
of the Lenders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv) place a &ldquo;hold&rdquo;
on any account maintained with Collateral Agent or the Lenders and/or deliver a notice of exclusive control, any entitlement order,
or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&nbsp;demand
and receive possession of Borrower&rsquo;s Books;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi) appoint a receiver
to seize, manage and realize any of the Collateral, and such receiver shall have any right and authority as any competent court
will grant or authorize in accordance with any applicable law, including any power or authority to manage the business of Borrower
or any of its Subsidiaries; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vii) subject to clauses
9.1(a) and (b), exercise all rights and remedies available to Collateral Agent and each Lender under the Loan Documents or at law
or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any provision of this Section
9.1 to the contrary, upon the occurrence of any Event of Default, Collateral Agent shall have the right to exercise any and all
remedies referenced in this Section 9.1 without the written consent of Required Lenders following the occurrence of an Exigent
Circumstance. As used in the immediately preceding sentence, &ldquo;<B>Exigent Circumstance</B>&rdquo; means any event or circumstance
that, in the reasonable judgment of Collateral Agent, imminently threatens the ability of Collateral Agent to realize upon all
or any material portion of the Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment thereof,
destruction or material waste thereof, or failure of Borrower or any of its Subsidiaries after reasonable demand to maintain or
reinstate adequate casualty insurance coverage, or which, in the judgment of Collateral Agent, could reasonably be expected to
result in a material diminution in value of the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.2 Power of Attorney.
</B>Borrower hereby irrevocably appoints Collateral Agent as its lawful attorney-in-fact, exercisable upon the occurrence and during
the continuance of an Event of Default, to: (a) endorse Borrower&rsquo;s or any of its Subsidiaries&rsquo; name on any checks or
other forms of payment or security; (b) sign Borrower&rsquo;s or any of its Subsidiaries&rsquo; name on any invoice or bill of
lading for any Account or drafts against Account Debtors; (c) settle and adjust disputes and claims about the Accounts directly
with Account Debtors, for amounts and on terms Collateral Agent determines reasonable; (d) make, settle, and adjust all claims
under Borrower&rsquo;s insurance policies; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse
claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same;
and (f) transfer the Collateral into the name of Collateral Agent or a third party as the Code or any applicable law permits. Borrower
hereby appoints Collateral Agent as its lawful attorney-in-fact to sign Borrower&rsquo;s or any of its Subsidiaries&rsquo; name
on any documents necessary to perfect or continue the perfection of Collateral Agent&rsquo;s security interest in the Collateral
regardless of whether an Event of Default has occurred until all Obligations (other than inchoate indemnity obligations and any
other obligations which, by their terms, are to survive the termination of this Agreement) have been satisfied in full and Collateral
Agent and the Lenders are under no further obligation to make Credit Extensions hereunder. Collateral Agent&rsquo;s foregoing appointment
as Borrower&rsquo;s or any of its Subsidiaries&rsquo; attorney in fact, and all of Collateral Agent&rsquo;s rights and powers,
coupled with an interest, are irrevocable until all Obligations (other than inchoate indemnity obligations and any other obligations
which, by their terms, are to survive the termination of this Agreement) have been fully repaid and performed and Collateral Agent&rsquo;s
and the Lenders&rsquo; obligation to provide Credit Extensions terminates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.3 Protective Payments.
</B>If Borrower or any of its Subsidiaries fail to obtain the insurance called for by Section 6.5 or fails to pay any premium thereon
or fails to pay any other amount which Borrower or any of its Subsidiaries is obligated to pay under this Agreement or any other
Loan Document, Collateral Agent may obtain such insurance or make such payment, and all amounts so paid by Collateral Agent are
Lenders&rsquo; Expenses and immediately due and payable, bearing interest at the Default Rate, and secured by the Collateral. Collateral
Agent will make reasonable efforts to provide Borrower with notice of Collateral Agent obtaining such insurance or making such
payment at the time it is obtained or paid or within a reasonable time thereafter. No such payments by Collateral Agent are deemed
an agreement to make similar payments in the future or Collateral Agent&rsquo;s waiver of any Event of Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.4 Application of
Payments and Proceeds. </B>Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and during
the continuance of an Event of Default, (a) Borrower irrevocably waives the right to direct the application of any and all payments
at any time or times thereafter received by Collateral Agent from or on behalf of Borrower or any of its Subsidiaries of all or
any part of the Obligations, and, as between Borrower on the one hand and Collateral Agent and Lenders on the other, Collateral
Agent shall have the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations
in such manner as Collateral Agent may deem advisable notwithstanding any previous application by Collateral Agent, and (b) the
proceeds of any sale of, or other realization upon all or any part of the Collateral shall be applied: first, to the Lenders&rsquo;
Expenses; second, to accrued and unpaid interest on the Obligations (including any interest which, but for the provisions of the
United States Bankruptcy Code, would have accrued on such amounts); third, to the principal amount of the Obligations outstanding;
and fourth, to any other indebtedness or obligations of Borrower owing to Collateral Agent or any Lender under the Loan Documents.
Any balance remaining shall be delivered to Borrower or to whoever may be lawfully entitled to receive such balance or as a court
of competent jurisdiction may direct. In carrying out the foregoing, (x) amounts received shall be applied in the numerical order
provided until exhausted prior to the application to the next succeeding category, and (y) each of the Persons entitled to receive
a payment in any particular category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant
thereto for such category. Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest
or obligation &ldquo;ratably,&rdquo; &ldquo;proportionally&rdquo; or in similar terms shall refer to Pro Rata Share unless expressly
provided otherwise. Collateral Agent, or if applicable, each Lender, shall promptly remit to the other Lenders such sums as may
be necessary to ensure the ratable repayment of each Lender&rsquo;s portion of any Term Loan and the ratable distribution of interest,
fees and reimbursements paid or made by Borrower. Notwithstanding the foregoing, a Lender receiving a scheduled payment shall not
be responsible for determining whether the other Lenders also received their scheduled payment on such date; provided, however,
if it is later determined that a Lender received more than its ratable share of scheduled payments made on any date or dates, then
such Lender shall remit to Collateral Agent or other Lenders such sums as may be necessary to ensure the ratable payment of such
scheduled payments, as instructed by Collateral Agent. If any payment or distribution of any kind or character, whether in cash,
properties or securities, shall be received by a Lender in excess of its ratable share, then the portion of such payment or distribution
in excess of such Lender&rsquo;s ratable share shall be received by such Lender in trust for and shall be promptly paid over to
the other Lender for application to the payments of amounts due on the other Lenders&rsquo; claims. To the extent any payment for
the account of Borrower is required to be returned as a voidable transfer or otherwise, the Lenders shall contribute to one another
as is necessary to ensure that such return of payment is on a pro rata basis. If any Lender shall obtain possession of any Collateral,
it shall hold such Collateral for itself and as agent and bailee for Collateral Agent and other Lenders for purposes of perfecting
Collateral Agent&rsquo;s security interest therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.5 Liability for
Collateral. </B>So long as Collateral Agent and the Lenders comply with reasonable banking practices regarding the safekeeping
of the Collateral in the possession or under the control of Collateral Agent and the Lenders, Collateral Agent and the Lenders
shall not be liable or responsible for: (a) the safekeeping of the Collateral; (b) any loss or damage to the Collateral; (c) any
diminution in the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or other Person, other
than any loss, damage or diminution in value due to the gross negligence or willful misconduct of the Collateral Agent or any Lender.
Borrower bears all risk of loss, damage or destruction of the Collateral other than as set forth in the preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.6 No Waiver; Remedies
Cumulative. </B>Failure by Collateral Agent or any Lender, at any time or times, to require strict performance by Borrower of any
provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Collateral Agent or any
Lender thereafter to demand strict performance and compliance herewith or therewith. No waiver hereunder shall be effective unless
signed by Collateral Agent and the Required Lenders and then is only effective for the specific instance and purpose for which
it is given. The rights and remedies of Collateral Agent and the Lenders under this Agreement and the other Loan Documents are
cumulative. Collateral Agent and the Lenders have all rights and remedies provided under the Code, any applicable law, by law,
or in equity. The exercise by Collateral Agent or any Lender of one right or remedy is not an election, and Collateral Agent&rsquo;s
or any Lender&rsquo;s waiver of any Event of Default is not a continuing waiver. Collateral Agent&rsquo;s or any Lender&rsquo;s
delay in exercising any remedy is not a waiver, election, or acquiescence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.7 Demand Waiver.
</B>Borrower waives, to the fullest extent permitted by law, demand, notice of default or dishonor, notice of payment and nonpayment,
notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments,
chattel paper, and guarantees held by Collateral Agent or any Lender on which Borrower or any Subsidiary is liable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>10.</B></TD><TD STYLE="text-align: justify"><B><U>NOTICES</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All notices, consents,
requests, approvals, demands, or other communication (collectively, &ldquo;<B>Communication</B>&rdquo;) by any party to this Agreement
or any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) upon the
earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail
return receipt requested, with proper postage prepaid; (b) upon transmission, when sent by facsimile transmission or electronic
mail; (c) one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid; or (d) when delivered,
if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile
number, or email address indicated below. Any of Collateral Agent, Lender or Borrower may change its mailing address, email address
or facsimile number by giving the other party written notice thereof in accordance with the terms of this Section 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; margin-left: 0.5in">
<TR>
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">If to Borrower:</FONT></TD>
    <TD STYLE="width: 75%"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">731 Market Street</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Suite 420</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">San Francisco, California<BR>
 94103</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Attn: <U>Rick Orr, CEO</U></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Fax: (415) 512-7740</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Email: rorr@adynxx.com</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">with a copy (which</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Hogan Lovells US LLP</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">shall not constitute</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">4085 Campbell Ave.</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">notice) to:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Suite 100</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Menlo Park, California <BR>
94025</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Attn: Laura A. Berezin &nbsp; &nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Fax: (650) 463-4199 &nbsp; &nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Email: laura.berezin@hoganlovells.com &nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; margin-left: 0.5in">
<TR>
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">If to Collateral Agent:</FONT></TD>
    <TD STYLE="width: 75%"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC &nbsp; &nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">133 North Fairfax Street &nbsp; &nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Alexandria, Virginia<BR>
 22314 &nbsp; &nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Attention: Legal Department &nbsp; &nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Fax: (703) 519-5225 &nbsp; &nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Email: LegalDepartment@oxfordfinance.com &nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">with a copy (which</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Greenberg Traurig, LLP &nbsp; &nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">shall not constitute</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">One International Place &nbsp; &nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">notice) to:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Boston, MA 02110 &nbsp; &nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Attn: Jonathan Bell &nbsp; &nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Fax: (617) 310-6001 &nbsp; &nbsp;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Email: bellj@gtlaw.com &nbsp; &nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>11.</B></TD><TD STYLE="text-align: justify"><B><U>CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER, AND JUDICIAL
REFERENCE</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">California law governs
the Loan Documents without regard to principles of conflicts of law. Borrower, Collateral Agent and each Lender each submit to
the exclusive jurisdiction of the State and Federal courts in Santa Clara County, California; provided, however, that nothing in
this Agreement shall be deemed to operate to preclude Collateral Agent or any Lender from bringing suit or taking other legal action
in any other jurisdiction to realize on the Collateral or any other security for the Obligations, or to enforce a judgment or other
court order in favor of Collateral Agent or any Lender. Borrower expressly submits and consents in advance to such jurisdiction
in any action or suit commenced in any such court, and Borrower hereby waives any objection that it may have based upon lack of
personal jurisdiction, improper venue, or forum non conveniens and hereby consents to the granting of such legal or equitable relief
as is deemed appropriate by such court. Borrower hereby waives personal service of the summons, complaints, and other process issued
in such action or suit and agrees that service of such summons, complaints, and other process may be made by registered or certified
mail addressed to Borrower at the address set forth in, or subsequently provided by Borrower in accordance with, Section 10 of
this Agreement and that service so made shall be deemed completed upon the earlier to occur of Borrower&rsquo;s actual receipt
thereof or three (3) days after deposit in the U.S. mails, proper postage prepaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, BORROWER, COLLATERAL AGENT AND EACH LENDER EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING
OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY
AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR EACH PARTY TO ENTER INTO THIS AGREEMENT. EACH PARTY HAS REVIEWED
THIS WAIVER WITH ITS COUNSEL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WITHOUT INTENDING IN ANY WAY TO LIMIT THE
PARTIES&rsquo; AGREEMENT TO WAIVE THEIR RESPECTIVE RIGHT TO A TRIAL BY JURY, if the above waiver of the right to a trial by jury
is not enforceable, the parties hereto agree that any and all disputes or controversies of any nature between them arising at any
time shall be decided by a reference to a private judge, mutually selected by the parties (or, if they cannot agree, by the Presiding
Judge of the Santa Clara County, California Superior Court) appointed in accordance with California Code of Civil Procedure Section
638 (or pursuant to comparable provisions of federal law if the dispute falls within the exclusive jurisdiction of the federal
courts), sitting without a jury, in Santa Clara County, California; and the parties hereby submit to the jurisdiction of such court.
The reference proceedings shall be conducted pursuant to and in accordance with the provisions of California Code of Civil Procedure
 &sect;&sect; 638 through 645.1, inclusive. The private judge shall have the power, among others, to grant provisional relief, including
without limitation, entering temporary restraining orders, issuing preliminary and permanent injunctions and appointing receivers.
All such proceedings shall be closed to the public and confidential and all records relating thereto shall be permanently sealed.
If during the course of any dispute, a party desires to seek provisional relief, but a judge has not been appointed at that point
pursuant to the judicial reference procedures, then such party may apply to the Santa Clara County, California Superior Court for
such relief. The proceeding before the private judge shall be conducted in the same manner as it would be before a court under
the rules of evidence applicable to judicial proceedings. The parties shall be entitled to discovery which shall be conducted in
the same manner as it would be before a court under the rules of discovery applicable to judicial proceedings. The private judge
shall oversee discovery and may enforce all discovery rules and orders applicable to judicial proceedings in the same manner as
a trial court judge. The parties agree that the selected or appointed private judge shall have the power to decide all issues in
the action or proceeding, whether of fact or of law, and shall report a statement of decision thereon pursuant to California Code
of Civil Procedure &sect; 644(a). Nothing in this paragraph shall limit the right of any party at any time to exercise self-help
remedies, foreclose against collateral, or obtain provisional remedies. The private judge shall also determine all issues relating
to the applicability, interpretation, and enforceability of this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>12.</B></TD><TD STYLE="text-align: justify"><B><U>GENERAL PROVISIONS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.1 Successors and
Assigns. </B>This Agreement binds and is for the benefit of the successors and permitted assigns of each party. Borrower may not
transfer, pledge or assign this Agreement or any rights or obligations under it without Collateral Agent&rsquo;s and each Lender&rsquo;s
prior written consent (which may be granted or withheld in Collateral Agent&rsquo;s and each Lender&rsquo;s discretion, subject
to Section 12.6). The Lenders have the right, without the consent of or notice to Borrower, to sell, transfer, assign, pledge,
negotiate, or grant participation in <B>(any </B>such sale, transfer, assignment, negotiation<B>, </B>or grant of a participation,
a <B>&ldquo;Lender Transfer&rdquo;) </B>all or any part of, or any interest in, the Lenders&rsquo; obligations, rights, and benefits
under this Agreement and the other Loan Documents; <I>provided</I>, <I>however</I>, that any such Lender Transfer (other than a
transfer, pledge, sale or assignment to an Eligible Assignee) of its obligations, rights, and benefits under this Agreement and
the other Loan Documents shall require the prior written consent of the Required Lenders (such approved assignee, an &ldquo;<B>Approved
Lender</B>&rdquo;)<B>. </B>Borrower and Collateral Agent shall be entitled to continue to deal solely and directly with such Lender
in connection with the interests so assigned until Collateral Agent shall have received and accepted an effective assignment agreement
in form satisfactory to Collateral Agent executed, delivered and fully completed by the applicable parties thereto, and shall have
received such other information regarding such Eligible Assignee or Approved Lender as Collateral Agent reasonably shall require.
Notwithstanding anything to the contrary contained herein, so long as no Event of Default has occurred and is continuing, no Lender
Transfer (other than a Lender Transfer (i) in respect of the Warrants or (ii) in connection with (x) assignments by a Lender due
to a forced divestiture at the request of any regulatory agency; or (y) upon the occurrence of a default, event of default or similar
occurrence with respect to a Lender&rsquo;s own financing or securitization transactions) shall be permitted, without Borrower&rsquo;s
consent, to any Person which is an Affiliate or Subsidiary of Borrower, a direct competitor of Borrower or a vulture hedge fund,
each as determined by Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.2 Indemnification.
</B>Borrower agrees to indemnify, defend and hold Collateral Agent and the Lenders and their respective directors, officers, employees,
agents, attorneys, or any other Person affiliated with or representing Collateral Agent or the Lenders (each, an &ldquo;<B>Indemnified
Person</B>&rdquo;) harmless against: (a) all obligations, demands, claims, and liabilities (collectively, &ldquo;<B>Claims</B>&rdquo;)
asserted by any other party in connection with; related to; following; or arising from, out of or under, the transactions contemplated
by the Loan Documents; and (b) all losses or Lenders&rsquo; Expenses incurred, or paid by Indemnified Person in connection with;
related to; following; or arising from, out of or under, the transactions contemplated by the Loan Documents between Collateral
Agent, and/or the Lenders and Borrower (including reasonable attorneys&rsquo; fees and expenses), except for Claims and/or losses
directly caused by such Indemnified Person&rsquo;s gross negligence or willful misconduct. Borrower hereby further indemnifies,
defends and holds each Indemnified Person harmless from and against any and all liabilities, obligations, losses, damages, penalties,
actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and disbursements
of counsel for such Indemnified Person) in connection with any investigative, response, remedial, administrative or judicial matter
or proceeding, whether or not such Indemnified Person shall be designated a party thereto and including any such proceeding initiated
by or on behalf of Borrower, and the reasonable expenses of investigation by engineers, environmental consultants and similar technical
personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Collateral Agent or
Lenders) asserting any right to payment for the transactions contemplated hereby which may be imposed on, incurred by or asserted
against such Indemnified Person as a result of or in connection with the transactions contemplated hereby and the use or intended
use of the proceeds of the loan proceeds except for liabilities, obligations, losses, damages, penalties, actions, judgments, suits,
claims, costs, expenses and disbursements directly caused by such Indemnified Person&rsquo;s gross negligence or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.3&nbsp;Time
of Essence.&nbsp;&nbsp;</B>Time is of the essence for the performance of all Obligations in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.4 Severability
of Provisions. </B>Each provision of this Agreement is severable from every other provision in determining the enforceability of
any provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.5 Correction of
Loan Documents. </B>Collateral Agent and the Lenders may correct patent errors and fill in any blanks in this Agreement and the
other Loan Documents consistent with the agreement of the parties so long as Collateral Agent provides Borrower with written notice
of such correction and allows Borrower at least ten (10) days to object to such correction. In the event of such objection, such
correction shall not be made except by an amendment signed by both Collateral Agent and Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.6 Amendments in
Writing; Integration. </B>(a) No amendment, modification, termination or waiver of any provision of this Agreement or any other
Loan Document, no approval or consent thereunder, or any consent to any departure by Borrower or any of its Subsidiaries therefrom,
shall in any event be effective unless the same shall be in writing and signed by Borrower, Collateral Agent and the Required Lenders
provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) no such amendment,
waiver or other modification that would have the effect of increasing or reducing a Lender&rsquo;s Term Loan Commitment or Commitment
Percentage shall be effective as to such Lender without such Lender&rsquo;s written consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) no such amendment,
waiver or modification that would affect the rights and duties of Collateral Agent shall be effective without Collateral Agent&rsquo;s
written consent or signature;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii) no such amendment,
waiver or other modification shall, unless signed by all the Lenders directly affected thereby, (A) reduce the principal of, rate
of interest on or any fees with respect to any Term Loan or forgive any principal, interest (other than default interest) or fees
(other than late charges) with respect to any Term Loan (B) postpone the date fixed for, or waive, any payment of principal of
any Term Loan or of interest on any Term Loan (other than default interest) or any fees provided for hereunder (other than late
charges or for any termination of any commitment); (C) change the definition of the term &ldquo;<B>Required Lenders</B>&rdquo;
or the percentage of Lenders which shall be required for the Lenders to take any action hereunder; (D) release all or substantially
all of any material portion of the Collateral, authorize Borrower to sell or otherwise dispose of all or substantially all or any
material portion of the Collateral or release any Guarantor of all or any portion of the Obligations or its guaranty obligations
with respect thereto, except, in each case with respect to this clause (D), as otherwise may be expressly permitted under this
Agreement or the other Loan Documents (including in connection with any disposition permitted hereunder); (E) amend, waive or otherwise
modify this Section 12.6 or the definitions of the terms used in this Section 12.6 insofar as the definitions affect the substance
of this Section 12.6; (F) consent to the assignment, delegation or other transfer by Borrower of any of its rights and obligations
under any Loan Document or release Borrower of its payment obligations under any Loan Document, except, in each case with respect
to this clause (F), pursuant to a merger or consolidation permitted pursuant to this Agreement; (G) amend any of the provisions
of Section 9.4 or amend any of the definitions of Pro Rata Share, Term Loan Commitment, Commitment Percentage or that provide for
the Lenders to receive their Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral hereunder; (H) subordinate
the Liens granted in favor of Collateral Agent securing the Obligations; or (I) amend any of the provisions of Section 12.10. It
is hereby understood and agreed that all Lenders shall be deemed directly affected by an amendment, waiver or other modification
of the type described in the preceding clauses (C), (D), (E), (F), (G) and (H) of the preceding sentence;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv) the provisions
of the foregoing clauses (i), (ii) and (iii) are subject to the provisions of any interlender or agency agreement among the Lenders
and Collateral Agent pursuant to which any Lender may agree to give its consent in connection with any amendment, waiver or modification
of the Loan Documents only in the event of the unanimous agreement of all Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) Other than as
expressly provided for in Section 12.6(a)(i)-(iii), Collateral Agent may, if requested by the Required Lenders, from time to time
designate covenants in this Agreement that are less restrictive by notification to a representative of Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c) This Agreement
and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.
All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter
of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.7 Counterparts.
</B>This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which,
when executed and delivered, is an original, and all taken together, constitute one Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.8 Survival. </B>All
covenants, representations and warranties made in this Agreement continue in full force and effect until this Agreement has terminated
pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their
terms, are to survive the termination of this Agreement) have been satisfied. The obligation of Borrower in Section 12.2 to indemnify
each Lender and Collateral Agent, as well as the confidentiality provisions in Section 12.9 below, shall survive until the statute
of limitations with respect to such claim or cause of action shall have run.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.9 Confidentiality.
</B>In handling any confidential information of Borrower, the Lenders and Collateral Agent shall exercise the same degree of care
that it exercises for their own proprietary information, but disclosure of information may be made: (a) subject to the terms and
conditions of this Agreement, to the Lenders&rsquo; and Collateral Agent&rsquo;s Subsidiaries or Affiliates, or in connection with
a Lender&rsquo;s own financing or securitization transactions and upon the occurrence of a default, event of default or similar
occurrence with respect to such financing or securitization transaction; (b) to prospective transferees (other than those identified
in (a) above) or purchasers of any interest in the Credit Extensions (provided, however, the Lenders and Collateral Agent shall,
except upon the occurrence and during the continuation of an Event of Default, obtain such prospective transferee&rsquo;s or purchaser&rsquo;s
agreement to the terms of this provision or to similar confidentiality terms); (c) as required by law, regulation, subpoena, or
other order; (d) to Lenders&rsquo; or Collateral Agent&rsquo;s regulators or as otherwise required in connection with an examination
or audit; (e) as Collateral Agent reasonably considers appropriate in exercising remedies under the Loan Documents; and (f) to
third party service providers of the Lenders and/or Collateral Agent so long as such service providers have executed a confidentiality
agreement with the Lenders and Collateral Agent with terms no less restrictive than those contained herein. Confidential information
does not include information that either: (i) is in the public domain or in the Lenders&rsquo; and/or Collateral Agent&rsquo;s
possession when disclosed to the Lenders and/or Collateral Agent, or becomes part of the public domain after disclosure to the
Lenders and/or Collateral Agent (other than as a result of its disclosure by Collateral Agent or any Lender in violation of this
Agreement); or (ii) is disclosed to the Lenders and/or Collateral Agent by a third party, if the Lenders and/or Collateral Agent
does not know that the third party is prohibited from disclosing the information. Collateral Agent and the Lenders may use confidential
information for any purpose, including, without limitation, for the development of client databases, reporting purposes, and market
analysis, so long as Collateral Agent or the Lenders do not disclose Borrower&rsquo;s identity or the identity of any person associated
with Borrower unless otherwise expressly permitted by this Agreement. The provisions of the immediately preceding sentence shall
survive the termination of this Agreement. The agreements provided under this Section 12.9 supersede all prior agreements, understanding,
representations, warranties, and negotiations between the parties about the subject matter of this Section 12.9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.10 Right of Set
Off. </B>Borrower hereby grants to Collateral Agent and to each Lender, a lien, security interest and right of set off as security
for all Obligations to Collateral Agent and each Lender hereunder, whether now existing or hereafter arising upon and against all
deposits, credits, collateral and property, now or hereafter in the possession, custody, safekeeping or control of Collateral Agent
or the Lenders or any entity under the control of Collateral Agent or the Lenders (including a Collateral Agent affiliate) or in
transit to any of them. At any time after the occurrence and during the continuance of an Event of Default, without demand or notice,
Collateral Agent or the Lenders may set off the same or any part thereof and apply the same to any liability or obligation of Borrower
even though unmatured and regardless of the adequacy of any other collateral securing the Obligations. ANY AND ALL RIGHTS TO REQUIRE
COLLATERAL AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO
EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY
AND IRREVOCABLY WAIVED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.11 Cooperation
of Borrower. </B>If necessary, Borrower agrees to (i) execute any documents (including new Secured Promissory Notes) reasonably
required to effectuate and acknowledge each assignment of a Term Loan Commitment or Loan to an assignee in accordance with Section
12.1, (ii) make Borrower&rsquo;s management available upon reasonable prior notice and at times and places reasonably acceptable
to the Borrower to meet with Collateral Agent and prospective participants and assignees of Term Loan Commitments or Credit Extensions
(which meetings shall be conducted no more often than twice every twelve months unless an Event of Default has occurred and is
continuing), and (iii) assist Collateral Agent or the Lenders in the preparation of information relating to the financial affairs
of Borrower as any prospective participant or assignee of a Term Loan Commitment or Term Loan reasonably may request. Subject to
the provisions of Section 12.9, Borrower authorizes each Lender to disclose to any prospective participant or assignee of a Term
Loan Commitment, any and all information in such Lender&rsquo;s possession concerning Borrower and its financial affairs which
has been delivered to such Lender by or on behalf of Borrower pursuant to this Agreement, or which has been delivered to such Lender
by or on behalf of Borrower in connection with such Lender&rsquo;s credit evaluation of Borrower prior to entering into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>13.</B></TD><TD STYLE="text-align: justify"><B><U>DEFINITIONS</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13.1&nbsp;Definitions.
</B>As used in this Agreement, the following terms have the following meanings: &ldquo;<B>Account</B>&rdquo; is any &ldquo;account&rdquo;
as defined in the Code with such additions to such term as may hereafter be made, and includes, without limitation, all accounts
receivable and other sums owing to Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Account Debtor</B>&rdquo;
is any &ldquo;account debtor&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
of any Person is a Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by
or is under common control with the Person, and each of that Person&rsquo;s senior executive officers, directors, partners and,
for any Person that is a limited liability company, that Person&rsquo;s managers and members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Agreement</B>&rdquo;
is defined in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Amortization
Date</B>&rdquo; is, (i) December 1, 2016, if the Equity Event does not occur or (ii) June 1, 2017, if the Equity Event does occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Annual Projections</B>&rdquo;
is defined in Section 6.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Anti-Terrorism
Laws</B>&rdquo; are any laws relating to terrorism or money laundering, including Executive Order No. 13224 (effective September
24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Approved Fund</B>&rdquo;
is any (i) investment company, fund, trust, securitization vehicle or conduit that is (or will be) engaged in making, purchasing,
holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business or (ii)
any Person (other than a natural person) which temporarily warehouses loans for any Lender or any entity described in the preceding
clause (i) and that, with respect to each of the preceding clauses (i) and (ii), is administered or managed by (a) a Lender, (b)
an Affiliate of a Lender or (c) a Person (other than a natural person) or an Affiliate of a Person (other than a natural person)
that administers or manages a Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Approved Lender</B>&rdquo;
is defined in Section 12.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Basic Rate</B>&rdquo;
is, as determined by Collateral Agent, the per annum rate of interest (based on a year of three hundred sixty (360) days) equal
to the sum of (i) Seven and six hundredths percent (7.06%) and (ii) the greater of (a) the thirty (30) day U.S. Dollar LIBOR rate
reported in the <U>Wall Street Journal</U> on the date occurring on the last Business Day of the month that immediately precedes
the month in which the interest will accrue, and (b) nineteen hundredths percent (0.19%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Blocked Person</B>&rdquo;
is any Person: (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person
owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the
provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in
any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports &ldquo;terrorism&rdquo;
as defined in Executive Order No. 13224, or (e) a Person that is named a &ldquo;specially designated national&rdquo; or &ldquo;blocked
person&rdquo; on the most current list published by OFAC or other similar list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Borrower</B>&rdquo;
is defined in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Borrower&rsquo;s
Books</B>&rdquo; are Borrower&rsquo;s or any of its Subsidiaries&rsquo; books and records including ledgers, federal, and state
tax returns, records regarding Borrower&rsquo;s or its Subsidiaries&rsquo; assets or liabilities, the Collateral, business operations
or financial condition, and all computer programs or storage or any equipment containing such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Day</B>&rdquo;
is any day that is not a Saturday, Sunday or a day on which Collateral Agent is closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Cash Equivalents</B>&rdquo;
are (a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof
having maturities of not more than one (1) year from the date of acquisition; (b) commercial paper maturing no more than one (1)
year after its creation and having the highest rating from either Standard &amp; Poor&rsquo;s Ratings Group or Moody&rsquo;s Investors
Service, Inc., and (c) certificates of deposit maturing no more than one (1) year after issue provided that the account in which
any such certificate of deposit is maintained is subject to a Control Agreement in favor of Collateral Agent. For the avoidance
of doubt, the direct purchase by Borrower or any of its Subsidiaries of any Auction Rate Securities, or purchasing participations
in, or entering into any type of swap or other derivative transaction, or otherwise holding or engaging in any ownership interest
in any type of Auction Rate Security by Borrower or any of its Subsidiaries shall be conclusively determined by the Lenders as
an ineligible Cash Equivalent, and any such transaction shall expressly violate each other provision of this Agreement governing
Permitted Investments. Notwithstanding the foregoing, Cash Equivalents does not include and Borrower, and each of its Subsidiaries,
are prohibited from purchasing, purchasing participations in, entering into any type of swap or other equivalent derivative transaction,
or otherwise holding or engaging in any ownership interest in any type of debt instrument, including, without limitation, any corporate
or municipal bonds with a long-term nominal maturity for which the interest rate is reset through a dutch auction and more commonly
referred to as an auction rate security (each, an &ldquo;<B>Auction Rate Security</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Claims</B>&rdquo;
are defined in Section 12.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Code</B>&rdquo;
is the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of California; provided,
that, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently
in different Articles or Divisions of the Code, the definition of such term contained in Article or Division 9 shall govern; provided
further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority
of, or remedies with respect to, Collateral Agent&rsquo;s Lien on any Collateral is governed by the Uniform Commercial Code in
effect in a jurisdiction other than the State of California, the term &ldquo;Code&rdquo; shall mean the Uniform Commercial Code
as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment,
perfection, priority, or remedies and for purposes of definitions relating to such provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral</B>&rdquo;
is any and all properties, rights and assets of Borrower described on <U>Exhibit A.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral
Account</B>&rdquo; is any Deposit Account, Securities Account, or Commodity Account, or any other bank account maintained by Borrower
or any Subsidiary at any time, other than Excluded Accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral
Agent</B>&rdquo; is, Oxford, not in its individual capacity, but solely in its capacity as agent on behalf of and for the benefit
of the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Comerica Letter
of Credit</B>&rdquo; is the letter of credit issued by Comerica Bank for the benefit of Borrower as a security deposit for the
Borrower&rsquo;s location at 731 Market Street, Suite 420, San Francisco, California 94103, and any replacements, extensions, amendments
and other modifications thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commitment
Percentage</B>&rdquo; is set forth in <U>Schedule 1.1,</U> as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commodity
Account</B>&rdquo; is any &ldquo;commodity account&rdquo; as defined in the Code with such additions to such term as may hereafter
be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Communication</B>&rdquo;
is defined in Section 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Compliance
Certificate</B>&rdquo; is that certain certificate in the form attached hereto as <U>Exhibit C.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Contingent
Obligation</B>&rdquo; is, for any Person, any direct or indirect liability, contingent or not, of that Person for (a) any indebtedness,
lease, dividend, letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed,
co-made, discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable; (b) any obligations
for undrawn letters of credit for the account of that Person; and (c) all obligations from any interest rate, currency or commodity
swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against
fluctuation in interest rates, currency exchange rates or commodity prices; but &ldquo;Contingent Obligation&rdquo; does not include
endorsements in the ordinary course of business. The amount of a Contingent Obligation is the stated or determined amount of the
primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability
for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee
or other support arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Control Agreement</B>&rdquo;
is any control agreement entered into among the depository institution at which Borrower or any of its Subsidiaries maintains a
Deposit Account or the securities intermediary or commodity intermediary at which Borrower or any of its Subsidiaries maintains
a Securities Account or a Commodity Account, Borrower and such Subsidiary, and Collateral Agent pursuant to which Collateral Agent
obtains control (within the meaning of the Code) for the benefit of the Lenders over such Deposit Account, Securities Account,
or Commodity Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Copyrights</B>&rdquo;
are any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship
and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Credit Extension</B>&rdquo;
is any Term Loan or any other extension of credit by Collateral Agent or Lenders for Borrower&rsquo;s benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Default Rate</B>&rdquo;
is defined in Section 2.3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Deposit Account</B>&rdquo;
is any &ldquo;deposit account&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Designated
Deposit Account</B>&rdquo; is the Deposit Account designated by the Borrower as the Designated Deposit Account in writing to the
Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disbursement
Letter</B>&rdquo; is that certain form attached hereto as <U>Exhibit B.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Dollars</B><I>,</I>&rdquo;
 &ldquo;<B>dollars</B>&rdquo; and &ldquo;$&rdquo; each mean lawful money of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Effective
Date</B>&rdquo; is defined in the preamble of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Eligible Assignee</B>&rdquo;
is (i) a Lender, (ii) an Affiliate of a Lender, (iii) an Approved Fund and (iv) any commercial bank, savings and loan association
or savings bank or any other entity which is an &ldquo;accredited investor&rdquo; (as defined in Regulation D under the Securities
Act of 1933, as amended) and which extends credit or buys loans as one of its businesses, including insurance companies, mutual
funds, lease financing companies and commercial finance companies, in each case, which either (A) has a rating of BBB or higher
from Standard &amp; Poor&rsquo;s Rating Group and a rating of Baa2 or higher from Moody&rsquo;s Investors Service, Inc. at the
date that it becomes a Lender or (B) has total assets in excess of Five Billion Dollars ($5,000,000,000.00), and in each case of
clauses (i) through (iv), which, through its applicable lending office, is capable of lending to Borrower without the imposition
of any withholding or similar taxes; provided that notwithstanding the foregoing, &ldquo;Eligible Assignee&rdquo; shall not include,
unless an Event of Default has occurred and is continuing, (i) Borrower or any of Borrower&rsquo;s Affiliates or Subsidiaries or
(ii) a direct competitor of Borrower or a vulture hedge fund, each as determined by Collateral Agent. Notwithstanding the foregoing,
(x) in connection with assignments by a Lender due to a forced divestiture at the request of any regulatory agency, the restrictions
set forth herein shall not apply and Eligible Assignee shall mean any Person or party and (y) in connection with a Lender&rsquo;s
own financing or securitization transactions, the restrictions set forth herein shall not apply and Eligible Assignee shall mean
any Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such
Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization
transaction; provided that no such sale, transfer, pledge or assignment under this clause (y) shall release such Lender from any
of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Collateral Agent shall
have received and accepted an effective assignment agreement from such Person or party in form satisfactory to Collateral Agent
executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding
such Eligible Assignee as Collateral Agent reasonably shall require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Equipment</B>&rdquo;
is all &ldquo;equipment&rdquo; as defined in the Code with such additions to such term as may hereafter be made, and includes without
limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Equity Event</B>&rdquo;
is the receipt by Borrower on or after the Effective Date of unrestricted net cash proceeds of not less than Forty Million Dollars
($40,000,000.00) from the issuance and sale by Borrower of its equity securities, on or before March 31, 2016 and the receipt of
evidence thereof by Collateral Agent on or before such date, which evidence must be reasonably acceptable to Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>ERISA</B>&rdquo;
is the Employee Retirement Income Security Act of 1974, as amended, and its regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Event of Default</B>&rdquo;
is defined in Section 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Excluded Accounts</B>&rdquo;
means any (a) Deposit Accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for
the benefit of Borrower&rsquo;s, or any of its Subsidiaries&rsquo;, employees and identified to Collateral Agent by Borrower as
such in the Perfection Certificates and (b) that certain certificate of deposit (or any replacement thereof) held with Comerica
Bank and identified to Collateral Agent by Borrower in the Perfection Certificates securing the Comerica Letter of Credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Final Payment</B>&rdquo;
is a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) due on
the earliest to occur of (a) the Maturity Date, or (b) the acceleration of any Term Loan, or (c) the prepayment of a Term Loan
pursuant to Section 2.2(c) or (d), equal to the original principal amount of such Term Loan multiplied by the Final Payment Percentage,
payable to Lenders in accordance with their respective Pro Rata Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Final Payment
Percentage</B>&rdquo; is Four and twenty-five hundredths percent (4.25%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Foreign Subsidiary</B>&rdquo;
is a Subsidiary that is not an entity organized under the laws of the United States or any territory thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Funding Date</B>&rdquo;
is any date on which a Credit Extension is made to or on account of Borrower which shall be a Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>GAAP</B>&rdquo;
is generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of
the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards
Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession
in the United States, which are applicable to the circumstances as of the date of determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>General Intangibles</B>&rdquo;
are all &ldquo;general intangibles&rdquo; as defined in the Code in effect on the date hereof with such additions to such term
as may hereafter be made, and includes without limitation, all copyright rights, copyright applications, copyright registrations
and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, trademarks,
service marks and, to the extent permitted under applicable law, any applications therefor, whether registered or not, any trade
secret rights, including any rights to unpatented inventions, payment intangibles, royalties, contract rights, goodwill, franchise
agreements, purchase orders, customer lists, route lists, telephone numbers, domain names, claims, income and other tax refunds,
security and other deposits, options to purchase or sell real or personal property, rights in all litigation presently or hereafter
pending (whether in contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and
business interruption insurance), payments of insurance and rights to payment of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental
Approval</B>&rdquo; is any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration,
filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental
Authority</B>&rdquo; is any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality,
regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative
functions of or pertaining to government, any securities exchange and any self-regulatory organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Guarantor</B>&rdquo;
is any Person providing a Guaranty in favor of Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Guaranty</B>&rdquo;
is any guarantee of all or any part of the Obligations, as the same may from time to time be amended, restated, modified or otherwise
supplemented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Indebtedness</B>&rdquo;
is (a) indebtedness for borrowed money or the deferred price of property or services, such as reimbursement and other obligations
for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital
lease obligations, and (d) Contingent Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Indemnified
Person</B>&rdquo; is defined in Section 12.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Insolvency
Proceeding</B>&rdquo; is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy
or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or
proceedings seeking reorganization, arrangement, or other relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Insolvent</B>&rdquo;
means not Solvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Intellectual
Property</B>&rdquo; means all of Borrower&rsquo;s or any Subsidiary&rsquo;s right, title and interest in and to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a)&nbsp;&nbsp;&nbsp;its
Copyrights, Trademarks and Patents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b)&nbsp;&nbsp;&nbsp;any and all trade
secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how, operating manuals;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c)&nbsp;&nbsp;&nbsp;any
and all source code;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(d)&nbsp;&nbsp;&nbsp;any
and all design rights which may be available to Borrower;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(e) &nbsp;&nbsp;any and all claims
for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the obligation, to
sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(f)&nbsp;&nbsp;&nbsp;&nbsp;all
amendments, renewals and extensions of any of the Copyrights, Trademarks or&nbsp;Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Inventory</B>&rdquo;
is all &ldquo;inventory&rdquo; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter
be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work
in process and finished products, including without limitation such inventory as is temporarily out of any Person&rsquo;s custody
or possession or in transit and including any returned goods and any documents of title representing any of the above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investment</B>&rdquo;
is any beneficial ownership interest in any Person (including stock, partnership interest or other securities), and any loan, advance,
payment or capital contribution to any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Key Person</B>&rdquo;
is each of Borrower&rsquo;s (i) Chief Executive Officer, who is Rick Orr as of the Effective Date, (ii) Chief Financial Officer,
which position is vacant as of the Effective Date and (iii) Chief Scientific Officer, who is Julien Mamet as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Lender</B>&rdquo;
is any one of the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Lenders</B>&rdquo;
are the Persons identified on <U>Schedule 1.1</U> hereto and each assignee that becomes a party to this Agreement pursuant to Section
12.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Lenders&rsquo;
Expenses</B>&rdquo; are all audit fees and expenses, costs, and expenses (including reasonable attorneys&rsquo; fees and expenses,
as well as appraisal fees, fees incurred on account of lien searches, inspection fees, and filing fees) for preparing, amending,
negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection
with appeals or Insolvency Proceedings) or otherwise incurred by Collateral Agent and/or the Lenders in connection with the Loan
Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Lien</B>&rdquo;
is a claim, mortgage, deed of trust, levy, charge, pledge, security interest, or other encumbrance of any kind, whether voluntarily
incurred or arising by operation of law or otherwise against any property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Loan Documents</B>&rdquo;
are, collectively, this Agreement, the Warrants, the Perfection Certificates, each Compliance Certificate, each Disbursement Letter,
any subordination agreements, any note, or notes or guaranties executed by Borrower or any other Person, and any other present
or future agreement entered into by Borrower, any Guarantor or any other Person for the benefit of the Lenders and Collateral Agent
in connection with this Agreement; all as amended, restated, or otherwise modified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Material Adverse
Change</B>&rdquo; is (a) a material impairment in the perfection or priority of Collateral Agent&rsquo;s Lien in the Collateral
or in the value of such Collateral; (b) a material adverse change in the business, operations or condition (financial or otherwise)
of Borrower or of Borrower and its Subsidiaries, taken as whole; or (c) a material impairment of the prospect of repayment of any
portion of the Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Maturity Date</B>&rdquo;
is, for each Term Loan, is November 1, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Monthly Reporting
Date</B>&rdquo; is the date following any month of Borrower on which financial statements are required to be delivered pursuant
to Section 6.2(a)(i) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Obligations</B>&rdquo;
are all of Borrower&rsquo;s obligations to pay when due any debts, principal, interest, Lenders&rsquo; Expenses, the Prepayment
Fee, the Final Payment, and other amounts Borrower owes the Lenders now or later, in connection with, related to, following, or
arising from, out of or under, this Agreement or, the other Loan Documents (other than the Warrants), or otherwise, and including
interest accruing after Insolvency Proceedings begin (whether or not allowed) and debts, liabilities, or obligations of Borrower
assigned to the Lenders and/or Collateral Agent, and the performance of Borrower&rsquo;s duties under the Loan Documents (other
than the Warrants).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>OFAC</B>&rdquo;
is the U.S. Department of Treasury Office of Foreign Assets Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>OFAC Lists</B>&rdquo;
are, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No.
13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant
to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Operating
Documents</B>&rdquo; are, for any Person, such Person&rsquo;s formation documents, as certified by the Secretary of State (or equivalent
agency) of such Person&rsquo;s jurisdiction of organization on a date that is no earlier than thirty (30) days prior to the Effective
Date, and, (a) if such Person is a corporation, its bylaws in current form, (b) if such Person is a limited liability company,
its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership, its partnership agreement
(or similar agreement), each of the foregoing with all current amendments or modifications thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Patents</B>&rdquo;
means all patents, patent applications and like protections including without limitation improvements, divisions, continuations,
renewals, reissues, extensions and continuations-in-part of the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Payment Date</B>&rdquo;
is the first (1st) calendar day of each calendar month, commencing on January 1, 2016. &ldquo;<B>Perfection Certificate</B>&rdquo;
and &ldquo;<B>Perfection Certificates</B>&rdquo; is defined in Section 5.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted
Indebtedness</B>&rdquo; is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a)&nbsp;&nbsp;&nbsp;Borrower&rsquo;s
Indebtedness to the Lenders and Collateral Agent under this Agreement and the other Loan Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b)&nbsp;&nbsp;&nbsp;Indebtedness
existing on the Effective Date and disclosed on the Perfection Certificate(s);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c)&nbsp;&nbsp;&nbsp;Subordinated
Debt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(d)&nbsp;&nbsp;&nbsp;unsecured
Indebtedness to trade creditors incurred in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(e)&nbsp;&nbsp;&nbsp;Indebtedness consisting
of capitalized lease obligations and purchase money Indebtedness, in each case incurred by Borrower or any of its Subsidiaries
to finance the acquisition, repair, improvement or construction of fixed or capital assets of such person, provided that (i) the
aggregate outstanding principal amount of all such Indebtedness does not exceed One Hundred Thousand Dollars ($100,000.00) at any
time and (ii) the principal amount of such Indebtedness does not exceed the lower of the cost or fair market value of the property
so acquired or built or of such repairs or improvements financed with such Indebtedness (each measured at the time of such acquisition,
repair, improvement or construction is made);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(f)&nbsp;&nbsp;&nbsp;Indebtedness
incurred as a result of endorsing negotiable instruments received in the ordinary course of Borrower&rsquo;s business; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(g)&nbsp;&nbsp;&nbsp;Unsecured
Indebtedness in an aggregate principal amount not to exceed $250,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(h)&nbsp;&nbsp;&nbsp;Indebtedness
in connection with the Comerica Letter of Credit, not to exceed $27,580;&nbsp;and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;extensions, refinancings,
modifications, amendments and restatements of any items of Permitted Indebtedness (a) through (e), (g) and (h) above, provided
that the principal amount thereof is not increased or the terms thereof are not modified to impose materially more burdensome terms
upon Borrower, or its Subsidiary, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted
Investments</B>&rdquo; are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a)&nbsp;&nbsp;&nbsp;Investments
disclosed on the Perfection Certificate(s) and existing on the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b)&nbsp;&nbsp;&nbsp;(i)
Investments consisting of cash and Cash Equivalents, and (ii) any Investments permitted by Borrower&rsquo;s investment policy,
as amended from time to time, provided that such investment policy (and any such amendment thereto) has been approved in writing
by Collateral Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c)&nbsp;&nbsp;&nbsp;&nbsp;Investments consisting
of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of Borrower;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(d)&nbsp;&nbsp;&nbsp;Investments
consisting of Deposit Accounts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(e)&nbsp;&nbsp;&nbsp;Investments
in connection with Transfers permitted by Section 7.1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(f)&nbsp;&nbsp;&nbsp;&nbsp;Investments consisting
of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business,
and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries
pursuant to employee stock purchase plans or agreements approved by Borrower&rsquo;s Board of Directors; not to exceed One Hundred
Fifty Thousand Dollars ($150,000.00) in the aggregate for (i) and (ii) in any fiscal year;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(g)&nbsp;&nbsp;&nbsp;Investments (including
debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent
obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(h)&nbsp;&nbsp;&nbsp;Investments consisting
of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in
the ordinary course of business; provided that this paragraph (h) shall not apply to Investments of Borrower in any Subsidiary;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;non-cash Investments
in joint ventures or strategic alliances in the ordinary course of Borrower&rsquo;s business consisting of the non-exclusive licensing
of technology, the development of technology or the providing of technical support; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other
Investments not to exceed $150,000 in the aggregate at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted
Licenses</B>&rdquo; are (A) licenses of over-the-counter software that is commercially available to the public, and (B) non-exclusive
and exclusive licenses for the use of the Intellectual Property of Borrower or any of its Subsidiaries entered into in the ordinary
course of business, <U>provided,</U> that, with respect to each such license described in clause (B), (i) no Event of Default has
occurred or is continuing at the time of such license; (ii) the license constitutes an arms-length transaction, the terms of which,
on their face, do not provide for a sale or assignment of any Intellectual Property and do not restrict the ability of Borrower
or any of its Subsidiaries, as applicable, to pledge, grant a security interest in or lien on, or assign or otherwise Transfer
any Intellectual Property; (iii) in the case of any exclusive license, (x) Borrower delivers ten (10) days&rsquo; prior written
notice and a brief summary of the terms of the proposed license to Collateral Agent and the Lenders and delivers to Collateral
Agent and the Lenders copies of the final executed licensing documents in connection with the exclusive license promptly upon consummation
thereof and (y) any such license could not result in a legal transfer of title of the licensed property but may be exclusive in
respects other than territory and may be exclusive as to territory only as to discrete geographical areas outside of the United
States; and (iv) all upfront payments, royalties, milestone payments or other proceeds arising from the licensing agreement that
are payable to Borrower or any of its Subsidiaries are paid to a Deposit Account that is governed by a Control Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted
Liens</B>&rdquo; are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(a) Liens existing
on the Effective Date and disclosed on the Perfection Certificates or arising under this Agreement and the other Loan Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(b) Liens for taxes,
fees, assessments or other government charges or levies, either (i) not due and payable or (ii) being contested in good faith and
for which Borrower maintains adequate reserves on its Books, provided that no notice of any such Lien has been filed or recorded
under the Internal Revenue Code of 1986, as amended, and the Treasury Regulations adopted thereunder (and it being understood that
such Liens are permitted to have priority to Collateral Agent&rsquo;s Liens in such property secured by this clause (b));</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(c) Liens securing
Indebtedness permitted under clause (e) of the definition of &ldquo;<B>Permitted Indebtedness</B>,&rdquo; provided that (i) such
liens exist prior to the acquisition of, or attach substantially simultaneous with, or within twenty (20) days after the, acquisition,
lease, repair, improvement or construction of, such property financed or leased by such Indebtedness and (ii) such liens do not
extend to any property of Borrower other than the property (and proceeds thereof) acquired, leased or built, or the improvements
or repairs, financed by such Indebtedness (and it being understood that such Liens are permitted to have priority to Collateral
Agent&rsquo;s Liens in such property secured by this clause (c));</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(d) Liens of carriers,
warehousemen, suppliers, or other Persons that are possessory in nature arising in the ordinary course of business so long as such
Liens attach only to Inventory, securing liabilities in the aggregate amount not to exceed One Hundred Thousand Dollars ($100,000.00),
and which are not delinquent or remain payable without penalty or which are being contested in good faith and by appropriate proceedings
which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(e) Liens to secure
payment of workers&rsquo; compensation, employment insurance, old-age pensions, social security and other like obligations incurred
in the ordinary course of business (other than Liens imposed by ERISA);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(f) Liens incurred
in the extension, renewal or refinancing of the indebtedness secured by Liens described in (a) through (c) <U>but</U> any extension,
renewal or replacement Lien (i) must be limited to the property encumbered by the existing Lien and the principal amount of the
indebtedness may not increase unless otherwise permitted by the definition of Permitted Indebtedness and (ii) may not have priority
to Collateral Agent&rsquo;s Lien in such property unless such existing Lien was permitted by the terms of this Agreement to have
priority to Collateral Agent&rsquo;s Lien;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(g) leases or subleases
of real property granted in the ordinary course of Borrower&rsquo;s business (or, if referring to another Person, in the ordinary
course of such Person&rsquo;s business), and leases, subleases, non-exclusive licenses or sublicenses of personal property (other
than Intellectual Property) granted in the ordinary course of Borrower&rsquo;s business (or, if referring to another Person, in
the ordinary course of such Person&rsquo;s business), if the leases, subleases, licenses and sublicenses do not prohibit granting
Collateral Agent or any Lender a security interest therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(h) banker&rsquo;s
liens, rights of setoff and Liens in favor of financial institutions incurred in the ordinary course of business arising in connection
with Borrower&rsquo;s deposit accounts or securities accounts held at such institutions solely to secure payment of fees and similar
costs and expenses and provided such accounts are maintained in compliance with Section 6.6(b) hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(i) Liens arising
from judgments, decrees or attachments in circumstances not constituting an Event of Default under Section 8.4 or 8.7;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(j) Liens
consisting of Permitted Licenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(k) easements, reservations,
rights-of-way, restrictions, minor defects or irregularities in title and other similar Liens affecting real property not interfering
in any material respect with the ordinary course of the business of Borrower;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(l) deposits to secure
the performance of bids, trade contracts (other than for borrowed money), contracts for the purchase of property permitted hereunder,
statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature, in each case, incurred
in the ordinary course of business not representing an obligation for borrowed money in an amount not to exceed One Hundred Thousand
Dollars ($100,000) outstanding at any time; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(m) deposits to secure
the performance of leases incurred in the ordinary course of business and not representing an obligation for borrowed money so
long as each such deposit: (1) is made at the commencement of a lease or its renewal when there is no underlying default under
such lease, and (2) is in amount not exceeding $100,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
is any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization,
association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prepayment
Fee</B>&rdquo; is, with respect to any Term Loan subject to prepayment prior to the Maturity Date, whether by mandatory or voluntary
prepayment, acceleration or otherwise, an additional fee payable to the Lenders in amount equal to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) for a prepayment
made on or after the Funding Date of such Term Loan through and including the first anniversary of the Funding Date of such Term
Loan, three percent (3.00%) of the principal amount of such Term Loan prepaid; provided, however, if the prepayment is in connection
with the acquisition of the Company by a third party on or before the six-month anniversary of the Effective Date, then the applicable
Prepayment Fee will be one percent (1.00%) of the principal amount of such Term Loan prepaid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) for a prepayment
made after the date which is after the first anniversary of the Funding Date of such Term Loan through and including the second
anniversary of the Funding Date of such Term Loan, two percent (2.00%) of the principal amount of the Term Loans prepaid; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;for
a prepayment made after the second anniversary of the Funding Date of such Term Loan and prior to the Maturity Date, one percent
(1.00%) of the principal amount of the Term Loans prepaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Pro Rata Share</B>&rdquo;
is, as of any date of determination, with respect to each Lender, a percentage (expressed as a decimal, rounded to the ninth decimal
place) determined by dividing the outstanding principal amount of Term Loans held by such Lender by the aggregate outstanding principal
amount of all Term Loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registered
Organization</B>&rdquo; is any &ldquo;registered organization&rdquo; as defined in the Code with such additions to such term as
may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Required Lenders</B>&rdquo;
means (i) for so long as all of the Persons that are Lenders on the Effective Date (each an &ldquo;<B>Original Lender</B>&rdquo;)
have not assigned or transferred any of their interests in their Term Loan, Lenders holding one hundred percent (100%) of the aggregate
outstanding principal balance of the Term Loan, or (ii) at any time from and after any Original Lender has assigned or transferred
any interest in its Term Loan, Lenders holding at least sixty six percent (66%) of the aggregate outstanding principal balance
of the Term Loan and, in respect of this clause (ii), (A) each Original Lender that has not assigned or transferred any portion
of its Term Loan, (B) each assignee or transferee of an Original Lender&rsquo;s interest in the Term Loan, but only to the extent
that such assignee or transferee is an Affiliate or Approved Fund of such Original Lender, and (C) any Person providing financing
to any Person described in clauses (A) and (B) above; provided, however, that this clause (C) shall only apply upon the occurrence
of a default, event of default or similar occurrence with respect to such financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Requirement
of Law</B>&rdquo; is as to any Person, the organizational or governing documents of such Person, and any law (statutory or common),
treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable
to or binding upon such Person or any of its property or to which such Person or any of its property is subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Responsible
Officer</B>&rdquo; is any of the President, Chief Executive Officer, or Chief Financial Officer of Borrower acting alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Second Draw
Period</B>&rdquo; is the period commencing on December 1, 2015 and ending on the earlier of (i) January 31, 2016 and (ii) the occurrence
of an Event of Default; provided, however, that the Second Draw Period shall not commence if on December 1, 2015, an Event of Default
has occurred and is continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Secured Promissory
Note</B>&rdquo; is defined in Section 2.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Secured Promissory
Note Record</B>&rdquo; is a record maintained by each Lender with respect to the outstanding Obligations owed by Borrower to Lender
and credits made thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities
Account</B>&rdquo; is any &ldquo;securities account&rdquo; as defined in the Code with such additions to such term as may hereafter
be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Solvent</B>&rdquo;
is, with respect to any Person: the fair salable value of such Person&rsquo;s consolidated assets (including goodwill minus disposition
costs) exceeds the fair value of such Person&rsquo;s liabilities; such Person is not left with unreasonably small capital after
the transactions in this Agreement; and such Person is able to pay its debts (including trade debts) as they mature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subordinated
Debt</B>&rdquo; is indebtedness incurred by Borrower or any of its Subsidiaries subordinated to all Indebtedness of Borrower and/or
its Subsidiaries to the Lenders (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory
to Collateral Agent and the Lenders entered into between Collateral Agent, Borrower, and/or any of its Subsidiaries, and the other
creditor), on terms acceptable to Collateral Agent and the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subsidiary</B>&rdquo;
is, with respect to any Person, any Person of which more than fifty percent (50%) of the voting stock or other equity interests
(in the case of Persons other than corporations) is owned or controlled, directly or indirectly, by such Person or through one
or more intermediaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term Loan</B>&rdquo;
is defined in Section 2.2(a)(iii) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term A Loan</B>&rdquo;
is defined in Section 2.2(a)(i) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term B Loan</B>&rdquo;
is defined in Section 2.2(a)(ii) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term C Loan</B>&rdquo;
is defined in Section 2.2(a)(iii) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Term Loan
Commitment</B>&rdquo; is, for any Lender, the obligation of such Lender to make a Term Loan, up to the principal amount shown on
<U>Schedule 1.1</U><B>. </B>&ldquo;<B>Term Loan Commitments</B>&rdquo; means the aggregate amount of such commitments of all Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Third Draw
Period</B>&rdquo; is the period commencing on the date of the occurrence of the Equity Event and ending on the earlier of (i) March
31, 2016, (ii) the date that is thirty (30) days immediately following the date of the occurrence of the Equity Event and (iii)
the occurrence of an Event of Default; provided, however, that the Second Draw Period shall not commence if on the date of the
occurrence of the Equity Event an Event of Default has occurred and is continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trademarks</B>&rdquo;
means any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and
like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer</B>&rdquo;
is defined in Section 7.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Warrants</B>&rdquo;
are those certain Warrants to Purchase Stock dated as of the Effective Date, or any date thereafter, issued by Borrower in favor
of each Lender or such Lender&rsquo;s Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>[<I>Balance of Page Intentionally Left
Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,</B>
the parties hereto have caused this Agreement to be executed as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Signature Page to Loan and Security
Agreement</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,</B>
the parties hereto have caused this Agreement to be executed as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;Hans S. Houser</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Hans S. Houser</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Chief Credit Officer &amp; Sr. Vice President</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Signature Page to Loan and Security
Agreement</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Lenders and Commitments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Term A Loans</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Lender</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Term Loan&nbsp;Commitment</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Commitment&nbsp;Percentage</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 54%; text-align: center">OXFORD&nbsp;FINANCE LLC</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">3,000,000.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">100.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">TOTAL</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">3,000,000.00</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">100.00</TD><TD STYLE="font-weight: bold; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Term B Loans</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Lender</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Term Loan&nbsp;Commitment</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Commitment&nbsp;Percentage</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 54%; text-align: center">OXFORD&nbsp;FINANCE LLC</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">2,000,000.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">100.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">TOTAL</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">2,000,000.00</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">100.00</TD><TD STYLE="font-weight: bold; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Term C Loans</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Lender</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Term Loan&nbsp;Commitment</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Commitment&nbsp;Percentage</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 54%; text-align: center">OXFORD&nbsp;FINANCE LLC</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">5,000,000.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">100.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">TOTAL</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">5,000,000.00</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">100.00</TD><TD STYLE="font-weight: bold; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aggregate (all Term Loans)</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Lender</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Term Loan&nbsp;Commitment</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Commitment&nbsp;Percentage</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 54%; text-align: center">OXFORD&nbsp;FINANCE LLC</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">10,000,000.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">100.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">TOTAL</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">10,000,000.00</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">100.00</TD><TD STYLE="font-weight: bold; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Description of Collateral</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Collateral consists of all of Borrower&rsquo;s
right, title and interest in and to the following personal property:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All goods, Accounts
(including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements,
franchise agreements, General Intangibles (except as noted below), commercial tort claims, documents, instruments (including any
promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates
of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and
all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever
located; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All Borrower&rsquo;s
Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions,
attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or
all of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, the Collateral does not include (i) any Intellectual Property; provided, however, the Collateral shall include all Accounts
and all proceeds of Intellectual Property. If a judicial authority (including a U.S. Bankruptcy Court) would hold that a security
interest in the underlying Intellectual Property is necessary to have a security interest in such Accounts and such property that
are proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Effective Date, include
the Intellectual Property to the extent necessary to permit perfection of Collateral Agent&rsquo;s security interest in such Accounts
and such other property of Borrower that are proceeds of the Intellectual Property; (ii) more than 65% of the total combined voting
power of all classes of stock entitled to vote the shares of capital stock (the &ldquo;Shares&rdquo;) of any Foreign Subsidiary,
if Borrower demonstrates to Collateral Agent&rsquo;s reasonable satisfaction that a pledge of more than sixty five percent (65%)
of the Shares of such Subsidiary creates a present and existing adverse tax consequence to Borrower under the U.S. Internal Revenue
Code; (iii) any license or contract, in each case if the granting of a Lien in such license or contract is prohibited by or would
constitute a default under the agreement governing such license or contract (but (A) only to the extent such prohibition is enforceable
under applicable law and (B) other than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406,
9-408 or 9-409 (or any other Section) of Division 9 of the Code); provided that upon the termination, lapsing or expiration of
any such prohibition, such license or contract, as applicable, shall automatically be subject to the security interest granted
in favor of Collateral Agent hereunder and become part of the &ldquo;Collateral&rdquo;; and (iv) any Excluded Accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms
of a certain negative pledge arrangement with Collateral Agent and the Lenders, Borrower has agreed not to encumber any of its
Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form of Disbursement Letter</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DISBURSEMENT LETTER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[DATE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned, being the duly elected
and acting <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>of ADYNXX, INC., a Delaware corporation with offices located at 731 Market Street, Suite 420, San Francisco, California 94103
(&ldquo;<B>Borrower</B>&rdquo;), does hereby certify to <B>OXFORD FINANCE LLC </B>(&ldquo;<B>Oxford</B>&rdquo; and &ldquo;<B>Lender</B>&rdquo;),
as collateral agent (the &ldquo;<B>Collateral Agent</B>&rdquo;) in connection with that certain Loan and Security Agreement dated
as of [_], 2015, by and among Borrower, Collateral Agent and the Lenders from time to time party thereto (the &ldquo;<B>Loan Agreement</B>&rdquo;;
with other capitalized terms used below having the meanings ascribed thereto in the Loan Agreement) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. The representations
and warranties made by Borrower in Section 5 of the Loan Agreement and in the other Loan Documents are true and correct in all
material respects as of the date hereof; provided, however, that such materiality qualifier is not be applicable to any representations
and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations
and warranties expressly referring to a specific date are true, accurate and complete in all material respects as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. No
event or condition has occurred that would constitute an Event of Default under the Loan Agreement or any other Loan Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. Borrower is in compliance
with the covenants and requirements contained in Sections 4, 6 and 7 of the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. All conditions referred
to in Section 3 of the Loan Agreement to the making of the Loan to be made on or about the date hereof have been satisfied or waived
by Collateral Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. No
Material Adverse Change has occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6. The
undersigned is a Responsible Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[Balance of Page Intentionally Left
Blank]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
proceeds of the Term [A][B][C] Loan shall be disbursed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 0.75in; font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%"><B>Disbursement from Oxford:</B></TD>
    <TD NOWRAP STYLE="width: 15%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt">Loan Amount</TD>
    <TD NOWRAP STYLE="text-align: right">$_____________</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Plus:</TD>
    <TD NOWRAP STYLE="text-align: right">$_____________</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&ndash;Deposit Received</TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">Less:</TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">&ndash;Facility Fee</TD>
    <TD NOWRAP STYLE="text-align: right">($____________)</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">[&ndash;Existing Debt Payoff to be remitted to [PAYOFF BANK] per the Payoff Letter dated [DATE]</TD>
    <TD NOWRAP STYLE="text-align: right">($____________)]</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">[&ndash;Interim Interest</TD>
    <TD NOWRAP STYLE="text-align: right">($____________)]</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in">&ndash;Lender&rsquo;s Legal Fees</TD>
    <TD NOWRAP STYLE="text-align: right">($____________)*</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><B>Net Proceeds due from Oxford:</B></TD>
    <TD NOWRAP STYLE="text-align: right">$_____________</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><B>TOTAL TERM [A] [B] LOAN NET PROCEEDS FROM LENDERS</B></TD>
    <TD NOWRAP STYLE="text-align: right">$_____________</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
[initial][Term Loan][Term A Loan][Term B Loan][Term C Loan] shall amortize in accordance with the Amortization Table attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate net proceeds of the Term Loans shall be transferred to the Designated Deposit Account as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; margin-left: 0.75in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt">Account Name:</FONT></TD>
    <TD STYLE="width: 35%; text-align: justify"><FONT STYLE="font-size: 10pt">[BORROWER]</FONT></TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Bank&nbsp;Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;]</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Bank&nbsp;Address:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">[&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;]</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Account Number:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">ABA Number:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">[&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;]</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[Balance of Page Intentionally Left
Blank]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Legal fees and costs are through the
Effective Date. Post-closing legal fees and costs, payable after the Effective Date, to be invoiced and paid post-closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Signature Page to Disbursement Letter</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMORTIZATION TABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Term [A][B][C] Loan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT C </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Compliance Certificate</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left">TO:</TD><TD STYLE="text-align: justify">OXFORD FINANCE LLC, as Collateral Agent and Lender</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left">FROM:</TD><TD STYLE="text-align: justify">ADYNXX, INC.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned authorized officer (&ldquo;<B>Officer</B>&rdquo;)
of ADYNXX, INC. (&ldquo;<B>Borrower</B>&rdquo;), hereby certifies that in accordance with the terms and conditions of the Loan
and Security Agreement by and among Borrower, Collateral Agent, and the Lenders from time to time party thereto (the &ldquo;<B>Loan
Agreement</B>;&rdquo; capitalized terms used but not otherwise defined herein shall have the meanings given them in the Loan Agreement),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;Borrower is
in complete compliance for the period ending&nbsp; <U>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</U>
with all required covenants except as noted below;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;There
are no Events of Default, except as noted below;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Except as noted
below, all representations and warranties of Borrower stated in the Loan Documents are true and correct in all material respects
on this date and for the period described in (a), above; provided, however, that such materiality qualifier shall not be applicable
to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided,
further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in
all material respects as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Borrower, and each
of Borrower&rsquo;s Subsidiaries, has timely filed all required tax returns and reports, Borrower, and each of Borrower&rsquo;s
Subsidiaries, has timely paid all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower,
or Subsidiary, except as otherwise permitted pursuant to the terms of Section 5.8 of the Loan Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) No Liens have been
levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower
has not previously provided written notification to Collateral Agent and the Lenders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attached are the required documents, if
any, supporting our certification(s). The Officer, on behalf of Borrower, further certifies that the attached financial statements
are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to
the next except as explained in an accompanying letter or footnotes and except, in the case of unaudited financial statements,
for the absence of footnotes and subject to year-end audit adjustments as to the interim financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Please indicate compliance status since
the last Compliance Certificate by circling Yes, No, or N/A under &ldquo;Complies&rdquo; column.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Reporting Covenant</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Requirement</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Actual</B></FONT></TD>
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Complies</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt"><B>1)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Financial statements</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Monthly within 30 days</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt"><B>2)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Annual (CPA Audited) statements</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Within [ <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] after FYE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt"><B>3)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Annual Financial&nbsp;Projections/Budget (prepared on a monthly basis)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Annually (within 30 days of FYE), and when revised</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt"><B>4)</B></FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">A/R &amp; A/P agings</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">If applicable</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="width: 5%; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="width: 5%; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt"><B>5)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">8-K, 10-K and 10-Q Filings</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">If applicable, within 5 days of filing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt"><B>6)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Compliance Certificate</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Monthly within 30 days</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>7)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Total amount of Borrower&rsquo;s cash&nbsp;and cash equivalents at the last day of the measurement period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>8)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Total amount of Borrower&rsquo;s&nbsp;Subsidiaries&rsquo; cash and cash&nbsp;equivalents at the last day of the measurement period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>Deposit and Securities
Accounts</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>(Please list all
accounts; attach separate sheet if additional space needed)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Institution Name</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Account Number</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>New Account?</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Account Control Agreement in<BR>
 place?</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 28%">&nbsp;</TD>
    <TD STYLE="width: 27%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt"><B>1)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt"><B>2)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt"><B>3)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt"><B>4)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>Other Matters</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt"><B>1)</B></FONT></TD>
    <TD STYLE="width: 75%"><FONT STYLE="font-size: 10pt">Have there been any changes in management since the last Compliance Certificate?</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt"><B>2)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Have there been any transfers/sales/disposals/retirement of Collateral or IP prohibited by the Loan Agreement?</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt"><B>3)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Have there been any new or pending claims or causes of action against Borrower that involve more than One Hundred Fifty Thousand Dollars ($150,000.00)?</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>4)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Have there been any material amendments to the capitalization table of Borrower or any amendments to the Operating Documents of Borrower or any of its Subsidiaries? If yes, provide copies of any such amendments or changes with this Compliance Certificate.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>5)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Are there any other updates to the existing Perfection Certificates necessary to cause the information&nbsp;set forth in such Perfection Certificates to be true and correct in all material&nbsp;respects? If yes, provide a statement below of any such updates, amendments or changes&nbsp;with this Compliance Certificate.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Exceptions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please explain any exceptions with respect
to the certification above: (If no exceptions exist, state &ldquo;No exceptions.&rdquo; Attach separate sheet if additional space
needed.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>LENDER USE ONLY</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Received by:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Verified by:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Compliance Status:</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT D</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form of Secured Promissory Note</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURED PROMISSORY NOTE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Term [A][B] Loan)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">$<U>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</U></FONT></TD>
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt">Dated: [DATE]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED,
the undersigned, ADYNXX, INC., a Delaware corporation with offices located at 731 Market Street, Suite 420, San Francisco, California
94103 (&ldquo;<B>Borrower</B>&rdquo;) HEREBY PROMISES TO PAY to the order of OXFORD FINANCE LLC (&ldquo;<B>Lender</B>&rdquo;) the
principal amount of [<U>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</U>] MILLION DOLLARS
($<U>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </U>) or such lesser amount as shall equal the
outstanding principal balance of the Term [A][B][C] Loan made to Borrower by Lender, plus interest on the aggregate unpaid principal
amount of such Term [A][B] Loan, at the rates and in accordance with the terms of the Loan and Security Agreement dated [_], 2015
by [C] and among Borrower, Lender, Oxford Finance LLC, as Collateral Agent, and the other Lenders from time to time party thereto
(as amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;). If not sooner
paid, the entire principal amount and all accrued and unpaid interest hereunder shall be due and payable on the Maturity Date as
set forth in the Loan Agreement. Any capitalized term not otherwise defined herein shall have the meaning attributed to such term
in the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Principal, interest and all other amounts
due with respect to the Term [A][B][C] Loan, are payable in lawful money of the United States of America to Lender as set forth
in the Loan Agreement and this Secured Promissory Note (this &ldquo;<B>Note</B>&rdquo;). The principal amount of this Note and
the interest rate applicable thereto, and all payments made with respect thereto, shall be recorded by Lender and, prior to any
transfer hereof, endorsed on the grid attached hereto which is part of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Loan Agreement, among other things,
(a) provides for the making of a secured Term [A][B][C] Loan by Lender to Borrower, and (b) contains provisions for acceleration
of the maturity hereof upon the happening of certain stated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Note may not be prepaid except as
set forth in Section 2.2 (c) and Section 2.2(d) of the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Note and the obligation of Borrower
to repay the unpaid principal amount of the Term [A][B][C] Loan, interest on the Term [A][B][C] Loan and all other amounts due
Lender under the Loan Agreement is secured under the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Presentment for payment, demand, notice
of protest and all other demands and notices of any kind in connection with the execution, delivery, performance and enforcement
of this Note are hereby waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower shall pay all reasonable fees
and expenses, including, without limitation, reasonable attorneys&rsquo; fees and costs, incurred by Lender in the enforcement
or attempt to enforce any of Borrower&rsquo;s obligations hereunder not performed when due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Note shall be governed by, and construed
and interpreted in accordance with, the internal laws of the State of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ownership of an interest in this Note
shall be registered on a record of ownership maintained by Lender or its agent. Notwithstanding anything else in this Note to the
contrary, the right to the principal of, and stated interest on, this Note may be transferred only if the transfer is made in accordance
with the provisions of the Loan Agreement, is registered on such record of ownership and the transferee is identified as the owner
of an interest in the obligation. Borrower shall be entitled to treat the registered holder of this Note (as recorded on such record
of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to
or interest in this Note on the part of any other person or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[Balance of Page Intentionally Left
Blank]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
Borrower has caused this Note to be duly executed by one of its officers thereunto duly authorized on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    </TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Term [A][B][C] Loan Secured Promissory
Note</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LOAN INTEREST RATE AND PAYMENTS OF PRINCIPAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: bottom; width: 16%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 20%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Principal&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amount</B></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 20%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Interest Rate</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 20%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Scheduled&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Payment Amount</B></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 20%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Notation By</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF CORPORATE BORROWING CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt"><B>DATE</B>: [DATE]</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt"><B>LENDER:</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC, as Collateral Agent and Lender</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I hereby certify as follows, as of the
date set forth above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I am the Secretary, Assistant Secretary
or other officer of Borrower. My title is as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Borrower&rsquo;s exact legal name is
set forth above. Borrower is a Delaware corporation existing under the laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Attached hereto as <U>Exhibit A</U>
and <U>Exhibit B</U>, respectively, are true, correct and complete copies of (i) Borrower&rsquo;s Articles/Certificate of Incorporation
(including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph
2 above; and (ii) Borrower&rsquo;s Bylaws. Neither such Articles/Certificate of Incorporation nor such Bylaws have been amended,
annulled, rescinded, revoked or supplemented, and such Articles/Certificate of Incorporation and such Bylaws remain in full force
and effect as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. Attached hereto as <U>Exhibit C</U>
are true, correct and complete copies of the resolutions duly and validly adopted by Borrower&rsquo;s Board of Directors at a duly
held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action). Such resolutions
are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked,
and the Lenders may rely on them until each Lender receives written notice of revocation from Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Balance of Page Intentionally Left
Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The following officers or employees
of Borrower, whose names, titles and signatures are below, are now duly elected and qualified officers of Borrower, holding the
offices indicated next to the names below on the date hereof, and the signatures appearing opposite the names of the officers below
are their true and genuine signatures, and each of such officers is duly authorized to execute and deliver on behalf of Borrower,
the Loan Agreement and the other Loan Documents to be issued pursuant thereto:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: bottom; width: 22%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Name</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 25%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Title</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 25%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Authorized to</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Add or Remove</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Signatories</P></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Balance of Page Intentionally Left
Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the undersigned hereunder subscribes his name effective as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt"><B>By:</B></FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Name:</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Title:&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">I, [___________], the [____________] of the
Borrower, hereby certify that [___________] is the duly elected and qualified [______________] of the Borrower and that his true
and genuine signature is set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt"><B>By:</B></FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Name:</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Title:&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Signature Page to Corporate Borrowing
Certificate</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Articles/Certificate of Incorporation
(including amendments)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT B </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Bylaws</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><B>DEBTOR:</B></FONT></TD>
    <TD STYLE="width: 85%"><FONT STYLE="font-size: 10pt"><B>ADYNXX, INC.</B></FONT></TD>
    </TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>SECURED<BR>
 PARTY:</B></FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>OXFORD FINANCE LLC, </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>as Collateral Agent</B></P></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A TO UCC FINANCING STATEMENT
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Description of Collateral</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Collateral consists of all of Debtor&rsquo;s
right, title and interest in and to the following personal property:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All goods, Accounts
(including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements,
franchise agreements, General Intangibles (except as noted below), commercial tort claims, documents, instruments (including any
promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates
of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and
all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever
located; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All Debtor&rsquo;s Books
relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions,
attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or
all of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, the Collateral does not include (i) any Intellectual Property; provided, however, the Collateral shall include all Accounts
and all proceeds of Intellectual Property. If a judicial authority (including a U.S. Bankruptcy Court) would hold that a security
interest in the underlying Intellectual Property is necessary to have a security interest in such Accounts and such property that
are proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Effective Date, include
the Intellectual Property to the extent necessary to permit perfection of Collateral Agent&rsquo;s security interest in such Accounts
and such other property of Debtor that are proceeds of the Intellectual Property; and (ii) more than 65% of the total combined
voting power of all classes of stock entitled to vote the shares of capital stock (the &ldquo;Shares&rdquo;) of any Foreign Subsidiary,
if Debtor demonstrates to Collateral Agent&rsquo;s reasonable satisfaction that a pledge of more than sixty five percent (65%)
of the Shares of such Subsidiary creates a present and existing adverse tax consequence to Debtor under the U.S. Internal Revenue
Code; (iii) any license or contract, in each case if the granting of a Lien in such license or contract is prohibited by or would
constitute a default under the agreement governing such license or contract (but (A) only to the extent such prohibition is enforceable
under applicable law and (B) other than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406,
9-408 or 9-409 (or any other Section) of Division 9 of the Code); provided that upon the termination, lapsing or expiration of
any such prohibition, such license or contract, as applicable, shall automatically be subject to the security interest granted
in favor of Collateral Agent hereunder and become part of the &ldquo;Collateral&rdquo;; and (iv) any Excluded Accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms
of a certain negative pledge arrangement with Collateral Agent and the Lenders, Debtor has agreed not to encumber any of its Intellectual
Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capitalized terms used
but not defined herein have the meanings ascribed in the Uniform Commercial Code in effect in the State of California as in effect
from time to time (the &ldquo;Code&rdquo;) or, if not defined in the Code, then in the Loan and Security Agreement by and between
Debtor, Secured Party and the other Lenders party thereto (as modified, amended and/or restated from time to time).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FIRST AMENDMENT TO LOAN AND SECURITY
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS FIRST AMENDMENT
to Loan and Security Agreement (this &ldquo;<B>Amendment</B>&rdquo;) is entered into as of April 28, 2016 (the &ldquo;<B>Amendment
Date</B>&rdquo;), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax
Street, Alexandria, Virginia 22314 (&ldquo;Oxford&rdquo;), as collateral agent (in such capacity, &ldquo;<B>Collateral Agent</B>&rdquo;),
the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including
Oxford in its capacity as a Lender (each a &ldquo;<B>Lender</B>&rdquo; and collectively, the &ldquo;<B>Lenders</B>&rdquo;), and
ADYNXX, INC., a Delaware corporation with an office at 731 Market Street, Suite 420, San Francisco, California 94103 (&ldquo;<B>Borrower</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Collateral
Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement, dated as of November 24, 2015 (as amended,
supplemented or otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;) pursuant to which Lenders have provided
to Borrower certain loans in accordance with the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Borrower,
Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement as provided herein and subject to the terms
and conditions set forth herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definition therein as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;&ldquo;<B>Excluded Accounts</B>&rdquo;
means any (a) Deposit Accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for
the benefit of Borrower&rsquo;s, or any of its Subsidiaries&rsquo;, employees and identified to Collateral Agent by Borrower as
such in the Perfection Certificates and (b) that certain certificate of deposit with account number X-XXX-XXX-530-45 held with
Comerica Bank securing the Comerica Letter of Credit so long as the balance therein does not exceed $55,000 at any given time.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby amended by amending and restating clause (h) of the definition of &ldquo;Permitted Indebtedness&rdquo; therein as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness
in connection with the Comerica Letter of Credit, not to exceed $54,885; and&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby amended by amending the definition of &ldquo;Permitted Lien&rdquo; therein as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the word &ldquo;and&rdquo; at the end of clause (l) of the definition of &ldquo;Permitted Lien&rdquo; is hereby deleted;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the &ldquo;.&rdquo; at the end of clause (m) of the definition of &ldquo;Permitted Lien&rdquo; is hereby replaced by &ldquo;; and&rdquo;;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the following clause (n) is added to the definition of &ldquo;Permitted Lien&rdquo;:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;(n) Lien on Borrower&rsquo;s certificate of deposit with account number X-XXX-XXX-530-45 held with Comerica Bank securing Permitted Indebtedness in connection with the Comerica Letter of Credit, not to exceed $54,885.&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Limitation of Amendment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The amendments set forth in Sections 2 through 4 above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b)&nbsp;otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">f.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&rsquo; rights.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">8.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment shall be deemed effective as of the Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto, (b) Borrower&rsquo;s payment of all Lenders&rsquo; Expenses incurred through the date hereof, which may be debited (or ACH&rsquo;d) from the Designated Deposit Account in accordance with Section 2.3(d) of the Loan Agreement and (c) delivery of&nbsp;evidence to Collateral Agent that the Borrower&rsquo;s certificate of deposit with account number XXXX00C has been terminated, which evidence must be reasonably acceptable to Collateral Agent.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">9.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">10.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of California.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Balance of Page Intentionally Left
Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,
</B>the parties hereto have caused this First Amendment to the Loan Agreement to be executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,</B>
the parties hereto have caused this First Amendment to the Loan Agreement to be executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Mark Davis</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Mark Davis</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Vice President - Finance, Secretary &amp; Treasurer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECOND AMENDMENT TO LOAN AND SECURITY
AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS SECOND AMENDMENT
to Loan and Security Agreement (this &ldquo;<B>Amendment</B>&rdquo;) is entered into as of January 31, 2017 (the &ldquo;<B>Amendment
Date</B>&rdquo;), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax
Street, Alexandria, Virginia 22314 (&ldquo;<B>Oxford</B>&rdquo;), as collateral agent (in such capacity, &ldquo;<B>Collateral Agent</B>&rdquo;),
the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including
Oxford in its capacity as a Lender (each a &ldquo;<B>Lender</B>&rdquo; and collectively, the &ldquo;<B>Lenders</B>&rdquo;), and
ADYNXX, INC., a Delaware corporation with an office at 731 Market Street, Suite 420, San Francisco, California 94103 (&ldquo;<B>Borrower</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Collateral
Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement, dated as of November 24, 2015 (as amended,
supplemented or otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;) pursuant to which Lenders have provided
to Borrower certain loans in accordance with the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Borrower,
Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement and the Disbursement Letters entered into
pursuant to the Loan Agreement as provided herein and subject to the terms and conditions set forth herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Capitalized terms used herein but not otherwise defined
shall have the respective meanings given to them in the Loan Agreement.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">Section 2.2(b) of the Loan Agreement is hereby amended
and restated in its entirety as follows:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Repayment</U>.
Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of
each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately
preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest
payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. On each of
December 1, 2016 and January 1, 2017, in addition to making the aforementioned interest payments, Borrower shall also make (i)
a payment of $83,333.33 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount
of the Term A Loan, and (ii) a payment of $55,555.56 with respect to the Term B Loan, which shall be deemed to be a partial payment
of the principal amount of the Term B Loan. Commencing on the Amortization Date, and continuing on the Payment Date of each month
thereafter, Borrower shall make consecutive monthly payments of equal amounts of principal, and the applicable interest, in arrears,
to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon:
(1) the amount of such Lender&rsquo;s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a
repayment schedule equal to twenty-three (23) months. All unpaid principal and accrued and unpaid interest with respect to each
Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c)
and 2.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">Section 2.5 of the Loan Agreement is hereby amended by
deleting the word &ldquo;<B>and</B>&rdquo; immediately following Section 2.5(d), replacing &ldquo;<B>;</B>&rdquo; at the end of
Section 2.5(e) with &ldquo;<B>; and</B>&rdquo; and adding Section 2.5(f) thereto as follows:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">Second Amendment Fee. A fully earned and non-refundable
second amendment fee in the amount of One Hundred Thousand Dollars ($100,000.00), which shall become due and payable upon the
earlier of: (i) the Maturity Date, (ii) the acceleration of any Term Loan, or (iii) the prepayment of a Term Loan pursuant to
Section 2.2(c) or (d).</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">Section 10 of the Loan Agreement is hereby amended by
amending and restating the notices to Borrower as follows:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">If to Borrower:</FONT></TD>
    <TD STYLE="width: 60%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">101 Pine Street #500</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">San Francisco, CA 94111</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Attn: Carin Sandvik</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Fax: (415) 512-7740</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Email: rorr@adynxx.com</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Cooley LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">With a copy (which:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">3175 Hanover Street</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Palo Alto, CA 94304</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Attn: Laura Berezin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Fax: (650) 849-7400</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Email: lberezin@cooley.com</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">Section 13.1 of the Loan Agreement is hereby amended
by amending and restating the following definitions therein as follows:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; margin-left: 0.5in">&ldquo;<B>Amortization Date</B>&rdquo;
means January 1, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">The Amortization Table attached to the Disbursement Letter
entered into on Effective Date in connection with the Term A Loans is hereby amended and restated in its entirety as set forth
on <U>Exhibit A</U> hereto.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">7.</TD><TD STYLE="text-align: justify">The Amortization Table attached to the Disbursement Letter
entered into on January 29, 2016 in connection with the Term B Loans is hereby amended and restated in its entirety as set forth
on <U>Exhibit B</U> hereto.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">8.</TD><TD STYLE="text-align: justify">Limitation of Amendment.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">The amendments set forth in Sections 2 through 7 above are effective for the purposes set forth
herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification
of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or
Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">This Amendment shall be construed in connection with and as part of the Loan Documents and all
terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and
confirmed and shall remain in full force and effect.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">9.</TD><TD STYLE="text-align: justify">To induce Collateral Agent and Lenders to enter into
this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Immediately after giving effect to this Amendment (a) the representations and warranties contained
in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such
representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no
Event of Default has occurred and is continuing;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Borrower has the power and due authority to execute and deliver this Amendment and to perform its
obligations under the Loan Agreement, as amended by this Amendment;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and
updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete
and have not been amended, supplemented or restated and are and continue to be in full force and effect;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">d.</TD><TD STYLE="text-align: justify">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its
obligations under the Loan Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding
on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order,
judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower,
or (iv) the organizational documents of Borrower;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">e.</TD><TD STYLE="text-align: justify">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its
obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization
or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision
thereof, binding on Borrower, except as already has been obtained or made; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">f.</TD><TD STYLE="text-align: justify">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of
Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy,
insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating
to or affecting creditors&rsquo; rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">10.</TD><TD STYLE="text-align: justify">Except as expressly set forth herein, the Loan Agreement
shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire
agreement about this subject matter and supersede prior negotiations or agreements.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">11.</TD><TD STYLE="text-align: justify">This Amendment shall be deemed effective as of the Amendment
Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto and (b) Borrower&rsquo;s
payment of all Lenders&rsquo; Expenses incurred through the date hereof, which may be debited (or ACH&rsquo;d) from the Designated
Deposit Account in accordance with Section 2.3(d) of the Loan Agreement.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">12.</TD><TD STYLE="text-align: justify">This Amendment may be executed in any number of counterparts,
each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">13.</TD><TD STYLE="text-align: justify">This Amendment and the rights and obligations of the
parties hereto shall be governed by and construed in accordance with the laws of the State of California.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Balance of Page Intentionally Left Blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the parties hereto have caused this Second Amendment to the Loan Agreement to be executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>BORROWER</B>:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 45%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ADYNXX, INC.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Rick Orr</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Rick Orr</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: CEO</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OXFORD FINANCE LLC</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/Mark Davis</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Mark Davis</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: Vice President &ndash; Finance, Secretary &amp; Treasurer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amortization Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Term A Loan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amortization Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Term B Loan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THIRD AMENDMENT TO LOAN AND SECURITY
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS THIRD AMENDMENT
to Loan and Security Agreement (this &ldquo;<B>Amendment</B>&rdquo;) is entered into as of March 30, 2018 (the &ldquo;<B>Amendment
Date</B>&rdquo;), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax
Street, Alexandria, Virginia 22314 (&ldquo;Oxford&rdquo;), as collateral agent (in such capacity, &ldquo;<B>Collateral Agent</B>&rdquo;),
the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including
Oxford in its capacity as a Lender (each a &ldquo;<B>Lender</B>&rdquo; and collectively, the &ldquo;<B>Lenders</B>&rdquo;), and
ADYNXX, INC., a Delaware corporation with an office at 100 Pine Street, #500, San Francisco, CA 94111 (&ldquo;<B>Borrower</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Collateral
Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement, dated as of November 24, 2015 (as amended,
supplemented or otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;) pursuant to which Lenders have provided
to Borrower certain loans in accordance with the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Borrower,
Lenders and Collateral Agent desire to amend certain provisions of the Loan Agreement and the Disbursement Letters entered into
pursuant to the Loan Agreement as provided herein and subject to the terms and conditions set forth herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 2.2(b) of the Loan Agreement is hereby amended and restated in its entirety as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(b) <U>Repayment</U>. Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. On each of December 1, 2016 and January 1, 2017, in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $83,333.33 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $55,555.56 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. On each of January 1, 2018, February 1, 2018 and March 1, 2018, in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $123,188.41 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $82,125.60 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive monthly payments of equal amounts of principal, and the applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender&rsquo;s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to (A) twenty (20) months if the First Bridge Financing Event does not occur, (B) fifteen (15) months if the First Bridge Financing Event occurs but the Second Bridge Financing Event does not occur and (C) thirteen (13) months if the First Bridge Financing Event occurs and the Second Bridge Financing Event occurs. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 2.5 of the Loan Agreement is hereby amended by deleting the word &ldquo;and&rdquo; immediately following Section 2.5(e), replacing &ldquo;;&rdquo; at the end of Section 2.5(f) with &ldquo;; and&rdquo; and adding Section 2.5(g) thereto as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(g) <U>Third Amendment Fee.</U> A fully earned and non-refundable third amendment fee in the amount of Two Hundred Thousand Dollars ($200,000.00), which shall become due and payable upon the earlier of: (i) the Maturity Date, (ii) the acceleration of any Term Loan, or (iii) the prepayment of a Term Loan pursuant to Section 2.2(c) or (d).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby amended by adding the following definitions thereto in alphabetical order:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>First Bridge Financing Event</B>&rdquo; is the receipt by Borrower on or after March 1, 2018 and prior to March 31, 2018 of unrestricted net cash proceeds of not less than One Million Five Hundred Thousand Dollars ($1,500,000.00) from the issuance and sale by Borrower of its unsecured Subordinated Debt to TPG Capital or one or more Affiliates thereof and/or to Domain Associates or one or more Affiliates thereof.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Second Bridge Financing Event</B>&rdquo; is the receipt by Borrower on or after April 1, 2018 and prior to August 31, 2018 of unrestricted net cash proceeds of not less than One Million Five Hundred Thousand Dollars ($1,500,000.00) from the issuance and sale by Borrower of its unsecured Subordinated Debt to TPG Capital or one or more Affiliates thereof and/or to Domain Associates or one or more Affiliates thereof.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definitions therein as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Amortization Date</B>&rdquo; means (i) April 1, 2018, if the First Bridge Financing Event does not occur, (ii) September 1, 2018, if the First Bridge Financing Event occurs but the Second Bridge Financing Event does not occur and (iii) November 1, 2018, if both the First Bridge Financing Event occurs and the Second Bridge Financing Event occurs.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Amortization Table attached to the Disbursement Letter entered into on Effective Date in connection with the Term A Loans is hereby amended and restated in its entirety as set forth on <U>Exhibit A</U> hereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Amortization Table attached to the Disbursement Letter entered into on January 29, 2016 in connection with the Term B Loans is hereby amended and restated in its entirety as set forth on <U>Exhibit B</U> hereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">8.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Limitation of Amendment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The amendments set forth in Sections 2 through 7 above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">9.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the&nbsp;date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">f.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&rsquo; rights.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">10.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">11.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment shall be deemed effective as of the Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto and (b) Borrower&rsquo;s payment of all Lenders&rsquo; Expenses incurred through the date hereof, which may be debited (or ACH&rsquo;d) from the Designated Deposit Account in accordance with Section 2.3(d) of the Loan Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">12.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">13.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of California.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Balance of Page Intentionally Left
Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,
</B>the parties hereto have caused this Third Amendment to the Loan Agreement to be executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the parties hereto have caused this Third Amendment to the Loan Agreement to be executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Colette Featherly</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Colette Featherly</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Senior Vice President</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amortization Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Term A Loan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amortization Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Term B Loan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOURTH AMENDMENT TO LOAN AND SECURITY
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">THIS FOURTH AMENDMENT to Loan and Security
Agreement (this &ldquo;<B>Amendment</B>&rdquo;) is entered into as of September 28, 2018 (the &ldquo;<B>Amendment Date</B>&rdquo;),
by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria,
Virginia 22314 (&ldquo;Oxford&rdquo;), as collateral agent (in such capacity, &ldquo;<B>Collateral Agent</B>&rdquo;), the Lenders
listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford
in its capacity as a Lender (each a &ldquo;<B>Lender</B>&rdquo; and collectively, the &ldquo;<B>Lenders</B>&rdquo;), and ADYNXX,
INC., a Delaware corporation with an office at 100 Pine Street, #500, San Francisco, CA 94111 (&ldquo;<B>Borrower</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, Collateral Agent, Borrower and
Lenders have entered into that certain Loan and Security Agreement, dated as of November 24, 2015 (as amended, supplemented or
otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;) pursuant to which Lenders have provided to Borrower
certain loans in accordance with the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, Borrower, Lenders and Collateral
Agent desire to amend certain provisions of the Loan Agreement and the Disbursement Letters entered into pursuant to the Loan Agreement
as provided herein and subject to the terms and conditions set forth herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">NOW, THEREFORE, in consideration of the
promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Borrower hereby reaffirms the security interest granted by Borrower previously in Section 4.1 of the Loan Agreement with respect to the Collateral (prior to the date hereof) and hereby grants Collateral Agent, effective upon the occurrence of the IP Lien Event, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent, for the ratable benefit of the Lenders, such part of the Collateral (as defined upon the occurrence of the IP Lien Event) that was not pledged previously or in which security interest was not granted prior to the IP Lien Event, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof. The parties agree that upon the occurrence of the IP Lien Event, the security interest granted in the Intellectual Property of Borrower shall constitute a first priority security in in the Intellectual Property. Furthermore, Borrower hereby authorizes Collateral Agent, upon the occurrence of the IP Lien Event, to file financing statements or take any other action required to perfect Collateral Agent&rsquo;s security interests in the Collateral, without notice to Borrower, with all appropriate&nbsp;jurisdictions to perfect or protect Collateral Agent&rsquo;s interest or rights under the Loan Documents, including a notice that any disposition of the Collateral, except to the extent permitted by the terms of this Amendment, by Borrower, or any other Person, shall be deemed to violate the rights of Collateral Agent under the Code.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 2.2(b) of the Loan Agreement is hereby amended and restated in its entirety as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(b) <U>Repayment</U>. Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. On each of December 1, 2016 and January 1, 2017, in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $83,333.33 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $55,555.56 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. On each of January 1, 2018, February 1, 2018 and March 1, 2018, in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $123,188.41 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $82,125.60 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. On September 1, 2018, in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $164,251.21 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $109,500.81 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive monthly payments of equal amounts of principal, and the applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender&rsquo;s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to (A) fourteen (14) months if the Domain Financing Event does not occur, (C) thirteen (13) months if the Domain Financing Event occurs and the Alliqua Merger Agreement Event does not occur and (D) eleven (11) months if the Domain Financing Event occurs and the Alliqua Merger Agreement Event occurs. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 2.5 of the Loan Agreement is hereby amended by deleting the word &ldquo;and&rdquo; immediately following Section 2.5(f), replacing &ldquo;;&rdquo; at the end of Section 2.5(g) with &ldquo;; and&rdquo; and adding Section 2.5(h) thereto as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(h) <U>Fourth Amendment Fee.</U> A fully earned and non-refundable fourth amendment fee in the amount of Twenty Five Thousand Dollars ($25,000.00), which shall become due and payable upon the earlier of: (i) the Maturity Date, (ii) the acceleration of any Term Loan, or (iii) the prepayment of a Term Loan pursuant to Section 2.2(c) or (d).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Effective upon the occurrence of the IP Lien Event, Section 5.2(d) of the Loan Agreement is hereby amended and restated as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Borrower and each of its Subsidiaries is the sole owner of the Intellectual Property each respectively purports to own, free and clear of all Liens other than Permitted Liens. (i) Each of Borrower&rsquo;s and its Subsidiaries&rsquo; Copyrights, Trademarks and issued Patents are valid and enforceable and no part of Borrower&rsquo;s or its Subsidiaries&rsquo; Intellectual Property has been judged invalid or unenforceable, in whole or in part, and (ii) to the best of Borrower&rsquo;s knowledge, no claim has been made that any part of the Intellectual Property or any practice by Borrower or its Subsidiaries violates the rights of any third party except to the extent such claim could not reasonably be expected to have a Material Adverse Change. Except as noted on the Perfection Certificates, neither Borrower nor any of its Subsidiaries is a party to, nor is bound by, any material license or other material agreement with respect to which Borrower or such Subsidiary is the licensee that (i) prohibits or otherwise restricts Borrower or its Subsidiaries from granting a security interest in Borrower&rsquo;s or such Subsidiaries&rsquo; interest in such material license or material agreement or any other property, or (ii) for which a default under or termination of could interfere with Collateral Agent&rsquo;s or any Lender&rsquo;s right to sell any Collateral. Borrower shall provide written notice to Collateral Agent and each Lender within ten (10) days of Borrower or any of its Subsidiaries entering into or becoming bound by any license or agreement with respect to which Borrower or any Subsidiary is the licensee (other than over the counter software that is commercially available to the public).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Effective upon the occurrence of the IP Lien Event, Section 6.2(a)(vii) of the Loan Agreement is hereby amended and restated in its entirety as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">prompt notice of (A) any material change in the composition of the Intellectual Property, (B) the registration of any copyright, including any subsequent ownership right of Borrower or any of its Subsidiaries in or to any copyright, patent or trademark, including a copy of any such registration (provided that notice of any new patent or trademark with the next-due Compliance Certificate shall be deemed sufficient notice under this provision, and notice in accordance with the terms of Section 6.7 with respect to any new copyrights shall be deemed sufficient notice under this provision), and (C) any event that could reasonably be expected to materially and adversely affect the value of the Intellectual Property;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Effective upon the occurrence of the IP Lien Event, Section 6.7 of the Loan Agreement is hereby amended and restated in its entirety as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Borrower and each of its Subsidiaries shall: (a) use commercially reasonable efforts to protect, defend and maintain the validity and enforceability of its Intellectual Property that is material to Borrower&rsquo;s business; (b) promptly advise Collateral Agent in writing of material infringement by a third party of its Intellectual Property; and (c) not allow any Intellectual Property material to Borrower&rsquo;s business to be abandoned, forfeited or dedicated to the public without Collateral Agent&rsquo;s prior written consent. If Borrower or any of its Subsidiaries (i) obtains any patent, registered trademark or servicemark, registered copyright, registered mask work, or any pending application for any of the foregoing, whether as owner, licensee or otherwise, or (ii) applies for any patent or the registration of any trademark or servicemark, then Borrower or such Subsidiary shall provide written notice thereof to Collateral Agent and each Lender with the next- due Compliance Certificate and shall execute such intellectual property security agreements and other documents and take such other actions as Collateral Agent shall reasonably request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in such property. If Borrower or any of its Subsidiaries decides to register any copyrights or mask works in the United States Copyright Office, Borrower or such Subsidiary shall: (x) provide Collateral Agent and each Lender with at least fifteen (15) days prior written notice of Borrower&rsquo;s or such Subsidiary&rsquo;s intent to register such copyrights or mask works together with a copy of the application it intends to file with the United States Copyright Office (excluding exhibits thereto); (y) execute an intellectual property security agreement and such other documents and take such other actions as Collateral Agent may reasonably request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in the copyrights or mask works intended to be registered with the United States Copyright Office; and (z) record such intellectual property security agreement with the United States Copyright Office contemporaneously with filing the copyright or mask work application(s) with the United States Copyright Office. Borrower or such Subsidiary shall promptly provide to Collateral Agent and each Lender with evidence of the recording of the intellectual property security agreement as to which Collateral Agent requests recording for Collateral Agent to perfect and maintain a first priority perfected security interest in such property.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">8.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby amended by adding the following definitions thereto in alphabetical order:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>2018 Financing Event</B>&rdquo; is the receipt by Borrower on or after the Fourth Amendment Date and on or before the Alliqua Merger Deadline, of unrestricted gross cash proceeds of not less than Ten Million Dollars ($10,000,000.00), which must be in addition to any proceeds received from the Domain Financing Event, but which shall include any proceeds received in accordance with the part (i) of the Deadline Extension Event, from the issuance and sale by Borrower of its unsecured convertible Subordinated Debt and/or equity securities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Alliqua</B>&rdquo; means Alliqua BioMedical, Inc., a Delaware corporation.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Alliqua Merger</B>&rdquo; means the acquisition of Borrower by Alliqua, on such terms and conditions as are explicitly consented to by the Collateral Agent and Lenders in their discretion, pursuant to a reverse triangular merger in which the shareholders of Borrower will, after consummation of the merger, hold a majority of the outstanding shares of Alliqua.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Alliqua Merger Agreement Event</B>&rdquo; means the entry into a merger agreement by Borrower and Alliqua, on or before October 31, 2018, which merger agreement provides for the Alliqua Merger and is in such form and substance as would not require the consent of the Required Lenders for Borrower&rsquo;s entry thereinto under Section 7.3 of the Loan Agreement, provided that Collateral Agent hereby confirms receipt of notice of the Borrower&rsquo;s intent to executed the foregoing merger agreement, as required pursuant to Section 7.3(iii).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Alliqua Merger Deadline</B>&rdquo; is (i) December 31, 2018, if the Deadline Extension Event does not occur and (ii) January 31, 2018, if the Deadline Extension Event occurs.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Deadline Extension Event</B>&rdquo; is (i) the receipt by Borrower on or after the Fourth Amendment Date and on or before December 31, 2018, of unrestricted gross cash proceeds equal to or greater than One Million Dollars ($1,000,000.00), which must be in addition to any proceeds received from the Domain Financing Event, from the issuance and sale by Borrower of its unsecured convertible Subordinated Debt and/or equity securities and (ii) the determination by Collateral Agent on December 31, 2018 that Borrower and Alliqua are actively engaged in the consummation of the Alliqua Merger but the Alliqua Merger has not yet been consummated and that no Event of Default has occurred after the Fourth Amendment Date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Domain Financing Event</B>&rdquo; is the receipt by Borrower on or after September 24, 2018 of unrestricted gross cash proceeds of not less than One Million Five Hundred Thousand Dollars ($1,500,000.00) from the issuance and sale by Borrower of its unsecured convertible Subordinated Debt and/or equity securities to Domain Associates or an Affiliate thereof.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Fourth Amendment Date</B>&rdquo; is September 28, 2018.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>IP Lien Event</B>&rdquo; is (i) the Alliqua Merger not occurring on or before Alliqua Merger Deadline, <I>and </I>(ii) the 2018 Financing Event not occurring.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">9.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby further amended by amending and restating the following definitions therein as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Amortization Date</B>&rdquo; means (i) October 1, 2018, if the Domain Financing Event does not occur, (ii) November 1, 2018, if Domain Financing Event occurs and the Alliqua Merger Agreement Event does not occur and (iii) January 1, 2019, if the Domain Financing Event occurs and the Alliqua Merger Agreement Event occurs.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">10.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby further amended by amending and restating the following definitions therein as follows, effective upon the occurrence of the IP Lien Event:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>IP Agreement</B>&rdquo; is that certain Intellectual Property Security Agreement entered into by and between Borrower and Collateral Agent that becomes effective upon the occurrence of the IP Lien Event, as it may be amended from time to time.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">11.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Amortization Table attached to the Disbursement Letter entered into on Effective Date in connection with the Term A Loans is hereby amended and restated in its entirety as set forth on <U>Exhibit A</U> hereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">12.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Amortization Table attached to the Disbursement Letter entered into on January 29, 2016 in connection with the Term B Loans is hereby amended and restated in its entirety as set forth on <U>Exhibit B</U> hereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">13.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Exhibit A</U> to the Loan Agreement is hereby amended and restated, effective upon the occurrence of the IP Lien Event, as set forth on <U>Exhibit C</U> hereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">14.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Borrower hereby represents and warrants that a complete and accurate list of its Intellectual Property as of the Fourth Amendment Date is attached hereto as <U>Exhibit D</U> and hereby covenants to promptly update such list as and when requested by Collateral Agent.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">15.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Borrower hereby authorizes Collateral Agent to file financing statements, amendments to financing statements or take any other action required to perfect Collateral Agent&rsquo;s security interests in the Collateral (as such term has been amended pursuant to this Amendment) upon the occurrence of the IP Lien Event, without notice to Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent&rsquo;s interest or rights under the Loan Documents, including a notice that any disposition of the Collateral, except to the extent permitted by the terms of the Loan Documents, by Borrower, or any other Person, shall be deemed to violate the rights of Collateral Agent under the Code or other applicable law. Without limiting the scope of the foregoing, Borrower hereby authorizes Collateral Agent, upon the occurrence of the IP Lien Event, to date as of the date of the occurrence of the IP Lien Event, and file the IP Agreement (form of which is attached hereto as <U>Exhibit E)</U> in the appropriate jurisdictions in which Collateral Agent may in its sole discretion choose to file the IP Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">16.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Limitation of Amendment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The amendments set forth in Sections 2 through 13 above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Nothing herein is, or is meant to be construed as, a consent by Collateral Agent or any Lender to the Borrower&rsquo;s entering into the merger agreement regarding the Alliqua Merger or the consummation of the Alliqua Merger.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">17.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral&nbsp;Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">f.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&rsquo; rights.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">18.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">19.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment shall be deemed effective as of the Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto and (b) Borrower&rsquo;s payment of all Lenders&rsquo; Expenses incurred through the date hereof, which may be debited (or ACH&rsquo;d) from the Designated Deposit Account in accordance with Section 2.3(d) of the Loan Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">20.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">21.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of California.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Balance of Page Intentionally Left
Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,
</B>the parties hereto have caused this Fourth Amendment to the Loan Agreement to be executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CEO</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS
WHEREOF, </B>the parties hereto have caused this Fourth Amendment to the Loan Agreement to be executed as of the date first
set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Colette Featherly</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Colette Featherly</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Senior Vice President</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amortization Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Term A Loan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amortization Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Term B Loan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Collateral consists of all of Borrower&rsquo;s
right, title and interest in and to the following personal property:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All goods, Accounts (including health-care
receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements,
General Intangibles (including Intellectual Property), commercial tort claims, documents, instruments (including any promissory
notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates
of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and
all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever
located; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All Borrower&rsquo;s Books relating to
the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments,
accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing, the Collateral
does not include (i) more than 65% of the total combined voting power of all classes of stock entitled to vote the shares of capital
stock (the &ldquo;Shares&rdquo;) of any Foreign Subsidiary, if Borrower demonstrates to Collateral Agent&rsquo;s reasonable satisfaction
that a pledge of more than sixty five percent (65%) of the Shares of such Subsidiary creates a present and existing adverse tax
consequence to Borrower under the U.S. Internal Revenue Code; (ii) any license or contract, in each case if the granting of a Lien
in such license or contract is prohibited by or would constitute a default under the agreement governing such license or contract
(but (A) only to the extent such prohibition is enforceable under applicable law and (B) other than to the extent that any such
term would be rendered ineffective pursuant to Sections 9-406, 9-408 or 9-409 (or any other Section) of Division 9 of the Code);
provided that upon the termination, lapsing or expiration of any such prohibition, such license or contract, as applicable, shall
automatically be subject to the security interest granted in favor of Collateral Agent hereunder and become part of the &ldquo;Collateral&rdquo;;
and (iii) any Excluded Accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of a certain negative
pledge arrangement with Collateral Agent and the Lenders, Borrower has agreed not to encumber any of its Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit D</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Intellectual Property</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Please see attached</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit E</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>IP Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Please see attached</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FIFTH AMENDMENT TO LOAN AND SECURITY
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">THIS FIFTH AMENDMENT to Loan and Security
Agreement (this &ldquo;<B>Amendment</B>&rdquo;) is entered into as of December 28, 2018 (the &ldquo;<B>Amendment Date</B>&rdquo;),
by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria,
Virginia 22314 (&ldquo;Oxford&rdquo;), as collateral agent (in such capacity, &ldquo;<B>Collateral Agent</B>&rdquo;), the Lenders
listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford
in its capacity as a Lender (each a &ldquo;<B>Lender</B>&rdquo; and collectively, the &ldquo;<B>Lenders</B>&rdquo;), and ADYNXX,
INC., a Delaware corporation with an office at 100 Pine Street, #500, San Francisco, CA 94111 (&ldquo;<B>Borrower</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, Collateral Agent, Borrower and
Lenders have entered into that certain Loan and Security Agreement, dated as of November 24, 2015 (as amended, supplemented or
otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;) pursuant to which Lenders have provided to Borrower
certain loans in accordance with the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, Borrower, Lenders and Collateral
Agent desire to amend certain provisions of the Loan Agreement and the Disbursement Letters entered into pursuant to the Loan Agreement
as provided herein and subject to the terms and conditions set forth herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">NOW, THEREFORE, in consideration of the
promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 2.2(b) of the Loan Agreement is hereby amended and restated in its entirety as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(b) <U>Repayment.</U> Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. On each of December 1, 2016 and January 1, 2017, in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $83,333.33 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $55,555.56 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. On each of January 1, 2018, February 1, 2018 and March 1, 2018, in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $123,188.41 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $82,125.60 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. On September 1, 2018, in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $164,251.21 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $109,500.81 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive monthly payments of equal amounts of principal, and the applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender&rsquo;s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to (A) fourteen (14) months if the Domain Financing Event does not occur, (C) thirteen (13) months if the Domain Financing Event occurs and the Alliqua Merger Agreement Event does not occur, (D) eleven (11) months if the Domain Financing Event occurs and the Alliqua Merger Agreement Event occurs and the Domain December 2018 Financing Event does not occur and (E) ten (10) months if all of the Domain Financing Event, Alliqua Merger Agreement Event and Domain December 2018 Financing Event occur. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 2.5 of the Loan Agreement is hereby amended by deleting the word &ldquo;and&rdquo; immediately following Section 2.5(g), replacing &ldquo;;&rdquo; at the end of Section 2.5(h) with &ldquo;; and&rdquo; and adding Section 2.5(i) thereto as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(i) <U>Fifth Amendment Fee.</U> A fully earned and non-refundable fifth amendment fee in the amount of Thirty Five Thousand Dollars ($35,000.00), which shall become due and payable upon the earlier of: (i) the Maturity Date, (ii) the acceleration of any Term Loan, or (iii) the prepayment of a Term Loan pursuant to Section 2.2(c) or (d).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby amended by adding the following definition thereto in alphabetical order:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Domain December 2018 Financing Event</B>&rdquo; is the receipt by Borrower on or after December 1, 2018 and on or before December 31, 2018 of unrestricted gross cash proceeds of not less than One Million Dollars ($1,000,000.00) from the issuance and sale by Borrower of its unsecured convertible Subordinated Debt and/or equity securities to Domain Associates or an Affiliate thereof.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby further amended by amending and restating the following definitions therein as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Amortization Date</B>&rdquo; means (i) October 1, 2018, if the Domain Financing Event does not occur, (ii) November 1, 2018, if Domain Financing Event occurs and the Alliqua Merger Agreement Event does not occur, (iii) January 1, 2019, if the Domain Financing Event occurs and the Alliqua Merger Agreement Event occurs and the Domain December 2018 Financing Event does not occur and (iv) February 1, 2019, if all of the Domain Financing Event, Alliqua Merger Agreement Event and Domain December 2018 Financing Event occur.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Amortization Table attached to the Disbursement Letter entered into on Effective Date in connection with the Term A Loans is hereby amended and restated in its entirety as set forth on <U>Exhibit A</U> hereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Amortization Table attached to the Disbursement Letter entered into on January 29, 2016 in connection with the Term B Loans is hereby amended and restated in its entirety as set forth on <U>Exhibit B</U> hereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">8.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Limitation of Amendment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">9.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">f.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&rsquo; rights.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">10.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">11.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment shall be deemed effective as of the Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto and (b) Borrower&rsquo;s payment of all Lenders&rsquo; Expenses incurred through the date hereof, which may be debited (or ACH&rsquo;d) from the Designated Deposit Account in accordance with Section 2.3(d) of the Loan Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">12.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">13.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of California.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Balance of Page Intentionally Left
Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,
</B>the parties hereto have caused this Fifth Amendment to the Loan Agreement to be executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CEO</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Colette Featherly</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Colette Featherly</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Senior Vice President</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amortization Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Term A Loan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amortization Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Term B Loan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIXTH AMENDMENT TO LOAN AND SECURITY
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">THIS SIXTH AMENDMENT to Loan and Security
Agreement (this &ldquo;<B>Amendment</B>&rdquo;) is entered into as of January 31, 2019 (the &ldquo;<B>Amendment Date</B>&rdquo;),
by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria,
Virginia 22314 (&ldquo;Oxford&rdquo;), as collateral agent (in such capacity, &ldquo;<B>Collateral Agent</B>&rdquo;), the Lenders
listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford
in its capacity as a Lender (each a &ldquo;<B>Lender</B>&rdquo; and collectively, the &ldquo;<B>Lenders</B>&rdquo;), and ADYNXX,
INC., a Delaware corporation with an office at 100 Pine Street, #500, San Francisco, CA 94111 (&ldquo;<B>Borrower</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, Collateral Agent, Borrower and
Lenders have entered into that certain Loan and Security Agreement, dated as of November 24, 2015 (as amended, supplemented or
otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;) pursuant to which Lenders have provided to Borrower
certain loans in accordance with the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, Borrower, Lenders and Collateral
Agent desire to amend certain provisions of the Loan Agreement and the Disbursement Letters entered into pursuant to the Loan Agreement
as provided herein and subject to the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">NOW, THEREFORE, in consideration of the
promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 2.2(b) of the Loan Agreement is hereby amended and restated in its entirety as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(b) <U>Repayment.</U> Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. On each of December 1, 2016 and January 1, 2017, in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $83,333.33 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $55,555.56 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. On each of January 1, 2018, February 1, 2018 and March 1, 2018, in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $123,188.41 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $82,125.60 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. On September 1, 2018, in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $164,251.21 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $109,500.81 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive monthly payments of equal amounts of principal, and the applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender&rsquo;s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to eight (8) months. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 2.5 of the Loan Agreement is hereby amended by deleting the word &ldquo;and&rdquo; immediately following Section 2.5(h), replacing &ldquo;;&rdquo; at the end of Section 2.5(i) with &ldquo;; and&rdquo; and adding Section 2.5(j) thereto as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(i) <U>Sixth Amendment Fee.</U> A fully earned and non-refundable sixth amendment fee in the amount of Fifty Thousand Dollars ($50,000.00), which shall become due and payable upon the earlier of: (i) the Maturity Date, (ii) the acceleration of any Term Loan, or (iii) the prepayment of a Term Loan pursuant to Section 2.2(c) or (d).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 6.6 of the Loan Agreement is hereby amended by adding the following Section 6.6(d) thereto:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(d) Notwithstanding anything herein to the contrary, on or before February 8, 2019, Borrower shall deposit an amount of Two Hundred Thousand Dollars ($200,000.00) in a segregated Collateral Account that is subject to a blocked Control Agreement in favor of Collateral Agent (and which Control Agreement is in such form and substance as are satisfactory to Collateral Agent). Upon the earlier of consummation of the Alliqua Merger prior to the Alliqua Merger Deadline or the consummation of the 2018 Financing Event, the funds in such segregated account shall be released to Borrower but shall continue to be subject to the applicable provisions of this Agreement (including being maintained in Collateral Accounts subject to Sections 6.6(a), (b) and (c) of this Agreement).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A new Section 6.14 is hereby added to the Loan Agreement to read as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">6.14 <B>Term Sheet Delivery for 2018 Financing Event</B>. Borrower shall deliver to Collateral Agent on or before February 1, 2019, an executed term sheet between Borrower and Domain Associates or an Affiliate thereof, for the equity or unsecured Subordinated Debt financing of Borrower that would result in aggregate proceeds to Borrower of Twenty Million Dollars ($20,000,000), which term sheet must be in such form and substance as are acceptable to Collateral Agent, provided, however, that for the avoidance of doubt, (A) the required term sheet amount of Twenty Million Dollars ($20,000,000), and the required proceeds of the 2018 Financing Event (as defined in the Fourth Amendment), shall each include proceeds of the Domain December 2018 Financing Event (i.e., $1,500,000) for purposes of measurement; and (B) the required term sheet amount of Twenty Million Dollars ($20,000,000), shall not change the required proceeds of the 2018 Financing Event (as set forth and defined in the Fourth Amendment).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 8.2(a) of the Loan Agreement is hereby amended and restated as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(a) Borrower or any of its Subsidiaries fails or neglects to perform any obligation in Sections 6.2 (Financial Statements, Reports, Certificates), 6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (Protection of Intellectual Property Rights), 6.9 (Notice of Litigation and Default), 6.12 (Creation/Acquisition of Subsidiaries), 6.13 (Further Assurances) or 6.14 (Term Sheet Delivery for 2018 Financing Event) or Borrower violates any covenant in Section 7; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definitions therein as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&ldquo;<B>Alliqua Merger Deadline</B>&rdquo; is March 31, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&ldquo;<B>Amortization Date</B>&rdquo; means April 1, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>IP Lien Event</B>&rdquo; is (i) the Alliqua Merger not occurring on or before Alliqua Merger Deadline, (ii) the determination at any time by Collateral Agent in its sole discretion that the Alliqua Merger will not occur on or before the Alliqua Merger Deadline, <I>and </I>(iii) the 2018 Financing Event not occurring.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">8.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Amortization Table attached to the Disbursement Letter entered into on Effective Date in connection with the Term A Loans is hereby amended and restated in its entirety as set forth on <U>Exhibit A</U> hereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">9.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Amortization Table attached to the Disbursement Letter entered into on January 29, 2016 in connection with the Term B Loans is hereby amended and restated in its entirety as set forth on <U>Exhibit B</U> hereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">10.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Limitation of Amendment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and confirmed and shall remain in full force and effect.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">11.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">f.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&rsquo; rights.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">12.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">13.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment shall be deemed effective as of the Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto, and (b) Borrower&rsquo;s payment of all Lenders&rsquo; Expenses incurred through the date hereof, which may be debited (or ACH&rsquo;d) from the Designated Deposit Account in accordance with Section 2.3(d) of the Loan Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">14.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">15.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of California.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Balance of Page Intentionally Left
Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,
</B>the parties hereto have caused this Sixth Amendment to the Loan Agreement to be executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CEO</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the parties hereto have caused this Sixth Amendment to the Loan Agreement to be executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Colette Featherly</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Colette Featherly</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Senior Vice President</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amortization Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Term A Loan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amortization Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Term B Loan)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 103 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT AND SEVENTH AMENDMENT TO LOAN
AND SECURITY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">THIS CONSENT AND SEVENTH AMENDMENT to Loan
and Security Agreement (this &ldquo;<B>Amendment</B>&rdquo;) is entered into as of May 3, 2019 (the &ldquo;<B>Seventh Amendment
Date</B>&rdquo;), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax
Street, Alexandria, Virginia 22314 (in its individual capacity, &ldquo;<B>Oxford</B>&rdquo;; and in its capacity as Collateral
Agent, &ldquo;<B>Collateral Agent</B>&rdquo;), the Lenders listed on Schedule 1.1 thereof from time to time including Oxford in
its capacity as a Lender (each a &ldquo;<B>Lender</B>&rdquo; and collectively, the &ldquo;<B>Lenders</B>&rdquo;), ADYNXX, INC.,
a Delaware corporation with an office at 100 Pine Street, #500, San Francisco, CA 94111, which will be re-named ADYNXX SUB, INC.
effective immediately following consummation of the Merger (defined below) (&ldquo;<B>Existing Borrower</B>&rdquo;), and ALLIQUA
BIOMEDICAL, INC., a Delaware corporation with offices located at 100 Pine Street, #500, San Francisco, CA 94111, which will be
re- named ADYNXX, INC., effective following consummation of the Merger (defined below) (&ldquo;<B>New Borrower</B>&rdquo; and together
with Existing Borrower, individually and collectively, jointly and severally, &ldquo;<B>Borrower</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, Collateral Agent, Existing Borrower
and the Lenders party thereto from time to time have entered into that certain Loan and Security Agreement, dated as of November
24, 2015 (as amended, supplemented or otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;) pursuant to
which the Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, New Borrower have entered into
that certain Agreement and Plan of Merger and Reorganization, by and among Existing Borrower, EMBARK MERGER SUB, INC., a Delaware
corporation (&ldquo;<B>Merger Sub</B>&rdquo;) and New Borrower dated as of October 11, 2018 in the form attached hereto as <U>Exhibit
A</U> (without any amendments to the terms thereof, &ldquo;<B>Merger Agreement</B>&rdquo;) pursuant to which, among other things,
the Merger Sub will merge with and into Existing Borrower and Existing Borrower shall become a wholly owned subsidiary of New Borrower
(the &ldquo;<B>Merger</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, Borrower, Lenders and Collateral
Agent desire to amend certain provisions of the Loan Agreement as provided herein and subject to the terms and conditions set forth
herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOW, THEREFORE, in consideration of the promises, covenants
and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,
Borrower, Lenders and Collateral Agent hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Definitions. </B>Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt"><B>2. </B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Joinder.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>New Borrower</B>. New Borrower hereby is added as a &ldquo;Borrower&rdquo; under the Loan Agreement. All references in the Agreement to &ldquo;Borrower&rdquo; shall hereafter mean and include the Existing Borrower and New Borrower individually and collectively, jointly and severally; and New Borrower shall hereafter have all rights, duties and obligations of &ldquo;Borrower&rdquo; thereunder.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Joinder to Loan Agreement. </B>New Borrower hereby joins the Loan Agreement and each of the Loan Documents, and agrees to comply with and be bound by all of the terms, conditions and covenants of the Loan Agreement and Loan Documents, as if it were originally named a &ldquo;Borrower&rdquo; therein (effective as of the date of this Amendment). Without limiting the generality of the preceding sentence, New Borrower agrees that it will be jointly and severally liable, together with Existing Borrower, for the payment and performance of all obligations and liabilities of Borrower under the Loan Agreement, including, without limitation, the Obligations. Either Borrower may, acting singly, request Credit Extensions pursuant to the Loan Agreement. Each Borrower hereby appoints the other as agent for the other for all purposes hereunder, including with respect to requesting Credit Extensions pursuant to the Loan Agreement. Each Borrower hereunder shall be obligated to repay all Credit Extensions made pursuant to the Loan Agreement,&nbsp;regardless of which Borrower actually receives said Credit Extension, as if each Borrower hereunder directly received all Credit Extensions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 104 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Subrogation and Similar Rights. </B>Each Borrower waives (a) any suretyship defenses available to it under the Code or any other applicable law and (b) any right to require Collateral Agent or any Lender to: (i) proceed against any Borrower or any other person; (ii) proceed against or exhaust any security; or (iii) pursue any other remedy. Collateral Agent and any Lender may each exercise or not exercise any right or remedy it has against any Borrower or any security it holds (including the right to foreclose by judicial or non-judicial sale) without affecting any Borrower&rsquo;s liability. Notwithstanding any other provision of this Amendment, the Loan Agreement, the Loan Documents or any related documents, until the Obligations have been indefeasibly paid in full in cash and at such time as each Lender&rsquo;s obligation to make Credit Extensions has terminated, each Borrower irrevocably waives all rights that it may have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of Collateral Agent and/or Lenders under this Amendment and the Loan Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any other Person now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with respect to the Obligations in connection with this Amendment, the Loan Agreement and the other Loan Documents, and all rights that it might have to benefit from, or to participate in, any security for the Obligations as a result of any payment made by Borrower with respect to the Obligations in connection with this Amendment, the Loan Agreement or the other Loan Documents. Any agreement providing for indemnification, reimbursement or any other arrangement prohibited under this section shall be null and void. If any payment is made to a Borrower in contravention of this section, such Borrower shall hold such payment in trust for Collateral Agent, for the ratable benefit of Lenders, and such payment shall be promptly delivered to Collateral Agent, for the ratable benefit of Lenders, for application to the Obligations, whether matured or unmatured.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Grant of Security Interest. </B>To secure the prompt payment and performance of all of the Obligations, New Borrower hereby grants to Collateral Agent, for the ratable benefit of Lenders, a continuing lien upon and security interest in all of New Borrower&rsquo;s now existing or hereafter arising rights and interest in the Collateral, whether now owned or existing or hereafter created, acquired, or arising, and wherever located. New Borrower further covenants and agrees that by its execution hereof it shall provide all such information, complete all such forms, and take all such actions, and enter into all such agreements, in form and substance reasonably satisfactory to Collateral Agent and each Lender that are reasonably deemed necessary by Collateral Agent or any Lender in order to grant a valid, perfected first priority security interest to Collateral Agent, for the ratable benefit of Lenders, in the Collateral (subject to Permitted Liens). New Borrower hereby authorizes Collateral Agent to file financing statements, without notice to Borrower, with all appropriate jurisdictions covering the Collateral in order to perfect or protect Collateral Agent&rsquo;s and/or any Lender&rsquo;s interest or rights hereunder, including a notice that any disposition of the Collateral, except to the extent such disposition are permitted pursuant to the Loan Agreement, by either Borrower or any other Person, shall be deemed to violate the rights of Collateral Agent and each Lender under the Code. Without limiting the generality of the foregoing, New Borrower hereby grants and pledges to Collateral Agent, for the ratable benefit of the Lenders, to secure the prompt payment and performance of all of the Obligations, a perfected security interest in all of the issued and outstanding shares of capital stock of the Existing Borrower and shall deliver to Collateral Agent one or more original stock certificates, if certificated, representing such shares together with duly executed instruments of transfer or assignment in blank, all in form and substance reasonably satisfactory to Collateral Agent, when due in accordance with the terms of Section 14 of this Amendment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Representations and Warranties. </B>New Borrower hereby represents and warrants to Collateral Agent and each Lender that all representations and warranties in the Loan Documents made on the part of Existing Borrower are true and correct in all material respect on the date hereof (as updated&nbsp;by the Perfection Certificate delivered to Oxford on the Seventh Amendment Date), except with respect to representations and warranties that are as of a specified date, with respect to Existing Borrower and New Borrower, with the same force and effect as if New Borrower were named as &ldquo;Borrower&rdquo; in the Loan Documents in addition to Existing Borrower.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 105; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Consent.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Collateral Agent and Oxford, which constitutes the Required Lenders, hereby consent to Existing Borrower, New Borrower and Merger Sub consummating the Merger on the date hereof, strictly in accordance with the terms of the Merger Agreement and, to the extent that any waivers and/or consents under the Loan Agreement or any other Loan Document, including, without limitations, Section 7.3 of the Loan Agreement, are required for Borrower to enter into the Merger Agreement, consummate the Merger, and for Borrower to perform their obligations under the Merger Agreement, Collateral Agent and Required Lenders hereby provide such waivers and consents.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Collateral Agent and the Required Lenders hereby consent to the proposed treatment of the Warrants as set forth in Section 5.17 of the Merger Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Collateral Agent and Required Lenders hereby consent to the payment by New Borrower, no later than ten days immediately after the date hereof, of (i) dividends of up to an aggregate amount Five Million Three Hundred Thousand Dollars ($5,300,000.00) which dividends the New Borrower has declared and are unpaid as of the effective time of the Merger (&ldquo;<B>Dividends</B>&rdquo;), no later than ten&nbsp;days immediately after the date hereof and (ii) payment of expenses related to the Merger in an aggregate amount of up to Two Million Two Hundred Thousand Dollars ($2,200,000.00) (&ldquo;<B>Merger Expenses</B>&rdquo;); provided, however, no portion of the Dividends or the Merger Expenses will be paid from the assets of Existing Borrower or from any part of the Term Loans proceeds received by Existing Borrower and until such time as New Borrower has paid the Dividends and Merger Expenses and complied with its obligations under Section 16(e) hereof, no Transfer of any assets of the Existing Borrower shall be made to New Borrower.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The following Section 6.14 is hereby added to the Loan Agreement:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>6.14 AquaMed</B>. Notwithstanding the provisions of Section 7.1, on or before June 30, 2019, New Borrower shall either complete the AquaMed Spinoff or, at the sole discretion of Collateral Agent and Lenders, cause AquaMed to become a Borrower hereunder and enter into such related amendments to the Loan Documents and into other related agreements as the Collateral Agent and grant such security interests in the assets of AquaMed as Collateral Agent and Lenders may require. Until such time as the covenant set forth in the immediately preceding sentence has been fulfilled, Borrower shall not Transfer any assets or property to AquaMed or incur any liabilities related thereto other than incurring reasonable transaction expenses in connection with the AquaMed Spinoff.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 8.2(a) of the Loan Agreement is hereby amended and restated as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(a) Borrower or any of its Subsidiaries fails or neglects to perform any obligation in Sections 6.2 (Financial Statements, Reports, Certificates), 6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (Protection of Intellectual Property Rights), 6.9 (Notice of Litigation and Default), 6.12 (Creation/Acquisition of Subsidiaries), 6.13 (Further Assurances) or 6.14 (AquaMed) or Borrower violates any covenant in Section 7; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The following Section 12.12 is hereby added to the Loan Agreement:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>12.12 Borrower Liability</B>. Either Borrower may, acting singly, request Credit Extensions hereunder. Each Borrower hereby appoints the other as agent for the other for all purposes hereunder, including with respect to requesting Credit Extensions hereunder. Each Borrower hereunder shall be jointly and severally obligated to repay all Credit Extensions made hereunder, regardless of which Borrower actually receives said Credit Extension, as if each Borrower hereunder directly received all Credit Extensions. Each Borrower waives (a) any suretyship defenses available to it under the Code or any other applicable law, and (b) any right to require Collateral Agent or any Lender to: (i) proceed against any Borrower or any other person; (ii) proceed against or exhaust any security; or (iii) pursue any other remedy. Collateral Agent and or any Lender may exercise or not exercise any right or remedy it has against any Borrower or any security it holds (including the right to foreclose by judicial or non-judicial sale) without affecting any Borrower&rsquo;s liability. Notwithstanding any other provision of this Agreement or other related document, each Borrower irrevocably waives all rights that it may have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of Collateral Agent and the Lenders under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any other Person now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise and all rights that it might have to benefit from, or to participate in, any security for the Obligations as a result of any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise, until all Obligations (other than inchoate indemnity obligations) have been paid in full, the Lenders&rsquo; obligations to make Credit Extensions are terminated and the Loan Documents are terminated. Any agreement providing for indemnification, reimbursement or any other arrangement prohibited under this Section shall be null and void. If any payment is made to a Borrower in contravention of this Section, such Borrower shall hold such payment in trust for Collateral Agent and the Lenders and such payment shall be promptly delivered to Collateral Agent for application to the Obligations, whether matured or unmatured.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby amended by adding the following definitions thereto in alphabetical order:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&ldquo;AquaMed&rdquo; </B>is AquaMed Technologies, Inc., a Delaware corporation, and a wholly owned subsidiary of New Borrower.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&ldquo;AquaMed Spinoff&rdquo; </B>is the disposition of all equity securities of AquaMed held by New Borrower to one or more third parties (other than the Existing Borrower) or the disposition of all or substantially all of the assets of AquaMed followed by a dissolution of AquaMed, in each case, without Transfer of any assets or property by Borrower to AquaMed or any third party other than payment of reasonable transaction expenses and without incurring any liabilities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&ldquo;Existing Borrower&rdquo; </B>is ADYNXX, INC., a Delaware corporation with an office at 100 Pine Street, #500, San Francisco, CA 94111, which will be re-named ADYNXX SUB, INC. effective immediately following consummation of the Merger.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>New Borrower</B>&rdquo; is Alliqua BioMedical, Inc., which will be re-named ADYNXX, INC., effective following consummation of the Merger.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Seventh Amendment Date</B>&rdquo; is May 3, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">8.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definitions therein as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Alliqua Merger Deadline</B>&rdquo; is May 3, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Borrower</B>&rdquo; is individually and collectively, jointly and severally, New Borrower and the Existing Borrower.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">9.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Exhibit C</U> to the Loan Agreement is hereby amended and restated in its entirety as set forth on <U>Exhibit B</U> hereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 107; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">10.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Exhibit D</U> to the Loan Agreement is hereby amended and restated in its entirety as set forth on <U>Exhibit C</U> hereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">11.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Perfection Certificate delivered on the Effective Date of the Loan Agreement is hereby updated by the Perfection Certificate delivered to Collateral Agent on or around the date of this Amendment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">12.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Limitation of Amendment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The amendments and consents set above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect. For the avoidance of doubt, this Amendment shall be considered part of the Loan Documents.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">13.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Neither the Merger Sub nor AquaMed had any liabilities or outstanding litigation immediately prior to the consummation of the Merger and the New Borrower has no material liabilities or outstanding litigation immediately prior to the consummation of the Merger (this does not take away from any other representation or warranty previously made or being made herein by Borrower), except as set forth on the Perfection Certificate for the New Borrower on the Seventh Amendment Date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">f.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (i) any law or regulation binding on or affecting Borrower, (ii) any contractual restriction with a Person binding on Borrower, (iii) any order, judgment or decree of any court or&nbsp;other governmental or public body or authority, or subdivision thereof, binding on Borrower, or&nbsp;(iv) the organizational documents of Borrower;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 108; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">g.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">h.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&rsquo; rights.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">14.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">15.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment shall be deemed effective as of the Seventh Amendment Date upon (a) the due execution and delivery to Collateral Agent of this Amendment by each party hereto, (b) Borrower&rsquo;s payment of all Lenders&rsquo; Expenses incurred through the date hereof, which may be debited (or ACH&rsquo;d) from the Designated Deposit Account in accordance with Section 2.3(d) of the Loan Agreement, (c) fulfillment of all conditions of Section 3.1 of the Loan Agreement (as they may be applicable to the New Borrower) and Section 3.2 of the Loan Agreement (as they may be applicable to Borrower), including, without limitation, receipt of the original Warrants exercisable for the common shares of New Borrower in lieu of the Warrants outstanding immediately prior to this Amendment becoming effective and receipt of original Promissory Notes being issued on the date hereof in lieu of the Promissory Notes outstanding immediately prior to this Amendment becoming effective.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">16.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Borrower hereby covenants to the following:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On the date hereof, deliver to Collateral Agent, copies of the filed and stamped: certificate of incorporation of Existing Borrower effective as of the Merger, certificate of incorporation and conversion of New Borrower effective as of the Merger and certificate of Merger, certificates of good standing for New Borrower for the State of Delaware and any other state in which it is required to be qualified to do business.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On or before May 7, 2019, deliver to Collateral Agent, original signature pages of Borrower for the Warrants and Promissory Notes being issued on the date hereof;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On or before May 7, 2019, deliver to Collateral Agent evidence of termination of the UCC financing statement (File Number 2015060107645) filed with the Secretary of Commonwealth of the Commonwealth of Pennsylvania;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On or before May 10, 2019, deliver to Collateral Agent a revised Perfection Certificate for New Borrower listing New Borrower&rsquo;s Intellectual Property;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On or before May 13, 2019, deliver to Collateral Agent of closure of New Borrower&rsquo;s accounts maintained with PNC Bank and no cash or other assets of the Existing Borrower or any portion of the Loan Proceeds shall be transferred to such accounts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 109; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">f.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On or before May 31, 2019, deliver to Collateral Agent a complete Perfection Certificate for AquaMed;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">g.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On or before May 10<I>, </I>2019, deliver a copy of the form W-9 for the New Borrower to Collateral Agent.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">h.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On or before June 1<I>, </I>2019, deliver to Collateral Agent an original stock certificate, if certificated representing all outstanding shares of the Existing Borrower and AquaMed, together with duly executed instrument of transfer or assignment in blank, all in form and substance satisfactory to Collateral Agent.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">i.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On or before June 1<I>, </I>2019, Borrower shall deliver evidence satisfactory to Collateral Agent that the insurance policies for New Borrower required by Section 6.5 of the Loan Agreement are in full force and effect, together with appropriate evidence showing loss payable and/or additional insured clauses or endorsements in favor of Collateral Agent.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">j.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On or before June 1<I>, </I>2019, Borrower shall deliver to Collateral Agent (i) a landlord&rsquo;s consent executed in favor of Collateral Agent in respect of all of New Borrower&rsquo;s leased locations where New Borrower or any Subsidiary (other than Existing Borrower) maintains Collateral having a book value in excess of One Hundred Thousand Dollars ($100,000.00) or its books or records (including, without limitation, its headquarters); and (ii) a bailee waiver executed in favor of Collateral Agent in respect of each third party bailee where New Borrower or any Subsidiary (other than Existing Borrower) maintains Collateral having a book value in excess of One Hundred Thousand Dollars ($100,000.00).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">17.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Collateral Agent and Lenders hereby covenant to the following:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Deliver the original (i) Term A Secured Promissory Note; and (ii) Term B Secured Promissory Note, marked &ldquo;cancelled&rdquo; to Borrower within thirty (30) days of the date of this Amendment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Deliver the original Warrants issued by Existing Borrower to Oxford and its affiliates outstanding immediately prior to this Amendment becoming effective within thirty (30) days of the date of this Amendment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">18.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Borrower hereby remises, releases, acquits, satisfies and forever discharges the Lenders and Collateral Agent, their agents, employees, officers, directors, predecessors, attorneys and all others acting or purporting to act on behalf of or at the direction of the Lenders and Collateral Agent <B>(&ldquo;Releasees</B>&rdquo;), of and from any and all manner of actions, causes of action, suit, debts, accounts, covenants, contracts, controversies, agreements, variances, damages, judgments, claims and demands whatsoever, in law or in equity, which any of such parties ever had, now has or, to the extent arising from or in connection with any act, omission or state of facts taken or existing on or prior to the date hereof, may have after the date hereof against the Releasees, for, upon or by reason of any matter, cause or thing whatsoever relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof through the date hereof. Without limiting the generality of the foregoing, the Borrower waives and affirmatively agrees not to allege or otherwise pursue any defenses, affirmative defenses, counterclaims, claims, causes of action, setoffs or other rights they do, shall or may have as of the date hereof, including the rights to contest: (a) the right of Collateral Agent and each Lender to exercise its rights and remedies described in the Loan Documents; (b) any provision of this Amendment or the Loan Documents; or (c) any conduct of the Lenders or other Releasees relating to or arising out of the Loan Agreement or the other Loan Documents on or prior to the date hereof.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">19.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">20.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of California.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Balance of Page Intentionally Left
Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,
</B>the parties hereto have caused this Consent, Waiver and Seventh Amendment to Loan and Security Agreement to be executed as
of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC., a Delaware corporation,</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">which will be re-named ADYNXX SUB, INC. effective</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">immediately following consummation of the Merger</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>NEW BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ALLIQUA BIOMEDICAL, INC., a Delaware corporation,</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">which will be re-named ADYNXX, INC. effective</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">immediately following consummation of the Merger</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 111 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,
</B>the parties hereto have caused this Consent, Waiver and Seventh Amendment to Loan and Security Agreement to be executed as
of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC., a Delaware corporation,</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">which will be re-named ADYNXX SUB, INC. effective</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">immediately following consummation of the Merger</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>NEW BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ALLIQUA BIOMEDICAL, INC., a Delaware corporation,</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">which will be re-named ADYNXX, INC. effective</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">immediately following consummation of the Merger</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Colette H. Featherly</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Colette H. Featherly</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Senior Vice President</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 112 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EIGHTH AMENDMENT TO LOAN AND SECURITY
AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">THIS EIGHTH AMENDMENT to Loan and Security
Agreement (this &ldquo;<B>Amendment</B>&rdquo;) is entered into as of June 30, 2019 (the &ldquo;<B>Eighth Amendment Date</B>&rdquo;),
by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria,
Virginia 22314 (&ldquo;Oxford&rdquo;), as collateral agent (in such capacity, &ldquo;<B>Collateral Agent</B>&rdquo;), the Lenders
listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford
in its capacity as a Lender (each a &ldquo;<B>Lender</B>&rdquo; and collectively, the &ldquo;<B>Lenders</B>&rdquo;), and ADYNXX
SUB, INC., a Delaware corporation with an office at 100 Pine Street, #500, San Francisco, CA 94111 and ADYNXX, INC., a Delaware
corporation with offices located at 100 Pine Street, #500, San Francisco, CA 94111 (individually and collectively, jointly and
severally, &ldquo;<B>Borrower</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, Collateral Agent, Borrower and
Lenders have entered into that certain Loan and Security Agreement, dated as of November 24, 2015 (as amended, supplemented or
otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;) pursuant to which Lenders have provided to Borrower
certain loans in accordance with the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">WHEREAS, Borrower, Lenders and Collateral
Agent desire to amend certain provisions of the Loan Agreement and the Disbursement Letters entered into pursuant to the Loan Agreement
as provided herein and subject to the terms and conditions set forth herein, and to waive certain Events of Default that have occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">NOW, THEREFORE, in consideration of the
promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">1.</TD><TD STYLE="text-align: justify">Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">2.</TD><TD STYLE="text-align: justify">Borrower hereby reaffirms the security interest granted by Borrower previously in Section 4.1 of the Loan Agreement with respect
to the Collateral (prior to the date hereof) and hereby grants Collateral Agent, for the ratable benefit of the Lenders, to secure
the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent,
for the ratable benefit of the Lenders, such part of the Collateral that was not pledged previously or in which security interest
was not granted prior to the Eighth Amendment Date, wherever located, whether now owned or hereafter acquired or arising, and all
proceeds and products thereof. Furthermore, Borrower hereby authorizes Collateral Agent to file financing statements or take any
other action required to perfect Collateral Agent&rsquo;s security interests in the Collateral, without notice to Borrower, with
all appropriate jurisdictions to perfect or protect Collateral Agent&rsquo;s interest or rights under the Loan Documents, including
a notice that any disposition of the Collateral, except to the extent permitted by the terms of this Amendment, by Borrower, or
any other Person, shall be deemed to violate the rights of Collateral Agent under the Code.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 113 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid; text-align: justify"><P STYLE="margin: 0pt; text-align: justify">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; text-align: justify"><P STYLE="margin: 0pt; text-align: justify">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">3.</TD><TD STYLE="text-align: justify">Section 2.2(b) of the Loan Agreement is hereby amended and restated in its entirety as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Repayment</U>.
Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of
each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately
preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest
payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. On each of
December 1, 2016 and January 1, 2017, in addition to making the aforementioned interest payments, Borrower shall also make (i)
a payment of $83,333.33 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount
of the Term A Loan, and (ii) a payment of $55,555.56 with respect to the Term B Loan, which shall be deemed to be a partial payment
of the principal amount of the Term B Loan. On each of January 1, 2018, February 1, 2018 and March 1, 2018, in addition to making
the aforementioned interest payments, Borrower shall also make (i) a payment of $123,188.41 with respect to the Term A Loan, which
shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $82,125.60 with respect
to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. On September 1, 2018,
in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $164,251.21 with respect
to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment
of $109,500.81 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term
B Loan. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter until and including June
1, 2019, Borrower shall make consecutive monthly payments of equal amounts of principal, and the applicable interest, in arrears,
to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon:
(1) the amount of such Lender&rsquo;s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a
repayment schedule equal to eight (8) months. Commencing on July 1, 2019 and until Payment Date immediately preceding the 2019
Amortization Date, Borrower shall make monthly payments of interest only. Commencing on the 2019 Amortization Date and continuing
on the Payment Date of each month thereafter, Borrower shall make consecutive monthly payments of equal amounts of then outstanding
principal, and the applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall
be deemed correct absent manifest error) based upon: (1) the proportional amount of such Lender&rsquo;s Term Loan, (2) the effective
rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to five (5) months if the 2019 Amortization
Date is September 1, 2019, and six (6) months if the Second Amortization date is August 1, 2019. All unpaid principal and accrued
and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be
prepaid in accordance with Sections 2.2(c) and 2.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Section 2.5 of the Loan Agreement is hereby amended by deleting the word &ldquo;and&rdquo; immediately following Section 2.5(i),
replacing &ldquo;;&rdquo; at the end of Section 2.5(j) with &ldquo;; and&rdquo; and adding Section 2.5(k) thereto as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Eighth
Amendment Fee</U>. A fully earned and non-refundable eighth amendment fee in the amount of Twenty Thousand Dollars ($20,000.00),
which shall become due and payable upon the earlier of: (i) the Maturity Date, (ii) the acceleration of any Term Loan, or (iii)
the prepayment of a Term Loan pursuant to Section 2.2(c) or (d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">5.</TD><TD STYLE="text-align: justify">Section 5.2(d) of the Loan Agreement is hereby amended and restated as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Borrower and each of its Subsidiaries is the sole
owner of the Intellectual Property each respectively purports to own, free and clear of all Liens other than Permitted Liens. (i)
To Borrower&rsquo;s knowledge, each of Borrower&rsquo;s and its Subsidiaries&rsquo; Copyrights, Trademarks and issued Patents are
valid and enforceable and no part of Borrower&rsquo;s or its Subsidiaries&rsquo; Intellectual Property has been judged invalid
or unenforceable, in whole or in part, and (ii) to the best of Borrower&rsquo;s knowledge, no claim has been made in writing that
any part of the Intellectual Property or any practice by Borrower or its Subsidiaries violates the rights of any third party except
to the extent such claim could not reasonably be expected to have a Material Adverse Change. Except as noted on the Perfection
Certificates, neither Borrower nor any of its Subsidiaries is a party to, nor is bound by, any material license or other material
agreement with respect to which Borrower or such Subsidiary is the licensee that (i) prohibits or otherwise restricts Borrower
or its Subsidiaries from granting a security interest in Borrower&rsquo;s or such Subsidiaries&rsquo; interest in such material
license or material agreement or any other property, or (ii) for which a default under or termination of could interfere with Collateral
Agent&rsquo;s or any Lender&rsquo;s right to sell any Collateral. Borrower shall provide written notice to Collateral Agent and
each Lender within ten (10) days of Borrower or any of its Subsidiaries entering into or becoming bound by any license or agreement
with respect to which Borrower or any Subsidiary is the licensee (other than over the counter software that is commercially available
to the public).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>


<!-- Field: Page; Sequence: 114; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">6.</TD><TD STYLE="text-align: justify">Section 6.2(a)(vii) of the Loan Agreement is hereby amended and restated in its entirety as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">prompt notice of (A) any material change in the composition
of the Intellectual Property, (B) the registration of any copyright, including any subsequent ownership right of Borrower or any
of its Subsidiaries in or to any copyright, patent or trademark, including a copy of any such registration (provided that notice
of any new patent, trademark with the next-due Compliance Certificate shall be deemed sufficient notice under this provision, and
notice in accordance with the terms of Section 6.7 with respect to any new copyright shall be deemed sufficient notice under this
provision), and (C) any event that could reasonably be expected to materially and adversely affect the value of the Intellectual
Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">7.</TD><TD STYLE="text-align: justify">Section 6.7 of the Loan Agreement is hereby amended and restated in its entirety as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Borrower and each of its Subsidiaries shall: (a) use
commercially reasonable efforts to protect, defend and maintain the validity and enforceability of its Intellectual Property that
is material to Borrower&rsquo;s business; (b) promptly advise Collateral Agent in writing of material infringement by a third party
of its Intellectual Property; and (c) not allow any Intellectual Property material to Borrower&rsquo;s business to be abandoned,
forfeited or dedicated to the public without Collateral Agent&rsquo;s prior written consent. If Borrower or any of its Subsidiaries
(i) obtains any patent, registered trademark or servicemark, registered copyright, registered mask work, or any pending application
for any of the foregoing, whether as owner, licensee or otherwise, or (ii) applies for any patent or the registration of any trademark
or servicemark, then Borrower or such Subsidiary shall provide written notice thereof to Collateral Agent with the next- due Compliance
Certificate, and shall execute such intellectual property security agreements and other documents and take such other actions as
Collateral Agent shall reasonably request in its good faith business judgment to perfect and maintain a first priority perfected
security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in such property. If Borrower or any of
its Subsidiaries decides to register any copyrights or mask works in the United States Copyright Office, Borrower or such Subsidiary
shall: (x) provide Collateral Agent and each Lender with at least fifteen (15) days prior written notice of Borrower&rsquo;s or
such Subsidiary&rsquo;s intent to register such copyrights or mask works together with a copy of the application it intends to
file with the United States Copyright Office (excluding exhibits thereto); (y) execute an intellectual property security agreement
and such other documents and take such other actions as Collateral Agent may reasonably request in its good faith business judgment
to perfect and maintain a first priority perfected security interest in favor of Collateral Agent, for the ratable benefit of the
Lenders, in the copyrights or mask works intended to be registered with the United States Copyright Office; and (z) record such
intellectual property security agreement with the United States Copyright Office contemporaneously with filing the copyright or
mask work application(s) with the United States Copyright Office. Borrower or such Subsidiary shall promptly provide to Collateral
Agent and each Lender with evidence of the recording of the intellectual property security agreement necessary for Collateral Agent
to perfect and maintain a first priority perfected security interest in such property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">8.</TD><TD STYLE="text-align: justify">The following Section 6.15 is hereby added to the Loan Agreement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>6.15 USPTO Registration Correction. </B>On or before
July 19, 2019, Borrower must deliver to Collateral Agent evidence (in such form and substance as are reasonably acceptable to Collateral
Agent) of registration in the name of Adynxx, Inc. of all Intellectual Property currently registered in the name of Alliqua Biomedical,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">9.</TD><TD STYLE="text-align: justify">Section 8.2(a) of the Loan Agreement is hereby amended and restated as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrower
or any of its Subsidiaries fails or neglects to perform any obligation in Sections 6.2 (Financial Statements, Reports, Certificates),
6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (Protection of Intellectual Property Rights), 6.9 (Notice of Litigation
and Default), 6.12 (Creation/Acquisition of Subsidiaries), 6.13 (Further Assurances), 6.14 (AquaMed) or 6.15 (USPTO Registration
Correction) or Borrower violates any covenant in Section 7; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 115; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">10.</TD><TD STYLE="text-align: justify">Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definitions therein as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Loan Documents</B>&rdquo; are, collectively,
this Agreement, the Warrants, the Perfection Certificates, each Compliance Certificate, each Disbursement Letter, the IP Agreement,
any subordination agreements, any note, or notes or guaranties executed by Borrower or any other Person, and any other present
or future agreement entered into by Borrower, any Guarantor or any other Person for the benefit of the Lenders and Collateral Agent
in connection with this Agreement; all as amended, restated, or otherwise modified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Maturity Date</B>&rdquo; is January 1, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">11.</TD><TD STYLE="text-align: justify">Section 13.1 of the Loan Agreement is hereby further amended by adding the following definitions thereto in alphabetical order:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">12.</TD><TD STYLE="text-align: justify">&ldquo;<B>2019 Amortization Date</B>&rdquo; is (i) August 1, 2019, if Borrower does not receive on or after June 1, 2019 and
on or before July 31, 2019, gross proceeds of at least Five Hundred Thousand Dollars ($500,000.00) (or such other amount that is
sufficient to fund operations of Borrower through August 31, 2019 based on a forecast that is acceptable to Collateral Agent in
its sole discretion) from the sale and issuance by Borrower of its unsecured convertible Subordinated Debt and/or equity securities
and (ii) September 1, 2019, if Borrower does receive on or after June 1, 2019 and on or before July 31, 2019, gross proceeds of
at least Five Hundred Thousand Dollars ($500,000.00) (or such other amount that is sufficient to fund operations of Borrower through
August 31, 2019 based on a forecast that is acceptable to Collateral Agent in its sole discretion) from the sale and issuance by
Borrower of its unsecured convertible Subordinated Debt and/or equity securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Eighth Amendment Date</B>&rdquo; is June
30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>IP Agreement</B>&rdquo; is that certain
Intellectual Property Security Agreement entered into by and between Borrower and Collateral Agent dated as of the Eighth Amendment
Date, as such may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">13.</TD><TD STYLE="text-align: justify"><U>Exhibit A</U> to the Loan Agreement is hereby amended and restated in its entirety as set forth on <U>Exhibit A</U> hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">14.</TD><TD STYLE="text-align: justify">Borrower hereby represents and warrants that a complete and accurate list of its Intellectual Property as of the Eighth Amendment
Date is attached hereto as <U>Exhibit B</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">15.</TD><TD STYLE="text-align: justify">The Amortization Table attached to the Disbursement Letter entered into on Effective Date in connection with the Term A Loans
is hereby amended and restated in its entirety as set forth on <U>Exhibit C</U> hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">16.</TD><TD STYLE="text-align: justify">The Amortization Table attached to the Disbursement Letter entered into on January 29, 2016 in connection with the Term B Loans
is hereby amended and restated in its entirety as set forth on <U>Exhibit D</U> hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">17.</TD><TD STYLE="text-align: justify">Borrower hereby authorizes Collateral Agent to file financing statements, amendments to financing statements or take any other
action required to perfect Collateral Agent&rsquo;s security interests in the Collateral (as such term has been amended pursuant
to this Amendment) , without notice to Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent&rsquo;s
interest or rights under the Loan Documents, including a notice that any disposition of the Collateral, except to the extent permitted
by the terms of the Loan Documents, by Borrower, or any other Person, shall be deemed to violate the rights of Collateral Agent
under the Code.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>


<!-- Field: Page; Sequence: 116; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">18.</TD><TD STYLE="text-align: justify">Notwithstanding the terms of Section 16 of that certain Consent and Seventh Amendment to Loan and Security Agreement dated
May 3, 2019, between Borrower, Collateral Agent and Lender (the &ldquo;<B>Seventh Amendment</B>&rdquo;), Borrower may maintain
one account with PNC ending in account number 235 (last three digits), provided that the aggregate balance in such account does
not exceed $20,000 at any time (the &ldquo;<B>PNC Account</B>&rdquo;) and no transfers are made to such account until such time
as such account is subject to a Control Agreement in favor of Collateral Agent, which Control Agreement must be in such form and
substance as reasonably satisfactory to Collateral Agent and must be delivered to Collateral Agent no later than July 26, 2019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">19.</TD><TD STYLE="text-align: justify">Limitation of Amendment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">a.</TD><TD STYLE="text-align: justify">The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and
shall not be deemed to (a) be a consent to any amendment, waiver (except as set forth in Section 20 below) or modification of any
other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower
may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">b.</TD><TD STYLE="text-align: justify">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations,
warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and confirmed and shall remain in full
force and effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">20.</TD><TD STYLE="text-align: justify"><B><U>Waiver</U></B>; Certain Events of Default occurred due to Borrower&rsquo;s failure to (i) close certain PNC accounts
by May 13, 2019, and (ii) deliver a Perfection Certificate for AquaMed by May 31, 2019 (which was ultimately delivered to Collateral
Agent), each as required in Section 16 of the Seventh Amendment (collectively, the &ldquo;<B>Existing Defaults</B>&rdquo;). Bank
hereby waives the Existing Defaults and strictly the Existing Defaults.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">21.</TD><TD STYLE="text-align: justify">To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral
Agent and Lenders as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">a.</TD><TD STYLE="text-align: justify">Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are
true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties
relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default (other than the
Existing Defaults) has occurred and is continuing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">b.</TD><TD STYLE="text-align: justify">Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan
Agreement, as amended by this Amendment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">c.</TD><TD STYLE="text-align: justify">The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent
deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended,
supplemented or restated and are and continue to be in full force and effect;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">d.</TD><TD STYLE="text-align: justify">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower,
(ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order, judgment or decree of any
court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational
documents of Borrower;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 117; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of,
or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof,
binding on Borrower, except as already has been obtained or made; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">f.</TD><TD STYLE="text-align: justify">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against
Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization,
liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&rsquo;
rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">22.</TD><TD STYLE="text-align: justify">Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment.
This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations
or agreements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">23.</TD><TD STYLE="text-align: justify">The Borrower hereby remises, releases, acquits, satisfies and forever discharges the Lenders and Collateral Agent, their agents,
employees, officers, directors, predecessors, attorneys and all others acting or purporting to act on behalf of or at the direction
of the Lenders and Collateral Agent <B>(&ldquo;Releasees</B>&rdquo;), of and from any and all manner of actions, causes of action,
suit, debts, accounts, covenants, contracts, controversies, agreements, variances, damages, judgments, claims and demands whatsoever,
in law or in equity, which any of such parties ever had, now has or, to the extent arising from or in connection with any act,
omission or state of facts taken or existing on or prior to the date hereof, may have after the date hereof against the Releasees,
for, upon or by reason of any matter, cause or thing whatsoever relating to or arising out of the Loan Agreement or the other Loan
Documents on or prior to the date hereof through the date hereof. Without limiting the generality of the foregoing, the Borrower
waives and affirmatively agrees not to allege or otherwise pursue any defenses, affirmative defenses, counterclaims, claims, causes
of action, setoffs or other rights they do, shall or may have as of the date hereof, including the rights to contest: (a) the right
of Collateral Agent and each Lender to exercise its rights and remedies described in the Loan Documents; (b) any provision of this
Amendment or the Loan Documents; or (c) any conduct of the Lenders or other Releasees relating to or arising out of the Loan Agreement
or the other Loan Documents on or prior to the date hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">24.</TD><TD STYLE="text-align: justify">This Amendment shall be deemed effective as of the Amendment Date upon (a) the due execution and delivery to Collateral Agent
of this Amendment by each party hereto, (b) the execution and delivery by Borrower of the IP Agreement, and (c) Borrower&rsquo;s
payment of all Lenders&rsquo; Expenses incurred through the date hereof, which may be debited (or ACH&rsquo;d) from the Designated
Deposit Account in accordance with Section 2.3(d) of the Loan Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">25.</TD><TD STYLE="text-align: justify">This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which,
taken together, shall constitute one and the same instrument.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify">26.</TD><TD STYLE="text-align: justify">This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the
laws of the State of California.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Balance of Page Intentionally Left
Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 118; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>IN WITNESS WHEREOF</B>, the parties hereto
have caused this Eighth Amendment to the Loan Agreement to be executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX, INC. </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/Rick Orr</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CEO</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">ADYNXX SUB, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Rick Orr</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">CEO</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/Joshua Friedman</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Joshua Friedman</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 119 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U><BR>
Description of Collateral</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Collateral consists of all of Borrower&rsquo;s
right, title and interest in and to the following personal property:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All goods, Accounts
(including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements,
franchise agreements, General Intangibles (including Intellectual Property), commercial tort claims, documents, instruments (including
any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all
certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities,
and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever
located; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All Borrower&rsquo;s
Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions,
attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or
all of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, the Collateral does not include (i)&nbsp;more than 65% of the total combined voting power of all classes of stock entitled
to vote the shares of capital stock (the &ldquo;Shares&rdquo;) of any Foreign Subsidiary, if Borrower demonstrates to Collateral
Agent&rsquo;s reasonable satisfaction that a pledge of more than sixty five percent (65%) of the Shares of such Subsidiary creates
a present and existing adverse tax consequence to Borrower under the U.S. Internal Revenue Code; (ii) any license or contract,
in each case if the granting of a Lien in such license or contract is prohibited by or would constitute a default under the agreement
governing such license or contract (but (A) only to the extent such prohibition is enforceable under applicable law and (B) other
than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406, 9-408 or 9-409 (or any other Section)
of Division 9 of the Code); provided that upon the termination, lapsing or expiration of any such prohibition, such license or
contract, as applicable, shall automatically be subject to the security interest granted in favor of Collateral Agent hereunder
and become part of the &ldquo;Collateral&rdquo;; and (iii) any Excluded Accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 120 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Intellectual Property</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Please see attached</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 121 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amortization Table </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Term A Loan)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 122 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Exhibit D</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amortization Table </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Term B Loan)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 123 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">NINTH AMENDMENT TO LOAN AND SECURITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">THIS NINTH AMENDMENT to Loan and Security Agreement
(this &ldquo;<B>Amendment</B>&rdquo;) is entered into as of August 21, 2019, by and among OXFORD FINANCE LLC, a Delaware limited
liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (&ldquo;Oxford&rdquo;), as collateral
agent (in such capacity, &ldquo;<B>Collateral Agent</B>&rdquo;), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined
below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a &ldquo;<B>Lender</B>&rdquo;
and collectively, the &ldquo;<B>Lenders</B>&rdquo;), and ADYNXX SUB, INC., a Delaware corporation with an office at 100 Pine Street,
#500, San Francisco, CA 94111 and ADYNXX, INC., a Delaware corporation with offices located at 100 Pine Street, #500, San Francisco,
CA 94111 (individually and collectively, jointly and severally, &ldquo;<B>Borrower</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">WHEREAS, Collateral Agent, Borrower and Lenders
have entered into that certain Loan and Security Agreement, dated as of November 24, 2015 (as amended, supplemented or otherwise
modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;) pursuant to which Lenders have provided to Borrower certain
loans in accordance with the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">WHEREAS, Borrower, Lenders and Collateral Agent
desire to amend certain provisions of the Loan Agreement and the Disbursement Letters entered into pursuant to the Loan Agreement
as provided herein and subject to the terms and conditions set forth herein, and to waive certain Events of Default that have occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">NOW, THEREFORE, in consideration of the promises,
covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby
acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Section 2.2(b) of the Loan Agreement is hereby amended and restated in its entirety as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Repayment</U>.
Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of
each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately
preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest
payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. On each of
December 1, 2016 and January 1, 2017, in addition to making the aforementioned interest payments, Borrower shall also make (i)
a payment of $83,333.33 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount
of the Term A Loan, and (ii) a payment of $55,555.56 with respect to the Term B Loan, which shall be deemed to be a partial payment
of the principal amount of the Term B Loan. On each of January 1, 2018, February 1, 2018 and March 1, 2018, in addition to making
the aforementioned interest payments, Borrower shall also make (i) a payment of $123,188.41 with respect to the Term A Loan, which
shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $82,125.60 with respect
to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. On September 1, 2018,
in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $164,251.21 with respect
to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment
of $109,500.81 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term
B Loan. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter until and including June
1, 2019, Borrower shall make consecutive monthly payments of equal amounts of principal, and the applicable interest, in arrears,
to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon:
(1) the amount of such Lender&rsquo;s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a
repayment schedule equal to eight (8) months. Commencing on July 1, 2019 and until Payment Date immediately preceding the 2019
Amortization Date, Borrower shall make monthly payments of interest only. Commencing on the 2019 Amortization Date and continuing
on the Payment Date of each month thereafter, Borrower shall make consecutive monthly payments of equal amounts of then outstanding
principal, and the applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall
be deemed correct absent manifest error) based upon: (1) the amount of such Lender&rsquo;s Term Loan, (2) the effective rate of
interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to five months. All unpaid principal and accrued
and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be
prepaid in accordance with Sections 2.2(c) and 2.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 124 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Section 6.6(d) of the Loan Agreement is amended and restated, effective as of Seventh Amendment Date, as set forth below:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything herein to the contrary, on or before February 8, 2019, Borrower shall deposit an amount of Two Hundred Thousand Dollars
($200,000.00) in a segregated Collateral Account that is subject to a blocked Control Agreement in favor of Collateral Agent (and
which Control Agreement is in such form and substance as are satisfactory to Collateral Agent). Upon the receipt by Borrower of
net proceeds of at least Ten Million Dollars ($10,000,000.00) from the sale and issuance of its equity securities (but excluding
conversion of any convertible debt) and/or convertible unsecured Subordinated Debt on or after August 1, 2019, and the delivery
of evidence of receipt of such net proceeds by Borrower to Collateral Agent (which evidence must be in such form and substance
as are satisfactory to Collateral Agent in its sole discretion), the funds in such segregated account shall be released to Borrower
but shall continue to be subject to the applicable provisions of this Agreement (including being maintained in Collateral Accounts
subject to Sections 6.6(a), (b) and (c) of this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definitions therein as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&ldquo;<B>2019 Amortization Date</B>&rdquo; is (i) September
1, 2019, if either the September 2019 I/O Extension Event does not occur or the 2019 Equity Event occurs on or before August 31,
2019, (ii) October 1, 2019, if either (A) (1) the September 2019 I/O Extension Event occurs, (2) the October 2019 I/O Extension
does not occur and (3) the 2019 Equity Event does not occur on or before August 31, 2019, or (B) (1) September 2019 I/O Extension
Event occurs, (2) October 2019 I/O Extension Event occurs and (3) the 2019 Equity Event occurs between September 1, 2019 and September
30, 2019 and (iii) November 1, 2019, if (1) the September I/O Extension Event occurs, (2) the October I/O Extension Event occurs
and (3) the 2019 Equity Event does not occur on or before September 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&ldquo;<B>Maturity Date</B>&rdquo; is (i) January 1, 2020,
if the 2019 Amortization Date is September 1, 2019, (ii) February 1, 2020, if the 2019 Amortization Date is October 1, 2019 and
(iii) March 1, 2020, if the 2019 Amortization Date is November 1, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD>Section 13.1 of the Loan Agreement is hereby further amended by adding the following definitions thereto in alphabetical order:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&ldquo;<B>2019 Equity Event</B>&rdquo; is the receipt
by Borrower of net proceeds of at least Ten Million Dollars ($10,000,000.00) from the sale and issuance of its equity securities
(but excluding conversion of any convertible debt) and/or convertible unsecured Subordinated Debt on or after August 1, 2019 and
the receipt of evidence thereof by Collateral Agent (which evidence must be in such form and substance as are satisfactory to Collateral
Agent in its sole discretion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"></P>

<!-- Field: Page; Sequence: 125; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&ldquo;<B>October 2019 I/O Extension Event</B>&rdquo;
is the receipt by Borrower, on or after August 1, 2019 and on or before September 30, 2019, of gross proceeds of at least Five
Hundred Thousand Dollars ($500,000.00) (or such other amount that is sufficient to fund operations of Borrower through October
31, 2019 based on a forecast that is acceptable to Collateral Agent in its sole discretion), which may include amount used towards
achieving the September 2019 I/O Extension Event, from the sale and issuance by Borrower of its unsecured convertible Subordinated
Debt and/or equity securities (but excluding conversion of any convertible debt) and the receipt of evidence thereof by Collateral
Agent (which evidence must be in such form and substance as are satisfactory to Collateral Agent in its sole discretion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&ldquo;<B>September 2019 I/O Extension Event</B>&rdquo;
is the receipt by Borrower, on or after August 1, 2019 and on or before August 31, 2019, of gross proceeds of at least Two Hundred
Fifty Thousand Dollars ($250,000.00) (or such other amount that is sufficient to fund operations of Borrower through September
30, 2019 based on a forecast that is acceptable to Collateral Agent in its sole discretion) from the sale and issuance by Borrower
of its unsecured convertible Subordinated Debt and/or equity securities (but excluding conversion of any convertible debt) and
the receipt of evidence thereof by Collateral Agent (which evidence must be in such form and substance as are satisfactory to Collateral
Agent in its sole discretion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD>The Amortization Table attached to the Disbursement Letter entered into on Effective Date in connection with the Term A Loans
is hereby amended and restated in its entirety as set forth on <U>Exhibit A</U> hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD>The Amortization Table attached to the Disbursement Letter entered into on January 29, 2016 in connection with the Term B Loans
is hereby amended and restated in its entirety as set forth on <U>Exhibit B</U> hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">8.</TD><TD>Limitation of Amendment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and
shall not be deemed to (a) be a consent to any amendment, waiver (except as set forth in Section 9 below) or modification of any
other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower
may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations,
warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and confirmed and shall remain in full
force and effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">9.</TD><TD><B><U>Waiver</U></B>: An Event of Default occurred due to Borrower&rsquo;s failure to deliver a control agreement for a certain
PNC account by July 26, 2019, as required in Section 18 of that certain Eighth Amendment to Loan and Security Agreement dated as
of June 30, 2019, which account has been subsequently closed and therefor such requirements with respect to such account are therefore
waived (the &ldquo;<B>Existing Default</B>&rdquo;). Collateral Agent and Lenders hereby waive the Existing Default and strictly
the Existing Default.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">10.</TD><TD>To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral
Agent and Lenders as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are
true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties
relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default (other than the
Existing Defaults) has occurred and is continuing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan
Agreement, as amended by this Amendment;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"></P>

<!-- Field: Page; Sequence: 126; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent
deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended,
supplemented or restated and are and continue to be in full force and effect;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">d.</TD><TD>The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower,
(ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order, judgment or decree of any
court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational
documents of Borrower;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">e.</TD><TD>The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of,
or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof,
binding on Borrower, except as already has been obtained or made; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">f.</TD><TD>This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against
Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization,
liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&rsquo;
rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">11.</TD><TD>Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment.
This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations
or agreements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">12.</TD><TD>The Borrower hereby remises, releases, acquits, satisfies and forever discharges the Lenders and Collateral Agent, their agents,
employees, officers, directors, predecessors, attorneys and all others acting or purporting to act on behalf of or at the direction
of the Lenders and Collateral Agent <B>(&ldquo;Releasees</B>&rdquo;), of and from any and all manner of actions, causes of action,
suit, debts, accounts, covenants, contracts, controversies, agreements, variances, damages, judgments, claims and demands whatsoever,
in law or in equity, which any of such parties ever had, now has or, to the extent arising from or in connection with any act,
omission or state of facts taken or existing on or prior to the date hereof, may have after the date hereof, against the Releasees,
for, upon or by reason of any matter, cause or thing whatsoever relating to or arising out of the Loan Agreement or the other Loan
Documents on or prior to the date hereof through the date hereof. Without limiting the generality of the foregoing, the Borrower
waives and affirmatively agrees not to allege or otherwise pursue any defenses, affirmative defenses, counterclaims, claims, causes
of action, setoffs or other rights they do, shall or may have as of the date hereof, including the rights to contest: (a) the right
of Collateral Agent and each Lender to exercise its rights and remedies described in the Loan Documents; (b) any provision of this
Amendment or the Loan Documents; or (c) any conduct of the Lenders or other Releasees relating to or arising out of the Loan Agreement
or the other Loan Documents on or prior to the date hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">13.</TD><TD>This Amendment shall be deemed effective as of the date first set forth above upon the due execution and delivery to Collateral
Agent of this Amendment by each party hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">14.</TD><TD>This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which,
taken together, shall constitute one and the same instrument.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">15.</TD><TD>This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the
laws of the State of California.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"></P>

<!-- Field: Page; Sequence: 127; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>[<I>Balance of Page Intentionally
Left Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 128; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties
hereto have caused this Ninth Amendment to Loan and Security Agreement to be executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 3%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 35%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 62%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">ADYNXX, INC.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">/s/
    Rick Orr&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">Rick Orr</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">CEO</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>BORROWER:</B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">ADYNXX SUB, INC.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">/s/ Rick Orr</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">Rick Orr</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">CEO</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>COLLATERAL AGENT AND LENDER:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">OXFORD FINANCE LLC</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">/s/ Colette H. Featherly</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">Colette H. Featherly</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">Senior Vice-President</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 129 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amortization Table </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Term A Loan)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 130 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amortization Table </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Term B Loan)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I></I></P>

<!-- Field: Page; Sequence: 131 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I></I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TENTH AMENDMENT TO LOAN AND SECURITY
AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">THIS TENTH AMENDMENT to Loan and Security
Agreement (this &ldquo;<B>Amendment</B>&rdquo;) is entered into as of November 1, 2019, by and among OXFORD FINANCE LLC, a Delaware
limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (&ldquo;Oxford&rdquo;),
as collateral agent (in such capacity, &ldquo;<B>Collateral Agent</B>&rdquo;), the Lenders listed on Schedule 1.1 to the Loan Agreement
(as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a &ldquo;<B>Lender</B>&rdquo;
and collectively, the &ldquo;<B>Lenders</B>&rdquo;), and ADYNXX SUB, INC., a Delaware corporation with an office at 100 Pine Street,
#500, San Francisco, CA 94111 and ADYNXX, INC., a Delaware corporation with offices located at 100 Pine Street, #500, San Francisco,
CA 94111 (individually and collectively, jointly and severally, &ldquo;<B>Borrower</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, Collateral Agent, Borrower and
Lenders have entered into that certain Loan and Security Agreement, dated as of November 24, 2015 (as amended, supplemented or
otherwise modified from time to time, the &ldquo;<B>Loan Agreement</B>&rdquo;) pursuant to which Lenders have provided to Borrower
certain loans in accordance with the terms and conditions thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, Borrower, Lenders and Collateral
Agent desire to amend certain provisions of the Loan Agreement and the Disbursement Letters entered into pursuant to the Loan Agreement
as provided herein and subject to the terms and conditions set forth herein, and to waive certain Events of Default that have occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NOW, THEREFORE, in consideration of the
promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Section 2.2(b) of the Loan Agreement is hereby amended and restated in its entirety as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Repayment</U>.
Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of
each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately
preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest
payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. On each of
December 1, 2016 and January 1, 2017, in addition to making the aforementioned interest payments, Borrower shall also make (i)
a payment of $83,333.33 with respect to the Term A Loan, which shall be deemed to be a partial payment of the principal amount
of the Term A Loan, and (ii) a payment of $55,555.56 with respect to the Term B Loan, which shall be deemed to be a partial payment
of the principal amount of the Term B Loan. On each of January 1, 2018, February 1, 2018 and March 1, 2018, in addition to making
the aforementioned interest payments, Borrower shall also make (i) a payment of $123,188.41 with respect to the Term A Loan, which
shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment of $82,125.60 with respect
to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term B Loan. On September 1, 2018,
in addition to making the aforementioned interest payments, Borrower shall also make (i) a payment of $164,251.21 with respect
to the Term A Loan, which shall be deemed to be a partial payment of the principal amount of the Term A Loan, and (ii) a payment
of $109,500.81 with respect to the Term B Loan, which shall be deemed to be a partial payment of the principal amount of the Term
B Loan. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter until and including June
1, 2019, Borrower shall make consecutive monthly payments of equal amounts of principal, and the applicable interest, in arrears,
to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon:
(1) the amount of such Lender&rsquo;s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a
repayment schedule equal to eight (8) months. Commencing on July 1, 2019 and until Payment Date immediately preceding the 2019
Amortization Date, Borrower shall make monthly payments of interest only. Commencing on the 2019 Amortization Date and continuing
on the Payment Date of each month thereafter, Borrower shall make consecutive monthly payments of equal amounts of then outstanding
principal, and the applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall
be deemed correct absent manifest error) based upon: (1) the amount of such Lender&rsquo;s Term Loan, (2) the effective rate of
interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to five months. Notwithstanding the foregoing, the
interest payment otherwise due on November 1, 2019 shall instead be due and payable on November 8, 2019 and the principal payment
otherwise due on November 1, 2019 shall instead be due and payable on the Payment Date in December 2019 in addition to any other
payments due on such Payment Date. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and
payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 132 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Section 2.5 of the Loan Agreement is hereby amended by deleting the word &ldquo;and&rdquo; immediately following Section 2.5(j),
replacing &ldquo;.&rdquo; at the end of Section 2.5(k) with &ldquo;; and&rdquo; and adding Section 2.5(l) thereto as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tenth
Amendment Fee</U>. A fully earned and non-refundable tenth amendment fee in the amount of Thirty Thousand Dollars ($30,000.00),
which shall become due and payable upon the earlier of: (i) the Maturity Date, (ii) the acceleration of any Term Loan, or (iii)
the prepayment of a Term Loan pursuant to Section 2.2(c) or (d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>Limitation of Amendment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and
shall not be deemed to (a) be a consent to any amendment, waiver (except as set forth in Section 9 below) or modification of any
other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower
may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations,
warranties, covenants and agreements set forth in the Loan Documents, are hereby ratified and confirmed and shall remain in full
force and effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD>To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral
Agent and Lenders as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are
true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties
relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default (other than the
Existing Defaults) has occurred and is continuing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan
Agreement, as amended by this Amendment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent
deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended,
supplemented or restated and are and continue to be in full force and effect;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 133 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">d.</TD><TD>The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower,
(ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order, judgment or decree of any
court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational
documents of Borrower;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">e.</TD><TD>The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of,
or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof,
binding on Borrower, except as already has been obtained or made; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">f.</TD><TD>This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against
Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization,
liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&rsquo;
rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD>Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment.
This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations
or agreements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD>The Borrower hereby remises, releases, acquits, satisfies and forever discharges the Lenders and Collateral Agent, their agents,
employees, officers, directors, predecessors, attorneys and all others acting or purporting to act on behalf of or at the direction
of the Lenders and Collateral Agent <B>(&ldquo;Releasees</B>&rdquo;), of and from any and all manner of actions, causes of action,
suit, debts, accounts, covenants, contracts, controversies, agreements, variances, damages, judgments, claims and demands whatsoever,
in law or in equity, which any of such parties ever had, now has or, to the extent arising from or in connection with any act,
omission or state of facts taken or existing on or prior to the date hereof, may have after the date hereof, against the Releasees,
for, upon or by reason of any matter, cause or thing whatsoever relating to or arising out of the Loan Agreement or the other Loan
Documents on or prior to the date hereof through the date hereof. Without limiting the generality of the foregoing, the Borrower
waives and affirmatively agrees not to allege or otherwise pursue any defenses, affirmative defenses, counterclaims, claims, causes
of action, setoffs or other rights they do, shall or may have as of the date hereof, including the rights to contest: (a) the right
of Collateral Agent and each Lender to exercise its rights and remedies described in the Loan Documents; (b) any provision of this
Amendment or the Loan Documents; or (c) any conduct of the Lenders or other Releasees relating to or arising out of the Loan Agreement
or the other Loan Documents on or prior to the date hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">8.</TD><TD>This Amendment shall be deemed effective as of the date first set forth above upon the due execution and delivery to Collateral
Agent of this Amendment by each party hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">9.</TD><TD>This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which,
taken together, shall constitute one and the same instrument.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">10.</TD><TD>This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the
laws of the State of California.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[<I>Balance of Page Intentionally Left
Blank</I>]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 134 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties
hereto have caused this Tenth Amendment to Loan and Security Agreement to be executed as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold">BORROWER:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">ADYNXX, INC. </TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%; font-size: 10pt">By:</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid; width: 42%">/s/Rick Orr&#9;</TD>
    <TD STYLE="width: 55%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">Name: Rick Orr</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">Title:&nbsp;&nbsp;&nbsp;CEO</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold">BORROWER:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">ADYNXX SUB, INC.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">By:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">/s/Rick Orr</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">Name: Rick Orr</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">Title: CEO</TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: left">COLLATERAL AGENT AND LENDER:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 42%">&nbsp;</TD>
    <TD STYLE="width: 55%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">OXFORD FINANCE LLC</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">By:</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">/s/Colette H. Featherly&#9;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; white-space: nowrap">Name:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Colette H. Featherly&#9;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Title:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">Senior Vice President&#9;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font-size: 10pt">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Page; Sequence: 135; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>tv531005_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-size: 10pt; color: Black"><B>Exhibit 23.1</B></FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; color: fuchsia"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; color: fuchsia"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in; color: fuchsia"><FONT STYLE="font-size: 10pt; color: Black"><U>Consent
of Independent Registered Public Accounting Firm</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: fuchsia"><FONT STYLE="font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="font-size: 10pt; color: Black">Adynxx,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="font-size: 10pt; color: Black">San
Francisco, California</FONT></P>

<P STYLE="color: fuchsia; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="color: fuchsia; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: Black">We
hereby consent to the use in the Prospectus constituting a part of this Registration Statement on Form S-1 (Amendment No. 4) of
our report dated June 7, 2019, relating to the financial statements of Adynxx, Inc., which is contained in that Prospectus. Our
report contains an explanatory paragraph regarding the Company&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also consent to the reference to us
under the caption &ldquo;Experts&rdquo; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>/s/ BDO USA, LLP&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BDO USA, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">San Jose, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 8, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>6
<FILENAME>tv531005_ex10-34.htm
<DESCRIPTION>EXHIBIT 10.34
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.34</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><B>SECURITIES
PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of [_____, 2019 between Adynxx, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to
the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act
of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), the Company desires to issue and sell to each Purchaser, and each
Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 promulgated under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Class
A Units</U>&rdquo; means each Class A unit consisting of (a) one Share, and (b) one Purchase Warrant to purchase [___ Purchase
Warrant Share(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Class
A Unit Purchase Price</U>&rdquo; equals $[_____ per each Class A Unit, subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Class
B Units</U>&rdquo; means each Class B unit consisting of (a) one Pre-Funded Warrant to initially purchase one Pre-Funded Warrant
Share, and (b) a Purchase Warrant to purchase [___ Purchase Warrant Share(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Class
B Unit Purchase Price</U>&rdquo; equals $[____ per each Class B Unit, subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii)
the Company&rsquo;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than
the second (2<SUP>nd</SUP>) Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Cooley&nbsp;LLP, with offices located at 3175 Hanover Street, Palo Alto, California 94304.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time)
and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following
the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed
between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York
City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock, options or other equity awards to employees, officers or
directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by the Board of Directors, including
a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors
established for such purpose for services rendered to the Company, (b) shares of Common Stock or options to purchase shares of
Common Stock to consultants, provided that such shares of Common Stock or options are issued as &ldquo;restricted securities&rdquo;
(as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith during the prohibition period in Section 4.10(a) herein, (c) securities upon the exercise or exchange of or conversion
of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common
Stock issued and outstanding on the date of this Agreement, including convertible notes held by entities affiliated with Domain
Associates, provided that such securities have not been amended since the date of this Agreement to increase the number of such
securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with
stock splits or combinations) or to extend the term of such securities), (d) securities issued by the Company or any subsidiary
thereof pursuant to acquisitions or strategic transactions or spin offs approved by the Board of Directors, including a majority
of the disinterested directors of the Company, provided that such securities are either (i) issued as &ldquo;restricted securities&rdquo;
(as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith during the prohibition period in Section 4.10(a) herein, or (ii) are subject to a lock-up agreement in favor of the Placement
Agent that prohibits any transfers or sales of such securities during the restricted period set forth in Section 4.10(a) herein;
and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through
its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall
provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which
the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities, and (e) the Units to be issued and sold hereunder, including the shares of Common Stock, Pre-Funded Warrants, and
Purchase Warrants issued to other purchasers pursuant to the Prospectus concurrently with the Closing at the applicable Class A
Unit Purchase Price or Class B Unit Purchase Price, less such aggregate dollar amount of Units sold pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo; shall
have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Haynes
and Boone</U>&rdquo; means Haynes and Boone, LLP, with offices located at&nbsp;30 Rockefeller Plaza, 26th Floor, New York, NY 10112.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(z).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction (other
than restrictions on transfer under securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright &amp; Co., LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing
in accordance with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and shall expire when exercised
in full, in the form of <U>Exhibit A-2</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Preliminary
Prospectus</U>&rdquo; means any preliminary prospectus included in the Registration Statement, as originally filed or as part of
any amendment thereto, or filed with the Commission pursuant to Rule 424(a) of the rules and regulations of the Commission under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pricing
Prospectus</U>&rdquo; means (i) the Preliminary Prospectus relating to the Securities that was included in the Registration Statement
immediately prior to [&#9679;] (Eastern time) on the date hereof and (ii) any free writing prospectus (as defined in the Securities
Act) identified on Schedule B hereto, taken together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), that has been commenced or to the Company&rsquo;s knowledge threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed with the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase
Warrants</U>&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Warrants shall be exercisable immediately and have a term equal to five (5) years, in the form
of <U>Exhibit A-1</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Purchase Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement on Form S-1 filed with Commission (File No. 333-232169), as amended
from time to time, which registers the sale of the Units, the Shares, the Warrants and the Warrant Shares to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Minimum</U>&rdquo; means, as of any date, the maximum aggregate number of shares of Common Stock then issued or potentially issuable
in the future pursuant to the Transaction Documents, including any Warrant Shares issuable upon exercise in full of all Warrants,
ignoring any exercise limits set forth therein<FONT STYLE="text-underline-style: double; color: blue"><U>.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Units, the Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to certain Purchasers on the Closing Date pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for the Class A Units and/or Class B Units as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any significant subsidiary of the Company as defined under Regulation S-X of the Securities Act, and shall, where applicable,
also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof but before the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement and the Warrants, all exhibits and schedules thereto and hereto and any other documents
or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Action Stock Transfer Corporation, the current transfer agent of the Company, with a mailing address of
2469 E. Fort Union Blvd, Suite 214, Salt Lake City, Utah 84121, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Units</U>&rdquo;
means, collectively, the Class A Units and the Class B Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.10(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Purchase Warrants and the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means, collectively, the Purchase Warrant Shares and the Pre-Funded Warrant Shares issuable upon exercise of
the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers,
severally and not jointly, agree to purchase, up to an aggregate of $[_______ of Class A Units as determined pursuant to Section
2.2(a); <U>provided</U>, <U>howeve</U>r, that, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser
(together with such Purchaser&rsquo;s Affiliates, and any Person acting as a group together with such purchaser or any of such
Holder&rsquo;s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation, or as such Purchaser may otherwise
choose, in lieu of purchasing Class A Units such Purchaser may elect to purchase Class B Units at the Class B Unit Purchase Price
in lieu of Class A Units in such manner to result in the same aggregate purchase price being paid by such Purchaser to the Company.
The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, at the election of the Purchaser, 9.99%) of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Securities on the Closing Date.
<FONT STYLE="color: windowtext">Each Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by
such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company. The </FONT>Company
shall deliver to each Purchaser its respective Shares or Pre-Funded Warrants (as applicable to such Purchaser) and Warrants, as
determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2
deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall
occur at the offices of Haynes and Boone or such other location as the parties shall mutually agree. Each Purchaser acknowledges
that, concurrently with the Closing and pursuant to the Prospectus, the Company may sell up to $[______ of additional Units to
purchasers not party to this Purchase Agreement, less such aggregate dollar amount of Units sold pursuant to this Agreement and
will issue to each such purchaser such additional shares of Common Stock and Purchase Warrants or Pre-Funded Warrants and Purchase
Warrants in the same form and at the same Class A Unit Purchase Price or Class B Unit Purchase Price, as issued to a Purchaser
hereunder. The Company covenants that, if the Purchaser delivers a Notice of Exercise (as defined in the Pre-Funded Warrant) no
later than 12:00 p.m. (New York City time) on the Closing Date to exercise any Pre-Funded Warrants between the date hereof and
the Closing Date, the Company shall deliver Pre-Funded Warrant Shares to the Purchaser on the Closing Date in connection with such
Notice of Exercise. Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via &ldquo;Delivery
Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing Date, the Company shall issue the Shares registered in the
Purchasers&rsquo; names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified
by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable
Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
legal opinion of Company Counsel, substantially in the form of <U>Exhibit C</U> attached hereto addressed to the Purchasers and
the Placement Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject
to the last sentence of Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions,
on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject
to the last sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent
to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
Shares equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to Class A Units divided by the Class A Unit
Purchase Price, registered in the name of such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
each Purchaser of Class B Units, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares
of Common Stock equal to the number of Pre-Funded Warrants set forth on such Purchaser&rsquo;s signature page hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
Purchase Warrant registered in the name of each such Purchaser to purchase up to a number of shares of Common Stock equal to 100%
of the aggregate number of Shares and the Pre-Funded Warrant Shares underlying the Pre-Funded Warrants initially issuable on the
date hereof, if any, purchased by such Purchaser with an exercise price equal to $[___, subject to adjustment therein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Preliminary Prospectus and the Prospectus (which may be delivered in accordance with Rule 172 promulgated under the Securities
Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
Purchaser&rsquo;s Subscription Amount with regard to the Pre-Funded Warrants purchased by such Purchaser, if any, as set forth
on such Purchaser&rsquo;s signature page hereto next to the heading &ldquo;Class B Units Subscription Amount&rdquo; by wire transfer
to the account specified by the Company in Section 2.2(a)(iii) above, or as otherwise agreed by the Company and the Placement Agent;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
Purchaser&rsquo;s Subscription Amount with regard to the Shares purchased by such Purchaser, which shall be made available for
 &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg
L.P. shall not have been suspended or limited, or minimum prices shall not have been established generally on securities whose
trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the
United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or
other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market
which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities
at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed
a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding
section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All of the direct and indirect Subsidiaries of the Company are set forth on Exhibit 21.1 to the Registration Statement. The Company
owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens
except as otherwise disclosed on <U>Schedule 3.1(a)</U>, and all of the issued and outstanding shares of capital stock of each
Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or
purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite corporate
power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, would not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity
or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business or
condition (financial or otherwise) of the Company and the Subsidiaries (whether or not &ldquo;significant&rdquo;), taken as a whole,
or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations
under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding has
been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and
authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by
it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company
and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith
or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which
it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the
terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance
with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) subject to obtaining the Required Approvals,
conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result
in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights
of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of
time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise)
or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any
Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law,
rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the
Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset
of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as would not have
or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)
the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus and any amendment
to the Registration Statement permitted by Rule 462(b) promulgated under the Securities Act, (iii) such filings as are required
to be made under applicable state securities laws, (iv) such filings as may required by the laws and rules of the Financial Industry
Regulatory Authority (&ldquo;<U>FINRA</U>&rdquo;), (v) such other consents, waivers and authorizations that shall be obtained prior
to Closing and (v) in all other cases, where failure to obtain such consent, waiver, authorization or order, or to give such notice
or make such filing or registration would not have a Material Adverse Effect (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and the Shares and the Warrants, when issued and paid for
in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and
clear of all Liens imposed by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be
validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from
its duly authorized capital stock the maximum number of shares of Common Stock for issuance of the Warrant Shares at least equal
to the Required Minimum on the date hereof. The Company has prepared and filed the Registration Statement in conformity in all
material respects with the requirements of the Securities Act, which became effective on [______], 2019 (the &ldquo;<U>Effective
Date</U>&rdquo;), including the Prospectus, and such amendments and supplements thereto as may have been required to the date of
this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the
effectiveness of the Registration Statement or suspending or preventing the use of the Preliminary Prospectus or the Prospectus
has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company,
are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, shall file the Prospectus,
with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective,
at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will
conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading; and the Preliminary Prospectus and the Prospectus and any amendments or supplements thereto, at the time the Preliminary
Prospectus or the Prospectus, as applicable, or any amendment or supplement thereto was issued and at the Closing Date, conformed
and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
As of the date hereof, the Company had 95,000,000 shares of Common Stock, par value $0.001 per share, authorized, of which 5,807,877
shares were issued and outstanding, and 1,000,000 shares of Preferred Stock, par value $0.001 per share, authorized, of which no
shares were issued and outstanding.&nbsp; The Company has not issued any capital stock since its most recently filed periodic or
current report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company&rsquo;s
stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase
plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently
filed periodic report under the Exchange Act. Other than the Placement Agent, no Person has any Company-granted right of first
refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the
Transaction Documents. Except (i) as a result of the purchase and sale of the Securities, (ii) 747,879 shares issuable upon exercise
of outstanding stock options, (iii) 3,332 shares issuable upon the vesting of outstanding restricted stock awards, (iv) 57,897
shares issuable upon the exercise of outstanding warrants, and (v) 81,624 shares reserved for future issuance pursuant to the Company&rsquo;s
equity incentive plans, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any
Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares
of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not
obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers).
Except as disclosed on <U>Schedule 3.1(g)</U>, there are no outstanding securities or instruments of the Company or any Subsidiary
with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance
of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary
that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which
the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not
have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of
the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have
been issued in compliance in all material respects with all federal and state or foreign securities laws, and none of such outstanding
shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities granted by the
Company. No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance
and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to
the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of
the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
since May 3, 2019 (the foregoing materials, including the exhibits thereto, together with the Pricing Prospectus and the Prospectus,
being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective
dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable,
and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) promulgated under the Securities Act.
The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting
requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial
statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent
basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements
or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly
present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates
thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements,
to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports or except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development
that has had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any
liabilities (contingent or otherwise), which is material to the Company and the Subsidiaries taken as a whole, other than (A) trade
payables and accrued expenses and immaterial liabilities incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered, in any material respects, its method of accounting, (iv) the Company
has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made
any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any shares of capital stock
to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending
before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated
by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists with respect to the
Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that
would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed
made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding or investigation
pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective
properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county,
local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;), which (i) adversely affects or challenges the legality, validity
or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have
or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor, to the Company&rsquo;s
knowledge (other than knowledge of such director or officer), any director or officer thereof, is or has been the subject of any
Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission
involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order
or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange
Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of
the Company, which would reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or
any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of
its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance
with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and
conditions of employment and wages and hours, except where the failure to be in compliance would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the
Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is
bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any
court, arbitrator or other governmental authority or (iii) to the knowledge of the Company is or has been in violation of any statute,
rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local
laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and
labor matters, except in each case as would not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;<U>Environmental
Laws</U>.&nbsp;&nbsp;&nbsp;The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to
pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or
subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants,
contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment,
or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses,
notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental
Laws</U>&rdquo;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws
to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or
approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually
or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation
or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all tangible personal property owned by them that is material to the business of the Company and
the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such
property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries,
(ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance
with GAAP and, the payment of which is neither delinquent nor subject to penalties, and (iii) Liens that would not reasonably be
expected to result in a Material Adverse Effect. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance except
as would not reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>. Except as set forth on <U>Schedule 3.1(p)</U>, the Company and the Subsidiaries have, or have rights to use, all
patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights,
licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective
businesses as described in the SEC Reports and which the failure to so have would reasonably be expected to result in a Material
Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither the Company nor any
Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or
been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement that
would reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary has received, since
the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has
any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as would not reasonably
be expected to have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable
and there is no existing infringement by another Person of any of the Intellectual Property Rights that would reasonably be expected
to have a Material Adverse Effect. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties, except where failure to do so would not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage at least equal to the aggregate gross proceeds of the offering pursuant
to the Registration Statement and Prospectus. Neither the Company nor any Subsidiary has any reason to believe that it will not
be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers
as may be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
With Affiliates and Employees</U>. None of the officers or directors of the Company or any Subsidiary and, to the knowledge of
the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or
any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement
providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for
the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee
or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest
or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii)
other employee benefits, including stock option agreements under any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance in all material respects with any and all
applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable
rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date.
The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that:
(i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii)
access to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect
to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to
ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s
certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries
as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation
Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the
certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation
Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined
in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect,
the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Fees</U>. Except as set forth in the Pricing Prospectus or the Prospectus, no brokerage or finder&rsquo;s fees or commissions are
or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. To the Company&rsquo;s
knowledge, the Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf
of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated
by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company</U>. Neither the Company nor any of its Subsidiaries is, nor will be immediately after receipt of payment for the Securities
, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct
its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration under the Investment
Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. Except as set forth on <U>Schedule 3.1(v)</U>, no Person has any right to cause the Company or any Subsidiary to effect
the registration under the Securities Act of any securities of the Company or any Subsidiary in any manner that would limit the
rights of the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth on <U>Schedule 3.1(w)</U>, the Company has not, in the 12 months preceding the date hereof,
received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company
is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to
believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.
The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing
corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing
corporation) in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and
the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation
as a result of the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed
in the Pricing Prospectus or the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing
representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company
to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby,
including the Disclosure Schedules to this Agreement, taken as a whole does not contain any untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under
which they were made, not misleading. The press releases disseminated by the Company since May 3, 2019 taken as a whole do not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in
order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading.
The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions
of any Trading Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa)&nbsp;&nbsp;&nbsp;<U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry
on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate
all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in
respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability
to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).
The Company&rsquo;s liquidity requirements and financial condition,
the Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization
or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. Except as
set forth on <U>Schedule 3.1(aa)</U>, the Company and its Subsidiaries have no other outstanding secured and unsecured Indebtedness,
or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo;
means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in
the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto),
except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course
of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in
accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb)&nbsp;&nbsp;&nbsp;<U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject,
(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of
all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid
taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or
of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc)&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent
or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns
from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person
acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any
provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd)&nbsp;&nbsp;&nbsp;<U>Accountants</U>.
The Company&rsquo;s independent registered public accounting firm is BDO USA, LLP. To the knowledge and belief of the Company,
such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion
with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending December
31, 2019.&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee)&nbsp;&nbsp;&nbsp;</U></FONT><U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting
solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in
any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given
by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to
each Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents has been based
solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff)&nbsp;&nbsp;&nbsp;Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except
for Sections 3.2(f) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been
asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities
of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the </U></FONT>Securities
for any specified term; (ii) past or future open market or other transactions
by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after
the closing of this or future private placement transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded
securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a
party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall
not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo;
transaction. </U></FONT>The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging
activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods
that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities
(if any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the hedging
activities are being conducted.&nbsp; The Company acknowledges that such aforementioned hedging activities do not constitute a
breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg)&nbsp;&nbsp;&nbsp;<U>Regulation
M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases
of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any
other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&rsquo;s placement
agent in connection with the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh)&nbsp;&nbsp;&nbsp;<U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the
failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge,
threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint,
or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received
any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket
clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing
of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall,
suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any
Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries,
(iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent
decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws,
rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have
a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material
respects in accordance with all applicable laws, rules and regulations of the FDA.&nbsp; The Company has not been informed by the
FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed,
produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product
being developed or proposed to be developed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Research
Studies and Trials</U>. The research studies and trials conducted by or on behalf of, or sponsored by, the Company or its Subsidiaries,
or in which the Company or its Subsidiaries has participated, that are described in the Pricing Prospectus or the Prospectus, or
the results of which are referred to in the Pricing Prospectus or the Prospectus, as applicable, were and, if still pending, are
being, conducted in all material respects in accordance with applicable experimental protocols, procedures and controls pursuant
to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being
developed by the Company or its Subsidiaries and all applicable statutes, rules and regulations of the FDA and other comparable
drug and medical device regulatory agencies to which they are subject; the descriptions of the results of such studies and trials
contained in the Pricing Prospectus or the Prospectus do not contain any misstatement of a material fact or omit to state a material
fact necessary to make such statements not misleading; neither the Company nor any Subsidiary has knowledge of any research studies
or trials not described in the Pricing Prospectus or the Prospectus the results of which reasonably call into question in any material
respect the results of the research studies and trials described in the Pricing Prospectus or the Prospectus; and neither the Company
nor any Subsidiary has received any written notices or correspondence from the FDA or any other foreign, state or local governmental
body exercising comparable authority or any institutional review board or comparable authority requiring or threatening the premature
termination, suspension, material modification or clinical hold of any research studies or trials conducted by or on behalf of,
or sponsored by, the Company or any Subsidiary or in which the Company or any Subsidiary has participated that are described in
the Pricing Prospectus or the Prospectus, and, to the Company&rsquo;s knowledge, there are no reasonable grounds for the same.
There has not been any violation of applicable law or regulation by the Company in its product development efforts, submissions
or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement
action, except where such violation would not, singly or in the aggregate, result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj)&nbsp;&nbsp;&nbsp;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk)&nbsp;&nbsp;&nbsp;<U>U.S.
Real Property Holding Corporation</U>. The Company is not, and since May 3, 2019 has not been, a U.S. real property holding corporation
within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll)&nbsp;&nbsp;&nbsp;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act
of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
 &ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly
or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or
more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm)&nbsp;&nbsp;&nbsp;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money
Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of
the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(nn)&nbsp;&nbsp;&nbsp;<U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plans was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value
of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has
been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock
options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their
financial results or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they
shall be accurate as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out his, her or its obligations hereunder and thereunder. The execution and delivery of the Transaction
Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized
by all necessary corporate, partnership, limited liability company or similar corporate or shareholder action, as applicable, on
the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when
delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such
Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo;
rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for his, her or its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities
(this representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration
Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities
hereunder in the ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on
which it exercises any Warrants, it will be either: (i) an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2),
(a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a &ldquo;qualified institutional buyer&rdquo; as defined in Rule 144A(a)
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with his, her or its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it
has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the
offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company
and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate
its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without
unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&nbsp;
Such Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such
Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.&nbsp;
Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities
and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser
agrees need not be provided to it.&nbsp; In connection with the issuance of the Securities to such Purchaser, neither the Placement
Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not,
nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that
such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting
forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall
only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase
the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives,
including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such
Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence
and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales
or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acknowledges and agrees that
the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on the
Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties contained in any
other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the
consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in
order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Shares</U>. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover
the issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise on a date that is at least six
months following the Closing Date, the Warrant Shares issued pursuant to any such exercise shall be issued free of all legends.
If at any time following the date hereof the Registration Statement (or any subsequent registration statement registering the sale
or resale of the Warrant Shares) is not effective or is not otherwise available for the sale or resale of the Warrant Shares, the
Company shall immediately notify the holders of the Warrants in writing that such registration statement is not then effective
and thereafter shall promptly notify such holders when the registration statement is effective again and available for the sale
or resale of the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to
issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and state securities laws). The
Company shall use best efforts to keep a registration statement (including the Registration Statement) registering the issuance
or resale of the Warrant Shares effective during the term of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Furnishing
of Information</U>. Until the earlier of the time that (i) no Purchaser owns Securities and (ii) the Warrants have expired, the
Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to Section 12 of the Exchange Act even if the Company is not
then subject to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules
and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms
of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act; provided, that the Company shall not be required to
file a Current Report on Form 8-K if the Transaction Documents have been previously filed with the Commission as exhibits to a
pre-effective or post-effective amendment to the Registration Statement. From and after the issuance of such press release, the
Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any
of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents.
In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality
or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their
respective officers, directors, agents, employees or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates
on the other hand, shall terminate. The Company and each Purchaser shall consult with each other in issuing any other press releases
with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release
nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any
Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall
not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall
promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the
Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission
or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal
securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure
is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such
disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably
believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt
of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that
each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent
that the Company delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company
hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries,
or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries
or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public
information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant
to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. Except as set forth on <U>Schedule 4.6</U>, the Company shall use the net proceeds from the sale of the Securities
hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s
debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices), (b) for
the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in
violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.7, the Company will indemnify and hold each Purchaser and his, her
or its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser
Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or
agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the
Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not
an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless
such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations, warranties or covenants under
the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations
by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially
determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party
in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company
in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the
extent that (x) the employment thereof has been specifically authorized by the Company in writing, (y) the Company has failed after
a reasonable period of time to assume such defense and to employ counsel or (z) in such action there is, in the reasonable opinion
of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party,
in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel for
all Purchaser Parties. The Company will not be liable to any Purchaser Party under this Agreement (1) for any settlement by a Purchaser
Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (2) to
the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach
of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other
Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof
during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained
herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any
liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on
the Trading Market on which it is currently listed. The Company further agrees, if the Company applies to have the Common Stock
traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take
such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market
as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its
Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations
under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic
transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely
payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until 90 days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any agreement
to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until such time as no Purchaser holds any of the Warrants, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents
(or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means
a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or
exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price
or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common
Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange
price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the
occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the
Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line
of credit, whereby the Company may issue securities at a future determined price. Any Purchaser shall be entitled to obtain injunctive
relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, this Section 4.10 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall
be an exempt issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any Person
to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered
to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each
Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as
a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition
or voting of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending
at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4.<FONT STYLE="color: windowtext">&nbsp; </FONT>Each Purchaser, severally and not jointly with the other
Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company
pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence
and terms of this transaction.&nbsp; N<FONT STYLE="color: windowtext">otwithstanding the foregoing, and notwithstanding anything
contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation,
warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that
the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company
in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are
first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any
duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance
of the initial press release as described in Section 4.4.&nbsp; </FONT>Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing
other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capital
Changes</U>. Until the six-month anniversary of the Closing Date, the Company shall not undertake a reverse or forward stock split
or reclassification of the Common Stock without the prior written consent of the Purchasers holding a majority in interest of the
Shares and Pre-Funded Warrant Shares, except to the extent required to enable the Company to comply (i) with required listing standards
of the Company&rsquo;s Trading Market or (ii) with the initial listing requirements promulgated from time to time by another Trading
Market as determined in good faith by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Procedures</U>. The <FONT STYLE="color: windowtext">form of Notice of Exercise included in the Warrants set forth the totality
of the procedures (other than the payment of the Exercise Price, if applicable, under the Warrants) required of the Purchasers
in order to exercise the Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order
to exercise the Warrants<FONT STYLE="text-underline-style: double">. No additional legal opinion, other information or instructions
shall be required of the Purchasers to exercise their Warrants unless required by the Company&rsquo;s transfer agent</FONT>. The
Company shall honor exercises of the Warrants <FONT STYLE="text-underline-style: double">and </FONT>shall deliver <FONT STYLE="text-underline-style: double">Warrant</FONT>
Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: windowtext"><U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
Purchaser is an &ldquo;Acquiring Person&rdquo; under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities
under the Transaction Documents or under any other agreement between the Company and the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.&nbsp;
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing
has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent
fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company
and any exercise notice delivered by a Purchaser), stamp taxes and other similar taxes and duties levied in connection with the
delivery of any Securities to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto and the Pricing Prospectus and the Prospectus,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered
via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto
at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth
on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading
Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight
courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices
and communications shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant
to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Securities based on
the initial Subscription Amounts hereunder or, in the case of a waiver, by the party against whom enforcement of any such waived
provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser
(or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required.
No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser
relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely
affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder
of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to
whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of
the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor
may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.7 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action
or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding
is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under
Section 4.7, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action
or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo;
signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser
may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand
or election in whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such
rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for
such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant
(including, issuance of a replacement warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or
in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction and a customary indemnity (which shall not include a posting of any bond). The
applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including
customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation
the defense that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each
Purchaser and its respective counsel have chosen to communicate with the Company through Haynes and Boone. Haynes and Boone does
not represent any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers
with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to
do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each
other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively
and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.18&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc.</U>&nbsp;&nbsp;&nbsp;If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after
the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other
amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages
or other amounts are due and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>WAIVER
OF JURY TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY UNDER THIS
AGREEMENT, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY,
UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Adynxx, Inc.</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 38%; font-size: 10pt; layout-grid-mode: line"><U>Address for Notice:</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:__________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With a copy to (which shall not constitute notice):</P></TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="font-size: 10pt; layout-grid-mode: line">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">ADYX
</FONT>SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Purchaser: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of
Purchaser</I>: _________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address of Authorized Signatory:_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Facsimile Number of Authorized Signatory: __________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DWAC for Shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Warrants to Purchaser (if not same as
address for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount Total: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Class A Units Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Class B Units Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Class A Units: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Warrant Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Class B Units: _______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pre-Funded Warrants:_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Warrant Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: ____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">o</FONT>
Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed
to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations
of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded,
(ii) the Closing shall occur by the second (2<SUP>nd</SUP>) Trading Day following the date of this Agreement and (iii) any condition
to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company
or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be
a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such
agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 39; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>lg_adynxx.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_adynxx.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  E@    $  0"6     0 !_^%%SFAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XV+6,Q-#4@-SDN
M,38S-#DY+" R,#$X+S X+S$S+3$V.C0P.C(R(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O
M8F4N8V]M+W1I9F8O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX
M;7!'26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(@H@
M(" @(" @(" @("!X;6QN<SIE>&EF/2)H='1P.B\O;G,N861O8F4N8V]M+V5X
M:68O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @
M>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B
M"B @(" @(" @(" @('AM;&YS.G-T369S/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O36%N:69E<W1)=&5M(R(^"B @(" @(" @(#QT:69F
M.DEM86=E5VED=&@^,S@R/"]T:69F.DEM86=E5VED=&@^"B @(" @(" @(#QT
M:69F.DEM86=E3&5N9W1H/C$P,#PO=&EF9CI);6%G94QE;F=T:#X*(" @(" @
M(" @/'1I9F8Z4&AO=&]M971R:6-);G1E<G!R971A=&EO;CXU/"]T:69F.E!H
M;W1O;65T<FEC26YT97)P<F5T871I;VX^"B @(" @(" @(#QT:69F.E-A;7!L
M97-097)0:7AE;#XT/"]T:69F.E-A;7!L97-097)0:7AE;#X*(" @(" @(" @
M/'1I9F8Z6%)E<V]L=71I;VX^,S P,# P,"\Q,# P,#PO=&EF9CI84F5S;VQU
M=&EO;CX*(" @(" @(" @/'1I9F8Z65)E<V]L=71I;VX^,S P,# P,"\Q,# P
M,#PO=&EF9CI94F5S;VQU=&EO;CX*(" @(" @(" @/'1I9F8Z4F5S;VQU=&EO
M;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*(" @(" @(" @/'1I9F8Z
M0V]M<')E<W-I;VX^-CPO=&EF9CI#;VUP<F5S<VEO;CX*(" @(" @(" @/'1I
M9F8Z2E!%1TEN=&5R8VAA;F=E1F]R;6%T/C,X-CPO=&EF9CI*4$5'26YT97)C
M:&%N9V5&;W)M870^"B @(" @(" @(#QT:69F.DI014=);G1E<F-H86YG949O
M<FUA=$QE;F=T:#XR-S$W/"]T:69F.DI014=);G1E<F-H86YG949O<FUA=$QE
M;F=T:#X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R
M871O<B!#0R R,RXP("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @
M(" @(" \>&UP.DUO9&EF>41A=&4^,C Q.2TP-BTP-U0Q,3HQ,SHU,%H\+WAM
M<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q.2TP
M-BTP-U0Q-CHT,SHT."LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,3DM,#8M,#=4,38Z-#,Z-#@K,#4Z,S \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*
M(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @
M(" @(" @(#QX;7!'26UG.FAE:6=H=#XV-#PO>&UP1TEM9SIH96EG:'0^"B @
M(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG
M.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ
M+S1!05%3:UI*4F=!0D%G14),045S04%$+S=107-51VAV9$<Y>F%'.7=)1$UU
M34%!-%%K;$Y!*S!!04%!04%"04),04%!04%%028C>$$[05%%<T%!04%!44%"
M+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="
M45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$
M0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H
M55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%1045!07=%
M4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%1
M1D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!
M0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&
M25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y
M9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH
M2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H
M<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#
M:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!
M24-!44E$0E%514)1645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%
M>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-0
M4TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0
M>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP
M=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y
M531Q-T9867$W1EA9<3=&6%EQ-R8C>$$[1EAM2#5S6&PS1G%T;$A&3DI(2#9"
M8F=R36]Q6$ER44@R>F5D;%%"9U-2,658-V5Y4T4T9T5J6FE7:5@Q-F1:,#A'
M-&Q)*W-W+W1T+R8C>$$[=GAF9DYH;6A(9VQS3U)D4'!S,"]&:#9J.5$V*V(S
M>D]49E%(67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6"8C>$$[67$W1EA9<3=&6%EQ-T960SEV<D]X9V$T=35K9VA8<3=M9WE525-K
M84%S<TUM5TU"8VI1635C9FUB-5-I5W-D>$IC2"M73TIX+W=!5"8C>$$[0T1-
M,E!:=5DX>%AX9%I,='941&MB*T)16"]+,B],+R]!0WDS6"]!>"]W1$YE5R]Y
M5FLW>"M09S!F>2]H-W!F6BMT34Y$+TU04DY9,28C>$$[0T]W:%-A1V57=G!E
M<7$P67%P66EQ<S%.9V5U534K>C4T-#A2;VAY9$PR=FEZ5$5"64HW,E0U9W4P
M5U1Z=W=24$Y--GAX24]4=7AO028C>$$[0C1K-%EX2DY":DM1:4Q/=UDU8R]M
M4#52:#5"8G=Z3VQ2=VII:TY34$)I;U@X8WI9.6Y::C!R-'5T;C)Z<&\O>%@W
M9UAN9FYV>DI9-B8C>$$[.7%%13EM:VEX=WAE;69504)*-44W54HX8S(K:# X
M<U532F18;D\Q9&)$4$U'3C="2G1%3DYA,"\O;4MG+W=#5&DU:S5V;VPW:CEZ
M:"8C>$$[86(K.6@O5VHY-S$O>D8U-S!R47(Y8D<V:&YK;&%*6F554W)X;WI-
M;TAX378X=6,Y<#E$4$Q(:4)$,D]S-U9X-$HX16=3879B*S%"5R8C>$$[6#5P
M*UAB;39J9V%/93-%:#0K=$MQ8T90879&;4\U,C9:6E!S>DI%6'-7;D8R-6AL
M25)Q479V<CEB36,Q>G55:CAY96-.2SAV;49,<R8C>$$[4U-45#%+4E)!1G5)
M-G-E4E55<G0Q>DLP,FMN;'5U46-(5SEO63E06$9D;G5385 X,DY!95)5*W$S
M435-1G)X:E!5,#=06$UK.6Q:2R8C>$$[-6AW4C(Y:$IQ<&9:*W1/9DUF;2]4
M3D%3,6$W4U=1,V9)>$I';W)23U!);FM6<#ES6FIA9E-3>3-68D]B<D\P365N
M<FEV,60S;"]A;"8C>$$[1G8X06UT-65M;FII349Z1TI'0S@R5D-"53 S-'54
M.7=Z26PR6&M!=7<T:T\S8TUI0E5H9C0W,#(Q8GIT-6(P<5IR935U<3-+:7!H
M:B8C>$$[4FYB-45G8U%F66Y-9D9O<W515T)S-65O-U1W66IW>6PV=35",FXU
M;"M5-39#4S1E,EEM9T5S8B]!2#%536\K:S5B4',S34]L=$]0="8C>$$[<E1Y
M-6UV94-Y5G)M0F)C,TA0;$-&-3@Q<7=+*TDT,7(Y1UE1:6)R<3=->D98,%-:
M=D\S;#!(831::#1I3C9F:4)M4BM4>61Z:69Y:"8C>$$[:#<O<TM,<V9-;6DS
M,&]I=')K3DME:4U'46XU8V=++U)L8SE03TES:'1X-G9(33!$=6U75751;UAL
M.6%754IM=7!6:6HX5S<O04-!,R8C>$$[3U)N35)&;'-X-'!43E)&;$Q0.$%'
M6&QZ;%0V,U-U,51(24(Y-5A+9GI74'9C<BM48R\X04XK,$IH96%N65=D<W0Q
M8WI"24AO169D<28C>$$[.&A5531G:S=:8DQ*1TES;EIX.&5#8S5C35)U;#8K
M8W9,>$Y$8VQF06U/4V@O=T-&>7(X,6HW,TI06FUF=2LP2G9"8U$S15-Z44]*
M228C>$$[;BMY-FUO4&),-'E"1FAW<'=-5%)&1F9H67!49"MA=$%T2D=I;75W
M2D9*1$MQ=3E#3S%60D=:14Y,:VM,06-82G)C54122WEY.#1E6"8C>$$[<GDU
M4S)H=6%4>4=K84]J<E4P<C%)<"M/1V5K>5)&:V)-8V9A1T=C=45(8W!Z;4TU
M:5$K8G9.;'(U9G-G>$%M=EIA:3-T-FIW4'AT=B8C>$$[6&=->3E*<%1L;#-2
M8T1T1%AX,#AB-7E0269J;SA:,6)6<C=68C4W,CEK.5-:+V]644)3:7(R1V1(
M:7A2>'@T63AN:712<4HU<#A5>B8C>$$[=6\R,6YE6%1&8E=#4S1:9G1,16I/
M4EAX0V<U3U5X2&UA8319-50K:T4K-%<Q8S)T,6%Y*VQC=WE14S!".4]65U)Q
M2&]A34%C67E%:"8C>$$[64YR4$A+2G%125!N<VYN-68O.$%+66%B+W)Y9CAM
M6'I&,2\Y>DPX9%$U,UI0*TUW*U X0753.6,X>&593$Q1.4]E.'5F:6)P1$%#
M028C>$$[.&I%9U57=FA7<#ES-2]4-$I:6F-)97<Q97)J9VAX4RM893A6,3=Z
M1G%E=5A1=4PU>#A)<$A#;%)'9SEL2E S;D]L=V%E3TE61C1J5B8C>$$[87I*
M;FQX5"M84D%15SEX8U-E;&)X4$Y+9"M%86PR<#AL<6-T;$E!5V1N2&A!>4Y2
M0DHX;#$Q6EAT;W=3-G0U8F0R1E975D=1:V5)1"8C>$$[05E)>FI,:V):5'A3
M:#E123DT<%@P4#A!-#=7;B]W1$U61"]Y8UA)-79O;#=J.7I04R\S<U V,&9V
M96IF;79O<7IA9$)Q<U5B3E!B328C>$$[27!3=3E)5W%A;B]696XS-7 K>3@Q
M4TU$>5 S=E,Y=F%B:6=-9T<X9'9H+V$X<WIE=DIV9&9*=75$5TY"=#=L,E4S
M2T0P-VQ19'<V-R8C>$$[5E X07)#:EIY,G-W94AK239D2'9E>G16-#)%4R]I
M-BLY-4XU,3%74%9036PU8WA.>F=6:$9#93-'34)45#),06Y.+V\X6$)I05!.
M-28C>$$[2'103TUU955H>35$-$XK4TY+;#%,>DY:26<K0S-D8FU9;G-K5$$O
M:3%"9S%U55%X2'HR*V%E>DU">34T:BMB-FHX1U4O;D@Y=E(O;"8C>$$[8R\X
M04UN34AS:FQ,-&9P9' W4F,X9CA!;F8W,35Y0U%A:EEJ;V,S1'IB:3(Y4V1Z
M,7%D.$Y+4S=&5U<O;"\U=&LP:2]7>75:0BMJ3"8C>$$[<&=(3&LO=6UO84UU
M.4%#>$A,3F9R.4E-:V5)9E50=&1X,E0R9V--*T-2.45V<R](5D]V4&UL>#96
M9')F<55J<S=X*T%"255,35)8:28C>$$[2S K,5%K9E1M3&]C=D=/13AW-TQT
M3$0T575-9E1,-S!L,#)F5$=U:T8O>BMQ='-Z4FUJ3%AO=RM86$UR2D=696YM
M-%=+8T1,,693>28C>$$[93,X-VI463=M,4)/;U%13%14-6AS-T1S2D-A5F]/
M-$=A<E=A95%X*TI'4'$V:CE4=G5Z=%1#5UE9<'E!:#!K9C O9#<R1C,K=3-/
M;R8C>$$[6&(S5GDO3U8K=$YG04)1041S335'95%Y3FPY3G<V5T]/4$1%8D)1
M=%!.,7!P5GEB9WI7-6MJ1$LP8WA"<%55*WI51W9H:'AZ35190R8C>$$[8W5J
M.%=00V(K0W(U,3%B5SE/,&IY>G$Q>D,O-DQK9UI'5VA"47EK=$5'0F]!,W!!
M54(Y.'E-:TI'36(W;D<P34U5<W57150V=4PK,R8C>$$[-U5&838W6C-A:')E
M9$I.<6Q14GE(>EAQ37A$66,T-%-/8DMD23$W5$Y/<T5V<D\T95!6-'IX=7)3
M5W!H;E%T*WI18D=L3C8W6FLT."8C>$$[<UE#=V96.3=R3E)P36U76FA)6&I0
M26IN16]J>D@U-V96249T-TU'0S):45I15#AB3E$X;$I"<'@S>G)/>DUC2G='
M46(O;R]A*V-D=28C>$$[6DUM1$MC2D96+W-H,VIY66Y09'%I;#-.1EAC;C(K
M:DYW279.>GDQ>E,Y+TXY=DA:,T]N,D5C5V]83V\K;DA(2$8K.6XU2S-)96QW
M3R8C>$$[,W9H3TE72D4Q=R],-'1F-6EF1$M%63-X95(R.7HV26E%9VE14T5'
M5&E/6DA4;%1E;6-O965Z,S!B<F9M.%$X.6%P3G%(;64Y36XR3"8C>$$[5U)R
M849F0EEM22]&<6Y/;C!725%X0W5U-W=V86UC-4TX<B]H4$-0:"LQ5#AO95AF
M,#=R2U=K:DUL<W%M4S1D2V-G;S9!5D(S3%5'2"8C>$$[5C9J=V]8,39)-U P
M9C5J3'=N-F5R,GEX,#-4-T-,,')+,VIT-"LV>'%&<C@V9&9P>FU:-4I43GE.
M=F-9<TU-67%)04AK.&TO3D@O;"8C>$$[2VXO-'=X9G%/9$(R6B]D9D5V23EU
M9C1X+VUH0F9L+R]!37!H<'8X07)Y9CAM6'EZ6"\S379X,41J.6LO-'I$-"]W
M0S5+62]M;'%K,28C>$$[>C5I*V]N84=X4E%G.%=L54]X*S9G>6YS>D5)-"M,
M<DPY1&LY=5IZ3$YW9$E$-SDR3V%$<%0V<G$Y<EE+4V]N:T%K8V1646)U=SEW
M=B8C>$$[5$UZ4&PX3T)L,T]T,'5N3V))241R.7HS3%-.0S!V4V)D26)+,U--
M<6]2<'5+*V\Y3S=S04-X3V-V;'IZ>4<U1C=V5#982&EJ54)8,R8C>$$[;C-V
M3V9Z8R\T-T9N+W=!=R]W1'AU8S-06E P2#-V3V4P2#DU2#--4C!0.$$T-U=N
M+W=$359$+WEC6$YH;2MI6'50,T]M,'8Y-T0K="8C>$$[2#<S=FPO6G<S,6Q0
M6GI#<U9X1S!B,'!7:D-L4EAU335317I'46M/:C9";'AI8U1%.&E+9E R;S)B
M,D]O6$YM-7$Y=$LX5$XT;$=+,28C>$$[*VUM9&)J;GA2174X4&YU8D=C8WI%
M+W=M:S0X<2MB3&I16711:FE8;#EB:DAP:S%01U9+:%0Q2%IJ6#9->#E6<%)L
M36(V9F,U;6<Q-28C>$$[,#1K0B]%4'19+VU7-C4V9BM5;6MO;&QD87%W+V5Z
M3V)E36XK4DM->$AZ62]H;6HW5GDK;U$W=#-Q=EHO04)#5U1Q5%AW2#=53BMC
M9B8C>$$[,CE(*U9Z+WI+>69:2$M8=R]3,"LP6%!(+VYF-S$U-4-G96%.1S9/
M>7%A9&%%,'IC13!(;EE#>4(U=F1B4'EN-6%H=%EO:'!L=$E%4B8C>$$[5C5Y
M47AU-U5(5FU+,4IZ;%HV<DM35'A(-79E-#E"9VI%1&=J.&=W9CAY4$HQ;EEX
M3'$K;F]S14)92F-7-FEI:&U0=W-G1W<X0TTR;B8C>$$[6C)R36IW4S-0475I
M-UHW3VI!94I$6612*W U+VTS961E-7HV4'!0;6YY-5IX871#3&E'5DDU=TMK
M15-C2V-G46%G+T5C-5AX2EEC:"8C>$$[-&1N=B]#:'%-565-5T-!9G-E6"MC
M=DIT,350;&EV3$=E4S8P2V1X13!5>D8U65A.4T%P04$T.%8R+TAX>F-A4%8K
M3G1,-FYM*S!D028C>$$[9$Y5;VTX6C(S-6HY:4)I=4]A2S9'<7-!4699-6Q%
M3T=*<457;#9H<4=P=U=';D)F6'5Y4DAY<458:4]41G%D9V]*>FEU,75Z5&IZ
M1"8C>$$[9TAP;GDX=3DY8CEM=3,T-3E,3'AI9D5W,7A(*V-#9E0X96AE;F58
M=GEN.'$V859U8C(S1W$V:U%':W5B=TQ+03E"+V1O4GA645(X3R8C>$$[,5)J
M:3!S66IF9&\Q9F)E8DMA:65#4&QT.'EY>3DP,U1R*S).<F97<U8Q86UL64IK
M5U).=6YW<T-.<WE$14A9=7)X-5IW4$9%:TAV1"8C>$$[>FYZ6"M31VI8550S
M;FQL:G!/<F]"-DM">4Q::E561')X9&@X3F9S+U-->&-M:T)'>G9T1C=16DE%
M1$PV-&8W2C58639X3DI*3&%88R8C>$$[8E<K;S)X2S--1$%I:%4P3DMN3E)/
M3E!8:4%)=4\T2T]&+TEO4$5N9F]09DYN,E!R>F=Y9T@V2F)(>3@O:#EZ>2]T
M6#)&*V,P<&Q$*R8C>$$[*WAG>6HS>6](,&9(<"]3<&U8:W8X=4IF349S=7 V
M,TY.0G W+T9A,CA%:&IE54=T5VM90V]4*UAI9#@V+U<V+W=Z=W<U.5AY5'-N
M<R8C>$$[9S5O*TIM*VLX:"MT-DIO=FM,>61O<S8S1VTV4F)16$MF,V1X-EEA
M5F%G9SA887),54=M>'I4-4Y6:VU+2DY0531T2FEG8FI%5VXR528C>$$[3U,X
M0CAY;WEE63E55G5O=34O=4UH22]!-3%M;4XT-"\Q42MF83!6;FXO5U S<'(K
M6"]M2S P6%='83E00S%U67I(2DYU94)"-4MA2R8C>$$[0U15-UI2<CE/8VM0
M5'I$;#EK-GE/1$HV=G!K3V9C.6HK=E=8;V974%AJ.4-N3#%E430P2&5T85IZ
M;D)+-G)D-U!X23%D:6YI+VXS5B8C>$$[<D164$U5='I9>65T04534#%!0T%3
M=&$P<C)Z<&1$:6Q$2%5U8GA883)O:&QZ8U5$67%M=GDO.$$K57<P,R]7:R]W
M0U1,-#8O*S5L*R8C>$$[3W)(<VXO1UEF2"]C;%4O36%*,#@T6'A98D]);E4K
M24U3:CEA;D(R96)W:C0O97HW66I7<&PU,3EY1#AO-GI&;RMV,C$W35 S04IJ
M;28C>$$[3S4T;R]W04Q.44%K.&5T0FQM<G=N2FI-4GIA3WHY4TU/65-03'$Y
M=G1D4G-,<3%7-W0W:$I,6FPU0U5-2U5)<G98<#E/8WA,2$M*;R8C>$$[:F0W
M<4=A16\X44YH-5 X06U:<2MN86IR35 Q2UE4:3-I.4]2,#-8;'E*;T0P4#!:
M=BMZ8U5O45!%2W-V2F1T-FE'5$E/13-W:&IM:"8C>$$[+W=$2&(P+R]!2FEO
M9BM4:35M6G9O;#=J.7IR3DPO97<O<E(K.3E"-7E,-DDX=2].8E%P63<V3%=)
M52\P95I&:75#3S!Q:S!9-R]T3"8C>$$[4692;3DW3'IG>$U$>F56-V4P<$5X
M;$@P;EDK.6='8EHU-61&1DI,2VM583AP2D=#279I>D=G2#,T0U%"6EI2:5-A
M2$UV9CA!44Y/+R8C>$$[4G5I,E9K44$X14M,3%1O6D])-6XV5W)N2C4X;DA-
M>3=Y*V<V6$0T94M-3S1$-3E70R]N2#EV4B]L8R\X>7,R;EI(2UAW+U,V1#)I
M-28C>$$[-"\X04\O,W)Z,C$O,W%H+S1Y3"]!35-'8F58279062]Q2'9$-DIJ
M+T%,=&9K4#%:>#5F4GAY67(K6B\O04-I8S,O1U=,+VE76B]:;B8C>$$[.3A0
M8UA69'0O=T-,2#-J-S-J961'.%4Y<W-T9C!N42]+1VQ8;7%4*VAB=D9$0VI"
M2&M*:V10:%5,1W)(96UC9G)C:UE:2D4O>FXP<B8C>$$[<VI36DTK3TUC67,X
M1CE"=#A71BMB.65M,35"4'%1;#!F>69B35I);FM&2CE2;5=V1TI)+VAK4E=7
M=35&4#1A,SAZ251%+W!J13)0328C>$$[:#9N1C)6:CA+941B3&UY>$U:5GEX
M>&QZ3CAI4C@S;#EN-6I7>&Q:2E9:<E9Y5$AU3U-I=C-6.&,W4%(V=4=P>&EC
M96959'AF2T\Q=28C>$$[>6,S6G5O3TA+4%0O04%Y+VY2-W@K:V1%,C S.'=9
M9$\Q83)U8DIZ1TEY9E5L8U9&1T9+8V0V9S5F:W=#8U1%=49H,5)X>D5O.4AT
M5R8C>$$[:R]M2C5F=DQA2C=I6#9T8U-506DT=DE$5VQ#<G%P0D)R;6EY-D1*
M13=B:#9N1#)R:6M">$AH;#--:V=U25HT:$Q#-&5-.4='655O:R8C>$$[1VDW
M1TUG4EE32%903W5M=TM98D)H95AP<4512&=G23=T23%&;U!N;5AI,&-J=DQA
M3&<U*S!94C)J-G!F:G$X3B]->7ES;FYI,7)46B8C>$$[5W5D5U-R-G)D0V]J
M:T%'>%5.+TEO0VUG,WEJ=$QS>55O;DM"6&PU9#=V.$$R5CEP-%%N2%-:2E=*
M6'=Y+W!%+U)Y-C)D*SA6,5EC4"8C>$$[3E5":$I+34IA9EE(4W9Z>FUV>35T
M.4PT;W95+WEV.$%Z;6=G<S1T33$Q>6)71E%K9#!!4UE1;TY%6E98:WEM;7A'
M-'I-=S9K-"]43"8C>$$[-F5H96,W5C=".%EN2F@K=G)(=C@O2FUU<V9N4#50
M=&).<$Y.;$]P,U911G0Q5U-%9&1Y>GE*46911&PK5%A103(S9%1P=EIR57IL
M5R8C>$$[46-%92]9+UE#<&56=GIE<V1:=5!1=6)15U0X9T-"2UI#15IL4EA.
M631X>#5U1DY$559R4VQ30FDQ;VMD>%106"MZ<SA%8FI,:2M&928C>$$[9&-Z
M,$8Y,VYA:"M:=FQ3-VQU;#%I=VA-<7-O:G4T;VQ:;C5#<#E59T$W8V1J;E5D
M;39O06-%:C=V,5!M=F)E9VM:94Q!6#!)2#-V3R8C>$$[33-,>E1Q8CE-5G!6
M=4Q7-70S0UA%5'=U5D1"2D9+;FDR-$Y$,D]2:DE(:V):>GAY:6%K2U1Z.'8O
M=T1L361.+S%P4"M43#5I-B\X028C>$$[=5IF:G%(3S=*+WAM2'@O,TI:,2M:
M9FQE-3%/>FDQ0WE1>5A6;T-R=V]P6C5%66EN14-T4W S*R].6#)B<5)!;4UU
M4F0O=T)T84=75R8C>$$[26Y(955E;F50,E!*0T-#465O-FI/9V5086]/=4LP
M<E,R='I$2$9*3$4P851!=$-Z06=-;TY+<EAQ2S5%4T(U9$=C<V-O9T5I<C5)
M:B8C>$$[42\X06IT868O=T%X55 X07EC6$E:=F]L-VHY>EIP9C<R2#EA4#-V
M;U!/4F92174X>&%3=7(V3&1A95=#;612=UDY039S2%5M;BM5;R8C>$$[>3=4
M-69$;4ID>FIA>E1J3FEL1'9E05HQ<C4V>50X=G1*3V\K6C=9,7!(6F8V6$HW
M*VUW-&HO9WE-=W1F;#1-4C@Y;EHY:S9F>$TT-R8C>$$[;RMR-6-V=&4R6GI,
M,T1Z8C@T+W0V4#A!2S4O-6Q:=75Y3U5V:"ML-6HR:34T+SA!3R\S<GHR,2\S
M<6@O-'E,+T%-4T=B95A)=E T+R8C>$$[<4AV1#9*:B]!3'1F:U Q6G@U9E)H
M>5ER*UHO+T%#:6,S+T=73"]I5UHO6FXY.%!C6%9D="]W0TQN,VHW,VIE9$<X
M57DS.#(W,D]Z+R8C>$$[04-H,&%3445Q8FDQ6#1E=CDQ264O=T%S-')T5$=:
M>DE(.#<Y8C=&-T=::&IN16XO0490.51W6B]-36QX4$1(06MJ<WI+=%!T3W=*
M<"8C>$$[=U)D.7HR>E9$4U5$8C9$3%AX+VA&1'$Y53AR9FMR-6<X=V%28S,R
M<&LV43!K6"LT=3-N5FA.-FY+=D]D2U924V]O0C$S<E196G-U>28C>$$[<'HP
M."M,*T4X>#-V0RLR1V94-BM!>&=82TA+6#@R*V9Z<F8Y8GI45W1',6Y23#4W
M2%9B5U,P=45**T=24T%W2#=313=-=G5--U1(;28C>$$[:DU813(K5#5D1V-:
M<5%P2&58+TYL,W!J0T=91S1S9CDY5D962DDS56XO:4YA65I#,DEJ5#!E4#AY
M3E-K.&U85CE"8C-$-EA$9#)L;"8C>$$[33525DE4,%I/47%T4CA01TE%:SEX
M;40T15!&2&924#)J.7)S4$AY*T%F-71X2#)(.6I'8G)Z+W!R2U1(1DTW.6Q9
M2V\K:SAJ;61'1B8C>$$[3W)M6D9D-6%B6&9-.&XQ3%1,4U=E*VY9<$IC<W1,
M4S)2:E%--T%.,$<K-'%C<3%'5TU"-G589#-T*VHP<S5Z.48X6&8S96%H*UI8
M-28C>$$[36$Y-5=I5%5B24YQ5VQL1BMT4U%O>&5'4E5R2S=O;TE72W%K:'$W
M9$0W.%IM>&II2D%Q3B]*.6\W2C=6-#AC65I$*SA!-2]Z=E S*R8C>$$[5'I7
M1SEK:&-34DYX661#37!L:4)&1C-S8S5I8D-9>&5:6E97:VE">C1G,"]H;$5T
M1T]H8W%084)!,T9S:3AH85IR,VTW>E195VQJ0R8C>$$[=W1)6C0U8C)903A)
M-&\S1$U796UX<#!(8S19-EE$8FU80S=1-U1%8UI*,D9F33EZ-T%Z85!M>5%A
M:C5%.')8-V,U3$I9;E!6;U S5B8C>$$[9FU%;TUY.&5U>7<U2#4W=79Z9&PV
M9DIU63$W='9U6#9:-4HX<S9C43!.:6MK<6M&6EIH-G)!9S%"0F5T1#AS1U17
M-5HX>CAT;5=(<R8C>$$[,T)J-5)&*V4O=T(V,U=V2D]G87AE9EA,,DIZ4'=#
M1F\S2T%H83!Q0C,S=S1D8FMX>#19.&MA;G,S1&UL>%1'+W95.4LX9RM89$QV
M-"8C>$$[<BLQ:FM&>$1Y35IE4FU!3$M63W@Y:FAY-B]*3TII95)964]Y<T=+
M66Y%2&E(;7E,34XR4U1A<C5/.'5A;5,Q>EI2:59J5G!O:#9C:"8C>$$[4'5Y
M,'(Y3UI/3%8U26-I-%=F<R]";#-L15@S.&EH.4\X9RM68D8O55-Y5UHK>'5#
M6F%F24Y59FAK.&UV>7DV,3=T;79$,E9P.%IS4B8C>$$[=C,W+T%(;VI84$M/
M:6$P,$Q8<U1C<F13<UIJ67 X2G!S86112V):1$)Q-31R-%1Z8DY6,F9I>C%X
M:FPX14)A+VQV-5AT<FU'-6EI;"8C>$$[.5-",6M4;$MX2$I$>492,S-'5WDW
M4GEY0D)R9GEC94A9,FYJ25-!3F<S>DQ+37=887-F.#DV<DIP=FQM-VUH9FAC
M4V-96517:'$W028C>$$[35)4=49Q8WDY1&E%.&]"-4]V-U5Z;D9G:U(Y6$EF
M1C1F;E500U!7=GES,%=/,C!6=%1907HS-TAI939X>'-602ML9U1N4#A!86U9
M>28C>$$[;G<Y2798.6AA65)X94HQ;CEW6G1M<V0T;$]V*U8Y23$S,% P9VIS
M8F9L-E)2>6A(3VY,<"]Q:DUJ0G%P-'(T97)H-G)1-#@Y8UDU9B8C>$$[<%-Y
M1#AT4$MK37E3:4=2;6I9349A5FET4G9U379L,FQL27$O<V-A2%EU;FE184\S
M;5=59T%#9S9$34(R<40Q:E-,2%8W0C='.55T028C>$$[-55K2U-P0E4Q0D)'
M5S1C<W-C=4M03G Q1VYH;6=94S5-92\U5F8U5"]W0CEZ9CA!23%S>2]W0U4X
M,VPX;EAF>4AP*S0O36\S>DXU128C>$$[.'9E6DY$9S!456]N+U(Y=$EK<U5C
M5&Q#1VI6;%AF-4UC,3)51V4U3S=V=$9N3VU.=T$U5G5H9DQV-5AE42],-TI*
M<#)J=T,U:EE-;"8C>$$[,4UO;6U6:#!+=2])<68X059P:TDT9U!0,W0K9G1,
M3FPU;6@S1&(X9D9L5U=/0VQU="M7.4$Q>4999%AS24PU17(V6FU137EC<58T
M3B8C>$$[.7!+,"]:3U=9.'-O1S1M;7),:&A-5DE7=W!V>4(O3'<S4')E:F-Q
M;&$O5GA/,W Y83 V8R]W1&AS>E U5'DQ,"M49R]Y5&@X+VUZ4R8C>$$[>3AS
M95AB3%-4;SET<'1S;6U/2U,R;G!+635$44%M4E-$>EDX4E5T56Y-4U=A6FQX
M16TS3FIG:$=00T%/1FEK4#5'+VPQ2&9F5W9Q328C>$$[:G)7;W1N;6-W:B]9
M,7)4-6Y-;SEP6FE+='A",E9G0G5V=%IR<"MM861P='-T<G Y<D1:,GDQ2W=W
M4G)'9TI.5#A+9T1F34MC>DDR5"8C>$$[6F,V1T]-4E5245)$;VIO>4]O6D="
M5FQ95D)",DE)3U)B06%93C5H+TI0.$%,:EA'.5-84VMS<'4X=&A3,DIR-'%G
M-$@O9V-G8UEC+R8C>$$[1#)N;6@Q=C,W<%AP+W=$>FIN*U=L<$U*6DE,<3E!
M+S-88U1K<#DP66IY4&AE6F)P9',U:4YU169$.6(P2%-D1#!84C=C,BMK,D9V
M628C>$$[44TS2F]R84I);$Q5035%24)5,$A83$)%0C%U5$Y/6G522CDV3G=T
M8G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)Y-S@P>G%D,7)-1B8C>$$[<D1$
M33ER0D-'2$9'2VU2,F)K86=E04%Z93EM8TU916MI>5AL=3-016YL15%#66=D
M,U9H.7)O1W,S5GI(8E$R8W9Q4VYI=DI'04AU4R8C>$$[44%!33)%<SA):7E1
M-F%':GEZ:TEI2G,K5#-U>7,T3$LP:'1)1C1W=TE%4F991$]5;DUY2DHU;#<O
M2&I%26E)-4)7>4Q.,DMU>%8R2R8C>$$[=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMV+SEK/3PO>&UP1TEM9SII;6%G93X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @
M(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @(" @/&5X:68Z0V]L;W)3<&%C
M93XV-34S-3PO97AI9CI#;VQO<E-P86-E/@H@(" @(" @(" \97AI9CI0:7AE
M;%A$:6UE;G-I;VX^-S4Q/"]E>&EF.E!I>&5L6$1I;65N<VEO;CX*(" @(" @
M(" @/&5X:68Z4&EX96Q91&EM96YS:6]N/C$X-SPO97AI9CI0:7AE;%E$:6UE
M;G-I;VX^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!
M;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L
M="(^4')I;G0\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @
M(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+VIP
M96<\+V1C.F9O<FUA=#X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#IF835F.&9F,RTU-#@T+3AF-#DM.3AF,2TW.34P
M9#!A,F-E960\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/GAM<"YD:60Z9F$U9CAF9C,M-30X-"TX9C0Y+3DX9C$M
M-SDU,&0P83)C965D/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z9F$U9CAF9C,M-30X
M-"TX9C0Y+3DX9C$M-SDU,&0P83)C965D/"]S=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @
M(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z-CDP-F8P-C0M8SAE92UA9C0Y
M+6%C,F4M.#%B9#@X9#-A-39D/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C8Y,#9F,#8T+6,X964M868T
M.2UA8S)E+3@Q8F0X.&0S834V9#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @
M(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.F9A-68X9F8S
M+34T.#0M.&8T.2TY.&8Q+3<Y-3!D,&$R8V5E9#PO>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z9F$U9CAF9C,M-30X-"TX9C0Y+3DX
M9C$M-SDU,&0P83)C965D/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 V+3 W5#$V.C0S.C0Q*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#0R R,RXP("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z-CDP-F8P-C0M8SAE92UA9C0Y+6%C,F4M.#%B
M9#@X9#-A-39D/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#$Y+3 V+3 W5#$V.C0S.C0X*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B!#0R R,RXP("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" \>&UP34TZ36%N:69E<W0^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T369S.FQI;FM&;W)M
M/D5M8F5D0GE2969E<F5N8V4\+W-T369S.FQI;FM&;W)M/@H@(" @(" @(" @
M(" @(" @(" \<W1-9G,Z<F5F97)E;F-E(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H/E@Z
M7# Q($QI=F4@2F]B<UPR,#$Y7# V($IU;EPP-B!*=6Y<6%!0(#@@4E532"!#
M;VYV97)S:6]N('1V-3(S,C0Q($%D>6YX>"P@26YC+B!3+3$@*#$S-B!P9W,I
M7$1R869T7# W($=R87!H:6-S7%5N=&ET;&5D+3(N:G!G/"]S=%)E9CIF:6QE
M4&%T:#X*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^
M>&UP+F1I9#HY-S,X,3$Y9BUB9&0X+69F-#8M.#<Q82TU-CAD9C(V.&4Y83,\
M+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(" @(" @(" @(#QS=%)E
M9CII;G-T86YC94E$/GAM<"YI:60Z9&9E9C=D-SDM,3$R.2UB931E+3EC9C<M
M.60W8S8U,S,P8CEF/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \+W-T369S.G)E9F5R96YC93X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I-
M86YI9F5S=#X*(" @(" @(" @/'AM<$U-.DEN9W)E9&EE;G1S/@H@(" @(" @
M(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=%)E9CIF
M:6QE4&%T:#Y8.EPP,2!,:79E($IO8G-<,C Q.5PP-B!*=6Y<,#8@2G5N7%A0
M4" X(%)54T@@0V]N=F5R<VEO;B!T=C4R,S(T,2!!9'EN>'@L($EN8RX@4RTQ
M("@Q,S8@<&=S*5Q$<F%F=%PP-R!'<F%P:&EC<UQ5;G1I=&QE9"TR+FIP9SPO
M<W12968Z9FEL95!A=&@^"B @(" @(" @(" @(" @(" @(#QS=%)E9CID;V-U
M;65N=$E$/GAM<"YD:60Z.3<S.#$Q.68M8F1D."UF9C0V+3@W,6$M-38X9&8R
M-CAE.6$S/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" @(" @(" \
M<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.F1F968W9#<Y+3$Q,CDM8F4T92TY
M8V8W+3ED-V,V-3,S,&(Y9CPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @(" @
M(" @/"]X;7!-33I);F=R961I96YT<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_N  Y!9&]B90!DP     '_
MVP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$" @(" @(" @(" @,# P,# P,# P,! 0$! 0$! @$! @(" 0(" P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# __
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M " Y@=,]_P!MNWO*HNTOSK/\Q"2CK'W?'K4>GI_F:O\ XJ)-X8]S?G7,>6L
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M?>=>?D/K4Z_(D.N/R'W5G=;KSSJEN..*/B2223YZ9<2"0A("4 2    '8 ,
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M"==-/"-Q97M$Y?5PES_@^7R9#C&/3I3N,Y6A*REI=)=H^F5(?2"$N)KI9;D
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M7N):H6&RM:U<$I'$_N#B3PCV6ZWU]XN=/9K2TJHNM6Z&VFT\5K5P'< )DDX
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M+K-9/H'M=TJ2A"B!/P6"4"1["O,?-CPB5O= )3VGWNP*C^^6##8>?C>- G^
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MC2^-1!<=7UK106+:IE7'!W)#<5;;R$@^20!Y#2-=1.G6+3K%NZTJ0EFX,9U
M?ZU)RK/E,TD]\6=](VKZK4&W"[+7+*ZFTU)9229GP5#,T/(G%([A"TN^+MI[
MZ<7Y\Y.Y'X:XZA<C<)6\]O)*^JJC2FWKW)D1EZ\8351WHUY)Z+!+JP4!PJZ_
M ?#4I;8[DZ#>TM0V;4%9[-?FD>$2L+RD),D'/(I'HR&,I2B'-Z=H=U*?6UQU
M'HRWIK=+OJ#V1M;8=2M21XH#9*5*](%0RS))( BE?&?<!59M*=H;6MFX?EL1
M:V)5):%20N4P2W)98=>;8<2\VM)!:=0A8\O'8ZF>JM8:2'FE)=IU"84G$2/
MX3!![087>TZJ%8ZJDJ$+IZ]M12I"P0H*&!209$$<P0(L,UD4\1VX:ILI4-MP
MNHAKD/*BMNJ&RG41E.%I#A3X%0 .VL0J@8*R[D3XI$BJ0F1V$RG*-N;O%2E
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M<",Z/2$^U)!BIBE+<6MUUQQYUU:G'7GG%O/.N+.ZW'775+<<<6?$E1))U)8
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M "2=@!N2?( >9/W:.. XQP2 )G@(T5>U]QDG#NWP9K*CANTY/NIE\%K04O\
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M>4I[YPD#3?17U';<!PR=R+G6'X%7#>7EV15=&CP)Z6IDE"9+AZ?$);C!9)^
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M<(E'6O1M<>#MML3MOH@C+[W\\JGE+N4S(1'BY0X$6<&I5(=+C$A56@.7$QL
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H:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tv523241_chrt-org.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_chrt-org.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ YP.$ P$1  (1 0,1 ?_$ .,  0 " @(# 0$
M       &!P4(! D" PH+ 0$!  (# 0$! 0            0% P8'" (!"1
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MU+S=%S5,(M\^>7_OG$+_ / WC-_L-ZSG'TX_8SG_ .H[_P#/!=L^M7[?%/\
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MI0[\N9N.C/P]C<*I"M[@3W14D4M.QR)A7$:L"4VJ_3J:2N.JJTBDF>(P]R6
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MSO[';ZX/QK+\NX6_JS+08CZ28N\4I2&$;R26C!O$CK"(>-/.\6C,Q$0@SML
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MT@D*H%LG?=.3%( 'J1^UF)W9G3+8/@.-YYALS:I1V<'9XF5V:2MCS>H,S/.
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M(]629A$1*4))08CU8CAC-@;0IF>-M'V7Y!BB<DX2<:Y15;>_PJLHW;-PPE1
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MDB(K+;Y/WCD+ 3Z[M0U$6;]VXLVFK=O:HX?4#ET=S$Y +>ES!Q#'1+PH?W
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M_>;M7U]D9Y)75#TD!0QR9^KDM7QFQX=!BOR[$U?J..6V)W%83=UUS$J,<_S
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M3NQ/8IMJ%3I3J8*&$,14"$S1PV+*(6!$2W@@:BOC6<=?GU^4B3EE@81M>V<
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M6(F?TV#R-MVSH\9$I2_LA,95/X96ZL4.@%>5NV2*5 (4)@2B6I:YBD5+E\D
M2K-"%>Z:5J]=J/H,Z1"Z?K&<5P>(M-=IQ2/;&+PQ.6:><@CU9_#C>>23P@U9
MO<CVCV-V=B^,Y]0^6\BQYXG)V(FQLMC]1)'!6JU1FGTT\:9JL,/C2=O[<N\M
M>W77M4-KJSYS5#VI?X(]Z:%K@U*V%W3*VMFD+#(&%P$4-<PR:+R5N>(S)V)8
M-.6(U$X)%*4P181"!O80[U.RN'QV:KM6R4>^,38Q=B,# V]AQR1D,D9MJ^A
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MF_N/'JGC'4:'S$7QIZ YWT3+_)V/RT^7+D)W$7+X7S?W'CU3QCJ-#YB+XT]
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ME7Q&8OIFVYD3&JC1"3A $@H8^GH +HOL+QK+\@"Q+C0A>"J E,<L\%<(Q,F
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M,;ZFK<-_15/24N'"8K+PQO,[%2\<[OZS9XPM'/J.SQ/ 9A\)X]7623(7_P"
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MV2NY*>:Q</\ :DE,I#+_ (2-W)_^-U/J4Z=" :M&*.&J/L",1 6_X!%F9O\
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M7^5QZ)XATVGY0]R?<KG_ %C(^>?>GQSN+O,F?MY?Y7'HGB'3:?E#W)]RN?\
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M[AU'MT9]6=F^KV,O8UH"NAL:S ,T?:+[HC<F$O==]-7$FT+0FT[6;5E",L%
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MM;) \1YK]5&KP/:KU@W1=>9VY*8Q.5V'5,, (981_$F6Q\65BPLDFF3FA.4
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MA1R;2=XRBC;MA?<1"HO)*V%*CFJS4Y!>C*(QN-&K5:L7B,(B\[6BFLC*/_E
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M "KR<;HN)W1A;G:V++=&\$=C\0"A<9W*%J,,3B3Y^9XK%PIE+J:3J.QF2_\
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MO3[:\_Z/D?(/N3X&7%W9S/V"O\ECUMQ#J5/S1[T^VO/^CY'R#[EV!\:^-9$
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M *NN3WCY:WZLQ]O^!]$Q'R=?\M/6?,.K9+YJ?XT^=SF?]77)[Q\M;]68^W_
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MFL)[V'>VOAF^C;9 ]ACV[7[-74%RQ5>F$3")A$PB81,(F$3"+[,KX_XE+_\
M=>M_^6L1SR[]//[)U_\ /6O]JG5I]9/[Q;W^:J?[%75/YNJYBF$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(MEN/'(!RJ1Y T/!RA=
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M!103W%7K9Z@9IN]CWN/TGQ]*IP+%VJ\8C:GH0/(>GOF[![NXG]XF!G<09WT
M?=%F;L6B?5&_<M<SO59Y"*K!.31AK[@;F%RVC[&<W[3=FU)^TG=;^2RP+9FD
M<:$\3FTYEG)M%^WYQ@>^/I!TD?7Z?I%TGEC$.]7>EREJU4O(N.0Q=I0[,4-.
MM/ZML3*]IQ#,+UT<WIXW"T+1E=KUX>)ER6^%QV  A=HXS_2#:T9F>L$A'HTG
M[D9"#<S,ZZ-<O96Y1%J,TTO*/3=$ZWOD4O[R3_7#@U=W\<XQ#4@_?$P^X[DS
M+#H4[B>%K$\:5F_N8D\,Y$:C3N)2D=Q;ML%^D[BBA7I0+;R9RD3<9?.!IM&
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MPB,A=QJ0 6CLVC[2$A?^1V=E5OP,N+NSF?L%?Y+-L];<0ZE3\T>]<]^VO/\
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M69_?F]Q+3*R]=8HS9>@&!_$.]ZRTQW$^59>LUW$XS(6J;N[-)#7FD!W;VMN
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MWV'8EJ-DCB%F6I!YFTSBVUAR^RG)HG,.FK%,6ENF:D_>US8F7%-1H %@\VT
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M8W*'!(WEU_#'%_=8O&4,?(6 CK8C9ULG7"*&F2%'[ =HL0Q%EE !339K*6:
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M2P]NZ,^A] @B"+6Q')>D0R=?Q!V('3L/D_GWT^M<4F_6T]TN"D+L+_&B=W[
MD_\ L$^QB]CLSZ:^[_I7]6:/.Z_\-R&R#D\0:D&ONS"S=LD6OX_B<?:XMVLY
M#JX[.9S5=E3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81?GH_N%?YY.5_P#/>QO\1+<_IM],O[O<
M-_NZ#^8R\#\^_MKE/Z=+_/=?UIX^4RS<?ZJO6W;DLZ+AMR76E%8_%ZXHJ*V4
M)O%58X>%T7/#U)^052Z*TYZF:?:<LA(?T=D9UQ:Z ]9/R;/3\EN<=PE&I,]*
M"O(<D]N2#=^H\7:PC'2LZ[?"+5W)O:VC>W3*'&\17X[3S^5N68VN23 (15@E
MV^"3,[D1VH/;N9VT%_QU_P -0&5*JG,H5M?'!CN>ZX^G.8FX#@939C+*/7CZ
M2M$C:5<3@DSMY$D.7FMBG2'6G4PY:!.8()0-@&$-XV:#'TQFY3)0H678RV_J
MM\>P';4FDFBK.[,Q#O\ W;,#DS:OJSJG_@\F0L$'&H[UZN.UG?\ 3.)L1:Z"
MX126&;7:^UW/4M']UM%@4M,W ML!34R*J;)5VHC.-3K*T2P64*+ 2*"4X%9Q
M"F&E-8Y&0<2D,":((DVA!+%H6]=&];R0>=P<>-;-27*@X<FU:=YHVA=G?1G:
M5RV.SOV?M>WL4<,)F9+Y8H*EHLF/MA:(WE;L9^V/;O;L=G[6]CL_XJW[&XF6
M-!TW'MM;&2;2RR+WA<EDVJI0UX^D3>+/$:LF;UZIB?J%.<YOSXY[_)@EAG^I
M(S2>VV5LG?9;,'1XKFF+R)Y.6:2O#BL=8"/]0\P/%()P13-)O=A !_>[6]\F
M?3=N[=&OLKPS)XZ+'#$$\V2OPF;P-";2QN!N#AM9R(G[-7]T7;V:?BJ<64];
M;=+7: .%6V,AG; A4.C["ED(DR:6LK8D(+5*G%VC9S8!Y;D*9,:$PPXXD!8"
MQ:%O>M;UO+Z/.866D&2BN52QTA,(2M+&\9$[Z,(FQ;2=W[&9G=W=43X/-#;+
M'E3M-? -Q1^%)X@C_P"4X;=S#VMVNVBDKAQKY%M*N4M[K05UMB^#,J:239$X
M57.D2N'QU:6H.1O\I3*6(LZ/LJLE(:,I4K"208$H>PBWH.^B)%ROB\P0RPY*
M@<=B1PB<;$+M*;:,X1NQZ&3.[:B.KMJW9VJ0?&.2QE(,F.O"40L1L\$K. OK
MH1:A[HOH^COHW8_\BCT0IJX+!CS_ "V!539,WBD3WO4IDT0@THDL>C6])]J]
MZ?WIF:UK:S;TDUVO^LFE_P!G_%_H_')5W.X/&68J62N5*]R;_)QR31QG)VZ>
MX)$Q%V]GNL_;V*-3PF9R,!VL?4M3UHWT(XXC,1?370B$79GT?7M?V=JM 7$&
M_C*8JV\VNOI/(8A<,Z>J]A2*/1.:.S^M?FL;*F:Q;3)XSMK4HYJY.QB-BVD5
MJCG)8W+20%Z$GWK=.W-^--GKG'9K,,5ZC7":5SDB$& MSEVO)N9XA%BEW"+
M)QD[Z$K=^%\A?"5L]#7DEJVY7C 0"4I-6T87=F#3;([Z1NQ/O=G9F[%'QT0_
M-%3SNPYLCL"$O<97U7N-1=YJ.<@9Y?&;,_/(02E18)J--&HHD2FPSJMI2SK"
MD&S%'F0A>8J>B2W(ZT^:K8O'E6L5YAL>)(-F+=')!X7[MH=7DD=_%]]Q_P C
MH/B-^\%8'X[9@Q%G(Y ;->S"\+A&=:7;($KFV]YG9@C9MC[-W^5?5@[1=0V7
MTW;U?,$?E<]JNR(1%Y;T[BLDE\'D\:8)-K2<*K>X^\/+6B;GGH2C"9_JQAG]
MGO0O]&^G)]'.X3)V9:>-N5;%R#_*1Q2QR''VZ>^(DY#V]GO,W;V*ONX7,XZ
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MB81,(F$3")A%]M?+S_CK)O\ LZ-_[!09Y)^DW]B*W^<F_P!*2VGZ\_WF7/\
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MN _B[ QLY.S>P=6U?1G=F[6[3:8CM616,B9*P>(^_IT8B-/CPT.S4].#@X#
M8("A[6MAINM'#UL?9%[ZH"P=(2PZ#TYYBYCD.3Y3)?K>30V()#9_#CDC.,1'
MLU:,39NQNS<_:[OVD[NO:WT\Q/"L)AWQO#+%6U%&[>-+%+%,9F[/H4QQN_:_
M;M%]&%NP69E<&:BM^3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
>$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tv523241_img.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_img.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M Q$!_\0 W@ !   & P$!              $&!P@)"@,$!0(+ 0$  00# 0$
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MQ-.)Y,_B!478@
M            UAO>SV9NC>W;GI%T)ZQZPJ=\9AAV5,]R=VZRNLJ3AV.3L.UY
M(>@Z\JLLOUQ9;,&OL\C<?DI2MLS6Y&;X#P%*^YE ^M6U.UW5?WO8N5]MNOF)
M]9,+]SS7;6(Q:;%-CL["Q.9N[358R=?9R+UN%71ZZYO*(T1VXRVR6[R1D:C
M?$V]"^!<_(@!$
M  '&\?#:OTI,OYC 'Y_77+3GM#YIH[W 7>]60)Q;?;?:SLS+I:R+F6<4V?/Q
M(]T_)PN?C>$U,A,2TGE8-I5&_P!6<]97!'R0</IH4\.IMTK5_M9M+^QKDO87
M*_;4Z^6G99K)2SEN!D%;CDW-8#M5F=OK"MO9D/7%KE5<^TR]$N9>,M,^=*D)
M4:$H,R\0*W]IER @
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MR(Z56OB5=<J4KP*VMMH:0EMM"6T(224(0DD(2E)<$E*4D1)(B+P(A)2?8
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MMUW3V+W5T=:ULC4+.9C*G7%.ERTW^&Y;=)0?Q5'X%:B\2Y'E"X0
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M@
M  %-=N[2Q/3&OLCV1FLY,"@QJ Y,D+Y+UI+Y\(B0(J#,O4ES9"DMMI^U1_(=
M_MC;>I[MUS'V_I$'/-R)]*]B7XI2]D8JK;/([[WMH/;O:F9O#<MU6=(PK3G)
M^,GRC"*\93E2,5XMFH#VC[4;%[1YU-R3*I\B)C$:4^C$L.8>7^%T=:2S)DU,
MD9(D6#S9$IUU1&9G\."(AM#[=]N=![<Z-#3]-@I:C**\Z^U\]R?CQ\(KP2-
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M]3U'1-0Q];TJX[6JXE^%ZU-/C&Y;DI1?UKC[C=<ZU;69W;H_6VS6_+ZV3XQ
MDV*4?NMVS#91+5HB^PD3V'"&I3?^VI;0WCJ&WG]S'R)*/O@_F@_^2T?I [/[
MZM=RNVFC;VMT4L["MSFEX74NFZOHFI(KJ/'%R@
M                                     #7N]Y?>$UZ^P3055--%=%A)
MSC+XS:S),I^0ZY'Q]B02>/,VTEAUTDG\#,C^0S?]*6T+-O!S-ZY,*Y$Y_I[+
M?A%).ZU[W5*IJB_Q$NYN1<U+2^U&#<:PXVOUN7%?B;;CCQE[DXSE3V]+,%7V
MG^L^!F(:R(H]NNQK);:,<RJQC(K:%YU-?6UM-838GJHX);928[#C1K1]I<\E
M]H^3(S\#&N>5D9&/:NT3Z97(Q?QHW4[+"T37]1M._IVGYV3BU:\RU8NW(57-
M=48N-5XJO Y7\1S",Y%9?P[+&7YRG40VGL>M4.2U-)\[R8J%1B-]32/%7EY\
MI?'@4PU/2YQE.&7BN$*=35V%%7E7CPJ^"J<MW;FY[-RW;O:7J<+EUM04L:\G
M-KBU!.%9-+BZ5HO<<4_&,GJ(Y3+C&<BJ(1NDR4VTI;"!$]=234A@I4F.VSZR
MD_!//)B;.HZ;E7/)Q<BQ=NTKTPN1DZ>VB=:>\HR]"U[3;*RM3T_.Q<7JZ5.]
M8NVX.7\*E.*5?=S/$'V'6+CQ,G/M1[NG:T[+P-?RIBD8KN*$_02HBU'Z",G@
M,.SL>FH3SY4R'#:<C<_TDN\?80Q\]2>T+.X.WUS6[<*ZEI4E=BUS\J34;L?@
MDU/XQ,S?0OW*R=E]Y[>U+]QK0=Q6W8E'\*RK<93QYI<E)TG;KXJ2\:&U87P+
M]1?X!K?-XQ$                               8W_=8FRHG3K-6XYJ)$
MVYQN+*-//'TYV2'N%<?T3=:2+]>FVS"[W4Q)2IU0M76OCTT_8V8A^N/(O6/3
MQJT+;:A<NX\94_A\V+X_2D:G)? ;*7S-%*Y'O8ODV087D%1EV*V3U/D>/S$6
M%/:1T-N/09K)'Z;Z$NI4VI1>8_ R,A\>HZ?A:M@W=,U&VKN!?@XW(.JZHOFN
M'$[+0M;U7;&LXVXM"OO&UC#NJY:NI)N$UP3I).+X-JC3,UNUNS>^:;V\M [4
MJMB6,/8659M;U&1Y,B'6JG6U<V5RA$:02HILD2"93XI21_=&)6W.WNS,KOEK
M>V\C!A+1,;#MSM6NJ?3"7R5:^:O&KY^TV5;S[W=T<#TC;6W_ (.JW(;NS]2G
M:OY'EVG*[;K?72TX=*HHKBDGP)DQ>SW"YT:ZMV>M=^X3I.WL'<RD9%;YG+9@
M_F8W+FQ=2U&6JNG>J^P^:E*+A/[P^'4\?:T>\.X[&X-%R]7Q8*PK4+"<O*_+
MBN/S1HFN"^!WFU\SN#>],FR<S96Z--VUJ%W]5*_=S'%+(K>NOIBW"=9*56^"
M,'F;2K:=F.3R\@NHF17;UY9+M+^$HEQ+B:<ESU[&,LD-I4Q+7]Y)DDB,C^ R
M^TBWC6=+Q[>%:G8Q%:CT6Y?>A&BI!KCQ7)FL/=-[4<O<VH7]7R;69JDLJX[N
M1;^Y>GU.MR'!?+)\5P)2/_+]OQ\!V7B=!1?0;7'M,S)<GIYB;4CDV8.09/%A
M<F9E]-^(J>+R\EX)]5Q8UM>I>U:M]T\F5O[T[%IR^/33]B1O2]"V1>O^GG3(
MW:^7;R,F,/\ -5V3_:V9+Q8 S#
M                          -1[W09DJ;W+V+]7Y_]4JL8A1?,9\?2,U;:
MVO*7_$\SBN!LW]/%JW:[4X'ET^:Y=D_\YSXFAOUMY-V_ZB-5=^OY>)C0C_FJ
M#:I[JMF/K]'ZR%[/B8H+BN!DE]MO=NTZ7L%J73M;F,QC6=[D5L_:XBJ-#=@2
MGI-;+?=<4XXPJ0E2GVDJ\%EXD+"]^]H;<R]D:GNK(Q8/<%G'@H7JR4DE.*5*
M.G)M<C,;T==T=]Z;W6T'MOAZA..R<G*O2N8O1!QDY6IR;ZG'K^\D^#+K=)[F
MV=L+W,I6!YIELJ_Q+!K_ &$UB=++B041J=+E6XR7H&S'0X9):01?>,Q;7=^T
M]NZ%Z?XZUI.-&SJ699QO.N)RK.DZ\:NG/V%_^VO<O>^[?65D[0W'GSR=OZ5?
MS?TMF4+:C;K;BN#C%-T7#BV6L=YK7=_H6];G/8[ MI8;)V1<-U6 XW.:DW.,
MJAOR78"[%A%9$-E$%GAE1>HKA9<>(N/V>QMH^9"_H^@YFG:K' MN>3=BU;O*
M274HOKE5R?S+@N!8OU1YO<Q8%W#W1N_2==V[<UJ\K6#CN+O8_3*;M^92W%I6
MU2$EU.DN=3&H+^F%T75%:NMLZ95]A]%SZ\C5-C[5PM4<D$9J-2[J,V:2X\?O
M)49#R>_;-K(V/K%F_P#U4M,OU_Z-EQNSF1=P^[VU\G'KY\-?PVJ>^]%?;6AN
M]I^!?J+_  #40?I-1$                               6D]Y-9RML=7
M=LXE7LJ?M#Q]=W6--I-;CDW'WFK5#3:2(U&MYN,I'AX_>%R^S^X+>V>XNF:G
M?:CC^?Y<VW1*-Q.%7[DVG]!8WU);,O[^[*:_MS%3EF2PW=MI*K<[+5U)?YW3
M3Z330,E)4M"T^1;:U-K0?)&E;9FE:3(_$C)1>(VKU32DG5-5^L_.\E)5C-4F
MFTU[&N#^TA]AE]G D47L+I,O[+RLNZOZUZV.XM$B1]=9%,OV<G;F.K?LSEG.
M4;+L-2?3:-)S3Y41GSY2%N],V!:TSN'J&_[>3*5S/L1M2M-*D.GIXJ7C]WD7
MPU_O1=UWL9H_9>6!"W#2,QWEDJ;;N)NXZ.%.'W^+J^"/+V%V">SOK[I71#^,
M1H+&GGKM]G($RG'GKA5Q)>D*]2,9$B.31N\>!GS^@?3H>RH:-O;5MY0R)3GJ
MJMIVNE)0Z$EP?C6A\&[>[7_[1VCVWVJNX,+4-O3NS5_J;\YW)2E]W\/WO:6W
M_P##]8]VRST>049^4R2DU+61(;))&9J6KA*$D1<F:E*,B+Y@J-T?+^3]QQ3E
MTP;5>I\$E[7P7UOA])N2=#-93-3=5=2XK:,J8MW,?3?6C3B30ZW,R%YRV4RZ
M@R)25QVY26S(_$O*-5W>C<-G<W<G4]1QGU8JO>7!KBNFTE"J]S:;^D_0YZ8=
MF9.P^QNW] SHN.H?HU>NIJC4[[=UQ:\''K4?H+PA:TOX
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M(Y!!4
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M@,CL_LJ[K^YK:COG6U"Y>B^>-8C5VL:O\2KUW?Y[Z>/0F9-ACZ9F
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MOAS;YMOBWQ;)P'6'>@
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MI"DJ(C(TJ3R2DF1\D9>!@FGR*6FG1\SD$D
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MF_IH9I2+P(6)+N$0
M     >5>2K*#539=16?C-G'86Y#J_JVX/USZ?W8YRWD+:CDO_C*(R(""T^E[
M1WLV%M6XN=17E+3:>>N(&6RTY%3V$A=K4U[5@J%50V4MJF(D-/H)+IJ01<\F
M0K453BTBGJ23='1%<-69SE>>5#-WD&!OX9 L:ZLM:4Y%[!N'9\.SBHF-F\W#
M9;.&\TTXDE)49^)F7/@*655K2G*A+.R-_P"&X%?X;BC-E1WN4Y3GV-82_C<7
M)*QF]J$Y$IXBMGJLU/3'6X:&B6IKR)4:5<\D0*+?$.27#VE2V<_PE_)'<-8R
MW&GLL8;4Z]C;5W7.7C3:$>=:G*Q#YS$$A'WCY1X%XGX"!5'5A;.UY93;:NK\
MWQ*;.H679%U$BY#5/OU4>.KROOV"&Y*CBM,*\%J7P23\#X 51]4^R]?9#&3,
MHLVQ2WBJL8]04BNR"LF-?BLOS?25WG8D+(ILKRGZ;7[Z^/ C )I\CI9K3XKM
M'&\XUC-NW$ILZ1^CR-O'KHH.1T<>]AN)CR&WX;AS*B:MDS<CN&23/R\ER0X,
MK'CEXT\:;:A<BXMIT:KXI^T^_2]0NZ5J-G4K"A*]8N1FE-*46XNM)1?-/DT:
MY6M-+]W>MV5=DLLZ=;]SO<%%UYSQJKL.M&]KM[+:K8N(E3L7%G^7,F?6W84.
M7-QS7]-Y/NNKX2?R5VF_.V5SM[M_0MP[6S,K)EJ.!*_?L7VI14HS<6K=*>"K
M2B?L;Y':=H/4=H'?[>N[M@]V-#TK2EHNLPP\/4M-A*U=49V878RRK;K"24IT
M;CP2\/$R#Q_<OJ]Y]>M99+UFJ6;3>.XSN*"+@-VX2YFJ[_&&72SA>;1&O*_&
M+%UM*-HG$H3),T*^!F0]KV8VWHV_+-[=.X+DL?9^G='ZIK[\KLFE"Q!OG*;\
M?X>)8KU:;@WCV+U:QVRVG8M9W<_6NO\ N[JKY'Z:,.N>?.G'RK<.2\;C468V
ML_W#V%U)K3JOO7#]L9YDFZ-X[]MM591"O\D=F83-6P\^4*+'H#:^C1 4ZQZ7
M"22?E5R1D9$+G=V^X^UMA;UQ=B9^W],N["R/*BY1@[>79C<C'\VW=3?SQZNI
MJ2:=*>)9#TO^G[N'WO[4ZMW:TS>^NXO>'2\3*RHPN7(W]+R[F-=E%XEW&<$H
MVIJ/1&=IPE&M>:+Z-T^Y]E,+2>N<.TYA$.Z[O[HRV?J/'-23U/*BX7F%.OZ?
M*\QR-GS-RD8QCT8_K&O.:$O\I2:O*2C%BN]6A7NVFX(:%I4OU=O/A&[@W51J
MY8N?=FZ<.J/W6N74FWP3,N?1]JNG^H3:61O;=\9:3@;?E.UK=GE.QEV.$L:'
M5QK=:3@Z5Z))\70PT;FPWLOIGJE+[N1NW6]K/MG7]DX.JK&2[F/&L[,I.1MT
MAU:L24Q] S2-2E>5+?!H]'DC(>,[N]N+_:W(P)6M2R<K5,G$Q[UR;;C%2O0<
MW"*K7ICP2KP?'@EP,@/2CZ@=N^I:[J^CZAM/1]+V/AYNHXMBU"WYF3T8-QVH
MWIWG1N[=HY-+[M4JM\3,-ICW2LMR;1&38;L#!8%/WUU[L"OT5D^F(ZGDU]KL
M&W))T.;U2"4Y)7A-I5*^O6I*C2@T*;)7!I4/>=E=!_\ $C5[^'K=QXF!I5J5
M_4+BI\EF%>,:NG5<:Z%SHW7E0QU]86J6_3_HF!K.R(+59[JO0Q] MR;K>R;E
M$X7NE54<9-SN.BK!4X2K2QO>&=;NPCJ3LWM]=;1SF3V+P'L_0:I*1#RVQ@X=
M#JYN75F.384#'HWEK4QHYSE&DE-F1DC@_B8OQWE[CZ7VEG@Z5MG1-*R]F9&%
MCW9V<BS6[<A>3<GYR:G&YTI=,D^$O P_](GI_P!?]4&3JNI=P]V[BTONCBZA
MJ5FUE8.53'Q[V$OR[:Q)+R+F/UJDXN/5*/C4R'Y#[GS?7SK_ +!>W_CZ)_9K
M65W3:\HM:8\YY)6[,SRN(T[@4S$(Y)<?.LOFWT.S7$(4F*A#BO\ BI%G^\6B
M:+L[!PMY;9E*]M'6K77B1E_66[BIYF-<?\5IOGS<:>//(_TG:ENSO+N34^TV
M]HVL/N)M6]T:K>BOR)8BJ[6H6UP2AD07"%4E<JJI<K$]I=/^P&\MF]3\K[\;
MDSRVM>Q&?V%?=: UQD=EAVK]/4'X+(N*S%J==3,1,M[UM"&BES)"UJ<<2I/C
MQR/,["[5X.^=K;CW)N^_DO4=-T^-['LVI*,(.5Q1?6G6M%[*4?-MEUN\?JCS
M.R6_MD=O^R6FZ9#0-9UNYAYV=EV%D963&%B<U*$I45E2E'@DN7@JFR_B.,5>
M%XOCV)4B7T4^,TM;0U:)+[DJ2F!51&844I$EXU.R'_19+S+49FH_$_$='8LP
MQK,+%O\ JX125>+HN!\^=FWM1S;N?D4\^]<E.5$DJR;;HER57P)C',?*
M                             &BA_P"9)/\ ^NO#TF7A_ _&#Y_25UD)
M<#83Z6E_Y>7GX_WA<_HP,'?4F_\ OOBKP_0K^G(H+["W_B3ZH_ZLYU_S%('H
M_41_NLS?]K:_IHZ3L!_O%L_]GN_L1^A2-:9GZ
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MG5*<1D3;=VW>K9LG*8[3>R'6/1GH:D172-2C02>301<0I)4H%&5>+=*OV?\
M&3([JO8EMUU3IJ!HV7CV<8O"@JL;N3+Q6/CV<MU>3-V=M4UM_"M)%J\64QD*
M<_UIIE'G5Y7#+Q,0WQ=.1+B^BE*L[N=ZNNLX:VMLK^'DK1U=CVLZ691LVCM#
M%L[G/,#L%955W\F)CT^?7QH]2S$.O;?6[ZKC;ZO DD1"8M+AXLB<*MM_<I]O
MM^@K[T[H[]_6![6SFF9J-B[MGGL+*XY'ZKL-F=':9HJA,A1J6J'75C:5,I/]
MPG3+X\B)\Z%<*]%6J290WJC;UF/[A[Y7EY-C5M/5;;@S;&?-<0Q$BQ(V(Q'G
MWGGG32VE"&T&9\F+]]S,3)SMK;,PL.$KF3=TN48QCQ<I.])))(Q%[$YV)I7<
M'NEJ>H7(6<"QN&W.=R348PC'"LN3;=$DDFS$_I79>MM']])NPU:BK=;:-[L*
MVQ!U%LN>:X->YG5=&),AQME:T1ZD\^DMJ-HUDDG"4GR^!CS._=0T[M/'1>S6
MEPA"YE9$,S5+L6WU9EQ_EV&^25E=*Z?!S9=_LUMS<_JAQ=W>JO<&3?R?[DP/
M[JV_BSBE*&C65+S\V$?O?VBXF^JGS6[<23-W*9B=>/;8DSGV8,.#WHGSYTR2
MXEB/$@PK&:]+EO/+-+;;##39J4HSX+@>5]7/3;[EXL;M%%1QZU\%Y<'Q^@N;
M_A?RE/L1KTL=.=R6GZ@H)*KE)Y,TDJ<VWP*K=8=Q:QV?[BN;]J9>LHM7JG*,
M[SO1^EMSR4J8J)^6U59'AW-K&4[Y6HZ\G4TJ/ZBO*2ED7E,^3'IMN7<;O-VR
MEE?I^O=6SK[CCS3;G?P+K?4NGF_);ZN"=%/P+9]RM)U?TE=\<?0;NH.&P>ZF
M!9R-0QW2-O"UK'@E9ZY+A%Y=I*/%IN5M<Z\*,]WR\OMCY<DS)!__ .@%81J-
M1$7_ 'FMF1FH_#@B+GGY#I?5NTM1TN7A_=>%_P"X9[G_  L83?\ ?]NE9K6-
M>_\ J9\?A[RI^_\ <VLM.^X=@7<*NU?$G:9Q[,\&Z_;_ -TP&52*R!FUQB\F
MNHLOEJC>>.^6,/RF83DDOW>#)2N221]ON.=OLWVKQ6[*AN'>%V,LQ\5.S@6%
M%V$X^'G2ZI.OWE%<SR';33]1]6_?W4M*AG2N[.[68%]Z-9^65G+UG+E/]<H3
M?-XUE1C'IKTSG+DF2?V_<8G^V%V7DPI#$N+8=^\;DPYC#B7(TF+*VWCKL>4R
M\DS;=8>:<)25$9D:3Y'Q^JSC8T:7A+0M/I[&O+=#O?\ #(^7=.Y(S7S0W-N%
M-4XIJ4DTUS33\"9-E;;QG;ON"66^*73M5LS1'0@]7X]L+958@YRUY[9U[\:Q
MNZPFC<BW$C7C,M*C6WSZ*$*]3P\ICD[4:CI_=+3M1[.ZVK3_ $[67H]^3=(9
MT5%7+'56G3D*+27\4/&J.J]2&UM>]-%W0/5)M>_E6LC6[=[3=SX%M?-=T*4V
M\;,E"G4Y8MV56^?ES?))F5OLYE6/9GMOV_,EQ:UA7M!?[J5:5-M6OMRH4Z$_
MB=FMMYA]HU(47"N#+XI,C(^#(>W[=Z=G:3MG>^G:E:G9S;.D=$X33C*,E=A5
M-,L;WGUK2]P;W[5ZSHM^UDZ5E;E5RU=MM2A.$L6\TXR7#_+PYF2TO@0L 9>+
MD1 D                                 -$K_P R(OGO=BZ>5'_L4Q4S
M)1>"#_$[PR2GP+E)D?/ZS,;"_2XO_+NZ_P#K]S^C P=]2;_[[8R\/T*_IR*&
M>PM_XD^J/^K.=_\ ,4@>A]1/^ZS-_P!K:_IHZ3L!_O%L_P"PN_L1^A0-:9GZ
M                                                   !#@OD7[ !
M$ 0X+Y%^P ."^1?L #@OD7[ !U9L&)8Q7X4Z,Q+ARFELR8LEI#T>0TX7"VGF
MEDI#C:B^)&7!D /&R!F[AXS8L87&IROH]4^UCD6U-Z-2(FM,>2"U,^B0IYJ"
MVLD^8FT\DDN"X'V8"P7G6EJ;N+3^M>8[:3GT5X]/5PZJ<J\#KM6>J1TR^]$C
M9EJ_E2\E77)6G<I\OF.*<E&O.BK3D8I\,]O[<V;9?G%]V)VY51L,V/ET3,\X
MU+J9JS@8]EMK!88C1H]U<V:D62Z<V8R?4CI+[_)D9\#)/5N]NU-(TS#PMB:9
M=EJ^!BNQCYN;T2NV82;;E;MPK#S*MTD^7 P=V[Z6.X>XM?U35N[>OV(;<UC4
M(YF;I6EJY#'RKD(PA&-Z]=I==EQA'JMI+JXU="[GM5TITUVMT%)T!E]2G':2
M Q#?U]?8RTS!NM;9#3H3^!7^+/(2GZ217N-I)2",DO->9"OCR6*NX<:>Y7<O
M:E<G/4)W'<\UNLU<K7KJ^;KS]IL8[;;DO=KLW'O;:LV8:7:L^1+%Z4K%S&<>
MF5B4%PZ''@N'!T9A#R7V=^\NY,%U?U8W5V*U"?6W4.:V.64VP\/QS(8^Z\EC
MSU&3L.RCR7T4T":_'><0IY#JDDI1J,E^!#SVZ;&\]\Y]F_NO+M9%RS;C#SFO
MS)QA%0CU*BZI**2J_95MLO)VPWGV.[&Z=F7NTV@YF!E9KN2_12N1>%8N7KDK
MUSRGQGT.[)R4*42=(J*Y9QV.E>AZ[K32]5Z;%FJ;6>.TT6!CQ5YDQ<5%O"_K
MX^61K!*2=+(_Q$SDKD']YQU1^;DCX%QMAZ[G=NM2Q]2VZU"=C@XOC&["7"<+
MB_$IK[U3%GO3M_![]:;J.G]P.K(>H2Z_,B^FY9NQ=;5RQ+G;E9:3MM<J4Y-F
M-S)_:\WAFVL$=7<LV7KBYZ_L[+:V6G)YE'=/[,EVC$HYC)S8ZY15#DEI_P 2
M<-Q1><O-Q]@OINSN#V=WOJ%C=NYM#S<K<6/;MJ&([L8X/7;5(-]*4W#CQA1)
MK@8G=L.U/JA[-:9E[ [;[PTS3-G9D\A7-1ACW)ZN[.4ZWH+KD[4;DO"ZI.2?
M%+P,FM?T\T6QUQL.KMKAL#(=5WU#+I\FK;=M,F5D$FQ+U)U_.EJ(WCO5S>)#
M<DC)QEY*#09>4A8W?.X=0[@ZKD:KN%J=S(73TI4A;@E2$+:_#&"HHTY4KS,J
M^SVV-/['Z3I^E;!<\9Z?/S%=K6[=O2?5<O7I?ZR=V3;N=7"2=.7 P>9E[,';
MYS5.1=,L*[9X2YTURG/H.=)D9E@TNRW1C!5L^/80J:-=1)3$2W*,Y%;)#ZW&
MC^X1F1%R0MQK>'N_7L3'TC4]0CDZ7B6HVK+NINY;M0;<+=:5:CU.E9<%P5%1
M&5FQNX79O8VN9F_M#VQ/ WWGWKM_)CBW%#"R,J_%1OY,K3^Y.[TISZ8T<JR=
M9-LS<=4^GVH^I>@J7K[@-4FSQJ/$FGEMMD#$>;;[!O+DE'D6096X;?DGR[A;
MAI4E1&A#));+[J1WNA84=O6;4-.E*%ZU)35Q.DNM.JG5<FGRIRHO86=[A;IS
MNYFKY6J;FC;NV<F#M^0UU6866G'R5"54X=+:::^9MM\RTC//;ARS'\QQ',.M
M.[)N 5V!95.S/"]8YM6N9=@&)7]FT\Q/<QF.J0W(K*^0W(<YC*)U"35]TT\$
M,I-%[\Z9F:7DZ5O_ $B&;>S<>-C(R\>:LY-ZU%IQ5UTI.2HOF33X<4S7INCT
MBZWIVOZ?N#L_N2]I6)I6=/,P].R[;RL'&R+BE&;QXN2E;MR4Y?EOK2K\KC0R
MCXLUD$?'Z5C*YE?89*S60V[V=51G(=;,M4,H3-DP8KJW'(\9Y_S*2@U&:2/@
M8ZZA+!GG79Z;"<-/=R3MQFU*<8-_*I-43:7!NG$S3TBWJ=K2\>WK5RU=U>-F
M"O3MQ<+<[BBNN4(MMQBY5:3;HN!,(^,[$
M      -%'_S)"?\ ZZL0/_\ I#&"X^?_ ,9R'Q_80V$^EM_^7MY?_D+G]&!@
M]ZDU_P!]<5^'Z%?TY%!?86_\2?5'_5G._P#F*0/1^HG_ '6YO^UM?TT='V _
MWBV?]A=_8C]"@:TS/T
M                     (<%\B $0!#@OD0 CP7R #@OD   AP7R( 1 #@OD
M '!?(                                    :)O_F1D&GO9BBS6:B<T
MGBQDD_@G_P"+7R."_E29_P HV%>EMU[>7E[,^Y_1@8/>I/\ _M<5_P#45_3D
M4(]A;_Q)]3_]6<Z_YBDCT7J(_P!UF;_M;7]-'1]@:_\ B+9K_P#+W?V(_0I&
MM,S]
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M/NN<90;7M49).C\'3B5N'0';
M
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M;MI1MQ5$EP27N/1'&5@
M
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MV=C/GY<TY1]TH?>B_BBK)>)$?S'FCVP
M
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M$<BVN'GV4WRK3KC^%M>#,E)>)$?S%@S,
M
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M/*CS(QNMF:2>C/I-*R^PR#B2>\
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M??-=9<HRC8\?JFB:IPZ"FV5],XG-)Z8KB>8L&\>0[^&&K@B,C\HJ=/+HOO\
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MZU(C)FY/*>5'<0Z25DIEPS2?)?8*;JI*GN*\>2E:37!.O[3(V.,Y@
M
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M/.J-2C(N5*/D_$ >L
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MFNPC"*IXGQ8MZ_?N2=Q=,8^'M]_$V-B^!?J'SGWD0
M
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M !2YMF[+LMV3V?V0VK';NU[?5DSI+)R9I>=D7:4<YOV?PP7RQ7!(N8'@"\(
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M&(5? A,HCQ8<2.VEJ/&CL-DEMIEII))(B(B(B'SG<'H@
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MLA:N+*XF5$ER'.E)A.1V(\0Y#1I<0P1NFHR(RY/]0J@D?'F3G&*4'2K,2_\
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MXF9F?@1$0 X(\R++2:HTEB0E/@I3+S;J2/Y&IM2B(P!V.2^9?M( .2^9?M(
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M]QRBG2*KX<#V\AUMJ.D1-QR1DU+'R"/28O,JY;5CE$F]M+>U=BJGP)M<=45
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MZJN\XGY,=P7'TB#:R$U0OHU>/G^"B^P4S5JGR=5?><EK]17\WHI[J_RE[1?
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M.55^U/2E)87C<U2'5$TUP:VR5]I^-2Z>J2J^93^>XI-1I3@E5</?]AD2[:;
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M9#B>?@9&9']@Y>?Q.K\F\N#AQ./_ '<=_P#/_<[G9_I.DD?Z)@4.Q??X2/\
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MCRI2V2N.?'@A#:1S8]BZKJ<E2*-C%/P+]1?X!PG;D0
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04I);IMD7W?,9\?8!'[3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tv523241_chrt-line1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_chrt-line1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#7 .$ P$1  (1 0,1 ?_$ 1   0 !! ,! 0$
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MH9>!:/$PI I[ZU$=RN5./?M0N1^@-H(U^%133=4G31O7@4T?"GB1B7'%X/\
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M<:B8G,SE+0TYX0R6TXHC["-)PJLLVJX:/=OX=J?)_>;"VI&)(*@
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MT"A5#QB%*DQ)%;B5.VIK,IQ!-I?1X)SE)2E$(WEW%Q1L/D9*+4N)&!!4
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M?(\$VDB2CPTJ(\YR<.S703Q*[5L/@3C3':$<B+ LI*/UB;9HI(T^@5/T[G>
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MIF?ZNH :%]3L\SZ  :%VZ%^C_D %#3Q_W=.[JG4_JZD .6A=X
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M58Y*)2M#T,]3/@(IQ);V$OR2(DD1=A%H7T"X:?I"2'R.0         &A=X
M         4,NW@1\-./89>:>A\ !@OB+8'AG">['-N[JQ7:Q3+[SS A1+UH;
M2V6[<4]$-A:YL6,RA'*[)=CDM6I?9F9]I@MCJ6;JJ453.C3CKJ?T.X!4J
M      "FA=NA:]\ 4-!&6FIEQ,]2X&1GKJ9'W.T 1P8GZ8NW[%6\2^MZ\5ZY
M+FR_>M-=IJ9%S24SXE!3(4KQEZE+<0IWPBD*-*-3_>TJ/3B(2H2Y)K<L7,DA
M$D                                                     !0_TP
M!4                             %..O<T_3 %0
M                       _1]  "[/K]H
M             !EKP,             _['_9_2                    UT
M_P"34 <==>PR\S@?F'KVEPT, 4\_QXI_8*]$ .1'J1'KKYO81^:7F "H
M
M
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M4VLU]32W'%H759\9QY1&HSU7VB"6ZNIZB!!37Z( J
M
M
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M?O-JWXPA\ K+FA[3=XOQJXS]YM6_&$/@%9<T/:;O%^-7&?O-JWXQ!\'V_P"
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M]J33BLOLQCU+C,]J++QI,S[IQFU'IVZ$,D?].7L(>]-F<XQD@
M         !0
M
M                                     #S[*NGP=W?S&>GK++[.!_8<
M.X?=%H?,1+<1^ZGY.?-J>GK[W^YX/MU&>O\ F%*;*$H8XQD     *:$? R(R
M[V@ J    #!/<-JK==L821:J3=F6'U:=QE.+:TRH^!]A.R&_,U,O,&6'R2[O
MQ*2WQ[_P9G8,1<
M
M
M  +"RBDEX^NY*BU(Z)-_BC$QWD/<1\Z%Y.7\_?\ R>GZ@S4^/V%.PE#& R
M          8*[B=4;KMC)EVJO'+#*C[=6U8KKSIIX]]QA)Z]O 9H?))]A26R
M45V_@S.H82X
M
M                                                           6
M'D[^S^[?Y$F_Q1B8[RKW$?/^7+^?OW S_K]A7C[24(<<R            8*[
MB_\ %=L8_KME?^Z>Y!FM_P"G/N,<_FCW_@S.H83(
M
M
M                            %AY._L_NW^1)W\68M'>5>XCY_P N7\_?
MN!F_7["O'VDH0XYD            P5W%_P"*[8Q_7;*_]T]R#-;_ -.?<8Y_
M/'O_  9G4,)D
M
M
M"P\G?V?W;_(D[^+,6CO*O<1\_P"7+^?OW S?K]A7C[24(<<R
M8*[B_P#%=L8_KME?^Z>Y!FM_Z<^XQS^>/?\ @S.H83(
M
M
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MF0C=O)34MD6FT2A@2
M
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M\KG4Z9FLU\3/4.!?$^#,^ *@
M
M
M   %AY._L_NW^1)W\68M'>5>XCY_RY?S]^X&;]?L*\?:2A#CF0
M #!7<7_BNV,?UVRO_=/<@S6_].?<8Y_/'O\ P9G4,)D   #4^^=:?X7L0>9E
M^S"^K56M0#W>U?>;/V(O[*,8?_>\LK_[6Z: /0P
M
M
M                   !8>3O[/[M_D2=_%F+1WE7N(^?\N7\_?N!F_7["O'V
MDH0XYD        "A:]TM/I@"H P4W%'_ .];L7[YWKE<_P#]$]QC-;^2?<8Y
M_-'O_!F=8PF0   -3[YUI_A>Q#_]^"S/_P"JM 'N]J^\V?L1?V3XP_\ O>65
M_P#:W30!Z&
M
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MQ+_\WEE?_:W3?K #T,
M
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M)E_\O<?]U_<?TLL&EIA7$J#/BG&]DH/NZ*3;M.(R^J/<'3^S0,BO_P"3L_\
MXN)_(1ZD.OJ'KDN#U?-O_P#3W#U8?8.D@
M                   0^;F^NQTS]HF4:GAW-V=95"R!1Y+D2J46F6C<M;\3
MDLJ-+K+LB!$4QS-J(R/E,RU$J,GN3964[<%_F24=E=M=WL1CY_J=NCK^457N
M';_]SB\O40G!<_:S'_)RW_B1]_Y%/]3OT=/RBJ[\G%Y>H@P7/VOW#^3E_P!\
M??\ D/\ 4[]'3\HJN_)Q>7J(,%S]K]P_DY?]\??^0_U._1T_**KOR<7EZB#!
M<_:_</Y.7_?'W_D/]3OT=/RBJ[\G%Y>H@P7/VOW#^3E_WQ]_Y#_4[]'3\HJN
M_)Q>7J(,%S]K]P_DY?\ ?'W_ )#_ %._1T_**KOR<7EZB#!<_:_</Y.7_?'W
M_D/]3OT=/RBJ[\G%Y>H@P7/VOW#^3E_WQ]_Y#_4[]'3\HJN_)Q>7J(,%S]K]
MP_DY?]\??^0_U._1T_**KOR<7EZB#!<_:_</Y.7_ 'Q]_P"0_P!3OT=/RBJ[
M\G%Y>H@P7/VOW#^3E_WQ]_Y#_4[]'3\HJN_)Q>7J(,%S]K]P_DY?]\??^0_U
M._1T_**KOR<7EZB#!<_:_</Y.7_?'W_D/]3OT=/RBJ[\G%Y>H@P7/VOW#^3E
M_P!\??\ D/\ 4[]'3\HJN_)Q>7J(,%S]K]P_DY?]\??^0_U._1T_**KOR<7E
MZB#!<_:_</Y.7_?'W_D/]3OT=/RBJ[\G%Y>H@P7/VOW#^3E_WQ]_Y#_4[]'3
M\HJN_)Q>7J(,%S]K]P_DY?\ ?'W_ )#_ %._1T_**KOR<7EZB#!<_:_</Y.7
M_?'W_D/]3OT=/RBJ[\G%Y>H@P7/VOW#^3E_WQ]_Y#_4[]'3\HJN_)Q>7J(,%
MS]K]P_DY?]\??^0_U._1T_**KOR<7EZB#!<_:_</Y.7_ 'Q]_P"0_P!3OT=/
MRBJ[\G%Y>H@P7/VOW#^3E_WQ]_Y#_4[]'3\HJN_)Q>7J(,%S]K]P_DY?]\??
M^0_U._1T_**KOR<7EZB#!<_:_</Y.7_?'W_D/]3OT=/RBJ[\G%Y>H@P7/VOW
M#^3E_P!\??\ D/\ 4[]'3\HJN_)Q>7J(,%S]K]P_DY?]\??^0_U._1T_**KO
MR<7EZB#!<_:_</Y.7_?'W_D/]3OT=/RBJ[\G%Y>H@P7/VOW#^3E_WQ]_Y#_4
M[]'3\HJN_)Q>7J(,%S]K]P_DY?\ ?'W_ )#_ %._1T_**KOR<7EZB#!<_:_<
M/Y.7_?'W_D/]3OT=/RBJ[\G%Y>H@P7/VOW#^3E_WQ]_Y#_4[]'3\HJN_)Q>7
MJ(,%S]K]P_DY?]\??^0_U._1T_**KOR<7EZB#!<_:_</Y.7_ 'Q]_P"0_P!3
MOT=/RBJ[\G%Y>H@P7/VOW#^3E_WQ]_Y#_4[]'3\HJN_)Q>7J(,%S]K]P_DY?
M]\??^0_U._1T_**KOR<7EZB#!<_:_</Y.7_?'W_D/]3OT=/RBJ[\G%Y>H@P7
M/VOW#^3E_P!\??\ D/\ 4[]'3\HJN_)Q>7J(,%S]K]P_DY?]\??^0_U._1T_
M**KOR<7EZB#!<_:_</Y.7_?'W_D/]3OT=/RBJ[\G%Y>H@P7/VOW#^3E_WQ]_
MY#_4[]'3\HJN_)Q>7J(,%S]K]P_DY?\ ?'W_ )#_ %._1T_**KOR<7EZB#!<
M_:_</Y.7_?'W_D/]3OT=/RBJ[\G%Y>H@P7/VOW#^3E_WQ]_Y#_4[]'3\HJN_
M)Q>7J(,%S]K]P_DY?]\??^0_U._1T_**KOR<7EZB#!<_:_</Y.7_ 'Q]_P"0
M_P!3OT=/RBJ[\G%Y>H@P7/VOW#^3E_WQ]_Y#_4[='3\HJN_)Q>7J(/+N?M?N
M'\G+_OC[_P BO^IVZ.G<W%5X_H8XO+U$)\NYR8_DY;_Q(^_\CUC!GS@WI8;B
M<M6;A+&.?9U0R%?DU=/MFEU2R[HH\:=+;9<?\"<^;$1&:4I#2M.8^.GT15QD
MMZ:,D+EJY_IR3\?R)JT+0ZA+C:B6A:24A:3U2I*BU)1&7:1D(+;SF
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MHIOP/YL]?U>[K^N9S7+T5"[G,S=O2BMT7<FYM+L3="Y1RCY
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M >'_ -@%&[Q'_ ^:%$,3[/ K^:?Z;OY&& ?D_HWVD*(8GR7@/S3_ $W?R+\
M^\"C?:0HAB?)> _-/=-W\C# /O HWVD*(8GR7@/S3W3=_(PP#[P*-]I"B&)\
MEX#\T]TW?R,, ^\"C?:0HAB?)> _-/=-W\C# /O HWVD*(8GR7@/S3W3=_(P
MP#[P*-]I"B&)\EX#\T]TW?R,, ^\"C?:0HAB?)> _-/=-W\C# /O HWVD*(8
MGR7@/S3W3=_(PP#[P*-]I"B&)\EX'%?2=Z;AI,CV7X",M#X%8-&(^SN'X$M
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MN7N7W1W_ /)7?/=[T:!_J&]%3ZK] LWJ]N*E_M;\Y\UMHVC>7'KH_F\
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M],>W;Q(O_$LTM?HMGY@F/S%7N(^O\N?F>O\ V^9X/M&?]?L*DH8XYD
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M>:*TX_B7Q*F_W&&&PBE=;/,'5F9VZ2.H]<6XO"NT>^[+N?/F4:#==<JN'Z]
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MZ'6K8=-#UQ46!1WZ;$H\MZDQ9!FA#*6E%X+SJC(CUK]Q>LG'>\7<OMX4)O\
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M2([,:?)?;Q-VQ/9_W2O_ (1B2#D             X*0DRXI(]---?TBU,^Z
M_ UP_G#G57E[!<#V_MWPM3'ZONMW@4^LV1B\HSC!MV?2:G*A6U6+KG,:.REN
MN*JQQX?(DB\.1JYBY=2+80]U=O\ ;]N!E-T*NG+-Z:VPNT<27I4H=PYCR-<=
M8S1F&YHS*O"R+LO2-2T1:&J;)-4Z6S;=!I<6/JXK0Y!/.$1&LS,3N5-U#)+)
M/5/Z>6)+]N7%N2=V>)[1OVS9!P[GMBJ5M;51HTI/*I<::AN*XEMU'#F+4^4Q
M%54LH[.'B8(;]-AVSSYP-B+%E<M#/Z:Y9&)[OGS(%PV!,?F4R7.E1TM38$QM
M+D;5QR&X9$HRU(E:EH9 J5J3+%&.#<G1\#,O=%OYV6=,;#5!CYURM1*"K&V/
MZ52;<L:"_&EWG<$6UZ W3*=$IE(-U)E(FIAI0CG6G52N!*,&Z%4N/!LT[MGM
MA;A>N%UN+!ZG]HXDKF$]LF%+LL^M1:G>$9PI=>I-F^--Q:?%J,>,S&F5BJ(D
MIU2E1D@DFHBY3,PI]Y+=4N5*?E]O8?)U)J,WT8.LO:N^K:U>% SWE/-]QW Q
M=.V>$3A7,IN^N6F5>A&_"147DR*I%0E#2VVC6V6AFDC+4YV4(DY.>)[GX[MZ
M[]F\R%ZB'74WZYJV@Y1PQ?\ TJ<V;3\?9MMIFP+NW Y"DUZ1;EA6W<\^GPZI
M6VFI5HTB&^GQ%Y2"-R0CSKGG2-1D(JMQ9JBJN7?]VTZ'+NTW">TKYK9GJD8/
MRY3\UTS)=S69>-U7A3&_ 1X]=D5FG+>HRXINO+8=IRSXZF1&3A:%IH*M<>TO
M;K5)NJIOY[27?YJ3I^:YLCO^O<[A_P"#9XBZW&*?S^S\392KD=J51JS%=T)J
M32IT=XS+AX-V(\VKZ7(H_H MY5[%5&B+T2G'K-^<&;S,>VR;<.S9%BWC4)<2
M$P3<-Z:S<[:F7#\'HCG-PN!]O 0V]B)A"/QS_4VO=3\S?.46A&?;YG?^Q^L)
M!H6?.2\M[JL:]7O99;&UW+=S6+=>3,)PJ/%A-U:I-6Q$ES;ZN"E.5:33(KZ6
MW'FXS9J-6G,HT$78#?,E5>Q-_;L.MSYT2NK)LSM*[^HQCSJ;5+)&9,?T-63;
M[M&M1+M9I=5@T]AJ9)I<!<NX*C D1X<4TI)#D5',V2M--3!NE7P(C%T45*3?
M;QW[^%.RA.MT^NMO;N<.DF?4'SA:EPR*MC*YZKB[*-*LNF19=1K5X4%NB2':
MK2J8R<:/#A38=P,*,C/1*DJ/L,B$>\E*KV[-_N_X51CRU\[%V,.HYRPKN5(M
M3+_T1IY]AF1Z'XZ6O8)PSY>\IYEBE<3_ .JSYYGSLO8S%;2KX$MRCBEK2A*/
M:G3T$:EF22)2O'%<I:J[=!*C-\"'=L)5Q/P9!U\YMW&N9ZW@=-ZD4A-2:Q-D
MBUL9Y,I]"KL=<68A%VU:C26VJE3E*6VW+:BU8DN$1F7.V1$9D%7N[/S,ER$<
M"KOK^6T_H.8^H=/IN/<=4"-'0FEP;&H5,98))$TF&Q;T.(ADD<4\G@5:$781
M!NW%7MVO=^9_/G^;Y>&QK\XCWM8[I4A]= F2<]PG8D35N&KQ2[7I\!UU@C-!
ME"\84DC[G:(WEG_EMP^V\_HMZER<3X<NFA'QX&>AD?F"-M2#1!ZH$V1=_P [
M-Z:UH55UQ^BVX]A0X<*3J[$(W2N>XY9LL*,T)\:?;0A7#BI&IB=VU$KXGA?!
M/\?R-Y2\K6I-Y6Y<5K5>.W(IERV]5J'46G4)<0Y#J,1<9TE-JU)?G%D9$>O8
M+1^9=YCGLBVJJB/YKG2 VJ6KO:W2]83I@UBX:Q:&$,@,7!=E(G492VYMO7!C
MK/M F6_+;CDZEIV(914H<8^Q4@SU%<3V)[43&"C&36R3HO"J3_XF[#AJUMH_
M0PV!V)CS*N6J/:^,L8%4FH]T7$XQ$K5YUZ8Y)JST.FPG7O#5&K/^>Y4$HDH[
MJDD9&)?);BR3W\:&KGE7,5Q_.7^HWMD5M9QC=%@;:MEMR3+PNK,M\1UE'N-;
MU8HDA4>(W!0;$9Z2=#T8:4ZM9EJ7FE5U>QEHT4L:VT+?^<>;A'<1=:_8FY+Q
M_-S+;6*<16O4(^*(R^4[JJ\VZKA6AA*?!O)):SCMDLR3J2$*/CH)KM:>[84E
M!22EMQ*OO_$ECKNY+YQ_4:$UN3QOMSV_47 35NMUZC[=IM5ISN4E6Y$B^.--
MNR'+>=D-OO4Y/(327O")-/!/80EM5JT0E))1V=M:U_+W$@/1KZIV.>I-:.3I
M<K",?;UN-QI<TBW,S8Z6W"74#J$!,>.FK+F-08,Y]ITEH3H\E9EH6BC+0A4O
M1M5X(FZ+CQ+L,20           !Q5]B?Z.Z -9GYP->]F6+DWILW)>MQP+;H
M%N;BIU3K=2J#B6X]/IZK;F--R'5*TT2XZ@TI+NF0/=45^_\ ,E1HO5-Z>42A
MT9H]V.*=4TR$7*JL/^%2:6&R-+J4Q#)*R/M(C,15%L$N-/%'8_G5^GC^5?BC
MV7D>HPQ(G ^:\4/SJ_3Q_*OQ1[+R/488D,#YKQ0_.K]/'\J_%'LO(]1AB0P/
MFO%#\ZOT\?RK\4>R\CU&&)# ^:\4/SJ_3Q_*OQ1[+R/488D,#YKQ10^JOT\O
MRK\5?2J[W^V&%4,#YKQ17\ZKT\^WRL,4_0]>'?4@C$A@?9XH^AOJF=/9427/
M7NSQ#'@P(K\R7*EW!X!IF/&2:W5J4XPE1F2$F9$1&:M.&I\#FJW<2,$J5X'\
M_P Z[GSD&[-_$&ZMJ&U:'6\<[8(];GTN\KID36DW#FV/2Z@MN&Y)3$0A5*M)
MQ3"7VH).N$ZHR6ZI9H:-%DL6U[BDYQM_"MLF:FIM(-!-Z$24Z<O#[$R[#+O'
MJ+NGL.*F_:;E'00^<JW9MA+&VRK>DNJ7U@^35Z?:.-<Q2:@ERX<3PI\@VH-*
MN(Y:5NUZTHK[R6VC-U+L-HR2DS0GE%9;$<B$E+L9_2#M:Z*#>EO4:Z[6JT2N
M6[<-.BU:C5: ZA^'/I\UI+T:5'>;,T.-/-JU(R[@JMQ<N     %A90+7'UW=
MG_D2:?'B7_1&7Z@M'>0]Q'U_ES_G_P#^3T_4&;]?L*5VDH0XYD
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M9A<?^9:G./LQ57N9^5/US]*9GIKZC->S%R.'+9_,ROPIN^*M?MVDF@V0>/@
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MIT%ETVW54Z-)G)0_4I2'$Z./):9;,R(DI/3F/&F]^YG(PVZ*,EB7V_X&9/\
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M/(A@E'O>QGYG_P!4[I=93K32.H[$?@O6)1N.E-OZ>_<;'8WX?DP
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M';,^*O!LH)""/N:F1<1.TJ?0                *&1'VD1_1+4 5
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M-?&8^FFNOAF]-.Z>O-IH1 0<4S82RU1+BK+OID-*+ZI+, <O&XOW3'].;]$
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M(CT$.KV.E"5AQ8JR4J<*?B66]T*-\+:"*+U4LLN:$9<CM-6VDN/ B4EY7;]
M1AV;D6Q;?FE[OR/T:Z$N]M*$\W53RXVKB9I:I1\A'YFKZ3/@&%?:H3_O2]WY
M'Z_F)][7_%7S![$GZH##V+WDXE^Z7N_(?F)][7_%7S![$GZH##V+WC$OW2]W
MY#\Q/O:_XJ^8/8D_5 8>Q>\8E^Z7N_(?F)][7_%7S![$GZH##V+WC$OW2]WY
M'%70DWL*TYNJKEY7*>I:TC70^S4M7^' *=B]Y&)?NE[OR.7YB?>T79U5\O\
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M P]B]XQ+]TO=^0_,3[VO^*OF#V)/U0&'L7O&)?NE[OR'YB?>U_Q5\P>Q)^J
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M%[QB7"4O=^0/H3;V3(R/JKY@,CTX'2CTX'P_^D=P,/VV_F1B_O2]WY'?8RZ
M&23W"83S+N5WS9)S[0<(UV1<ENV;58)0T*JBXLEAA7C:G'20TER09J+E,S+4
MBT$T1$GBWMMKN_ V8(<5F#$C0XY&EB*RVPTDSYC)MI)(21GW3(B$E3Z0
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MP/5("CY,>VNV/=)0?96!ZI 4?)CVUVQ[I*#[*P/5("CY,>VNV/=)0?96!ZI
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MV$\^K5C57%)\#^@(=6]_$R14(K=\5-YLKEKJ9_2^IK]#O@0<@
M
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M!;UWE9_)+_"_N9E-T]/\%&VSNZ8KMCO?<:5%^J!9T?@9ED1$6A "H
M
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M>5E\DO\ "_N9E-T\O\%&VW_[UEL__42!!=[S,T"
M
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MB"5O7>5G\DO\+^YF4?3M4:MDFVOF(R,L6V\GCW22RI*?VI$(+O>9H 0
M
M
M !8>3O[/[M_D2=_%F+1WE7N(^?\ +E_/W[@9OU^PKQ]I*$..9
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MMEQ+NHBD@].^6J0^\M7%M,S2/7N&7T2T FA4"
M
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M]7G3X<F+":)EELXJ(SB=&R,R2>D@;QZ1UN[K^CQS]ZGF>9*+IL6RFWWGY/\
MU,>D^F>BWJOG.A-(N3NY#+VX2C*;JWB<EO\ ^B9ECLYH
M
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M\UGU_4__ #B<XN/\&Q_VKI*T-F'B<
M
M                                  L/)W]G]V_R)._BS%H[RKW$?/\
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MG&=N<7&<6MZ<7M1V@N<0
M
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M]1]#ZY?Z<ZJR=[):UEY.,[5Q4:[4]TD^#3:+Z'..N
M
M                                           6'D[^S^[?Y$G?Q9BT
M=Y5[B/G_ "Y?S]^X&;]?L*\?:2A#CF0   !@-G'< !QYT&HT<Q<Q<3+ZGUP!
M4M>[](!L*@#!3<6>NZW8OYMZY7/_ /1/<@S6_DGW%)_-'O\ P9G6,)<
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MH0
M
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MD/"F?T[.Z5FI9+4+4K6:@Z.,E1H]NY+/934LM'-Y*Y&[EYJJE%U3+E'#.6
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M">7M7W/^/?5)6<Q"#HY0FME=S<722KQ6TREU'9JFF"H
M
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M3L'BL?\ @&/24?6#;S'<5\6C_P  QZ2CZP;14>+1_P" 8])1]8-HJ/%H_P#
M,>DH^L&T5'BT?^ 8])1]8-HJ4\5C_P  QZ2W]8*LCQ*^+1_X!CTE'U@VDU'B
MT?\ @&/24?6#:*CQ:/\ P#'I*/K!M%>\IXK'_@&/26_K!M('BK'\"QZ2W]8
M/%6#[6(_I*/K=X "C,EIHRP7'N-(+AYG#MU ;]CW$2O4TZ7EL[WJ-3KTLNH4
MVR<XVI ?A4NN2(Q^M%TTLW/&$4:XD1N1U2VGN;P$CBIOPAD?#0:YZXZ!RG4]
MK^9EL-O5HQHI;E-+<I=JX/V/92GN?Z/?K+UGZ<=0N]/Z_:NZCZ<9VXIW+,9?
MYN6N4PN[E\54JJF.&Q2PJFTU%:3<&Y#IW[A)U/8?E6/DBS)\9-6IRT$_3:Y
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MDH^L&T5'BT?^ 8])1]8-HJ/%H_\  ,>DH^L&T5'BT?\ @&/24?6#:*CQ:/\
MP#'I*/K!M%1XM'_@&/24?6#:*CQ:/_ ,>DH^L&T5'BT?^ 8])1]8-HJ/%H_\
M QZ2CZP;14>+1_X!CTE'U@VBH\6C_P  QZ2CZP;14>+1_P" 8])1]8-HJ/%H
M_P# ,>DH^L&T5'BT?^ 8])1]8-HJ/%H_\ QZ2CZP;14>+1_X!CTE'U@VBH\6
MC_P#'I*/K!M%1XM'_@&/24?6#:*CQ:/_  #'I*/K!M%1XM'_ (!CTE'U@VBH
M\6C_ , QZ2CZP;14>+1_X!CTE'U@VBH\6C_P#'I*/K!M%1XM'_@&/24?6#:*
MCQ:/_ ,>DH^L&T5'BT?^ 8])1]8-HJ/%H_\  ,>DH^L&T5'BT?\ @&/24?6#
M:*CQ:/\ P#'I*/K!M%1XM'_@&/24?6#:*CQ:/_ ,>DH^L&T5'BT?^ 8])1]8
M-HJ/%H_\ QZ2CZP;14>+1_X!CTE'U@VBH\6C_P  QZ2CZP;14>+1_P" 8])1
M]8-HJ/%H_P# ,>DH^L&T5'BT?^ 8])1]8-HJ/%H_\ QZ2CZP;14>+1_X!CTE
M'U@VBH\6C_P#'I*/K!M%1XM'_@&/24?6#:*CQ:/_  #'I*/K!M%1XM'_ (!C
MTE'U@VBH\6C_ , QZ2CZP;14>+1_X!CTE'U@VBH\6C_P#'I*/K!M%1XM'_@&
M/24?6#:*CQ:/_ ,>DH^L&T5'BT?^ 8])1]8-HJ/%H_\  ,>DH^L&T5'BT?\
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M>!R;FRW <TX&;;N-*I.,C/NI)V D_IF,L-L)%)-UCW_@S.H8BX
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ME>E<BK<9._E;<G7#=BD\2AM6*/!)T)K-2T[_ -#O'V?I#:Q^>9R
M
M                                            6'D[^S^[?Y$F_P 4
M8M'YB'N(^?\ +E_/W[@9O^\]A0E"'',@           &"NXS_%=L8_KME?\
MNGN09K?^G+N,<_GCW_@S.H83(                  'GF4L76;F*QJ]CV^Z
M4S5K<N"&Y%DLN)3X:,Z;:TL3X3JB,X\Z(M?,VLN)'P/4C,C^IHFM:AT]JEK5
M],FX9NS*JY/FFN*?%?B?,UC2,CKNG7=+U&"GE;L6FN7:N31J%;YMC]S;0[SI
ML=B?(K^.[C-ZIVW<T>,N,Y&?CR?WVE3C1JVS/BI4VH]#)*D*(R'Z >F7J9D>
MOM.G<E%6=6LTC<MMUJFMDU_=>WN>P\%^IOIKGNA=0A&S*5S1;LL=NY%4<6G5
MQ=.*V/M1*%TQ^HY JT&B;><XU-JG5>,3$#'-YU"5R1ZO%)KP;=O55Q\_WNH,
MK;+P+FO*HE<I]A#27K3Z07;-Z[U;TS!SLRK+,68K;%\;D:?I?%&Z?1SU:MYB
MS;Z5ZDDH9E?#8NR>R:2?P2K^I49/HE1*(C(R,C(C29&1D9'W2,NTAY8VUHST
M]5/=N.0                      "AD1EH?8?;IP^D ,&M[.P?#>]RSF*-?
MD=RBW?1V'F[6ORE,M'6*0:^928[O.1%,@>%6:O!J/SNJC+34QU+JKI#3NJ,L
MK>8K;S<52-Q*K78^<:[:<.!Z/^G;ZF^O_ITU^6H=,S68T',23S.2NM^5=2IM
M7[9T26);Z*NXTD]X6S[+>Q_,,ZSKF*HO4N)/3+L3)%-8D0(-?B%R2(<N+);/
M_J=38U(G6N;5*RX<-!Y5ZBZ>U'I75)9'-UV.L)I/#<CPE'\5OBZG]%7H'Z]]
M#?4?T%;U[1O)CG;EK#G<A<E&<[$OEE&47\]N6W#*FU/:;"?3/ZS-LWK2[)P#
MN9>8MF[Z72J?;5NY0F3%*I]WN1?^JP$5_P ,1^(U5;"6VS=(^1Q:=3XJ,QMW
MH7U2MR5G1.HJ1:2A"_6J?!1N\G2B4MSI66UMGY7_ %@_T_=9Z=SNH^J'H_&6
M<T"]?N7[^G0BL>54OBF[-/GMIU:C3%%.FY&QVAU#B$.-K2XVXA+C;B%$I#B%
MD2D*0I.I*2M)ZD9<#(;Z1^3$HRA)PFFIIT:>]4V.O<S] *@
M
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M8
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MSC);5^)JK;X=EMR;,LFTNKV34Z_5;&EJBU>S;OE$93Z5/:<YW:7-EQ4I24R
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MTXSBU6CI55WI\ST4<]5.J@2
M
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MGW-;4;,]3_1_KGT@U'+:5UOE5ELWFLO"_;2>).$XJ2=>YHR!'9C5X
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MPZLT^.AZQ-?\PY:-&WL\V*JE-+FU2O;4ENU+_9^CZ T(;U*@
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MUS1_.5]0WTV==?3SU)_MG4EOS='OMO+YF";MW(\$WN4Z;T9NE^C4=O/.F\J
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MA&1]G'4M2/N&7?(^\.SFL"H
M                 +#R=_9_=O\ (D[^+,6CO*O<1\_Y<OY^_<#-^OV%>/M)
M0AQS(           !@KN+_Q7;&/Z[97_ +I[D&:W_IS[C'/YX]_X,SJ&$R
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M\#V5Z4>IF5ZVTU9+..,.H<O"*N1K\]$O\Q=^]KF28Z]SN\-2[PTQ4W <A(
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M:5V5J-V-V,5LBYPDL>ZLJLGH(]1NH_,LJ
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MF+>;O].Y.TKTX24HPE"U&U&#DFTWABFU78VT]IL3E]'7@7<T^B-]'Y2%0
M                                                 %AY._L_NW^1
M)W\68M'>5>XCY_RY?S]^X&;]?L*\?:2A#CF0           #!7<5_BMV+Z^[
M7*WU?@GN33],98?Z<N[\44G\T>_\&9U#$7
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MY<G=S,VW*<Y.4I-[6VW5M]I]PN8
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M8FZJQ*HKQ")2,FT>F3G[3N>+&9;EOU%J.MR%3:FZE*5R(<F0VE&JS,T$K4N
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MT@!4 - (H@!(        -2[X
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MXAUM:2-#C:TN-K29:D:5I,TJ(R[I#7<DXR<9)J2X/8=\C)26*+31SU(Q'"O
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MN9_]K[1JYK^H8?D/S-=SYI'_ ($<X?\ ^3]Z_P#R8F6]]Y6W_HP[C:S$%@
M                                            +#R?_9_=O\B3?XHQ
M:.\K+<1\_P"7+^?OW(S?]Y[""4(<<N      !33_ ).X *@  ,%=Q?\ BMV+
M_P!=<K?W3W(,UO\ TY=Q2?SQ[W]S,ZAA+@
M        '0W+;=&O"WZQ:]Q0&*E0Z]3Y-,JD&0A*VI,.4V;;C:DJ)1:D1ZI/
MM)1$9=@Y&3S>9T_-V\]DYN&:M34HR6]-<OQ./F\I8SV5N9/-14\O=BXRB]S3
M1K;]2CI^XDVI;9=P>ZVSY$]F)C.DTFXHUKI6I:)!U2ZZ%;LEO4BT(F2K/.GS
M$CT1IOU%:[E\G&QJ%F-[,)4Q/W?VF@=3^G[I_,9^>;R,Y6,NVY.$7L;I5]G
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M]RU<LS=J[%QN)T::HU[&;(A<A=@IVVI0>YK:CZ10N
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MHWK,-M?AA.44O90]M'VS7@    !34N^ 2KN&I=\@%&5
M       !C1O*E,0]I>YM^0X3;18&RFT:CUX+?LJN,M%P_7..D0 UX/FD#B%[
M$,WFA1*(]S]ZZ:'YC9_J"9?,^\K;_P!&'<;6VH@M4
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M=9O*R=(W;;?^)?F<)Y#/+?8O?]27Y'[>N$'[NA_?#/VP9?-M_NCXHI_%S/\
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MZ[97_NGN09K?^G/N,<_GCW_@S.H83(
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MTW4-(S4LEJ5F=G-0='&2:?\ :NXW-D-0R6IY>.:R%V%VQ)53BT_^!=0X)S
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MZCH.M:1?GEM4RF8L7K<FI*=N4:-=K5"X]3[OTN!_IGV#E'R2H
M                         L/)W]G]V_R)._BS%H[RKW$?/^7+^?OW S?K
M]A7C[24(<<R            8*[B_\5VQC^NV5_[I[D&:W_IS[C'/YX]_X,SJ
M&$R                                     4)*2["(OH$0 :%W@!4
M         4,B/4C(C(RT,CXD9=XR[P;B*)['N,1L[[)< ;@42Y%Y6A#BUZ2V
M:4W%2F&8M2;<Y.5+RC0E*9"D\#\]VF7:._=+^I?572CC;T^_*66C_P!W)MQI
M^!TGJ3T]Z9ZI3GJ-B/\ )?ZTEB1!MG#HMY6L]JJW!BN]*9?%,C+?E,T=Z&Y
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M9C3+]N]::_2TVO8>B#Y)],
M            IH7^P >:9=Q+8V;\?W!C'(U(9KEG7,U%;J],>^PDE!FQZC%-
M1GKQ9EQ6UI[RDZCXVO:'D.HM+N:1J*;REW#6CHZQ:DFGP::3.W]"=<]2>G'5
M.5ZQZ3ORRVO9-R=JXM\<<)0EXQDT^QF$B.DSL;0VA!X=HJ^1))YU$9J41%VF
M>O$QKY>C'1B5,%]__>2_,]%R^N+ZCY2<EK^857PW!72:V.*^QP[14=_SI_I&
M9@_1CHQJF"]_^$E^87UP_4>GMU_,,RGP#MGQ#MGHE:M[$%LQ;8I-P3V*E5(L
M5.B),R.PJ.RZKNF:65F7=X#N73'26D])Y>[E]*4U"[-2EB;;JE1;S2OJAZP=
M=^L&HY?5>N\Y/.9[*VG;MREO49/$UXJIZ9<^.[%O*$_ NBTK?K4>2A3;A3Z5
M"D.<J]=>5YQDW4&9GW#+B/M9K3-.SNW.6+5UKC**;7M:J=/T;JOJ3I_,1S.C
M9[-9>[!IK!<G%;.:3H_ CDS#T?\ 9OE=<V8S9#=FU::2U+GV^A+?[\LN+W@3
M4E'/W1T#4_2GI?4,Q+-6U<LWI?M=5V;'L/6707UY>OW1$;>7GJ+S^2MTI"^V
M]BX5VNA&+DGYN>PXY(E8MW .M>%4I;-.NNVT$RP1J/1KQJ!(=<6DBX<QI(R[
MPZ1FO1/-8ISRF=MRA^F,H.+]K3=3V/TE_5CNPA"QUITM&6%;;F6S#J^W#.*2
M?94C3SET:MX^$77IM'H<#)D2&?A6I]C*D^.^"2DE>&;C/H;?\*DSTY4^>[HZ
M1J7ISU1I-F=W,0Q6XK?;K+$NY;?$]>^F_P#4"] ?4>,<MJ&8NZ/?N*DH9S#@
MKR<HMJCWU>PP^I61-UNVNO(;.IY-L2JQ%ER0:J=990TM&FJ2;=-2$DGO#J&7
MOZGI*=W*RO9:Y7YDW!^#H;ZSW27H?ZOZ8Y*SHVIY&:VSM>4VT^-5MVDAN&.N
MENLQNZVU>D2E92@L(Y3C5J6[ D*Y"))DJ2TRI1*,D\"TUU'=M&]4NJM)MN%R
M<<XG_P"+7QQ1V^X\J>H/]-?T3ZN@Y]/7+VBYF3KBM04X[>46Z4[21_'GSBG&
MM1-E&2\'W#;JG#;2X];E=B51EKFT\(ODFMQEFE&NNFNN@[QE/6Z*A'_<,A+S
M./E337LQ4?L/)?5?]*+K#*8I=']1Y7-I5HK]F5MNFY? Y*K)2,*]3;:'FR Q
M*I63Z/:TN0I"&J7=\N-29BEKX$A)+=4VI7-P+CQ,; T[U(Z3S\8^9F8Y>_)T
MP7?A=7XI^)XO]0_H]]=O3O-2R^=T;,9VQ!5=S*QE=@ES=%5;#.:BW+;]Q1&9
MU!K5,K$-\M6I-/FQY33A=])M.*U'=K5^S>BIV9QE%[J-.O@>;M0TG5-*OO+:
MEE[UB_'?&<)1:[TT=V0S'SRH                H9\O$^S]'U"\T =6FMT8
MS-!5BEJ7S&GE\?B<Q*(]%),B=,^9)]SM FA15;HZ5$2JS2D\>)*G1"5] B-X
M@!V:'$.$E2%)6E9$I"DJ)25I,M2-*DF9&6@$',      6'D[^S^[?Y$G?Q9B
MT=Y5[B/G_+E_/W[@9OU^PKQ]I*$..9            ,%=Q?^*[8Q_7;*_P#=
M/<@S6_\ 3GW&.?SQ[_P9G4,)D
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M?Q+V;SV<AUX^^5
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MNV5_[I[D&:W_ *<^XQS^>/?^#,ZAA,@
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M5QJK@W22[T9&=S]'_8'4#M)4
M                          !^+\=B2@VI#+;[2OLFW4)<0KZ*5$9",*::
MEM3YE[=VY:FIVI.,UQ3HSPO*.V/!69J1*HF1,;VY7H,U!HD<\)N/(6@^7@4A
MA+;B#X=PR'P-0Z6T'4[4K6:RUOXEME%89>QK:C9/1GK%ZE>G^?AJ72NKYO+9
MFTZQ^-R2?^%MID:&4>A'LKOWPKEM,WKC*2LU.(5;-7;DQ4NGH>KD:H,N>$:+
MN():?HCH.<]&^G+EJ4<A<OV)OBWYE.Y.GWGL#HS^I;]0O3&&&L2T[6+*V?\
MQ%IQE3LE!JC[:,C;S#\WDOJF&^_A;*4.X([9+6B'=S3<*4XE/$D(<CFIM2C[
MFNAZCH^K^C>LY6UBTB]#,SXJ5+;IV;T>N.@?ZJO3F<<;?J'HMS*W73XLJW.*
M?-J6U(BIR/T^MZ6!YU2<D8WNDJ?3732=?ME3KT1_E5IX1OP&CIEKWR[@U[J_
M2>N:9)6<]EKLNZ+E%?\ 26RA[8Z3^J;Z>O4W+VHV]7R7\J]'_1S%%*/8\6SW
MG1XRWQ[Q]L]1DPK4R)<5N3#046;3Z]%<F(4TTYS$RN-.\XA1.(^R(M=!BR6N
MZ]HGP9#,W\O6GPQEL:6W:G4^CUC]-_H!ZOY6&9UO2LKF[">*%RS)0HVJ54H;
M7LX;B0C%W7_W46HAJ%?MHV'D&(2D$[.D-S:54DI+0EK)R&HV5DHNX:/-'=\E
MZO=5Y=PMYC^/>M+>YQ:D_;%_@>6>L_Z7?HKK;EF>E\]J>EW]M()PN6Z\%2>U
M/VDG&&>OO@"[6XU.RC9U<LVO//(;)ZD+]<J-R&E!+6XZ^3+[2TN'V:&1E] Q
MWG3O6C3KUY6-2REVTGOG!J4%XTD>-_4#^F#ZHZ#*>;Z-S^6U#381;I=7EW:[
M:)*-8M4X["5?%.]+;5F6-&79.4[:E3'_  :3I,F<U%J3;CA$:6E,.F6JM>'
MS&Q=)ZSZ:UJYY.G9JW.\J?"]CV]C_ \4=;?3YZO= 79QZBT7.0R\:_YL8.5M
MI<5)<.\RE0XAQ"7&U)<0M)*0M"DJ2I)\24E1'H9'J.T;]VXTQ)2@\,TU);TS
MEK]+Z.G^PS @J    #"#J4DD^G[O+-9$I"=MV8'%\VAIY$6/6EF9Z\-$D6OF
M"KW%H_,OMP,+_F]B5(Z5.V]*]265*DDK7MU\7IY?2[!=TQ/O,5O_ $H_X437
MZB"X      %AY._L_NW^1)W\68M'>5>XCY_RY?S]^X&;]?L*\?:2A#CF0
M        #!7<7_BNV,?UVRO_ '3W(,UO_3GW&.?S1[_P9G4,)D
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M_E'3#MQ4
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MC[Q&]4$%J,L/].7<4E\RYI_@_P S.D8BX
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MI^!VHP&<
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M^>\OZAM)5^FI9F/3'I"V].OUYP]T:'X'?U2&WZQZ>F__ .G1^^A/T-Q'Y@@
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MYLS<;3SJ6O+S;J/X%HK3C.&_KW^8N7Z8R1^27VXE7\R?VW&<PQE@
M            ( $@
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MF$^[%%.GLJ7QKYGZ.(^8<\:_H/@%05     _1J
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M#>.MI*I&6:0T^9>?0S2J6MHCXZ<IJ22CX%W>Z%8<"<+K\S.1X_WA=S+=-/\
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MPB^F?*,D/].7VXE7\R]OW&<8QE@
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ML07UEVNQ%8OK<M3"C[J#DQ&E_10,MM?!+N*2?Q1[_P &9U#$7
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MI0PY#7M%U23CIV:L7I+>HS3]R/3!\8^L
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M -T]R#-;_P!.?<8Y_/'O_!F=0PF0
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MUEI8<Q;G;ERE%K[T=HM9G+YA5L3A-?W6G]QVPP&8
M                  +#R=_9_=O\B3OXLQ:.\J]Q'S_ER_G[]P,WZ_85X^TE
M"'',@           &"NXO_%=L8_KME?^Z>Y!FM_Z<^XQS^>/?^#,ZAA,@
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M<^XQS^>/?^#,ZAA,@                                 4,N[W=-!%
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MTL5V;;<KDN<I.K;?:]FY;$C,\:^.[@
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M?^Z>Y!FM_P"G/N,<_GCW_@S.H83(
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M_P!'<'',Q7M %-! *B=P
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M_KME?^Z>Y!FM_P"G/N,<_GCW_@S.H83(
M
M                           4T_4T %#0D^!EYG:8 $A)%H6I%KK]D?;K
MKWP!73L\P 5             4T  B(N_]4P(2H?C(BQIC*X\MAF5'=+E<8D-
M-OLN)UUY5M.I4A9?1(Q:$YVY*=MN,UQ3H_%%9PA<CAN)2CR:JO>> Y$VK8$R
M?#=AW3C>W%^'42W)5-I\:F2U*+4^+L5I!'KS'KJ6H[7I'7/56B7%<R.<O;.$
MI.2]YUS5.C^F]8@[>>REIUXJ*3]Q'1FKHX8DO"*2\55]VQ:@3JG#:J3;DZ"Y
MJG@VIR,WXPA)*XZDD^T;=Z<^H;7=/G_YY96:MM;XNC]^PU1U'Z!]/:G#_P I
MF\K<KRJN[9M[2/F_>BIN*I*#.SZS8=VM(4XIU'KH[ 4ZV2>!--U%B,HW5?5&
MV-*^H_I#,/\ \PMYK+RX?"I4??%O9R-2ZM].'4]I-:;=RMZW5U4FU5;MB:WO
MBV80W_M,W1X*F'3I5H73;;YI4\4^WRG)8/P2B2;C4J$>AI(RX'KV$-E:5UWT
M5U/#SH9BQ?A6E)N-=O!IFN=0]/>N.F8NSE[-W+W4OFMU7M31WN/=Y6[7 [C5
M+HMYUQ'(I"WXET-OU G$-IY#0DY)J4C3C],<;5O3WH/JF/G9K+6^QVZ1W\Z'
M+TGU"]0>D[BL6[\KDW2JO)OOH_S))\3];FJ4:)'I>6L>3+CJ!:I>JEO2(,8R
MU,M%+8E2&-2(NW0:=U[Z:\OF)N_H.;C8L\(W%)KW)FW-#^I'R%'+:]E9W<SQ
M=MQ_%HSCL+K#[1KM>BTZL56Y[0K#YI2J-5:!)=B(-1Z%I/B&\QH1]O'@-8ZK
M]/G7V0C*]EH6<QEEQC-)_P#5=&;(TOU^]/\ /SC8OW[EC-R_3*#^];#/6S=P
M6&;_ (<6;:F1;8JB)B$+:914XZ)>B]-"<BK6EYM6I]AD-6ZCTGU'I5R5O/92
M]!QWO"Z>)M'(=2Z%J=A9C)YFU*W+^\D_ ]@;=;>;0ZRXAUMQ)*0XVHEH6DRU
M)25),R,C(=?:E%TEL9]Q-258T:9^@BI)U56KE'H,<YE:JD"E1"X&_/DM16]>
M\2GE((_I#/E\KF<W/R\M;G<GRBFW[C#>S%C+QQ7YQA'M=#\Z1<-"KS1OT6KT
MZJM%VN0)3,E)>:9M*5P\T3F,GF\H\.:MSMR_O)K[RMG-9;,[<O.,UV-,[@CU
M[OF_2''.05      %AY._L_NW^1)W\68M'>5>XCY_P N7\_?N!F_7["O'VDH
M0XYD            P5W%_P"*[8Q_7;*_]T]R#-;_ -.7<8Y_/'O_  9G4,)D
M
M
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MEM_)+N_(I/YX_P"+\&9U#$7
M
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M7+N*37QQ[_P9G6,19 "0
M
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MU/\ N&']ZL>@ 40];J?]PP_O5CT "B'K=3_N&']ZL>@ 40];J?\ <,/[U8]
M HAZW4_[AA_>K'H %$/6ZG_<,/[U8]  HAZW4_[AA_>K'H %$/6ZG_<,/[U8
M]  HAZW4_P"X8?WJQZ !1#UNI_W##^]6/0 *(>MU/^X8?WJQZ !1#UNI_P!P
MP_O5CT "B'K=3_N&']ZL>@ 40];J?]PP_O5CT "B'K=3_N&']ZL>@ 40];J?
M]PP_O5CT "B'K=3_ +AA_>K'H %$/6ZG_<,/[U8]  HAZW4_[AA_>K'H %$/
M6ZG_ '##^]6/0 *(>MU/^X8?WJQZ !1#UNI_W##^]6/0 *(>MU/^X8?WJQZ
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MY6+_ /1/<8RV_DEW%)_-'_%^#,ZQB+@
M
M
M                  !8.4D$YCV[DGV>LLP^'?)LS+],A:.\A[B/K3_W<=.Y
MZ_:?2Y!F_7["A*&..9     !YO=      &"NXK_%;L7_ *ZY6_NGN09;?R2[
MOQ12?S1_Q?@S.H8BX
M
M
M     6'D[^S^[?Y$G?Q9BT=Y5[B/G_+E_/W[@9OU^PKQ]I*$..9
M   ,%=Q?^*[8Q_7;*_\ =/<@S6_].7<8Y_-'O_!F=0PF0
M
M
M                                 +#R=_9_=O\ (D[^+,6CO*O<1\_Y
M<OY^_<#-^OV%>/M)0AQS(           !@KN+_Q7;&/Z[97_ +I[D&:W_IS[
MC'/YX]_X,SJ&$R
M
M
M  !8>3O[/[M_D2=_%F+1WE7N(^?\N7\_?N!F_7["O'VDH0XYD
M P5W%_XKMC']=LK_ -T]R#-;_P!.?<8Y_/'O_!F=0PF0
M
M
M                                +#R=_9_=O\B3OXLQ:.\J]Q'S_ER_
MG[]P,WZ_85X^TE"'',@           &"NXO_ !7;&/Z[97_NGN09K?\ IS[C
M'/YX]_X,SJ&$R
M
M
M !8>3O[/[M_D2=_%F+1WE7N(^?\ +E_/W[@9OU^PKQ]I*$..9
M ,%=Q?\ BNV,?UVRO_=/<@S6_P#3GW&.?SQ[_P &9U#"9
M
M
M                                  L/)W]G]V_R)._BS%H[RKW$?/\
MER_G[]P,WZ_85X^TE"'',@           &"NXO\ Q7;&/Z[97_NGN09K?^G/
MN,<_GCW_ (,SJ&$R
M
M
M    !8>3O[/[M_D2=_%F+1WE7N(^?\N7\_?N!F_7["O'VDH0XYD
M   P5W%_XK=C']=LK_W3W(,UO_3GW&.?SQ[_ ,&9U#"9
M
M
M                                 L/)W]G]V_R)._BS%H[RKW$?/^7+
M^?OW S?K]A7C[24(<<R     '45FO4:W:?(JM>JM-HE,BI2J14JO.C4VG,DK
ML-V=,<:C-E]%1'P#[@=1;%^67>K4AZSKNM>[&HBDHEN6U7J;7$Q5+(^5+YTU
M^231JTX<QIU EJA=P$  8*;BB_\ >MV+^9>N5_[I[C&6W\DNXI/YH]_X,SK&
M(N
M
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MF(2W)\">I$GPJ$D1^8%=E. .Z
M   ?)-A1*C%>A36&Y,20CD?8=+F0X@C(]#+S%$1A6FT'[M-MM-H;92E#2$DA
M"4EHE*4EH1%YA$#;;JR$E'8MQ^@$@
M   'Q3X$*IQ78-0C-2XCZ>5UAY/,VX7;H:>[V"4VG5;R&DUMW'[QH[,1AF+&
M;2RQ';0RRT@M$MMMI)*$)+N$E)<!#=74G=L/V
M             '!Q"'$+;<22VW$FA:5%JE25%HHE%WC(^($->!U]+HU+HS+C
M%*A1X+#SRY#C<=!)0MUSBI9E^N48EMO?P"26X[,02
M                ?A)CL2V'HLEI#T>0VME]EPM4.M.)-*T++NI4D]#!56U;
MP<(<.+3XS4.$PW&C,))#3+2>5M"2X$22[A!5O?O(22W'U 2
M   !0RUX'_M+]0 "(B[-?JF?U-=0 +7NZ?\ 8[FH X+6E"34I1)2236I2SY$
MI0DO/*-1EH1$7;W@W[%O!!CN5^<6]*W:QFR9@;)>;Z_4+SH\J+3[BG6!85SW
MO:-MSY<Q<,X59N>@PI5,9DPEMFI]#:W#90>JA-&MM"*P>QM)DR.+<IX^S58-
ML90Q;=5)O6P[QIC56MRY:+(*3 J4)[7SZ%$25-.-J2:5MK)*T+(TJ(C(02>@
M@                                  \7W$Y\QSM<PEDC<#ERHU"E8VQ
M5;<JZKOJ%)I$^O5*+2(CC33KD.D4MF1.GO\ A'TD2&T&?'7L(PVO8MX;257L
M2(((OSKOHM2(#TUS/^2(C[;9+*F2,!9B.>XLUD@VFBCV>]#-Q)*YM?"DGE+M
M[@$[-VPRBV-]?'IR=0W.\3;CMGR'?U?RE4+;N*[(=*N?%MY6G3I%'M=AJ567
M$U>LTUB$A]B.\2TMJ6E2R(]-3+0148=E2:0CU+_L&79P[#$D%0
M                      'AFX[<7BC:EAB_,_9MN/VIXQQO2'JS=->*'*J#
MD2(UH6D>#":>E2Y#CBB2A"4F:E'H WEI;.MWV#]]>WVR-S6W6X:A<V)[_776
M+?JE6HE2MVJ>-VS7:E;=:ASZ-5H\:;"D0JK2G4&2TZ*(M2,R,C EJAD\>A<=
M=.^>G#Z?T-?TPJ01\;1.I_L^WQ9-S1B;;ID&H7C>.![CK-LWZQ)MJL4FF-3J
M%5UT2H/46K38;<&M043F^5#K*U)<29*+AQ$%FJ>PD)$E0
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M(DJY^'GM0K7?O)P85LIA6Y=FVAMI%V%]#N]H$%0
M           %K7M95JY&M*OV-?%#I]RVE=%-?I-?H-481)I]4ITDB)Z+*8<(
MT.-KT(]#[I:@.\@FZD^UKIV;&ME&<<\4;:!ANHWU1[950,:43UCA,U:NW]=\
MN+;5 AT9;IN-G/8DU7QDB)"CT9,NZ)Q2:I5E5"W%UPQ\%^7$\5^;]]'2@[,+
M?K>\7)=/I;F?]P5(.L4^ELTU<=6-+4N0TSGJ*RZ^3:RGU%DTDZ2$)0VVI1%K
MSJ!NKJ]_VVDQAY<<"?VKN]GVW&S61:%Q[?,+3_:8@DJ
M              *'KPT[X TJ_G1.#.I%7]J&;<NUC<5C:B;0+1KMLH/!EL(N
M&/<USTR;46F8TNO35T6- DOPY2^+2Y+J5?[I%S:E#W]A:*I6CKL^WV\25GYL
M2EDNBCM!\"TEK][RHI9-H2GG>/+=[>%=5RZ<RW#,S-1\3U /AW'#JK=2/)%H
M9.M/IR;,K5DWUNPS[3W*+4;EAS4E3L-6Y6HIM2KAJ2(S;TANIHISINMFOP:&
M4GS&?>G>MA5NC5-_Y<604?-$;/J&/-R6_+'-:F%6:_CFY+KLRLW#X-27:U4J
M%>J*9.J+INF;A+ERXBEF2C,^/'LU#M+?I:7-?<T;ZI&1]GZ.X!4J
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MI0%FZXX9FI:E<_:?$SU#B'2FSG^"-R0"H
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M)="G&ZTO1*'FD%3B/5.OV9:]I:J/>QC4ULW5IX5V^W\#;J @
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M<Y4I4>A$DNZ0.OL(PPKB2^+_ (+\$3)D6FOFGK^D1?3[ )*@
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MY>!$DDD1<$D1:::%W-"(B^@0 Y@
M                           "FA:Z_H_1Q %0
M               !0R(^TM0!4  !30B^F *@
M        &FO;Q                                       !30N]]4
M5 %-"_5_3/7]4 -"UUT+7OZ<0!4
M
M                                   U+O@
M
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M(R_5(@!4
M
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MWM;F]E-X87OZ=>."*JW0;<JE <8EM7S62I5.J#\<HZT$Y"9-53;)"R)>I&7
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M(<H13;4TEV&QUM+W889WJX-L[<'@>YFKFL&\X9/QGM"1,ITQHDE,I528)2_
M38BST47V*B/4NT.TEJFPR6 @
M
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MBMT)N,LUMZ&HE%HH^)D>IB:23I^ Q)JM/>77T&-NF\'".]G<A7<TU>A4:B9
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M#MFZWB-<A9KK,Z;*4S+Y5&TK5)<I:::$1G5(M+GPJ36B2H
M
M                                                 #\SM &KK\Z
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M[>Q(F0 D
M
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M;H!8K]?Z_P#M @H7Z.W33S-0'$Y
4                       #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tv523241_chrt-line2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_chrt-line2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#20.$ P$1  (1 0,1 ?_$ 0P  0 !! ,! 0$
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MSQ$E#M2ZA9$M"T*;,B-+B5)4A6./(HCPZ@ YXEUR]T@!3$L2[8N0]F)>Q^\
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M3CW\4BHZ6+4RJT1919F6[E?GCG[#H%#N*_+BFHI<.P;%K"&J/-G_ "F\E$:
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MC%SJ:PS6ZW 9:3":ES'(RV$&EP\4+/M=I*E;]Q2?#3AE1M[%TORWEP,Q]4E
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M;9?6[(WN?H%D6I17MXNVYVET&GP7#7R]L:V#Q"C6##:;JMC/<B2
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MG:6M^Y\J(LW4G94*+ H5_-U:J,+89@K6N&I^G-24PI3T93JB0I:-A&>P13'
MOQ.E'0^UK1X?.E/B"VA;-C:K<LHN9-O6=5Y-;MJ.[4JC3'J74):(S<EYF1 D
M,K,Y#<1M*R5O$9)PY,1/00G0O%:FG7*2RLBX.FRWK3C1<F:?:,JQF+0=DRY#
M/T:FMR&Y5.7)==.2XAY,E>*C7O=ML,M@4PH')N7%TF,^2G"TT0Z?<A,U=,N6
M.3,&D9+9U7!4KFS&L^35JK4(]>JU398COO+E292I4=MMF,A+:&U))"4D6T13
MU#B=:K!F"<GU9KA!OI0TQI[KU*BM/N2&85(S,O.G0F5NO+D+0U'CU%*$-&XL
M]G5(35K81*,)NLXQ;ZT9(::N"5P[M)695'S:R1R>J-N7O07&'J94Y=Z7)5T-
M/QU)4T\N--FK9=<2I!?=$>/5!U>T148)J$8JJZ$2QF6)D?6QV=?$L,.0P!J'
MZS=/$KAK<7O)#B*6W3G(VG'.&Y2MG-[Y+0\ZNC7-=K$VAS3?ALLJ+F7W)R)3
M9ECR&7*0C%+JJ6I67&MK5']C^QFPOJ@T2Z2>(;9^6AZ@; A9HVW:=4@7]E]+
M.I5*F' GO=Y3HT^.[ ?CN?E^]FM]"R,\$X&1&%,,2$Z/K+S9GZ;LG<X\BJQI
MKS$L^+<.3-<M6!9M2M!^3*:9?H%,1%1!A]]-.HE([V3":-*R7O8IQ/$&JBKK
M4M7HRT#Z7] .7U5RPTMY>(R^L^MU3Y9JU/.JU"KN3JD?.%WR\_47GW#7@\KD
MP+:"2#DW1=",Q4-(01DEMM&/421$1X<F."2Y!) )I"3WDMMI5U3))$9D>SE(
MB,P!'/K"X3F@_796(-RZD,C*-=UT4]E4=FYJ=-GV[75LJ4I1-R:A2'XSDG<4
MLS)2\5EUPZQ@_B2=-E46OT]<#SAK:9+CB79EGI_AN7! >9?@5*\+@K=XNP76
M,>:5%16Y4AMHR,S/DY< J^D+ACC%13ZDB0#.S3IDKJ+L)[+'.?+JVK]L=Q!)
M:H=:@H=8AJ2A+:7("T<V[!=2A)$2FE)/ B )M.I&S8G +X6>75XLWS;FFNF_
M+<68B=%15+AKU5ID:0VO?0IFG2YBXZ$I5MW<,-@.KPKAZ2$HQ?%&,5+S(S?U
M1Z@\J]#^FZZ,TKG-BW[2L&VCIMMT*F1MY3\UF,<>B4BFPF4J(RYQM!<A(2DM
MI[1&$53H+*LG7TD/O 9TSW'/HV<'$-S2HS-.OG5]>UV7G:T9\E'4H-D5"XIY
MTY]YM:$G#3+9803:,<>;21[",L9P%>JE<:;MW8;&H$%A]1NFG)C5GE3<.2F?
MEEP;]RWN8D_*MOSG'V&W5H0\VV\V]&<;>:?:0^LDJ)7\8]@$ITV=*H?#TO:1
ML@-&N7<?*K3IE_3LO+(CNH>32(#LB1SCK;?-)=>D27''G7"2>&)GL+D BN%.
MA%LM7'#CT;ZY8#$/4MDM;M_2(A-)B5E2I-*KT9++B76T-5BFN,2]U*T%]T:M
M@#HHTFC$G*_@#<+7**]*'?UI:=6'+AMR8Q/I+E>NFX*["8EQ5D['=7 J$UR.
M\;3A$9$HC+$N0!2"=5&*?4D9IZNM!VF#7+D[3,AM2.6T.],L:)6Z/<%%H$6=
M-HGR74J$TY'ISD*13'8[C+3,=Y;9MEVBD'@9"**E"4VB]V2^2^7.GO+"U\H,
MIK>:M:P++IA4NWJ(R^_)3"B(Q,D&_(6X\\HS/:I1F9B0VWB]IJK>N859F!PX
M<H:6I1I75M05"0TDFW%;Z8%"FON$:T)-#9$A7\;#'D+:(>U%X-)-LOSH*X,/
M#4U?Z"M(>:&:60C-7NB;EE3)U6J=+K]?M[Y5J:UNMR':G#@RH[4A"B83@E39
M88^R"KT%)QA\+C%KK2)_=.VE'(/2EEXYE9D+EU1;!LJ0XMV=2Z:AQ:J@ZN-W
MH;T^2^IQZ6Z<?M,5F>PSPY3$^TCS;"U&G#AT:1-)F9^;><.0N5$&Q[]SP6A>
M8]5CU"H3&JV2'ER";*',D/,1VS><,S))8'R<@BB+2DVN@QJS?X&'#,SPS5J.
M<]\Z=J>J_*N^U*JL^A5ZM4"%4)3*U+*1)IM.F-Q%..&?;X)(E<IEB)55LV%6
MHR?%)1<M[2J?7OK@C\-',*?E]5JYIKMR-5\L4QD6K5:'4*K1:BP41]4A@YLN
M%*2[/<0ZHSWUF:SQPQPV"*5VEE+IHJ^8OWJ6X<6CG5[:EO6CG_DS0;Y@VK1X
M-!H%2D.RX=P4ZE4V.W&AQ6J]#>9J2TM--E]VM6W$^4S$^TAT::DDXOH>PLII
MKX+_  Z-)UUL7SDWI_I-,NR*ZA^+7*]5:I<TV,ZA6\E;*JO(D(0I)\AX8E@0
M;=I$:0^!17F5#*W4UHRTUZPK:1:>H?*JW<Q:2RVMN(NIL*:J,$EGB?>=2C+9
MF1\%;2W588@.BCHT1_Y?^K]\*W+6Z*9>%NZ;XSM9H\^/4:<=:NBX:S#CR8LA
M$EA10ILU;)H0ZV7:F1I]@'5]+]82@G51BFNI&;&JO0)I4UJ6K9MDZB\K*9?5
MLV#.:GVK3%29=,9I3C),)0RT5/=82J+NQ6RYLRP(D[!#29*DU5;4]YA-?'J_
M/"HS!N*E7-7=-4-B72"C%'A4BZ;DI=(?**I"VN_*7'J'>TG:@L<2+':)Q6PA
MJ,L91BWYD2CY-9%Y4:?;#IV6>3UDT2QK*I:#1'HE'C):86:D[BG9*SWG)+SB
M=BE+-1F6SD$4]9+DWM,!M3?!6X<&KBZOIQG%IZH\J[5O+?D5^U:I5;0J$QUQ
M)I<5,<H<F,W(-S'$\4XF9;1:K*M1E\44_.JEU-(W"_T2Z&YTBKZ;\EJ/95>D
MQWXKUPORYM9K:V9.[SZ/E&I//OH)W=+>W3(S$5?22J)4BDEU*AG]NF:<#/$^
MO]O]_P"T ->?UB#1K?&H+3KE;GUE! *5FCI/S"7F ?,K4W.?L&5 WKH3'4VE
M2WUP)--BO$W]Z:S+:'0_,*5I3:G7U=!EQHZS9R'XL6@!BW,P+<.Z+3K%!@Y7
MYP6;5"FP%NUFAP:8N21N(./)2U*=:0\A:%<I&6)X&0CH+/!IK8S*71MH8TUZ
M!<M*EE'I:L!O+RQ:Q<4JZJA2?E.H5,WZU+89C/2C?G.NNIQ:826Z1D75Y3,Q
M*2(<FSR&5_#;T>Y-ZG\Q-8N7>5$2WM0&:F^J]+S9JE2<*J..QDQ'W/DUR2N&
MRM]I!;^"=IGB6 BBK4GCEP\)G,;+9GO&TTHSY3-)8GCMVXI/JB2HYAD\,66O
MQ$<OXH#$[<"PPP+ L,"+D+###9U,, !'+G1PG]"VH'4C;&K/-/):#<&>EHNP
MI%'O$JO5HBBD4Y*40W9,%B4F)(4PA.Z6*2Q2>!B*5VEU-K82%SZ73ZI39E&J
M4*--I-0@R*;.ITII#T273Y3"XLB'(96DT.QWX[BD+2>)*29D?*)H4(<+S]7[
MX5-]7?)O:L::8$2K2YO?\F/1;EN"DTEV0;A.J-=,BSBC&VM?*C#="K2H@U%X
MRC%OK2)*LM,HLDM*F6<BW\MK4H&6>75J4N75Y[5,C<S&C0:7%4_*ES'$DN3(
M6U%9,S,S4HR3@18F(I1U)JY41JM985^Y.+MQH;5SJM:A2G]+&CNL%+@5JK,N
M1(M4K5")TH:V([J#[XD3JFVR9%R[B<3P+DE8JN\EU3HUA'IWM[O,;C)%AAAL
M(BPP+87V"Y"("I4         %#21F1F1&9<F)$>'M;-@ J *8%MV%MY=G+[?
M7 %-Q...Z6.&')L]SDQ '( 4W2QQP+'KX%CUN7EY !4 <=U/WJ>OR$ .6&'(
M                          .*D[Q8>SC^[KD ,5\Z]#VD'4=66+BSWTX9
M19KU^.TEAJM7G9='K%3)E!XH:5-D,=\N(1U"4I6&)X 2I-*BV%W\K,F\J\C[
M3@V+D_E_:>6]H4U!HA6]:%%A46F1R,S49HC0VFT&HUF9F9XF9@&V\7M+E$1)
M+ @(*@                         "TN;F0^3&?= *U<Z<K[(S1MXC6:*3
M>MO4ZO1&N=+!PV43F75,[Y$1*W#+$*$IM8HM;DYH;T?Z?*M\NY):;<H,L:UR
ME5K2LNCTJ>@\2,E-RF6#>;46&PTFDR$40<I/:S*LBP/_ '/9Q$D%0
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M<:6AQM9$I"VU)6A1'M(TJ29I41EU@!S
M
M
M                                %#]T :Z6O7@ T_7#J.N/4$_K,STR
MO7<3+*/H;;$E7R+3.;:2US<#<J,3!CM.U2:<2ZX+#:JD24GLE));FON9K6ZV
M^$C#RWU>:?.'SI<UQZ@;[U*7M/@WI?+U5JTYJ!9]BQTS)"YDV/!JYI<DI)E#
MI$MY33>SG$JVH!T>Q8DI37XI>E]'HIT^LW_]+>3E7R"R&RVRFK]Y52_ZU9MM
MTZDU.ZZP9]^U:9&CH;?D+(W'32E;B3,L5&>WE$+8'BS($2
M
M
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M&'R]4\"(;BS\$BK59(DU8_YEG#DYEO\ Y*<!MV6.X
M
M
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M<P^WVJC:=;-)\F!B"<>G ]P
M
M
M           L-J40E>4=QX_Q2CJ+VR<P+]\7M_$5>S LSMZ,_P#._M?(O8%O
MWA'X3-\:1<        .MUM+S3C*\30ZVMM>!FD]U:32K!1;4G@?+U !J#\6;
MA":+\J;)S S2M*A7S3KMJ%BW9=*I*[SFR&V*Q"4Z^AR&A;:.994MW:@S5L+8
M>(U[48JS-[BL_?N1K3$PD]7^X1>D#7)I0S#S S^BYE7+=5O9KS+<I\^+?4R
M35**DQ9:&EH./(-QQ+SBNV,RP+8-#8RRQ@GOJ;KVFK3CEII1RAMK)'*2'4X5
MC6J<Y=+8K%2<JT\G*A).5)4_-=0VIPU.JV=J1$0)4);;VE^0(
M
M
M                                    L1J1_9'<GX$?]*0O#XBKV(LO
M_5H_G?\ 0@M^\*_A,WQI&H          0:<;M9ED)=Y)V&64MW8G[#DA*,/L
MDDR&XM_V$_,57]I$PL]4Z_\ 8@SC_P#7I*_V#$&A+XGZ"T?[*/I]IM/"
M
M
M                                             %B-2/[([D_ C_I2
M%X?$5>Q%E_ZM'\[_ *$%OWA7\)F^-(U          "##C=X>8>\^OYH[GQ+V
M"E+P_?,;FW_83*_O(F&'JG7_ +#^<?\ Z])?^P8@VTOB9:/]E'T^TVG@
M
M
M                                             6(U(_LCN3\"/^E(
M7A\15[$67_JT?SO^A!;]X5_"9OC2-0        *'L(S]@ 08<;G]A%YF?(>4
M-S=7#DEN=D;FV_ZB:Z65H^\CU-F&/JG6'0@SBPVD>>DOD,C_ /H&+MQZHVS^
M)DQ3[N->OVFT\!(
M
M
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M[)N]Q4I1J7"UYMA(T,BGD\
M
M
M        "Q&I']D=R?@1_P!*0O#XBKV(LO\ U:/YW_0@M^\*_A,WQI&H
M    $9/%T,N@_F9CRF4?[<2?B,8^+M?_  J]3_UK?_$>P_H45?J-T;_>_P"*
M!H4Q<#9P,L>W4>!<N&"<.3K#RHO.?IMO?VE>H_6?*W@@]BL=A>UUL2^R*M[<
M50VZIBJFVMZNLRIK(S.]9J,R?S&II$6.))[WHR4'LP+#>YSJ<N SUX'/^LU3
MSV/9-_:?#7\UR:GXD\N*F,=)N?TKM>RAL5CT"?*$
M
M
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M^!TEWVJ0_%_4/LN+[$?#G\UZTH^(G+5V/PRTJ[CYKN'VFQF/01\G
M
M
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MV\3^??$_-6-3Y\S][/YO+V^[MRN2XG&%:T6$>DEN'+G20
M
M
M                               +$:D?V1W)^!'_ $I"\/B*O8BR_P#5
MG_G?]"BW[PK^$S?&D:@  P! !QC]?N;MBW1E+P]-#[RYVN/4V_(E4*8EUB%3
M<N[!HS??-8N&HU64M+$>?)3_ ,RC S)M"U&9'ABPZ1C3W:<5>G8M[9%SE?:'
M&\X3V<64><FJ3.1W6?D+FK=J,O\ ,*S;7K<VNUBQZA7H,J=!J;=/G1(*GFX;
MD)24OQS<;)1$E2NV+&72F%4_.1_6_B<9>94].W9O-RBV*ZQ<]N4.XXT:5#8K
ME*@U5J).:-B9&1.CMR4L2F3,S;?:YS!1=0R$$TI@?7D-F\P\R2S;-YIQHG"+
M$T&M"D[Y;2VIQQY0"-'WB/\ "_I6BVKW1FZQFY7LR9.;]0F5!$"N4]4=^A&U
M-)3C"'SERD/-'WX1D9&C[G:D89\;[[6BY&*V2S,NR*?VGT-_+-RL9?4/>SE6
MJ9'96NWC7V&!^E/21:>N?,.FZ:[INUVS4W36:378%533"JL=;EN+?FRH<B.I
M22W9$?$DGR;V&.S$8M\+\S'*\X6)S^&[%V_,W1K#T'T/_,RY5S>N>"5K6+%.
MYT[,.<T]K4^&*]A_0#R!T^Y9Z=<O;9L'+RU;<H;5!H5-I,VI46AP*1*KC\&*
MW'<J50.&RVIZ1*6V:U;QJP,\,=@]<R=7U'YXDL$GT%],2]P025 50 BJ $@!
M5 !5     BJ "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J
M"J "J "J "J "J "J "J $@    BJ "J "J "J "J "J "J "J "J "J "J
M"J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J
M"J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J "J $@  %4 (J
M@ J@ J@ J@ J@ J@ J@ J@ J@ J@ J@ J@ J@ J@ JBPVI(__1)<9'U4L%L(
M^7G4D7M<HO;VD2^TLQMZ-&&W'OS## __ *DQPY.L+5?&*8&< TBP %#_ '>W
MU !_.PU\%J^S-]9VD9:Z4KAIU#SM7E[5*/8M<NR0XU1;?M>?9DR579:5*:DG
M';8I--=P4E!GM/ L1"KV_8:DE2CIM2\W34S6S5OCBI<$BX,L-3&M/-7+#4QI
M?O;,>FY<WO;E'D5:KRZ!6KJC37J34(46NTJF.PY$5<!Q3;[.*$F6"MAF1VJ:
M5)1_6CVKKZ_-ZC<ZRIS"H6;&6=@YFVTEQNW[^M*@W71FG4$VZU3ZY3H\^*RX
M@B(D+:;>))D6S$A!9JCH>?SQS88R2R[K.8DRAS:_3Z&279T.#(C1Y"6%$K\H
MA4I:&U8*(BP+$\3&^TS2\_K6?MZ;IL./-W942;P]+Z$;+4-1R.DY.YG]0GP9
M6VJMTJ_0MYJ*\3C7">L.@DNC6U+MBU[,2<&)%GJ0N8_)DRT.2'W'&U&E6*6D
ME@6!%@-I]5/A9'D+P_T;-:A-3U?,9FY)I/W8^[!</H/8/Y0_BC9\0OJ=UG*Z
M9%QTG(Y2%N+DN%R=+K;Z>FB(_= V;IY":D+0S<73G:O'LUBJU"13(YES\QM4
M)QI2&]Y:$F:4N&KEZ@\O>!N@1YJ\3])Y=XU;GF<RDI/8FHR?;@C[#_F9Z[#E
MCZ3.8>89PE<MY6%N4HQ56X\:K3S8X=.PW2LG-95^9ZV%2\R,N-/-T5RV:LEY
MN'-*X+<B&J1'62)+2V)=08>;)"CZQCV+SCRMGN3.8;^@:C3OK35&J-.+V/#>
M?F;Y-YKT[G7EW+\Q:6V\KF(UQ5&GN:>PN(WG=J'YP^<TN7$374-%V6P:^79B
M2JIN\GLCK3C'>O2=H777L^\^CY[,\MG_ %7[QY-O_C1:'+U?_I<1PQWHG#K[
M/O'GLSR]&"\/*>T/G<*+HDAAU]A3SUYX^B_>'E/:'SN%%\R&'7V%?/9GEZ,%
MX>4]H?.X47S(8=?8//9GEZ,%X>4]H_.X4CO7J)PZ^PHK.S/3=/<TOWAOX'N[
MUT6ANX]3'"K8X HQWHCU]GWG0QG;GX>/?.EZZ2Y=WF;JM-75[7'?JJ?XOVQ+
MC'I:&'7V?>?H\]F>7HP7CY46A\[B*+HDAAU]@\]F>7HP7AY3VA\[B*?K+U?I
M&'7V#SV9Y>C!>'E/:'SN%/UEZOTC#K[!Y[,\O1@O#RGM#YW"GZR]7Z1AU]@\
M]F>7HP7AY3VA\[A3]9>K](PZ^P>>S/+T8+P\I[0^=PI^LO5^D8=?8//9GEZ,
M%X>4]H?.X4_67J_2,.OL'GLSR]&"\/*>T/G<*?K+U?I&'7V#SV9Y>C!>'E/:
M'SN%/UEZOTC#K[!Y[,\O1@O#RGM#YW"GZR]7Z1AU]@\]F>7HP7AY3VA\[A3]
M9>K](PZ^P>>S/+T8+P\I[0^=PI^LO5^D8=?8//9GEZ,%X>4]H?.X4_67J_2,
M.OL'GLSR]&"\/*>T/G<*?K+U?I&'7V#SV9Y>C!>'E/:'SN%/UEZOTC#K[!Y[
M,\O1@O#RGM#YW"GZR]7Z1AU]@\]F>7HP7AY3VA\[A3]9>K](PZ^P>>S/+T8+
MP\I[0^=PI^LO5^D8=?8//9GEZ,%X>4]H?.X4_67J_2,.OL'GLSR]&"\/*>T/
MG<*?K+U?I&'7V#SV9Y>C!>'E/:'SN%/UEZOTC#K[!Y[,\O1@O#RGM#YW"GZR
M]7Z1AU]@\]F>7HP7AY3VA\[A3]9>K](PZ^P>>S/+T8+Q\J+0^=Q-(]+0PZ^P
MZ'L[,^^U[WTOW5U-XWKIM0MF)X[I(JJNH)X8[T/7V'6[G;G^2D<UI>N<TX$:
M]^Z;6(R[4\23NU0R/!7V@X([T,.OL/UEG;GEAMTOWCCU?_&>T>7V,:OC@'#'
M>AAU]@\]F>7HP7CY3VA\[B.']9>H8=?8//9GEZ,%X^4]H?.X</ZR]0PZ^P>>
MS/+T8+Q\I[0^=PX?UEZAAU]@\]F>7HP7CY3VA\[AP_K+U##K[!Y[,\O1@O'R
MGM#YW#A_67J&'7V#SV9Y>C!>/E/:'SN'#^LO4,.OL'GLSR]&"\?*>T/G<.']
M9>H8=?8//9GEZ,%X^4]H?.X</ZR]0PZ^P>>S/+T8+Q\I[0^=PX?UEZAAU]@\
M]F>7HP7CY3VA\[AP_K+U##K[!Y[,\O1@O'RGM#YW#A_67J&'7V#SV9Y>C!>/
ME/:'SN'#^LO4,.OL'GLSR]&"\?*>T/G<.']9>H8=?8//9GEZ,%X^4]H?.X</
MZR]0PZ^P>>S/+T8+Q\I[0^=PX?UEZAAU]@\]F>7HP7CY3VA\[AP_K+U##K[!
MY[,\O1@O'RGM#YW#A_67J&'7V#SV9Y>C!>/E/:'SN'#^LO4,.OL'GLSR]&"\
M?*>T/G<.']9>H8=?8//9GEZ,%X^4]H?.X</ZR]0PZ^P>>S/+T8+Q\I[0^=PX
M?UEZAAU]@\]F>7HP7CY3VA\[AP_K+U##K[!Y[,\O1@O'RGM#YW#A_67J&'7V
M#SV9Y>C!>/E/:'SN'#^LO4,.OL'GLSR]&"\?*>T/G<.']9>H8=?8//9GEZ,%
MX^4]H?.X</ZR]0PZ^P>>S/+T8+Q\I[0^=PX?UEZAAU]@\]F>7HP7CY3VA\[A
MP_K+U##K[!Y[,\O1@O'RGM#YW#A_67J&'7V#SV9Y>C!>/E/:'SN'#^LO4,.O
ML'GLSR]&"\?*>T/G<.']9>H8=?8//9GEZ,%X^4]H?.X</ZR]0PZ^P>>S/+T8
M+Q\I[0^=PX?UEZAAU]@\]F>7HP7CY3VA\[AP_K+U##K[!Y[,\O1@O'RGM#YW
M#A_67J&'7V#SV9Y>C!>/E/:'SN'#^LO4,.OL'GLSR]&"\?*>T/G<.']9>H8=
M?8//9GEZ,%X^4]H?.X</ZR]0PZ^P>>S/+T8+Q\I[0^=PX?UEZAAU]@\]F>7H
MP7CY3VA\[AP_K+U##K[!Y[,\O1@O'RGM#YW#A_67J&'7V#SV9Y>C!>/E/:'S
MN'#^LO4,.OL'GLSR]&"\?*>T/G<.']9>H8=?8//9GEZ,%X^4]H?.X</ZR]0P
MZ^P>>S/+T8+Q\I[0^=PX?UEZAAU]@\]F>7HP7CY3VA\[AP_K+U##K[!Y[,\O
M1@O'RGM#YW#A_67J&'7V#SV9Y>B_>/E/:'SN'"NEKU##K[#H?SMS[))=[:7[
MJ-6);Q/73:A%NX[=W<JIXG@)X8[T,.OL^\[$9VYZ;B><TOW>2\.V)-SVD:<=
MNPL:MB' MZ&'7V'/SV9Y>B_>/E/:'SN(X8[T,.OL'GLSR]&"\/*>T/G<13]9
M>K](PZ^P>>S/+T8+P\I[0^=PI^LO5^D8=?8//9GEZ,%X>4]H?.X4_67J_2,.
MOL'GLSR]&"\/*>T/G<*?K+U?I&'7V#SV9Y>C!>'E/:'SN%/UEZOTC#K[!Y[,
M\O1@O#RGM#YW"GZR]7Z1AU]@\]F>7HP7AY3VA\[A3]9>K](PZ^P>>S/+T8+P
M\I[0^=PI^LO5^D8=?8//9GEZ,%X>4]H?.X4_67J_2,.OL'GLSR]&"\/*>T/G
M<*?K+U?I&'7V#SV9Y>C!>'E/:'SN%/UEZOTC#K[!Y[,\O1@O#RGM#YW"GZR]
M7Z1AU]@\]F>7HP7AY3VA\[A3]9>K](PZ^P>>S/+T8+P\I[0^=PI^LO5^D8=?
M8//9GEZ+]X>5%H?.XG@6]##K["S&>V;>>55R^J,"5IVN*AT^0\RB=5)5?M^6
MF,R3B#2LV(50<<21F>TSQ+J#5MQC7%E98+94]=S]0Z,'.?)Z^^^^,.]-]O?_
M /F3>PWM[=QWNUY1-(\?32GVD5EZ:_89S#0+  /X.P -;#BP<.74/&U;9'\5
M'0!18=<U,91QZC:F8-B*>A1Y%]635Z8JD*ETYN>11)\Z)$=<COL+/?<9=Q1]
MRHCC G%]*KL\ZW5]A@]GSDYQ5^-1<F2.0.I;3<YIJTR9=YA4S,S,VI74S%IS
MMTU.W8LEBFLP4(4],FO(=F.<PTRDF^W4:MF!E/FVA[G@O/CYO,;?&6EAT?*[
M+RRLN;?;)NAV/;-&MBE(PW=V#1H+,&,6'4/FV2 2;;J]I''Q=:S<E*TRQV*$
M](8A52ZV(E=..I2.<A)I\QUMIPTECN*>29^R9#./@%E\G?YRG/,T=V%AN%>A
M\23IZ#"OCGF,[9Y.4,HVHSO4G3ICPMT].\U",PD(3ES<9MX&A4MI1X8GBHS/
MMCY3QQ&R_,#<I<F:'Q5XEFI_\,3UW^179A#ZBM?=OAQL0>'_ .\V^@L'DTZM
M&8-$:2K=;EQ:U'DD>TEL_(]0=W3+#J+82?V!X+^G*<X>-W+DH/WO\07_  3/
MT _F5Y/+9KZ(/$%YF*DK6E6I1ZF\WEHM^J<EZ3;WX%57N&9D7F=3*I-E2*32
M<PI#5#8>4:F([#C"3<**1EVJ%&1;V&S' ?3'ZI;&6M\UY.]9C%7KF3BYM;6^
ML_('])5[,W/#Z_;ORE*W;S]Z,*]$.-TIU$Z \O'JD"     2"F'LF7N?PD%
M,#ZY_:[  J  @                                      !0SV<IEAR
MX?[Q]<2#\SCB6S2:GFV][D)Q2$X[3VD1D1G[8E$.BVE>^&OY2Q\*WV0H]PJM
MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+
M'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%;[(48
MXEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7
M\I8^%;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9
M"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[
MX:_E+'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%
M;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9"C'$M
MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+
M'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%;[(48
MXEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7
M\I8^%;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9
M"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[
MX:_E+'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%
M;[(48XEO0[X:_E+'PK?9"C'$MZ'?#7\I8^%;[(48XEO0[X:_E+'PK?9"C'$M
MZ*&^V?)*8(RY3YQL]FWEV[ HQ6.]')IYMU2DMR&G327;$VXVM2>L9DDL2+ Q
M'435/8?H  0                       D%B=1ZWF\I;B-I]QD]U@E&C M]
M/.EVJMG(9]06AM(>XLKOKZ-._P Z>_W[CO?_ &+ANX8_9%_Q]1%%2AG -(L
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MS\/<OX:<L6^5[,E.=J4G*?S-MMOUU,QACXR"
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MA'A@>"L#(2U3SE$]J?0_:;=J3Q+'V5%]@E&1?:("2H
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MI"$[VX[BE1I3O$6. G:13IZ#,0CQVD!!3$BY3( ,2ZY>Z0 K^[]WN@!R[2
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M6M&_'DPG'$%5:+48JDID4^IQB,EM/-[Q&2L-U23(R JT9<D)
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M"?,>[_#;OL/Z,\'_ $*)_P#)8_Z) ]MVO[./\E>P_)OF?_<7/Y<O:S]0U#1
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MZ2I)%&[9@E8I21'CO=3EJMN(=%"D/AJ;JQ88%R'L(MGL"Q0J
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M(U-LM-J47\8T()./V<!ZQ@N&*B]J2/SHW9JY=E-;')OUNIWBQI@
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M6)X<@]"^"5SBR>>M_+=AVQ9\(/S5;:CXL:)/I>D>RY(V%!G,^6
M                      %#^U[0 M3G!DAE+GY:)V#G3EW:N9]E*JM)KAVS
M=](BUBDE5Z'.9J5)J!19*%)[XAS&$J29&1'M2HC29D8BA<.C46DV[2J=0J!3
M*?1:+28C$"F4BE0X\"FTZ#&;)J/$A0XS;3$:.R@B)*$)))%U )/J
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M?&1]<DI_A2?7 =)4DF7*HS]LB+J?\$B  T[<<?M%M]WJ@"AI/J+/W$G]C[D
M<L.3J^SL]O\ ? %0              <5_<+_  3_ 'C CJ-4'A4_^_<XF'_J
MND?_ )1+)$OR]87Q2\Z]AM@""0             _++AQYL:1$EL,RHDJ.[&E
M19#+;T>3'>0IMYA]EQ*FW6GD*-*DF6!D>!@#'C*+2!I<R%NNYK[R8R RGRQO
M2\WG7[INNSK*H=%N"M+>5O/%,JD6&B6IIY6U:$K)"CVF0!88=!D>22+DZV
MY      "Q&I']D=R?@1_TI"\/B*O8BR_]6C^=_T(+?O"OX3-\:1J
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MAXJZ)FFY.U/2J8[(M7);//M-APAGD^594
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M]Z3I7THVMQZ)/B4
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M40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40
M40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40 40
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M9W(.[>]"J'2@L[Q=O+P#,[D'=O>A5#I06=XNWEX!F=R#NWO0JATH+.\7;R\
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M3V (HAS+7YIO\1/8 DIS+/YIKX-/8 BBW#F6?S37P:>P HMQ7F6?S3?XB>P
MHAS+7YIO\1/8 D<RS^:;_$3V (HGM',L_FF_Q$]@":4V#F6?S3?XB>P!%$4Y
MEG\TU\&GL *+<.99_--?!I[ "BW#F6?S37P:>P HMPYEG\TU\&GL *+<.99_
M--?!I[ "BW#F6?S37P:>P HMPYEG\TU\&GL *+<.99_--?!I[ "BW#F6?S37
MP:>P HMPYEG\TU\&GL *+<.99_--?!I[ "BW#F6?S37P:>P HMPYEG\TU\&G
ML *+<.99_--?!I[ "BW#F6?S37P:>P HMPYEG\TU\&GL *+<5YEK\TW^(GL
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MYC,
M
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MS.H9 /-@
M
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M3[6SR+^9#I-K2OJ:SW<JD<QI^4NOK<[>/:B8<9./!(
M
M
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M@
M
M                                              6(U(_LCN3\"/\
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M=DN'^3CLU*(Z\YAU$-)<WU<G4(PH]S'%%]*/LE[)8""Q4
M
M
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M:
M
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ME^U$HW"2(RX:6BHCQQ\PEF'MV'MC.GR>R*K8:C^Q>PD3$D
M
M
M                            6(U(_LCN3\"/^E(7A\15[$67_JT?SO\
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M>;DTJ$J3&ILXR66\TN7&:2HR/EQQ+ C$JE,-AIR;<JRVT1*8)*@
M
M
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ME88GD+9I'AR;([J2Y?8(;N.PXF5:X[E["1(25
M
M
M                   L-J462<I+CQ_C%'(O;YTA>&VI619G'_JS_P [P_\
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MM%6.P_,-9Q=7EYA[[8YV#3C4QY-/BV="]B)%,2/DVX<HN5IO*@0
M
M
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MC@/5?A4T^7E1UHUVH_.C^8ME[UCQZS;O*BG62QZ'BNQ]1,H,GG@(
M                 ^-<->H]JT*LW-<-1C4B@6_2Y]:K=5EJYN+3J53(KDR=
M-D.8'N,18K*EJ/J)( L71;3"RC\3#0O7I;L*E:DLMY,AI2FUH56V8Q$I!&I6
M!RRCI/M2Q$56TFC.R5Q*M#<.J0:,_J1RW^4ZC,8I\2*S6F9:W9DI:6F&2.+S
MR2-;BBVG@6T3AO%'N]AFY3I\.JP8=2ITEN9 GQF)D*6RHE,R8LEM+S#[2B(B
M4VZVLC(^J1@1U'[
M
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M@B(A**;3]XD
M
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MS+VY5ZW%5[3\AO/FB9CESG;5M"S47#,974,Q;<6J-<-V:6'F1<D<F=2
M                      AH]8(_]T+K&_\ )JP?_P KMA MOI(E\+_DOV%W
MN#=_[MK2S_ZOV?\ OR2*Q^$U+GQ>A>PDY%B@
M
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M%8[#4N?'ZO82="Q0
M
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MG&-?DVT1]#?S4>0;MZQH_/\ ;C_56X.Q*26%:[&_3@;40]&GQ7
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MMZ/V"YH
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MF^E"L-BB(R,SPQQPVD1EMY1[//R[M4DUN9S)6/4/EZNS[($'(
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MO3]-32=W,Y+,6;:;V5G<MQCCT5>)>4CQ_P!_$<R8_*@
M
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MW;=I4*FTNHOLJ[9116X%(CNM/I)6SMN4N4^IO77J.$22\QL3$9'R""2H
M                 XF?M<NTSV%@ (8?6"Y+3'"'U@)>62%/T"PV64D1F:W"
MS7L>5ND1;=[F&%J/V"%HPE-^ZME'VI&G>NV[4'*;I%IK^BV7DX-IX\-G2P:3
M(R/+]D]I&1[9DG]XQ7AE#W9;34[R%Q\<'6))V0 J
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MV4W-$IQ;2+]W[^T9-/%I4
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MN^#O*G@QXJKEWD^+CI5RQ&XHOHXNC#!TWDI(R,>,@
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M?#CCBGZ";(AF58(^=P$@
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MMQYAN92Z]![B$%?46[:E1)1XE@MGK)[B&;SYE%0                  ^0
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M=6VZML_2+&D
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MC5QP8K]TL9)1LS8=\)S0N1NL1H-1H%O425'9CQW]W_.F"<4M]XF2Q5@>TS+
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MCO\ &49)2BTTT>5;MF[8N.U?C*%V+HU)--/K3Q1WXBQI@
M
M                                              6(U)?LCN3\&/\
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MM96M>[@HU\RH?'_7=26L:SFM54>#^(OSN<.[CDY4]%3THW1Q(
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MDFL<:&46\7V.OCV?8_?'8MAADY
M
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M_$"Q:JHW[USN\?Q<*=.Q?H-TY"MY"%??)2KW2(Q\XVJ-KK/H<G55.0C9L)
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MQ>S[A]@ 5QQ_WC+]\
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M*7L+'R]S=IV,W=L/;"Y)>IT/IIEKBO9>W=6R4$_6JGUQH&N
M                            !3 NM_!U,/W@!X*^,KLNLR:<_2K]LJV[
MMI\E!MOQ:[2HL]MQ)IW3)1O-J5M2?7&PSVE:;J=KN=0L6KUI]$HI_I.R\N\Y
M\U\H9J.>Y8U'-Y'-0=5*S<E!I^AD,.IK@5Z<\SF*A5,F$KRAN60IZ0TW3UR9
M=O$^O>7N*I+\DV6XY*41$AHVMTN0]F Q7K?A#I&84KVCR=B])X1DW*'HJVT?
M03P?_,G\6N3KUK)^(#6NZ1!*+<U&-^BI^]4:MTZ9<57M-:/4#H:U4:2Z_(7=
M%IUYJDP9KQTR\K8[[>ITEJ.XKF)V_%Q?A*<2@EF2R[7KC!>L\KZWH%Z4<_:E
M",7A/\+_ ),O8L'U'U_\+?J3\%?'+3HV]'SN5>=NVTKF4S/"IIR7O0]["=-F
M&W<>^R+XJFL_(V53HD/-:O75;\!^.VY;=VN-5F(<1AQ/.PVN_P!EYR.2FTF6
M*329=<;O2N=^9M&E%9;-WNXC1\$WQQ:712=:+HP:.M>)7T3_ $^>)-F[?OZ)
ME<EJEV,FK^53M2XI)TF^!I2QQQJNHV6])?&CT]Y]O4:ULP6WLJ[YJ!M0T%4W
MD/4&H3C+=P9E)2E<,G5EVI+WDEC]T,Y\N>+.C:I.&4U6+RN>FTD_BMO_ 'L'
M'TKTGR \<OR]_%3PPAF-:Y7<=;Y;M5D^[35ZW#KCBI46VE'U$QE-J]-K,5F?
M2*A"J<*0VEYF3!D,R676EIQ0I#C*U),C&5;=VW>BIVI1E!]*::]:/ N;R6;T
M^_++9ZU<LYB+HXSBXM-;4TTCZ1'C^[KC4-J5         !!WQ7=4/$XR KUI
M-Z%LA*)F_0:A167JPN=&4_**LJF24O1TO$T\4=MN,AO#M%8F84)HVO<HW7I=
M," *W^/KQF[PSNKVEZV='%NSM0=L$['KME'+@H5 G-1TR'FB_P#!1O.G&0K%
M1&E.PN436BK]A7WVW%)53QQ9LT<+;/[7+GGEQ6*IK=RFI^5UX,NMG384&(J'
MB6\27F'&]TB<W%8EO&18[OLB&\<-A;A:BG*BGN3J2L@0
M
M          !8C4C^R.Y/P(_Z4A>'Q%7L19?^K1_._P"A!;]X5_"9OC2-0
M       C%UM?MZTQ_P"L*G_M&G#<V?@D1^)$F<7_ $:-_D&?T:1MG\06P[P)
M   #K6DEDM"N1:#2?7W3(R,OM_;!-IU1#2:H]AHWZRZ4W9VIS/*ET]*HWR/F
M5=C4)1(-LD&U6IG-*;/K<FZ?6'TS\/,P]0Y,TR_=:DKF3M.2\\%4^;7B5EO\
M.YPU/+VEPW(9FXXO9CQ.E#<ITY7$FZ<BLIZSO&MR18-J$^M1[QJD(HD)#RC/
MJFI9&8^>'.&3>0YHSV6>Q9J[3S.;H?0CE?-QSW+^3S$>G+V_^!%ZQULYX
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MC\4_,C<001%B9$1'O*VD1%R*/K 2<P
M    <3,\=A8EU\<.R8$''><_-_\ 9EV J24)3F.!HPVX?=$9X8EM(B+D(A .
MT2                                               +$:D?V1W)^!
M'_2D+P^(J]B++_U:/YW_ $(+?O"OX3-\:1J          $8NMK]O6F/_ %A4
M_P#:-.&YL_!(C\2),XO^C1O\@S^C2-L_B"V'>!(    !J3\6^POHGJ1K=15$
M:0S=[+MPI=0VE!R#EFMQ:S4DB-3A.XD9\IF6(][> ^J?Q_)UFRI>]8I;\W#A
M[#PSX[Z8LCS1/,SAA?XI^>J)P>%K>TF^-(&7LR7(5(D4QDZ,O?4:E-I@)0TA
M)XJ-1$:2V8CS-XWZ;#3.?\W:@J0G+B7^]B>CO!349ZIX>9#,W76YW,4_0DB1
M<8B,L                                                  %%%B1
ME@1X[#(^0RZI;>N0BB)3HZHQISWTB:=M1]K5:ULU<K+3KB*M'=9*N1Z/!IMU
M4UYPC4B=2[DA1V*M"EM.$2B4ETL3(R5B1F1\%JG+.A:Q:G;S^6M2E<6,U&*N
M+K4TN*OI:Z&FG0RYX:^.WBOX2ZS8UKDG6\]EIV))]S*[.YEKB7X+F7G)VIQ:
MJFG'S4:3-:+5UP$LPLNJ55+STT7/-S1IC,@WCL.K1X\2Z8D%1K6OO2>AU$:K
M)BM_\%#BBZF.T8'YF\(]1TZ$\WHDWFK%<+25+J75C2=.JCZ:'U_\"/S..5N:
M\[9Y?\8,G;T;-RC3^-M.4LO*=$EQ0:<K?$^MQ6\@^CS<^-.=W**)/S*R>NZC
MS3(UPY-PVE.;E,+-)&1L*B)E-K4C#^.VXGEQ+''%4+NHZ/G>*W*Y8SUI]#<9
M1?M78?1R]E_#+Q9T&N8MZ1K^A7[5?>C8S47&2KTJ3BTG^K*+V4>R;S1OQYLT
MK#=AV?JHAKS/MDRA0X=]4N-#I]VTAMM1-NOUAF(PTS7FS1BI2S24@SPZF(RS
MRYXO:EE9QL:]'^(RVQS5(W(]>"2EAMXL:X\3/G+X_?EF<E\RV[FO^"EQ:-K%
M9SED[LISRMUO%1M2E)NRZX)5X.PV8=/FKO3]JBI+E5R:S%HUSKC(:7-I!/IB
M5V";J=[<DTJ0I$K\FHL%*2E22,N49RT/F;1>8;7>:7>4YTQ@_=FEO<7C3K55
M7I/C]XI^!7BEX,YY9+Q TG,9.,V^"[PN5F='MC<BN''H3:=.@R8'8#$0
M!IWZ=O\ _I[U-?\ R:H__D[IX/H](CMGYD;AY?PG^^8 J
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M[].F?C=Y?NZ=&3?<3::KL^XG%'F8](
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M<E>NSQX9/9*370;<?[N0>G3X8  !%4 )
M 4/D^R7[Y #3U]8W273FX7*^K]**Z@S]A-T6THB^P;A^Z'0_00O[6'G?L-ON
MD_\ S53/]7PO^]FP)/H                                   H9=4MA
MX<OV\#]@ 0%^LDKW.&)?.\M3:EYCY8)023P,W#N>(KML#/ B2D_LB'T5WEE\
M,O,2,\-YUU[0MIA<=<4XL\K:.DUK,U*-+<B8V@L3/'!+:2(L>0B(0MA-SXV9
MMX"Q0J      +$:D?V1W)^#'_2D+P^(J]B++_P!6C^=_T(+?O"OX3-\:1J
M        $8NMK]O6F/\ UA4_]HT\;BS\$BK^)$F<7_1HW^09_1I&W?Q$K8=X
M$@    &-.KZTBO/3GFG2BC%*D-6S-J$1K=)2C=@ESRS26![4L)4?V!W+P^U#
M_#><,C?;X8.\HM]4L/:=6YUR$=1Y9S=AKB?=-I=:1J@\.^ZW[4UJ95$I_O6F
MU&K'3IG.&2$&N9.9C$VHSV8EC[>(]V>+61AGO#C/-1XK\855.J+9X5\(,]=R
MGBCE+<GPY>5N:==_'%)&ZGU3]DR/J=;#K^P/G!7H/HF5$@
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M+'K8I,RQ&O5'%SMW+;I<BXOK5#LQ$E!B *_NZG9 %,=N  J
MH?)]DOWR &GKZQN:>G/PO2)6+GTEK1J1B7:H^E5O[CF'_#5O%_Q0Z"*KO8?[
MWL-OFCX%2J618[*=!]SO9O _L@2?2
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M?3   1BZVOV]:8_]85/_ &C3QN;/P21#^)$F<8L(T<CZC+1?]@D;9[23O
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MSF!>9O-D3IMM/[A;I&6*C-MPBPV];$<A#PQY"R:XY93+<+ZOT''2\4>?,_\
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MM/$95T;ZDLG;E75<M?7\CA?M9BO6OIRGFX\.GYBU%5_%7$P^O'A"ZMK/0OY
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MD&2DF77)2<2'$M23HU1G)*49*L6FCE[GN_[@51)4
M                4P+]WL !@ !%MQ_<?M[" G XFDE<J$'[>W]](4";6QLZ
MSC,*Q)4=@R/8>+:#Q+K&1IVBCA!X-)KS%U=N+%2E7SO[SSU3LFT*RA:*K;-#
MGI<P-92J9$=-1EU3-31F9[!I3RF5FJ3M6VNN*^XY3)\PZ[I\E+)9S,VFMG#<
MFOM+9573-D%6E*<JN4]E3%+/%1NT6+VQ^R24)(]HX7-\I<MYY-9K)V)I[?=^
MZAW'(^,'B=IJ4<EKFH6XK92]+[66DNOA_P"E2[$NE(RFMB ;J-U1P*>PVGK8
MDC=P+W=HX:?AKR6U2&1MP?ZM5]YWG1?JA\;-%:=K7,Y=C%X<<VS&>[>#1HYN
MQ]I]^UW:>I"L5% 9:9-:3Q[7%*DF1;1Q>:\*>7<PN&S*[:CTJ+^_89?T/\P#
MQ]T.U*W:SJNU6'&VZ=AK*\4_2MEII'STI=CY8JEHHE1H[DZ0Q*WUK:7_ )JI
M"<5&:3,B>/'=/ ><^:]$L\M\R9C1\O<E=R]N,)1<MJXDW1OI/L1]%?C5S?XZ
M^&U[F/G)0>HV<PH1DJ)->\G[",3GFC,SWC(NH6Z>)>QLQ+ <%5'LCN+B6ROI
M/J4J&5?K%(HC3O,JJE2B0>>-)FELY+R&4JV%B>!KQ/9U!7"..TV6?S#TO3[^
MI3CQ1L693IOX56G5L)_+*X!>8E\V9;=W4W-"VHC5P4J+4FV)2I:G$(D(WB)?
M-0C01F74WCP,9=T_PHUC/Y*UG82RW!=@I).4JT>*K@SY><P_F>\J\M\P9O0L
MYHV;N3RM^5MRBHT;BZ=,ZX>@]'_AW\U_K8L_W)_ZH-[_ )/ZW\V6_GR_9.*_
MU6>2/^QY_P#H?MC_  [^;'UL6?[D_P#4Q'^3^M_-EOY\OV2?]5GDC_L6?_H?
MMC_#OYL?6Q9_N3_U,/\ )_6_FRW\^7[(_P!5GDC_ +%G_P"A^V/\._FQ];%G
M^Y/_ %,/\G];^;+?SY?LC_59Y(_[%G_Z'[8_P[^;'UL6?[D_]3#_ "?UOYLM
M_/E^R/\ 59Y(_P"Q9_\ H?MC_#OYL?6Q9_N3_P!3#_)_6_FRW\^7[(_U6>2/
M^Q9_^A^V/\._FQ];%G^Y/_4P_P G];^;+?SY?LC_ %6>2/\ L6?_ *'[8_P[
M^;'UL6?[D_\ 4P_R?UOYLM_/E^R/]5GDC_L6?_H?MC_#OYL?6Q9_N3_U,/\
M)_6_FRW\^7[(_P!5GDC_ +%G_P"A^V/\._FQ];%G^Y/_ %,/\G];^;+?SY?L
MC_59Y(_[%G_Z'[8_P[^;'UL6?[D_]3#_ "?UOYLM_/E^R/\ 59Y(_P"Q9_\
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M7#BP(=5%K\3/8<W,Z+O,[Y=]=\;F_P#\+Y#^ZY/OQ%??K4FCWF=@TB0 *'R
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M@6.SEP$;_,)?"OY:-OF-_H['^1:_Y"1+VD+8=P$@
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M,_\ A]XDZ?SOEW!Q5G4H+WH5K7>UTD@(Q29,
M
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MF$$D                      4P+''J@!@7L^Z?9 # O9]T^R *@
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M/DP,ATH[=YBN/[L# %<2,
M                                           !8C4C^R.Y/P(_Z4A>
M'Q%7L19?^K1_._Z$%OWA7\)F^-(U          ",76U^WK3'_K"I_P"T:<-S
M9^"1'XD29Q?]&C?Y!G]&D;9_$%L.\"0    #''4?I-R&U9VM"LW/BPZ??- I
MTHYD&)-6\V<:098*<;<96A1&H@Q&&-4FF85L\$7AJL-&RC3E;Q(/89',G*P+
M_@XN]KB)JR.&.Y>HNCD;PK=#>G/,&'FGE%DI2+5O: :3AUEB7,==84@\4J2A
MQTV\?L<@5P"C%.J25>HD1$$@
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M>7X9Q<7ZI),R-E<]DL];[W)7;=VWOA)27K39]_']W^^-J;H8@"H
M
M       L1J1_9'<GX$?]*0O#XBKV(LO_ %:/YW_0@M^\*_A,WQI&H
M   1BZVOV]:8_P#6%3_VC3AN;/P2(_$B3.+_ *-&_P @S^C2-L_B"V'>!(
M                     4,\"QPQ+[?N #CO'B7:[.OB6SVR##T@KO;<,#ZF
MWV_8Y0> 56<@  %,=I%@%05      %#/#'_> %-X^M^^?[Q!@!B>&)EAR=7'
M]V  Y   *&9ER%C_  !7> 1XECAA[  J ..\>.&'V<<"QZPBJ](]AR$@
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M\<,,#Y#QQ' =72<Y7IZ#D
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M5
M       %B-2/[([D_ C_ *4A>'Q%7L19?^K1_._Z$%OWA7\)F^-(U
M   ",76U^WK3'_K"I_[1IPW-GX)$?B1)G%_T:-_D&?T:1MG\06P[P)
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M35=-ST(W,I?MW(25522=3V^)CC3?E0)
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ML.P@)
M+$:D?V1W)^!'_2D+P^(J]B++_P!6C^=_T(+?O"OX3-\:1J          $8NM
MK]O6F/\ UA4_]HTX;FS\$B/Q(DSB_P"C1O\ (,_HTC;/X@MAW@2
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M(\NZ?'(9**4(K%]+\Y?8=9.<
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M=N7VL#5'DA4(T:@9B7K&@QS-,FF5N9-G132G#\B;-04Z323-/\3=P$:MX?\
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MI_V<G3B6^.]=!(Z1D9$988&6);<<2ZY'U2&'_/M,L8=&PJ
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MW3+]X 5   4(L.J8 J
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MUR4VI1&./G;N6W2Y%Q?6FC>0N6[BK"2DNIIGZ!0N
M                    6(U(_LCN3\"/^E(7A\15[$67_JT?SO\ H06_>%?P
MF;XTC4          (Q=;7[>M,?\ K"I_[1IPW-GX)$/XD29QMD:/[##7Z-(V
MSVDK8=X                                               "F!=8O
M< %0
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M^UA@SY39;,SZYFA.)F-N6.X
M
M                 %#+$C+K@"V69^3.5V=%)AT+-.R*#?%)I\I4V%"KT)$Q
MF+*6WS2GV4K^Y6ILL#ZX LBC03H[;3N)T^9<$D\=GR&UAMY?XP$U;>)ZBR='
MNF;+BYHEXV-DU9-L7- P[SK%*I+4>9'P,S(VW2Q41D:L2#KZ2*O?[#)0
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M0  ",76U^WK3'_K"I_[1IXW-GX)$?B1)G%VQH_\ D&OT:1MGM)6P[P
M
M
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M +1IPW-GX)$?B1)G%_T:-_D&?T:1MG\06P[P)
M
M
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MB3.+_HT;_(,_HTC;/X@MAW@2
M
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M0
M
M                                                 L1J1_9'<GX$
M?]*0O#XBKV(LO_5H_G?]""W[PK^$S?&D:@         !&+K:_;UIC_UA4_\
M:-.&YL_!(C\2),XO^C1O\@S^C2-L_B"V'>!(
M
M
M                        6(U(_LCN3\"/^E(7A\15[$67_JT?SO\ H06_
M>%?PF;XTC4          (Q=;7[>M,?\ K"I_[1IPW-GX)$?B1)G%_P!&C?Y!
MG]&D;9_$%L.\"0
M
M
M  L1J1_9'<GX$?\ 2D+P^(J]B++_ -6C^=_T(+?O"OX3-\:1J          $
M8NMK]O6F/_6%3_VC3AN;/P2(_$B3.+_HT;_(,_HTC;/X@MAW@2
M
M
M                                      %B-2/[([D_ C_I2%X?$5>Q
M%E_ZM'\[_H06_>%?PF;XTC4          (Q=;7[>M,?^L*G_ +1IPW-GX)$?
MB1)G%_T:-_D&?T:1MG\06P[P)
M
M
M             "Q&I']D=R?@1_TI"\/B*O8BR_\ 5H_G?]""W[PK^$S?&D:@
M   4,\.H9^T6( )/>+'!1;>118& *@  (Q=;6'G[TQ_ZPJ9F7L?*-/P]W ;F
MQ\$BK^)$F<;9&CEUF6B_[!(VW26.\
M
M
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M9@L&62/J--E[B"&A+:_.2MB.T02
M
M
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MII#>/)CN))./V<!3:ZDG;^[]VP
M  >(S%LYF_;/K%JO/=[HJC;*>>(L=Q3,AI\C^SS>'V1,725>@AJJH?4M.@HM
M>WJ50&W.=33(C<9+F&!K)!8;Q^R8.C=42MAZ+;^X\! *@1B4_=R@25
M                           63@9/QH&;M4S1;FFIZIQTM.0S(\$**(W%
M,R/DVDC$6JN&E,2$7LP%21R@                                  I@
M76 %G;XRGBWC>EJW@Y+-A^VDJ0AG=Q)Y)O<\6)^PHS$IT3(>-"\1%R>QLQ]K
M9@75$$E0                                   !X',BQV,PK6E6U)?.
M.W(>C/\ .DDC-*HSJ74E[1F74$IT=>DAJJ/1V[22H-#IE&0HG$TZ(W&2ODWB
M;Y#ZO7$/;4+8?; D      "G[N4""H@D"0   '3(CL2FE,26&9+"RP6S(:0\
MTO:6!*;<)2%%[9 #\%/H5%I)N'2Z33::;IF;AP($6(:\3Q/>..TV:L?9 ><^
MH18%@ *@#I4Z1$1D2U8_>H4K875V%M2(Z2<%M.Q*M[ \#+VR^R)(Z3D
M                             "AF1%B9X$ ./.%O;N"\2ZNXLT\A']T2
M<.J !K(NHL^OVB_M;.7$ <B42BQ+'[)&1^X8 J
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MRVC<90AMQ:'M[$R+#$]@JMF)=[<-AD6)(
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M;3Y1";H:LTE)I;#*W89\FTNKA^\8DH5
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M2'4D7/.,QTDG>/$S(BQ,$3);'TT)9!)4
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M"YJOQ<,O5TFYXGD+\$MG6_=@!5[3D
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M)NQ9L9F2Y+B/QU&:5$ZA&)ELV MA-Q/B;1(()*
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M2;HWE&9F9F5RU$L3,^K@0DK/;Z"=0"H
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M$VRHQ%NKBT=R,CF(SZ><=W9,?#<<+>,MXCVB%V%I)IX[2_@DJ
M     !:;//**V,^\H\PLGKQ;-RW,PK8JUL50R03JFF:G$=C]\(0H\#6P:R67
M)B18 ,:^7J-1/319/$7]7GB9A:<,M-+US\0+3]F1>$O,'+.Y,MVKC@U"PY<P
ME1)5NU:'&HU9-!/H)E9IQP_)F:5'M,.C$E1>-,57>EY;Z]9F=PS]">J;.S7#
MF=Q5M<MO-9975>U!IMIY69"S&JC(K5D46G+F26951DSX\0XQLHGDTA&YO&:#
MWB+JD_41).M<$]BICYZOKVFSL1$6'L%A]@ 5
M          !#[QU;1U YF\,[4'D]IDL^N7AFGF[&M6Q(S="2ZN52+;JEY4%Z
M[*HXW':>?>9*@1GV%-DDB-+RC,R(ML,8NJHJTZ70NCPC=,%2TF:$\D,I[HHC
M-&OFF6TTN\&TQ"B2'*H\HUJ3*2:$.*=9;,DF:MHGH):2]U;$28@0
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M6U%=NZWZJ4EEFG3G4&;D4V'Y+A\XT:CQ,TD>)B,>G::E%!N*;:?63F 0
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M;/?KT=LB>?0RI:U-MK<QP(SV$%*8(K)\3J9% 0                  #8
M                                     "F!=8O< # N7 L0!4
M                            #EY=H IAR<GN?O=8 5P+]WL@!@76 %-T
ML<=O\  J                                  !@0 I@1?[O4+K>P0 ;
M#V[/;_W0!4                               4,B/E(C]L ,"ZQ !ALP
M+#DV;-GN;-@ 8%L/J]D ,/:PPPY/W; !4
M                                                      4Q+KEU
MN7J]8 5
M
M
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MY1":9:4)1Q9D")*@ 4Q+KD !F1?NQ_> %0    4Q( 5 %",CY  Q+K\O\/(
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M 8EUR+V]F.S'9U]@ 8D?(>/M;0!4
M
M                                  8F:\R0>BG5>2R(TGI[S9V*Y/\
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M!.J+C*IK9F2%DX1;^&PB/$2DV4JFVDFI+>;/Z>3'89'@98;2PW2Y#ZI #D
M
M
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MII18'B8%<5@]I^X
M
M                  ]WE &/FJW+FYLW=-.?65MF/QX]U9B94WM9U =F$GO5
MJIW!0)M*CK=-1;I))4@N781\HA["8NDE4B\]7_T+9Y</70G!T_Y]KIIW;#S
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MAX[=I](
M
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MMM,LI2V@L$F9X$6)GB(PZ-A%6WCM/5B0
M
M
M
A                                        '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tv523241_chrt-line3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_chrt-line3.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1" 'L I # 1$
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MTB-3DY15%V+",S14=+34-746HD-SLR1%@K*#1#8G-__:  P# 0 "$0,1 #\
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MHU?23C76>]6P>QJ3?<:/FR9<.)12CV+_ $9DK?EPWVTNIU.-M1")K%7OP4
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M853$;8#US%S!K$WE>\^GDRV8Y>7*Y+N);)GQ<+:_9!0K%:,Z KCC2OF5I_C
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M^CC9!B;9ON3574]QQLP=B9$SQ]/DOW(\<QK),JN1H-EI7%KL'9:CUM1P&S&
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MYHV4NN-74OQ76VV4MA2*4[%GI8BF/IRC-]0[*S;+/"-9+;"NS'RU3AE0)%'
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M&K-_E<<I3Y-O3SW'$?MY2"=2SRPV)B-
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MV*XK4CCD*&VV;AWH6]@9[4W(4-K*=U@M=@QWX,.>I%*U[7WO#+D
M                                     !KMYKOO"YI[\PC^\!%@L:LW
M^5QRE/DV]//<<1^WE()U+/+#8F(T
M             -;FS7+ZOV*WSY>^[5):M:%FB638.^^,ZL6Y?NE'].S%3&72
MEKQH\46C*JUJIW9/I6K=F]/K?^@X=.MKPHS,5F)[EN=BM?8LVJ@^3==YK;M'
M3%LMM8\TGBBT,YR)@PG'*X\N$T04"UUIE.54L^7PFR9C'7IES6#'DIU;1*K1
MHB:7(2FA56H%CS9CFF3YLII1K"^V8]X;U35XJ9#"4*4C3)96/&[)<WMM?,.R
M1T)NE<&,K6S,1*Y+BUM;2]Y2M:5MM83EGO96V&Y4>[F':B<MF>7GS.'!IT7V
M@N:QN<(I>,#LW89GW.-LH=J!8\(\O?JKDM9YTZ6ID,9BF MCK<<,YK[35F&N
M+!A5.6:\)>U@WD%Z*L+6K7376<FVL[1D8 <C]DJY0D)<<R"TW],<HJB0L/:0
MG3&#;<N%KJV+(91\>!,2E2Y5))Y&MV.[LC+?DSWJG*V42=IMJ?-$3H$#RIKG
M#3ZA5JK":X&S%+@CYMFV @+:.GJ24E*B.U>Y]B,G'4]-6#6#%?BPVULQF,EM
M.I=42JTB=7C( Y>FC6JCU.R/K9J?!$'OU2;AYH'W?&<=-UI. XUU-02E500#
M"FDDBYG*E'%)#)Y\F&MU;+LI;'=6G&R@5(MB-&#89Y;#?CF?N9K+KSD:DC,_
MF4&F)A=$:V-#.U;X_;;5BM6BM<0*.W"[UK*[;G0F*^3-0S812+B?'H4LRUX9
M*6J1'&?%KQU#Y#<M:_39JR;E[?IR;"ZCZ$.Y]O?377!2A1G,E<92^]2*X4(&
MG_*Z"K7KSVHS+EV_*5QY,-,&?/BLK9C)E>F2O52+>/'1](XC8
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M1UX+G-XX .)W,EO\MHZ\%SF\< '$[F2W^6T=>"YS>. #B=S);_+:.O!<YO'
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MCKP7.;QP <3N9+?Y;1UX+G-XX .)W,EO\MHZ\%SF\< '$[F2W^6T=>"YS>.
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M@\RG$#B_MW,EO\MHZ\%SF\< '$[F2W^6T=>"YS>. #B=S);_ "VCKP7.;QP
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M(K,:RGA&@                ! &/QE2^]"OVREB]C,^:$^(T
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MYMMCR9)BO'C?=,M@@Z[PP             @4WTY<7W=-];L(K,:RGA&@
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MMGZBW^WWFQB^,6+I^UV\\T4GXFVP68<E/#GLGE[XHO4/GO+
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MZ>V97M&'AP            ! IOIRXONZ;ZW8168UE/"-
M " ,?C*E]Z%?ME+%[&9\T)\1H                 0ZU]H)]^$?UQ+@D_:F
M 4                 1JSZ3JO>T]VKE%C5)T=@C]Y$_0I?SFP0C1V@4
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MK=A%9C64\(T                 ( Q^,J7WH5^V4L7L9GS0GQ&@
M        !#K7V@GWX1_7$N"3]J8!0                !&K/I.J][3W:N46
M-4G1V"/WD3]"E_.;!"-':!0          8Y_6W^SG\Y@%,^:[[PN:>_,(_O
M18+&K-_E<<I3Y-O3SW'$?MY2"=2SRPV)B-        -9'.<^2QWD]P9S>?D
M2=&QAL^E-OH]8]=SPLZD)\17YO\ \VO^S_<J HGR_LV3)&,STR7=+H;I[LV6
M<:<*TMNV<DO+6G&E*<>.7)=7C7ZM1V-UU#>]1OMR[Z^<F3'CLQ6S,1%,>*V,
M>.WAKRV6VVQ,\:1Q>T]==-V'2^J;;#T_'&+%DZ7LLMT1/FR9=MCOR7>'-?=-
MU.^5[AUWBP            ! IOIRXONZ;ZW8168UE/"-
M " ,?C*E]Z%?ME+%[&9\T)\1H                 0ZU]H)]^$?UQ+@D_:F
M 4                 1JSZ3JO>T]VKE%C5)T=@C]Y$_0I?SFP0C1V@4
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MNS$]<WLQI.[S?^9<R.*^4            @4WTY<7W=-];L(K,:RGA&@
M           ! &/QE2^]"OVREB]C,^:$^(T                 (=:^T$^_
M"/ZXEP2?M3 *                 (U9])U7O:>[5RBQJDZ.P1^\B?H4OYS8
M(1H[0*          #'/ZV_V<_G, IGS7?>%S3WYA']X"+!8U9O\ *XY2GR;>
MGGN.(_;RD$ZEGEAL3$:.-    :<]N(_BN=^8U!$);1I*&Z]>L.D&S4J--C/<
MWUAAK4QMN5H&;J^[S)+,9+$%)X1O&#DS7)N?)T\Z255SIG!7%6Z_)2]C,Z^#
M&CJE!<3.0#1]NMTR%C4U;3!O-U'?S<6^Q7[F2GJ03&%&[_..E3SV9,%#:"N)
M:JL*V?+3-:2O,FKKZ7_9@=CU?+.C];U\V3VPU_=#0@R.UHQ&.M4T$&!J3:YB
MNM"(AN2R4V'>N8D9X=%=1II=Z^PC>19NICQE#S>*(5]G7#&,WEO21P>-YO<C
M;;'N7;NLC./6"-T&/LT2.HD??)+9B]<6B3>HH%<>-=Q,BL))=#9V\M;9DJ1[
MJ8^C6ZMO7Z\.E4LMX#:ZB5;Z/6/7<\$D)X10!5G>2^EFEFWEU;:UI;K#/5:^
M"QU>9]<?1Z-U&SH_6=IU?)9\6S:[G%FFSA[\8K[;YMX\(YN6G'AQ?2Z/TS)U
MKJVVZ/BR_!R[O/CPQDX_R<Y+HLB_AQ]V9KPX\&9(CR4S13&66EO0IDCYF7TM
MX\>C2YN)MU*<:=2O"E1U=UGC=;G)N;8Y;<F2ZZG=S3,T^:K@W^UNV.^S;*^[
MGOPY;[)N_*FRZ;>;CQXTKQ9"' Z@           "!3?3EQ?=TWUNPBLQK*>$
M:                 $ 8_&5+[T*_;*6+V,SYH3XC0                 A
MUK[03[\(_KB7!)^U, H                 C5GTG5>]I[M7*+&J3H[!'[R)
M^A2_G-@A&CM H          ,<_K;_9S^<P"F?-=]X7-/?F$?W@(L%C5F_P K
MCE*?)MZ>>XXC]O*03J6>6&Q,1I\D6RO-@V,8>W6T#+<FX49:L-^+&+O*F,J'
MW>QHP4;4)PZZF=>5C6E\N?&["N:2WJI[5)CW5>YZ>GG2A502U#%C2BUQ\K>9
MKK@XZS5]/FO+W><FP%!\D2.TKF#(4@Q!&CW?;%OPFR][+>3K9:*O.AIW%S^3
M*>+W-Q</YR=;,U]V:RN'A?6MU*U&6XT9A!6'YEU\@?8MOIK3V A>*YN:Z,M%
M7(D-V66 U9"1$IP$;,N(HMIR8[$I6)DE4OASWV6Y\=EN6EE]UO'A=6E11/9H
MEBTPI&%@Q'#&SJAMA6Q6:/9FJAY3)F,K#.8Y9'F?)>1NKE9-IHSDR42[N)+I
MWW5ZWU:@E(>=A37: =;&VH,[7F$XH@QIJRQG<"JVHBCYJQVAJ:Z9PX2V=94$
MMI)222.JF4L6QXZY\EEV7K>.VSCT;:4H**6<YSY+'>3W!G-Y^0 G1L8;/I3;
MZ/6/7<\+.I&B?$4 57WG]Y1M_3_X8)Z_ZK'5]7S!F_C9,1W2]1Z(_P#S+I7_
M #';?^=8S##O_1'%GN<,C_V93!;?+'R/F]>_X[O?];S?^9<R.*^2
M    @4WTY<7W=-];L(K,:RGA&@                ! &/QE2^]"OVREB]C,
M^:$^(T                 (=:^T$^_"/ZXEP2?M3 *
M(U9])U7O:>[5RBQJDZ.P1^\B?H4OYS8(1H[0*          #'/ZV_P!G/YS
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MZ;ZW8168UE/"-                 " ,?C*E]Z%?ME+%[&9\T)\1H
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MRR;;HNI37@L\.P\F      "!3?3EQ?=TWUNPBLQK*>$:
M $ 8_&5+[T*_;*6+V,SYH3XC0                 AUK[03[\(_KB7!)^U,
M H                 C5GTG5>]I[M7*+&J3H[!'[R)^A2_G-@A&CM H
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M?ME+%[&9\T)\1H                 0ZU]H)]^$?UQ+@D_:F 4
M        1JSZ3JO>T]VKE%C5)T=@C]Y$_0I?SFP0C1V@4          &.?UM
M_LY_.8!3/FN^\+FGOS"/[P$6"QJS?Y7'*4^3;T\]QQ'[>4@G4L\L+MR2]&7'
MC%<[UD4WA3V.W$G.I.8Z93#RS@+I>*MMN?)E2DTDI'S]E*WTI7'BP9;Z\?\
M-J(U+Y.=DYY9>OSHYBNG9)W:;O9+VBEF755:E.<&QLY:^8)NE!K);>.L=RQJ
MQM6)#:LTI,28"_8[2N3GFAX,1' 4Q7];KBOK=IC1]1.KJ8BHNL^NR,VWRL2>
MW4B"XD2T"2W$4/D%^1$4@P&^52GTN$57'A5"2N[2.+&?,XC-EIC'F,76Y*4O
MI6@RU#.H*    UD<YSY+'>3W!G-Y^0!)T;&&SZ4V^CUCUW/"SJ0GQ%
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M]LI8O8S/FA/B-                 "'6OM!/OPC^N)<$G[4P"@
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M3,W5F:=E5[Z4X#NOS=R   "!3?3EQ?=TWUNPBLQK*>$:
M $ 8_&5+[T*_;*6+V,SYH3XC0                 AUK[03[\(_KB7!)^U,
M H                 C5GTG5>]I[M7*+&J3H[!'[R)^A2_G-@A&CM H
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M64\(T                 ( Q^,J7WH5^V4L7L9GS0GQ&@
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MQ0\4,Y5%JK]SFZ_%8[R4_P#Z&<WGY 0F8HV,MGTIM]'K'KN>%G4A/B*
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MV2V^S?8+LL1&MD6Y;\5+O&MDS\DLO#E?$ $"F^G+B^[IOK=A%9C64\(T
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M<ZC]?S5X)^9/O(6V4I93%2VVE*0F&_!M\*I5O#S.SU?_ "*QT6=5C1/"*
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MI8O8S/FA/B-                 "'6OM!/OPC^N)<$G[4P"@
M     "-6?2=5[VGNU<HL:I.CL$?O(GZ%+^<V"$:.T"@          QS^MO\
M9S^<P"F?-=]X7-/?F$?W@(L%C5F_RN.4I\FWIY[CB/V\I!.I9Y8;$Q&GRR3G
MM;M7=Y2I^9.;PTM,'#K?+\QM>#]4Y"@[5)QK^5IQPW$U68JH8N>S8)2H^T6>
M,^:N9M92&$P8QE3N"RW(IY[+[+JQ7Q;$.43M3LAL(W9P9.R*_BD%SPR;@G+A
MDNK%1H[7;EF98+:4LO>%9#;C6MP,^R4=>W.X,B MYDPLGX\E]<-,I(MGMRVW
M%AN+$: ''"GUJ .0&LCG.?)8[R>X,YO/R ).C8PV?2FWT>L>NYX6=2$^(H
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MMI/"*WVW74MX<:ZK^CSKXH @4WTY<7W=-];L(K,:RGA&@
M ! &/QE2^]"OVREB]C,^:$^(T                 (=:^T$^_"/ZXEP2?M3
M *                 (U9])U7O:>[5RBQJDZ.P1^\B?H4OYS8(1H[0*
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MNPBLQK*>$:                 $ 8_&5+[T*_;*6+V,SYH3XC0
M        AUK[03[\(_KB7!)^U, H                 C5GTG5>]I[M7*+&
MJ3H[!'[R)^A2_G-@A&CM H          ,<_K;_9S^<P"F?-=]X7-/?F$?W@(
ML%C5F_RN.4I\FWIY[CB/V\I!.I9Y8;$J]2E?ZA&FGE/TDW[B64=A5[5W<K7V
M+(FG.<'E.N&,'GJ6M2.>:[N?]J=F>)RUX6SPV3JF9<ZN0N4#=+L-A:TWGR5+
MX<&.M,5MJS1M?9!)V)K,:2<_5U+=#Y3VR@DGFYD-$R-I$<3K*I97 XEU';F9
M26<R E*ZO9F,%R5QPW<4PY+<5<V6MG3NC3U     #61SG/DL=Y/<&<WGY $G
M1L8;/I3;Z/6/7<\+.I"?$4             =4]7@4->9][YN%:^92O6[NK_@
MXB=KEP?Y:S\^/K:OM)MP=3&=J= #6=NS^O;7<R!&3;2EUNN*:(X15Q%5"96F
M$VG*R2I.0J?3CY7+;6W)AS8[,EEU.%:4J/0;'T9ZNW6TQ[G:]+ZCEP7V1-MU
MNWRW6W136+K;)MF/DF8>K_>5GP8_7G5;;K[;9_&7\)F.V:KLL#9K7&5W!^"L
M73]"TD.;L,PH_@ZPY28[O7*)Y/K=#9[N2WUU0/\ 89:[-93)EZWT+.G;TJTX
MT'#U'TSZDZ3M_P 7U78;W;;6L1SY<.3';6=(YK[8BLTGAJ\7;FPWS2RZV9\)
MAE1-].'%Z(3?6[$/C:PW&LIX%                 $ 8_&5+[T*_;*6+V,S
MYH3XC0                 AUK[03[\(_KB7!)^U, H
MC5GTG5>]I[M7*+&J3H[!'[R)^A2_G-@A&CM H          ,<_K;_9S^<P"F
M?-=]X7-/?F$?W@(L%C5F_P KCE*?)MZ>>XXC]O*03J6>6&8M[C,SD],-IC>N
ME'1=/):!I0SP]:RBO9SNND;$TE.]HVMHGUO/V4N56J8>QL?0OZ>7A3A7S!%G
M1HGV!F!P[(N+>W8/!LMS"M;4[4Z)X4LU3CU@Q=.$,8U.5WNWU4K@J[8>>L5D
M#\^/)YSMBPMB]',%CR1W)R%JX[[+35QC'IGQ?15KXN28YH$A%R34A%VM,C@B
M*-ER6FP4Q]:*-R3%9FHI]^();%UW-ULNCNHP;+V6].[A;CI3C7S1EJ-&7P4
M  !K(YSGR6.\GN#.;S\@"3HV,-GTIM]'K'KN>%G4A/B*             /XY
M\=N3'?9?QI2^RZRM:=2O"ZVM*_Y*B3%>/<U9=-E\71K$PUZQU/.B,',ALPWD
MG&+SF6,$@JQLIEP9$RY=R9VU9W*,=U[L"7CQ54+<Y:ZF7HVTMZ=*CCMZG&VL
MMP_B+HBV(CS3&G#LE^C]5]'^OO5/4,OJ*_I6:9WMTY8FRWW9YOR:SHQU2:X
MEO>[53!"SW9+NSHT7;.WKN-I=CUO)8CI.*;4^ISK)<O7AGO+YJ8^/'JVW>8/
M:](ZEAW?HCK&'XOQ+YW.RF(K,S2)SUU^6'ENL^C?5'0,=F\ZQLLVVVD\UL77
MQ$1-TTI'?5LV2_3=P_=TWUNPCQUOEAY[ME/BJ                 ( Q^,J
M7WH5^V4L7L9GS0GQ&@                !#K7V@GWX1_7$N"3]J8!0
M           !&K/I.J][3W:N46-4G1V"/WD3]"E_.;!"-':!0          8
MY_6W^SG\Y@%,^:[[PN:>_,(_O 18+&K-_E<<I3Y-O3SW'$?MY2"=2SRPV)B-
M-"K:EF;#.^+":1I]R#F9!KFW;*1X=0<RPM7M[/%J'RG%J16XTS!._+4E>SDR
M4\5BN4+5IV+C6;:9K*4S=45CM\*_8WU4ZG4$;     &LCG.?)8[R>X,YO/R
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MWH5^V4L7L9GS0GQ&@                !#K7V@GWX1_7$N"3]J8!0
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M[/;[7=V7QC_#XL>&R[X=U+KIQXXB(FMT17MA=.EU.'UOJ?T#A>6E^@
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M$3S3%:3I"U6.ZMV.RZOFW6VW5_PTXCL:O&W1RW3;'9+]@@
M( Q^,J7WH5^V4L7L9GS0GQ&@                !#K7V@GWX1_7$N"3]J8!
M0                !&K/I.J][3W:N46-4G1V"/WD3]"E_.;!"-':!0
M     8Y_6W^SG\Y@%,^:[[PN:>_,(_O 18+&K-_E<<I3Y-O3SW'$?MY2"=2S
MRPV)5IQI_3]3^L1I\CNRDA1TTGQS#T78V;=]8FWM,S#*9[1Z,M95_:M 0G2R
M#C81;=8UF#H_ATOC@R4EQ\J6+%8\,JWC/9LBMV:75[\!;%;6W3''M?4+KZ8E
M,W L)&IS*DR4V&8CC<Q,)).J6JGE)3S,U&RR"5(=A5J3[#+NRXW9BZU_H^A2
MG1^QX#+4:,O K5)L\G.J?-^H?U0.RW,T11.3TYGG815N@V4WG#+K>DB$)3AN
M*VGD47JP5="<AE!C='=JD>JET,]@&CRF5R',.>S!BLI>QF=7]XZWH08(Y4\5
M[D[-.C*K7-J%6-8Z7.?4$=*.R4]LQHC'J JY597,I+;1S<I.FXJ:O.F\Y1+)
M44+L^;+A+8[[[6LE:<98-Y,FSYF=UC?]O._<F-=NWVU]L$)SD52+9/2G_'C2
M8+^U;UO<.5OPL2(JI^]*@9K2Z9=B"AY[<>*ATZDGLAKI*=3X21,,<<W/=A+=
M7+^W4C''K'NFA9U&+78U[7RY];'>B1D4R8E(L4[NGWJ9S5(%6QDNP]<L/76]
M;KBNMO\ ,J"UX-]S9]*;?1ZQ_E5SU0GC)"?$4                 40<&JC
MV5)OF24HTV?E6&#,EYV+E=3>:C6B1PHYLXT6@3;B8=Q97XPG.IE\M4_!2E]N
M//;CK=U>B/;;7U?L;.D;7H_4NE;7>6;3XD67Y+\]EU,E\WS'\EELB8K/;%7!
M=BOF^;K<EUM>SA]L*U[H0#/;6U@F%PK&ZDQOQ+1VX7.GF<O,*!$]'<1;$LIE
M;TU0.MZ,$E;+%L]/\Z\L9PY:<.I?09OZCTSKT3T?I70MG9U#/$VV769=S-T3
M,5K$9,UUD_\ Q1,/7^@]]M^C^K=EU+J.6;=GBRUNNF(X1RS%=.^5\9)VNA2'
M7!B9[]5GH37J)1)4KA0(AEY[D.PS=V;%@N[M,ABN%$IFK>5OZ6'LCKV.E*5N
MMI2ZWCX/-N<6WI;EFZOA;,_5$M])]'=?]08+M[TK'BOVW/-M;L^#'-8U]W)D
MLN^>E$W#>RL.SZ==B;&#C55938UB!E=26NLE],542,+HM5KD QE37VVVT>SE
ME2B$;ZWDPX\F/C@NI6M*\*5N'<X=Q,QBF9F-:Q,?7$.MUWTIUWTWCP9NKX8Q
MX-Q.2,=UM^/);=.+EYXB['=='N\]M>/;#.XYWG0            ! &/QE2^]
M"OVREB]C,^:$^(T                 (=:^T$^_"/ZXEP2?M3 *
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M<N2ZXJC?.<^2QWD]P9S>?D 2=&QAL^E-OH]8]=SPLZD)\10
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M?7_K_P 'UA:?2E8^9^@5 &/QE2^]"OVREB]C,^:$^(T
M(=:^T$^_"/ZXEP2?M3 *                 (U9])U7O:>[5RBQJDZ.P1^\
MB?H4OYS8(1H[0*          #'/ZV_V<_G, IGS7?>%S3WYA']X"+!8U9O\
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M.X3Z?SD0NR*W%[>AG[&Z]CIQI9=;2Z[CO%ML.&[FQQ-?&ZZ?KF7S^M^LNO\
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MBS)N.DV9<DQ_"O\ Q&XLYOGMLMCYEK!VGCD 8_&5+[T*_;*6+V,SYH3XC0
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MH=[L?F,^=Z &@                !#K7V@GWX1_7$N"3]J8!0
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M&SZ4V^CUCUW/"SJ0GQ%                 $"F^G+B^[IOK=A%9C64\(T
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M*    UD<YSY+'>3W!G-Y^0!)T;&&SZ4V^CUCUW/"SJ0GQ%
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M"1C7/8LQG)VY\MI7.8P/."K,&?*7I?3%DS8;,U]++JTK=;2^[A7JU'4ONO\
MQEED>7DN_P 5[K8XL,_NZZAGNMMG/'5-I$74XQ$XMQ6(GNF8BJYX[;PH
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M?B[LUM>:.:+[+L=G";*TF)F>:G"BX=OF4ZM*TX4\SZ_"@[?!X=^@
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M^(H                 @4WTY<7W=-];L(K,:RGA&@        !Q7S/\-O\
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M .-/K@''CYG5       !&K/I.J][3W:N46-4G1V"/WD3]"E_.;!"-':!0
M       8Y_6W^SG\Y@%,^:[[PN:>_,(_O 18+&K-_E<<I3Y-O3SW'$?MY2"=
M2SRPV)B-        -9'.<^2QWD]P9S>?D 2=&QAL^E-OH]8]=SPLZD)\10
M              ! IOIRXONZ;ZW8168UE/"-         #BOF?X:?Y*TK7_(
M)(I]JZMHQ/)L?@-JR:4S4VKF&ZN$T>+%\M+;LJ'6VZN/-ELOI;=3JTKPZM![
M#U1@S7QTVZRRZ;?V5M^,1,Q_#<6*)]Z/\*5I_P )6Y_R^B>JI'_?QY;\-N/Y
MN_\ 1G[G+0_"5N?\OHGJJ1_W\/PVX_F[_P!&?N*'X2MS_E]$]52/^_A^&W'\
MW?\ HS]Q1^K'$W\N2S%B7$C+ERWVX\>+$I$\F7)DONI;99CQV9KK[[[[J\*4
MI2M:U$G!GB*S9?$1_@S]Q27\3'XRI7>A7[92QQ]C,^:$^(T
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MENBVV-:6Q$\(K+CNPX;IK=;$R\YY/C2#X*4#>#AN?^0CM?W@>N?[5WW]-?\
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M<MLVY(LC)28R66?P9UBJQ2SZ3JO>T]VKE'8C5XV='8(_>1/T*7\YL$(T=H%
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MIM]'K'KN>%G4A/B*                 (%-].7%]W3?6["*S&LIX1H
M            0!C\94OO0K]LI8O8S/FA/B- #QCSCJ/Y&*$R$@L=GOH@GF+C
M9$B\6RBN8F3-W8[L-YDJ66B1W"7,7X;JV5OLMI=6VM:<>%1V]GU#J'3KYR=/
MSYL&2Z*3..^ZR9CNF;9BL>"3;;=YHB6/+M7=9^%?^SQ!M/Z:1*PNI_B0!]&/
M4_J6/_<=]_3Y?X[/PL?Y-OT0P9RVRI4CIU%Y(D7P%"9-=F,J4*%<6/ 6*EB\
MWR/AP%R^#%;9BPX,.&VEMEEM*6VVTI2E*4'V?WCWW9/66ZR9)F;YLV\S,\9F
M9VV*LS.LS/;+."GP8B.^?K7I'BG*          "'6OM!/OPC^N)<$G[4P"@
M               "-6?2=5[VGNU<HL:I.CL$?O(GZ%+^<V"$:.Q=3I4X<> *
MQY'\7-6,\SYS-?$<Q7R&_5N2')V8<R'.O.=P%DTHHYBG7/O0I?A2L/1PV_8V
MUI6OU1BRR+*T[;IGZ7T^I=6WG5?@?C)B?P^WLPV4BE++*\L3WSQGBR*-OF
M      ,<_K;_ &<_G, IGS7?>%S3WYA']X"+!8U9O\KCE*?)MZ>>XXC]O*03
MJ6>6&Q,1H       !K(YSGR6.\GN#.;S\@"3HV,-GTIM]'K'KN>%G4A/B*
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M7XZX^/'I6UH%)2;HTKQ;YFUU$JWT>K_Y5<]4)U6-$\(H
M @4WTY<7W=-];L(K,:RGA&@                ! &/QE2^]*OVREB]C,^:$
M^(T    IIS"DE47=+MATA$3%!95C[!,82*6E$S*@H'<W=).NZR5)$\68R9R]
M"VM>C99==PI7J#V/[O<N#;>M>FY\]UMF*W<5FZZ8B(]V[C,SPAP;JL[>^(UH
MN/CK2MEE?J]"WC3ZW4IU!X[MGY7/V4?T          $.M?:"7?=']<2X)*8!
M0                !&K/I.J][3W:N46-4G1V"/WD3]"E_.;!%C1V@
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MF!?S)][?'^!2#R9$'^W9S OYD^]OC_ I#BO+&@ZO4K-G,!KQ\WCS)][*\?\
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M@_V[.8%_,GWM\?X%(/)D0?[=G,"_F3[V^/\  I# &V/+[C:.-6=EI#9$Z\P
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M4X@N5KNMH.U+0G<S7<V%U/SDE-(5B))23S>&_"8PX\EM;:%97
M    !Q==2VE;KJTI;2E:UK6O"E*4ZM:UK7S*4 4<C+F0Z53"N.Y"9$V)YBC,
M9;ODLVXW,T7^PH^<D:1\>[FON28UDM^M1M1[+4>LQ0I3$IK;84U=,(UK;7+G
MMMNMNK:)6'O=;MTM<=L[W,6@Y[JZZIM FWE=<0';'4F10Y\3:>& V99KU3VM
M++/9#B7&"\2Z?GO2%\B5,(ZE;AO[',Y.C=PA$PM."@               *9F
M^8%J22GW^S.9E+/9*M'H1C/+;:P9*R1P5E-3;^!U)T3'9MQL^^%B4LGFZ:Q&
M\38RN"Q=R8\MG1*UNOMMJ2L.U'^^NJ,H3@HZ[,>4,JO*!!5?+?)ELK%D9'93
MK<<79\A636O'4KK;13HJDQTQN9P9<:\F-Y:4SR1?@S4-8L76<O0M"L+A"*
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M_%[5>"5<8L-W(J^E-1-P**#4UBOR83%4+/2I/IV75QW=8XVUK;P$6(I"X@*
M             "HV[\?["ROKZXXUUM-L$B[WNJ(3>=YA_O\ >L78,T2GC]EL
MG([5D!@,*27(SWLYFK3,F)RKA2LUZ7><N.8ZTSX,5*V$EI7@YC3QK^RHM?4K
M:OI[$B+6GFKSR]#<;ZRI<N3:<1(LD&--AX83GJUXT*0,P'8M1A&[PDA#,)AU
M#25/.:;],REV*4H6KC!.QL_Y;3?<]K=VOE98:CM8S5V*W3F6:8I;#Z:S@8KJ
MMC111V,R49U*['=B<BNEH99%4V,=<&$BIDB:A854\60SAQYLM]M$K$-D0B@
M             \3)2$JNB.G\V4(WW/6W$RW2A(Q_IW8^P5560SQ!..=<LK2_
M'V*<,69.E3JTZ/&@$OD#38'VHD_4PMK+#B3N0Z'EEY8$SQ9LY&&S\1.2.(RB
MZ<&LP6,W(YAW6QT.M@M)F)USY7T)4;=A5DJJNW5-K6%E(\8S9+L)LS?D8X_.
MW<ZW.XSLMS"5+9IAQ7-,:1 R='&U""T=FB%9(@A47I2=<M?I%L8R6UY/:[16
MEW]$3>2<N(^>)ES*47.K%2Y<QDNIF#L7C5MY$:              !Q7S*_4Z
MGF@/E'<$12G?N$\5Z]I;6TGG)S8T"6&UK.GPS)&?0!SP4EK: TT/:A<DHLT,
MD38W_2"R5'.>5\KMP*)-_D["/<?(8QXNO5A8335$?B77EIZCJT*S>WI9TPV0
MV>>.P3Z<$-2&WXM36H6C+:YB)#X0)H6VX2C.0<.P;@F5#/IV%#5U$]EP'360
MUAPWDS%M@CL?1J(V            UV\UWWA<T]^81_> BP6-6;_*XY2GR;>G
MGN.(_;RD$ZEGEAL3$:
M
M   &NWFN^\+FGOS"/[P$6"QJS?Y7'*4^3;T\]QQ'[>4@G4L\L-B8C0
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MY 7D5<HGF;B9^J.J$5.A$W9QZ94Y4EGST+&;>%>-E_1NIP\P"L2F@4
M                                     !KMYKOO"YI[\PC^\!%@L:LW
M^5QRE/DV]//<<1^WE()U+/+#8F(T
M                     -5G.N;+I=W+1V*1&8U'4]G#DSP\H%6RR&TMO!T*
M)9%G2-%I4JDMIMD%1<5LI)*(9S%^,L7RY*8L5UW1X4J+"3HKALG*QOF%2IHY
M&NM\/;!YF[".W4;[33#,DGP%+L"LMB-6%$1UJ!%HHRS-+.8AISOB25U5+IF
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MO"YI[\PC^\!%@L:LW^5QRE/DV]//<<1^WE()U+/+#8F(T
M                                       #BM*5\VE*_P!= '%;:74K
M2OU?Z:T^IP 8*@36J&M9D-TH,/-8T@XGT\5*0'NKK3G=3X=CR>2J5(IYIP.E
MY/A:<3J7CV-+2RI/!4R<R6EB9;%AQ4LQV6VT%&=J4I3S '(
M                               #7;S7?>%S3WYA']X"+!8U9O\ *XY2
MGR;>GGN.(_;RD$ZEGEAL3$:              !7+9S9=J:MLEL/)SLR2I"SO
M21FI%329D2MY-<[V<+R>79]44@G):NO-LA=BOHF9:Y+[S=G0I3S*@DS177R@
MS@I__P ]N8OX%HQ\>(%3R@S@_A[<Q;P+1CX\0*N?*"N'^'MS%O O&'CQ /*"
MN'^'MS%O O&'CQ /*"N'^'MS%O O&'CQ /*"N'^'MS%O O&'CQ /*"N'^'MS
M%O O&'CQ /*"N'^'MS%O O&'CQ /*"N'^'MS%O O&'CQ /*"N'^'MS%O O&'
MCQ /*"N'^'MS%O O&'CQ /*"N'^'MS%O O&'CQ /*"N'^'MS%O O&'CQ /*"
MN'^'MS%O O&'CQ /*"N'^'MS%O O&'CQ <>4&<'\/;F+^!:,?'B!4\H,X/X>
MW,7\"T8^/$"IY05P?P]N8OX%HQ\>(%3R@KA_A[<Q?P+1AX\0*N?*"N'^'MS%
MO M&'CQ /*"N'^'MS%O O&'CQ /*"N'^'MS%O O&'CQ /*"N'^'MS%O O&'C
MQ /*"N'^'MS%O M&'CQ J>4%</\ #VYBW@7C#QX@'E!7#_#VYBW@7C#QX@./
M*"N#^'MS%_ M&/CQ J>4%<'\/;F+^!:,?'B!5SY05P_P]N8MX%HP\>(%3R@K
MA_A[<Q;P+QAX\0#R@KA_A[<Q;P+QAX\0#R@KA_A[<Q;P+1AX\0*GE!7#_#VY
MBW@6C#QX@5/*"N'^'MS%O M&'CQ <>4%<'\/;F+^!:,?'B!5SY05P_P]N8MX
M%XP\>(!Y05P_P]N8MX%XP\>(!Y05P_P]N8MX%XP\>(!Y05P_P]N8MX%XP\>(
M!Y05P_P]N8MX%XP\>(!Y05P_P]N8MX%XP\>(!Y05P_P]N8MX%XP\>(!Y05P_
MP]N8MX%XP\>(!Y05P_P]N8MX%HP\>(%7'E!7#_#VYB_@6C#QX@5<^4%</\/;
MF+>!:,/'B >4%</\/;F+>!>,/'B X\H*X/X>W,7\"T8^/$"KGR@KA_A[<Q;P
M+QAX\0#R@KA_A[<Q;P+QAX\0''E!7#_#VYB_@6C#QX@5<^4%</\ #VYBW@7C
M#QX@./*"N'^'MS%_ M&'CQ JY\H*X?X>W,6\"T8>/$"JS.N.PC>V582D^V^S
M)&CV]$>[NCQPLN5T!-;3X;SI9*G5*7$]724E=<B?AZ!BE+L=V,YEI?9=2M>%
M>-*".+/H*              #7;S7?>%S3WYA']X"+!8U9O\ *XY2GR;>GGN.
M(_;RD$ZEGEAL3$:              !KVY@=*5OT@XTX_&$:X><O@6/L9N[/E
M8LVWR29L!NY >D*%,LB09#2AKI-.S4Y*T0+MS(E.3R[/D")HNC^,VU)!+'D<
M3%;>!6?I]47S"1<743.+ 4+6&,%F:^MR"=:*(Q]O% VG1G=_+ .ULO[7LW7O
M59X3[74+8>^>3,JMQX0T\KFO(KB96RDULXT?-1DY+7&B)ER5?:O6E5>SLPGD
MMP9\^.KY46KS;];UK3LCG7]DZ8P?GVP?\7.;9A19CFVI<"?$4=ZS$W"W&LRU
M)V24F0 I+JC,SR=*_F2OP?3$$RE$[TLR<N5K\%<5ES@M99:U*YE:?M5)43QD
M4B!58*V](8V(?$AX%MWE%)0C"5]8MA4'6V3XEH2(('8#K3L+X/'LQ-?Q'2MI
M@D4Q7U)6W&*VX"Q-5:F5S7ME=A/[/C4U;TQ8SLDN>H4G6;KK)-V5.,J/(Z0H
M)V'-P4HI[A<*3";C<"T9>=Q;%G3;R:7;U@\<LP9[*%L64[1P2L_.V':M;.OK
M9QC1+(Z?#A-EMAQ)4KM^;"RU(^$\Z88G6(WW2,W#%2:C$&EW/DA&H\D%PX+G
M!C4$JRS"F%\MI+)0]6TL*S\RY@C3CCP 5.?FZ<*1N[UMD.0G,N5<;YC$54+V
MYKO.SP1;LN8J7.65(.1JQXL-]5Q=9,V\;RQG+9;?QLK6EUMU*>IZ?Z-ZUU/:
M6;W:W;.,%\5CGW>VQW:TXV7Y;;H^>(<5^6W'/+=%U9[K;I]L0\CY0G7G_D_8
M#_NI[+>*L=W^[[U%^5T_^O;/]>Q^)Q]V3]"[[G/E"->?^3]@/^ZGLMXJP_N^
M]1?E=/\ Z]L_UY^)Q]V3]"[[G'E"=>?^3]@/^ZGLMXJP_N^]1?E=/_KVS_7G
MXG'W9/T+ON/*$:\\>'<_8#_NI[+</^JL/[OO47Y73_Z]L_UY^)Q]V3]"[[CR
MA.O/_)^P/_=3V6X_]58?W?>HORNG_P!>V?Z\_$X^Z_\ 0N^YGB'9[84YDED^
MQ2[ZP8$$V5(G[7Q&4AQH8NSF\-^?#4@4D)LMHTJ8:8\=>GD+69<>.[A;=6EU
M:4K\'K'0NH=#RV8M]\";K[:Q\+-BS12)IQG%??$3X3,2Y+,MF3RU^B8^MI:Y
MKG,R4M89Y:K(CN>&)&^?6:+4K;B>8[<BZQTU9V$9AJ5&@U,>N[5+NJZJJ:<[
M@A8A(3@)6)%+#]%Y+0<=;JX3=V++\B&IE8/;7:V=]4),9LM1Z56-CX&W3:[6
MAV!&B5N0;4N*MR'&4RUU\R9EDI@3U6R!]CBJM=A<"F8R*%S:.HV SAIUE0R8
M[!6C"NY.P6T7*MB. MCY&G$YM/4PWG!#D]Q$XB;3:)-ZRX[$EQR U)KBK*AM
MTJJL]HQ6O)9HDY"62X]@*QQ;>HWVWGDF_(='&'M-T'OOC ?+C:LG1YL7&2[(
M*03:+]GR<[FSC7C"[B?,A,BS$T-=FP4+%V:DLX[1XF2))75LIXP004\O6F \
M=-WG"PXQQ7&YI,MR) _+VVQF")7.:9DD1]$BNX&>Z215..FT19+G$_%@/%RJ
MN34$W/DQV9KJ='-@RV5X]6VHBSPAA*8N9'(T3RE,"87U>Q.: -==AM;M>)IF
MG--J>B.LHK[,(.OJBUW+'L06QXK4>2:T538=++KF$ZX4/+9@Q79R53M];R^&
MT2JMCYYR[=A\FB---;+257\[I?W,3,>?:'9QMP>Q$9HZS3OEBE4["D1*AMVG
M5!7=2TH8L36;V%NY[L) OFJI*V.A?LG.HG,S>R.:1(VQI!J*>EVHJC.N## $
M;;#RZ0>\U-Z%EAGHDI/"56.V8[CS"99SZ2)0E'*LP@Y[[L)H\VF]0J4*Y.[%
M*G<=MMI"U84C;F.S;@EZ34[8UDJC2CM YDDDZ]1HM,U_-;)G(,1BZA.><EMN
MR8TL$>&3*PGMI.;.)0ID**UIP\JKM,5IBTNDUL/0[61'5S:I#B*.,\LSYJ-;
M'K*D#5F>]J]9ZMJ>$Y^N"2&[ L2YYO5(^EI*_1DUR<*R(Y(XI8>*8R!MY)>+
MHY\.4[3/AIBRN!5;'6G<23Y7GAY:_3=KR2@AY$(48FQ; O19?)RX3<\3OUSN
M-H%,3MO+,5CV,>1T!;;MV)222MZ\F6]=I<6535MM;JEBM6L]?W@F1Q3UL@^U
MB6=E(;AO7/>MCZND5EF09$$@:JMIM)BY%K9<138"CD5T&=7,KS$X7L9)VKC4
M,T3V1A/)9PQ]CB-8LY)JB8(WTFB0G8S=@G[)>R[#8+WV]GN%&ZW3$'Q M:@N
M)NL)PRHR&% ^%5++:7L.VI6<&9AEU#'(&>PRV\B[7,D]#+;DQ8,1%A-,IPV1
M6<W+IFJ3IW<\E)/,*C:1%Y]Q*I-U@)S%BQR&8VRSQ'1V*+FZT4AX(Z4SVNA'
M6RHX%155Z*=QK <R78S&.M<B5CV,[[>\PB4=<'_-3=8&KQ:8V=K5 ,=[+SD\
MU";4^-CJ?&SW<4LHAM(C=JYH]>%SXD9))1$?/8$\\>0$LYBOICO4RV3H4REF
MKRIKF1S.W5N2X=>>I:(E;2HKWU^:42Q B;#%7 RY$+[(D)!66<HNZ7#$2(=8
MX-,YOQ(YCCI+%T%PXR=B72U-SJUQC#TE$K*"_MTS9,R<:@ZV-;M:ME"^^$4Z
MD+11"?R5+J1W%0F$T=K)X>S*<YIDM2TVVCVMR.XBB,;4$<F;M.&">0P4*F,G
M8F-P/E5SY?NZ,SS6[-,Y6F.7]C6N0W++2J:06*_(+B OJS(JJ693PD-MQ5!+
MM;*RGS;&KKB]K-(R?QK+M+'23Y3TE2[&LNNREC!4?4N%N=S')'UCE.78ZCO5
M_!-:?K_J2V=T9?=JI-:?%I1*B52>LR-%=0FJE9(]?!UT222P0^8.IA#+<G)B
MECRY<9A13[\&'LP3-%:I\YC.QN=C/UI'(JQZP2@UGCRSY29ZNVY01)CH\=<]
MR=N#D26D758<CEL$6+(M4N,G F+Z.6[NDB?9>.]/63=.CGH*RWY"-/+O1WH[
M":ZV\%^Q5R([?(Y%!1L0T-8<RO4MBK;2_L!!;Y)26E0Q]EU,1;!ER5IYEHS=
M=%L5G1VMCL\W4-WCV6WY?C9+HMCFNBRVL]]UTQ;$>,RJE7?J *?_ '2<_K^]
MAV+\SZG'_FQ'5_'8>[)^A=]SVT_NT]1Q,QS].K$_Z;M?UK-33GU@O..5^4D0
MN^J-5MU5**6-7C*0V\Y[^XY3 =.=S64NME/=ZO2N Q;UGL4EF[(OXV8NG?;=
M;3L69;+[/B16+8[XF)^BE7G-_P"GNH=.ZI9T?<3@G=Y.6DV9L5]GO:5R6W39
M'C68IVL*_P!ON /_ !2<_P#NP[%?[D95'!^-Q?DY/T+ON>C_ +M/4<<.?IW]
M=VWZUFAA[ 1]([,<[];>!]XV^T;C]JO:XHQD1HKM]4Q+QK!ON2V'0V4AQ+M.
MP\MO6ZDBN?KV7CBQ]++2ME.:W-9?9SQ%U(_P9K]%'G.I>G>H]+W^+INYG;SN
M<U.7DS8LEO&:16^RZ;;>.M9BFNC#']OO7_\ \3G7_NQ;%>+'@."=[BBLS;DX
M?X%WW/1Q^[7U%,T^)TZO^N[;]:SA$<[,2;2ZT:8V![XL* 8)EE#\-(VD".<M
M<I_&8RX.P2[];;=SJF.EA:[KEY:W+;BKPI?6VMUM*]C%EMS6\UE8CQB8^N(>
M;ZYZ>W_I[)CQ=0NP3=EMF;?A9L>:.&M9QW71;/RT5NYHLKO^"^7KMS+\6.A2
M9<AQ[##F<K1=:.2(**J@K!*TOUA13B"HG*R><.8+;[NMX\I;/;?=PIT*CD?"
MG3@U,R?L[L:VHUF*0-8Y;WD=3*8NF>T4@RR[]MX Q1N@1X_&O&6):A!>B9<>
M$#Q*I+KUR/3"8M,IN/&LI>1*IDS&+,-^+!7-4XKA3GS8<D$;2M'7I8C:(3Z
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MS7?>%S3WYA']X"+!8U9O\KCE*?)MZ>>XXC]O*03J6>6&Q,1H
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M4![LET[D;)*K:=K55B2ZW%],RO''CQ*".L)N8P042>2_'=2F3%?=96MM>KU
M6-&P$%              !KMYKOO"YI[\PC^\!%@L:LW^5QRE/DV]//<<1^WE
M()U+/+#8F(T
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1*_X9UCI]#ZH<$GF[=/F?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tv523241_chrt-line4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_chrt-line4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#:@.$ P$1  (1 0,1 ?_$ 1X  0 " @(# 0$
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M.?_:  P# 0 "$0,1 #\ W^
M
M
M
M
M
M
M
M
M                                               < !J ..=_H[/*
M7)]3LZ:\I #G7ZG\M/JZ>B &O\W)KR@!KR<A:@#@S[')RF>G*>GU?2U[  \@
M
M
M                                                       !IL?2
M;$YWO3<?LJPU@O+5Y8QN6\;8NJN43Q7JTB BJW5;4^LSZ'$>C-&29CLR:TTT
M23/UVA)/DUUQ;QQ/)&KC@Z8EUG!7XAD+B$[,+*N^XY42+G/&3#&,<[6WSR:J
M5,O^TX[='JDV9#<64AERJR(9O.'S2;Y[GK?6FD4P?,CQP#\G7CE*E<4"L7?<
MM;N!$#BL[N:9;C%8FORBH%O-W6R[3Z)3D/O/G$@PFG22ALEJYI$1:GH1BX,L
MJK!^!3GPYN&+#XG4S>YF+-&[+=S9E?MG=]EBQK?8Q[D;WEH,:F4^NSW6>B8E
MTV6AYV/SDDI"%(YI&6O(HM,5R/))I<^/,L$X.N3MQ^ >(GO1X5.2<TU_<9AS
M;O9EO9 Q7D.[&X,NZZ*5S/4=V1;E>K<+I'')#2:@OI8SCBC8=5IH1D?.J,)4
M:\\/O_<8CRC9%[\7?BT;J]I&:]TV3-M^'MGUG6^QBW"V'*]$LF]<ES:[6995
MK(U2JDR/)E5J"EFGMEHTE9--J224DC593BRUZ57&E%Y%T'#OX?>0=@55RE9T
M7=%DS/. +K9H56L"U,P28]?O:Q;M9-YJXY"+I:AQE2J-58B620R7-3STZJ1J
M@E*J5#%RZDN9:*78+ZPIB<@    TP.)_C_?!O/X_UI[#]NO$JW/[$+%G;!K?
MS2^_B"^,JN6BY<%OWU?T"HN.XVLO,6)*2[6+@BO1VWJB<OIB;B-I4EPB3S,J
M85\OO,:X_3]Q^#-O"'XXFQ7#^3=V&!N/GN+W)7S@VR+BR2_AS.='O^19-XVQ
M8],D7?<=/:8RMN$SQ8LFOO4^A&W$9GT1MB2:U,KF1FW%J5$5FQIL$WYV[N6X
M:NWK?IG6KV+A&E7UA^%>>6*]=-Q4VS,;V?7*)4YUHWC6';ANJI1Z=;]HR[GH
MK[\)4V6?0Q7VD+=6OURC6.!?4DVK=CM93D6T,/JW+8 3EO(5OT6[;!Q:K,F.
MBR+?%JW+'=EV[<UH62=Q^,URV_7XK"W(4V%%?C2FT*4TM1$9A1BJ*]MB]Q8H
MV?XAW7WYGWBYXSW;X_JF\C(E7E9CRMG"UX%F;7YESQ+5@TK:1,N^\,ZY)HEM
M3;&E,=(Q2ESJ*XERIZ(I;!KU</%O"F)%ZEP$.9$J$2+/@2H\Z#.CL3(4V&^U
M)B3(DEI+T:5%DLJ6S(CR&5I6A:%&E:3(R,R,0IC;&V<,+9E?O6+A_+^+LK2<
M;75.L3(L?&U_VG?+]@WO2UK;J=FWJS:]6JCEK753G&U)?ITXF);)I,EMD9&%
M&#'%9WI[.;<R@WA"X=V>V>A9I=D+B-8AK.=\6TO*#DIMJ2^N,W8$ZZF+K7(0
MQ">6:"B&HD,K/31*M+1\/$57'P(F<;3(E_XFX46^?(^++WN[&V0K0P=6*O:=
M]6%<=8M&\;8JS56H[3=3M^Y:!,I]9HU0;;=4E+T=YMPDJ,B/0S"/'Z']A&0Q
MK5(O/</PB^#C=5X\3^N;"+ZK%O\ #URM>N>;NR=4*/<^Z:YJAME=J-Q[>KDN
MRK9GQ+5;TN#-]8K;M9F-2:E69%1D49;SE/EK2;K)<>967\77=UJ6';M6O"^+
MGMZS+2H$4YU=NBZZU3;=MVBPDK0VJ95JW5Y,.F4V*EQQ*3<>=0@E*(M=3(3C
MP!'2!ONV/U7&->S92]Y6U.I89M:L4^WKGRY W#XBF8QMROU=YN-2J'7K]CW>
MY:M(K%3D/(;CQI$MMYY:B2A*C,B%H^/@*K@1FXB-B?*7<>Q"KTKB2Q=AL&V=
MVN-+R:H4>_&[6C;V(3$^G26=K\7HLQ8L:NYG(K)$RB"EFY$R4R"TIKY'S5/#
MAXD_<6)W_D7'V)[1K5_Y3ONS<:V);<-VH7%>U_W/1+-M&@P&&UNOSJU<EQ3J
M=1J7#9:;4I;K[S:$I(S,]"$*:WG'QWM/.;0-@N8-C>[8W[;O[BM[:\57%E':
MIG8I%"O.SYUEYW5>&.:S>N);I73[AMR75:)%.I4EZ2]&7(B-=,T:VD\W**]Y
M5X5(^#-F"N5VB6S29]?N2L4JWZ%2HZY=4K5<J$2DTFFQ&]"7*GU*>]'APXZ-
M2U6XM*2U[(QI7!%,(X5W:[5-R<FLPMNFYK;YGV9;C3$BX8F%<SXXRG)H3$I1
MHC/5EBQKDKKM+:D+29(4^2"69:$9AY^ )!@"E/C=\0S-&QW!V&L>[3+5@WGO
M3WH9JM_;KMFI=6IT>KT6AW'6G(OO[?56I4E91ZC'MMB?$890\AR(W,J#+\I"
MXK+S:ZD1E+&<^&_](;V-8^N+?3B#B]9FWMYNL-FG75>VS:=CK)%WX[O^C)K]
M#<N2U<:8Z?OV][?N&8Y!CF:8](M*V*JJ$4E$"3&D.D2[XCP+<N)1Q:<A[2^&
M-A/<K8.%J_0-X&\%.'<6X$V[98MRM6]=%F9[S);R*I4;>OVU*S%IE29FXMZ"
M<V]$F=J,3*DQ&CK=0W))8)8AO J1REPP?I%FW_$EP;Z[,XQ>7L^[J;,M6-D^
MZ]D[5HW75L07,=OQ(M8NC'./K8CWY7\:W7<CE*H_:\&FT['U)]^YRW(\=YEV
M03SK"O\ D'@7,[EN*??VV[@HS^)#E'"=>Q%N =PA:+J, Y(MJZ;8J=K;B;[K
M%-QU3K;K]L753[?NMBVJ+?E254G&I+4:3)H,8UH7JXAPU%7R&-/,I2M7A4_2
M*,C82I&]V1QK\M4/=5<&/8F4J#M,8AW#$PL[.JEGMU.F6)5XE'OB%A*GW!(C
MS3C.,-X[ETIFI$ASIE&7;"'"7F/#R+X.$QQ,*=O%X8V/=Y>YJNV1A>Z++;O"
MP]S=?O"J4?'%B6?D#%MPO6Q<=P5F9<=1@TNRJ?7XI0:H['F.1D0'JB<<BYB$
M&J-<@B>=U;R-H=BQ<6SKWW4[;[.@YQI5!KN%)EU9QQC;T7,%$NEN$];%9Q;(
MJ]T0V<@4JXV:E'7 D4DY;,Q,ALVE+):=5&4[AE[<+@+;[;4&\\]YQP_A"SZG
M);ATVZ\O9+LO&MM5"6Z32FHL&NWG6J+2Y<EQ+R#2AMU2C):="Y2$HP9#MBZ;
M9O:@4JZ[,N.A7=:]<BIG42Y+8J]/KU K$):E(1,I58I4B73JA%4M!D3C+BT&
M9&6O('#B##&0-V^U/$U_4/%.5-S>WO&F4;G<B,VUC;(&9\<6;?UPO3S83!:H
M=G7'<E-N*K.352FB93'C.&X;B>;KSBUM&#NEIYOPO?M]W_BVQ<O8OO3)N*%4
MA&4L=6G?]J7'?>-5W P[)H*+_M&CU:9<%G*K<9E;D0JC'C')0A2F^<1&8E&*
MF4 !2ID+*>4<R<=/ FW.Q[ZR5;N%=GVS#)&Y'/\ ;UJWK6[6Q_D+)6?+K@XJ
MPK9F2+?HM8AMY!<M:A6W5K@IT.I17Z?"=7TZ%=/ZT9<(U_;]N)*XT_;]N!=6
M,2FGSDO(_$GXZ.\_=S@#8]O1N'AX[#MD%].X.N;/.*Z76:EE3-^=J)-4[<C5
M,J%O7CC&](5$HE8H;L="*?7J;3CI*VWWCJ"IY,,Y-47[?M@8K%DHN&(GBX[)
M=^]U\/#>]?&5]]^U>[,/KRI@'?K5<?WW*C6O7J(XJ!(QOE3(<V/=D.BW+<42
MCSEJI->N>IS6GV83\64\FIFV3"A<2_(MSVVHY.8H9;AL&G+V[^]G6!BEEFP3
MDX+]^D5%VC?+$P5?Z7&7OLW2):HOOV4'ITQ7C1SB;7S91E/LXQSW@O-EC/90
MPUFC$V6\:1E5),C(F,<C6??MC,*HQO%6$O7;:M8JM :523CN%))4@N@-"N?S
M=#T48/D8BW.;;-P,JXH.!=PF#\VS;0ENP+LAXBRQ86295KSF'&V7X=Q1[-K]
M:>HLMEYY"5MR2:6E2B(RU,A*,%%-<SOFYGZ4?9VWEK,.46L!RN&9*O\ DX1;
MOZZD8DD7TF_;JAIO-_'*:J5H.W6F'&;:*H*AG+)MM*>DT21%G1=/T?>8^/T_
M<;(PP,@ *6>*YN)RC4[_ -J'#,VQWS<^.-P^_6\ZRW=V6;$EU:F7KM\VHXL@
MG=6<LK6U7Z6EGQ6O*N4Z$FW;>GKDQG6)TYUV*KMME@ADDN+X$?)%H]5ROA/$
MEP8GPQ>68K$M2_\ (L650,/V1D;*-&8R?EARSJ?3T5E-HT^\*_XZ9-K5)AR8
M[U3?CIGRR4^EV2KG.\Y4Q93J-I[P]H]^Y/GX1L;=-MRO3,]*3)55,16GF_&=
MQ9/IJ89Q2F*GV#1[GF77#3%.<STAN1$\SID<[3GIU48)&B  "!_$PW)9MVG;
M*LV9GVV8,O[<9N H]#B4/#N*\=XYN_*E4JE^754HE!HU<KEGV,TY<<^S;/5.
M55JMT"F5+APUM)=0MQ"BJ\R,UF*SPN_I!UH84N+?O<_',R-;^Y2AXMJ>9[CV
MT5J@UZ-MYH;]%L15=J5FSJ74+O:PE1YD"GT\V)*?DR;I;512X\HS,UR57\U/
M$>!>EP^N)+=FY?@W6;Q(,G6(N+>])V^YGR)?UJ4.GR:= NNY=ODC(%"N6?:,
M%+E3DQJ1?=1QT]*@LI-Y3!3":3S^86LP;\@4!;3=G7&OXPV#;&XD]3XV61MH
MRLNRKGNC$.W/ UO7>K$UM4"UKVN&BV_;]VP;$S1CBV))'4K?-F6W5:/<E05#
M/F5!R2]TL<5^'[?YP7(< [?-N+WP[8-P&,=XCU,KFX79UN%R!M)R;EFQ)KM'
MI>67K2AQVDWI3IUOQ;:<I-RM.2)$5Z53V873)8C3VTL/2%M-&J8^-?L(G7#R
M,@\+O<-DZR\Z[MN%?N:O^Z<F9MV>UV'D7">6\A5V5<%^Y\V8Y:G*K&,+KN>N
M5.7/K%TWGB:;5$6G<-5DO./RWT0W'E+D./.+26%45<B[$8E,98GS7AK/=K.W
MQ@S+6,LT64Q6*A;SUX8GORU<BVLS7Z1T/OK0W;@L^JUBDMUBF=LM]L1C>)YG
MI$\]*><6H'E6,T8=MW)UH83N#+&-*%F;(-)JU?L+$=8ONUJ9DZ]Z%0(\V77:
MU:%A3:JQ=5RTFBQ*;)=ER841YF,W'<4XI)(49 8WRWO,V?8!N2!9N=]UNVS"
MEWU5*5TNU<MYTQ?C>Y*DE28:TJ@4.\;IHU3F)4BHQS(VVE:D^V?^VG51@D'2
MJM2J[3H=8H=3I]9I%183)I]4I4V-4:=.C+UYDB'.B./1I+"].1:%*2?IA2F#
M!]  >MUUIAIQ]]QMEEEM;KSSJTMM---I-;CCCBS)"&T((S,S,B(BU, 1BD;W
M]EL3$]/SU*W>[7HV#*M695N4K-$C/V*&<3U.X84GM*90:?D5R[$V?,K,2871
M.Q6YBGVW?6J22N06CX^ ) 6I=UJ7Y;M)O"Q[GMZ\[2K\4IU"NBU*U3;BMVM0
ME+6VF92:W2),RF5**IQM22<9=6@U),M=2,3AQ!K[_1M,XYISQMQWXUW-^7<F
MYBK=G<4_=#CJT:QE*^[HOZJ6OC^WK$P7,H%CV[/NJJ5651;0HDNL2W8E-C+;
MAQG)3JFVTFXLSLOQ/U(N!<GF+>CLZV[UN);.X#=CMIP9<D]IQ^#;^8L[8NQE
M6YK++,*0Z]$I5ZW31)\AIJ/4HSBE(;,DHD-J/D6DSE"F>;9NBV;UH5-NFS;B
MH5VVQ66%2:1<=LU>GUZA56,EUQA4BFU>E2)5/G,)?:6@UM.*22TF6NI&%*<0
M8>S3NOVM;;5TEK<3N4P#@-RO$I5#;S3F/'>+%UI*.EYQTE%\W'0E5$D] O7H
M>?IS%>D84\? &::'7:)<U)@5^VZQ2K@H55CHETNM4.H1*M2:E$<U)$J!4H#T
MB',CKT/1;:U)/3LA2F#!@?)F\3:-A6]:/C7,FZ;;EB7(UPN06:!8&3,WXSL.
M]:X]4W8K%-:H]JW3<]*KM3<J#TUE#"66%FZIY!)U-2=;1@^QN,N&53]LV=[K
MM2N/PYL+!63[AMJY+?J3C$F+*C6!7*E1ZY1*O3GDNLOL/(;?C26'"4E1)6A6
MNABQ_$D^9'P*3>!AONLB@<$_8_G+?OO'M*@WCDJH[B:0]E[=SN#HM(N._JM;
MVZ'.U)I=+<OW,5VQJE=%1HEIT*/&88.4^[&I\-MM"4LM)).)385I%8I%P4R#
M6Z!5:;6Z-4X[<NFU>D3HU2IE0B.EJU*@SX3KT67'<+E2MM:DGZ!A2F#!A/-.
MZ_:UMM726MQ.Y3 . W*\2E4-O-.8\=XL76DHZ7G'247S<="5423T"]>AY^G,
M5Z1A3Q\ 9DMVY+=N^BT^Y+3KU%NBW:NR<FE5^W:I!K=%J<<G%M'(I]5IK\F#
M-9)UM2>>VXI/.29:ZD84IQ!]H 4C[O,ZY*W'<23;9PR,"Y OG&]O8ZMRG[VM
M]&2<9W!<]G73#Q/:%S4^F8AV[P[UMQ^DRJ#\N=[/H?KK4:<W/D6W"4TE)QI$
MH9+!5?[?M]Q'QH6PU3/&#J)DSY%:UF;%%(S)XD2LF_)+5,B6A3\F?)O!D3(D
MW(/B'+K#5T^)$.53I#;M6[4[0;<8<2ITC0HBE&^!:HZGB;=MM4SW<EQ6;@O<
MUM\S1=]GF:;MM7$V9\<9&N2UU%(EQ#*XJ'9]R5BIT0RE0'VO^<M-?UC+B>RA
M1%*,$@P    :/W&8XO>XN_-\&U?!FRC(=YV#M.PIO^P)MYW%9WQ9?%9M@LU;
MC+CN")5[LV_0Z[;$R$JO6!BZQ(ZV[EA%)<BS*M5D,RV31&CJ<\D8XJO-?YC%
MO!^AL;\7_<UNYVQ;0I58V*8(OW/&Z7*60K2P[B^#9F.:]DFEXSF7<BJ2JEEW
M(5-I%'J].I=E6A3:,XVJ95>AI3=2F1"E+Z$UI/!4\2LH0O\ X.WT@/%-B5[=
M;:?'AR[D#<M9=N5N_7]O<Z!>S6 :Q5:/;M2[9MBD0[GR56<2U-,N#'2F*W4<
M<Q*<=0<)Y:65H*0=XRP^P<$71\,+=K<7&(X3-I99O>=<V%<EY>LK(^(<AW5A
MBY[CL"OVID6UY]7LB?D?%ER6]6(%R6I(DRHS%;@(:F\^"\[VJIQY#9J<<'7P
M8\O$[%P?MWN2,_X=RKMXW+5)N?O/V"Y5J>U_<O4%&PT_D.5;:7ODTSZQ"94H
MHU*S?9D--2)1'T;M2CSC;)+9(222\0BW08E
M   #4NXY<IZ#Q6N$G,C&27XU:GOM&9$9=(U<TUQ&I&1D9&I/*6AZC%\3RVU7
MV_<1LS98<OZ/5Q=K=W@4@IU3X>_$-O\ J=AY+M2@K.*[B')-Y36YSE4*&MSW
ML.B4:LS$5-!N=$N3#;6PEWI$J4B^/H8_]+CZ\_I\2QSZ-_,IE0L;B<SZ-48U
M7H\_BK[KZA2*M#6ER'5*7-KT*13ZC$<(S2Y&FQ'$.H41F1I40?823J_.K^TI
MQX;.S/B1;D*'OYNO9CQ+;FVE42B[P,TP*?B6-8,:Y+>K%SNUJH+<J<JM*KD.
M71':B3*&U/MQG5)YJ>3UA&(L3*=4^/%OPX%A?T9"FVU:]0WR6'F>GU^7Q#;(
MS-*I&Y*^KKK3M6J%[6\;<,[4GTU#D>.=.@,]"1.-'TQDHT<UPRYQ"JGH25:<
M:X^U_P"8FMQ.N!;:V^S/MF[R<);C<B[/=WUB6O2[8IN3L?0(51I5R1[?J#LZ
MW9EWTM,BDU254J*EXF67F9J/ZEEE"D'T:5$\*&-?%UK^WU'1>&[O%WNXCWTY
M'X2O$$NRT=P>1[+Q?;^8,0;IK'I4VVGKZL.K4^<\[2[]H%0U(J]"<I+J5/M+
M6M,KGMJ6^V;3Q"M-JO)>AL7%V"T[&A:"F)R    #1JXH=B<0?(WTEZS+<X9F
M:L68#W,JX;-!FM7]F&DTNLV>BP8N1,A^-=&.'5\29IB%5*DXY$Z!?O*:TDVK
M1]K4R7EC3#E]YCX_3]Q\[>CL@^EC7;MPR32=P6]';3N9P65"J%1S#@; M0MS
M$.0,KXSIE-G3KXL)F[:#M*P=4W*1=UM,2:;*@MUYOMU$HFS9>+D*+B5DVLF[
MHL![N/HH^<LF;;L91L(XVH.T^N8L3A6)4)-9C8JN#&EP46V:U:$:ORXT25<D
M)#D5$R-4GD%)GQIC;\@DR%NI3DN-?)_83PIYF2N"'P=MGYX V0<33,EF7+F#
M?I?N,;*SZ6<[SR5?[R+>=OW'S-/LRW*%CFAW'1L5-T&Q<:U&)3:8U*HDI^$;
M*5H=);,?H8WC7QH5<"%?"2VDT;?5PQ./+M1K#413N8.)5O%HUKRYL:'*9H^0
M:3;6);FQM7^9.2<="Z!?U%ILQ*]4+0;/.2M"B)165.IUX59BN'T(FCL0XL,B
MP/H[5W[K\I/M-YVV&XLR#MKR-;MQUJE+J*]PN''HV,L16]<<DV7"C56^Y%;M
M)4A#T9Q[IZDLDIE:)<?C6.)? K6R5%SWPK?HSF#K?QU<=>L+>+Q.,_8_CY#R
M;)DRJ!?-"R-O%@U_(M9JE0KU(Y]9HUSQ,/X\B4"1.4:JA"<4XX@FI"&TMWQ\
M_O'AY%C5L_1$^$W"V[1L8W5:F4Z]G-^SF:;5=S\3+F0:;>4:]7*7':G73;]@
M-W K$$:FM5A#CT2GS:!.)$=9-/.O*+I1CA7R+B5C8-SSG:[OHZ_&OVC[A;[E
M94O+AXWUF/:K;V1YYRG:E<./[1K5O0Z'#J4V5-JCM071:[3*JU#<5*>4S250
MXQFHF"=<SIC7U7L1/\AE/B@?[@_Z-]_YP7!^_P#0QO\ &,?Q+U*^!('BEXQJ
M7%DXXFWCA,9.O^]K(V;8-VP2=X.:+.LFK*HM3S/=TBYI-%IM$E5%M3S42G08
M\NC1FI"F')42/(JQQC9D/QY3%2HOK^NA*XE;'TCS@+;.MAVQZ?NMV*0+YP#3
MZ+>-B8[S;B)K)^2;\L3*UH7A=$)5!J515D6[[IKT>MVI?5/I<EICMMRG.)3T
MO:R)##3Q1<&7Q+9>/5_[^_1Z?_OH.T/_ -ZVB,N?]9?>8^"]/W&--YFW&G\9
MKC[W9L4W&W=>![)>'UM?LK+EQ8;M.Z*W:+&1\Q97BVY4*?,J\NF/(D:KM[(+
M#3M0BN1ID6'3#BQW&CF27#Q_*9>)!+CA<'O;GPV:9L3R-LK=OO%&"LJ<2+;!
M:F4MO%0R+>.0; GY/HU'R+4<:Y1HK^1:W=-VTZX:1;3-TT^3_P!\7([S56(N
M8DFVR38TJEXU#^XS-](BW/;>\L<47;!P\]]NYR^-LG#HQ[A:#N0S\JR*'?-=
MJ&9,HUJX;K@V+8$R'CJSKRN&/"ATRW(RV)[D.3'AIFSE-I8F=K243@L1Q95A
MO>O;Z.YMQQS;>Z'@B;L;SP9OXV^7C9%ZXWMVFP]\\RV\QPH-R4^-=]HW5-S;
M8M2HL!-0MR5(><8.ITRD5-B.[3Y;:V9:N;$Z"A_2%P-DMO-.#<,YB9CM0VLL
MXHQWDMJ(REQ+,5N^[0H]THCM)><=>2TPFJDE)+4I1$7*9GR@\'1%7#'B:D7T
MC&]=QUI<6'@B/[8[4MZ]<W)>W(TG M"O>4N#8S&7<@)Q]9-.N:Z)""4:Z!9<
MB;3:S46DZ*>B4\V^<GI"464<$GXX_88O%^P_%N,X>/'XV0XRRAQ$;1XU%^;F
M\JX:LV?EW).UN[<>W1!P/=5F6%"BW/D"@6?9KN1;DL$Y1VS;3O0,TRSK=G3>
M<\B/*AR)"G%3"O\ D+X&(^,UOGO7<GA#Z.1O8P[BNFW->&5=Q]*RS9>(;BGO
M1+6<W&0XV.*985KU:J-IF2';?H^5G92$*]:]+@L'ZYE:S4BI>'A5$\V2/S%P
MQOI!V+[7O+?+1N-C<]][B;&M6X,G5/:;#Q]6*)MHJWBW&J5US<>6W19F0Y6,
M)I3(L!,&*Y+L:#TAN]&Y):0GIU3BZ+[/V]I>"Q(_\:#?$_Q'_HO&*-WL"B-V
MQ5<CY@P]#RI;4)#_ +W42]+'OJ\;"O6)3%2>G>\7Y-]T!$JG*6XISM)]@G%F
MYSTASIPI]Z'+U-X:(44HL8H)1RA%'9*&47H^U2BDVDHY1NA_JNUR:TYG-];S
M=-.08E- C:\E"?H_'TCXZ?\ ^#I;]MXJ**3"]:>EM%(V_FKM)!*-"2[27&U,
MB+G(YG*>A:>1_C?T_88K@OH)3;6OH^FRO=?PA</[F-UKF6,M;J\@[$<?W59&
M9967+VI!X6M*V,,0BP58..;#HE1I^-D6QCK'U*H].6Q5Z/5URWV9#[BS=?4H
MHJ.27H.";.C<$GA48!XP7#SQ-N>XG%PY7W47';E,N;;GM\MFJY7R+8MLX#Q'
MB*H%:%)CVY#Q_<]MN7'=U6J]/D3IM2K*YY2&SC,.-+;BMZ1O!5"XL]_!XSM>
MO#IX<'T@"V[)N.X;ZM[AR;F=T%"VZP+RFE5&J34+:I%PVU;KLB,LVH\2D5"Z
M;8A5:J1(O1,.R'I;K;:7I#BEVB^M_5B/\AD[A<?1SMBN\38OC;>#OX8RGN?W
M4;TK/9W 73EJL9@R5:50L=[)T>16:%"M6G6=<]'I-7J--I,Z+(ER;A8K1/U,
MG.C;9A\R&B/B5'YOHUNVVL[/>*%QL-L5:R'<>5E83<VS6+0K]NZ2Y*N6NV/3
M$9+7CI-9<6_(0B;2;!?IL%331IC,%&)MAMIE*&TU\']'V$7'VFZ,,#(H8X+3
M3^=\G\3_ (B=9AGTFZK>O=6),2U*14WZP^_MOV:PU80QPY#>6VS"I<&JW7&N
M*6N'$0;:75ZK>D*(EIREAA^W+]YBL<2^<8F1_.WX-V!>*%OQPINWP-M;W;HX
M=F"+6WP9]O+/F?[(MVJ73G_+^=[\C41*[6H2J/<>.ZU9ENV-:="I!2%PK@@R
M')$\W5+>YC;#>;\7XU9$7'['\S<0GAC<3'"O"NW];II^^G#F\#&=\W?M8W)7
M32JA$R=;]]8SIU9J]P6;>\FM5V[+JEPJE0+=4;A5"K5HF9LV$J/+)+DQ")2J
M'B0.VO<.K%7$?XW?'6QIN6K5]UO:_8>;L&WQ?6![3O>OX_H&7<F%3LATS%E5
MOVM6?*I%X2Z%CVB2;I4Q#A5*"E<ZK-/N*6<=LBK^Y?8#'%N\+'%F,^.EF/A
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M*'DK),5AI!E-5/LB33YE->1ZYMLY7/</G.,I1F\(_MZ_N,?']O0V61@9
M                            -"   -" #0
M    4 \5_A);CMT6XO">_P!X?.ZEC:=ODP1CRNXNI]:N6E.U;'.2;%D.W+6:
M#;EUML4RX6X"(E<NJH,RG)=%K\23!G%SX2EQ&"54R,@I:W!+XMF^#).)*AQN
M>(5C3-V <*9#H^2Z3MUV\6C2:3;&1K@MEYB11&[YG4[#>"Z0S"E%.GQ9BG*/
M59O:"C9CR&#D*6Q4Z(&W2,2@                      !C#-F(K,W 8;RO
M@K(T21.L#,N.;UQ;>D2$^46<]:]^VY4;7KJ8$M3;Q0Z@5-JCAL/<Q1LO$E9$
M9I! U),?<(;Z1[LWMVE;8]CO%@P,WL]M]^I0+1<S!85.<RK9%L5ZX*L_-IE#
MB5O 699C2Z129B9,5$*[*9&*<XM$=N$A"'3M>'[?YR%WG".X6E/X9V,<L.W=
MEZO[B-S>YR_V<M;F<[W'#.!*O6]DQYQQ:928CTF?4$6Y09U;J3S"Y<AZ5(DU
M&2^KHDN(CLFZ@MN$*                !6MQ,-D=W[N\=XGO3!-T6]CO>!M
M.R_;6X#:OD.ZY%9B6G$O:A.)B7+C[($FWH=2K)XQRQ:3LBC5Q#$28M#3C;Y1
MWS9)I=3IZ$:J6+T=VK/4BE/5^%3Z=77:;!=K5/I-1D5BE0*LY%:74H5,J\NF
M4655*?%F&M#,EV'$<?;22U,M&HT)A3Z0           _)4%SFH$UREQHLVIM
MQ)*Z=#G37:;"ESD,K5$C3*BQ!J;T"*_()*''D1I"FD&:B:<,N88%;'#:V0WE
MM9H^?,Q[@ZW9M\;S=X^8:UFC<G?-BKJ<JT(/1.2:3BW#]@U&MTBWZQ.QUARQ
MNBIM.?E4^#(EON29+C+9NDVC)NO#@1*A9D,2@       !\NN0G:E1:O3F#;2
M_/I=0A,J=-26DNRHCK#9N*0E:DMDMPM3))F1>@8+B&5(\##8'F;AH\/BQMJ6
M>Z_C>Y<BVS?^3[IG5;%%;N2X+.=IUZ73(K=*:BU&Z[1LBL+F,17B2^E<!"$.
M%HE:RY16ZI>GWD7B7!"%                    *Q-Z>RC(V3MRFSS>[MDK
M=G6ON4VOWA,M"ZH5]UFX;>LO-6U3)KK,#,>([GJUM4"ZYL2K4UHDUVUY+E,F
ML1:[%23B6T/J>:R3\'P(T6=C$H           &.,P+RLWBO(:L%PK*J&93L^
MOMXOBY(K56MZP57R[39#5M/7A6*#;=WUF';T6J+;=E=K4V6\XT@T)01JYR:J
M5Q!$_AM;(:3L&VMVUAM^O,WYE>Y*]<F7=QV6RB*B3,Q;A<E3_?[)N0)3*]'&
MHLVJK3$I[)DDV*7#C-F7.2HS-U9$J$]Q"@
M
M
M
M
M
M
M                     !CNZLO8GL6JL4*]\GX\LZMR8::A&H]TWI;=OU5^
M MQUE$YFGU:I1);L-;L=Q).I0:#4A1:ZI/05)O@?DI&;L,7!4(M)H.7<85NJ
MSE]'"IE(OZU*E4)CA::HBPH=6>DR%EJ7(A)F!>F2\&9/ Q
M
M
M                                                & *_=T?"WV'[
MT,@4S*>YG;W;>5+^I%N1;1I]Q56LW=39,>W8<R94(].Z&@5^EQ'4-2ISJB4M
MLW/7:<[0B(I3&I:O!.AK0;*-B>UV^/I!F>6-N&$HV.MN^P:TZ%1IDB@URZI=
M$KF:EPJ>F;"=F5"LU*+-<AUB3TJF26>B8JT&1*)8G%X&>"75^:E/;C^[VF[
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ME[!U#ML7D^+OQ5^[ HAU/DO8.H=MB\GQ=^*OW8%$.I\E[!U#ML7D^+OQ5^[
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M*]!JJV\X9>F1S5-%I]93A",J\?0E9A#\2^(OR8V%]ZU*%7 2_$_4R@!
M
M
M                                             "+.]@M=K.8_[N0_
MN_2!'P*N/T/[#VZ?^)C^S5K_ #_)GK_K#P+^8E"*8@       ! GB6?HCW__
M &VWONLP(QS]"4V$/Q+XB_)C87WK4H5<"R_$_4R@!
M
M
M                               "+.]C]%G,G]W(?W?HXC*N)[?U,?V:
M?\,@\"_F)0BF(        0)XEGZ(]_\ ]MM[[K,",O@_0E-A#\2^(OR8V%]Z
MM*!<"R_$_4R@*8@
M
M
M    $6=['Z+.9/[N0_N_1Q&5<3V_J8_LT_X9!X%_,2A%,0        @3Q+/T
M1[__ +;;WW68$9?!^A*;"'XE\1?DQL+[U:4"X%E^)^IE 4Q
M
M
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M:=O56MO&>O3R:18]"MJV89I+D),:&TGTQ3!TK@=V
M
M
M                        !%G>Q^BSF3^[D/[OT<1E7$]OZF/[-/\ AD'@
M7\Q*$4Q        "!/$L_1'O_P#MMO?=9@1E\'Z$IL(?B7Q%^3&POO5I0+@6
M7XGZF4!3$ "@;<&E/\0SP]5:$2CVB[J"-6G*9)I+!I(S]$B-1^J(C/\ +[?^
MB7\BF
M
M                                                  !%G>Q^BSF3
M^[D/[OT<1E7$]OZF/[-/^&0>!?S$H13$        ($\2S]$>_P#^VV]]UF!&
M7P?H2FPA^)?$7Y,;"^]6E N!9?B?J90%,3C7TM3^M_+T !0-N#6@_I#/#U22
MDFI.T;=0I2"41K2E=)9)"E)[)$HT'H?HZ'IV#$X<3/\ )7U_Z)?SK]<*F (]
M10<@
M
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MJ=B.GSL2GZ3>;NI/C^5_7A>XG_3R%];3T-?1&[#YHGD
M
M
M                          BSO8_19S)_=R']WZ.(RKB>W]3']FG_  R#
MP+^8E"*8@       ! GB6?HCW_\ VVWONLP(R^#]"4V$/Q+XB_)C87WJTH%P
M++\3]3* IB:0?'?+_P"Z!U_\E&-/_P!BGCJ#W4_]N,[ZV?\ ]WM']&O\L_\
M_P 6\K_^-ZA_SX%-@UV?0 L?X22#7O\ L"^NTYM>6OT>4B2DC3]374<AVCCN
M[2/_ ,1M?>=2?GGE3Y7MS8<<M3[3?O(=X3^8 Y
M
M
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M:7\NFOZ%J.=R]G6,WE^FS9E*ERZ\<(*F+-\(O1['9]#ZO*.[9_,\<@
M
M
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M\I?=@#'DQXYVC\++:[^4ONP!CR8\<[1^%EM=_*7W8 QY,>.=H_"RVN_E+[L
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M(AQ"DSI+,1@Y51F,4^GQB>?6VV<B=/E-,,HUYSKSB4)(U*(C<> /U@
M         "F3Z0S_ +EWB _D<I__ $A66*N/T/[",PY]%Q_W%&QG]IG_ -,/
M<$(4O^
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MYRBDL(P<$;$NV/\ 1LV]_D/Q/]X5 &SEP.HDN+]3.($
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M];AIL-AADDWEE"T:=DN]9$HXQJ:?J,JZ[LF.2'24KI7E*5J9&0/B$40;_P"
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M1<F7;B%     (L[V/T6<R?W<A_=^CB,JXGM_4Q_9I_PR#P+^8E"*8@
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MM*4N1-FR%N29<EQ;KBU*49@W4&:!              %,GTAG_<N\0'\CE/\
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MVVZ2MW82MSB_Z4)I27TI'U"/74?H/QG(
M      *9/I#/^Y=X@/Y'*?\ ](5EBKC]#^PC,.?1<?\ <4;&?VF?_3#W!"%+
M_@                                     % _'5X:VX[B*]0GJ]R,;1
M^K9NHI.9\A_*)=54MCIK4I_O'SF+=][+9N/WRJB^T'?ZMSM=)>M]<>IZ91:7
M'FB-?87\#$H                                         &C#M)_\
M;0-[OY(;C_Z ]O8SY_U5]QCR]?WF\\,#(                         BS
MO8_19S)_=R']WZ.(RKB>W]3']FG_  R#P+^8E"*8@       ! GB6?HCW_\
MVVWONLP(R^#]"4V$/Q+XB_)C87WJTH%P++\3]3* IB   % ?%_Q^4:[K!R R
ME3:*C2Y%&DFE/K793*S2VLU^BIM#J>0=K_EZU9ST_-Z3)UE"XIKR3_?0ZO\
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M .D*RQ5Q^A_81F'/HN/^XHV,_M,_^F'N"$*7_
M
M-&':3_[:!O=_)#<?_0'M[&?/^JON,>7K^\WGA@9
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MI'4;>)9\GK4>^*3(^4C_ /<A)+DT/E#P*ON)481_$QB/\F-A_>M2@#XOU,H
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M]V<1     *?=N'^^/XD7Y$MHWWH2Q/$S?X%ZEP0I@
M
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MU#'T#W-8CK.Q,U&*ZG<T^4XKF^BJ^O$Z'[:O3T3N#EUP4=15N7E'J:K['0W
M2DQC(C*0P9*(E$9.MF1I/L*(^=H9'Z?8'SS2?#Q.^X[9C?\ =#'MK?VPM&2J
M';,;_NACVUO[8*,M4.V8W_=#'MK?VP@.>V8__=#/MJ/M@)5'';,;_NACVUO[
M8*,51SVS']G9]M1]L JAVS']G9]M1]L JAVS']G9]M1]L JAVS']G9]M1]L
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MWA,!U,'M%Q'H>CU_I/0R)19$NPS29ER&1*J1I,R^J1D'$=3/2G:'BE!?^_\
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MBQWV8T^\JU5*>:UU"-$4;\6?(?0\DTRO1/UJB(RY-2..G%E4FTX^%"1/._\
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M,C+E)1&6I&1EKJ1EZ([6)IJJQ1_/4ZIT?$\A0
M
M                                           !%G>Q^BSF3^[D/[OT
M<1\"KB>[]3'7_P FG_#(/ OYB4 IB        $">)9^B/?\ _;;>^ZS C+X/
MT)380_$OB+\F-A?>K2@7 LOQ/U,H"F(    !4+Q>;*75L68^O1IA1E:EP56%
M+D(3R$W6H\!45MU1<I)Y\!PTD?)J9CL%\ONI++Z[F]-D\;]F+2_J.5:?ZR-%
M]^-._4;>R^?2PR]YU?\ 72I7V'ZN#W=S=0P!==A],3DBR;S745)-7.<9BWA#
M[<80I.IJ2DYE-DF7U3,>/YAM/=K=F7U6E+>9RW3ZNR^E_5*)C\O^>A<V=<TQ
M2K<RU]MKQ2O>^O;)2+<!H$WL                       'B?H?Z/\ 0 -4
M_B5\+3>;N3W@Y'R[BFT+-JECW##MB/29U7O:/1ICITR@0H$HG8"Z=*6US9+*
MB(^=ZXN4=8-Y; W7J6ZL_J&3ROQ,I?O1E"2E%52MVXXIM4=8O ^VWR@_.C\O
MO:'L)I.Q-[Y_4+.Y,K<S$KL+64E=@OB7ISC2:N1K[K7A@0/_ ''?$4^ ../G
M+B^!AQK_ (9[T_\ ,I?Z\?WG9G_WCWRH?_>FK_\ \OE_\J89S5PM=]>WFV$W
M_=^))-1H4'II,^J8RK:[OFV\Q%)"CJ%2C4N+$J<2/Z[D<90Z9$1F9$1&9>KU
M;9NY-$L+,:ED[L<KQ<TE.,:-+WNFKCQXM46+;5#G_;SYT?EJ[JZR]KZ#KL+.
MI7:1A;U"RLK"^Y571;E<E*W.7]&;BN571$\N&IQD+EPK,BXCW-5BKW;C)2XM
M-H5TR5N3+@LR4A\H[K,M<@U/S*:AM6BF5J2IM2#/4M3'(-C=Q<]M2:RF?=W-
M[=E2BZNJ=G^E;;QE"E:PK_5?/K)\WOR!:/W#R\]]]G<O8R.\$I7+V6BE&QFX
MN/4G%1PC<;6$E5-.E'1&VUCS)^/<M6U!O#&EXV]>]MU%AF1&JMNU2+4H_,?0
M:VT2"CN+=AR-",C:=2AQ)D9&DC(QVDTK6M*US++-Z5?MW[#2?NM-QKP4H_BB
M_*23/ACNO9NZMC:O=T'=^GYO3M7LR<96K]N5N58NC<>I)3CRE%N+PHSO1&9G
MH9:?Z?3'M#C1Y
M
M                  BSO8_19S)_=R']WZ.(RKB>W]3']FG_  R#P+^8E"*8
M@       ! GB6?HCW_\ VVWONLP(R^#]"4V$/Q+XB_)C87WJTH%P++\3]3*
MIB     1'WTV@=Z;6<LT]+*7G*7;[ERH)1$:FRMY15-YU&I'HI$9A>I_];J.
M?]KM1_PW?6GW6Z*Y=^&__P!)[J7M:.$=Q]/6H[+S]FE7&PYK_075]Q4#PA[_
M $43.E[X[4X:"ONT#KB&M3)*WK5Z!+/US0Q+?T](N=]4=A/F#TEYG:^5U=?_
M #7,=%?*[Q^M1^HZ_=@-7AE]R9S1J^_FK"NT\*6DHK[7]9L;%_Q_ZQT\.W
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M<68MXNU-\*U<9/%/P5F!'KZ&GJ_\/9&S6=/SR
M
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MJGX'92,S[/\ R_SC]YZ@Y
M
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MZH'(H
M
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M:=*KR?%';73L_E]3R-K4,J^K+7K:G%^353MH_"?M
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MHO%2BTTTSZ@_0?C
M
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M(
M                 19WL?HLYD_NY#^[]'$95Q/;^IC^S3_AD'@7\Q*$4Q
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MU#1\]<TS5;-S+ZC9ETSMSBXSC)<4TSZVI'Z(_4?A.0          !P?8/ZP
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M NP7_+_PC9IU?.0
M                           $6=['Z+.9/[N0_N_1Q&5<3V_J8_LT_P"&
M0>!?S$H13$        ($\2S]$>__ .VV]]UF!&7P?H2FPA^)?$7Y,;"^]6E
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MY[3KL;N6GP:=?H?)KQ.YZZCUQ^\Y
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M3A/\?Z7J]WI3]Z,4G&E%1_07YCLB?,0
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M%8=?)Q5LW+&0KH4U"DS$&;*DI(E$S*8,C[)'Z0W=K.W]F=UM%CF;%R$Y]/\
M9W[=/B6WQ<9KCZQDN1IG1]P;S[5ZN\KG+<XV')==F?\ =W%PZK<N'I)<G4OK
MVP;YL0[F6WJ72W9%FWS";:7*LVY'XK<N6A:?ZR30IB%I9J\5ETC2KFDEQ.I:
MI]$NJN]^U^X=E25^^EF=+EPO6TZ+RFN,73U7F=H-F=R- WG%VLJW8U&'XK-R
MBD_.#X2C7"JQ\B:>O9[/(-;FP3D
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MNC*Y.S^6SE[?Y816&-6_%DG2',#3H
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MN6<S'C&::?UG8;)YW*9^PLSDKL+N7EPE%II_2CL@_&?J
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MU5:5W&TJ_D7.35J[3JL7J4=;5V-8RP:PPDO%$DR/7T-!RHU&<@
M
M                                (L[V#+JM9B3J1&JW8A)(S(M3*NTE
M9D6IEJ?-2?J",J^Y_8>W]3']FGT^3\67IAX%K[]24(IB<'V#U[&@ UAN,/;N
MXK<1O?VIX6N?9UFW+NP+"3U/SGD:[,7]HRSR5E=*Y4>@V6]"5.BO%3+4:0RZ
MX:R+GO2%FD_6EI'Q_;]O\YY(>J_S$*-G6Z6IO_2,MX=YM;6\[T^HWMMPQA9S
M^/BI=(.Z,=1(!VG'C7!<U,;FHBQ;>>B0.:@FW#Z)+S9%KIRQ5X^'^8K2QBWC
M3]YNEQW>F89>-M;72MH<Z)PB2XWSTDKHW$E_16C70R] R&1XCJ=_V>U?UI5>
MTWJM5*&U5VF&U52BOG&J<3H)3$I*XSY&1H4I3/-/_L3,"IT=2I3?-M>@8ZVY
M73=$?)60[B=I]0HZ3I]P5AR9 <;DR4Q^<II2E:+0?-(C](Q'3V%KU)HEUBK;
M?!J^*L75$LC9 AG+QY9\LX\6KN-QVCFT*%,-IEM*T]&TT<CF)+T$D0H;HZ'>
M^J[#\J.2._;ONH8>9.KT'5=A^5')'?MWW4,/,=7H.J[#\J.2._;ONH8>8ZO0
M=5V'Y4<D=^W?=0P\QU>AR6UZ&1D9Y0R0>AER>_;I:EZ)?]L/LZ@7J\D4*;]\
M*<6?.F)=V^T_'.VVQJQC?,5D7IB>U,F5W*\=,]ZWZS-88BW'+ITEU9M29%*C
MGJVI/K%.&9<I$,?L,FHO%/$SGMAM?BCO7+B/&&;=MELX[Q)1J+:-GW7>ULY:
M:J=7IE*H5'I]%D5.G4YM_P#K7#1#-Q+1%S?7:=@@Q^@ON)8/$MWZKL'_ &,G
MY(2G_9+W[=/0O0+7I"U]09&'57D.J[#\J.2._;ONH8>9.KT.#VMPE%HK)^1S
M+TCK3IEZAN:!1>9>I^0ZK<'3FGD[(QI,]32=9<YNOUNDY.R!*\J'YI>T^@SX
M<FG5._[ZJ%/F-J:E0IE0)^,^A:=%$MIPU(,S+Z@0E.U-7;,I0O1>$DZ-8UP8
MGTW(.W<C&5J7%-53PIP*WMU7"R4S16KIV[-/UFN,O+.M6G5Y<9M51C+3JJ33
M'EI0TN0E1?\ :5&7.YW(?(.RO;;O0LHHZ/N^XUE5&D+Z3;3Y3IX>?D==>XO9
MR.>KJVT[<?USE6=EM*,EXN-<*^7B5NV)?V9-K-Z-VG>#5\V73#D$[7[+==F4
MU$QKD(Y$%?/2P\3:'"T4T9IY2+L\@VYNO:FVNZ.A_&R5VU.\FG;S%MIR3QPE
MXX\GR-4[5W1N7MCK7Z;4K5V&5DGUV)I]+6'O0\'TJG#GYEU>!;GV_P"XTVZ?
M8V<,B1;O[0*=.M"HUF5"J;!-Z%*5$:?5S)C#"C[+:U'S>4R[.G47=7;G<^SD
M[NIVG+3^KIC=C1Q?*M.#?FCM?MCN!MO=WN:7>C^M4:RM-4DN=$^*]"475=AG
M_P#71R3W[=]U'",#F/5Z#JNP_*CDCOV[[J&'F.KT'5=A^5')'?MWW4,/,=7H
M.J[#\J.2._;ONH8>8ZO0=5V'Y4<D=^W?=0P\QU>@ZKL/RHY([]N^ZAAYCJ]!
MU78?E1R1W[=]U##S'5Z#JNP_*CDCOV[[J&'F.KT'5=A^5')'?MWW4,/,=7H.
MJ[#\J.2._;ONH8>8ZO0\5;6H*_Z>3LC*T['.K#BM/K:N&'M%?0=5J"1:%D_(
MQ%Z15EPB]3I- P+U/R!;6H"3U3D[(J3_ .QK#B?]3A!1#J?D>75=A^5')'?M
MWW4,/,G5Z#JNP_*CDCOV[[J&'F.KT'5=A^5')'?MWW4,/,=7H.J[#\J.2._;
MONH8>8ZO0=5V'Y4<D=^W?=0P\QU>@ZKL/RHY([]N^ZAAYCJ]!U78?E1R1W[=
M]U##S'5Z#JNP_*CDCOT[[J& ZO0X5M;@JY%9/R,HO256'%%ZAN&%$7J9PC:U
M ;TYF3<B$9?_ -77REZ1^OY2T%3:=8X,DJ334DFBO[>CP<L;;CK>EU^T[EJ-
M$S!%YSL"XJF;*XE8232D^]]6)MO4TNK).CAZ\WE,:F[@]MK>Y%_B>A_#R^M1
MKU)JEN\O!3HO=DO"2\ZG=WY3OG.W7\O.>>BZQ\34]@7VNNQ*3E.PT_QV6WR>
M,?&B-8G)>#=Z_#0OZ+<%8C7-C!RJR7:71;]MFI&_:MVL1'DR"@.5&$LF5N/(
M0E?:[Y)<(C/FZZ&.NN;TW<&U-2M3SUJ]DM1BVX23PE2C?1.+I-<*I^RE3[<;
M9[A?+I\Y6S[VAY*YE-7M1LN5[)WX=.:RCN1<'<C":ZDXU=+D&U5*M,"\[97Q
M#MOFX2'1++S)F&]L09<=CQV%/U*KOL6I7Y+:$HDIC51U:F(TB2Z9<Q+G,(]3
MY2&]MJ=Y<EGXQR.[HQRN>P2OQK\*YRZ_X)/S5.;/CU\P_P#+P[F=J<SF=Q=N
MK5W7-BJ<I=,*2S%B+=56W^*48KBU5K##$NBB;:*;-C,S(^6;_EQ932)$:5#K
MRW8TEAY).-/L.MOK;=:=0HE)-)FDR/DY!NBW<MWK:NV9*=J2333JFGP::P=3
MYZ7K=[+W96,Q!POPDXRC)-2C).C33Q33P::JC]/5=A^5')'?MWW4>3 \75Z#
MJNP_*CDCOV[[J&'F.KT'5=A^5')'?MWW4,/,=7H.J[#\J.2._;ONH8>8ZO0=
M5V'Y4<D=^G?=0P\QU>AXGM:@F>IY.R,:O^N.LNF?H>CTFH41>I^1Y=5V)Y4<
MD=^G?=0P)U>@ZKL/RHY([]N^ZAAYCJ]!U78?E1R1W[=]U##S'5Z'![7(9]G*
M&2#T,C+6M.GH9=@R_K>0R# O4_(YZKL/RHY([]N^ZAAYDZO0=5V'Y4<D=^W?
M=0P\QU>@ZKL/RHY([]N^ZAAYCJ]!U78?E1R1W[=]U##S'5Z#JNP_*CDCOV[[
MJ&'F.KT'5=A^5')'?MWW4,/,=7H.J[#\J.2._;ONH8>8ZO0=5V'Y4<D=^W?=
M0P\QU>@ZKL/RHY([]N^ZAAYCJ]!U78?E1R1W[=]U##S'5Z#JNP_*CDCOV[[J
M&'F.KT'5=A^5')'?MWW4,/,=7H.J[#\J.2._;ONH8>8ZO0=5V'Y4<D=^W?=0
MP\QU>@ZKL/RHY([]N^ZAAYCJ]!U78?E1R1W[=]U##S'5Z#JNP_*CDCOV[[J&
M'F.KT'5=A^5')'?MWW4,/,=7H.J[#\J.2._;ONH8>8ZO0=5V'Y4<D=^W?=0P
M\QU>@ZKL/RHY([]N^ZAAYCJ]!U78?E1R1W[=]U##S'5Z#JNP_*CDCOV[[J&'
MF.KT'5=A^5')'?MWW4,/,=7H.J[#\J.2._;ONH8>8ZO0=5V'Y4<D=^W?=0P\
MQU>@ZKL/RHY([]N^ZAAYCJ]!U78?E1R1W[=]U##S'5Z#JNP_*CDCOV[[J&'F
M.KT'5=A^5')'?MWW4,/,=7H.J[#\J.2._;ONH8>8ZO0=5V'Y4<D=^W?=0P\Q
MU>@ZKL/RHY([]N^ZAAYCJ]!U78?E1R1W[=]U##S'5Z#JNP_*CDCOV[[J&'F.
MKT'5=A^5')'?MWW4,/,=7H.J[#\J.2._;ONH8>8ZO0=5V'Y4<D=^W?=0P\QU
M>@ZKL/RHY([]N^ZAAYCJ]!U78?E1R1W[=]U##S'5Z#JNP_*CDCOV[[J&'F.K
MT'5=A^5')'?MWW4,/,=7H.J[#\J.2._;ONH8>8ZO0=5V'Y4<D=^W?=0P\QU>
M@ZKL/RHY([]N^ZAAYCJ]!U78?E1R1W[=]U##S'5Z#JNP_*CDCOV[[J&'F.KT
M'5=A^5')'?MWW4,/,=7H.J[#\J.2._;ONH8>8ZO0=5V'Y4<D=^W?=0P\QU>@
MZKL/RHY([]N^ZAAYCJ]"/FZO $6TMO>3;@;ON]:PY3:/'D'#JU37)A/)7.CP
M^:\TI2N=H<LC(_0,OJB/#$5KAY$B]?\ Q,M>3]&K7ZGXLM>QZ0>!?S5)0"F(
M 'CIZ1]D^P9\G8[!%_, (B6=L@P%8>[C)V]JW;?G1,\Y<LJC6#>M?54GEPI]
MO4/M+M..F"9<QM:2IK&IZG_VHM ,J^[0EX78 Q.0! GB6?HCW_\ VVWONLP#
M+X/T)380_$OB+\F-A?>M2@7 2_$_4R@!       .-"_Y/0+ZI?5 #0N7ZO\
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MSF'DK9<-_HW$F1DK0]0JJDZ73'P)RE_+_@_T"D
M
M      "+6]C]%G,G]W(?W?HXC*N)[/U,?V:?\,@\"_F)0BF(        0)XE
MGZ(]_P#]MM[[K,",O@_0E-A#\2^(OR8V%]ZM*!<"R_$_4R@*8@
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MC;6775K<<<VY80<<<69J6XM>,[84M:U'RJ4M1ZF?HBB7XGZDC@(
M
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M0:*E&4).$TU-.C3P:?)I\/0W5&4914HM.+X-<*>#/>(4
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M\QM[=.3OY/5<O=E"<+D)1JXNC<6TE*+I@U@T=\'MCC14OQT?]T]O8_(Y6O\
MWK'$Y&4?'T?V$V-G'Z(>U;_S;\'?]&-KBDE^)^I) "
M
M          !%G>Q^BSF3^[D/[OT<1E7$]OZF/[-/^&0>!?S$H13$
M($\2S]$>_P#^VV]]UF!&7P?H2FPA^)?$7Y,;"^]6E N!9?B?J90%,0
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MB_%/F=N-&UK3M?R$-2TNY&YE;BJFN*?)KP?D9('ISVH
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M+X/T)380_$OB+\F-A?>K2@7 LOQ/U,H"F(
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M8RMC)]^=T6,K:5G*QU2YTQ4>B*73'\,:*BKC@2WU(; -%U.=2 '&I>F .=0
M 5                           @[O/G\0NGT^R7MA5O[9KAJI3YIW_"W&
MU>]Z1!73B0S[WHH$BS67GD.J<Y_2&X78/D] "JGB5<4?=QQW;ASUD;;-2L \
M,CY0\:XYL[(=9K;N6,^)HTJEWO(FT^E-PJ>5'5-1-BRJ<ZMY+IDT2#;T4?/(
MQ*^!ETX=3>!<-M*E[P)N,E/;UJ/A*B9;55Y2D0\#5&YZG9C=%5H<1LY-UM-5
M)<UI6I*/3FJ+0^R+ZF+Z? E&!
M            (L[V/T6<R?W<A_=^CB,JXGM_4Q_9I_PR#P+^8E"*8@
M ! GB6?HCW__ &VWONLP(R^#]"4V$/Q+XB_)C87WJTH%P++\3]3* IB
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MS/HNPY2I5-<XR6*^E>!, NP0U]Q.>
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MJ22DF2DGRD:3)1&7ID9'H9#V:::JN!Z)IIT>#.=2Y?J=D4@U_E_Q !J .=0
M                 P!4YB'3]\9O![&O5.V__7_^?=1_XA/$\K_NEZ_O+8Q3
MQ                                                !%G>Q^BSF3^
M[D/[OT<1E7$]OZF/[-/^&0>!?S$H13$        ($\2S]$>__P"VV]]UF!&7
MP?H2FPA^)?$7Y,;"^]6E N!9?B?J90%,0
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MZM)M.CIR?!G<#2M:TO6K"S&F7H7;=$_=:;5>:,CD>H]+6I[0Y%
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MK_+ZP Y         !4WB#_?&;P?_ #3MO_\ HKE2$\3R/^[7[<RV04\8
M                                            19WL?HLYD_NY#^[]
M'$95Q/;^IC^S3_AD'@7\Q*$4Q        "!/$L_1'O\ _MMO?=9@1E\'Z$IL
M(?B7Q%^3&POO5I0+@67XGZF4!3$
M.#+4 05W<[%["W1.0[C=JT^T<@4J!VC"K\!MM^-4(S)K7&@U>,X7]8TVMP]%
MI/G$GD&T=@=T=5V/&625N.8TFY/J<'@XM\90:],4:VWUVVTK>O3F;LYV-3MQ
MI&Y&CJO",T^***+'V67_ '[NDS9M6I=RT)FZ,#43'ER7C77T.E!E4;)E%16Z
M$NDIT_K)D=A9MO(5R=(DS(]!O!?,%M-V7)9;-+,*E(NE&_58HTM_P#W1\:D\
MWEOTC;74E+J2].'#]Q8M7N#G9SUGPD4#*ER,WW&B..3I51BQ'Z!59YI2IMA$
M-'-<IL5M9FDE(-9JU(STT'$<I\Q.H1U&3S>1LO2G+W5%M7(QYU_,WR=*'*LU
M\OVE7,A']-G<PM42K*4J.$GX)1_*EY5*X;YPSNPV4UTJS&D7#;<)QWHF;LM*
M4])HLU#*^E;:DJ02F4*6DN=T;J=?0UU&X],W)L+N3E?T\XV;UVF-JZDIJO+Q
MPYHU)J.W-_=MLQ\?+SNPRU?[RU5Q:3\5X5XT9)C#'%JRW;DB'3,J42CW_0V^
M8U(JD1E5'N1EHG/ZV0M31'#F/$1Z:+0GZXX7N3L%H&<C*]H5VYE,T\5%OKMM
MTP6.*7HV<OVWWYUFQ*-K7+-O,Y:M.N*<;B2?%K@_J+E<&[O,'[@$L1;'NIAN
MXW65/.6G5^; KK?1I(WR:CK4:)26C/\ I-J/7LZ:#KGNCM]N?:3<]3L-Y-.B
MNP]Z'ECX5\SL-MS?&W-T12TN_%YEK&W+":IQP\:>1)O4_2^M_P !G]0QPDY<
M>7H@                                        #C0M-/0_D8 :>AZ'
M8T]#3TM 'F?"JUK6W74*;K5!I%40LC)13J?%DFHCY-#4ZTI78+TQ^'-:9IV=
M5,W8M7$_XHI_<>SR.M:OIDE/3\U?LR7#HG*/V,P'<VS/:Q>+CKUQX(QS47WU
M&IY]5OQF7W%*+0U+=C="I2C],QQ?-=N-CYQMWM-RW4^+BG%_\EHV=H_S ]ZM
M C&&D[EU:U;BJ*/QY-+T4JHBQ>/!QX?5X.R)2L&T^WILDCZ65;55JE-6:]#+
MI$MG)?90LBY/6I(N3L#T6:[/;-OQZ;$+^77_ (=Q_P#2ZC=6@?/W\TN@6X6(
M[DNYK+PX1S%NW<PY5Z4VO5D8;K^CZ;-JR\\_;MT99M%;NG-8CW#'JD)HR+3^
MKCRXC:D<X]#/U_I^F/0YCL?I3C3)Y_-6Z?Q1A<]K=&;DT3^:9W^T^W&UJN3T
M//*/YI6)6YOUE&3^SD1CO;Z.-;RNF?L'<5<*4\IL4RX;8I;R25RZ$J<R\;AD
M?8/D(>@S?9+5;4'+(YZU>GRG!P_YK:-Q;=_FTZI%1M;FVGE7+QN6,Q<7_(:I
M]9#2^N MO+LN0N98%TVG=\)D^<RJ#6)=$JZ%)YW*<;I":>3R<A(/7E'#<_VK
MWIE(N3R=G,\_ASC7Z%)5.P6VOYFOR_;AM++[HR6=R&8E@^NU&]:?^E2J?J1^
MK.V_BOX 6ERD4;/D>#&==-4RRZA+J=-:[5)'KY"4.<C*DJ+F<A\[0QQC_ =P
M:3U2GD\]E5'\R4TOH<71^PVCIW=OY(>Z,.G/9C;$LQ-*D<W"-NX^JN$6UB^?
M+ ^+&X@_$ZPY*;BUC(^5J.IA!&J%=MK.S8ZFN>E.CRI5.>9(E+3IJ:B5J?)V
M1Y,KNK<FG_\ [)JF=MJ.%)3JOI5R)["]\K'R<[_LROY#2=$S"D_QY;,J$JT\
M.F<7PQI2AG&V./7OEMPVV*L6-;J0E2>E17;9=BREI1H3A$]!=BN(4HB/T#(M
M>P.2Y'N?OK++#/6[\/Z=F$OKBT:XUK^61\MNKIW,B]7R4VL'9S"E%-\,)J2=
M/4DK:OTC'+D53";PP#9%6;]:4IRCUZJT]S3G%SUL)=3(3JE/+H9'J/>9?O/N
MZRZYC+Y&]%/^G!M?15)FH=;_ )3FQ;T92T#=&HV)?E5VS;FO)2HX\7A5$Q;#
M^D*8 J:F6[^QO=5M$YT1./4F2S54,&M2>D6IMY$=;B6DZF9)/G'R:=D>^R/?
M6?535-+N*'.S<C*GT2Z:_::!W-_*O[HY.,I[8U;)9QJM%=B[;?*C3DE7SP)W
M8_XM>Q?()1^ULQTRW.V->:=UL.4=+9$GG?UQN=)T6O8+4<OR7>;9.:N*WF+M
MW+2?_>VVDO5JIUHW1\C7S);6Z_BZ!>S;AQ_3-7:^E*5)A6CN)P5?O0G9V6[
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M+.]C]%G,G]W(?W?HXC*N)[?U,?V:?\,@\"_F)0BF(        0)XEGZ(]_\
M]MM[[K,",O@_0E-A#\2^(OR8V%]ZM*!<"R_$_4R@*8@
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M0_$OB+\F-A?>K2A5P$OQ/U,H 0
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M<8M,[D/7'[0
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MXO\ OK,X+VM4^LRAKR%H>OU=.S_P<H]^<-1Y
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M6BFEU0?I)8>TW5H>[-O[BMJYI.:MW9-?AK22]8O&IG8<7.1
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M[)'J6J::2NSR%V#T^J%/-BJY(]7R#WZ9\]6?,@+4?*:C5$U,S[*N1LB+4_J
ME3Q8<O)'F6"K^)*VSSW?RFEDI*FU=IJ2M*BT4E23;T,E$>A_4&6'2XO&+XI\
M#&D>I2I2:Q33Q3YD;,M<,G$^<HSL;)MP5:X.F2LE/=HTR+(,UERF<F/';D&9
M*+4CYVOH#AVJ; V=K-S]1G,E;_4K\\/<E7Z*5]&;CV#\P?>7MCF(7MFZ]G<K
M&,DU'JZXT7ATRJOJ*O\ +WT=>V'XC\G"&9:I3ZBM2ULTZ^8_;E/:U3JEM,J$
M@Y"FS7Z:2-)>F-1:SV5U.-UWM"S=J5ER;^'=BXT7@E.-6^6)](.W?\UG7<M\
M+*=RM"M9FQ"$8RO91]%R;7&3C+W4_'#BRJR_^#9Q!\7UJ>FW<7*OF+!<5VI<
M6/+CIZW*BVCUR76(+\J'/;-1=A"]#U&O<_V\WC8F[.8TR[>2=*V^FY%\FG54
M^T[N[7^?_P"5C>>GVGJVM+3;UQ>]8SV7G2VWQ3FHR@_5>!U*F[M^)3LE6>+:
MS<N5\9^]SB)#MN7Y0W)Q);D*6XTEFI52+4(YLNEJ2.B=/FI['(/P935]S[1S
M#REC,YO).$UU6).D:JCITS3XK%]+/<ZCV(^43YC[#WCIN5T757?A*$<SD;R@
MTU@V[=N4)=471OKABR?N#>-Q69T*'!W WID^DU W.@=K%AP:'+A=&9I)N6]&
M?BH<)*"U-1(U-6HVKI/?+/V'\+7]/A?MQX3L24)4_I1>#?IQ.A'=/^5)KT,]
M>SO:+6[;R,JR5C.MN2?\$9)8>5?:63V-Q!]J>0UPVJ9Q&JA;$^8IIE-%OVCQ
MK7FKDNI)1M,2Y5-.(:4%JE2N=ISN77T!L/(=U]CY^V[ES,7,HTEA?@X8OPK2
MC]3IONCY$_FJVIUSS.U,WGLE;3<KN3<+\>E?F:A+J5<&ETU\B?MK6)=]\4N-
M7+,W75NZ:1+:;?8J-!J= JL1QM:2,E)=A0GD)UU[!Z&7UQS?(:EIVIV5?TZ_
M;OV9*J<)*6'T<#J_K6@:YMO.ST[<&2S.2S\'TRMWK<[<DUQPG%?4=Q1A#)O-
M+I-Q>1>?RZ\Q%%YO9]#G4W7L#]U/-GI^J/(\OD0R5V.L7DC7_P"0HG@T*>;'
M5'D<_(ADOSBLC^U4/P:%/-CJ7)''R'Y*\XK)'V%$\&A3S9>J/(?(?DKSBLD?
M843P:%/-CJCR'R'Y*\XK)'V%$\&A3S8ZH\A\A^2O.*R1]A1/!H4\V.J/(?(?
MDKSBLD?843P:%/-CJCR'R'Y*\XK)'V%$\&A3S8ZH\A\A^2O.*R1]A1/!H4\V
M.J/(?(?DKSBLD?843P:%/-CJCR'R(9*\XO(_M=#\&A3S8ZO)#Y$,E^<7D?VN
MB>#0IYL=2Y(?(ADKSB\D?843P:%/-CJCR'R'Y*\XK)'V%$\&A3S8ZH\A\A^2
MO.*R1]A1/!H4\V.J/(?(?DKSBLD?843P:%/-CJCR'R'Y*\XK)'V%$\&A3S8Z
MH\B/6Z_$]ZV_MYR96*IF6]KHCPZ1&<D4NJG"3"ELG/88)MXHL=D_6.2$J+DT
MYQ%KRD0<.+P)5/!*CHR0.I=3/7T.K7K_ #?)GJ&%/(?FJ2?%,3@^Q_+_ (.4
M 0YW9\/S9EOJAVA"W:[>K#S:BP9-0EV=+N9FJ1*M;KU51&;J3=,K=OU*C5EJ
M).*(T;K!OFPM3:5&CG)(R#R/T[4MA&SO8]3;AI>U';]8F%6+M7'7<DFV8]1E
M5BLE%4ZY&8GU^O5"L5Q^%'<=4I$<Y'0I4>I(U >7@2]+L?RY?J_S@#D 0)XE
M9$>T>_ST[$ZW3]'_ /FK"?0[/9[ /@/!^A*;"/XF,1_DQL/[UJ4"X%E^)^IE
M "                                                       'BI
M)*(R,B4DRT-)EJ1E]4CY#U#&M5Q'D0,W(\//!FX21(N),21CR_'4'S[GM%J/
M%9J;B6TH:.O4<D(AU TD@BYZ>C<Y3,S48VILSN[N?:4(Y-R6<TI?]E=;;BGQ
MZ)\8^F*\,#66\.U6V=W3>;G&64U/_O;-%U<NN-*2^I\VRCS-O#PW*8DN&=%I
M=FR,F6JS':DPKVLR.\M2V5DI1Q95*)PZA!EQ#+FJU(TJ,C4DS2:1V<VSW>V9
MK^4C<OYE9+/-M.S>:X\U.G2T_#E6C\3K5N/M#O+0\Y*&4R_ZW(435ZS52I_"
MX5JFN?!T]#[.!]]NX?:X[XGW#%GW?:T=YHG;/OIJHQJM1FV$FVXS1)KY=NQD
MN)+^@OGM<Y):$7*/S[J[6[0WQ'_$,I*&7SS3I>L.+C.OC-+W7ZJCIXGZ]L=S
M]W;(G_AVI1GF<DFJV[RE&=M+BK;>/MJJETF$>(YMOR]3XZ:M<S>+[I42>V+7
MOAYJ$X2S5S4G#JJ-:;-2O34M%DI)=DB'6W<W9S>6W[K>7LO/9'PNV<?;'\2]
ME#L3MKNUM#<-J*G?CD\\^-J\U%I^4OPOZ']!.BDUJD5Z&W4:)5*?5X+R4K;F
M4V9'FQEI47.3S7HZW$<I'Z>HUAF,MF,K<=G-6YV[JXJ2<7[&;)LW[.8MJ[8G
M&=M\'%IKZCZ8\!Y0
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M2M34A:&RYO(1\A#G^@]W-S9"4(:A.WJ&13HZI0NTX_WD?=<EA2L4J'4WN?\
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M>R=V%VU)53BTU]1V4?B/U
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M)9^B/?\ _;;>^ZS C+X/T)380_$OB+\F-A?>K2@7 LOQ/U,H"F(
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M>\
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MM'4MH:;F<GJ>:MYN_F,Y=O\ 5"'1&/Q).72HU:5*TPXTJ3,&NCGX
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MN/Z#,PAFVE6U-J,T_P"''!M>1+G4:_.<C4/L U+^7U] !R
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M[IN=BXYJS-QDOO\ 1K%';/3\]E]2R=O/922EE[L%*+7)G;!^$_8
M
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M/7;DI0?BL3]>H\9F<@
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M#]"4V$/Q+XB_)C87WJTH%P++\3]3* IB
M                                               <'REIH1^F1]@R
M]'4 :[?%'V@6!MNPSG;>?:E7JK5$LV)4K_NK'?0QW(RSF2F"EE;TLC0J-&.;
M*4X;*DZ-H/1)GH.P^T^_68TK3K6FZ_EOU$+%I0A<MNDY**I%33PJE1.5<>1H
M/=78W*ZOJ%W4]#S+RUZ_<E.<)JMM2EC)QIBJO&G-GVMKG# ;R;:6-\MY+OLO
M$F_+*M#(-*MRV6W&*F_3+MH--N*GT^JS9*.9&>8C5$FWC;)9&I/K>0>YUWYA
M+4\KT;<R<HYJ2_%>::CZ*/%GJ=$[!NUF5<W%G%<L0E^"RFE*G-O%+Z"<UZ<+
M+:]=40DTN#=%HST-(::G4FM*=01M$:2=?AR&NC?<6>AJU41'Z0X)IO?3>^1G
M6_.QF++=:3A]2:=5[#F^I]E=DZA"D+5VQ=2IU0FU[5P9 K,G"0O^TFEUK#EX
MJOUN,A3J:56&F*17$N$9J0B&XPZJ,[S2+D,S)1GZ VIMWO\ Z1GW^FW#EOTK
M>'5!N<*>=54U?KW834<E_M.WLU+,../3<2C*O@HM.GM(H47*F\S9W5'(%1?N
MRSR>(D+@W13WZW09*&%=(6BWS*.EKTE)41F1\@Y[F="[<]P["NVEE\PU^:U)
M0FJ^F)PBQKO<KM[=^'FW>LVVO^TB[EO#SX)$L<:<8#)\&:PUDZQ[7NBE&9=M
M5"V&Y=%J+;>I%TK,5UZ9%=6?I&:2U' =9^7K0[MMRT7-7[%_PC=I./TM),YO
MHWS :G&Y&.MY6U=L>,[58OZ$ZHM!PSO\V[YFD0*5 N?Q5N.H&AMBA75T5/=6
M^O4B9;FDM4):S46A>O+74AI'<?:C=^W(2OW;'Q\G#C.U[V'.G'ZC=6W^YNU-
MQ.-K+WU:S4N$+GNOTKP)H,2&9+:7HSS,AE>II>8=0ZVHO32MM2DJ_F,:VE&<
M'TW$U+DS8$91FJP::/?KJ(4
M                            XT[/U?3#B#D0 4        !%G>Q^BSF3
M^[D/[OT<1E7$]OZF/[-/^&0>!?S$H13$        ($\2S]$>_P#^VV]]UF!&
M7P?H2FPA^)?$7Y,;"^]6E N!9?B?J90%,0
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M#4E23+L&1C@,HR@W&::?FCG$91DJQ::/:(4
M                                                (L[V/T6<R?W<
MA_=^CB,JXGM_4Q_9I_PR#P+^8E"*8@       ! GB6?HCW__ &VWONLP(R^#
M]"4V$/Q+XB_)C87WJTH%P++\3]3* IB
M                                               !4OQT?]T]O8_(
MY6O_ 'K'$Y&4?'T?V$V-F_Z(>U;_ ,V_!W_1C:XI)?B?J20 @    !QH7I$
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M4
M         (L[V/T6<R?W<A_=^CB,JXGM_4Q_9I_PR#P+^8E"*8@   _GT_E_
MQ     @3Q+/T1[__ +;;WW68$9?!^A*;"'XE\1?DQL+[U:4"X%E^)^IE 4Q
M
M              .#['\O^(_0 &KOQ;^(C1=Q.S7=KM*Q;MDW<UC*%U4>IX^H
M$I.&:TQ;=1GTRX(29DQNL.F3:Z3.APGR9<3J:^<D].:9C%L\G0U["<'#_P")
M!9%[6YMNVN+P#N?LZ\J%B/&UBU2X;VQ)6*'9D"MVG9='H53*977CZ%J.4ZGN
M$EPRYJBT,5/@1QXNN"+J"['J_P"L4P.0         #$!U2Z+'M"](;L&Z[;H
M]?BNMJ:6BI0(\E?1GV4H>6@WF_\ \4R'[\CJFHZ9<5W3[URU-.ONMJK\UP9^
M3-Y#)Y^#MYRU"Y!JGO)/[2M3,W"HQ%?<Z?6K J\RP*C+4IU%.0VN316WU((E
M+2E*R?;0I9&?-(C(M1N?;G?;<&EVHY;5K<<W9CAU<)M?9])J/</93;FKW99G
M3W+*9B7A'\%7Y+VE:^2>%MN1L)Z14K?BT6_:;"/IF*A0*F[&JJ$I2:C4BFOD
MS(2M'8,R(R49#<^C=\=FZK%6<U*YE+\E1QN1K#Z9*JQ--:OV/W;I=QW\B[6:
MM1=5*,G&:](NF*^LQM9NX[=IM9FIH$J3=5%IL-9K>HEV4^6_"4@S2:D-2)*#
M:;2I)=E*N0>YU+9VP=\6_P!7!6+EV2PG:DE+V+%GK,AO'N!L:Y^DS2OQLQXQ
MNQ;BUY2X+VEC>*.,%9LJGLQ<N6368%02:$.UNUFV9M+6G1)*<<C./$\A1*Y=
M$ZZD-.Z]\O.HV[KN;?S5N=KPA=JI>VE/:;7T/Y@-(OVE'6\O=M7/X[:ZH?O+
M$\4[O=OV8VVRM"_Z4B<I*5>]5;<31JB7.Y-"9G*;)9D?(>AGRF7IC4&N]O=V
M;=D_\0RDW:7YH>_'VHVWHF^-L;@@GIV:MNX_RR:C+V,DJTZT^VEUAUMYI9:H
M<:6EQM9>FE:#-*B^L8X9*,H2Z9IJ7)G+$U)5BZH]@A0
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MP*ON)2822I&&<2(6DTJ3C*PTJ29:&1E:U*(R,O0,C!<"R_$_4R>*8@
M
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M:<@
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M1V_CVSIAQ*7D)IJ&T<R@0):F6&95$F&TRTX^HD))1DE.A=@BT>9:M.BYG?\
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M 40ZF.K#&\NFXOYQ('X,!1#J8ZL,;RZ;B_G$@?@P%$.ICJPQO+IN+^<2!^#
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MM*$7 LOQ/U,H"F(
M
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M^OZ/K^7_ %.D9BW?M>/2\57FN*^DRB/1GN
M                     (L[V/T6<Q_W<A_=^CB,JXGM_4Q_9I_PR#P+^8E"
M*8@       ! GB6?HCW_ /VVWONLP(R^#]"4V$/Q+XB_)C87WJTH%P++\3]3
M* IB
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M582BUY-'[]?1+E+Z@\1F-?Y?Z !R
M      BSO8_19S)_=R']WZ.(RKB>W]3']FG_  R#P+^8E"*8@       ! GB
M6?HCW_\ VVWONLP(R^#]"4V$/Q+XB_)C87WJTH%P++\3]3* IB
M
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MT)380_$OB+\F-A?>K2@7 LOQ/U,H"F(
M
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M",O@_0E-A#\2^(OR8V%]ZM*!<"R_$_4R@*8@
M
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M6E N!9?B?J90%,0
M
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ME^)^IE 4Q
M
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MO&8S%_-WYYK,R<[]R3E*3Q;;Q;9OZS9M9>U&Q8BH6()**6"27!)'U!X3R@
M  $6=['Z+.9/[N0_N_1Q&5<3V_J8_LT_X9!X%_,2A%,0        @3Q+/T1[
M_P#[;;WW68$9?!^A*;"'XE\1?DQL+[U:4"X%E^)^IE 4Q
M
M
M                       "FOZ0;+1#X,V_]:VS>*1AJ)3DIYNJ6W*O?EG4
MMF2X9DHFV8CLPG5K/0D(0:C,B3J3B588^3^PMYMO_P 'Z#R\A4:EEZ'+_P Q
M8Y/YO]0!\3[8$       BSO8_19S)_=R']WZ.(RKB>W]3']FG_#(/ OYB4(I
MB        $">)9^B/?\ _;;>^ZS C+X/T)380_$OB+\F-A?>K2@7 LOQ/U,H
M"F(
M
M                                         4\<?]M"^#5Q!R6E#A%@
M>:X1+2E9$XU<]MNMN$E9*(EM.I)25=E*B(RY2(P*N/T/["VNV_\ P?H/8Y:-
M3#_^86=-/J?Z"^KV0(?<        19WL?HLYD_NY#^[]'$95Q/;^IC^S3_AD
M'@7\Q*$4Q   #@CUT^KZ  Y   0(XEAD6T>_2/\ VIUO)+ZI^^C2]/L4F?\
M,(^!>?H2GPA^)?$7Y,;"^]:E"K@)?B?J90 @
M
M
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M^*$GV?\ L#5]4"^#]"5&$?Q,8C]#_P")E8?WK4H!+BS* &(
M
M
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M/?\ _;;>^ZS C'/T)380_$OB+\F-A?>M2A467XGZF4 (
M
M
M                                  19WL?HLYC_ +N0_O@HXCX%7$]O
MZF/[-/\ AD'@7\Q*$4Q        "!/$L_1'O_P#MMO?=9@1E\'Z$IL(?B7Q%
M^3&POO5I0+@67XGZF4!3$
M
M
M           BSO8_19S)_=R']WZ.(RKB>W]3']FG_#(/ OYB4(IB
M$">)9^B/?_\ ;;>^ZS C+X/T)380_$OB+\F-A?>K2@7 LOQ/U,H"F(
M
M
M                                           !%G>Q^BSF3^[D/[OT
M<1E7$]OZF/[-/^&0>!?S$H13$        ($\2S]$>_\ ^VV]]UF!&7P?H2FP
MA^)?$7Y,;"^]6E N!9?B?J90%,0
M
M
M                "+.]C]%G,G]W(?W?HXC*N)[?U,?V:?\ #(/ OYB4(IB
M       $">)9^B/?_P#;;>^ZS C+X/T)380_$OB+\F-A?>K2@7 LOQ/U,H"F
M(
M
M                                                  !%G>Q^BSF3
M^[D/[OT<1E7$]OZF/[-/^&0>!?S$H13$        ($\2S]$>_P#^VV]]UF!&
M7P?H2FPA^)?$7Y,;"^]6E N!9?B?J90%,0
M
M
M                       "+.]C]%G,G]W(?W?HXC*N)[?U,?V:?\,@\"_F
M)0BF(        0)XEGZ(]_\ ]MM[[K,",O@_0E-A#\2^(OR8V%]ZM*!<"R_$
M_4R@*8@
M
M                                                        $6=[
M'Z+.9/[N0_N_1Q&5<3V_J8_LT_X9!X%_,2A%,0        @3Q+/T1[__ +;;
MWW68$9?!^A*;"'XE\1?DQL+[U:4"X%E^)^IE 4Q
M
M
M                             (L[V/T6<R?W<A_=^CB,JXGM_4Q_9I_P
MR#P+^8E"*8@       ! GB6?HCW_ /VVWONLP(R^#]"4V$/Q+XB_)C87WJTH
M%P++\3]3* IB
M
M
M  19WL?HLYD_NY#^[]'$95Q/;^IC^S3_ (9!X%_,2A%,0        @3Q+/T1
M[_\ [;;WW68$9?!^A*;"'XE\1?DQL+[U:4"X%E^)^IE 4Q
M
M
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M ,[B7[55?< H*KD.ISN_\[B7[55?< H*KD.ISN_\[B7[55?< H*KD.ISN_\
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M"@JN0ZG.[_SN)?M55]P"@JN0ZG.[_P [B7[55?< H*KD.ISN_P#.XE^U57W
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M3[6L^V[=FR8A.%%?ET:CPZ=(=C=*E#G:ZW8YFCG)29ITU(NP!&=W
M                              88MC'-8H>:<HY(DS:>[1[XH=DTNFPF
M>G.HQ7[:A2(TMV9SV4L$T^IXNCYJU'H7*1 *\^",S%ZG\OYP!R
M                          ,,;A,=5G+.&L@XZM^73H-7NV@R*3!EU8WR
MIS#SYM&3DDXS$A\FTDD^5"%*(]- \2KZ3(-E463;=FVE;LUUE^90+9H-%EO1
M^?VN])I=+BP7W6.D2ESH7'6#-/.(CYIEJ!*UQ9V8
M                <'_+L_\   ,14;'U6IV:+TR2]-@KH]R6?;5O0X#?;'OB
MQ+HLF4[)>D<YHHQ1W4NES.:LU&?9(@+7"AEX"
M              8)W,XPKF:<$9,Q7;DZGTRLWM;QT6#4*L;Y4^*MR=#>==D*
MBM/R4F4=A?,-"><2^;H:>R3$84QK^R,VQ6U,QX[*S)2F6&FU*21I0I3;:4*-
M*3Y229ER:AY@_2
M
M
M                                           "OK>KQ,-LNQ*J61:N
M7JA==>R%D5B7.M'&F.*"FZKWJ=(@N]KR:TJE*FT]J+2DRB4TEQQU/2.(4E!*
M-*M(W0R46QLGXEFV[??-OF@8D?NZW+XQSV@]=6/,DT-FUKT@TZI])VA6$4E$
M^H)DTJ3T?(\AQ1)-1$K0S"J#BUCQ+!==?Y=D4Q
M             (Z[H]S%D;3,45+,&0:)>EP6[3)\2GO4ZPZ$FX;@<?F-2G6E
M,T]<N"A324Q%<Y1N%IR>F(W3'P+&+DZ(J"NOZ2)L3L.W)MW7O86Y^U;:IQM)
MFUJLXHIT2"PMYQ+3;:W7+O(N>M:TD1%J>IA55H9=#2JVJ%T>WO.=C[F,*XXS
MUC5=2<L/*5MQKJM==8A>]U452Y;KS37;T(G7RCODMA1&DEJ+T2,RY13%JCH9
MD @                                 =.O[(-DXML^X;_R)<]&LVS+4
MIDNLW#<E?G,4ZE4NG065R),B3)D*0@N:V@^:DM5K/0DD9F1&J5)O@1OV1[Y,
M \07#M3SKMNKE5N''5,R+>>,EU6KTLZ0])N&QY,5BJ/Q(RGWUN4N6S/8?BO*
M-)NL/)4:4ZZ &J&8L]9UQIMJQ)>^;LO7 S;./<?4617;CJSI$XMJ+'+0F8L?
MG)5*F2'#)#;:>52C] M3($JNA@+87Q MO'$>PY/SGMJJEP56Q*;=M6LN4]<E
M'31*BBLT=+*Y)%#1,G).,XU(0IM7/U4D^4B -4Q\";9'J6H$.0
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MZ1,J,9LDM'482#027].<71D9F?*#P=2K&&/G]QL<C(\8
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M4RE6RS'CD9)22UH;4DUGIJ:C,S[(J>'TB:472/ V,2['_5_X>744\9R
M                          /QU"!"JL"93*E%9FT^H17X<V'(;)UB5%DM
M*9?8>;5R+;=:6:5%Z)& ]#7CX^UQ;;]N'#7N3!%)Q59,F[\[W'$L#!6.J1;<
M5R>[?-;K;%6JUQ4-B*A,N-/C-*<-R2E?.4;Y(5JDS(L7P/)'J;J2:V$[#;AH
M?"AQ5M"S=D')EN56Z;$C/WI5K#N9NWKWM^%<#D:IKM6FW%(IU5[1;3"2EF1H
MR:_ZUQ!&79%IA0G527.B\2!&QG:)@?9=Q]\M8CP#:DFW+91PNTU:J3*M69]P
MW!<-;EY\PL<RLUJL5%Q;\F=+Y%.&1)0:]3)*2,B*+!T\!+&*EXFT(7^LB/U3
M,]/YAD8'(                                #I]3L:RZO<])O.KVO0:
MG=5 I\RET2X:C38TNI4>GSY$>9,CT^3(0XN&4B3#:6I3?-5ZTN70S(U/$O4T
MNFN#-7?;HU;>ZWZ33F?<EMWI-,<P9M7V>2<)Y:RK:T-;%LY&SA<=?.(JWO?2
M,;E*N&71X,A9I?9YO.*D*7SEIYBU3B9.J5/&GWU(F<3:\[[X9/&*<WJ;=I./
M-W&1\Z8_5;U\[1J\F77\O632O>?2+7K%5 965L05*9)[74GET\EH41MKU<E>
M7$O%5HWAP_=]YG/Z/73<>;N-R6Y+B8W7D6UK.W+9(JU<H=R[1+#6[0Z?BVDR
M%''=J-P6]4B34)\UY:N9TZ.?H\GG/*2HT$HN-627X?V\/O-O@9&
M          :^NY%G<WL'XG=Y[V<7;4<S;RMNV\'#EA8YS1;>W:C4VZ,SX?R)
MAF*NFVM7:;9]6J]O4VNVA<]N*90XXY-94U*0Z1J3HV2YP=?V_;]O7*M8T_;]
ML3ZFTK'>XC>SQ!5\1S/^W/(>T7&&%,7U##>W3#F9HE-I^:[LJUS*-Z\[\OJ@
MTV95(EMT:"G^KI[:7UJ?6X1I4M+2U*>-? -TC3Q_;]Q?L*8@
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MTFTV*8                  !QH7\O1^OZ@ <TOJ_7UY0!R
M                       .-"UU #0O4['U/^$ <]@
M                   <<TO].O\ HT_U !I_+0OK>EZ0 :%Z/+_+ZF@ XYI?
MZ_\ 3_I+D 'D                                 XTU_E_J]( -"_F]
M+^7* &G\_P!< <<TN734M3UY# ')$1=@ <@
M       .-"]7U/4[  <TB['( &A?5]4P T(M/J?R^L .0
M
M
M
M
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M!;DB?;;UO-UZJ6[I4ZZR]T=/GN5*CO$EI39^LYJC,B40C>)DHMKS)OBF(
M
M
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MR,W(<I]19U/HIL-;AMNIU/1:3%(?6
M
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M24TXDRTYR#T,RT,[Q,6NET,K 0
M
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M
M
M                             !P?*6GJ_6]'_0 .BV!B_&V*:9,HF,<?
M63CJC5"HR:O.I-BVM1+3ILRJS%FY*J4J#0H,"-(GR5J,W'EI-Q9GRF8%;;XG
M>P(                         /Y?R[( QY=6),6WU<-KW;>V-[#N^Z;(F
MLU*S+CN>TJ#7JY:E1C.G(C3[<JM4@2IU$F1Y!](AV,MM:%^N(R/E M6E1&0B
M+0NR9_7/4"'(
M
M
M
5                        #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tv523241_chrt-line5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv523241_chrt-line5.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#:@.$ P$1  (1 0,1 ?_$ 0L  0 !! (# 0
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M)!87HK+2D[.T&<)S@S14)355-QA$=)1E=39&_]H # ,!  (1 Q$ /P#?X
M
M
M
M
M
M
M
M
M
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M6A1I41:D8$'O
M
M
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M9:993P*0DB05I*F/-E8O#U(R#S78W.'Y %U;<-Q]Y\SK(7,HVBY$W#X]PSN
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M\$VWNAV[7#G"EJX:GANAYLQK5LJTY7#!7PS\>0+FD7=#5P5.,>CD-/1(:/\
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M%58R77&%2*;5Z5(E4^<PE]I:#6TXI)+29:ZD84IM!9[-.Z_:UMM726MQ.Y3
M. W*\2E4-O-.8\=XL76DH[7B.DHOFXZ$JHDGL%Z]CQZ<"O8,*;]P+TT.NT2Y
MJ3 K]MUBE7!0JK'1+I=:H=0B5:DU*(YJ2)4"I0'I$.9'7H>BVUJ2>G6%*8,%
MA\F;Q-HV%;UH^-<R;IMN6)<C7"Y!9H%@9,S?C.P[UKCU3=BL4UJCVK=-STJN
MU-RH/364,)986;JGD$G4U)UFC!>JMU%J1:-7JU)G-OL/6Y/J--J5/DI=:>:<
MICLF'.@S(RU(<;<0I+C3K:C(R,E)/J,%M(>PUMOL\6^BGM\G#%.?-^^\* Q5
MJSF+-5NOYGW<Y_BQY]4*G7W(@46ANY#S%=C;\WO&.I#,:,<M79H-*$)(C(A+
M6"]'WL+:S9-M:Z[6OBWZ7=EE7)0+PM6N1^_*+<MK5BG7!;]8B=HMGOJEUFDR
M9=.J$?M6E)XVG%IXDF6NI&*[-I):O-.Y_;3MNB4N?N)W#X,P)!KDA,.BS<TY
M:L'%L2L2UM2WD1:7)OFX*$S4)"V:>^LD-&M1I8</31"M'/<"Y=EWQ9>2+9I%
MZX\N^U[]LVX(;-0H%VV7<%)NFV:Y D(2XQ.I%>H<N=2JE#?;42D.LNK0I)D9
M&9!2FT': !"%S'\_Y-RUNYVC\J';;D:Y<:7SG8Y>XG=QE#'-T5.T\CXDV88G
MK,956IMG7;:]<H]VV'>>>;VCLVS K$%:9,*(<I3:D*=0ZBR2I5_3Z?Q(?!$M
M5;S3A6R\AV/A2Z,OXTMK+F0J36JICG%=S9$MFFY.OZC6G3)U5N6K6A9M8K+5
MW7?!MZD4F5*J$J)'DIC,1G77UI2A:BJ2=(QON_VEYDOJMXOQ#NBVZY5R7;,B
MH1;DQWC?-F-+XOJWY5(?E1JK&K=I6Q<U4K])D4R3!?;D(?CMJ96RM*R2:%$4
MT8,BA    #2E^T/<V?<=%OZB[:]B-Y9)QWCO;CN'P7:F]'<IC"ZI]GD64<E5
M"9,L?;%;EY6Z_'K"JA$HM&FU*ZXT26PLN!J%)2;:9#3MTL/I]/IS(WFTAS!M
MP>5-K6SC.^<L&84OS<1F:S;2::Q9A[&]EW3D"Y[MOJY:S2[5MQ7DM9E,J]Q3
M[?MZH5M%4JYL,ZM4F%(7Q(TXBJJ;]A)K-6WR@?M!&X>R+;W59/YXF8<"[CKF
MI-#R/3=KUI4/(=NX:LZJ3N]+OIF/;U@6CE&SK%BO4:;47:;5H2[&K40T1BC/
M*FL="9>WZ?1D;B3?D;;Y,^<Q;9UN#Q1O$7*H.Z';!E[)6SW.F0L:5)%E5&Z:
MQ1J05.+(=LU6S#IK%G7W%5,DL.2Z,45AJI0$SX2(R7FV&35,>?V!8EV>47ND
MR=<KNYKE][HKQE7KNRY=^2HV,Z[?M=EU"5<^=\ 71 37MOV?*[*JS;,NJW1=
M=GK3%K\A!+2NIQN^%JUF)U26];/I]/:$^),^*D@
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MDFQSE'F"[6.6/R?-EV%N6YGREY&JFZ%FZ,,;#\P[G[DI.,*-3*=,R'5T9)W
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M+BQS)M+T=33G"X;;[K93^7Z<?]HWFR\*D@
M !"!MSY8N6\.<US=!OVKF0+'J>.LX1GF[>M&FKK9W72EOMOMFW5VY5,8I:$M
M(=_A-2'=3(NC0115QWEW)=/3C7 ^9SUN3A1^;G@&S+<M6Y;:QMN#Q)<$JK8M
MR1<<28]2&Z17DQ6KLM"XW:1&E5A5&K*8,=YI32'3CR&.(D&3B]95=Q1T>#/D
M;>^55F?%W(T1RO+DR#C]>8%XXO\ LYR_*0]<$JP&JA=.4J[?D%YIV1285?5
M;@U)MAQ1PR<2KBT09%TU=>DNG'JKC1&5'*0V.7ML%V&8XVG9:K]H7Y<=I/W0
MFM5.V"GS+8JD&O2B7WJEJN4^!)>97%,TNMNL<)I4:>DA+*[*+%T7K(\MJ/)
MRWMQO#FD6-3-PD*S]N&_JG]]X^5C$ZQ2\GX=NGY1J))J"$.0Z;22911*N^PX
MF++TD(T0>A'J!;JWX[3'.#RO/M'F*K)G8!PMSC,:53!C$55NVI=>2<<MR,YV
MS:ZY!:JBWJO'ES72=8:A:H:=.OK<C]!1W6-"43U8$-X[<?1]/62[<J#E/8CY
M6F)K@MFV;FK&4\Q9/JI7/FG-=T-$S7[ZN1]:Y+YH9.1*=ATIF9)6I"%O.N.*
M/C<4:M H0VMWTYDL@D@     _/ZV8[Y.8GRG\]<S&SK<Y)&^/==;6X'?[GC,
M]M9$MJR,Y6#;ZK>EWG7J71ET54';%E"!=%*K4!E$Z-46)K;#S#Z.!*DZ.*M)
MUPYLK%?8B\&\#/'..^T!XMHNP^VN4]DSEZ8-O?)M@5/.N<MS%1N]1T6W+/JY
MW2S)H].OW&&#*K4H42I0HDDX](IU5F3)45N-VT9IYY:"V?3["621\[/:QE*=
M<W(3L;!&)LKY6M#;7S =N9WE5K$L"ZKW9L#&6/JAC:D'>N0IMKTBI1+2MV'3
M**IV34)ZH\-LFW%*624J,IK6OI7WD4^PE)YS]BWODWE5;\+ QM9MUY"OR[=N
MU[T6U;)L>W:O=MW7-6);#"8M)M^VZ!#J%9K-2DJ+W#$9EQU6G0DQ$=OJ?V$O
M9ZT>AL.V[L7UR;=IVU?<#8M<H+-V<OO$6$LNX\O6WI="N>A?+.#*+9]WVY<-
MM7' 9GT6X:0N0\T[&F1D/193>BT$I)D45HZC<:WW(>V-;XI/,#M0M].+<CV_
MC#DX8%RCM;VGWE?N++CLZTLNW+D;-648D'*^.*[<D.+2[LI].Q*_)I;<BD.U
M*.Q2FJ*XM]#KA+DRWA]/IL5 2B<ZK99O9+<SL[YK_+=MBEY/W-[/X->QUD'!
M%4JS-(5FS!-V39[LVWJ<Y)J%&A5)=)*Z:V4J"Y-8D.,U!,J":IL-EE\N&\/Z
MB,G<AOGYX7.3PO<6P;$'*)RIL-HN9$TVQ=Q&X7<9/O2%;%.QE55J5=4>ST9'
MQ)B!F/&J[5*?8FG3_*JH'3Y'>[#;,A]B61!F7_,;V%7]AFF?9LMO&W['&5\R
MV-LPW\;3Z?D2];/Q_<UV-6Q8^.Z]C"-<N6<FR;6I51IEBV_/?ILNI39LU<6G
M1>)WW:6VSX5:I^E?>*4,A]^^%LQW=]H#Y*F7[4Q-DVY\2XOL/=Q$R7E*WK"N
MJM8YQY*N3$]ZTZWHM\WO3:5)MFTI%=J$EMB&B?*CJDO.(0V2E*21ORKU_8B-
M_L,*]Q5I<R7DL\Q_=QO/V:[-[JY@&R_?[4+<R3EK"V+9%=;R3C/.5,?=BU.K
M4VCV=:U[UYA=PUNYJC/748EMU=B;#FK1.-AR W(<8-$XU(\,Q[EN8;O+YS7(
MNSOO&VA5#9)BVL;@K_H&VC ]VURI57*B8]M^:NXLLWYD")6Z%:58IBJRQ<]O
M0HJ)5'I#Q_(\A)Q$\!./%]S^P@GCM#"V8XWVHK*F>9&)LFQ\&S^5C3K @YG?
ML*ZFL3S;[1ES'%2794/(KE*39\J[$4Z$\^=.1,5,)EE:^SX4*,CV+T?>-_K^
MXP O.WN9CR%-[>\'*6TW8[=?,.Y?F^#)M1S_ .;3#R[C3E3#F9[DD/NW! :1
M:EJY/NV!2U5*L.(6I5O56FS:3'A=F_3WX\I*S=5]-I-*'1[&H7-5W7<]?E4;
M[-VVT2_,!8B.C;F*-9N'[=M2ZK]I&US&T3"F0Z31JIN(S'3[=@6Y2,DYFO>X
MWC8AU!FDK;A1:>TEA#[RV&Y>Q>L@R(W0XYYEG*)YBNZS?1LGVEU'F [/]]";
M-OK.>!K4K-01E3&^8K*@OPZE6K4I%%H-R5[L[B8ESGH\NG42O%(*<J-,CMKA
M077XVHG871VN[QN=YS*-SF"JE V6W1RE]E6-[F5=.X:K9CH5KWKF3-U-ICK:
MXV*+8I&:\/VE<MNT^YY5/<8=J=+MB"]!B/N2$U4G4Q&7V%*C>;28J2:SO-5V
MD;U\!;_<)<YCES8OB[B,CV;BBH;=MT>UIRHPJ/6,N8CFS9$F@UFT*C+9?D)J
MM)J,YE<M,/2:TJCT]UMF5'[^CN63K@0^)'_FG(_-,^T0Q<8[-+[Y8>3N6]LX
MC9?LC(6Z3*.X6K7>=UW/9]@52/6%6=CNG7IBG"M><J58[]1WLJG4^42IC*3=
MG1F&I"%%@OI]/6'M)(^<#LGW?VKN:V>\UKEI8^MO)^XW:);E5PUDG;U/DTZA
M.9NVW7&]4$JMF@U&7)ID54ZT4W-6#;BKDH>2B>F5#)R5#1$EDZ^DAX>@C-W)
M[FN;[SZL;JY>%$Y3N7N79A+(]^8\7NCW"[C*_>3<:F8MM:[X%\]Y6 S>^&L+
MO5>JO5VRF36U28]Q+E*[",^F%%DN2Q"IO)9*OSMN7GN%R=MEV:9*Y>\*+/W.
M<L3+V/LOX(LFK2H4<[[LVQ:!3Z/6+":D.2Z!#DU*H(M>C/+AKDQHM5B0Y,$R
M)<EHT2G5^EBE$1';F]_O/*YL.&KGY<V/.3EE/9Y6<T0#QKN W$YGD7[#Q33K
M&D5"#2[ZEVA6+XQ;8%N4VDSD(?X^\JM=U1DTIQ::>U(=-#YEO#YF9/.YV+W]
M9&P/E [6ML&)<J9FI&UG?!M!H]59QI8-X9"K%&Q]C'%]_P!LUC(UVP[8IU>F
MT2@G.4T].J$HT1&'YB4J<(UI(Y3]ZNZJ(IAZB4#GZXXR'ESE!;W,<XHL*]<G
MY#NG']H0K8L/'=JUV]KTN.8QEG'T]^+0K6MF!4ZY5Y$>!$=?<1'8<4AEI;BB
M)"%&546+Y8YLZ[X7*<L3'\RU+FB7[$Y=]KV=*L:50*M'O*-=[&VR#17[4D6N
M]$17&+F9K*3AK@*8*6F41LFV3A<(E?CKNJ0]AKE[6N5%GO=O]ESP_LXK]HWG
MMYW9X\O_ "GFO$5OYBM:Y<773:^5+.W)9<N2SV:Y3[EH]/NJS47K9MPR8T2I
M)8:6PU5&I:36QJEPON&)]R@<W+[0+D:R6]F37)?R+8^[>?;,;'==W?WA6;NM
M[;?;]6J-+B46=EA4A>/UX\<=I)51%4=13;[J;27V7B9BO=FJ,EA4C<9+_8_F
M7F^3Q1G'4*2F3N4SB^RI7_;6B7:D=3B>DS,B?86GI[J3$/8O1]Y*)'N>-2\W
M7URY\MX$V]6)>-\Y,W57'C;:['79]J7/=I61:6:;VI%KY%R)=<6UH4I^DV3:
M>/W*D[4:A,7%IT9"T]\/H2HB5,=OT] 9)WC''MM8CQMCW%-F0FZ99^,K'M/'
MUJ4YEMIEF!;=F4&!;E#A-,L(;9:;BTRFM()*$I2DDZ$1%T"KQ=23[URV]2+N
MMVOVI7XB)]"N>BU6WJW!<-243:16H+]-J41:DF2B1)AR5H,R,CT4"='4&EG@
MS(W->^SN4?(6RVU.6UECF<[.6,KW?>NU3*^!JI<$>[K4LR_ZE+KSMF7Y1L?8
M@R_7&)L&HQ)<N:=0ID9#53GN]A.>B.PV6[/9AL^GTJ0MI(SRE]KV]'-6^C<9
MSC.81ARD;;<FY<Q#;^W#;KML:GE5[EQAANCUJF5JO5B]9:#:-NNUZJVU$[V.
M4TBHJ1(FJ6S#8<88,WN"*_9I<)9GPAA+F$TO-.(LH8@J=Y<S?<%?=H4[*5@7
M9CZ?=5D5FTL7QZ1>-N0[MI-(DUNUJK(@/MQZA&2[$>6RXE#AFA1$EM?I87W'
MH\LS"&:;&Y[7/!RQ>V'\I6=BS*GU??-ADNZL?7;;V/\ (_R+0%,5CR#O.KTB
M';EW_);Q\,CY/DR.Q5T+T$RI3V?80MOM^T][(.$LSS/M2V#,]Q,190E8+I7+
M(J]B53-,:P+L?Q-3;W<O_,4UNSJAD=JDKLZ%=+D.I1W4T]V8F6;<AI1-Z.(,
MX6Q^C[R=_K^XBFOW<WOMY9?/$YJVX/%G*3WA[W,=[F%8,MRUKJQI8V8[<LMN
M-8N,;-<FU>B7I;NW_+E#O!AZIOO0UIC+93&?BN)4M2B-*#>%/1]A"6_T_:9^
M8+^T$\PK+.;L.8KN[[/5OCQ):F2\J8]Q_<^5KGE9N5;>,K>O*[:1;E:R%<*:
MGLPMRFJH=ETVI.U*64BHP&#CQE]I)83JZFI8VJ0!K+[+Z#/VG?:.>9]B&Z%/
MPJ#S!=O^#=W.&J@Y"D1Z=<;N'UR[$ORWVI? F%(N&B7'>M<DFRV;BRI[9/.&
MA3A)59XJOH^K#^!78S[F_'"69[M^T0\F;,MJXBRA<V(,98LW/0,D96M^P+LK
M.-<?3J_C/*D"APKWONG4F3:UJ3*S.GL,Q6I\IA<AU]M*"4I:2-^7V_8B=Y]S
M[4OA?,6>^4Y>./,%XFR9FF_Y6;\+52-8^);#NK(]X2*92ZW/>J529MJSJ56:
MRY IS2B4^\3)MM$9&I1:D(6Q^C[T&3"9/V9[2]S=*Q[/W.;6=OV?:U9=L,4J
MVI><<+X^R;4[5BU"- >JU.HK]]6Y6I5$8FRX;:I#+)MI<<:2:R,TEH>T(M#^
MB0Y5G^6ML+__ *1L!_U!$$F/_,ZV-9[N_8-3<.\J>_9FRO,6 [SH&3L$VA@*
MOE@/'-S,T.379%PX<K]$LPZ'9JK,O,[DDSN\*A%72'ZU'CKF([%;ZCE<R&1!
M3>=1SV<FT>?MGL/D09CQQNAK%$.T3S]=US7C%V\VW<]3B-4YV^H,ZKXMMW'Z
MJ=2GZDW,::*_YK32F5DI;Z6W$%.__:-QF'C#D0.T7D*7ERHKQR-3)&7\IT*J
MY&O#)I?*4ZUJ?N+FW[1<L4*2P;*(-9J%G6[<MK4JEOO*3WS.@QG7U-<3W8$J
MJ\@8.8WYOW/(VGV18VSW+?(KS-GS.6/;;HV,*!G_ !7<M[.8.O)NWF"LRU+Q
MK]4MG$5_V3&342HR9E2<=N^BH6VZ3RV:<VXDB/%^GF%@N1*IR(-@FX'9O@_/
M^7MX2J-#W?;[=PMY;IL]VG;E0@U:AX_KMYSZC5(=F,U*G/SX$RJ09=;G2IYQ
MIM0B,R9BF&)4AMDGW8;",>;/9G;J?M/^2K[H$M%1QIRU-@UNX?N2=&CO'$@9
M[W"UZJ7<Q02G]Y,,RYDC&UVS#DDF0^W%=I9-<*7C?)N=B^GTV#>;+(J2:R'V
MB+!.Z&T:ELXYF6P[%]^95W5[1+RO_&<^R<86U?%XW?=>'<^V+7K5J3Y6QCZ!
M4;DJ\6R+A<2Z1,I;1':J\EYPS2@N&R="&B03DQ;**WLAY7.W? 56.KV=F&NX
M]E9-RY49K3%0N.@9LS$RY>%U%/C5J+)@RJQ8L^K,TOLI#+K"SI24N$X1J-1O
M'D@B!.^=_G.=VN46^]IW,IY,5P<XR U>5X1+,W#8GQQ3G,?Y-QO,CG'CJO#'
M>+MN&:+$AORZ+<)Q6VY%-MZ1WFIV)(8F/LR93C9L&W:9H?9[^7WN!P+E[?3O
M?S?MKLS8E2-X=8L"G8KV26 ]3CHV*K4L$JXY,K=0@492:70E5JIU4U0:>AF*
MXP3DMQ4>.T\PR@Z; N)+QR[=Z&:=Z5H9LN3-6RO+>RFI8LS?<>*K4MO+B[M7
M4,JVE1:929\'+%M^5V+,5R$6W7'ZBXPRF.Q4(Y+C*X9:SU2F&J"IGA=?_P E
MKE_\05G^CI(+:'L/SO.1COHYH7+QY<5G7EB;E^7AS(]H67,B9-J%D4;!U7N2
MDY@P)DVAW:=LWO;]S4NU,:9;K5Q6+=S4")5Z>\W1DHC3)$PG):"2EI4M>ZF%
MM)^>43M$WR9BWU;B><=S*<:4;!&7<IXUI^ =M6VZ!+1,J6(<+0:M"J$^7<RF
M)TQ3-8J'R'&0T<Q9SY+\VI2'(\%EZ+$;-[@BQ7*9V;;K*MRG><[MS=M/)VV?
M-VXG>KOW\R-3RA:-Y8KJ-2@Y'PCA^WK&O:D.W!2:5656)<U9A/PD5V V\TE+
M<A<=:W6#21OWV^;&XPNV"<PCF^;"MN>,N7+:/V>_+=Q9AQ129%HT[,M/D7%9
MF$KJJZ8IUYR[[UN:G8LJ6+*]7*I3TJ*H5-G(<=BH5#A;2MM_2.9XO'AQ(V(O
MYR)=H.^6R-^?.4MOF4X?O"D7=O L"PKGO#*MO6E<:<"WK*OQ=\5.]K2Q?DU^
MWDV#695KTK+C-.^3H<N2JGJI[[))=;C+<$UICA6J%*^QEF-L&8.<3]GJLZ\M
MC#O+$RES(]LU R3?MP[8\R[>Y]V/3X]IWC6GKA[VNF!CS%&7ZI22D3WI,V93
MZI3*:]%JLV2W'F2HA1G%PZ4)6TSUVF[$.9/S!<$<SR]^:3?=_P"#XW,(LB1C
M7;YLY7D*Y;KL;:E;]%C/JMZ^8]CSKCKMHV]6Y]<I=%>=CQ&(U0F(@S),SL7J
MB;+$U29&+,3\'<R;G@<M;%>.]D6X'DJY7WGW5ARW:1B3&VXS ER7M6+)O6T;
M09;MRS*]=U?M3#>7*9*5\B%3T*F5.7;4UYAA;LV.S(.0IN&2B<;E@L<TB^<5
M[@<Y<R^3;]@7)F:KRYV!=H%F6QC9N'MSQI%I=55#@5J\;/H[]XW=>-WNU)GM
MHU8K=5=@M0F]4QI,B1%885&U&L)RC=P?.<Y/VP>T*=5.5;G?>#@;(=Y9!KMO
MXII-M9'PYN6VX9 1>#E'K]'NFPW<49'O6ZL89 ID6'7Z/.1;C*69DR>ER4EE
MIHG#_"@MI,#RG]E&]'<9O$W3\VGFAXNI.%<B9_PZ[MCP3MEAO+14\8X#DS(Y
M5\[K3'FO2HU4JD6BQF6#G.*J4AV74)+C,)IV+&1+=-FTBE=I@+@*]N;E]G57
ME#9Y:W+JR?S.=D,C)-Q7MM8O[ \JZ"OBRZ1?%2J%8GVY>B;"Q?EVKL);.$IZ
M;&G4&&VQ5WWGH]1>CRX["(>S#82C-+EO;9>8KO>YHC7.'YD.#:?M/MW#^$:O
MAC9WMEFU)-9O"WV;QAU:GU^]ZQ'=EO3K=DE1+NK\6:[48M,J]3DU-""B1H,)
ME+QT2H-YM8BI)K+[+Z#/VG?:.>9]B&Z%/PJ#S!=O^#=W.&J@Y"D1Z=<;N'UR
M[$ORWVI? F%(N&B7'>M<DFRV;BRI[9/.&A3A)59XJOH^K#^!78S[F_'"69[M
M^T0\F;,MJXBRA<V(,98LW/0,D96M^P+LK.-<?3J_C/*D"APKWONG4F3:UJ3*
MS.GL,Q6I\IA<AU]M*"4I:2-^7V_8B=Y]S[4OA?,6>^4Y>./,%XFR9FF_Y6;\
M+52-8^);#NK(]X2*92ZW/>J529MJSJ56:RY IS2B4^\3)MM$9&I1:D(6Q^C[
MT&3"9/V9[2]S=*Q[/W.;6=OV?:U9=L,4JVI><<+X^R;4[5BU"- >JU.HK]]6
MY6I5$8FRX;:I#+)MI<<:2:R,TEH>T(M#^B0Y5G^6ML+_ /Z1L!_U!$$G0]S_
M "6N6+O"M'"6/LX[4+0F6!MQIU[4G"-B8UN7(6![+QW3<BU*BUF\X5#M3!=W
MXYH)1ZY5K?BR5I>CNDV\E:V^!3SQK UM^=K]G.V-8.VHX[NWE[;$\IUG-52W
M08;M:ZHN+KMW49WN!O#M91=*K^DS+0G7YD!FFT)KO.'WS52A-+A&:"3(:-SW
M4JF\$YFYC'$#DM<K'-%K<IO:?DFZKW;JLM6'<08YIF7-QE;I>4,K3J90:GDN
MH4FO57(E[U.@69!C?*KT;B=@F]#;:6VAIYU0+';N1!JS<M7?)O,Y?4&[\BU[
M[.KS&-S.\W,=3J-P;@-X^3VL]^<G(U7J<M<EZFT&'+V57"O']D1R-!-4J+.D
M*<4@E2)$@T-=D;J*&X%RK^81N&Y@-G9<N7<'R\LY\OBJ8XN:VJ%;EL9P<OEV
MH9(I]=I=1GSJ]0%7OA;#+Y0Z'(A(CO%'8G(XWD\3C9Z)5&ZI)'_9[,[=3]I_
MR5?= EHJ.-.6IL&MW#]R3HT=XXD#/>X6O52[F*"4_O)AF7,D8VNV8<DDR'VX
MKM+)KA2\;Y-VV+Z?381O-ED5)
M                            #5QWB\F_F3V/O;SOOSY/>^RR=NE^;HH]
MK.YPQ%FZUV*Y858N.W(;M+7<-/K$^P,Q4E^(_$DN2HT&3:ZWX-0=DK:G$W)2
MW&M6J(H=OV+<F?>G+WF8VYBG-^WG4;=MN.P=;%9H6!<<8QHB+=PQBJJ5YFLT
MBIW1';B6EC>DU><[1:GVC3,6UZ.2:@I,B0Y+<BQ5-JX<Q0V7Q4D
M              (^>:%R_P"T.9KLRRAM*NR\ZKCAZ\%42OV=D*D02J[]EWY:
M51;J]KUR70E3J65PT9$MLV)\ I41<J$\ZAM]ATT/(E.A#->]_E=?:@KLMJ;M
MEO/G 8%I^UJI6[-L&=?=O6,V[GQZR7Z6["X.^8F![6O9-4E(<.*XXG(R9*8Q
MZE*7H38FOO5^X4PH;(G+XV-XFY<FTO%6TC#3]6J=J8W@U)^HW1<*VEW#>MX7
M+59=PW?=]:[W2F.Q)K5=J#JVHS1=C"B)9C-_Q;*1#=?0$C-(02
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M4U%J-UVC9%87,8BO$E]*X"$(<+1*UETB6ZI>C[R%O)@A!(
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M@
M
M
M
M
M
M                                               4,]"U]C[W^DR(
M 6JK^=L*6K6I]N7-EO&UO7!2U,)J=#K5ZV[3*M3E2H[4N,B=3IE19EQ%OQ7T
M.H)Q"34VHE%T'J&PLH2>Q'VK3REC2_'I$:Q\@67>$J(TEZ5%MFYZ+7),9E:C
M0AV0Q3ILAUEI2R,B4HB(S#:0TUM.]D9'TE]W=_=(""H
M
M
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MHJ[/I4GV$G& !Z#]*IDF2Q,DT^#(F1=3BRWXD=Z3&,S-1FP^XVIUD]3U]R9
M#WB+0M/N_< %0  $:_,<;UI^V][4M&MP-E(-.FIF;U5IRD*^\78&*LLG1>M$
ME L5
M
M                                                        =8 @
M4T_]$7_&[P_L=[BE=YR;_7]Y/6+G&        $;O,9_F;;K[>XBP2_8^4V!#
MV?3F3O7I7W$D0D@
M
M
M        ($M3^J'KW?KNZ_\ P;44_+ZB^_\ F^\GM%R@        1N<QG^9M
MNG]XFP?Z38$/83^9>E?:B2,20
M
M
M                  $"7]D/_&Y_)A3\OJ+;_P";[R>T7*@       !&YS&?
MYFVZ?WB;!_I-@0]A/YEZ5]J)(Q)
M
M
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M"I<N[;I=BOW%<3\-E+3E7K3T*-"B.5&:I/&X;;3:34?00L5;JZG:P(
M
M
M                                       ($O[(?^-S^3"GY?46W_S?
M>3VBY4        (W.8S_ #-MT_O$V#_2; A["?S+TK[421B2    BNV<EIS$
MN;5[=Y;/#/VS^KVYU]'L"%M99_A7K)41)4
M
M
M                    "!+^R'_C<_DPI^7U%M_\WWD]HN5        "-SF,
M_P S;=/[Q-@_TFP(>PG\R]*^U$D8D@ #CQ%UA]H(K]G2T_I$N;5H9'_YX[/"
M/0R/0_J]+,R/3J,B,1O9=KW5ZR5 E$?5W?N_<(*[BAR!.H D
M
M
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MVSI/<67UV>K+4\]/+=$LNK/P^FU*[UU5R=:T2I1;W4F#&VSP8
M
M
M                                  0)?V0_\;G\F%/R^HMO_F^\GM%R
MH        1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20 !^=[S&M2WW;LS[AYT
MOPC+H_\ XLZ>O3J/#7<N/<VIK?\ U/-_^\W3^K+Y3%7Y:.QUO_[M9+_V2,+-
M2/7HTZ#/HT^]W"(RZQTVP]#TIM-BC[.41^?[<,?%U8@HI:'KTFJ\X!D?WBT/
M]L;=\+?_ .VWO_\ &W?_ &V6/R@_NS-?^&':JIMUZ]_[I,V[1ZA/PE
M
M
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M$_#D
M
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M/3IT(3M*N,EBU@9-B2
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MIC:W^Q;;;-PSX4DG0BL\*K@_XD+&CY&^D*$@
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M\<>UC_GOVR)_+Z_X$;S>9$$@
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M?8E,,R8SS4B-(:;?CR&'$.L/L.H)QIYEULU-NM.MJ)25),R41ZD*DGE
M    !TS(N0['Q)8=X90R9=%'LG'U@6Y5[MO.[K@EH@T6W;<H4)ZH5:K5&4OH
M;CPXC"E&1$I:C(DI)2C(C U1;A^UDV?==V5^5M+Y:&\O=;@2T)2XEUYYM*C5
MBD4FF]XU"IIJ\]N@T3'M_P -JEL6_ 148RZE5J8^\AQ2'F8W9J6<T(KQ)O\
MEF\U[:9S6,7W%D/;57:_$K=A3X%)R;BR_:=$HF1+ GU1,TZ1)JM-@U&JP)M
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M;1CQ_DF[,=.N.W#$HENL3BJCUJJE)(H;79)>)L^(T\:H!G^
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MG?\ ^@-8".WU/[ ]GK7VF#?V5G_H.=HO_C_<C_SFLO P;#H@D
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M&^>GI_>VDYS3[\)4;N0]S;3\<:PQW8U:W%X>+V2T_;_![ R,P$Y@
M           XJ2E:5(6E*T+2:5H41*2I*BT4E23U)25$>AD?6 -/K?M]DJV\
M[I]]5B;BL0WI&P-@R_;GG7%NOQ!;E-[!VHSVR74W*QAA3+9TVU)E_5 CCU9A
MU'>L)QY4Z*@UFMA5JIXO:12FS8;6.#\'XHVW8HL?"&$+(H>.L78ZH<2WK1M&
MWHB8E/IE.B)T-2M-7ID^8\:GI4IY3DB5(<6ZZM;BU*.I)=8
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M_P#6&>03_P <>UC_ )[]LB?R^O\ @1O-YD02
M              &IA5,09<5]KHMS,J<4Y,5AYO9>_;KF64V#=BL9-UX\65UH
MJ.Y?Q4@[414C?6EKL3EDOME$WIVADD7W>K[R-_K^XVSQ0D
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M-]H/_P#6&>03_P <>UC_ )[]LB?R^O\ @1O-YD02
M
M   &C#]E _Z0KGD?\;UN?\MVY47EME_J_B5CL7H-YX4+
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MSQ/GI9/O'3,Q8M*4DKJ@Y6I)-JO4EA5*N.XR0T5IUGKT_L^Q]X9F:E.8
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M@       !&US&U**E[<D\/N#W!6.I2O84FJP"07LEJ2U?=U0R5]=22420
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M
M
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M%B@
M
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MD)^@3JM 4VW4X5/J$B1$D/,K=2;27#]QKJ6G2/?'=>7AK_C[-0AC\3(J4?\
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M^(KR0\RM9],N3O&-/\!"KXBO)#S*UGTRY.\8T_P$*OB*\D/,K6?3+D[QC3_
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M<Y%I^V9_N]8DJ5 $;G,9T^1]NAZ?VA[#+7[]38Z-/;$/83OIS7W$D8D@
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M;^[H'J<_GRVLYD>HD@
M
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M1_\ E1D;>\3:A'4.PLA%/JGE[?P)/_-;P^QHSF&LC8X
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MG2G(
M
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MY&[:[EO0R67N3LZG*-?@W%26"Q498QE3'8ZM8T/PW\T?*GYH\%*>>[VTQ_\
M=Y7OAPSMB2NY>=6U%U7O0<N$HJCPJS.(ED9Z?=W/:&>GG Y
M
M                                                    @2_LA_XW
M/Y,*?E]1;?\ S?>3VBY4        (W.8S_,VW3^\38/])L"'L)_,O2OM1)&)
M(       PMY@MJ+N[:CDR*VTIYRD,TBX4H26IZ4BK1'G5D77HTRI2C]A)&-D
M>)<^M/[\R4VZ*XYV_P#?@_O^LP#R?D?ZAV1G;5*N,(S_ -R29"YRI;R*VMTR
M+?-9H+)%K7)1%D?0EPJ#3DW!'49GT:D[2>!/=XEZ=T>D//&F_O.QOW=*_LK]
MN?H^)+X;^J=?0CSGX)U&.3[TGE*T>=LSCZ?A14D_52GI9LZ%U?=_N#Q,MA[+
M*B0                            '$TZGKJ9?>_9_"% 8"[Z=@F)]ZU@N
MT:X(4:A7]2&WY%IWO#CM(J$*:MDT(:FN(22Y<)9]:5:Z=.@UQWUX]R/=MC]S
MEFK&MVD^BXE^+_)<_P 47[5M1Z<^6SYG^]_EV[G6?TJY/,]L7W&.9RDY-PG!
M/%P3PC-;FMIJ(9MV5;R^7/?T#)\.!6V*=;%12_1<L6:AY^CM$ZI;:6JFM@U+
MC-26=4NI<239ZZ'H72/,NL:!W%VOF8K5;-S+W(37P[\*NVY8T<;B_"]ONRI5
M88U/W=\=?,1\O_S9=L7>SLQ=RTLWG+/3=TW--*ZZ4;=OJHI.,J.+B^K# G V
M"\\"S<CG0,7[I'85GWG(<13X.2"X8]KUAPFC-I=8ZRIK[BT\/:="#-1:]9F-
ML=F^7[UF4-,[P]Z#=(YJ*V+&GQHK%;EU15.*WGYQ_,]_;C[@[2_==Y^%XW,_
MV_!.Y/(8RS%I5Q5K_'%+\NW;0V$J'<-$N>F1*U;E6IU=H\YM+L2ITF9'GPI#
M:DDHE-R8[CC:M2471KJ7=(;_ ,GG<IJ&7CF\C<MWLK)54H24D_6C\L=2TO4M
M&SL].U:Q>RV?MMJ5NY"4)1:=,8R29]@M>[I^Q^[^Z/J/@*@
M
M                                               "!+^R'_C<_DPI
M^7U%M_\ -]Y/:+E0        C<YC/\S;=/[Q-@_TFP(>PG\R]*^U$D8D@
M   #I61[81>E@WC::R2HKAMRKTHDK(C0:YD)YIHE$?<[11#L='SKTW5<OGU7
M]*]"7LDCX=3RL<]I]_)R55<M2C[4S4XV45I^V=V.!9;J7(SKV4$6N^ES5"FF
MJ_,G4E:7"49&E*D.$1Z^R0][>2\M'.]A:M;C1Q61=Q>FW&,\/9]1X3\9YJ61
M[[TNY<3C)YV=IIX-*;N+'Z;T;?:==.D?GP>^BH
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M <Q(
M
M  "!+^R'_C<_DPI^7U%M_P#-]Y/:+E0        C<YC/\S;=/[Q-@_TFP(>P
MG\R]*^U$D8D@      #YU7JE/H=+J%9JTIF#2Z5#DU"H3)"R0S%AQ&5OR'W5
M'T$AII!F?LZ#EL6+N:OPRV7BY7[DE&*6UMNB2]+..]>MY>U*_>:C:A%MM[$D
MJMOU&F[=U[4N/G.O9)QTT]3J7!R"NZK0:D:=M$.!.[XB&YPD1:D\V9D9=>H_
M133],S$^U[6C:NU._/*?"O-;'U1QH?G_ *EJ=B/=M[6M)3CE[>=^+93XQPQ]
M+J3(;<.:?Y77?;MA9=MV/33N*;#I$&ZZ:KLV&)\IQF,PJIQU>X2PZXY[I2=#
M3KJ/.G>7@S^GZ?>U7M^]*:LQ<W:EBW%5;Z7Q5-AZ$[1\V6M3U"UI6MV5;N79
M*,;D?P]3HEU+=5O:31%U%TZ^W[/ME[0\WINN)Z *BP
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M+=RS<E:NQ<;L9------8--.C33P:9YQ<H
M
M                             ! E_9#_ ,;G\F%/R^HMO_F^\GM%RH
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M,]S3[7[XR=S+9JK=N;3Z+T%*G7"6QKCP,@4:Z=/2?L^S][VAE)K Y
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M/EKF4U:W&+E;FO>2DNJ+]:Q.]CMC'
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M.&8U7*6,_/+X2BWTYG*SDD_=DO>2?LJC8<Y;O-VH&Z25)QMFHZ+9&3(4!B3
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MT 5
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MG&2::=*/<;B3355BF>34NK4M1))4
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M#[R'XW[R\6]Q7NV.]<E=R>IV9N/O)],TG^*$MDHOD7CXB]DAD-3!"H
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MFV/*F6[-R?R:Y+(]EZOF]:TBQW-<Z;N8@HSMN4;-807#"E-U*'RN7NJ)D/F
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M$KT82>+C&Y@Z;/62X)(BUT/7J_"7[XWRG5'A?GO.8
M                                                       ($O[(
M?^-S^3"GY?46W_S?>3VBY4 "AF1%J?4 *ZZ@    C=YC/\S;=/[Q%A'^Q\IL
M'^\(>RA.]/FB2(20        $?\ S(__ +#\._W_ /EC_P#_ $,VT -A(
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M=QY-9[2+T;ME[:;8OA);4R[1*(^H=#6AW)R$[0
M           'JRHC$UAV-*99DQGT&T_'?;2ZR\VHC2I#C:R4E:%$?21BERW;
MNP=N[%2MR5&FJIKFCDM7KUBY&]9E*%V+JI1=&GQ36*9!KO\ >2]CG<-3ZE?6
MWY-$QEF-R:S+>CSDO,V=<<93CBJA%ELPDFY G.<1*9>(C0DTZ*+0QH[NWP]E
MK[EJ':;5G..596).EJ>VO2Z/X<JTXQ:JJ;S](OE?_N$=W>*LW9[;\I?N-8[
M5IQ4H4>:L2HNB47-TG!4:E%M-IU3JC7@LO(&\OE29R;I=8IE6MQRGSU+J%K5
M!V1)L:]:>CB:><A2T$420Q);5[EQ&BDF8TAE\QKO9^NN[9^)D]:LR]Z$OPW%
MPDMER#W26[' _5CN'M;Y?_G<\;O.:?>L9N-VU2&8@HQSF4N/%*<7[T91>U/!
MX\3:$V9<WW;;NL=@6G6)$C$V476V&G+;NM^,W2*I,4TGC.@5OC2R^VZ\1DEM
M9)6749GUCT-VOY;T;5KEO(:S']EJ4E1-NMF;_P L_P K;V1EQVGXS?,%\AGE
MSPC"[KF1C#7.S(MR68RRD[MN">'QK5*Q:6V2;7 EL)Q"B2I*B4E9$:%),E)6
ME1$:5),M24E1'T&0VXFI)..*9X;:<6U+!K:<M2UT^[[N@205        1OY2
MV8W_ 'WOBQMNCIM]4"G6A9-$8I4VTI-.E.U><M!QC<=8FH5WNV2CC^YU+HXC
M&H-<\>ZKJ?D++]VV;UF.0M.TW%J77^G%II;O>;KR/6G9GS!=L=M?+CJ_AC-Z
M;F;NNZCF)7(9F-R*M03ZJ)P?O/\ %CZ"1_0]/9/33[XV^>2^1'!N!V6WMF#?
M#M7W2TF\Z!2+6P!3JC$K%L38,Q^L5MV?*JKRU0)32N]64+:J"2/C+4C1T=8U
MCW%V9JFK][Z=W'E[EF.1RL;*G%UZ_P!*[<N/IW>\I]..RAZT\6_,)V[V#\N/
M>WAC.Z?F;^M]T7;<K68C.*M65"-M+KB_>;3@WAMJ=6S5M*W81-QM][@=J6<+
M)L5S+%%M*FY M._[?J57I[L^SZ%"MN!5Z8[37$J0\Y2J<PE25=!*;U[HZ?N'
ML?O'_O9F>Y^T<_:R\LY;A&Y&:=:PA""W--4@FMZ;9W/COSCX0O\ B73/%GFW
MMS4=2CH>8S-S)9G)7[=J:AFKT[\[5Q7%BE<N3::QI*AYMO6R?...=T<S<KEG
M-E-R55+@QXFU*_3FJ9,AE'J3+T]<=RC&ZLVX],;1-,NS/IU(AQ=I^/.Z-)[N
MCW1KN>M9J\[4U<:4NIRE%125<.F-$UZ65\J?,/XX[L\+V_$/8_;MW2,EE=5>
M9L7'<C+JMM035VBK*XW#;LQ/G9NV)Y<IF=*WN7V9Y4M[$F4;[A)H^3*7>-*F
M5>T+JIS+K<J*^<6GJ0^U-CRFS5Q?]<>@MK_C?7+/<$NY>R,ZLGG+[E\:$OPO
MJZ7)QP:I)Q3::VI-'U>.?F5[&SGC;+>(/F"T7-:[V;IESXNGW,K<A:S66FTX
MRCU3P<)1:37(O5MVVZ9WM^1>-Q[GLU,Y<K]XV\_:KM"HM/>I=G4BD2)+4EQ5
M/@R5&YWV? :.,RUX3';=J=E]QY:_FL[WCJ#SUW,V'9^&J_#C%M-NC_-M2HC7
M?E;ROXUU6SD-)\.=O2T+3,AFXYE7KTU<S5R[&+BE.<<.G?3B8F6YR^-S^V.\
M+JE[*\_6K;6.;ZK,FOUW'V4J+5:U!I-5EN/+D2K?>IKJ>P)SM2T0KW)&DSZU
M#%+'C+O/M?.W;G9>IV[>0NK&%R/#"-<&GTK!25)4HMQO+5OFE\-^8M!R5CYA
MNU\[F^[--R\;-G/:==MVIW+<4E&-Y7%C2CQ6-&EN,X<%84S=:% O"3F?,IY)
MO>[Z1,@J5$@.0+7HDAYEUMARF0'%&ZEILUI)1=9D7LF,U[7[5[GT_+9N[W#J
M+S>HYJU*-*/X<&U@TG]VX\X^2O(?CK7M3R%CQ]V__2.V\AF(S2E-3S%Z*:;5
MR:PJ\:<&1TXKY:N[;;!:$).V7<S;EO7?7ZC5)^2J7=E$JM4L:KR9LEUV//HD
M!MPY%.EQTN&9Z:$I7[(UWI?BKOOMJS"_V_JMNUG)QZ;T$GT-+"#C5.K2VMJO
M ]7]Z?-WX-\R:]<?F'L_-YK0<K9MPR%S+7K5O.6HPBDX79M=-R,J>E+F9U;-
M=H$C;K1+VN;(5RQLAYSS)69MSYAO:/'=8IM9K$]]Q1PJ5&E&J0S2(D0FF6T+
M/7A;U,;%[$[$?;-K,9W5;O[G7<XY?&G^6DI.3BO2VY2XR;I@>:_F \\6_*^H
MZ=H_:N3GI7C;M_+PR^E9.4E*Y:M0BEUW91]UW92<IR:PK+ QLNK9-N[Q5D._
M*ULJSS8F.<=9'KB[NK5@7];U5JT6E794&^SK=1HSM,<03;516TVX:#+0EZGU
MF,0O^..\=$U3,WNR=1CEM)S,W<=J5:QFZ5VIJBI@]M*+<C;VB?,1X*[V[4TS
M3OF'[9U/5NZ])RRRMK.Y*_:MRN9:VZV875<3J[:;C5;51;$9";1]H]Z8>N2^
M,Q9UR+'RYGO(K-,IM;NF'!=@4>CV[1"D_)="H462I4AF,RN:\I1G_"-6I](R
M;L7L3/Z#G<QKW<69_>=P9BBZ\6H15,$WC5TH]U$DC5?G7SGV_P!_:1IO8/C7
M29:%XQTF5RY:RTYJ=V[?O=/Q+UZ4?=<FH12X)&>J2/IU]GH^]^#_ $#:/VGF
M4Y
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M-N+)"Y/,#Y9+3"3ZW'$<P;;=(4@NYJ3$9:OO) AXHD$XD^SU_?\ :_"!)R
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MI)D:3+5*DF1I,M-=4F6NI:#5&S V<FGL.1&1]0 J
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M354RY1*(]-.Z.X,2.76                'W?=^V
M
M       *&9%UB&"!;I^J+IH>OUW^+33IT[VT_;"I??Z__E$]0DH<5_P3_;/[
MQ'J?[@;0:I^<<R[=<I<[NYK\W.W]5;8P]R_;(M2S\9V-7+2N*HV[?F;;BH\B
MZJ_>,!N-3I,.8FTV[L88;?(E)-V":2/0^B-^)S14NFJ6/T^X]?[/#N"Q'<FX
M3FMT*CW<B;7<G;S?+FSX"J74(JZI;?D3':5-2I48H\127C,C:<4A22TT($5D
MFZ\GC[$;7)*)6NG<Z/V>[^T).,M?EFC9'K=M(B8PN&';5Q)J49Y50G,D^RJ
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M JN"^L>1VYKTCT#Q8W[P!5<%]8\CMS7I'H'BQOW@"JX+ZQY';FO2/0/%C?O
M%5P7UCR.W->D>@>+&_> *K@OK'D=N:](] \6-^\ 57!?6/([<UZ1Z!XL;]X
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M9:?L]&G3['WAKRN-#.3R$>I:_?\ WQ(*@
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M0<@
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M?CWM=D-J2Y7RB?*;CZ8\9">-3AJT272"5,2')T46\*+["=G337VQ)4J
M
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MJ:G_ ,H%Y?A C^"^PEU @
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M@TXT6PEX$$@
M                                        $"7]D/\ QN?R84_+ZBV_
M^;[R>T7*@       !&YS&?YFVZ?WB;!_I-@0]A/YEZ5]J)(Q)
M                  !%$#K=T6K;MXT:90;FI,*LTF<VMF3"FM(>:4APN%7#
MQI/@49%UEH8^O)9[.:=F(YO(W)6\Q!U3BZ'SYK*9?.V)9?-0C.S)4::K4A/W
M4\J]MMFHWMMT7)<D&\_,JEA5*2EPEM\)*2FWI*B(TN$Z1_Q:O]4^CJ'I3L3S
MJVX:9WBHJ*24;\53?_SBX4WGG;OGPA;O*>H]IMJ])MRLR>#V/W'N=5LV&$&
M]Z&>-IMP*LFL,2:A;5(G&S<-@W2V^W,BH0LRD%29#QD_ DD2#-)EJA6A=&AC
M9_=7C?M7O[*?U++-0SMR'Z=^U2C;V=26$E7UFM.V?)'=/8>:_I6H1<\G:E2=
MF[5226UP;V;#88VZ[K,5;DZ"FI655TQ*W'0W\KVI5'6F*U =6E*E<#"E$<N.
M2C,B<01]721#R+WAV)K_ &;F_@ZE;ZLJZ]%V.,)>O<^3/5_:G>FA=WY3]QI=
MW]5?BMRPG%^C>N9DT7W:Z:_N#"UL,M*B0
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M+@E3_<)1#<8(E:]9.)$U(E%*C6)G,+%
M                    @2_LA_XW/Y,*?E]1;?\ S?>3VBY4        (W.8
MS_,VW3^\38/])L"'L)_,O2OM1)&)(
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M_P#/B[U>Z1KHHS4TD_OI+V!7><B_X;^G F1%CC
M                            ($O[(?\ C<_DPI^7U%M_\WWD]HN5
M    "-SF,_S-MT_O$V#_ $FP(>PG\R]*^U$D8D@
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M^FUYBOYCD7_#?TX$R@L<8
M          ! E_9#_P ;G\F%/R^HMO\ YOO)[1<J        $;G,9_F;;I_>
M)L'^DV!#V$_F7I7VHDC$D                                   %#+4
MM/NZP!#AO\V$7=E6X2RQAUAB?<LEI+=RV\]);C*FICM&3<J IPB2MY1%H:==
M3,>B/%/E73]"R?\ 0>XVX9*+_2N)-T;>R5-QH3RGXQSW<&86M]OI2S]*7(-T
M4DJT:YD(MH8KR3D#(V0,067:-2KV3,62X5/R+:<-*#J%GS*G$:FTUNM<1DF.
MF5%=2XVHM2-*B&^__$7L90=Q:GEG"-*XNN.."WU^XT5_X==]2?POZ;?4Y52;
MI2N[&NY[/29@W-RQMT](M2B7'3:/3:Y4)T!N?5[:I]4CM5:A/:<:8/2I)3)#
M2"2:N _X1F7<&-9+S9V/?S]W)WKD[5J,^F%V46X36QODGNKN,CSWA3O2SD;6
M;R_1=ORBI3M1DE*#6Q5_,UOY[#IN/]TNZ/:74E6A445>$W%>)<BVKQBR'&4(
M)1EJRMW4DH<)/0:5:=(['5^QNQN_K"U"T[<I/9<LM)U/ATOOGOKL.[_3LY"Y
M1/&%U-X5W,E8P7S5L27BVU2\LLN8_K9DVA-2:9>F4&6Z:S2KB6V2W(A)(]>)
M1&0T1W/X)U_36[^@-9O+;7%M*<53AA4WAVUYM[;U2*LZNWE,S6E6FX2=:8-5
MH286;D2Q\@TY%4LJZJ+<T%:243])FM2=",B/5325=LC37IU26@TQJ.D:GI%W
MX&IV+MBZMTXM?7L9M[(ZED-2M*]D+UN[::VQ:9W'C3J1:])]S[Y:_O#KC[<=
MIR                                       !3K[G[H \:VR<(R6E"T
M]/0M*5%W>LE)/VA645)8I/TDQ;BZQJCK-9L>T+B1P5RV*'54Z&7^W4V(\H]2
MTZ5&UKU&.OS>C:3GE3.9:S<],%_ [C3^X]?TF75IF=S-A_Y+DE]YCW>VR3;)
M?QN.5S$UJD^ZCLUOQ*='CK41D:>)7 WH:^$S&(:AXN[)U&3G<R5NW-[X>[]A
MM3MWYBO,?;"C#3=<SOPXNJ4[DI?:S#2_.2CLQO:4Y.;M^KT"4ZE25JIDI"6S
M,]=#2UPH2CA-0Q/,^#.W)U>2S.;R_)237L9Z [9_N'?,'V[866EFK&:L+9\2
M+KNWXUV&(E^?9X\,RV%O6#DZ[J;-7Q_[/5%LN0D]UOA)"5*ZS/77N:#H<]X/
MSMNVOZ7J/5/A<MK[4;W[9_NJ^0K%Q0[GT?(WK"2]ZVFI\]OU&&E]_9Z,Z4Q,
MB38>2+6KY-ZJ8@U%10)"R+@T)+YI(B4?28QC-^).^LM%RLQRF8BMRGTR?J>!
MZ [;_NI>-LY*%GN;2<YEF_Q3A[\?7$Q1KW)GYBMHRE/T2Q(]99B+[5J70K[B
MM/ZM%Q$XU'4^E9J/KT'07?'?>%N#>8TNX\,>GHG]CJ;MTO\ N!?*AKMA6]2U
M*67N7%1QO9.3CCN<NFAU5_!G-4Q'HM-IYLIS,(B2:Z=+D5*(2"41)29QWC)2
M>+VACUS0]6T]MRRFH9>*WJ-Q4]C9WEOR1\E'?58RSW;MVY<W7(QMRK_,L#N5
M'YF7,9PFEFDUA5PM*8=)@VKDM^IO.+5%2@G6EK2R[TZ(Z=3[H^S3^[^Y-.3M
M9+4\Q!1W3QIZ>NACVH?)[\IOD64L]D/VLNI5KE[UM)*3='M7$R!M?[0/N;H)
MLQKJL.S:RILB0]WTS(@ON'U<7"KL72/4N@97E?*_?>7BJ7\KF(_Y[>WUQ9J[
M6O[6WAS4^J]HFIZAET\5TN,TOM1F'8/VB&R'8T=O(V):HQ)4ILGG;>=4MMLN
M-).*2ATU\?"DE&1:])Z#)LAYOURU[NIZ?:N+_%;GT_4ZF@^Z/[4O<4+LI=I:
MY9E92=%?5&^";5*8T,Q+,YZFQBX$(\H;CN:S%\"3/Y2M^9*2E>G\%1Q$K5P^
MP9$8RS(^;>W[KZ<_ELY8=-JAUJOJ9H/N#^VM\R6ER_\ NK*9/4(U_P";OPC5
M?S-&3=H<T;8M>:V44K/MKQ^^$$MHZNW.I2=.@M%*DQT\*E&HN@QWECR_V'>N
M?#GFY6I_]9;G'VU1IW7?DR^9/M^,I9WMC.S47BK3A<]G3+$R<M3<3@N^%,(M
M+*]CUY<E24L)@5Z$LW5*3Q)2DEN(]T9=P9-DN].U-1FH9+4,M.;V+K2?UT-/
M:UXJ\D=N1E/7-$U++1A^)SLS5*>A,NVQ4($K3O:;$D<75V$EE[77JT[-:M=1
MD4,Q8N_\*<)>AI_8S!KN5S-C_C6[D/\ 5%K[4>WQ%[?[1CE. IQ)]G]_N"*H
M%B<@[G]ON*+F19N2,MV99ESKI\>JIHU>JJ(4PZ?+6XW&EFA:="9>4TKA,SZ>
M$QBVK=[=JZ'GOZ=JV=M6,YTJ73*M4I;&Z)[39G:OAOREWOH[U_M'0]0U#1U=
ME;^+9MN<.N*3E&JWJJKZ40X9&W+X$G\X3;]EZ'EFRI&-+>VA7U:%:O-NK-*H
MM/N6HW;<\V%1GY&GN9DF+.:6DM.I0^)>2.Q7:=[^IY?HBZ;7M?JYG?\ _P"W
M3SLI*Q_W5UGJDFZ_ =*)^GE]9,/CK=1MXRW<Z;+QMERS;RNE5/EU9-$HE2*5
M.53H"HZ9DM+9(21M1U2F^(]>CB'UZ1WSVIKV=_IVDYVU>SCBY**K5J.W:ELV
MG1]V>%O*G8NC?]X.[M"U#3]%5V-KXUZWTP^)/J<(UKMETRIZ#( 98:P
M                                           "!+^R'_C<_DPI^7U%
MM_\ -]Y/:+E0        C<YC/\S;=/[Q-@_TFP(>PG\R]*^U$D8D@
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MK0]?8,NO[PZ"IW)77N=/=_<T_")!4
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MI?>_8'KW?R/YS.1R(]?N^^)!4
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M7H,W*G"/73_K2:_=%7]/K)6."XDDPL0
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MI?M_OBJ+%0
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MIKVH\TYS(YW3K[RVH6KEG,1>,9Q<6O4TMY]#C]KKT_T_@_='/B?*>02
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MZ5MR6?6G<+8J2/N>[JL0]#^^:"$/83157I1)'PE^[KK[8D@Y
M                       H9:@!PE^_^[U_O@!H7L=8 IPEKK[>H <)?=]W
M< '+J      4*<)?=^S^$ "21?L?=^X *&DCZ_O!M&P<):ZET?>Z"[G1][H
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M)&7<Z2ZM>@R&-8U.^W'(2            *:%KKW0 X2/H^[JT %0
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M+5ZU>@KEF49P>^+37U&D[UB_E[CM9B$[=Q;5).+7I3HSW"/4<IQ%0
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M:-APG&Y'J@TXO>G5'LBI8
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M34DULP]>PVQE,[E,]95_)W(7+4E5.+3^FT[/J7LD/C/I*@
M                                                  :%['W%U
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M-^VU5=,D_JVEU=2]DOVQTAW ,R+K/015 :E[)"05ZP
M                                                 'I2X<6<P[%G
M1(\V,Z2DN,2F6Y#+B5:ZI6VZE2%$9='274.*]9M7X.U>C&=IX-22:]C.:Q?O
MY6XKV6G*W>BZJ46XM/DU0P\S/L$VN9SI=6@WABR@,S*JP\TNL4F&S J+"W4F
M1.L.LI22%H4>I::#7^M>+>T-84I?MEE\S+'XEKW6GQHL&;[\?_,_YI\;YRQF
M-!UK-2R]F2:M7)N<&DZT:;W[&0G9N^STP'6ZC4,'9(6PZAMQRGT.Y=";?<,S
M-+*Y6G TGJ+74:GU3PMW#E.JYHV;M9F"V1NKHDU_J6%3]$_'7]U+-0G:RODC
M2%*VVE<O9?:EQ4=K]A%E<O*3YB^*)DJ;1,55>I-0C6\57L*Y84HW&VC4KMD1
MXTIN3TEH>AI,Q@>?[%[KR\7//:7F)1BL7"*N)+9MBZ^P]IZ1\\WRG=\9>&7U
M+6[%F5Q*/PL[EYQHWN<I1<?76A]'&G,'W_;+IGDE=AW<W$BN&2+=R-2YW TV
M@R2ZF,[*;4E;;AEQ:DKI,^@?)I7<G<7;=WX.EYR]84=MF[5Q5=W3/%>H^3O#
MY6?E?^82Q_7-#_82OW%C?R%R%6WBNI1>#6RE-B)-;,Y_%$NO%M]V]DNUIMG9
M"D6?6HUKW);Z7'8GE!)@.,4U:4(XC86S*4EPE'U&0V O,>O7-(S&0U#+J6H7
M+$XVKUETZ9N+47*+V4>-3QSW!_:_U'1.]-,U3M#.V\_VM#/V99BQ?:4O@1FG
M<5=Z<4UZ&0M.\RC>^Y(=>^L#>9DIU;C3/?JC;;2KCT21:Z\/"X9=/3H-:O6=
M?:75J6H5_P#GI;3]#(?*'\N<;48+M;3^I12<NA5;PQ^JI:_%.\?<M@VQZ?C?
M$N5J]8UE4JI5^KTZWZ&]WK B5&Z:]-N6OOLLHT0E=2K=2?DN&1=+CBC[HY\Q
MW!W!F;WQYZAGE)I*D;K2P5*T6_#ULC+_ ">_+AEH?"AVMD7;Q_%&NUMUKMVL
MVU^2+G3+F?-N=^7/EV\*I>M9I627J-3ZM57>UE)AHI$22Y'U/J2A3Z3]CI&^
M_"VHZEG\AJ%O4+]V_&SF8*#N2<I+JM]4E5\VC\9O[B_C;L7QAY9TS1NQ,A9T
M_3[VD*[.W;5(N7Q)14O2Z,FE+H(B]H;L/SW*@    \;S9.LNM'U.-K;/[RTF
MD_WP! OK_P"B'P]&GUWNOVN]M-12F%>1R5Q]9/8+G&        $;G,9_F;;I
M_>)L'^DV!#V$_F7I7VHDC$D                        $ BKWCT?+M W-
MX0S%CS%-=R;3K*H-9C5"'24*)"7Y[K9(2MXOX"TDT1D-Z^.[_;^;[+U3MW5\
M_:R-W,W8.,I<(UW>LT]WW9UW*=VZ9K^D9&YGK>7MW8RC!TIU=+3_ /)+<9HN
M'=]O.M2?@R%@2?AFV*_)ICEQ7E=#Q.D4",^F0['C-JT3J;B4Z]&IF0[CMO)^
M/O&^H0[HN:K#4<[:4OAV;2I[S5*M^@Z3N2]WWY#TRYVQ:TR>FY&]TJY>NM/W
M:U:C'CZ2XV[K;W><+;+A'$F.*)4[QDV#<%M-3#@,F\^;$-2%39JD:ZI9-]:C
M+V$F.H\?=VZ;<[UU/7M8NPRUO-V;M.IT57L7IH=SWWVOGUVAI^B:1;G?GE;]
MFM,7TQ:JV2;VTU)8MNWH\MI3$IFB4MF4RK^$U(:@1T/-J]A2'$F1C2>=E">=
MO2MNL'=FT^3DZ&W,JIQRMM3PFK<:^FBJ8)[+,<7W8V0=S]3NZVY]#@77D&#4
M;<E3&S;;JT!IJHDN3&/IXVTJ=3T^V-I>2M9TO5-(T2SI]Z%V]8RCC<4=L9/I
MP?,UQV!I&HZ;JFLW<]:E;M7\XI6V]DH]-*KUF,N]C;#ERMY[DW-A^CSY% W'
MVE1,49?JL!@U)H5);JM+A.3Y'"9:1TTR,3JE'W24,S\:=[Z!ENU(Y+N&Y&.:
MT7,3S64C)_CGT2=%SZGTI>@P[R)V3K>;[GGG- MURVLY6&3SLUMA:ZTNKU0<
MG[226[<'4BXMO-1P,PX46FN8];LNGS$()'8R8E+;C0J@:$]7^VM)=47=XC[H
MTSI_=&8R?=T.ZIKJOK-_&DN*<JN/^[@O0;=SW;N7S?;$^VX^[8EE?@IK=[O2
MGZGB8'6;N$WCXCM:FXMJVU.X;WJ=GP&+<IMX4R;P4NL1X"2APY[J-#,D*:0E
M1Z&7N1M74NT/'?<&>GKV7UVUE;.8F[DK,E[T'+%Q1K?(]T=^Z'E(:+F-$O9J
M[8BK:O0DNB:C@I8X\V9&[7MNU9Q%CW(UQ73P2LI9DD5R\;N8CD7!"JE9;G3&
MZ,RK_6.,Y-[-7<XD$,.[W[PR_<&L9/)Y'#0M.4+-IO\ -&#C%S?IHVO295V=
MVM=T+2LWF<W1ZSJ$YWKM-TYU:@G_ )4U'U'V]LUEW7;6TV-9U>HDNE74F!E-
M@Z-*0;<DGJO=-W2J:DTGU=]LSFE)]E*B'S=[:CD,[W]+4<I=C/(]65?6GA2%
MNTI8\G%I^@^CM'(9W)]F1R&;MN&;2S"Z7M]^Y=<?:FGZS$*TK2EXQY:];M7+
MQ5;']51.NQ?>:T+9J2I4N[I4RDQ3;29*-FI%PD?<X%#8.HY^WK7F>UGNW?AY
MNRX6L=L:*TE-UXQQ]9@NEY"YHGB*>1[@Z\K>3O56R57=DXK^;#U,Z;C.[\DV
MY:%I7>_L$MZH2;?HT>2Q>$:/ 34Y,*,R3ORPA#B5+*1(CI[4S/IU/H'9ZWIV
MC9S4,QIT>Z[T(7KK3LMRZ4VZ=&&Y/#T'R:/J&K9?(6-0GVO;=VU;3^(NCK:2
MQDM]6L?29'9%RTWO%V09N7C"W:F_=<VWGK<7:!M]I4&ZXS/I[KT%I*="<-+;
M*S+3N(&&Z-H$O'7D[3/ZY>A'(1O*Y\6M(]'3))OVKVF1ZWK$?(/C34UH5J4L
MY<R\[2MM>]\39T^U,[+0,&WA>'+YH.%*A"<MZ_7<80(<>)4$\#M,N6EU$JQ3
M6I!*/^+<[XBH2?L<0^+-]SZ=IWER[W+:DKVE+.R;<=DK<X]$FN*HV?;E>V]0
MSWBVSVY=7P=3>1A%)_DN1I*->:DD6*L_+^]IZPF\$S]O=4AW0S0W;/1E*8\1
MT),-,-<#Y76R?0X\B*HN#IT,TC*=1[=\9K5GW5#5[<\B[OQOVJ7O]5>KHKPK
MM,>T_7O(DM._[N7M*G#/1M_"_=-IVVDNGKIM?)%Q-F6WVYJ7MIR#B'*5%F4U
MVXIE8@*74(_9KDHE-/$U44-JUXDMRC0M/L\(Z;R/W9DK_>F3[AT.Y&<;,82]
MU[*4]WV51VWC_M?.9/LZ_H&LP:N7'.+;5.I2K[WMQ.E8SRQNQVZT"'ABXMO-
MP9+A64VY1K=OB@/FJ)5J2S(=*FJ>+W7#P,&DM>XDB+N#LM:[?[![PSDNY,IJ
M]G)7,RU.Y9N+&,J+JIZZ^FI\&CZUWKVKE8]OYO2[N=MY>/3;OVVJ3BF^FJW/
MIH9_8+NW)M\6?*N+*EC%CVLRJU*32;:.04F3'H34:$B,_-41F:9,B83ZN'N(
MX1JCNC3]%TO/QR>A9K]YEXVEU7*43N5E5+DETKTU-E]OYW5M0R3S6L9;]I?=
MQ]-MNK4:*C;XMU?HH7L&-H[P"0           !Q,CZ#+N?=H(8.J7=95KW[0
MYUMWC0*9<5$J#"V),"J1&932DKT/B;-Q*ELN)-)&2DF1D9%H/MT_4<_I.:CG
M--NSLYJ#JI1;7_+Z/2?)G<CD]2R\LIGK<+N6FJ.,DFFO61#YMY1=I5551KF%
M+HE6U,43TI%KUHN_:>^\1&I$2+-/W3"%GT>Z+3I'H3MGY@=0L*&5[EL*]:V.
M[#"7I:W^HT+W)X$TG,RGF^W+TLM?;KT2]Z#Y+@1+W3A3<AMWN!<]Z@7U9TVF
MOJX*_069Z8:C95Q&^W)ADICL3X>@SZ-#,;[R/<O9W=^4^%"[E<Q:FOP3<>K'
M"C3QJ:.SO;'>O9V;^+;MYFQ.$OQVZ]+ICNPI]S9('A#FW7C06(5 S39[=S1V
M$LLJNJBN%"J"&FS0V;DZ&LE)DO*0DU*,B(]>L:E[F\ :=FISS7;68=B3;?PI
MXQKM]U[E7 VCVUYZS=B$<KW+ENM))?%A@^'O1XTQ,Y[^YG6WBU+.H=Q6[.EW
MI5JZQVZ+9IVC50I1I,T*:JZED:8KO&6A%TZETC6&D^$N[\_J%W)YR$<ME[3I
M\26,9<X<50V=JGF/M'3\A;SF6NO,7;BJK</Q+E+@SK.&.:1B')5RQ+8NRC3<
M</U!U3,&I5:8U)I:W34264/R4I;)@WC,]#/H+0?;W)X-[AT7)2SN0N1SD8*L
MHP34J;Z+>?)V[YH[=UK.1R.;C+*7)OW7-KI?I>XD_A2XTZ,S,AOLRHLEM#T>
M1'<2ZP^TM"5(=:=0:DN-K29:&1](TE.W.S-VKD7&Y%T:>#3X-;F;AC*,XJ<&
MI1:JFM_HXGM$>HJ2
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M=(G^5Z#%>M7KE?M1/X-\'Y@       0)?V0_\;G\F%/R^HMO_F^\GM%RH
M     1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20
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M_<?M:?M  9&?X2_<_<#F 1'J?3T=S[ND/0/25($"HD
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M]UI_8=@U^_\ M&0^2I]!4
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M)[1<J        $;G,9_F;;I_>)L'^DV!#V$_F7I7VHDC$D
M
M   4/H(S$,&M1ONV5Y#QQD6_\MVE245C%EQU>?=3KD!/ JU5325/JT6>R7_
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M,M7K5^"N691E![TZKZCZ'$7=U+[Y:%U:G^T.&IR'(2
M                                               "AEKI[!=SV?8_
M: #00"HD'$B/4]=/V-2_TB <A(       @2_LA_XW/Y,*?E]1;?_ #?>3VBY
M4        (W.8S_,VW3^\38/])L"'L)_,O2OM1)&)(
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M![Y'K[/W:#B3J<A42
M                                "!+^R'_C<_DPI^7U%M_\WWD]HN5
M       "-SF,_P S;=/[Q-@_TFP(>PG\R]*^U$D8D@
M
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MC6=RU>LR<+T7&:=*-4^TV'"=NY%2MR3B^&)[XH6
M                                                   @2_LA_P"-
MS^3"GY?46W_S?>3VBY4        (W.8S_,VW3^\38/\ 2; A["?S+TK[421B
M2
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M/H3A<BIP:E%[*8GN"A8
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M5]J)(Q)4
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M"=N3C<3C).E&FC.8RC-*4&G%[T>P*E@
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MKTK[B2,25
M                                                         #JE
MUV7:=\4Y5)O"W*1<E/7QI[VJD)J4E!*+W9LK6GM6#41=:%),Q]F1U/4-,O?N
M--O7+-WC&37^Q^L^7.9#)Y^T[.=M0NVFMDDG_P GJ(W\T\K3#M[0),G'$B78
MMP*6J0@G7%SJ9)=4HU&TX6A/1FEI/0M"5H9%W!N3MOSGW'IMU6]8C'-939@N
MF2]&YFI>XO"_;FJ6G/3:Y;-UK7:F]]2)_*_+FW&8M-^J1+5>O&!!/OINI6H;
MLUZ*TVLS0\I,?A>;=;T(S+3H&^M!\P]H:XE8N9A9:]/#INTBG7=CA0T7KOAW
MNK19/,Y:T\S:@^I2MUZHT;:V</J.BV'N'W68!J,5QBKWG!@PI+9R:/=,&HOP
M9$=E9&J*GOMHDM$I'N35J6@[75>T>P^[++4K>6G<DL)VI133>_!^NAUNE]W^
M0.U;ZE<GF/@Q>,+L9.L5N3IZJDH.(^;M9U7<BT_*UHS[<?=4VRY4J47?L(E&
M9)4^\2?=,LIZ3,:0[@^7W4,O&5W0<Q"]!;(RPEZ%Q9NCM_SWI.=<;.M6)Y>Z
M]K7O1]+IL1)M9.XW!V0XS4JT\H6?4R=2DTL?+<%B2DU%J251Y#S;O&G70RTZ
MQI/4^S>Z-(FX9_(YB%*X]#:]J3-QZ?W5V[JL%/(9S+W$]RG&OL;+S1I<66R3
M\63'E,*Z4O1WFWVC+VG&U*09:>V,=G;G;?1<BXRX-49WL9QFNJ+3CQ1URH7W
M9-*D%#J=W6U3Y1]'>TRMTV._KKIH;3LE*R/7VA]MG2M3S$/B6,O>G;XJ$FO:
MD?-<U#(V9_#O7K49\'.*?L;/O0:C3ZFR4FFSH=0CJZGX4EF4R?WG&%K1^Z/D
MNV;MB71>C*$^$DT_8SZ+=RW=CU6I*4>*::^H]T<9<
M                           #BM/&E23_ -8C+]L@! MJ7U0_:^NYI^QW
MOJ*?E]1;?_-]Y/6+E0        C<YC/\S;=/[Q-@_P!)L"'L)_,O2OM1)&)(
M
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MOO)[1<J        $;G,9_F;;I_>)L'^DV!#V$_F7I7VHDC$D
M
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MR>T7*@       !&YS&?YFVZ?WB;!_I-@0]A/YEZ5]J)(Q)
M
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M)L'^DV!#V$_F7I7VHDC$D
M
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M4        (W.8S_,VW3^\38/])L"'L)_,O2OM1)&)(
M
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M!_I-@0]A/YEZ5]J)(Q)
M
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MD8D@
M
M  *&1'[/[9EU_>^\ *@                                       XF
M1=PNGV=3]@RZ^G01@"%7[/HU$:Y8..68*DKI[6X/?,B :"T:5"3O<W!=ZJ:2
M1F1-*9T,B]L1%)+#Z8?P+3;<L>?V_P 2:HDI+J(6*G(       ! E_9#_P ;
MG\F%/R^HMO\ YOO)[1<J        $;G,9_F;;I_>)L'^DV!#V$_F7I7VHDC$
MD
M
M                                         '$R,^K7]@P!"O\ 9]83
M=,Y8F.J8RM3C-+W [XZ8RI1&2C8IV]G<!"9XR-2]5J:8(S,U&9F?29GTFI1%
MI?B?I?VLFJ J        $"7]D/\ QN?R84_+ZBV_^;[R>T7*@       !&[S
M&?YFVZ?WB+!_I-@0]A*_$O2ON)(A)
M
M
M         !:C)&<\,8@D4:)E7*V/\<2K@[X50HUZ791+:>K!1"(Y/R<W5ID5
M<M+!&7&;9*X=>D,-A*3>Q$&/(:W8[:[;Y<.,*'=V><06Q=5:SQO-K3=L5K(-
MM4ZMMLW3O)SI<-(2JF3:@Q,0J=2:M'D,D;9&XP^VLBT41B*JE=Q+3;;7%_:;
M#\>0Q+89E176Y$:2TU(CR&5I<9D,/(2XT\RX@S0XTXVHC2HC,C(R,A)4\P
M     "!+^R%_C<_DHI^7U%M_\WWD]HN5'5TGU$ ([N8AS.=J_+6Q/4<C[@;R
M9*M*@.2;2Q?0'6)^0;WD]H4=B/1:&EPGTQ%R5DER4Z2([1:FI6A&'VDI;]Q=
M78EO"L7?KM;Q?NJQO0KAMJS\I4^H3J71;I8:CUN$JEU6;1I;<Q#"W&5'WW 7
MPJ2HR4G0RZQ"=0U1\C+P20 !&SS&B,Z7MQ61EP%N"L=*B]E2JK 4@_\ V)-J
M_;_;AIDK%8<423"2
M
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M:+0^X6HC=4E;EQ:)(R+3_=/\/M"2*(J
M
M
M                      ."T$M"D'J1*(R,TF:3T,C(]#+I(^D* @7XC^J'
MKJ?%]=W^%_WMK[/LBFZI??3=7[R>L7* RU+0 <>'JT,]"[G1IT=7<Z !737K
M_9[@ KI]WW??   1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20
M
M
M                                         $"7]D/_ !N?R84_+ZBV
M_P#F^\GM%RH        1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20
M
M
M                                             $"7]D/_ !N?R84_
M+ZBV_P#F^\GM%RH        1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20
M
M
M                                                 $"7]D/_ !N?
MR84_+ZBV_P#F^\GM%RH        1N<QG^9MNG]XFP?Z38$/83^9>E?:B2,20
M
M
M                                                     $"7]D/_
M !N?R84_+ZBV_P#F^\GM%RH        1N<QG^9MNG]XFP?Z38$/83^9>E?:B
M2,20
M
M                                                         $"7
M]D/_ !N?R84_+ZBV_P#F^\GM%RH        1N<QG^9MNG]XFP?Z38$/83^9>
ME?:B2,20
M
M
M $"7]D/_ !N?R84_+ZBV_P#F^\GM%RH        1N<QG^9MNG]XFP?Z38$/8
M3^9>E?:B2,20
M
M
M     $"7]D/_ !N?R84_+ZBV_P#F^\GM%RH        1N<QG^9MNG]XFP?Z3
M8$/83^9>E?:B2,20
M
M
M         $"7]D/_ !N?R84_+ZBV_P#F^\GM%RH        1N<QG^9MNG]XF
MP?Z38$/83^9>E?:B2,20
M
M
M             $"7]D/_ !N_R84_+ZBV_P#F^\GM%RI0ST+7H_9/3_08 CQW
MF\TK9IL+KML6GN(R6JAWC=\ ZM1;/H%(J%SW,Y1RD/Q2J\BD4EEZ3%IZGXRT
M$XLB2:D'IKH9B*K>646^!W?9/S!ML',%LV\;VVS7PY=M-L"Z$VA>$&HTR90J
MW0:R]3H]4BMSZ146VIK,>;#D:M.FG@6IM:2/B0HB5(:IS,UR,SZRT_9U_P!!
M'J)(*@"-WF,_S/MT+_\ *'L$_;_G./KT?LB'L)6U/FB2(20
M
M
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M(P]ZLV:OB$+WX8\&.D?I&'O5FS5\0A>_#'@QTC](P]ZLV:?B$/WPFHZ3Q/\
M,@**P_*E;;,SQXL9I3S\AV!#2VRRA/$MQPS5[E*2(]?O!MV#I?/V'JTWF6PJ
MU C56D;=,QU*F36NWASHL."[&DL<2D=JTXE9DI)J09??(Q#= HU53WOTC+W<
MVSYJ/_O"$7^^ =)7](R]W=LV:OB$+WQ"<>#'2/TC#WJS9J^(0O?B,>#'2/TC
M#WJS9J^(0O?ACP8Z1^D8>]6;-7Q"%[\,>#'2/TC#WJS9J^(0O?ACP8Z1^D8>
M]6;-7Q"%[\,>#'2/TC#WJS9J^(0O?ACP8Z1^D8>]6;-7Q"%[\,>#'2/TC#WJ
MS9J^(0O?ACP8Z1^D8>]6;-7Q"%[\,>#'2/TC#WJS9J^(0O?ACP8Z1^D8>]6;
M-7Q"%[\,>#'2/TC#WJS9J^(0O?ACP8Z1^D8>]6;-7Q"%[\,>#'2/TC#WJS9J
M^(0O?ACP8Z1^D8>]6;-7Q"%[\,>#'2/TC#WJS9J^(0O?ACP8Z1^D8>]6;-7Q
M"%[\,>#'2/TC#WJS9J^(0O?ACP8Z1^D8>]6;-7Q"%[\,>#'2/TC#WJS9J^(0
MO?ACP8Z1^D8=]6?-7B^%[\2.D]-SF4Q&J@Q27-NF8FZK*BN3HU.5"A%+?AM*
M4AR2VUQF:FD+09&?M"*CI/;_ $C+WJSYI^\<&%K_ /K&"8Z2OZ1E[U9LU?$(
M7OA/J8Z1^D8>]6;-7Q"%[\1CP8Z1^D8>]6;-7Q"%[\,>#'2/TC#WJS9J^(0O
M?ACP8Z1^D8>]6;-7Q"%[\,>#'2/TC#WJS9J^(0O?ACP8Z1^D8>]6;-7Q"%[\
M,>#'2/TC#WJS9J^(0O?ACP8Z1^D8>]6;-7Q"%[\,>#'2/TC#WJS9J^(0O?AC
MP8Z1^D8>]6;-7Q"%[\,>#'2/TC#WJS9J^(0O?ACP8Z1^D8>]6;-7Q"%[\,>#
M'2/TC#WJS9J^(0O?ACP8Z1^D8>]6;-7Q"%[\,>#'2/TC#WJS9J^(0O?ACP8Z
M1^D8>]6;-7Q"%[\,>#'2/TC#WJS9J^(0O?ACP8Z1^D8>]6;-7Q"%[\,>#'2/
MTC#WJS9J^(0O?ACP8Z1^D8>]6;-7Q"%[\,>#'2/TC#WJSYJ^(0O?A5\!TGD:
MYBDEYQ+36V7-:G%GHE/R?"Z3T,^OBT[G[ G&E1TGRZ5S,*?7J>S5J'MXS!5:
M7(=E,,3H<2"ZPZ]"?.+*:2I"E%QL2$FA1=PR,/L(2JCZ'Z1E[N;9LU>+X7OP
M)Z1^D8=]6?-7[$"%[\@'2/TC#WJSYJ^(0O?B,>#'2/TC#WJS9J^(0O?ACP8Z
M1^D8=]6?-7B^%[\3CP'2>-SF+NN-K1]6G-*%+;<))_)\,_=<)\!Z$K7AXC+7
MV"!H*+KO,2>\;K^I7\I^0UV=_?6V\J?)[Y+=^6/DOO#MNW[WXN'L]?<\6NG$
M*[J>HMC78^/UD]8L<9175]WL^WT " .T;UNG8%S2-]=7R/A/-=4VS[WO,QFV
MR,V8SQ7?>7Z!0<E6#B*@XRO.RKCI>-*!=%P4B3/G6RN4UQ1#/_:F#,B:4;B8
MK0O1R6&-/I_ [[M6H=Y[N^9-EG?I<.'<AXCQ/B+#E#VR8#?RM:E:LFZ,K-.U
M^Y;RN;(U.M6XX%-KM%H4=VY%16TRX[3BE+3H7&APD&JNO(-J,5'?O)OT]):]
M&A]6G26G<Z2ZQ)0:=.OW=T 8T[KVW5XC>1'C'(=7>F/4DE$8I#B2.\*/QK0D
MD+4C@07NE$6O#J721F0CB3'\2,EM.KK_ &S_  ZB2"H@
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MNVU)2I*CZSU(C/740MA,MIE()( @
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M2,B,CZ#(^DCT %$(0VDDH2E"2Z"2@B2DM>GH26A%T@#D
M                      IPEJ2M"XB(R)6G21&9&9:]>AF0;J;@5
M                               4,B/K#:#BA"&RX4(2A.JCX4D24ZJ/
MB49)+0M5*/4_9, <P                    !Q4M"-.-:4:]7$HDZ_>U,@!
M4C(R(RZ2/]G][H %0                                   !12DI+52
MB27LJ,B+]L^@ >/MV?\ NS7Y1'X0!Y",C(C(R,CZ2,NDC+V2, 5
M                           %"4D]2(R,TGH9$9'H?L'IU& *@"B5)46J
M5)47LI,C+]P 5                                  !P-QM)\*G$)5^
M*:DD?[1GJ .8 H:DD9)-1$H^HC,M3^\768 J
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MA4^169U0D1XG?C?2A*^$S21@G43325=IM#"2@
M        'C<)2D+2A? LTF25D1*X%&1\*N$^A6A]SN@#7NWA\IZY+LQON0W!
M7;ODW(T/-$.#>>2+2N"VLA5>V<=VG0K5H*JE0+2.THDF.V3"/DY:%OMO(+5X
MM&E<)\=:5Q9RJ>*C%41X>1[O:W'[@.6-?>4\AT:OYORSANY;^LVTFFI3;=>R
MJ5HT:#+HL9%2J3C27YD^2[P*=<4I:B5H7$K0CE-M595JLE6B3^E3"O;Q?7,]
MJ_.RV-W9O:N:I8PL[/>%-V55M/:[0+BD%;5I4>S+-973RNR@PY!TR;<")+C$
MDGI*7)3;B"/4B4";KB6DETX4I_M1MWB3B
M      ##[>?MTR%N?QQ2,8V3G.[<$4J9<<23?5>L9V1"NBMVNUPG)H=,J<1Z
M/(@+D&1\1DXE"B/W>J2X3AITP+1:3JZU^E37LW18TO7E%;XN5E4-NN?,^Y(M
MS=YN F;<<VXVR[?]1O\ AW':ZV[;J'E#08$I+3%.G4QZHNK<=)*G&B-LDK(C
M5K#23PJ73<ZI_3Z4,N.=%EVN^?[E_;3KUS'=.VG;!N0R;<,;+^<+6KDFTIRZ
MU;5"J4ZR\>NW@T_$B6[!N*M,QTO.OO(93VR%K2I*.$&JD1PQ6TP6?;JFR'G
M;%<%;+MT&7=PN/,\R7XVXS'UV93D9<I]DVB3U5;>N&IS8;S]+I+S<&-V[;;S
M3+Z"2EQ)FE:3!46PM+JDO>^GT9N"%U%]X6.$J                *'[76 -
M4[[+E=5,H=@;[-OEP28-)RQB?=?>;UVV:^F)%KM/IU4K=Q(A5*3%0AN2_#=6
MQH3Q\2"-:=#]UTPE3:6EBL-M7]IT[DU47SS\XKF;[I+0.15<4PJW5K)HUW0F
MS<M^L5[Y;C4]<"+/3QL2'FXL"0Z:4J,R[/4R+I(17$M*JC]-QMQBQQ@
M                             '%75][VB/\ ?Z !J+[$[7J_-<YQVZ??
M7ERC/5O;ULJOBO;?]JE$JK[LJW6JW950DV[5[LHD)PDM)E5"L4Y^HO+U6GOA
MY7"9)X"*-]5L+[(T>W9_'^!MTETD1GW?N[I$8DH5
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MI%Q)UAK%,E4Z7].!.:1D?49'][I$E2H
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MZ<A3OD*_DRO5N/;$EQ<IP^WCMI?0I1FA:3Z0IC7>*U7,DM$D
M
M
M
M
M                !0ST^[[W27L]?< %"41]P_O]&FFFNNI&9: #D      '
MW?=^V                   "AF1=/<]GN%]\ 4XBU,NZ77[1>SIUZ=  KK_
M */W0!4       !Q-1$>G=[G46OWM3+70 <@
M
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MZD8$<MY]$
M
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M?1T=!%LY%76N.#+TB2
M
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M4GN"R*2V^HE- @
M
M                         "FA>P0 J *:%[!?M%]W< %="]@ 4T+V"_:
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M2C/N@5JFZH[?H6FFA:>QIT= 40*@
M
M                                                           ?
M4?\ IZOV0!Q_UO\ 5_WP Y                            *>QU?<9=0!
M%"[G\']C[W<^[J#>#D
3                      #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tv531005_ex1-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv531005_ex1-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Q @4# 2(  A$! Q$!_\0
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M6."%Y975(T4LS,<!0.I-06/HKB;/7-=\8N\V@-#INC*Y1;^XB\R6X(X)C0X
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MX;ZE/X9UV]\":L0LD4C264F,"0'DC\1\P_$5ZK4U=&ET15%IIRZO<\K\(?\
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M>4_#NWAM?BEXOM[>)(88VVI'&H55&_H .@KUBBO\7R7Y#P_P?-_F<?\ %/\
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ME & ,<#I7T;116-2ISV5K6-Z5+D;;=[F9KVL1:)ICW4L-Q.Q^6.*WA:1G;'
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
</SUBMISSION>
